<SEC-DOCUMENT>0000875045-17-000029.txt : 20171024
<SEC-HEADER>0000875045-17-000029.hdr.sgml : 20171024
<ACCEPTANCE-DATETIME>20171024163534
ACCESSION NUMBER:		0000875045-17-000029
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171024
DATE AS OF CHANGE:		20171024

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		171151278

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-2017930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sC7B9012206DC5E3AA77A4D9BA94C986B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-Q</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:5px;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:9px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number 0-19311</font></div><div style="line-height:120%;text-align:center;"><img src="biogenlogostandarda10.jpg" alt="biogenlogostandarda10.jpg" style="height:61px;width:185px;"></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:4%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, MA 02142</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:120%;padding-top:5px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">area code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files):&#160;&#160;&#160;&#160;Yes</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:42%;"></td><td style="width:19%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated filer</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;No&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;20, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211,476,936</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s2C3517FBCF925D24AEFB95C14E3F5835"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">FORM&#160;10-Q &#8212; Quarterly Report</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Quarterly Period Ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:81%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;I&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s0518C1F974B554BEBFDB83DDAD24CBA8"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">FINANCIAL INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements (unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sDB8148C63A725265A29AA825EBBA734F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sDB8148C63A725265A29AA825EBBA734F">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s47B28A9495985BF89815BFBD349D80FE"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s47B28A9495985BF89815BFBD349D80FE">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s3714EB4A814E5DFBA5926DB5D4F2D416"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2017 and December&#160;31, 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s3714EB4A814E5DFBA5926DB5D4F2D416">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD723CD706A215290977F0221C21714A3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows&#160;&#8212; For the Nine Months Ended September 30, 2017 and 2016</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sD723CD706A215290977F0221C21714A3">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s055C8070DE2C5701ACA9BC26173396B9"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s055C8070DE2C5701ACA9BC26173396B9">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s960C8B8BB46B50E1BA6049EDAC45111F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s960C8B8BB46B50E1BA6049EDAC45111F">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8AA499E0D16D5DBF88AC8C50A8E2D1C7"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8AA499E0D16D5DBF88AC8C50A8E2D1C7">62</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s52A970458CDF5CEBA2EE1BDB9A68E404"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s52A970458CDF5CEBA2EE1BDB9A68E404">64</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;vertical-align:top;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">PART&#160;II&#160;&#8212; </font><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;" href="#s54141034EDF65B13A7B411687240F71B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;vertical-align:top;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s5609205B337B59799C4038DC70EE31A1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s5609205B337B59799C4038DC70EE31A1">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8EF79B8AB6795AA7A3733979EDEAF8D5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s8EF79B8AB6795AA7A3733979EDEAF8D5">65</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sA74663ABBB395DEBAE04CEFBEC821383"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sA74663ABBB395DEBAE04CEFBEC821383">79</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE6316983798E53938D463A2870EB91CF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#sE6316983798E53938D463A2870EB91CF">79</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s644BD61231225B6ABE32B29F9D576C3E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;">Signatures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;vertical-align:top;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;vertical-align:top;" href="#s644BD61231225B6ABE32B29F9D576C3E">81</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="sA6E4171AEE385B0188DB3F5D814CFD5C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues, contingent payments, milestone, royalty and other payments under licensing, collaboration or acquisition agreements, tax positions and contingencies, collectability of receivables, pre-approval inventory, cost of sales, research and development costs, compensation and other selling, general and administrative expenses, amortization of intangible assets, foreign currency exchange risk, estimated fair value of assets and liabilities and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to business development opportunities and research and development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits and the potential costs and expenses related to our corporate restructurings or other initiatives to streamline our operations and reallocate resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs to limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits, costs and tax treatment of the spin-off of our hemophilia business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws and accounting standards.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the E.U.).</font></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are registered trademarks of Biogen. BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, CIRARA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are trademarks of Biogen. ALPROLIX&#174;,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174;, RITUXAN HYCELA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and other trademarks referenced in this report are the property of their respective owners. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="s0518C1F974B554BEBFDB83DDAD24CBA8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I FINANCIAL INFORMATION</font></div><div><a name="sF5346C88BA9359A08E7DDFEB7FAE2750"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDB8148C63A725265A29AA825EBBA734F"></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,642.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,315.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">406.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">317.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,144.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">996.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,077.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,955.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,966.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,576.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">370.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">416.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,120.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,100.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">529.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,666.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,439.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">433.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,363.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,452.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">108.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">674.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">82.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,424.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,530.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,088.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,312.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,653.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,425.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,878.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,264.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(149.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(169.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,609.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,367.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,729.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,094.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">383.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">337.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">892.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,047.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,030.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,047.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,053.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.80</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.95</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.79</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s47B28A9495985BF89815BFBD349D80FE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,053.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(35.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,235.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,014.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,827.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,976.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,235.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,012.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,826.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,971.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="s3714EB4A814E5DFBA5926DB5D4F2D416"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions, except per share amounts)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, <br>2016</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,548.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,960.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,441.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">518.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">300.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">967.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,093.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,568.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,062.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,995.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,019.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,127.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,300.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,335.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23,073.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">573.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">121.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">298.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">279.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,455.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,448.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,419.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,938.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">716.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">722.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10,224.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,748.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">59.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(329.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">16,107.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12,860.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12,848.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23,073.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="sD723CD706A215290977F0221C21714A3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(unaudited, in millions)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,047.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">992.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">505.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">97.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(39.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(56.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(225.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(238.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(170.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(155.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(504.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">170.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(147.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other changes in operating assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(250.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,032.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,472.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,185.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,093.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,631.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(900.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(900.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(636.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(434.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(910.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(110.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,193.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,903.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,365.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(348.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(12.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash contribution to Bioverativ Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayment of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,671.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(326.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net (decrease) increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(832.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">776.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,548.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,084.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s055C8070DE2C5701ACA9BC26173396B9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited)</font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s1F1F26E62DF5598FBDAD4494EA8C1282"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS and relapsing MS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. We intend to invest in the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the following new standards effective January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounting Standards Update (ASU) No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">January 1, 2018. We expect to adopt these standards using the modified retrospective method. We have performed a review of the new standards as compared to our current accounting policies and our review of customer contracts and collaborative relationships remains in process. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues and revenues from anti-CD20 therapeutic programs. During the fourth quarter of 2017 we plan to finalize our assessments over the impact that these standards may have on our results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. The adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. The new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard will be effective for us on January 1, 2018. We expect to adopt this standard using the modified retrospective method applied through a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. The new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard will be effective for us on January 1, 2020; however, early adoption is permitted. We intend to early adopt this standard as of October 31, 2017, during our annual review of goodwill. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for us on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will be effective for us on January 1, 2019; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s264DD0A731325CA6BC34368FDCF3C41A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May 15, 2017, we completed an asset purchase of the Phase 3 candidate, CIRARA (now known as BIIB093), from Remedy Pharmaceuticals Inc. (Remedy). The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. Under the terms of the purchase agreement, we will have responsibility for the future development and commercialization of BIIB093 and have agreed to pay Remedy certain development and sales based milestone payments, which are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. Upon closing of the transaction, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB093 has not yet reached technological feasibility. </font></div><div><a name="s86A131C319005591A0CD65FC1331D002"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date), and are expected to terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ's and our consent. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as cost of sales in relation to these services during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the United States (U.S.), which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement. Under this arrangement, we distributed these products as an agent of Bioverativ and also provided related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations did not reflect recognition of activity or balances related to these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our condensed consolidated statements of income for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$604.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><a name="s15AEEE4329AD578882C25AE580963B02"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">422.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,681.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,123.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(320.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,547.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(431.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(519.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">102.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s377A913010FB57B289C7817E488FC658"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">208.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">647.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sACD3776614F25647A5F0193D8C8DD3BF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(532.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,675.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,002.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,067.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,934.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,295.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,276.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,019.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$674.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. Amortization of acquired intangible assets for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$413.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property related to TECFIDERA, as further discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$322.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,293.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The increase in acquired and in-licensed rights and patents during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payments due to Ionis Pharmaceuticals, Inc., which became payable upon the approval of SPINRAZA for the treatment of SMA in the E.U. and Japan, respectively, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Samsung Bioepis, which became payable upon the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. and net amounts related to our TECFIDERA license rights, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement, representing the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We paid the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in February 2017 and recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information related to these disputes, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">404.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">389.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">256.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">244.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">762.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,127.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill.</font></div><div><a name="s337BF2C195645012B8E3450921B228F4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,250.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,238.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">628.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,536.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,049.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,867.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,030.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,048.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,494.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">492.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">515.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other. </font></div><div><a name="s1B24CFE9A0185CD7A23B31D5D269D9CF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">871.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,042.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,043.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">954.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">957.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,960.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,961.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,792.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,795.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,362.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,472.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,185.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="s66E23F119E95515AA3939FB0E5C5B273"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,573.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,637.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020 attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020 with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$366.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:40%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s54CD4020975E5F4592131A2AA81AA9D5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,580.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,439.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), where we are building a biologics manufacturing facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$968.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$235.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the construction of this facility.</font></div><div><a name="s8D599004AA285A91837F2C517604D221"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$720.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by share repurchases totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below, and an adjustment to retained earnings of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$852.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting the spin-off of our hemophilia business, as described in Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$348.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available to repurchase shares under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, which was completed as of March 31, 2017. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><a name="sAADF71FF103558608A616992EC8F0C3D"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(176.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(33.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(329.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(78.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(258.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:23%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><a name="s31D1869D754E5119A8E61230E344D933"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,053.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s3E8E808A3E68529FAF9A0ED657598CA5"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14. Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">2017 Omnibus Equity Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan) for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;1.5-to-1&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div><div><a name="sD8C115CB49055E6EA728BAD9AF328775"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:45%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we are earning a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div><div><a name="s3E17A4C6F3C95F439D12EDF7E836D245"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(66.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(188.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(149.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(169.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$714.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">611.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">241.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">157.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,455.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017 we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="s02198D5543D25A68BC95034F44A1D80C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of AD. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the research and development costs incurred in support of the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><a name="s500CD7B71EC853AE94D87F474153AD93"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 1, 2017, we finalized an agreement with Bristol-Myers Squibb Company (BMS) to exclusively license BMS-986168 (now known as BIIB092), a Phase 2-ready experimental medicine with potential in AD and progressive supranuclear palsy (PSP), and made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to BMS. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. We may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former stockholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payable to the former stockholders of iPierian upon dosing of the first patient in the Phase </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2 PSP study for BIIB092 and we may pay the former stockholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments, and potential royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payment were recognized as research and development expense in our condensed consolidated statements of income for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the European Medicines Agency (EMA) announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. The outcome of the EMA review process may affect the market for ZINBRYTA, which may result in the impairment of all or a portion of certain assets related to ZINBRYTA. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our condensed consolidated balance sheet includes ZINBRYTA related assets, primarily related to inventory, prepaid tax and intangible assets, totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Offsetting these amounts, we also have an unrecorded tax benefit related to certain ZINBRYTA assets totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;share of the co-promotion profits or losses as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&#160;2016. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of an overall net loss within the collaboration, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in each of the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net and record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as revenues are recognized and related costs are incurred. We also reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses in the E.U. and Canada, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, during the third quarter of&#160;2016,&#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was approved for use in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively. These approvals triggered milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;during 2017, which were capitalized in intangible assets, net in our condensed consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$197.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$438.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$73.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$82.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in royalty cost of sales within our condensed consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA, triggering an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment due to Samsung Bioepis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss in accordance with the cost sharing provision of the commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits, as compared to net expense recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect sharing of the net collaboration profits in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in connection with these services as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><a name="sE46EC4E476FD53E78E6078202C8B5AD9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July and September 2017 we filed patent infringement actions pursuant to the Hatch-Waxman Act against parties who filed Abbreviated New Drug Applications (ANDAs) for generic versions of TECFIDERA. We have sued the following parties in the United States District Court for the District of Delaware: Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceuticals, Inc., Slayback Pharma LLC,&#160; Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Pvt. Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torren Pharmaceuticals, Ltd., TWI Pharmaceuticals, Inc., Windlas Healthcare Pvt., Ltd., Accord Healthcare Inc., Par Pharmaceuticals, Sandoz Inc., Sawai (USA), Inc. and Zydus Pharmaceuticals (USA), Inc. We have also filed actions against Stason Pharmaceuticals, Inc. in the United States District Court for the Central District of California, Zydus Pharmaceuticals (USA), Inc. in the United States District Court for the District of New Jersey, Accord Healthcare Inc. in the Middle District of North Carolina, Par Pharmaceuticals in the Southern District of New York, Sandoz, Inc. in the District of Colorado and Mylan Pharmaceuticals in the United States District Court for the District of West Virginia. No trial has been scheduled in any of these matters.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EPO has scheduled a hearing for January 2018 on Biogen&#8217;s and others&#8217; oppositions to Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. In July 2017 the District Court of The Hague ruled that the Dutch counterpart of the patent is invalid and we have appealed. A hearing has been scheduled in the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for the first quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We regard this matter as closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><a name="sa2f7ff46af3f405cae6675f90dbb9853"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014, we entered into a collaboration agreement (Eisai Collaboration Agreement) with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&#160;Under the Eisai Collaboration Agreement, Eisai had an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 23, 2017, Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement (Aducanumab Agreement) for the joint development and commercialization of aducanumab. Under the Aducanumab Agreement, the two companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of development costs for aducanumab incurred in support of the agreement until April 2018. Eisai will then reimburse us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of development expenses for the period April 2018 through December 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;thereafter. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, both companies will continue to jointly develop BAN2401 and E2609; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai have also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets (excluding China).  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration arrangement with Eisai, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neurimmune</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 23, 2017, we amended the terms of our existing collaboration agreement with Neurimmune. Pursuant to the amended agreement, we agreed to make a one-time </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in royalty rates payable on potential commercial sales of aducanumab.&#160;Our royalty rates payable on potential commercial sales of aducanumab will now range from the high single digits to low-teens.&#160;This payment will be recognized in the fourth quarter of 2017. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#1c5a7d;font-weight:bold;">(unaudited, continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rate payable on potential commercial sales of aducanumab by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in exchange for a one-time </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the Aducanumab Agreement, Eisai may elect to share in the benefit and cost of the royalty reduction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For&#160;additional information relating to our collaboration agreement with Neurimmune, please read Note 17,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><a name="s960C8B8BB46B50E1BA6049EDAC45111F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K).</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products and, unless we develop, acquire rights to and commercialize new products and technologies, we may be substantially dependent on sales from our principal products for many years. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will be dependent upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and successful execution of external business development opportunities. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how by developing, manufacturing and marketing biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the E.U. In August 2017 the European Commission (EC) granted a marketing authorization for IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Corporate Strategy Update</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we announced an updated strategic framework to optimize the value of our MS business while investing for the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect the continued performance of our commercial assets and the expiration of the contingent payments related to TECFIDERA, discussed further in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Contractual Obligations and Off-Balance Sheet Arrangements&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report, to enable us to invest in and build an industry leading neuroscience pipeline. We view investment in growth as our top priority, but also recognize the value of opportunistically returning excess capital to shareholders through share repurchases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to deliver positive results in the near term while investing in the next stages of our growth, we will focus on the following strategic priorities:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">maximizing the resilience of our MS core business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">accelerating efforts in SMA as a significant new growth opportunity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing and expanding our neuroscience portfolio;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">focusing our capital allocation efforts to drive investment for future growth; and</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">creating a leaner and simpler operating model to streamline our operations and reallocate resources towards prioritized research and development and commercial value creation opportunities. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of up to $170.0 million, primarily in 2018, and our goal is to redirect resources of up to $400.0 million annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017. For additional information related to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s2B7D0EB6C042513FA66988483DA0F760"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="biib-2017930highlights.jpg" alt="biib-2017930highlights.jpg" style="height:426px;width:317px;"></div><div><a name="sBDADAB29125355AEBA08A157A2864EA0"></a></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.79</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 22.9% over the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our income from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3,077.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 4.1% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$2,622.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 3.3% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by revenues from SPINRAZA and BENEPALI, partially offset by the elimination of worldwide ALPROLIX and ELOCTATE revenues resulting from the spin-off of our hemophilia business on February 1, 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$406.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 28.0% over the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was driven by royalty revenues on sales of OCREVUS.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$48.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of 50.5% from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,424.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the </font><font style="font-family:Franklin Gothic Book,sans-serif;">third</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;quarter of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing a decrease of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the same period in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This decrease was primarily driven by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in research and development, an </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in cost of sales and a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">6.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;decrease in selling, general and administrative expenses. These decreases were partially offset by an increase in collaboration profit sharing and losses on fair value remeasurement of contingent consideration.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3,032.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6,570.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions or biosimilars of existing products and other technologies. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. Drug prices are under significant scrutiny in many of the markets in which our products are prescribed.&#160;Drug pricing and other health care costs continue to be subject to political and societal pressures.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition,&#160;our sales and operations are subject to the risks of doing business internationally. For example, the full scope of implementation of the U.K.&#8217;s referendum decision to voluntarily depart from the E.U., known as Brexit, remains unclear; compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and results of operations from these developments remains unknown.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our competition and pricing risks that could negatively impact our product sales, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:8px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Key Pipeline and Product Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the EC approved the use of SPINRAZA for the treatment of SMA in pediatric and adult patients in the E.U. SPINRAZA was reviewed under the European Medicines Agency's (EMA) accelerated assessment program, intended to expedite access to patients with unmet medical needs. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the Japanese Ministry of Health, Labor and Welfare approved the use of SPINRAZA for the treatment of infantile SMA and in September 2017 the Japanese Ministry of Health, Labor and Welfare approved the use of SPINRAZA for the treatment of pediatric and adult patients with SMA.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA (daclizumab)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the EMA announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe RMS who are unsuitable for treatment with other DMTs.&#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA, following the report of&#160;a case of fatal fulminant liver failure, as well as four cases of serious liver injury.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie Inc. (AbbVie), please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS (Ocrelizumab)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the Roche Group announced that the U.S. Food and Drug Administration (FDA) approved OCREVUS for the treatment of RMS and PPMS. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 and September 2017 the Roche Group announced that OCREVUS was approved in Australia and Switzerland, respectively, for the treatment of RMS and PPMS. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our agreements with Genentech, please read the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Revenues from Anti-CD20 Therapeutic Programs&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of this report.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI (adalimumab)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the EC granted a marketing authorization for IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our agreements with Samsung Bioepis, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab (BIIB037)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 we announced results from a recently conducted analysis of the long-term extension (LTE) of our ongoing Phase 1b study of aducanumab, our anti-amyloid beta antibody candidate for AD, which included data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24 months in the titration cohort and up to 36 months in the fixed-dose cohorts. The results are consistent with previously reported results from this ongoing Phase 1b study and support the design of the ongoing Phase 3 studies of aducanumab for early AD.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 Ionis Pharmaceuticals, Inc. (Ionis) announced the initiation of a Phase 1/2a clinical study of IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in patients with mild AD. IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain. We have an option to develop and commercialize IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB054</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we completed enrollment in the Phase 1 study of BIIB054, an anti-alpha synuclein antibody, in both healthy volunteers and patients with early onset Parkinson&#8217;s disease.</font></div></div></div><div><a name="s054C4D5C21555B68968F718CB4491315"></a></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,774.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,828.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,265.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">58.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,269.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">848.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">711.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,376.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,045.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,622.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">85.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,642.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">85.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,315.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">406.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">317.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,144.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">996.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,077.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,955.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,966.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,576.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:17px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:5px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,069.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,033.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,138.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">41.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,966.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">662.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">25.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">708.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,000.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,107.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">469.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">515.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,510.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,489.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">41.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">270.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">521.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">364.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">240.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Product Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">99.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">253.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,622.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,642.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,315.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><a name="sA6458E0FB4AB55ADAED9F3B6C9F46FDE"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;"><img src="biib-2017930tecfidera.jpg" alt="biib-2017930tecfidera.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TECFIDERA revenues was primarily due to a decrease in unit sales volume of 7%, partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by a decrease in unit sales volume of 4% and higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 21% and 20%, respectively, in existing markets and new markets where we continue to launch the product and expand our presence around the world. These increases were partially offset by pricing reductions in certain European countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TECFIDERA on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S., primarily resulting from increasing competition from additional treatments for MS, including OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2017930interferon.jpg" alt="biib-2017930interferon.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volumes of 11% and 12%, respectively, which was primarily attributable to patients transitioning to other MS therapies, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to an overall decrease in AVONEX unit sales volumes of 18% and 15%, respectively, primarily due to patients transitioning to other MS therapies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that overall Interferon revenues will continue to decline compared to prior year periods as a result of increasing competition from our other products as well as other treatments for MS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. AVONEX revenues totaled $397.7 million and $1,218.2 million, respectively, as compared to $421.8 million and $1,264.0 million, respectively, in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world AVONEX revenues totaled $139.9 million and $413.4 million, respectively, as compared to $158.3 million and $485.8 million, respectively, in the prior year comparative periods.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">PLEGRIDY</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, U.S. PLEGRIDY revenues totaled $75.6 million and $221.6 million, respectively, as compared to $83.9 million and $228.2 million, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, rest of world PLEGRIDY revenues totaled $48.8 million and $147.7 million, respectively, as compared to $44.3 million and $129.0 million, respectively, in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;"><img src="biib-2017930tysabri.jpg" alt="biib-2017930tysabri.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TYSABRI revenues was primarily due to a decrease in unit sales volume of 6% and 2%, respectively, and higher discounts and allowances, partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was primarily due to a prior year favorable adjustment of approximately $20.0 million to previous reserves estimates related to a government price reimbursement program in Italy included in our discounts and allowances, partially offset by a 1% increase in unit sales volume. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TYSABRI revenues was primarily due to the recognition of approximately $45.0 million of previously deferred revenue in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA), as discussed below, and an 8% increase in unit sales volume, partially offset by a </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">prior year favorable adjustment of approximately $20.0 million to previous reserves estimates related to a government price reimbursement program included in our discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate relatively stable demand for TYSABRI on a global basis, with patient growth in our international markets offsetting modest patient declines in the U.S. primarily resulting from increasing competition from additional treatments for MS, primarily OCREVUS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;"><img src="biib-2017930zinbryta.jpg" alt="biib-2017930zinbryta.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with AbbVie, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy (SMA)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;text-align:left;text-indent:18px;"><img src="biib-2017930spinraza.jpg" alt="biib-2017930spinraza.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of SPINRAZA in the U.S. in the fourth quarter of 2016 and the rest of world in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Ionis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BENEPALI and FLIXABI</font></div><div style="line-height:120%;"><img src="biib-2017930biosimilars.jpg" alt="biib-2017930biosimilars.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="sA32B5AAC3A42560CAB4F310D2923E2E2"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN and GAZYVA collaboration operating profits and royalty revenues on other anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;"><img src="biib-2017930anticd.jpg" alt="biib-2017930anticd.jpg" style="height:340px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables provide a summary of amounts comprising our share of pre-tax profits on RITUXAN and GAZYVA in the U.S.:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,039.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">961.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">172.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">191.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">866.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">770.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">325.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">301.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:22%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,164.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,969.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">544.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,596.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,424.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">996.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">947.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN annual pre-tax co-promotion profits in the U.S. in excess of $50.0 million decreased to 39% from 40% in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and was further decreased to 37.5% in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12 month period exceeded $150.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 the FDA approved RITUXAN HYCELA for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia. This new treatment includes the same monoclonal antibody as intravenous RITUXAN in combination with hyaluronidase human, an enzyme that helps to deliver rituximab under the skin. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues was primarily due to selling price increases, an increase in RITUXAN unit sales volume of 4% and 2%, respectively, and an increase in GAZYVA unit sales volume of 39% and 33%, respectively, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160; For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, collaboration costs and expenses decreased primarily due to decreases in selling and marketing and research and development costs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration costs and expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as depicted in the table above, excludes certain expenses charged to the collaboration by Genentech that we believe remain the responsibility of Genentech and we are not obligated to pay under the terms of the collaboration agreement. Accordingly, we did not recognize the effect of those expenses in the determination of our share of pre-tax collaboration profits and Genentech has withheld approximately $120 million from amounts due to us in relation to collaboration activity for the first quarter of 2017, representing Genentech&#8217;s estimate of our share of these </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expenses. We remain in discussions with Genentech about a resolution relating to these amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excluding amounts under dispute, for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in 2016, collaboration costs and expenses increased primarily due to an increase in RITUXAN product cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, other revenues from anti-CD20 therapeutic programs increased primarily due to the launch of OCREVUS in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS, a humanized anti-CD20 monoclonal antibody, for the treatment of RMS and PPMS. Under the terms of our agreement with Genentech, we will receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we will receive a 3% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS was approved for treatment of RMS and PPMS in Australia and Switzerland in July 2017 and September 2017, respectively. Marketing applications for OCREVUS are currently under review in numerous markets worldwide, including in Europe, Latin America and the Middle East. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration with Genentech, including information regarding the pre-tax profit sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><a name="s894B10AC5A455C8AAE6EE0479C115D82"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">12.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">21.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">158.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">48.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">265.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from collaborative and other relationships include revenues earned under our 50% share of the co-promotion profits or losses of ZINBRYTA in the U.S. with AbbVie and revenues from our technical development and manufacturing services agreements with Samsung Bioepis. Prior to the spin-off of our hemophilia business, other revenues from collaborative and other relationships also included revenues earned under our manufacturing services agreement with Sobi on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX in their territory, which included substantially all of Europe, Russia and certain markets in Northern Africa and the Middle East. Bioverativ assumed all of our rights and obligations under our agreement with Sobi on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other revenues from collaborative and other relationships was primarily due to a decrease in net losses recognized in the U.S. territory under our collaboration with AbbVie, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;recognized in the prior year comparative period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other revenues from collaborative and other relationships was primarily due to the impact of the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration agreements with AbbVie and Samsung Bioepis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;"><img src="biib-2017930otherrevenues.jpg" alt="biib-2017930otherrevenues.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in royalty and other corporate revenues was primarily due to lower contract manufacturing revenues related to the volume of shipments of drug substance production provided to a strategic partner.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><a name="s9DB07A7A37D15D17B05E4DF6509D56B6"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates take into consideration our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which will have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:left;"><img src="biib-2017930reserves.jpg" alt="biib-2017930reserves.jpg" style="height:373px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 21.4% and 21.8%, respectively, as compared to 20.8%, respectively, in both of the prior year comparative periods.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily driven by an increase in rest of world product revenues, due in part to an increase in biosimilar revenues, as well as an increase in gross selling prices, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments relate to Medicaid and managed care rebates, co-payment assistance, Veterans Administration, Public Health Service discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher Medicaid and other governmental rebates and allowances in the U.S. and managed care rebates, due in part to an increase in gross selling prices and the launch of SPINRAZA in the U.S. in the fourth quarter of 2016, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recorded in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return provisions were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our reserves, please read Note 4, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reserves for Discounts and Allowances,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><a name="s9D08FED9846158DAB46364745C3E0EEA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">370.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">416.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,120.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,100.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">446.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">529.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(15.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,666.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,439.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">433.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">462.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,363.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,452.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">108.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">674.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">82.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">408.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">225.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,424.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,530.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,088.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,312.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s17D9271C86475ECFAB1FE6AA119FEC94"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2017930cos.jpg" alt="biib-2017930cos.jpg" style="height:292px;width:317px;"></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in product cost of sales was primarily driven by lower contract manufacturing, the impact from the spin-off of our hemophilia business on February 1, 2017 and the accelerated depreciation recorded in the third quarter of 2016 as a result of our decision to cease manufacturing in Cambridge, MA. These decreases were partially offset by higher unit sales volume related to our biosimilar product shipments and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher unit sales volume related to our biosimilar product shipments and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017, lower contract manufacturing shipments and the accelerated depreciation recorded in the second and third quarters of 2016 as a result of our decision to cease manufacturing in Cambridge, MA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our Cambridge, MA manufacturing facility, please read Note&#160;3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Restructuring, Business Transformation and Other Cost Saving Initiatives,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in royalty cost of sales was primarily driven by lower royalties on sales of TYSABRI resulting from the expiration of certain third-party royalties and the elimination of royalties payable on sales of hemophilia product resulting from the spin-off of our hemophilia business on February 1, 2017. These decreases were partially offset by the recognition of royalties payable to Ionis on sales of SPINRAZA.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the recognition of royalties payable to Ionis on sales of SPINRAZA and higher royalties on sales of AVONEX and PLEGRIDY in the U.S., as described below. These increases were partially offset by lower royalties on sales of TYSABRI resulting from the expiration of certain third-party royalties and the elimination of royalties payable on sales of hemophilia product resulting from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 28, 2016, the U.S. Patent and Trademark Office issued to the Japanese Foundation for Cancer Research (JFCR) a patent related to recombinant interferon-beta protein. This patent, U.S. Patent No. 9,376,478, expires in June 2033, and was issued following an interference proceeding between JFCR and us. This patent is relevant to AVONEX and PLEGRIDY, and we will pay royalties in the mid-single digits in relation to this patent during its life.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s2A5E0EFD9BB652ED86DBF8D7E67391A8"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="biib-2017930rd.jpg" alt="biib-2017930rd.jpg" style="height:746px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-align:center;"><img src="biib-2017930rdpie2017.jpg" alt="biib-2017930rdpie2017.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-align:center;"><img src="biib-2017930rdpie2016.jpg" alt="biib-2017930rdpie2016.jpg" style="height:266px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in research and development expense was primarily related to a decrease in milestone and upfront expenses and decreased costs incurred in connection with our marketed products and our late stage and research and discovery programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to milestone and upfront expenses, partially offset by decreased costs incurred in connection with our marketed products and our late stage and research and discovery programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in milestone and upfront expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to the $75.0 million license fee paid to Ionis in the third quarter of 2016 upon the exercise of our option to develop and commercialize SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in milestone and upfront expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to a $300.0 million upfront payment to Bristol-Myers Squibb Company (BMS) upon the closing of our agreement to exclusively license BMS-986168 (now known as BIIB092) and a $60.0 million developmental milestone that became payable to the former stockholders of iPierian, Inc. upon dosing of the first patient in the Phase 2 progressive supranuclear palsy (PSP) study for BIIB092. These amounts were partially offset by the prior year license fee paid to Ionis upon the exercise of our option to develop and commercialize SPINRAZA discussed above and the $20.0 million upfront milestone paid to the University of Pennsylvania upon entering into a collaboration and alliance agreement in May 2016.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our agreements with BMS and Ionis, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our marketed products for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to a reduction in spending resulting from the spin-off of our hemophilia business on February 1, 2017, and a reduction in spending related to TECFIDERA, partially offset by increased spending related to SPINRAZA following its approval in the U.S. in the fourth quarter of 2016. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in spending associated with our late stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to the approval of SPINRAZA in the fourth quarter of 2016. These decreases were partially offset by increased costs associated with the development of aducanumab and costs incurred associated with the development of E2609, a BACE inhibitor that was advanced to a late stage program in the fourth quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in spending associated with early stage programs for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily related to spending associated with the development of BIIB092 in AD and PSP pursuant to our June 2017 agreement with BMS, BIIB074 in trigeminal neuralgia (TGN) and BIIB076 in AD. These increases were partially offset by a reduction in costs resulting from our discontinuance of development of amiselimod in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="biib-2017930sga.jpg" alt="biib-2017930sga.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decreases in selling, general and administrative expenses were primarily due to a reduction in operational spending resulting from the spin-off of our hemophilia business on February 1, 2017, and the execution of targeted cost reduction initiatives, partially offset by an increase in commercialization costs associated with SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The comparative decrease in selling, general and administrative expenses for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;month comparative periods also reflects the discontinuance of our TECFIDERA television advertising campaign in the second quarter of 2016, partially offset by an increase in corporate giving throughout 2017.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><a name="sE7CBF0079A5B57E1AC4030914BC37E21"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="biib-2017930amortization.jpg" alt="biib-2017930amortization.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long range planning cycle was updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The results of our TECFIDERA, AVONEX and TYSABRI analyses were impacted by changes in the estimated timing of impact of other existing and potential oral and alternative MS formulations, including OCREVUS, which may compete with TYSABRI, TECFIDERA and AVONEX. Based on this analysis, there was not a significant net change in our near-term expected rate of amortization for acquired intangible assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant process. The occurrence of an adverse event could substantially increase the amount of amortization expense associated with our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$413.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of amortization and impairment charges associated with our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property related to TECFIDERA acquired in the first quarter of 2017, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and in the first quarter of 2017 we recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our licenses to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. The intangible asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into the agreement, through December 2020, the last month before royalty payments could first commence pursuant to the agreement. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information related to these disputes, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">In Process Research &amp; Development (IPR&amp;D) related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon a number of variables, including estimates of future revenues and the effects of competition, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from a clinical trial phase to the next.&#160;We are continually reevaluating our estimates concerning these variables and evaluating industry data regarding the productivity of clinical research and the development process.&#160;Changes in our estimates of items may result in a significant change to our valuation of these assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. Our most recent impairment assessment as of October 31, 2016 resulted in no impairments. Changes to clinical development plans, regulatory feedback received, life cycle management strategies and changes in program economics, including foreign currency exchange rates, are evaluated regularly. The field of developing treatments for forms of neuropathic pain, such as TGN and idiopathic pulmonary fibrosis (IPF) are highly competitive and can be affected by changes to expected market candidates and changes in timing and the clinical development of our product candidates. There can be no assurance that we will be able to successfully develop BIIB074 for the treatment of TGN or STX-100 for the treatment of IPF or other indications, including our ability to confirm safety and efficacy based on data from clinical trials, or that a successfully developed therapy will be able to secure sufficient pricing in a competitive market. Changes in events and circumstances for these programs may have a material impact on the value of our related IPR&amp;D.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the amortization of acquired intangible assets and our TECFIDERA settlement and license agreement please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sE9667ADC5EF05990902F331030608523"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</font></div><div style="line-height:120%;"><img src="biib-2017930acquirediprd.jpg" alt="biib-2017930acquirediprd.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May 15, 2017, we completed an asset purchase of the Phase 3 candidate, CIRARA (now known as BIIB093), from Remedy Pharmaceuticals Inc. (Remedy). Upon closing of the transaction, we made a $120.0 million upfront payment to Remedy, which was recorded as acquired in-process research and development in our condensed consolidated statements of income during the second quarter of 2017 as BIIB093 had not yet reached technological feasibility. For additional information related to this transaction, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our condensed consolidated financial statements included in this report.</font></div><div><a name="s75D404130A8A569A8E30DD2D1B720F54"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="biib-2017930collaborationps.jpg" alt="biib-2017930collaborationps.jpg" style="height:293px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) reflects the sharing of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our 50% sharing of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie in the commercialization of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of biosimilars in the first quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we shared collaboration profits and therefore recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to net expense of $7.4 million and $1.8 million, respectively, in the prior year comparative periods. The increase in profit sharing expense for the comparative periods was primarily due to increased collaboration profits resulting from increased biosimilar product sales.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect AbbVie's 50% sharing of the net collaboration profits in the E.U. and Canada as compared to net income recognized of $2.7 million in both of the prior year comparative periods, to reflect AbbVie's 50% sharing of the net collaboration losses in the E.U. and Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our agreements with Samsung Bioepis and AbbVie please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sBD99067A432F5D6DB6506F0BF1B6EA27"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="biib-2017930glfvcc.jpg" alt="biib-2017930glfvcc.jpg" style="height:233px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular factor or factors. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The change in fair value remeasurement of contingent consideration for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in 2016, was primarily due to the increase in the probability of achieving certain developmental milestones based upon the progression of the underlying clinical programs.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><a name="sD148F2AE7B735C8C917FED51D286466F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="biib-2017930oie.jpg" alt="biib-2017930oie.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in foreign currency exchange gains, an increase in interest income and a decrease in interest expense, partially offset by other than temporary impairments recorded on strategic investments during the year.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s2962D41DC57153EAA484F0EBEF107664"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="biib-2017930incometax.jpg" alt="biib-2017930incometax.jpg" style="height:333px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include variability in the allocation of our taxable earnings among multiple jurisdictions, changes in tax laws, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we are earning a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For more information on our uncertain tax positions and income tax rate reconciliation for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 15, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><a name="sD5999E9ACF6259B28BC7D5537C275E4E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br>September 30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br>December 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Change&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,548.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(33.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,960.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,062.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,829.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,570.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">573.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,938.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,511.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,517.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,568.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,732.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3,448.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,419.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,119.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,312.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s3620153D14165C708F9A303381F34B41"></a></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$765.4 million in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$454.8 million payment made to Forward Pharma for the litigation and settlement charges that were accrued as of December 31, 2016; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$300.0 million upfront payment to BMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million payment made to Forward Pharma to license intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$636.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million net cash contribution made to Bioverativ; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$230.0 million in upfront and milestone payments made to Remedy and Ionis.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 billion in total payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$434.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;text-transform:default;">$348.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned from our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The undistributed cumulative foreign earnings of certain of our foreign subsidiaries, exclusive of earnings that would result in little or no net income tax expense under current U.S. tax law or which has already been subject to tax under U.S. tax law, are invested indefinitely outside the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Of the total cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately $4.4 billion was generated in foreign jurisdictions and is primarily intended for use in our foreign operations or in connection with business development transactions outside the U.S. In managing our day-to-day liquidity in the U.S., we do not rely on the unrepatriated earnings as a source of funds and we have not provided for U.S.&#160;federal or state income taxes on these undistributed foreign earnings. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to certain risks that could negatively impact our financial position or future results of operations, please read the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; sections of this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$348.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available to repurchase shares under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, which was completed as of March 31, 2017. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash used for share repurchases, the payment made to Forward Pharma in connection with our January 2017 settlement and license agreement, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, net purchases of property, plant and equipment, upfront and milestone payments made to BMS, Remedy and Ionis and the net cash contribution made to Bioverativ. These cash outflows were partially offset by cash flows related to operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion aggregate principal amount of 2.90% Senior Notes due September 15, 2020;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion aggregate principal amount of 3.625% Senior Notes due September 15, 2022;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.75 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These senior unsecured notes were issued at a discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect to redeem our $550.0 million aggregate principal amount of 6.875% Senior Notes due March 1, 2018 during the fourth quarter of 2017. As a result, we expect to recognize an insignificant loss on the extinguishment of debt in other income (expense), net in our condensed consolidated statements of income. For additional information on our 6.875% Senior Notes due March 1, 2018 and related interest rate swap contracts, please read Note </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015, we entered into a $1.0 billion, 5-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had no outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair and carrying values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We define working capital as current assets less current liabilities. The change in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects a decrease in total current assets of approximately $1.2 billion and an increase in total current liabilities of $28.5 million. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The decrease in total current assets was driven by a decrease in net cash, cash equivalents and marketable securities, as described above.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in current liabilities was driven by the reclassification to current liabilities of $550.0 million of our 6.875% Senior Notes due March 1, 2018, as these notes are due within one year, partially offset by a reduction in accrued expenses primarily due to the payment of the $454.8 million charge that was accrued as of December 31, 2016 in relation to our settlement and license agreement with Forward Pharma. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="s4AF582D51D715CC9A1E93947B2585B6E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,032.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,193.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,903.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,671.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(326.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="sB62F5302A3535FBAAAC6521C098BF8E5"></a></div><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cash operating items such as depreciation and amortization, impairment charges, acquired in-process research and development and share-based compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes associated with the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows provided by operating activities was primarily due to a decrease in income tax payments in the U.S., partially offset by&#160;the $454.8 million payment that was accrued as of December 31, 2016 and paid in the first quarter of 2017, in relation to our settlement and license agreement with Forward Pharma. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities was primarily due to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">the $795.2 million payment made to license Forward Pharma's intellectual property related to TECFIDERA in the first quarter of 2017, the $120.0 million payment made to Remedy for the purchase of BIIB093 in the second quarter of 2017, the $60.0 million and $50.0 million milestone payments made to Ionis in the first and third quarters of 2017, respectively, related to the approvals of SPINRAZA and an increase in purchases of property, plant and equipment primarily related to the construction of our Solothurn, Switzerland facility, partially offset by an</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in net proceeds of marketable securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">. </font></div><div style="line-height:120%;padding-top:9px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to approximately $1.4 billion of cash used for share repurchases in the first half of 2017 and the $302.7 million net cash contribution made to Bioverativ in connection with the spin-off of our hemophilia business in February 2017. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="s146CA12FECF358AF9760A259D6A018E3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, capital leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, TYSABRI contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been no material changes in our contractual obligations since </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TYSABRI Contingent Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Corporation plc (Elan) full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the terms of the acquisition agreement, we are obligated to make contingent payments to Elan of 18% on annual worldwide net sales up to $2.0 billion and 25% on annual worldwide net sales that exceed $2.0 billion. Royalty payments to Elan and other third parties are recognized as cost of sales in our condensed consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to another third party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix, Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN), formerly Panima Pharmaceuticals AG, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we record contingent consideration liabilities at their fair value on the acquisition date and revalue these obligations each reporting period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may pay up to approximately $1.2 billion in remaining milestones related to these acquisitions. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, Fumapharm Products). We are required to make contingent payments to former shareholders of Fumapharm AG or holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12- month period. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we paid $900.0 million in contingent payments as we reached the $11.0 billion, $12.0 billion and $13.0 billion cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2016, the first quarter of 2017 and the second quarter of 2017, respectively, and accrued $300.0 million upon reaching $14.0 billion in total cumulative sales of Fumapharm Products in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We will owe an additional $300.0 million contingent payment for every additional $1.0 billion in cumulative sales level of Fumapharm Products reached if the prior 12 months sales of the Fumapharm Products exceed $3.0 billion, until such time as the cumulative sales level reaches $20.0 billion, at which time no further contingent payments will be due. If the prior 12 months sales of Fumapharm Products are less than $3.0 billion, contingent payments remain payable on a decreasing tiered basis. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible will be recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level has been reached.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately $3.1 billion, including approximately $0.6 billion in development milestones, approximately $0.9 billion in regulatory milestones and approximately $1.6 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones had not occurred as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately $25.0 million of milestone payments during the remainder of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in addition to the $40.0 million due to Ionis for the regulatory approval of SPINRAZA in Japan and the $25.0 million due to Samsung Bioepis for the marketing authorization of IMRALDI in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). Our contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately $35.0 million in our condensed consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately $455.0 million in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have approximately $80.0 million of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div><div><a name="s8292A1FEAE915BABABD59A075292A845"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report.</font></div><div><a name="sAECD6162D9D8506280551C9C89ACF6CE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of our critical accounting estimates, please read Part&#160;II, Item&#160;7 &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K. There have been no material changes to these critical accounting estimates since our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Form&#160;10-K.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><a name="s8AA499E0D16D5DBF88AC8C50A8E2D1C7"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia, and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. voted in a referendum to voluntarily depart from the E.U., known as Brexit, and in March 2017, the U.K. formally started the process for the U.K. to leave the E.U. The macroeconomic impact on our results of operations from these developments remains unknown. To date, the foreign currency exchange impact has been negligible since we hedged the balance sheet foreign currency exchange risk. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of exchange rate changes on revenues and net income diminishes as significant exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our condensed consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our condensed consolidated statement of cash flows.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $210.0 million and $172.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $53.0 million and $50.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in some international markets in which we operate have implemented measures aimed at reducing healthcare costs to limit the overall level of government expenditures. These implemented measures vary by country and include, among other things, mandatory rebates and discounts, prospective and possible retroactive price reductions and suspensions on price increases of pharmaceuticals. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure favorable prices in a particular country may impair our ability to obtain acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale distributors, public hospitals and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s52A970458CDF5CEBA2EE1BDB9A68E404"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;4.&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:10px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:10px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s54141034EDF65B13A7B411687240F71B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Part&#160;II&#160;&#8212; OTHER INFORMATION</font></div><div><a name="s5609205B337B59799C4038DC70EE31A1"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Please refer to Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s8EF79B8AB6795AA7A3733979EDEAF8D5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current revenues depend upon continued sales of our principal products, and, unless we develop or acquire rights to new products and technologies, we will be substantially dependent on sales from our principal products for many years. Further, following the completion of the spin-off of our hemophilia business, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market, and revenues from sales of our product for SMA. Any of the following negative developments relating to any of our principal products may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including lower-priced competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">constraints and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition, or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was recently approved by, among others, the FDA, the EC and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in these and other markets. In addition to risks associated with new product launches and the other factors described in these &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221;, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within the SMA market, which may impact our ability to develop relationships with the associated medical and scientific community;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, greater financial and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition from generics and biosimilars in many markets.&#160;Generic versions of drugs and biosimilars are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of generic or biosimilar versions of our marketed products, as well as lower-priced competing products, likely would significantly reduce both the price that we receive for such marketed products and the volume of products that we sell, which may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of lower-cost biosimilars, follow-on products or generic versions of branded MS products sold by our competitors, and the possibility of future competition from generic versions or prodrugs of existing therapeutics or from off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract new patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, revenues and results of operations, and could cause a decline in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products are dependent, in large part, on the availability and extent of coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors' reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting pilot program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason including efficacy or tolerability concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to secure adequate prices in a particular country may not only limit the revenue from our products within that country, but may also adversely affect our ability to obtain acceptable prices in other markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to maintain adequate coverage, pricing or reimbursement for our products would have an adverse effect on our business, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products, and could cause a decline in our stock price.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. As a result, our business and reputation may be harmed, our stock price may be adversely impacted and experience periods of volatility and our results of operations may be adversely impacted.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals and enactments to reform health care insurance programs could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that results in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures to reduce health care costs to constrain their overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possibly retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries to higher-cost countries. These measures have negatively impacted our revenues, and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenue, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges and other adverse impacts on our results of operations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing progressive multifocal leukoencephalopathy, a serious brain infection, or liver injury, in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We can provide no assurance that we will successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or that the protection obtained will be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. If we cannot prevent others from exploiting our inventions, we will not derive the benefit from them that we currently expect. Furthermore, we can provide no assurance that our products will not infringe patents or other intellectual property rights held by third parties.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenue for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon successful development of additional indications for our existing products as well as successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung Biologics or licenses or acquisitions from third parties. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations, and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends in large part on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our clinical trial related activities and reporting. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization, including most recently our chief executive officer and our chief financial officer. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition and results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">number of reasons, such as management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot assure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.   </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with current Good Manufacturing Practices (cGMP).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under the agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying contract with our collaborators or other third parties may fail to provide significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control or could result in termination of the research, development or commercialization of product candidates or result in litigation or arbitration; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are pursuing opportunities to expand our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we believe we currently have sufficient large scale manufacturing capacity to meet our near-term manufacturing requirements, it is probable that we would need additional large scale manufacturing capacity to support future clinical and commercial manufacturing requirements for product candidates in our pipeline, if such candidates are successful and approved. We are building a large scale biologics manufacturing facility in Solothurn, Switzerland. Due to the long lead times necessary for the expansion of manufacturing capacity, we expect to make significant investments to build or obtain third-party contract manufacturers with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity due to the growth in our business, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors including nation states, organized crime groups, &#8220;hacktivists" and employees or contractors acting with malicious intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure and believe we have taken appropriate security measures to reduce these risks to our data and information technology systems, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of the products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulations governing the health care industry are subject to change, with possibly retroactive effect, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the hiring freeze implemented by the federal government in 2017, including at the FDA, could impact the review and potential approval of new products, which may adversely affect our business and financial condition;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the European Medicines Agency's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use, or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., there are several proposals under consideration to reform tax law, including proposals that may reduce or eliminate the deferral of U.S.&#160;income tax on our unrepatriated earnings, penalize certain transfer pricing structures and reduce or eliminate certain foreign or domestic tax credits or deductions. Our future reported financial results may be adversely affected by tax law changes which restrict or eliminate certain foreign tax credits or our ability to deduct expenses attributable to foreign earnings, or otherwise affect the treatment of our unrepatriated earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to U.S. tax reform proposals, the adoption of some or all of the recommendations set forth in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities in the countries in which we operate could negatively impact our effective tax rate.&#160;These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates, in particular the recent strength of the U.S. dollar versus foreign currencies, which has adversely impacted our revenues and net income; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.'s decision to voluntarily depart from the E.U., known as Brexit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws and tariffs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the Foreign Corrupt Practices Act prohibits U.S. companies and their representatives from offering, promising, authorizing or making payments to foreign officials for the purpose of obtaining or retaining business abroad. In many countries, the health care professionals we regularly interact with may meet the definition of a foreign government official for purposes of the Foreign Corrupt Practices Act. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product; recalls, seizures or withdrawal of an approved product from the market; disruption in the supply or availability of our products or suspension of export or import privileges; the imposition of civil or criminal sanctions; the prosecution of executives overseeing our international operations; and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Risk Factors&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar and the currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from hedge ineffectiveness or from the termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Samsung Bioepis, and our success in commercializing biosimilars developed by Samsung Bioepis, is subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payers do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective matter are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase stock or that we will repurchase stock at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes stock repurchase programs, including most recently our 2016 Share Repurchase Program. The amount and timing of stock repurchases are subject to capital availability and our determination that stock repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of stock. Our ability to repurchase stock will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in, or the completion or expiration of, our stock repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase stock at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation and distribution of Bioverativ. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we distributed all of the then outstanding shares of Bioverativ common stock to Biogen shareholders in connection with the separation of our hemophilia business. In connection with the distribution, we entered into a separation and distribution agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between us and Bioverativ going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time (including under the manufacturing and supply agreement pursuant to which we will manufacture and supply certain products and materials to Bioverativ).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business as an independent public company is intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service (IRS), or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition, or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ has agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. The separation and distribution agreement provides for indemnification obligations designed to make Bioverativ financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation. It is possible that a court would disregard the allocation agreed to between us and Bioverativ and require us to assume responsibility for obligations allocated to Bioverativ. Third parties could also seek to hold us </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation and distribution agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The separation of Bioverativ continues to involve a number of risks, including, among other things, the indemnification risks described above and the potential that management&#8217;s and our employees&#8217; attention will be significantly diverted by the provision of transitional services. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Bioverativ is unable to satisfy its obligations under these agreements, including its indemnification obligations, we could incur losses. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the separation activities and related events could adversely affect our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not achieve some or all of the anticipated benefits of the separation of Bioverativ, which may adversely affect our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may not be able to achieve the full strategic and financial benefits expected to result from the separation of Bioverativ, or such benefits may be delayed or not occur at all. If we fail to achieve some or all of the expected benefits of the separation, or if such benefits are delayed, our business, financial condition, results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Stolen inventory that is not properly stored or sold through unauthorized channels could adversely impact patient safety, our reputation and our business. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><a name="sA74663ABBB395DEBAE04CEFBEC821383"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;2.&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our common stock repurchase activity under our 2016 Share Repurchase Program during the third quarter of 2017:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:17%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced&#160; Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">July 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">August 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$348.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;remains available to repurchase shares under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, which was completed as of March 31, 2017. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this program. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="sE6316983798E53938D463A2870EB91CF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><a name="s7920C06B88AD552A8585F1DAE3815801"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT&#160;INDEX&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2017930xex311.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2017930xex312.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Principal Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-2017930xex321.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September&#160;30, 2017, formatted in XBRL (Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flows, and (v)&#160;Notes to Condensed Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;+&#160;&#160;&#160;&#160;Filed herewith </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;&#32;++&#160;&#160;&#160;&#160;Furnished herewith</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><a name="s644BD61231225B6ABE32B29F9D576C3E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;" href="#s2C3517FBCF925D24AEFB95C14E3F5835"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;padding-left:492px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:27.34375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Accounting Officer and </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interim Principal Financial Officer (principal financial officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October&#160;24, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2017930xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEEB7C4E5CC3659ED80D44C7447C4625A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October&#160;24, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2017930xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5954C50340625075BA1DE9708AF8EF86"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Gregory F. Covino, certify that:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this quarterly report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: October&#160;24, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Accounting Officer and </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interim Principal Financial Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2017930xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s188436104C855C10ADF045317C589288"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2017 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October&#160;24, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:52%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: October&#160;24, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gregory F. Covino</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Finance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Accounting Officer and </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interim Principal Financial Officer [principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>biib-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:2CB705BBE5E1532FB7B8575DBA7DB584,x:7ec8fb769881470ea44a45b681d30fe8-->
<xbrli:xbrl xmlns:biib="http://www.biogenidec.com/20170930" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20170930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:RemedyPharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ReserveForCashDiscountMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:WorkinprocessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">biib:FinishedGoodsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_StatementGeographicalAxis_country_US_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-F8E1FAA8ECD851A880B9327A46045CB3" unitRef="usd">410000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-D4B24077BA6157AF959AB2716A1F7143" unitRef="usd">490000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalPotentialPaymentstoNoncontrollingInterest contextRef="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-749DBE9B0D841EA2ADF535C782F26747" unitRef="usd">50000000</biib:AdditionalPotentialPaymentstoNoncontrollingInterest>
	<biib:Additionalreductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-5DF1BE553B225E207B524AFBE2A4403A" unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q3YTD" decimals="-5" id="Fact-AC51ACCD0C6E5A0EA2D9349DBBFC0A46" unitRef="usd">-2400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-FCEC7F9967FB53B29AE67B95C0608E82" unitRef="usd">-11200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-ACED85F4C5B05D9FA134B6D89FB33987" unitRef="usd">200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-9A915A41FB515C1181C69DFD27C51D06" unitRef="usd">8600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-84B661164A84519C95E49A18C9DBA749" unitRef="usd">277500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2017Q3" decimals="-5" id="Fact-A2DB2E19CA4C54CDBB572D3D6EB63BB5" unitRef="usd">269300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-9DF235CEBCB35BD3ACE287F813A8D284" unitRef="usd">276800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2017Q3" decimals="-5" id="Fact-C4DF3595EF2353A1A70698F4CF9EAB0D" unitRef="usd">269100000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2016Q4YTD" id="Fact-8BE48080207A5E41AD32C48C9BC67C21">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2017Q3YTD" id="Fact-0029AC437C2B5DFFADC5067A192D62E5">P17M</biib:AverageMaturityOfMarketableSecurities>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="D2017Q4_us-gaap_StatementGeographicalAxis_country_JP_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-004E414AFCFB239F3F0B3ADEA001DE19" unitRef="number">0.20</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="D2017Q4_us-gaap_StatementGeographicalAxis_country_US_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-590C4BABDF86D47C92563AD278DD0AB9" unitRef="number">0.55</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="D2017Q4_us-gaap_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="3" id="Fact-E4DB2BC9337D82DF3A993ADDBB06BE16" unitRef="number">0.685</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="2" id="Fact-45F655F571A857C999FA0DBB6719FDCC" unitRef="number">0.50</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Collaborationexpensesaccrual contextRef="FI2016Q4" decimals="-5" id="Fact-B470E4BB441C55D2BB4FB0844354769F" unitRef="usd">130900000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2017Q3" decimals="-5" id="Fact-A386E781CBBE5390A9B3D0754EB608FC" unitRef="usd">180100000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q3QTD" decimals="-5" id="Fact-E1372920FA6D5478B7D82A2CCF20ECB0" unitRef="usd">4700000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-D99F9D68BEC852648C8789124255AE24" unitRef="usd">7400000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q3YTD" decimals="-5" id="Fact-5DC46C8961E050AD80778FC8B2EBB858" unitRef="usd">-900000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-ACA7F8D48C7F0257953AE73869A9A53E" unitRef="usd">1800000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-D0CEA924181D978184273077F065938E" unitRef="usd">2700000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3QTD" decimals="-5" id="Fact-7DCC0FC286E1542A8F7C96A9DC0563D1" unitRef="usd">35200000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-B8E7DF830B785E36AF18B9DA0F265A8E" unitRef="usd">34500000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-5F3311428EBE997A5424E7343A59E134" unitRef="usd">700000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F70D04F99AA252ED89CCD177F82A5CEF" unitRef="usd">82500000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-B22B5E6AA32059FCA7207819B4331BE1" unitRef="usd">80500000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-58FCCF58693F5CEBB03D2E0F5D6D0AAC" unitRef="usd">2000000</biib:Collaborationprofitlosssharing>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q3YTD" decimals="-5" id="Fact-91A20274D4235E398A65A9AB77C6E2C0" unitRef="usd">2123200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-3D136A3B8BC35D94AC04E89DF240CE29" unitRef="usd">1681200000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-D6940C0BB8925D6C8A51F54CD7C0671E" unitRef="usd">422000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-3D3CBDC3AD265B8A9AD0053DFEA99080" unitRef="usd">20000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DevelopmentalMilestonePayment contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-23984E590B855925B5B225AE96B5DA80" unitRef="usd">60000000</biib:DevelopmentalMilestonePayment>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2016Q4" decimals="-5" id="Fact-262E03D292F15854BDBC3F37D2B89E97" unitRef="usd">300600000</biib:DuefromantiCD20therapeuticprograms>
	<biib:DuefromantiCD20therapeuticprograms contextRef="FI2017Q3" decimals="-5" id="Fact-E77DCD99B5B6508B912ACE71AACC9D94" unitRef="usd">518000000</biib:DuefromantiCD20therapeuticprograms>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q3QTD" decimals="3" id="Fact-79E683637B4750EE937BACA3FB8AB3FF" unitRef="number">-0.018</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q3YTD" decimals="3" id="Fact-C5E1BA7F0C1A5E16AA79EFCE486BACC4" unitRef="number">-0.017</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q3QTD" decimals="3" id="Fact-2D1668C03C0D5529BE20D6E43FDB4BF2" unitRef="number">-0.020</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q3YTD" decimals="3" id="Fact-D2992CB6B3EB5A94A73A085054772F5C" unitRef="number">-0.021</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EquityMethodInvestmentOwnershipPercentageMaximum contextRef="D2012Q1Feb_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-4BE1745623635B498513A7F4BF0DFBFB" unitRef="number">0.499</biib:EquityMethodInvestmentOwnershipPercentageMaximum>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-917304337E3B5726858F6A9400138FCB" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-F9BE22A6F06C59AF8403EB3FFE1F3514">Indefinite until commercialization</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2017Q3YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-03EB99056ED8546B9301216703D3F9F5">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2017Q3YTD" decimals="INF" id="Fact-DB803D92D7F85664AC6FB788ABC8325A" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-BB9FF49C12905D4EA9FE016F48662CAA" unitRef="usd">1039400000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-107C5F9B813D50E49030BA929F1372E9" unitRef="usd">1031200000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2016Q4" decimals="-5" id="Fact-25F443DA104B5512B32E844AF28204EA" unitRef="usd">47400000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2017Q3" decimals="-5" id="Fact-B8EFF6CA3F9359E4A5202EED2BDA1C84" unitRef="usd">49700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:LicenseFee contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-684D254192F75D44A743023D4FA5B80D" unitRef="usd">75000000</biib:LicenseFee>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q3QTD" decimals="-5" id="Fact-4E37654ABC26695608A4302D41821017" unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q3YTD" decimals="-5" id="Fact-5D924EA420E495438205302D67B99609" unitRef="usd">100000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C81C40BFF3928331BF78302CD6BD9BB8" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q3YTD" decimals="-5" id="Fact-625C53D92850B1FE3C54302D14C4E5A2" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q3YTD" decimals="-5" id="Fact-6B58EE8A9C3C5843BC8CA1BCCFDA9657" unitRef="usd">1547300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-AA27AD0A6ED850CDA9A37F5D4274396D" unitRef="usd">1227100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-8649284D6743579183699C5C4B359E12" unitRef="usd">320100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-EB3F07FF74BA5918BFDBD689E31F8803" unitRef="usd">100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q3YTD" decimals="-5" id="Fact-42DB2A7F93D3530986834FCEFB8B1095" unitRef="usd">519200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-A062B31E3D9855E0A84E94A3FD11F2AE" unitRef="usd">431600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-41F6DD3C2A9C5F42B732426F0329C0D5" unitRef="usd">70400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-7E610F92CAFF56F1A7F39062F1448969" unitRef="usd">17200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-55A52D5CD05C5DF3936E59FEE0D84D3C" unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-2AAB08447D6657FF9963F85CF01BE934" unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-82AAB5519A4342E3271D3AE5F4C5C446" unitRef="number">1</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2018Q2_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-DE9912C7D845FB4737F53AE64E1D7146" unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2019Q1_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-FE8F822C9C21A7ECA2213AE800CAF2B4" unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B7AF513A7609529AA40D2BFA62ADF804" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4DE107375C18556C8640D21D9BB2A359" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-71FC1ED8483356B89F14D530BE241959" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-40EC676D8D9A5E5FB244C991730102F7" unitRef="usd">34500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-69BFDE446E0950BE84D80E2BD19EBF79" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7062331FFA0A55CFB1FC5C83141D17A1" unitRef="usd">30100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0A520813B6D758C88921E110138CC778" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-90C4A5FD33D85CC6A7D8822E363E089F" unitRef="usd">30100000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:Reductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-96E8080D990C8EAA5FA04AFAFBDE11D8" unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
	<biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement contextRef="FD2017Q3YTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-D7FBCAACE02F57499B77A379B86DB5D5" unitRef="number">1</biib:ResearchAndDevelopmentCostInSupportOfCollaborationAgreement>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q3QTD" decimals="-5" id="Fact-53ADB697255556CD952DC832C3D3EF1E" unitRef="usd">317600000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q3YTD" decimals="-5" id="Fact-A011DF5676575534BFDFB0CEE6E5CA42" unitRef="usd">996300000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q3QTD" decimals="-5" id="Fact-501236FAC3E654218EE9F8FB9C8F5722" unitRef="usd">406500000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:RevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q3YTD" decimals="-5" id="Fact-6D5E128E0AB55F53BFDF6502745A9FF7" unitRef="usd">1144200000</biib:RevenuesfromantiCD20therapeuticprograms>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q3QTD" decimals="-5" id="Fact-2DCAC920C7C850AA8D7DA88201612A5B" unitRef="usd">50700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q3YTD" decimals="-5" id="Fact-44506BF4E064507390846065E96A5142" unitRef="usd">147700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q3QTD" decimals="-5" id="Fact-CF95E162FC325F128FDB54D903CEF057" unitRef="usd">40600000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q3YTD" decimals="-5" id="Fact-DF3C205A689751F7842080D7AB77BBAD" unitRef="usd">120000000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:StrategicInvestmentPortfolio contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-0E5ECC0324DF5646827219909AB6D153" unitRef="usd">99900000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-4990CD302EF25B949A531B4F85E2AA8C" unitRef="usd">84900000</biib:StrategicInvestmentPortfolio>
	<biib:TermofBioverativManufacturingandSupplyAgreement contextRef="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-BD90DF33EFD5542B9EBEB104EF27EEDF">P5Y0M</biib:TermofBioverativManufacturingandSupplyAgreement>
	<biib:TermofBioverativTransactionServicesAgreement contextRef="FD2017Q1QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" id="Fact-D357E23A52D25672B573A7496769F629">P12M</biib:TermofBioverativTransactionServicesAgreement>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-8243B800A34C52F29279D70666FF7BF4" unitRef="usd">49800000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax contextRef="FI2017Q3" decimals="-5" id="Fact-62D9E0AC7F625C20BE63C4A52A28ADD4" unitRef="usd">-113000000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
	<dei:AmendmentFlag contextRef="FD2017Q3YTD" id="Fact-EFB249E7ED2757D68A49F4C58BC786F6">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q3YTD" id="Fact-F1864E27A6445FFFB8CC74ACDD0775D1">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q3YTD" id="Fact-A73ACA9CBEDD526ABEF87F2B640866D8">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q3YTD" id="Fact-92F13C395E5D5CCD8FD30F96E3D41582">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q3YTD" id="Fact-BB29007C412257D1B898BBC4BDFE4336">2017-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q3YTD" id="Fact-6CA9BC1939DC5C17AF42AF019F1B7039">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q3YTD" id="Fact-9E3736B8273A5BA68A79D9295647BB88">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q3" decimals="0" id="Fact-672211F4590C5295AA52F9FBC0683853" unitRef="shares">211476936</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q3YTD" id="Fact-7C1ECDFAEFFE5365A0556334C60998D3">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q3YTD" id="Fact-EBB2B2253DAA5C14B4E7E06F0C46A964">BIOGEN INC.</dei:EntityRegistrantName>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FE0A1C17DCAA5C049154D61601CF1B54" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-870DF7E001DC5993B3E19B6025DA1467" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8BDAD8A6632A5351AF50AA21573D3DFB" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-BF002F07384D59CDB70E0636892D7CD5" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-987AD28A3FDC5012A31E252E592B9CE5" unitRef="usd">871700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2016Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-22FC0A6AFBF6554AB45376394AF20843" unitRef="usd">902100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_CurrencyAxis_currency_CAD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C614B50C8A0F5BE9AAD45B9119D0D81B" unitRef="usd">19700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_CurrencyAxis_currency_CHF_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-58F151F9CB4D5590B1137EFE7364BEC3" unitRef="usd">5100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_CurrencyAxis_currency_EUR_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8E822C3B3651530E95D8EC4AB430A9CC" unitRef="usd">1573400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_CurrencyAxis_currency_GBP_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DE68F40A9B79542AB4673811188787EC" unitRef="usd">39700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-170288291E7D51E98F7C57C501F093F3" unitRef="usd">1637900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-719CD70E77FC56EFB8980C4ECFBFF178" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q3_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-EC68015B068A5A06B8C2BD68E5C39DCA" unitRef="usd">366200000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-C86352C3FF295566A528D53E61EBCCB6" unitRef="usd">279800000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-6F5F7D8479C4594EB9A5CE8BE61C88F7" unitRef="usd">298700000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-DC74618CA7355CA289828619DE02BA6A" unitRef="usd">1441600000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-EB5992B96FEF5FCFAEF628A1D85FC3A6" unitRef="usd">1567500000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-4DA8C0E6D5C85405A13F5DED61BB119D" unitRef="usd">195800000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-CC5D943F63795B94AAAA5E02A2506DB5" unitRef="usd">190800000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-5" id="Fact-3D694FE965F453F8B757932A7F713FFE" unitRef="usd">1439300000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q3" decimals="-5" id="Fact-C9CAD9F7BA2C59949A6D03EE1D2B5528" unitRef="usd">1580600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-05AC0F05A75150FCADA4700AA283FB22" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C9176F8E333855979DD731220A2A843A" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-C0E7A3359F96573594D6FF80A69B84E7" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-63BDF1ECA22A544EAD3DE04E4A5B5ECB" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8A9AC0D1D98757B4AD49665E1AC57B89" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3" decimals="-5" id="Fact-91E320B86CC65CD7BF919D7464AE53EF" unitRef="usd">-300900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-259BA6B6634D5E5BB03CEB3862755255" unitRef="usd">-36500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-947E06DE17CD51098C0E0084C2466E6A" unitRef="usd">-6800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D071C55DBE95541083D37C5F017FD807" unitRef="usd">800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-81020194F62A5974B1694C1C9B2EA90A" unitRef="usd">-258400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-D5F1AEE4D4E65F35AE046C8167B394F6" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-4989E56DD0915B0FA50EAAA651B6A0FA" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E0643D7F2098509D907D59D9E45C76DF" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-2CE212ADC7ED5C38AB8B0C7BDC0435EE" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-AAA2C098C0B55821B7514D50E2C09874" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q3" decimals="-5" id="Fact-F416EB8519115D0CA0582A3414F419C5" unitRef="usd">-329400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-C1D35E61923A5B51A228A6F1726964FF" unitRef="usd">-33200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-E7D4EDF6354B55E992083DE920B33693" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5CF40B7315965597AEDBAA384E4B30BA" unitRef="usd">-4200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-203DA30C86A456FA8B4D55F365735473" unitRef="usd">-187500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-5" id="Fact-6D7D7C829A8653E1ADCFB73F0D901DBA" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q3" decimals="-5" id="Fact-7A2B6108656E53A69CC44ED9CFDC0A2D" unitRef="usd">59200000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-0A5A3EE1A5585296907EEA4DC4C3CA7C" unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-8B6180BD93F7538AAC192E1B887DAE27" unitRef="usd">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-622D0D6A5F7C5F9F838576CF736C5666" unitRef="usd">5700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-933467CF88805B9F87F8858166CD73A7" unitRef="usd">28500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-F611E17B5F67502E82A30FADFABD70C7" unitRef="usd">9100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-6ED6F02C60145B7B8692256927F75008" unitRef="usd">36100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-2F8B0F8B5FD955378862EA6947A4EDFD" unitRef="usd">22700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-E7D40E89DB6C579088AE6FFC8AF9BC4A" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-EF6E4A6DE28F52F38436368EB8BE0B94" unitRef="usd">31200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-283BF26EC5795BA29383C53FB9F0A19B" unitRef="usd">12700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-43DB160917555283AE3F7120E6321BA2" unitRef="usd">8900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-D51DE246ECE355F2871A4C73C0A93B21" unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-0AED4CD7973F5F4B9ACBD65EB9A76B3F" unitRef="usd">92500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-83DFB4F8287C5EA7B25605BC3F728D66" unitRef="usd">17300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-BFB638F92D8B56E5B69D0180116B9EDE" unitRef="usd">105200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-5EE95EBAD7595542B0F6A0F4E7328AEB" unitRef="usd">65600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-7BA1E53574E05AA09C5BE4F8A438581C" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-836A902D68E453CAA5BF24C60244AEE3" unitRef="usd">94600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-968446ED0CD85816B68B00429CDCA555" unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-2CC1E50EF1365A1ABF06821382639022" unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-1813C42AB86B529EB8EA79A8544AFE64" unitRef="usd">4500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-C216C8E19FB357F1A9B571641407AEF7" unitRef="usd">26700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-9A5C43B0E72559EFBC98697B867080D6" unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-59E2198D487C500B8197F1D8FDB61204" unitRef="usd">29700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-2A2ED69EF8D65585BA35AEA6DD859CE1" unitRef="usd">19500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-08B993495C8756C29264F32DB3116709" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-FFA4840896D559ECAB5A202EC15AEA8E" unitRef="usd">23600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-DED08EE31C90541B860542490DBE14D0" unitRef="usd">13000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-BA21AA685A5350D3B0A86920B9639496" unitRef="usd">7400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-AD1971BE01375DBC8B9AEC43A2280E4B" unitRef="usd">17100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-59D47217DF1C552EBA6549DBB62B53F3" unitRef="usd">81200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-A9EC6A66B6255CD28AEEB5C8120482CF" unitRef="usd">8900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-011B00A3D0E25EB2A36E74AB92152A76" unitRef="usd">88200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-D1CFC315DB575EBABBFFA38AE057B8B2" unitRef="usd">55700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-7CAB2914A0B75F4B9A4019E4B901CF1A" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-152A0691DE9E5F0493FB53F43743C181" unitRef="usd">71900000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-8C27E3DE1BD45AF7863F158BEA6BBD43" unitRef="usd">53900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-14C5286F1D7B53D79AF68BD5FD9AE9C4" unitRef="usd">158400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-DAC3795DED515D62B384408067AFD62F" unitRef="usd">43100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-466075012DA85C6D8F4CAED58BD9FF28" unitRef="usd">127600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q3QTD" decimals="-5" id="Fact-41A38F9497B05499889E3F23D00BC8D6" unitRef="usd">99700000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q3YTD" decimals="-5" id="Fact-E769C91A5084576C84D043DE7A47EA28" unitRef="usd">281400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD" decimals="-5" id="Fact-EEED49B2FD3F5879A2184F6B9C65A8A2" unitRef="usd">108900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-EEC4878597F25ABEBA17ADA26D945AE0" unitRef="usd">30400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1E7D0D97E8E95DE8A8CFF142AA7F47D9" unitRef="usd">674900000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-301BE573673B5BFBAD84390AD92E3860" unitRef="usd">413400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AssetImpairmentCharges contextRef="FD2017Q3YTD" decimals="-6" id="Fact-5F98AACA18B45F03BB2CC1DB8C28C685" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-5" id="Fact-66B346EF202758C59A5F861D536E888E" unitRef="usd">22876800000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q3" decimals="-5" id="Fact-40BAEC6435D1548EA8A07A99B48B8986" unitRef="usd">23073200000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q3_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-6" id="Fact-CE60CE80629FA118C3B034BB08F8AB17" unitRef="usd">200000000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-A5FC49E5E20E5F36AA34625D91778EF9" unitRef="usd">8732200000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-2C8F3AA65BFD5781A0C0EE78D3BBF43C" unitRef="usd">7568000000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4E693001BCC952C28B12648E82224B99" unitRef="usd">24900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3DB6338D1C4E537CB183417C64F5B580" unitRef="usd">7533100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1AE8EF94C34D57159AE216B7CD76055D" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AB0EF3C515585F0186BA0AC976B5F44B" unitRef="usd">7558000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1E7F325A4688511E9A5D40F3DB0D44E1" unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-34278621B7DC50EC8807F1C9BE85DA24" unitRef="usd">6238200000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8B6E842F9E3356389702B36113D46CD3" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E1C103CE49625B419424E7E61556B2F2" unitRef="usd">6250000000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-149D02E1A59059108F27CC218112F24F" unitRef="usd">1008300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-5" id="Fact-7EB98F4AD0A157539D4B2BEC8AAC6278" unitRef="usd">5406300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q3" decimals="-5" id="Fact-2FAC203076B150D8924D2CADE257D5C3" unitRef="usd">5026200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4" decimals="-5" id="Fact-A81AA6A5A7FE518595BC499D79B7430E" unitRef="usd">5398000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B887EC67F1FF58028D430B5DF0452265" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-74C1932DA7615F1D9DA1A72F504441A8" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DFCC7A6C3B40548DA63B18001050712F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DECD50E5089B54E9B48838816E1BC490" unitRef="usd">561700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D16FCAA2A8AA5F13B3B1662336760D20" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8A24DEC28828505BA412B40A41F66E01" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-40B69E30893A526AAA120E50162747A6" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9B9B3F05780351DA9F585C3621027174" unitRef="usd">2663800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B381C97BC41259D993DE32FB2CA20206" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C416F1DF61695EBD8877BD0E8B16179E" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-93FAFC04746D537A88269E1B51522F3F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B574CD7C5CE650459230875830CFF997" unitRef="usd">2172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-3D600CF4CAD45C7A93B5D85A5E321E71" unitRef="usd">1408600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-CFA06A08EAC65C3E8017A4758E18704E" unitRef="usd">1255200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-70F1E6721225539499D0E3ACFA0F2C20" unitRef="usd">1156000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-36AC382E6AE05874A28EE783EB9A8AC5" unitRef="usd">1016500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0E276F649002545892F3748962434AE8" unitRef="usd">4000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-2E3DF40C018E58DF8EA3D93A74B38B04" unitRef="usd">557700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-AFE6F1CB85C6581E82A9F2D963220AA8" unitRef="usd">24900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3" decimals="-5" id="Fact-6978DC1C92665157A46DFDB766D20296" unitRef="usd">5022200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CB00D625B55A5182924B9D06016BB2D2" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CA530E0444F6574DB9A890E8E4C1B7F5" unitRef="usd">567500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-704D3EFC64CF5A9CA57794ACF5414363" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-49423B3F00655DF0A33EDDF85255CAA6" unitRef="usd">567500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-65790F8B5988512BA9922165538FF07B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-76B83AC9DFEC514F9D3B6F7E0EEA8370" unitRef="usd">2584700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3C30978A84045F6A813FCE518EB7B13B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5B6C1332D27354929086DA635A8D46FB" unitRef="usd">2584700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-BEEC4F35ADE252CF9CF425B163F4F495" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5D97D9A229255D15824E9051D7FAA976" unitRef="usd">1870000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F1364A395F3653828806C1C252050CB1" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EBCFA60408ED5AFA889DC728A8369378" unitRef="usd">1870000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-FF8E9A0BDC1B509B9CDABC1ECEF3BBD2" unitRef="usd">1042900000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-16FB7BE5C39E5EB89461F240DD21CB4C" unitRef="usd">1541800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-249ED7EACB8553F8A2C920E38C5657B2" unitRef="usd">916000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-AB4A4A59B91251FA911B36619C04B5A7" unitRef="usd">954000000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-07BF1A841EBE5774964DA839B691F97E" unitRef="usd">1300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-D239DFCC049A5AA996C36F995A04EC27" unitRef="usd">566200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-7097510DE79D5E73A003FA92D504A330" unitRef="usd">11800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-D3CBD0D335C7564999C6CDD11354FF99" unitRef="usd">2900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-4E50EAC3C6E35F279EBB70E41E3DBEE4" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-3EFDA697C8635963861CFBB4DA991337" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-9A35964997CE583D8033547BC3344FD4" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-5774E198C0AF5A49B8A55F5103F314A5" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F103AD616D5F5D2C86407902D3AE1692" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-705FF8817E88547A8AC15CE8C4A1D75D" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-36DDF2DD6E085B1EA5DE152E6B02F421" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3" decimals="-5" id="Fact-AE30666BA402598CAD114C76BE4CE388" unitRef="usd">4100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-17CA454DE26D5BAEBC147EB2A854A291" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-98D4F783A6805E8EB6BDB1334C6CC65F" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-32E8AB21180055C88411A4DEC4E66ED8" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-0D433E4E219759CD805D957D2070E8BB" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-DF3D2C2177405F6480AA93A10C83ECB8" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-A526F32871F7586286DDD91B10A85E10" unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-4BD41D37C6E15CBFA66463C897A81F1F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-5" id="Fact-024AB8909C40529A84BED78CF1CBA93E" unitRef="usd">11200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-21E7C2FDA3085663A1C5EE35698F9591" unitRef="usd">600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-E3B44F9CE62B5BF79BC1126B43058396" unitRef="usd">4700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-D4D14B60C7EF5C0A97BCA5D2D53983F6" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-9CE5996C2BD25424888371175B2F830A" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F4EA36777517529694D90AE21F4A7D8F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-254BAEEB94545DE8824D797895DB4E90" unitRef="usd">2200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-C4A5347FB88657429B589D3E32EFB227" unitRef="usd">9300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3" decimals="-5" id="Fact-4579757A82215B739741148FB6716521" unitRef="usd">8100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-CE8C53077BB95CBD803342E4CA0953DC" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-C3B2535638FF5C7CA4C46D25CCEC8678" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-0F04655B46715589834DD966BB711062" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-6E02861484A55D9AA6308BE9E8899FE9" unitRef="usd">3400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-157D92EDA66D58D994150B4A5B29F27A" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-279010ADFA1658628D19A8E86D84F787" unitRef="usd">1400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-D84A9B94926057F687E25E5684AA17E9" unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-6EB7F815B2065A28AF60DA6C211682C4" unitRef="usd">5406300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-01D14B153347532F8319921250B759D0" unitRef="usd">1409000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-446EF8370A79544EBC9CD6C6008613E7" unitRef="usd">1258700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-65D3C9F1D79F5EE09EF666635F97F8C8" unitRef="usd">1156100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-5D51FAA0F30155B1A931F1808F591C5C" unitRef="usd">1019400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-6BF4D209C2105FC481F1AB3822B57F75" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-55D220EB0BBA54FCA1AB460249960541" unitRef="usd">559100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-05E35D9E5A7F5033B8AF9A0358CB2EC1" unitRef="usd">33500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3" decimals="-5" id="Fact-FC8777AA50375BC9B3A1D47EDDFABD14" unitRef="usd">5026200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-7A2D6F51482B5F8AA63FB994130B28F7" unitRef="usd">1043100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-B3674B85A32255048BDB9AA56997E0AE" unitRef="usd">1541700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-05DF1729B89256399A5468FD47C0DC88" unitRef="usd">916800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-52712C00198953E383385BBCDB54DA4F" unitRef="usd">957000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-0556A7F217B95E19AF8306D827D31FF1" unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-93F3F26CFC7D583A910342C465764686" unitRef="usd">566300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q3_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-ADCF5666EC3E5326844977068FC2982C" unitRef="usd">14400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-B170F7530F4C542DAEEC5DAAF2CE7847" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-6C89198089D05D5097E3D25F6C59DD71" unitRef="usd">1960200000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-ED1CA801EA29595B976EFA87C2921609" unitRef="usd">2559700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2017Q3" decimals="-5" id="Fact-88452EA9D55D5ED9A109FE0F83812BA4" unitRef="usd">2795700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-70D3863725BB5052BACEFA5FF857CEB5" unitRef="usd">2552600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q3" decimals="-5" id="Fact-8C402A47554C5ABEA287CF92B0458780" unitRef="usd">2792900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-5" id="Fact-32A5AA16CDCF52CDA226EF4CE47B5E35" unitRef="usd">2569100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2017Q3" decimals="-5" id="Fact-9376F928AE43503BA16FD51A30C886A5" unitRef="usd">1961200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-F8CB5B3BF9135731BA01F215F480BD53" unitRef="usd">2568600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q3" decimals="-5" id="Fact-39387FC8ABD658F48DBE4B90889ABCBB" unitRef="usd">1960200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q3QTD" decimals="-5" id="Fact-D9A2EF43B3515B65A8D928BEAF22C650" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2215FD285A335650B6647C7E35C54FB6" unitRef="usd">2100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q3QTD" decimals="-5" id="Fact-9995F242A0AD53578EDFB8AB1D4358E8" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1CE88800E1925AFEA5CD139C5D6FAA53" unitRef="usd">2700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q3QTD" decimals="-5" id="Fact-251BAA458A41580CB993AA1C1EDDDBD8" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q3YTD" decimals="-5" id="Fact-8E332785B85C5FDEB69619C6AA25FFB7" unitRef="usd">2700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q3QTD" decimals="-5" id="Fact-42686874B87856468ED78EBD494DF92C" unitRef="usd">1200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q3YTD" decimals="-5" id="Fact-19F59CC816E151BA9AB7D0447CA23659" unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-53B3FC7AC5F45BEBA23FC90230E03655" unitRef="usd">2829400000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-9B66044251E354E9B40F0A85BA50580D" unitRef="usd">3062000000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2015Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-169FCCB30E915AE7AF3DE7192F053736" unitRef="usd">506000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5BE2E7BC4BA057A196F6DEFDA6389D95" unitRef="usd">515700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ED54629BE2DD585DB86A1929C2BEAD30" unitRef="usd">521600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D40E64F726395A049E6CFC1EF7B363AD" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-278BBFDCD40958C6BB6A887B56A7CD1C" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2432B903C74E5BE0A482814011A8B3BD" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F0AF1AD1B3645A118B315F952D0BE635" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CDEF7BE056015534AFFA6F91888E0600" unitRef="usd">492100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4136A8A9BB45561199908CD6DC7A7DA2" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0D50F5E87D845739B9BA89FDF313816E" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EBD0C4D5DFEF5AC1AEED9B31C65AEE0C" unitRef="usd">522100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E77235E03A505737AB4C955F50C38E4E" unitRef="usd">522100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-90C9B345487056EABA4258E0FA2C2DD1" unitRef="usd">580800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-32A0ADD1F8B35D51ACE1DE54FB450CBE" unitRef="usd">611500000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-FE585498024F5653B6C289A8991971DC" unitRef="usd">246800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-D8D9D1FBD7C0587AA3E53E13FCF7B4FB" unitRef="usd">280000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-1673F249A65850328B69B1A897E0BA34" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-5" id="Fact-3B4AF2F720D6532CB758B85D49F37D86" unitRef="usd">2084800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-5621E12E95E859E0A72785356E8B19F6" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-5" id="Fact-69EB588E3640556F9B5B74AAC8D34C5C" unitRef="usd">1548100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7F574409CEFD5D378B8C5CA36538EDF2" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C7F4BC648B5C59559EE9BD5BBADA28AD" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9E2E59F9A84257CCB50261B268170CCC" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-37EA7D3917C85EF5AA97FEA4BEF69FD5" unitRef="usd">2039600000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0A8B6E533CDA569A8395AFCAECA285CD" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-74B87EB13E02548289CBEF14F0B915E4" unitRef="usd">1184300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D5D5BDB4E7725AA6A40E044CB5A520EC" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DF76D58F87585584A9EA32DACB23EE09" unitRef="usd">1184300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-5" id="Fact-0E788733828A5BD58340D0E5F674170B" unitRef="usd">776100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-5" id="Fact-C2BD2943D8C85930B26D3982D1567D42" unitRef="usd">-832800000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-E12A119B25705D83B8A2941B000440D7" unitRef="usd">2039600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-8971C6AD0C685F7EA68A20F7680C518B" unitRef="usd">31000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-8B5BA2DB890059FDA8380EAAC13B3C7C" unitRef="usd">1266900000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-6ACDE1791D555D2CA30991BCF4C904A9" unitRef="usd">741700000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-0CD196AFED8A51DB8B83BB392D7AA4BB" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-5" id="Fact-B1330E4CE1575E26B5B698730A486A0A" unitRef="usd">1184300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-E705EFB12E61598C9C43AAD5CB674A0C" unitRef="usd">126400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-C9777DFFA4CB54739EFEA69F21D095F4" unitRef="usd">144800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-80CC531F7E7456F3B66DCB3505F08ECD" unitRef="usd">871100000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q3_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-9F1A55BAF322574D8B24050582A9BD95" unitRef="usd">42000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-F66F426A4AF0511895C70F4CC9A0D40F" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q3" id="Fact-87A725FD845C5C7F980C8E845E39BFD3" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-763F2C90E0BA5015A346FEF6037DD6BD" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-2AB28252E6FB58C096CB138585DD6B49" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-583BEA6CDB8B5D92A69C98E42271B4B7" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q3" decimals="-5" id="Fact-9D8C7FDF7EC45EB9AD4A9114825CBF13" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-10A179E078FD5F83AB7A95AE5CA5FC23" unitRef="usd">1014800000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-75BF38FB1A835DF9AC8453D174E8311C" unitRef="usd">2976700000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-E1433D8394C35ED18DA85080DFD63B4E" unitRef="usd">1235500000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-E31AA2325FD9528F8388E86B4400E992" unitRef="usd">2827000000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q3QTD" decimals="-5" id="Fact-9A60A66E1F00522EAF2224263D974598" unitRef="usd">2600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q3YTD" decimals="-5" id="Fact-51688292A58451558E1F35E3803E7363" unitRef="usd">5700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q3QTD" decimals="-5" id="Fact-96382227EAA15AB7921263EF8326B260" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-5" id="Fact-535DD49F0AF157D48ACCF40C04A9AAA0" unitRef="usd">100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q3QTD" decimals="-5" id="Fact-3B86673EF7BA5BC786F7FE4EFC5B4349" unitRef="usd">1012200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q3YTD" decimals="-5" id="Fact-063AF46DC8DD53C184C57159EA2A33DF" unitRef="usd">2971000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q3QTD" decimals="-5" id="Fact-DBEDF53AC916526CA3FA26CEED02B67C" unitRef="usd">1235500000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B9825C90B20854B1AE3C28BB01B40BB7" unitRef="usd">2826900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-984F870A5EA553B98EEAF5F56579AD35" unitRef="usd">481500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-1E92865A89EF5376A6584CAA6EE5F26E" unitRef="usd">968800000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-20492EE18C1E515FBA02A684BA8FA8CD" unitRef="usd">134000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-0D8C92B5BA8552A3BDE0C54CAD99C754" unitRef="usd">157600000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q3QTD" decimals="-5" id="Fact-734CE118953E53D5A08EAACC5AE3F575" unitRef="usd">416900000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2C2E7BAD151A5EFC9649AD2A7F0422A1" unitRef="usd">1100200000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C17BAC369FAD5599A7CC2141ACA54D64" unitRef="usd">370000000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-1D6FEE6EE80F5ED69978DF662D35EE1C" unitRef="usd">4500000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q3YTD" decimals="-5" id="Fact-0BF7C55CAE6550E595F554BD893D89F6" unitRef="usd">1120800000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostOfGoodsSold contextRef="FD2017Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-BDF638FF36F55AE0B2B5F14C6D67EE15" unitRef="usd">11100000</us-gaap:CostOfGoodsSold>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3QTD" decimals="-5" id="Fact-5CCF3A5D370357C8A94D6C5DB1BF16B7" unitRef="usd">1530500000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q3YTD" decimals="-5" id="Fact-BEFC2C749E49552E9F9C450129FE3DCE" unitRef="usd">4312600000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q3QTD" decimals="-5" id="Fact-19652D884CCF556F94DECDD0C0C0FAFB" unitRef="usd">1424300000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q3YTD" decimals="-5" id="Fact-D72E453BFD755733AC5FA97D9B5DE37B" unitRef="usd">5088500000</us-gaap:CostsAndExpenses>
	<us-gaap:DebtCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-B8CF6CD42F07587E9EAC2D6BAA1D34CA" unitRef="usd">4700000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-E1DDB39F417B5029A8C7FCAA6A8F0C90" unitRef="usd">573200000</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2016Q4" decimals="-5" id="Fact-EFA8A292ED1B57FA9991808042B8A637" unitRef="usd">6808400000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q3" decimals="-5" id="Fact-5D1B1010BC9E5F9C89841CEF24F7F954" unitRef="usd">7048300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-66831BA4CBB852769B10BB196B4B33AF" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-E76D8B94BF8A582291FB5C65CD65873A" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-A11647F73AB654699BE7E51A01D3E085" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-5E1FCA9282D45A6BB1D0E9734ADA9CA8" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-3FEAB368C2A655B7BA8FD40210663AC6" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-5" id="Fact-B6EA795DA13256909E8E27EBE3B72531" unitRef="usd">-56800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-5" id="Fact-EA28CF591055500A960E39F4CC9B1ECC" unitRef="usd">-39700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-A605B5E8EE06544E9ECCC2CEB76C3FD0" unitRef="usd">93100000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-7FEB996F0E8C549FB4CC5C0345C5B057" unitRef="usd">120700000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3YTD" decimals="-5" id="Fact-C015BEDA812E5E8083CF02CB62F09649" unitRef="usd">505300000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3YTD" decimals="-5" id="Fact-8B834B2D8F5057ABA6371F5DCFC04497" unitRef="usd">992000000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-E1C36DA118F752BAA402F28EA9B59520" unitRef="usd">50400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-C11BB5A9731D54A7AAE9C9B3745ED909" unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-F1FE9F8A73F7539FB6A0280D6C2BF652" unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9B31CEC8CCC75E749F102AD63041325F" unitRef="usd">1300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-C14E4763F60633A1E53F3020852371DE" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9271C44AD10454C4A8D2D321D09FD8AC" unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-CD13DDA798A052CBBE3F36D0759FD0EA" unitRef="usd">4600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5BC419A24DCE5615B2B8761B979984E5" unitRef="usd">80800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-245CF100ADB15CD789B671F28BC77448" unitRef="usd">1200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-1F822F889B705DAA910881C83E9C1820" unitRef="usd">24200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-0E73EB821515546AA343014EF973AA8E" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-A5C8B676BAF55946B8B135BA490C043E" unitRef="usd">-5200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-70AF75FE85915E05AB7812E7B40A1E00" unitRef="usd">-400000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-170E25C513D55F06A9A7104B5138DB7F" unitRef="usd">-700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-0AD4642DD5F25025A56BEBDA58FEE235" unitRef="usd">500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-8C52D70161F05815AF0410DEA0FAE2DA" unitRef="usd">-18800000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-01B5C92FFA245C9C9CFAE14636A791AF" unitRef="usd">700000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-4FD77593E26E5916937CAB2F1E2A2CC4" unitRef="usd">-15100000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-CD4950EBF3715AD39F55A6A3DF7B915F" unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-76EF635AFE9E5A2AB89AAFB2F13B265E" unitRef="usd">-600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-E50FDF31664C5E6296B0FB1B3D995384" unitRef="usd">-300000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-E426D58F09EB563E888E02ACD185CB66" unitRef="usd">3400000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-2FE79DC2FAF35216B64D82C5AEAE8626" unitRef="usd">200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q3QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-D97D81B934935AF7B1B0AAF145105C77" unitRef="usd">700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-86C4A1206D59530DBEAA88CBB088EB78" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q3YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-9DA7293258CE531D8EBD4B6F0AE582F2" unitRef="usd">6700000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-C99E36B84F3F576F800BB07AD6CFD76F">P18M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-2B8A7AEDB363592F90F8AFBF2CAFABA9">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-1827C3D93E95519682B7988F46002D71">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-C2088E59F2765535840BF990F028B368">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DirectOperatingCostRoyaltyExpense contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-A3676E57EEC508ED88B7307CC704A617" unitRef="usd">34000000</us-gaap:DirectOperatingCostRoyaltyExpense>
	<us-gaap:DirectOperatingCostRoyaltyExpense contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-DF80B16E1274422971D8307D2398364F" unitRef="usd">64900000</us-gaap:DirectOperatingCostRoyaltyExpense>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-1D43F67B604254D4AA6609E94276C18A" unitRef="usd">144700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-3854FA9B3EB5576F95FA9D337A2BD164" unitRef="usd">87800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-97EC66B97CCA5362A4BB9EF33CDB5606" unitRef="usd">302700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-BC8AC52A422457138747E333F61A021B" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-8E92EBC187F7518DA1B355D3CADE006E" unitRef="usd">56800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-FDA2A61CFE005A75966B3739D919DC7B" unitRef="usd">116100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_FinishedGoodsMember" decimals="-5" id="Fact-AAFCE4BADCAF5D97B6992837C8D33FF2" unitRef="usd">31600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember_us-gaap_PublicUtilitiesInventoryAxis_biib_WorkinprocessMember" decimals="-5" id="Fact-FF6A5DC4615B5B29B400FA89394FB2E3" unitRef="usd">84500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-6F29F53229AE5B2D8C892157552581B4" unitRef="usd">53700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-C6A6033D1C6E5920896EEA43D527EB8E" unitRef="usd">67700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-BF3315EFBD7E59DCA5C990692DE8B549" unitRef="usd">20200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-7B5E431883DF502988D099EA6E5E5125" unitRef="usdPerShare">4.72</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3YTD" decimals="2" id="Fact-B806CF16933158939B37CDF6C778680E" unitRef="usdPerShare">13.95</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-A15A5C81D2385F39AFFF8353BB32E7B8" unitRef="usdPerShare">5.80</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3YTD" decimals="2" id="Fact-5D5A00B205E9512E8712D20F6076F432" unitRef="usdPerShare">13.32</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-184E550021965BD08486454379EB867D" unitRef="usdPerShare">4.71</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3YTD" decimals="2" id="Fact-EFF2FE4647F0568F889557B12B727BC3" unitRef="usdPerShare">13.92</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-E963050E29CE547B8D8D77A1AF30AAFF" unitRef="usdPerShare">5.79</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-EE773E82914A506B906C8DE8EBF17156" unitRef="usdPerShare">13.30</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q3YTD" decimals="-5" id="Fact-389085D8AC3E5F3786F455EFA995B055" unitRef="usd">700000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q3YTD" decimals="-5" id="Fact-08A07A54B55355F9A035B61C14A0BAFC" unitRef="usd">54400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q3QTD" decimals="3" id="Fact-CB0F57B256945C58892FAE157A443C3F" unitRef="number">0.247</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q3YTD" decimals="3" id="Fact-45C9F6A5A58F56CEB943F3B0C9D5BC1C" unitRef="number">0.256</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3QTD" decimals="3" id="Fact-969E5A1F55DA5D05B33AE76817FCDB66" unitRef="number">0.238</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q3YTD" decimals="3" id="Fact-01205158DE2454D9982B67E270760464" unitRef="number">0.239</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q3QTD" decimals="INF" id="Fact-9B5F3F973BA157498CA0C6613B621D27" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q3YTD" decimals="3" id="Fact-DD85CE0733F25179A26304A32E34C345" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q3QTD" decimals="INF" id="Fact-D45B6273FEB25D55973B46869C4C5232" unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q3YTD" decimals="3" id="Fact-153313ADE13458FB9AB37AF46ABBC32F" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q3QTD" decimals="3" id="Fact-03A7FD63567A5A958FD9C97C77215C5B" unitRef="number">-0.101</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q3YTD" decimals="3" id="Fact-49D2E51F839A5EB98BFEAD6C7992F93E" unitRef="number">-0.094</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q3QTD" decimals="3" id="Fact-D5F5D9216CEE54E3BEF54A7A9F304B81" unitRef="number">-0.114</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q3YTD" decimals="3" id="Fact-1FDDE8921A4F5560B4C03D7F37B8D0FE" unitRef="number">-0.114</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q3QTD" decimals="3" id="Fact-460E0C835441561BA8768D911543B318" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q3YTD" decimals="3" id="Fact-172B6C0B7D4E53D588D4DEE0A2B54C05" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q3QTD" decimals="3" id="Fact-BE77B3EEDA245C75A30F66F22CF8E27F" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q3YTD" decimals="3" id="Fact-38E313ABA13C5AFD8AEFC75BDD3AB2D8" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q3QTD" decimals="3" id="Fact-F1490800529556289569A8FF5DBE7EF6" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q3YTD" decimals="3" id="Fact-15B4517128DB5CAAB9CA7A69A06AB248" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q3QTD" decimals="3" id="Fact-C7ECC409DF0C5394B13AA83630FB4B94" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q3YTD" decimals="3" id="Fact-FBDD375311665B9489A6186D3F980004" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q3QTD" decimals="3" id="Fact-66F86B5B11465E2EBC0B71FDC0D2F873" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q3YTD" decimals="3" id="Fact-FE2A3BA340D95BA5ADD83B9CE5BE25D3" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q3QTD" decimals="3" id="Fact-8ACC0780545D50DE9AB5E645C729FDCA" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q3YTD" decimals="3" id="Fact-5D7D51677DC0586DA1C6538D05AFDA5C" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q3QTD" decimals="3" id="Fact-10CB875246DF5356B0824464447944E9" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q3YTD" decimals="3" id="Fact-B8F439CF1AF35262BDCF5F2268227CC3" unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q3QTD" decimals="3" id="Fact-E7B5FB34E1BE513C801FFC0EBD551B88" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q3YTD" decimals="3" id="Fact-4D37E3C348315F88B662367347E4655D" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q3QTD" decimals="3" id="Fact-4101DA83CB3C5B13BA2DE25E2254CDB3" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q3YTD" decimals="3" id="Fact-710707C45A235F8C965A6A39981E0789" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q3QTD" decimals="3" id="Fact-DE88356E63135A68B6EB517CAC12823F" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q3YTD" decimals="3" id="Fact-79FFD4A259FA5AD4940E2D8FB6A29146" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-9728EA3A1C7E5DB7BF73E49C858EFA9D" unitRef="usd">282900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-352FE04C4D77561C945D1B4FAE032A5B" unitRef="usd">241900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q3QTD" decimals="-5" id="Fact-CF07771C66D0547A9FAFACF7A4FBAC59" unitRef="usd">3200000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2217B65512245A15AD791B7C0E0DC65B" unitRef="usd">10700000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q3QTD" decimals="-5" id="Fact-6A68023D4AE95A8492475D881E4AC475" unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q3YTD" decimals="-5" id="Fact-732AD3D93C995996BA0CAE81831D5CD8" unitRef="usd">7600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-F12901FA5A0F5BC0B0ED152205C72F35" unitRef="usd">14600000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-5D896C719BF7552DACA94F67753024D3" unitRef="usd">42500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C1655AD901E55770AF34C84B73E8E3F5" unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-2FB52149D94656D8AA66F58B1A014E1B" unitRef="usd">31800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2017Q3_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-66030B7D25015AE09EC53CBCFB1E3AD5" unitRef="number">0.054</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q3QTD" decimals="-5" id="Fact-F3D781D07FA2578389E27863626B8B94" unitRef="usd">-5900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q3YTD" decimals="-5" id="Fact-9655429A3ED952B58692AB6432CDE65C" unitRef="usd">-18800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q3QTD" decimals="-5" id="Fact-B3EC641B3A395D3ABB27354BC988528A" unitRef="usd">-30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F8D4D820E29C5D2C9D11AF8168D585F6" unitRef="usd">-61200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q3QTD" decimals="-5" id="Fact-F315AD12800959A6993D1B763E40F99D" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2016Q3YTD" decimals="-5" id="Fact-5479FE7FF8DD5CFE851E36D624C07569" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2017Q3QTD" decimals="-5" id="Fact-64E52B669A5D5861B31D1D3D23348CAD" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2017Q3YTD" decimals="-5" id="Fact-634F963FE5785F358ABCC3CC4C4655AA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q3QTD" decimals="-5" id="Fact-3104521DC8CC5745A5F035EECFDEF3EC" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2016Q3YTD" decimals="-5" id="Fact-1D07DA0941BE5F7A80CA6F58AD4A1AC0" unitRef="usd">3200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q3QTD" decimals="-5" id="Fact-6798A870F8C358DE83008ED401931924" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1ECEFF0DDDF05F35BEEA76E0AA31EDA2" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementsChangesInValuationTechniques contextRef="FD2017Q3YTD" id="Fact-0A9B13DBFF2F5751ACBFA79B798AB388">0</us-gaap:FairValueMeasurementsChangesInValuationTechniques>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-7BA828A6E68455FA86E51E21FD968642">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-3D11FBA61FEF51AD945B63F1457E75F3">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-F0815A58452454A1BDEEF6892552A746">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-3300B11D00A256E0BBA2FEA9C118933C">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-2DF6C6099611530E920844D5E3A22115">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-9975F0183F615E419AA4C9853D5F99E3">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4" decimals="-5" id="Fact-3DE0FD0C274955BDA62D4BC2478BDB69" unitRef="usd">3934000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-89DEACFDC4DE50869B09C58A510910B6" unitRef="usd">776100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-B6396012942F5AA6B9C91A08E0BE1846" unitRef="usd">523600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-305B18D90D135FD68CB6BAD5030F0016" unitRef="usd">2634300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-06336F9599365E52838FE526FD25B55E" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-754D6A80F0735E42A9846349A164526D" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3" decimals="-5" id="Fact-2C53CDD52D7754C7AB861FD0093CAEB4" unitRef="usd">4276400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-45C3D94431AA586F8DB9516B64B9287A" unitRef="usd">1067900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D73F342D6B9F5710BA3559A77A7BCCF3" unitRef="usd">532700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-75D3030EBFD2564AA31135BBE58C417A" unitRef="usd">2675800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-3B9C11A226025A2EA500B298841242AB" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-A7E6140880EF52ED8406FB0907F1D365" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2017Q3" decimals="-5" id="Fact-F38E971842EA58D1AEF360299DA13C16" unitRef="usd">421300000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2017Q3" decimals="-5" id="Fact-9C654C2DFAD15E19A0073A589ECE2990" unitRef="usd">106800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2017Q3" decimals="-5" id="Fact-8254AEBEA6685365B14F081425833BC1" unitRef="usd">244700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2017Q3" decimals="-5" id="Fact-CB4277CF77535B36B8ACA876209ABFEE" unitRef="usd">256600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2017Q3" decimals="-5" id="Fact-46BE99B95B2A5748877E9CB9E8FB0B95" unitRef="usd">389600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2017Q3" decimals="-5" id="Fact-6859EE3AED5C57D8B0D2615F7E6C14EB" unitRef="usd">404000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-FF60D10E9EBB5E1EB6530DA6BF8DB262" unitRef="usd">3481700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-2538FAC127B851ADAE35D5D2C12A027B" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-02A122A69BFD5E2E8B50D81102CF8567" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-91CF00A669D3536580A0B42343DF5BEE" unitRef="usd">4002600000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-D7A8D8F65613504FB0BD7E598A5F008B" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-788CDE6381485B4E83E1A2617026129A" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-D9ED30439AE25EDE8CC11C1E04851B6A" unitRef="usd">2705600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-CD346B1D2BD954A98AADD3515A1A4ECA" unitRef="usd">19700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2016Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-56871C87EEBA510780645BF4369999EB" unitRef="usd">371000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q3_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-709421B96CF652D783F821C3F56F4F0B" unitRef="usd">2293900000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-044EDF5943895E6F86B5E74AD222DC14" unitRef="usd">2934700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-C4DBAD698F2C5969B9B1EE8A7BE2D61B" unitRef="usd">10600000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8A9ABBDA7EB35D32A1ACF822006CB22F" unitRef="usd">329500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_ProductOrServiceAxis_biib_AVONEXMember" decimals="-5" id="Fact-4008B475324E50028941E2284F0AB0B8" unitRef="usd">322500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q1QTD_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-924958BEBCE8595FBC24635A1D997339" unitRef="usd">795200000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q2QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-2C13BE380F8C515E9C82593252753B80" unitRef="usd">50000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-95C25DAA8E0780790F01300FDDAE5538" unitRef="usd">25000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q3QTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-54E80ED63820C3B208ED300F5614B538" unitRef="usd">40000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-67DD6B0EB83E581CA7C2A79AD1EBA1F1" unitRef="usd">150000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B3EC0575499450FAAD772CD59742E8EA" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5D7BFF6DA68753459D495457FFDE3FCC" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3D9E751BB8B95AB682B340BAEA94341C" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FEB1F57F58D158159310C537A81D0E48" unitRef="usd">61000000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8165954E3A2255A99429293F6C861569" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-481F0F92045C5093A0A9F488A0D01CDB" unitRef="usd">1600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B5A82FC1CAB75F8581B4E4A489135757" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A73DEF1C3E2E58EFB14FCFFF15C73A11" unitRef="usd">1600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2F2C5458F2905DC495BBB1BDE2DA095D" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-313D4EF5E22E5E0CBB4285FD16D88FA9" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8A15B69B2AFD5530B5A56F9A21349E4F" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-434790DC700557CCA0C4F6454880C76C" unitRef="usd">13600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D0FF62D14F0850DFA41C0C8CD403D91F" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8D09595B219F5EF8A03D5D187798EE87" unitRef="usd">106200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FDF784251F9A50B692AE497544431FB5" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-432B5C2F56C75170A9C9616488F18232" unitRef="usd">106200000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-A931D4D4E05654428D9148BF194512CA" unitRef="usd">-4900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-AB767751F9BB5AC8910A2655810A7ED4" unitRef="usd">-2600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-852557FB7E4256C990DE45B1CBBA3671" unitRef="usd">6700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-5B9100CD7F2352829A4C44CC9F073816" unitRef="usd">8400000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q3QTD" decimals="-5" id="Fact-256CC354968B5F5790A3523F0DF778DE" unitRef="usd">-400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q3YTD" decimals="-5" id="Fact-FB7871094041557092288225A9E66630" unitRef="usd">-16600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q3QTD" decimals="-5" id="Fact-7B0AB2B01CA05216901F6D3727020EF7" unitRef="usd">1200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q3YTD" decimals="-5" id="Fact-0F5B644A3ECA506EB9BA73BD580A2619" unitRef="usd">5700000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q3QTD" decimals="-5" id="Fact-B6BA59EDA01954D3897C2CA9303D01AB" unitRef="usd">800000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q3YTD" decimals="-5" id="Fact-D8F0661E2F7259159E229CC02BB260BA" unitRef="usd">-300000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q3QTD" decimals="-5" id="Fact-775F75DDF4F856B386C6CA8824CE0FB6" unitRef="usd">-4000000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q3YTD" decimals="-5" id="Fact-14FAF2CA326553F990EB32775D74C670" unitRef="usd">-15000000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-5" id="Fact-C5B01C62FFE85BD4A6C67830524DB08F" unitRef="usd">3669300000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q3" decimals="-5" id="Fact-CE717BC94BED507993C9F951A28BCE03" unitRef="usd">4127500000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q3YTD" decimals="-5" id="Fact-FAB270F5751056669CCA3EF688D607AE" unitRef="usd">762400000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-D0F89C02F0C65F988CF1A19E11390277" unitRef="usd">900000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2017Q3" decimals="-6" id="Fact-BCAFE768698C52BA80F214B3CCAF330A" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-5" id="Fact-3D4CDA09EC4F5CCBAA3B15B8864284DF" unitRef="usd">9900000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q3QTD" decimals="-5" id="Fact-71140ADFA62B54C1AC32C163FB71689C" unitRef="usd">1367200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q3YTD" decimals="-5" id="Fact-7E08A84E6FE258229E2F180F1B23EE5E" unitRef="usd">4094800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q3QTD" decimals="-5" id="Fact-D24563FC1DF55D90A2AC6912C0158FD4" unitRef="usd">1609900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q3YTD" decimals="-5" id="Fact-0DC5B143F1F3584BAD5D3796E4E54DB9" unitRef="usd">3729000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q3QTD" decimals="-5" id="Fact-6A979C985CEC5583A3FBAC36EAF55A1F" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q3YTD" decimals="-5" id="Fact-3ECD9B686B71595CA2E4895F827CAFC3" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q3QTD" decimals="-5" id="Fact-701CBFA6B4B3524A8A18D023E1829217" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q3YTD" decimals="-5" id="Fact-22A41FA6AC6954FF96844D31AB1256B6" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2017Q3_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-E2594B9D37E25A6E9735FB9803F22350" unitRef="usd">60000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD" decimals="-5" id="Fact-C9CF1DADCEA15FA18B3F5B696D09CF8E" unitRef="usd">337000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-0486C8936C2657A79CFF3DE05B7E1D4C" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-6DF4280943BA519E94073C86134DBCA9" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2025F71180685F458A2EDD0EB80E4216" unitRef="usd">1047000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-73629C3DEB7151B5886625E380DC2AD1" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-524EB1D259DD527E8F59E91B08E4561D" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD" decimals="-5" id="Fact-49213441ACC954B09AD4B7E4FE27B69C" unitRef="usd">383800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5569CBC76E015759930D0CF22300D7C8" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-721B6EA3816257ECB9C38B049246A7BA" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD" decimals="-5" id="Fact-E286584033F85BCCA12132BAA4EF49E6" unitRef="usd">892600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember_us-gaap_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-9C37D570EF575421ABACF6420C4845A8" unitRef="usd">137600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-1A8E98E23ABA5812A6A5B86B026BC4FF" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-F152A5A038F752558E64B7B87C40B10A" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q3YTD" decimals="-5" id="Fact-E7C42D434FF05A7D96660125D02B4F72" unitRef="usd">238100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q3YTD" decimals="-5" id="Fact-2F0B9527A2FC53CB93E0CFDC9B2768BB" unitRef="usd">225800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q3YTD" decimals="-5" id="Fact-11F792DE8F2A55FF897679A96F83B8B7" unitRef="usd">-147400000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q3YTD" decimals="-5" id="Fact-35092460A1FF5897A1E9836149B2710B" unitRef="usd">170500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-15B32993FB7D5683B09B2399E178023A" unitRef="usd">-175500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-EAFB3971078A54E1AE40AD5AA7381DA1" unitRef="usd">-504500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6430900E3D3552B9AAEE3BC1358D5EDE" unitRef="usd">155100000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F5043B2FB6CD5FEA87E77AA9CAE128A4" unitRef="usd">170300000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q3YTD" decimals="-5" id="Fact-5C6D066C5B7650BEA77B86324DB99537" unitRef="usd">-62000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2017Q3YTD" decimals="-5" id="Fact-C9F15B3402945AC396C531D6BF9D79FB" unitRef="usd">250200000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-7543CB65D12857A9ABDADF2EE3729632" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-B96B81CA9C435C189E585B3E75DB1D0D" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-28D0B511BFB255A4BF89CA64D148548A" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-1606233452B65D38B607785AAC90EB40" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-851E021EBE265F4EA8CAA33BA5E5B561" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2800AAA00E925420A28AEC1FEE45EA8C" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-84AF82370F085DEFB324567F083B16A0" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-836B4B36F2FA5098A680033B3C090511" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-703ADBEEA6405ED79562BF418B372849" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-410DC25B2828554D9E3463F253DD2DF8" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-403DD524CE8051D68406142745285F87" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-BA9D33F78C0A5DAA90BB5CEECD591398" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-41AC363D381A51DCB41D86C5E31ACFD6" unitRef="usd">648000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2016Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-102B29A03BFF50ECB9926D2F633374E5" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-4E0379E69A6F580B8F702F407EA7F293" unitRef="usd">680600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q3_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-B106B9A539495C068F0004E01064A7D3" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-A5E6FBE274FD5F7FB0C6ECFA9612A629" unitRef="usd">7742300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2017Q3" decimals="-5" id="Fact-2FA38D910FA65FE79F495CDBB822E869" unitRef="usd">8295800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-5" id="Fact-C67ED1C2AAC9598DBBB6F680D79C34B1" unitRef="usd">3808300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q3" decimals="-5" id="Fact-F86979EBFCC9527F9D38F3BF5AD6D531" unitRef="usd">4019400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-8BBF31E09EDB5976ABE8C6832AA0F076" unitRef="usd">66000000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-166E161C3B52594A94C7B7925F80D91D" unitRef="usd">195200000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-E001489941CE501FAEC38CB8F6347419" unitRef="usd">61800000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-E8145D7FA50C52DB85A53A18B3CC0B8B" unitRef="usd">188800000</us-gaap:InterestExpense>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-B223F48FBF8B55D599E0EA4C717CD178" unitRef="usd">170300000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q3" decimals="-5" id="Fact-4993EA79162951BDB4CC928877623278" unitRef="usd">175500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-5" id="Fact-84C735C9C1D9531CB3572EA4019500EF" unitRef="usd">1001600000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q3" decimals="-5" id="Fact-AA983BE352875E77A0E89894EC617289" unitRef="usd">1007200000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-F46010BEE99352D3A6C8D7CF89E49E0D" unitRef="usd">37800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-2CE656FBFDC651C98B481508F61FD8B2" unitRef="usd">24000000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-E49CF006829E5DF0AB314A5D9C0F2169" unitRef="usd">170400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q3" decimals="-5" id="Fact-8AAECCA6E1B957E79804BA688E482D4F" unitRef="usd">208100000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2016Q4" decimals="-5" id="Fact-E9E866176C6D5BF98B92A8C242F2C390" unitRef="usd">698700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q3" decimals="-5" id="Fact-2AB1C7CF73635845BC02516E061819BE" unitRef="usd">647600000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3QTD" decimals="-5" id="Fact-1FB66BFBE89A5179BB29AEE0FE909498" unitRef="usd">16400000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q3YTD" decimals="-5" id="Fact-7636B1005908563CAB4122F1181B7751" unitRef="usd">43000000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q3QTD" decimals="-5" id="Fact-407FA6FA2C5758729B67C8ABF7B5421C" unitRef="usd">20600000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q3YTD" decimals="-5" id="Fact-7995F465C4E6507F945038070887F1CF" unitRef="usd">54200000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DE48A838AA745B698A647DA81049090C" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9DCD29DAC5BE58B780B8F0914E8339DC" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DAF36C431720584ABC6B3DECD8DA7EB5" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ED6A7D1DBAAA5EEDA1ABD1AD449A082D" unitRef="usd">24900000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-86BF16E4BD125B9197ED969ED2F8020A" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-078ADA8F81AF5B4D93482F7A4859DBE3" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2C7F6826959D5726A8A31950B3FE3587" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5351D42C4A8A5F54AAE99B08E167BBB9" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-5" id="Fact-5C1E4933A402572C8731A9B1C42172FD" unitRef="usd">10748200000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q3" decimals="-5" id="Fact-7D4A144A2592510191076314853C9F41" unitRef="usd">10224300000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-623153D837E257EDB00F809EBB9647CD" unitRef="usd">22876800000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q3" decimals="-5" id="Fact-01E1565AD6B15202AFA4AC74D47F0290" unitRef="usd">23073200000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-058BE1EB81F55742A58FC039C93F6304" unitRef="usd">3419900000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-E54666A41A3A5815AF0DAFAE95F36D76" unitRef="usd">3448400000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5DBDE90F8B1E5FB99632C8774E3A7EF6" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B272CE15F73F50EEA5FDF5597619BEBD" unitRef="usd">13600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F45A5DD462E15353BF6B58B5BFBB2AAF" unitRef="usd">467600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-264541CDF03D5BB58B020448E8939A98" unitRef="usd">481200000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-96B8DA8D5BC35BFF80FEB51B93C08227" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-389F9458DC0150849BD49CB5053C8DE5" unitRef="usd">106200000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C09449F5647D5F74922C7231871582E7" unitRef="usd">522100000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E1DE799A452559C39AF9B03FB01B400B" unitRef="usd">628300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-29826854D3815912ADDB85AE9408E2D3" unitRef="usd">155500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:LitigationReserve contextRef="FI2016Q4" decimals="-5" id="Fact-3A91D62C4A4D5511B87F8D2DF20CA1EB" unitRef="usd">454800000</us-gaap:LitigationReserve>
	<us-gaap:LitigationReserve contextRef="FI2017Q3" decimals="-5" id="Fact-86C4BAB7943B5E0CB8DB9900D4A94DBC" unitRef="usd">0</us-gaap:LitigationReserve>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="FD2017Q1QTD" decimals="-7" id="Fact-5E87711B54515827AB664FF0D659BF3E" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-38B6ACEF2C495054A406C96A009D6701" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2016Q4" decimals="-5" id="Fact-8FA0C9275F3C59DB8F88B9CE38F72F55" unitRef="usd">6512700000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2017Q3" decimals="-5" id="Fact-9C16C732C90853E591AF93F5AEB0A63A" unitRef="usd">5938300000</us-gaap:LongTermDebt>
	<us-gaap:MinorityInterest contextRef="FI2015Q4" decimals="-5" id="Fact-71432E1B9EE258D2944C83C122F6DF33" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q2" decimals="-5" id="Fact-9F604B45886A53EE810FF0A241BFDF8F" unitRef="usd">-100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q3" decimals="-5" id="Fact-7F2618F635A857A18A10E4249DE4C251" unitRef="usd">-2700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4" decimals="-5" id="Fact-10B434827C87565983A34D89BD1C697D" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q2" decimals="-5" id="Fact-056A2E2EA4A75DD0AF11C17575DB05FF" unitRef="usd">-11600000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q3" decimals="-5" id="Fact-381F1B27A0195BD7934E31DEF04B9689" unitRef="usd">-11600000</us-gaap:MinorityInterest>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-A0AF0E17680C55B9A0B36BB54D0BD5DB" unitRef="usd">-326100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-02AE734C405056CBB3326575D3B4DEF1" unitRef="usd">-1671900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-824B625278DB514B8D8014C1CBFB465D" unitRef="usd">-1903100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B4BF342B21365B39B1DF220DC83B3A51" unitRef="usd">-2193600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-14BF18396C8C5772B4ECD9A14E4C1ADA" unitRef="usd">3005300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-7281B1757B5B53EB8CFDF7514FDD7616" unitRef="usd">3032700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-79E8E274F31E5086A9E8B5D72A9F7D8A" unitRef="usd">1032900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-D052A78A0ADA5B3E9EC09F191457EC07" unitRef="usd">-5300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6A8E45C7166958908E45F318CABA49AB" unitRef="usd">3053600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-9E3C05A1D3F75FF68F35FF7090D6B40A" unitRef="usd">-1300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-5C19F914EF58567883E2DA8A19D0B8DE" unitRef="usd">1226100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-EDAA7E3B49E452C1B68B2167BF5B6FB1" unitRef="usd">-18800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-5" id="Fact-6976BC8AF51B5D88B4FAEF423CE00816" unitRef="usd">2836500000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-16EAFFDFA8775C08B185BB594009167B" unitRef="usd">-15300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q3QTD" decimals="-5" id="Fact-5E8CA85AF27D5F47A0E0C0BBADD399E8" unitRef="usd">-2700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q3YTD" decimals="-5" id="Fact-B7C8AB009ECD57B698504B4B379A7FFC" unitRef="usd">-5800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q3QTD" decimals="-5" id="Fact-43F3ACE4195A54B79F5B3D6F02CBEE52" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q3YTD" decimals="-5" id="Fact-0063850021E358E6979CA9F3AF930405" unitRef="usd">-100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q3QTD" decimals="-5" id="Fact-489210EB46815253AA308A0E9534B17C" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q3YTD" decimals="-5" id="Fact-86477E063EE058309AEB546F37CFC77F" unitRef="usd">900000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C5771C30FEC7502D839793871656CF96" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2017Q3YTD" decimals="-5" id="Fact-68D009BD9EC8576380B28E6D498D8218" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-1CB35640442A52618259F6D48D4998C5" unitRef="usd">-58100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-842876B1CEA95691814849C337C9C281" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B33935D4DE3056D3BFAB7A763020D89F" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-89DA74BB52F555CBBA142892BC9168BC" unitRef="usd">-169400000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-70140131ADA6540D94D88D42C243FC8F" unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5723ADC7F329580DAA8B245A15C4C9FA" unitRef="usd">-600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-BC2AA617C6165F9AA814FB1609CD62E2" unitRef="usd">-43600000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-24A1397378185601BF72DDF595FB06BE" unitRef="usd">100000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-89F53FEEB34155069D1E021D594BFC30" unitRef="usd">-900000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-3BCF1A8AA02E593896F8D6C422A110E1" unitRef="usd">-149400000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-88EE2A192C215B07AB4F2275C07AA6CB" unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-2F5F4CD7D34A58E2971B8D1AF7675176" unitRef="usd">-1700000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2016Q4" decimals="-5" id="Fact-854CAE0F0168560D83BDC6818A65CCCE" unitRef="usd">6499300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-D7BF17386B3A5E3EB5F0150495289F93" unitRef="usd">6000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-DDAFDCC9C11257E98E99D781A0108ED6" unitRef="usd">1721500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-C8C04AF3E920573FB44FE71D7E72FE46" unitRef="usd">1734800000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-19B8B935758F5BCD81A2A8B86EEEA972" unitRef="usd">558500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-0BC7E7377DF9590C8043CC97DFC7A7CF" unitRef="usd">993200000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-BCB48B284E035600A863744C62CDEB54" unitRef="usd">1485300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3" decimals="-5" id="Fact-C76B1C1A01165F239C559B6C564581FD" unitRef="usd">6494700000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-6259B505809D5F53B16C6F81ACAB4B2D" unitRef="usd">3300000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-7114BA1497535A71BF01224A441FA7E3" unitRef="usd">1721900000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-99C5ACF77C7759CBB175B4131B8B9B2B" unitRef="usd">1735900000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-C040B4BE28E65E468F3C80334A406EC8" unitRef="usd">553100000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-3AD4F80A7FB05BD7B76469A58692AE30" unitRef="usd">994000000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-CDD1BD4C746458BEA0C044CED093A47C" unitRef="usd">1486500000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-F2C975B539CD53B69A756175D176E820" unitRef="usd">6100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-B7F101B9195C59F9A09ED9E63D94AAEB" unitRef="usd">1874500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-0597D872286B56779361B6DC88100E78" unitRef="usd">1796000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-F73F9C9E05E3549E9B2C0F814659DE57" unitRef="usd">583700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-6348636AF9165200AB7483648828474C" unitRef="usd">1026600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-96DFFEEF175B55B6B962AE11E77430E2" unitRef="usd">1521500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-7FB1E6459CB5545FA59609641B75CB3A" unitRef="usd">3200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-32E39DA86F5A5DDE89DBF2C39F3944DE" unitRef="usd">2030800000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-CB3845F152175F3F8A7624BDDE15D6B3" unitRef="usd">1867000000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-6053A68EEED650E58F785111AF2C42E5" unitRef="usd">561700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-154187373B905D7E9806622C388DA11B" unitRef="usd">1049400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-D3C9D1F17A13554AA52671A8AF216347" unitRef="usd">1536200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2017Q3YTD" decimals="0" id="Fact-EDA69D9C60D7523B8630ACFC0ACBB116" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-2135012F754E5113ADCAC2C0C707367C" unitRef="usd">200000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-89F80F7A543458E6BE114DF456CC4031" unitRef="usd">400000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-FE5A39D6181C512B8D8A7AB017E0269C" unitRef="usd">500000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A33FED07ADA153BDBAF2050F1453D0DB" unitRef="usd">700000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-4AB342DE4DA3517A88AD37BE15A33093" unitRef="usd">1425300000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-5" id="Fact-1EE3B49132D3544CBCD0D910BE8A128E" unitRef="usd">4264200000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-67CD037A56E75F339E09C95F63B3A9E6" unitRef="usd">1653500000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3YTD" decimals="-5" id="Fact-A5DD511BCCC15BA1B488FA95C2B4A290" unitRef="usd">3878400000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-6DA43B76019A504CBACBD0E9D53EFCB8" unitRef="usd">685700000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-ED0B92CDED7F5841A7C943F812EC8F68" unitRef="usd">606100000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-EAA2A6A572475EC8AA0182C4470BFB51" unitRef="usd">1093300000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-D814FB1F1B0753ABADCA69DE2607BEE3" unitRef="usd">967000000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-BABEB79AA1B450B48D5BDCA7F47C6148" unitRef="usd">1335800000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-76EF453E0B415F29A5C23E27147334EA" unitRef="usd">1300400000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2017Q3_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember" decimals="-5" id="Fact-6E360A3431405D7AAE3AD702F1D2D42D" unitRef="usd">235000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0C56835FB9665C3FBAF2581E08FE1937" unitRef="usd">-5400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-96559D5C39285C15993D6C0D737493B6" unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-39DB145F553455C798D6A0225D7632FC" unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-7811580A3930547FAFD08608DDF15246" unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6661BDA383ED5AB989B40DF8FBF7FDA3" unitRef="usd">-78200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-D17C5D5FECEF53E4BF23FC1AD82682D0" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D4E3405917D75139B72CED0ADC6E82F3" unitRef="usd">-17900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-066508D00685580CABE4F2384F5DE99F" unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-7BB608D6D88B5C1599D82DE1B01D9B6B" unitRef="usd">-62800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-2AB7AEF4A47E5C14846D53712F1E1A19" unitRef="usd">-24800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8735F6D5BD205728A67AC8C80D5F1CC9" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-9D1C648F11EA5508A1D10BAE5806EEBD" unitRef="usd">-176500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-5B591341793251878EF56300BCA05879" unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8A9FF00FFC91513FB60FBC4F60BA55E5" unitRef="usd">146700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-5A929507EC705FACBA78F2500567FF4A" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2ECF0D3326815221B97A1928CD787CF8" unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-F6242994BFF150B0A24860F4D5A32FC4" unitRef="usd">-35500000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-62CBCECEB1205B3F9A3743620462099E" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-30284321611A5AC3A91407C1DC6F24EF" unitRef="usd">-14400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-2D5FAEEB96B85FFA89103AF76CA34F95" unitRef="usd">-62800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-2F41183E56835E28BF8159673CA1D654" unitRef="usd">43900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-7908D5762DE05385AE93149504F13922" unitRef="usd">146700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-AA4358A3E44A53AD9837F2A12E05EA33" unitRef="usd">-18100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-33889F0CB0B6599E87982347CCA0BCDE" unitRef="usd">-76900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-E276586D314F5864804BFD62DF27982D" unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-6D4AD561BD64503CAE7FEFE48B5E6C5A" unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B745BEB91A5354B9AF6E1538E9B8F06E" unitRef="usd">1600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B6A04D89B48A50949E76E6F684F6131C" unitRef="usd">-62800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-D1FC62A69EFF59B096A3F606D2ABB477" unitRef="usd">9400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F1479F1C255652F8A5CBC145486A872C" unitRef="usd">-9500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-122B3E8FCD665B5787F06C8EE21F89EE" unitRef="usd">-500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-B7D83B6AF2B95E038FA875AB26C6534C" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-7BB26F3747B055788578188CE6B61C1D" unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-4AAFC691450D5595975A21AB0C6B4502" unitRef="usd">146700000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q3QTD" decimals="-5" id="Fact-6CEEB1813B885E2F9F356203B697F13A" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-EB889130870B5B0DB43BE30B0C80FBA8" unitRef="usd">-1300000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q3QTD" decimals="-5" id="Fact-4051CE58449852399E048236A945CB88" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B879917405165E538252A3D088F9B66B" unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-764B49B7124A550DA14B4DB0A033E7D2" unitRef="usd">2903500000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-0C406F0A78705AC9B6A3999F24A06C40" unitRef="usd">2455200000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-5" id="Fact-E249F2EC079C5BC58182C0DC5C491564" unitRef="usd">722500000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q3" decimals="-5" id="Fact-00CEBFD39D5E508F87EC7CE0BD33D277" unitRef="usd">716900000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-FA2F2109CABE5384ACF1D65CAAF94BF2" unitRef="usd">-45300000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-DE27D606633B56F38366396CAB1E85EE" unitRef="usd">-126900000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-CAE0593B0DD25B06B8E6E53060433937" unitRef="usd">-4400000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-86355E566191522499DA4B41E1BE95D3" unitRef="usd">-14300000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-FCF04976A92450298CA9ACB5DB8597D9" unitRef="usd">-5100000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-3DF4A593A1625A468E0F3446EDC90C42" unitRef="usd">-8200000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-7ECB809F99195DDBAD505352BF7BC7C3" unitRef="usd">98600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-EB2AC7F93F265973B74CD6CF534F53E5" unitRef="usd">400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3YTD" decimals="-5" id="Fact-716AFDAE3865524493A8C2DB7AF2416E" unitRef="usd">265500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-D886B89B81925E5D8F8A84644D15BA9E" unitRef="usd">17300000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2016Q3YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-7F77B978B9FFE5E959DD3077829B5A72" unitRef="usd">13500000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3QTD" decimals="-5" id="Fact-A7315A568695586387536E7DA8AA8357" unitRef="usd">48800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3QTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-BD321BC160875BE3BE55E80E12A20440" unitRef="usd">5000000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3QTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-CF9CCB724B505FDEBB7A9643D6FD582D" unitRef="usd">8800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3QTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-E2826BA2F2E057659322EF7B1FD6F000" unitRef="usd">2800000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3YTD" decimals="-5" id="Fact-12426868F6CB581FB83F41E3B91894FC" unitRef="usd">180400000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-911437953CBF587BB548FF37D3217A10" unitRef="usd">12100000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3YTD_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-4E5090C6EF3553099CFDF0311A244AFC" unitRef="usd">23700000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:OtherSalesRevenueNet contextRef="FD2017Q3YTD_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-B1D58731D2D65F4C8F842981803F44B2" unitRef="usd">12600000</us-gaap:OtherSalesRevenueNet>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-1A2835C7C3545C3D95EE39D842D6EE78" unitRef="usd">12800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1BA28B197E17548A8AD36D2F53101621" unitRef="usd">5100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q3YTD" decimals="-5" id="Fact-B12248E91DE15A49A563CABF0F5FA1E5" unitRef="usd">348900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-24C142A0E6739C3AAE9F30255C4CE9C0" unitRef="usd">348900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q3YTD" decimals="-5" id="Fact-EE24B2404270587E836E0A5D1952C9F3" unitRef="usd">1365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-E0C348571DBC520BAD94E6AC975D7428" unitRef="usd">365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-01AE2408607757C9A09979A5BF015205" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2016Q3YTD" decimals="-5" id="Fact-47E7AD89E26850948A91A526D13256F3" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2017Q3YTD" decimals="-5" id="Fact-D9641F87984359E0BF73AE4B00C8289A" unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-5" id="Fact-F37824896275536CBA0AEF41A2833655" unitRef="usd">12400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-5" id="Fact-A10FAE11C34F5D9BA9AF5FC8758FF577" unitRef="usd">10700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-E278CD4E1D3053DCADB490118BD50F3F" unitRef="usd">5631700000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-80FBAB609C0E559A9ED3059B28355050" unitRef="usd">4093900000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember" decimals="-5" id="Fact-F5D61F5CFB7A51508248A7EF9E8CCBFA" unitRef="usd">120000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6E4785C8A4CF5C0C90347A785FD03CC9" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2017Q3YTD" decimals="-5" id="Fact-D12A92BB6F515F4186961A3F0014B436" unitRef="usd">120000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q3YTD" decimals="-5" id="Fact-8415D8DF08A45819A643607A72B54A2E" unitRef="usd">110400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q3YTD" decimals="-5" id="Fact-A3E29AEC32AF5653806ED3C71821842F" unitRef="usd">910400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q3YTD" decimals="-5" id="Fact-FFDAEAC15C6651948977BC8F9EDAACFD" unitRef="usd">900000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2017Q3YTD" decimals="-5" id="Fact-0317DD16D03F574FB81DCACB60C7A660" unitRef="usd">900000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6E8DCF8F597F55DAA0A6EFDC3E72D13C" unitRef="usd">434000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-5" id="Fact-8CC4632A2408562AB4FD795888801D89" unitRef="usd">636800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToMinorityShareholders contextRef="D2017Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-5136447010A585B72EEB35C27F4B82D2" unitRef="usd">150000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-DD58D86196F95645A866042D062F810D" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-813AC64EA51A535EB4918C35A5423A1E" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-083150AB817653E7A35D4D316CBE2414" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q3" decimals="-5" id="Fact-9F786821002054FDAE3BFEDFC53F338C" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidTaxes contextRef="FI2016Q4" decimals="-5" id="Fact-390EE2CE93765A1A9CCFDC697CEB7061" unitRef="usd">817000000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q3" decimals="-5" id="Fact-CC24E72B10A25E7886214FDECA5BE2B0" unitRef="usd">714400000</us-gaap:PrepaidTaxes>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-88031EEF7058549CB575B6434754E1D5" unitRef="usd">37900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-3A6DB158040D5445AF8ED57ADAFB953E" unitRef="usd">10100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q3QTD" decimals="-5" id="Fact-64F73F45ADD15028913BA60ED5AC4E8D" unitRef="usd">2362200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q3YTD" decimals="-5" id="Fact-4F587F7F0B1350CCA259C8802789D071" unitRef="usd">5185800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q3QTD" decimals="-5" id="Fact-1D2F033879D75FE98DF9194548918026" unitRef="usd">888100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q3YTD" decimals="-5" id="Fact-635848DD78705DEAA0AA8297C467A306" unitRef="usd">4472600000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProfitLoss contextRef="FD2016Q3QTD" decimals="-5" id="Fact-C2E4CE87ED7E5DDA826CB88850502DB0" unitRef="usd">1030200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2016Q3YTD" decimals="-5" id="Fact-DCEDEAAF442D56F5B438E3497AEE4F79" unitRef="usd">3047800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-F53C2ACEF8EB5A6B8401A97C3BA623AE" unitRef="usd">1226100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q3YTD" decimals="-5" id="Fact-DCC27CB905125143A77D9A763972D2A0" unitRef="usd">2836400000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-8C51032CCA5E50D3A89377AFAA164BC7" unitRef="chf">64400000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentAdditions contextRef="FD2016Q1QTD_biib_FacilityLocationAxis_biib_SolothurnSwitzerlandMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" decimals="-5" id="Fact-2420BB1985235044A6D7376010C1DC69" unitRef="usd">62500000</us-gaap:PropertyPlantAndEquipmentAdditions>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-5" id="Fact-3118B715F37E5314BD21F54EDC6EE5B0" unitRef="usd">2501800000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q3" decimals="-5" id="Fact-9002A57F43665E8EA22FB02713E9D05A" unitRef="usd">2995900000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD" decimals="-5" id="Fact-E5C7F64ED38554CFAF990C0F6E6D82ED" unitRef="usd">1300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-09D2FDDDEBC25287B2CB2A57523CDF95" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-77F6651461885A558320013B9373FFE4" unitRef="usd">900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0EB30E214B0B51EF90607BDFF92F280C" unitRef="usd">400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FCE28DE5300953A6BF737851AD51952A" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q3YTD" decimals="-5" id="Fact-31AF433AA22650D5BC2DA683FCD829CE" unitRef="usd">15300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-EDB27CE790185EA8922F81DCCF3500BF" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-22BF18AD0BE752519F01BB87A17E1B3D" unitRef="usd">14200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-F3A7ABEB187952CC8D7ADC20BB4BD45F" unitRef="usd">1100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-5E564C2A20CB5868B0BF8D27A56FED60" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfBankDebt contextRef="FD2016Q3YTD" decimals="-5" id="Fact-AC87956112A456063685E6F4EA66F6E5" unitRef="usd">2700000</us-gaap:RepaymentsOfBankDebt>
	<us-gaap:RepaymentsOfBankDebt contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B68329F62A21FE03F4B0E6F513D24B26" unitRef="usd">3200000</us-gaap:RepaymentsOfBankDebt>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q3QTD" decimals="-5" id="Fact-98EDCC0383DE5120ACDBE073324BF971" unitRef="usd">529000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q3YTD" decimals="-5" id="Fact-BE28136D6F54594FAF0E8063DB3D7D23" unitRef="usd">1439400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q3QTD" decimals="-5" id="Fact-71E1909411F85EA0839FDE410B07507C" unitRef="usd">446400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q3YTD" decimals="-5" id="Fact-715ED5AC18805A09B8264A6D8CD20712" unitRef="usd">1666000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-55DD4463DDC8539898FCC50DC6AB25CC" unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q3QTD" decimals="-5" id="Fact-EF87BAB186FB5468B131172811627E83" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q3YTD" decimals="-5" id="Fact-3694967D70045689B76AF32FA09B5C19" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q3QTD" decimals="-5" id="Fact-386C3C70D1965B46AF3BC3CDEEEBC9E5" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q3YTD" decimals="-5" id="Fact-7028DD8981F657F39FEA4724B0CB0C8C" unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringCharges contextRef="FD2016Q3QTD" decimals="-5" id="Fact-F6287F0964B259D88B19B5DB90ED2E05" unitRef="usd">11600000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q3YTD" decimals="-5" id="Fact-6B1B3C354C32567DA450936F91733F07" unitRef="usd">21300000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3QTD" decimals="-5" id="Fact-031352A8CA5053608C69A4413D1002F5" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q3YTD" decimals="-5" id="Fact-79BB3E3675D559AD9082908D0349D81D" unitRef="usd">0</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-5" id="Fact-9734213FA46D57F7BA91127EFC38110A" unitRef="usd">15071600000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q3" decimals="-5" id="Fact-927D427B81C856499D5D0078E2A48215" unitRef="usd">16107700000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-5" id="Fact-F02A7BBEDBE35C36A14DD11FCDD62313" unitRef="usd">2955800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3YTD" decimals="-5" id="Fact-A1029D99600C596B90348E35B903D332" unitRef="usd">8576800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-5" id="Fact-5FB9684ECC455F8B9443B7FFC032B815" unitRef="usd">3077800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3YTD" decimals="-5" id="Fact-32DE2ED68F455F16B8C9215B7B8935FD" unitRef="usd">8966900000</us-gaap:Revenues>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD" decimals="-5" id="Fact-EDC9C5B10371548AA9E1C23CF54B2251" unitRef="usd">2539600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-3AB7FC0217805D1C873C5E3778CCBCBF" unitRef="usd">217000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-4B4DC92EFE8D5C9B9D3C1F3517AAF666" unitRef="usd">73300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A6CE1CC0E0335F9CBBE7AB79F45AD7AA" unitRef="usd">5200000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3YTD" decimals="-5" id="Fact-9D9502832A4E5E1E90DC45DC3F487ED2" unitRef="usd">7315000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-7A79ED27725A5A0398FE8C5923AB8F6A" unitRef="usd">604700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-08E2CB2A7ACF52C1990EFD3C8C8A42E4" unitRef="usd">82400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2016Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-7FFF6A28ED1D56D0A79337F64DD6473D" unitRef="usd">700000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-30CDF6F5A0AE5E2BACCAEF9AF423370D" unitRef="EUR">41800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q1QTD_us-gaap_StatementGeographicalAxis_country_IT" decimals="-5" id="Fact-BD18E23808385B129A9F73CC0F66A7CC" unitRef="usd">45000000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3QTD" decimals="-5" id="Fact-8121B72E660555179A45A249DD4B58DD" unitRef="usd">2622500000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3QTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-BBDCA983A7B25ED49AE1816657148841" unitRef="usd">197600000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3QTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BF41F168D75A577D9995D622C90C14AC" unitRef="usd">18800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1EA71971EDF05574B21A67A1D1228B05" unitRef="usd">7642300000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-3A556D03FD2C5F63BDFBEDD2EAC92AD6" unitRef="usd">74400000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3YTD_us-gaap_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-822261BFF4BA534EB19288A2308E51E0" unitRef="usd">438800000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SalesRevenueGoodsNet contextRef="FD2017Q3YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-872AC6A62AA352B59B0A339ACB29B373" unitRef="usd">15100000</us-gaap:SalesRevenueGoodsNet>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-A7C8268E477B5C83A8DC58EAD302F652" unitRef="usd">462700000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-88471B64D9835D2A977290F6FE4020B6" unitRef="usd">1452400000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-62E8A686A81950F68BDABEF7E698BDC2" unitRef="usd">433800000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-1311EAD884CA5014984C44C8B0926838" unitRef="usd">1363100000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-5" id="Fact-10711C68510B5496937EBF6C0A3BCB86" unitRef="usd">117800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-5" id="Fact-F4BCDDD2D3E15E52A26D24EA8FE814C4" unitRef="usd">97400000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" decimals="-5" id="Fact-5C4B6FC2F5025BA184AF018B6BB82F79" unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-2150F6970CA55713BEE2019B68F21558" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2017Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-8" id="Fact-FBA535AD69125C2BBAC18BDF15862A36" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-6B843DC4BDFE50B6892EA30C47E210F8" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-63A47AD8709F52CA80383161D1AEFF1F" unitRef="usd">12140100000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3" decimals="-5" id="Fact-6F640C7885EA58FF96094DE9759D7544" unitRef="usd">12860500000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-5" id="Fact-8ED6BBDD701C5D219EB425AC2BAD1608" unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q3" decimals="-5" id="Fact-154B8BE755A95F1AAE5EA87CD2FF4117" unitRef="usd">12848900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B51A787B4A845EAA85C44D0A95C188BC" unitRef="usd">852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-5" id="Fact-471381B3E4C55EDBAD319B4B6019C0BC" unitRef="usd">720300000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
	<us-gaap:TaxesPayableCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-1C3500F8160D514E96A86DC7D3E8305C" unitRef="usd">231900000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q3" decimals="-5" id="Fact-9404B6DD9354544E97F0A287E4A5FEC3" unitRef="usd">121300000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-89AFCF62C03BFE81B3BA3024BB941CE4" unitRef="shares">1100000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-6A79E77D1EA85056A6E500A121D296C0" unitRef="shares">1300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q3YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-78DB995E3E1955F5A4525DE6AC2131D7" unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2016Q4" decimals="-5" id="Fact-969B7818A50D5D65B339CA3B11E0B3E0" unitRef="usd">2611700000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q3" decimals="-5" id="Fact-95C807473CF2547A8C9B9106C39F8471" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q3_us-gaap_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-6" id="Fact-587C353E77EB38823D4B3082247BEE3A" unitRef="usd">100000000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-5" id="Fact-9FBD84F4FB485DA2B3CE2BBE405C8F84" unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-21B407FB2700598F952D7963074693CC" unitRef="usd">166900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-A883EFE3677D5AD899F0C5EC0C8D3CB9" unitRef="usd">438600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-22790B60D7E259E1885B67204AD585E8" unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-EF85F03DE60255E39EECA610ADEFED21" unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-4FCD5CD5EA4056C2A959C71A619F20F6" unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3" decimals="-5" id="Fact-88C7A2BA335E5D1E903BD058766BB8D6" unitRef="usd">664600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-8A9B7DE8376C5D538E3257B500447000" unitRef="usd">197400000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-E9F0D5F0871458CC81194C9F213CD149" unitRef="usd">467200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-072E068D0E1D5DEABB4444024BC1A9C6" unitRef="usd">516400000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_ReserveForCashDiscountMember" decimals="-5" id="Fact-56E29C9C420A5DBDAB2D936E58E097DE" unitRef="usd">102900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-ADAE5684003657C2B6DDC746DCA6241A" unitRef="usd">45300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q3QTD" decimals="-5" id="Fact-33B63E73224F51159885F70C6246A2B7" unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q3YTD" decimals="-5" id="Fact-1C90DCA2443B5610A64D9D9E1A8AFB49" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C2C1B52C48B65525A720AF7F79D2016C" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q3YTD" decimals="-5" id="Fact-84F55F7252225CCB8AA15FA6E016DED0" unitRef="shares">300000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q3QTD" decimals="-5" id="Fact-1D4EAD19E0F15648BA06EB0456E28748" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q3YTD" decimals="-5" id="Fact-BA8F552CAC8C588595B75EB735091353" unitRef="shares">219400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q3QTD" decimals="-5" id="Fact-F506C2CD8BC15233A631D741C3F19C52" unitRef="shares">211800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q3YTD" decimals="-5" id="Fact-C0AF6D295FD450E893534453ECF18314" unitRef="shares">213300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3QTD" decimals="-5" id="Fact-70D8C4E5D31A5BCD946C70E09F5B4BF9" unitRef="shares">218900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q3YTD" decimals="-5" id="Fact-31E7A99F1A2B53079432F40E3C80AD38" unitRef="shares">219000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q3QTD" decimals="-5" id="Fact-A31A2C3B7F3550A9B332ADE158E28A16" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q3YTD" decimals="-5" id="Fact-294ADEEA5BD45A758C49D40CC3148435" unitRef="shares">213000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-18FBEC4291535F40958EDD7D9A082A6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;422.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,681.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,123.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(320.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,547.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(70.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(431.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(519.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;102.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;516.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-C6E247F5A6E15D96814320459AFC96FC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS and relapsing MS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. We intend to invest in the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2017Q3YTD" id="Fact-A238AC957FB356D6B670C872967763BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(532.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,675.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,002.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,067.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,934.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,295.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,276.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-0BD4CB4C53F05B7CA6C69DF3B9A1E3F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-177EF14E7F6E513782A6D0C65D75053B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;197.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-D199C083918F5142ADA23D52C5362CBF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;43.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(66.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(188.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(43.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(58.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(149.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets include prepaid taxes totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$714.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$817.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations and milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;611.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;241.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;180.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;190.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;157.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;606.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,455.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Pricing of TYSABRI in Italy - AIFA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017 we recognized EUR&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2017Q3YTD" id="Fact-AF1388AB9C075B97AA895B56F3CC8B5A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,042.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,043.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,541.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,541.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;916.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;916.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;954.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;957.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,022.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,026.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-162D084E29ED58528FBF50BC511F8AD1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-F956F209A46D5A9E84BD3CBFB4BB7CE3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May 15, 2017, we completed an asset purchase of the Phase 3 candidate, CIRARA (now known as BIIB093), from Remedy Pharmaceuticals Inc. (Remedy). The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. Under the terms of the purchase agreement, we will have responsibility for the future development and commercialization of BIIB093 and have agreed to pay Remedy certain development and sales based milestone payments, which are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. Upon closing of the transaction, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB093 has not yet reached technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2017Q3YTD" id="Fact-3EF4156344A85AD58D112ABFBBB999F9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;126.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;42.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;871.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,042.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,043.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,541.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,541.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;916.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;916.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;954.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;957.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;566.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,022.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,026.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,408.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,409.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,255.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,258.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,156.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,016.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;557.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,960.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,961.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,792.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,795.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,022.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,026.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;888.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,362.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,472.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,185.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$84.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-094C4BE9221D5ED5AD27C95E06952D08">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On June 1, 2017, we finalized an agreement with Bristol-Myers Squibb Company (BMS) to exclusively license BMS-986168 (now known as BIIB092), a Phase 2-ready experimental medicine with potential in AD and progressive supranuclear palsy (PSP), and made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to BMS. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. We may pay BMS up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$410.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former stockholders of iPierian, Inc. (iPierian) related to BMS&amp;#8217;s acquisition of iPierian in 2014. In June 2017 we triggered a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payable to the former stockholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092 and we may pay the former stockholders of iPierian up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$490.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments, and potential royalties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Both the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payment were recognized as research and development expense in our condensed consolidated statements of income for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 the European Medicines Agency (EMA) announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&amp;#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. The outcome of the EMA review process may affect the market for ZINBRYTA, which may result in the impairment of all or a portion of certain assets related to ZINBRYTA. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our condensed consolidated balance sheet includes ZINBRYTA related assets, primarily related to inventory, prepaid tax and intangible assets, totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$200 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Offsetting these amounts, we also have an unrecorded tax benefit related to certain ZINBRYTA assets totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;share of the co-promotion profits or losses as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&amp;#160;2016. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenue of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect our share of an overall net loss within the collaboration, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in each of the prior year comparative periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net and record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as revenues are recognized and related costs are incurred. We also reimburse AbbVie for their &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses in the E.U. and Canada, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada in the prior year comparative periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;SPINRAZA (nusinersen)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the agreement, during the third quarter of&amp;#160;2016,&amp;#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;SPINRAZA was approved for use in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively. These approvals triggered milestone payments to Ionis totaling&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;during 2017, which were capitalized in intangible assets, net in our condensed consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized product revenues totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$197.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$438.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, on our sales of SPINRAZA in the U.S. and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$73.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$82.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recognized in royalty cost of sales within our condensed consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership interest was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;The exercise of this option is within our control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We began to recognize revenue on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA, triggering an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Samsung Bioepis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss in accordance with the cost sharing provision of the commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$80.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits, as compared to net expense recognized of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect sharing of the net collaboration profits in the prior year comparative periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$23.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in connection with these services as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these and our other significant collaboration arrangements, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2017Q3YTD" id="Fact-52DD8BC6749358749B74C902360B5D4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(176.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(33.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(187.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(329.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(62.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(78.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(62.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(76.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(258.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-2FEA52C555F557298FB799C4EC13C4D6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-D41D8AA6A6E15E43BDA953A60C345C1A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,573.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;39.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,637.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We expect all contracts outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020 attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020 with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$366.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$902.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recognized as a component of other income (expense), net for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as compared to net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q3YTD" id="Fact-40744F2F0AFC56DC970AA3645586F62E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;55.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;94.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;88.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;105.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;81.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&amp;#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Spin-off Related Equity Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&amp;#8217;s and Bioverativ&amp;#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;2017 Omnibus Equity Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 our shareholders approved the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan) for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&amp;#160;1.5-to-1&amp;#160;ratio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-27DDBF29728B587EA6C7DC5B5C056CB8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The services under these agreements generally commenced on February 1, 2017 (the distribution date), and are expected to terminate within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ's and our consent. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$302.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as cost of sales in relation to these services during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the United States (U.S.), which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement. Under this arrangement, we distributed these products as an agent of Bioverativ and also provided related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations did not reflect recognition of activity or balances related to these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these amounts were not significant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia related product revenues reflected in our condensed consolidated statements of income for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$217.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$604.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Results for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, only reflect hemophilia-related product revenues through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-66B96E1CA1905C1099176CF2EE8382F5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,836.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,053.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;213.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2017Q3YTD" id="Fact-563877EA739E5D5CA22B474D8746430E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,584.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,584.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,870.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,870.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;567.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;567.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,238.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;628.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; material impairments of our assets measured and carried at fair value during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In addition, there were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;553.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,536.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,486.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,049.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;994.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,867.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,735.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,030.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,048.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,494.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,499.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;492.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;515.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;521.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;521.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$280.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$246.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q3YTD" id="Fact-41E4ADB84DE555248F79427A812DA557">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;492.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;515.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;506.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;61.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;521.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;521.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-EBE5B85B387254F19BFD6E139C72E420">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(532.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2,675.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;329.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,634.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;371.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;648.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks&amp;#160;and&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;tradenames&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed&amp;#160;rights&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;and&amp;#160;patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,002.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,067.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,934.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,481.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(776.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,705.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8,295.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4,276.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,019.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,742.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3,934.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,808.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amortization of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$108.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$674.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$99.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$281.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in the prior year comparative periods. Amortization of acquired intangible assets for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$413.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property related to TECFIDERA, as further discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$322.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,293.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The increase in acquired and in-licensed rights and patents during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payments due to Ionis Pharmaceuticals, Inc., which became payable upon the approval of SPINRAZA for the treatment of SMA in the E.U. and Japan, respectively, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment due to Samsung Bioepis, which became payable upon the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. and net amounts related to our TECFIDERA license rights, as described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;TECFIDERA License Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this agreement, representing the fair value of our license to Forward Pharma&amp;#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We paid the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in February 2017 and recognized an intangible asset of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$795.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&amp;#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information related to these disputes, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 (remaining three months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;404.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;389.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;256.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;244.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;762.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase in goodwill during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$900.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$137.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-129AC2CE4D7A5ED886EF941A80293D75">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, compared to the same periods in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we are earning a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-62AF21001D3B57D893B4BD1E94924D72">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;208.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;647.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,031.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,007.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,031.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balances in the table above as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$84.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2017Q3YTD" id="Fact-DA29E084F17F5A14A387A8EEC2057B40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,960.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,961.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,568.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,569.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,792.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,795.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,552.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,559.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;269.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;276.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;277.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,022.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5,026.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,398.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,406.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2017Q3YTD" id="Fact-01D9682E36815838B9FB661232BA6880">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Abbreviated New Drug Application Litigation relating to TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June, July and September 2017 we filed patent infringement actions pursuant to the Hatch-Waxman Act against parties who filed Abbreviated New Drug Applications (ANDAs) for generic versions of TECFIDERA. We have sued the following parties in the United States District Court for the District of Delaware: Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceuticals, Inc., Slayback Pharma LLC,&amp;#160; Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Pvt. Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torren Pharmaceuticals, Ltd., TWI Pharmaceuticals, Inc., Windlas Healthcare Pvt., Ltd., Accord Healthcare Inc., Par Pharmaceuticals, Sandoz Inc., Sawai (USA), Inc. and Zydus Pharmaceuticals (USA), Inc. We have also filed actions against Stason Pharmaceuticals, Inc. in the United States District Court for the Central District of California, Zydus Pharmaceuticals (USA), Inc. in the United States District Court for the District of New Jersey, Accord Healthcare Inc. in the Middle District of North Carolina, Par Pharmaceuticals in the Southern District of New York, Sandoz, Inc. in the District of Colorado and Mylan Pharmaceuticals in the United States District Court for the District of West Virginia. No trial has been scheduled in any of these matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&amp;#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The EPO has scheduled a hearing for January 2018 on Biogen&amp;#8217;s and others&amp;#8217; oppositions to Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 6, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangibles Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Patent Revocation Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&amp;#8220;Administration of agents to treat inflammation&amp;#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. In July 2017 the District Court of The Hague ruled that the Dutch counterpart of the patent is invalid and we have appealed. A hearing has been scheduled in the German action for early 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On May&amp;#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &amp;#8220;Consolidated '755 Patent Actions.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for the first quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We regard this matter as closed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-40EC7FCE525052A7A313C2B6F5565BE2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the following new standards effective January 1, 2017:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounting Standards Update (ASU) No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method. We have performed a review of the new standards as compared to our current accounting policies and our review of customer contracts and collaborative relationships remains in process. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues and revenues from anti-CD20 therapeutic programs. During the fourth quarter of 2017 we plan to finalize our assessments over the impact that these standards may have on our results of operations, financial position and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. The adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. The new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard will be effective for us on January 1, 2018. We expect to adopt this standard using the modified retrospective method applied through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. The new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard will be effective for us on January 1, 2020; however, early adoption is permitted. We intend to early adopt this standard as of October 31, 2017, during our annual review of goodwill. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for us on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard provides guidance to better align an entity&amp;#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will be effective for us on January 1, 2019; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-45FDBCD901955E78963DB1E480550F18">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,580.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,439.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2016 we purchased land in Solothurn, Switzerland for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), where we are building a biologics manufacturing facility. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$968.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$481.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to the construction of this facility. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$235.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-707E5EC166E25F848B49C1080C0AAF96">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;888.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,362.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,472.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,185.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2017Q3YTD" id="Fact-4DC8D33916295FDF9C5EB44FBD3D5B22">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:22%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-5FB195EDDD8054209B45A082077A0951">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations and milestones&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;611.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;580.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;241.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;282.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;180.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;130.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;190.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;195.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;157.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;134.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued TECFIDERA litigation settlement and license charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;454.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;606.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;685.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,455.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,903.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2017Q3YTD" id="Fact-13CCDB26926E5922805797F8CF3700C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(176.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(24.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;14.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;15.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;146.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(9.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(33.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(187.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(329.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(62.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(78.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(17.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(62.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(76.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(258.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(300.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-C43A189FDC6756CB8D49B3AD8F7D7812">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair and carrying values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875% Senior Notes due March&amp;#160;1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;553.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;558.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,536.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,486.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,521.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,485.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,049.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;994.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,026.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;993.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,867.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,735.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,796.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,030.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,721.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,874.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,721.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7,048.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,494.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,808.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,499.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-35CAB9B385C754EBA74C64ED63C337A9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of less than 90&amp;#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;126.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;42.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;871.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;741.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,266.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2017Q3YTD" id="Fact-82C8A48AC84259D7AC78837238DA3532">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;17.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;26.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;81.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;13.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2017Q3YTD" id="Fact-621E8D98D323505EA4E845C42C787BD8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(18.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Effective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized into Net Income&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;(Ineffective Portion)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2017Q3YTD" id="Fact-0A0307CBB3D454EBBCAFAB24D9BDB0D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;80.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:40%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivatives:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivatives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2017Q3YTD" id="Fact-94E3043C8EE8534E8814F05ACA623769">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q3YTD" id="Fact-9C3C49C428A1512EA0D68042190A4867">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,836.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,053.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;213.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;219.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q3YTD" id="Fact-DBE71F094E8A5F12A604B1CBFAD503C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q3YTD" id="Fact-8743112755A5591DACE01DD7BA8DF276">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;55.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;94.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;43.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;53.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;127.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(2.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(7.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;40.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(10.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(31.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;29.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;88.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;105.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2017Q3YTD" id="Fact-F5BF7F9E64EB5EE59CB713741E03E97E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of September 30, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,184.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,584.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,584.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,870.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,870.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;567.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;567.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;30.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6,238.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;628.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;522.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&amp;#160;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&amp;#160;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&amp;#160;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,039.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,663.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;561.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,558.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,533.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;481.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2017Q3YTD" id="Fact-BE54F0E41FBB55BC8982458A12E4520F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;762.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;4,127.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2017Q3YTD" id="Fact-E7B2814BB74256CDBE46EDBAC1B3BDC1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;208.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;647.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;698.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;170.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,031.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,007.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,001.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,031.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-363E4B32BC32553DBDA87C8A6E35E1A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,573.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;39.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;19.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss franc&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,637.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;871.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2017Q3YTD" id="Fact-B1A3ADBB8F6C50FEAA9DA5CF71ED27F6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;54.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;43.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(61.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(66.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(188.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(43.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(58.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(149.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-994AB81D06A05EDDBFBF3F1CB2E9220D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;422.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,681.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2,123.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;2.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(320.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,227.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(1,547.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/credits relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(70.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(431.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(17.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(519.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;102.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;516.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;45.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;December 31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;197.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;166.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;467.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;438.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;664.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2017Q3YTD" id="Fact-79611E3166755F26A6D91477153711DB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;As of &lt;br clear="none"/&gt;September 30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 (remaining three months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;106.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;421.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;404.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;389.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;256.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;244.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q3YTD" id="Fact-563A57F57CE85D44A9D21D43B96086B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS and relapsing MS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. We intend to invest in the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&amp;#160;GAAP). The information included in this quarterly report on Form&amp;#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&amp;#160;10-K for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K). Our accounting policies are described in the &amp;#8220;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Notes to Consolidated Financial Statements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8221; in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form&amp;#160;10-K and updated, as necessary, in this Form&amp;#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&amp;#160;GAAP. The results of operations for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the following new standards effective January 1, 2017:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounting Standards Update (ASU) No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to these standards, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies: New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method. We have performed a review of the new standards as compared to our current accounting policies and our review of customer contracts and collaborative relationships remains in process. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues and revenues from anti-CD20 therapeutic programs. During the fourth quarter of 2017 we plan to finalize our assessments over the impact that these standards may have on our results of operations, financial position and disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. The adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. The new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard will be effective for us on January 1, 2018. We expect to adopt this standard using the modified retrospective method applied through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. The new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&amp;#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard will be effective for us on January 1, 2020; however, early adoption is permitted. We intend to early adopt this standard as of October 31, 2017, during our annual review of goodwill. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for us on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard provides guidance to better align an entity&amp;#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will be effective for us on January 1, 2019; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-134076D83A9F5F4DB79F91444C80D796">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total equity as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, increased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$720.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This increase was primarily driven by net income attributable to Biogen Inc. of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, partially offset by share repurchases totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as described below, and an adjustment to retained earnings of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$852.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the spin-off of our hemophilia business, as described in Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We did not repurchase any shares of common stock under this program during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased and retired &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$348.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; remains available to repurchase shares under this authorization.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock, which was completed as of March 31, 2017. During the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we repurchased &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this program. We did not repurchase any shares of common stock under this program during the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Noncontrolling Interests&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Three Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Nine Months &lt;br clear="none"/&gt;Ended September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income (loss) attributable to NCI, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value of net assets and liabilities acquired and assigned to NCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Translation adjustment and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;NCI, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(11.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q3YTD" id="Fact-B0F0365FC8E68E1D384535BD4D6421ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;20.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and E2609 Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2014, we entered into a collaboration agreement (Eisai Collaboration Agreement) with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&amp;#160;Under the Eisai Collaboration Agreement, Eisai had an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 23, 2017, Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement (Aducanumab Agreement) for the joint development and commercialization of aducanumab. Under the Aducanumab Agreement, the two companies will co-promote aducanumab with a region-based profit split. We will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the U.S., a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;68.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the E.U. and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of development costs for aducanumab incurred in support of the agreement until April 2018. Eisai will then reimburse us for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of development expenses for the period April 2018 through December 2018, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; thereafter. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, both companies will continue to jointly develop BAN2401 and E2609; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Eisai have also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets (excluding China).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our collaboration arrangement with Eisai, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to our consolidated financial statements included in our 2016 Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Neurimmune&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On October 23, 2017, we amended the terms of our existing collaboration agreement with Neurimmune. Pursuant to the amended agreement, we agreed to make a one-time &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in royalty rates payable on potential commercial sales of aducanumab.&amp;#160;Our royalty rates payable on potential commercial sales of aducanumab will now range from the high single digits to low-teens.&amp;#160;This payment will be recognized in the fourth quarter of 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rate payable on potential commercial sales of aducanumab by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in exchange for a one-time &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of the Aducanumab Agreement, Eisai may elect to share in the benefit and cost of the royalty reduction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For&amp;#160;additional information relating to our collaboration agreement with Neurimmune, please read Note 17,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q3YTD" id="Fact-44DFB52AFC445A089F43E59D0AC7B67F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-8B169B3C9734509794967A40D5DF0B3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of AD. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and are required to fund &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the research and development costs incurred in support of the collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total carrying value of our investments in biotechnology companies totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to our consolidated financial statements included in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Form 10-K.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>biib-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20170930" xmlns:biib="http://www.biogenidec.com/20170930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2121100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2421402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2421403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2321301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2106100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2406401 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2127100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails">
        <link:definition>2427401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2427402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited">
        <link:definition>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2118100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2418402 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2318301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2122100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2422402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2322301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2120100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2420402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2420403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2320301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2114100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2414402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2414403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2414404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2414405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2314301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2116100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2416402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2416403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2416404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2416405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2416406 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2416407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2316301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOff" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOff">
        <link:definition>2108100 - Disclosure - Hemophilia Spin Off</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffDetails" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetails">
        <link:definition>2408402 - Disclosure - Hemophilia Spin Off (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffDetailsTextual" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual">
        <link:definition>2408403 - Disclosure - Hemophilia Spin Off (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffTables" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffTables">
        <link:definition>2308301 - Disclosure - Hemophilia Spin Off (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2124100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2424402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2424403 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2324301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2112100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2412402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2412403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2312301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2110100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2410402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryInventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual">
        <link:definition>2410403 - Disclosure - Inventory Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2310301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2126100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2426401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2128100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2125100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2425402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2425403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2325301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment">
        <link:definition>2119100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails">
        <link:definition>2419401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowances" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances">
        <link:definition>2109100 - Disclosure - Reserves for Discounts and Allowances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails">
        <link:definition>2409402 - Disclosure - Reserves for Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2409403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesDetails1Calc2" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2">
        <link:definition>2409403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesForDiscountsAndAllowancesTables" roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables">
        <link:definition>2309301 - Disclosure - Reserves for Discounts and Allowances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2123100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2423402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2423403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2323301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2129100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsEisaiDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails">
        <link:definition>2429401 - Disclosure - Subsequent Events - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNeurimmuneDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails">
        <link:definition>2429402 - Disclosure - Subsequent Events - Neurimmune (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramYearToDateMember" name="A2016ShareRepurchaseProgramYearToDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017OmnibusEquityPlanMember" name="A2017OmnibusEquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AdditionalPotentialPaymentstoNoncontrollingInterest" name="AdditionalPotentialPaymentstoNoncontrollingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DerivativeInstrumentsTextualAbstract" name="DerivativeInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DevelopmentalMilestonePayment" name="DevelopmentalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DuefromantiCD20therapeuticprograms" name="DuefromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageMaximum" name="EquityMethodInvestmentOwnershipPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinishedGoodsMember" name="FinishedGoodsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HemophiliaProductsMember" name="HemophiliaProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IPerianMember" name="IPerianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" name="ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" name="ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RemedyPharmaceuticalMember" name="RemedyPharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" name="ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprograms" name="RevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnSwitzerlandMember" name="SolothurnSwitzerlandMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativManufacturingandSupplyAgreement" name="TermofBioverativManufacturingandSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_TermofBioverativTransactionServicesAgreement" name="TermofBioverativTransactionServicesAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_WorkinprocessMember" name="WorkinprocessMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>biib-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20170930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20170930.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:href="biib-20170930.xsd#HemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:href="biib-20170930.xsd#HemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:href="biib-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:href="biib-20170930.xsd#SubsequentEventsEisaiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:href="biib-20170930.xsd#SubsequentEventsNeurimmuneDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_PreferredStockValue_4fb6195d-d905-dac7-e5a0-79f324993f79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_04f0961a-a0bc-88cf-6658-3f950da4a458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_TreasuryStockValue_40678492-c421-af67-b276-f663f9ff2f98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00443492-92dd-7fc1-13b6-792f3e163e73" xlink:to="loc_us-gaap_MinorityInterest_cb565c4d-35c2-d825-4672-f1619e51c133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_TaxesPayableCurrent_8544ed0a-bea0-b1fa-ce65-66a1927d2672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DebtCurrent_f84a497d-68eb-d3d3-1597-16bfb6772366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_314eb579-3ee1-408c-39f2-e62f2f37befc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_InventoryNet_7eab44cf-1ea1-ca2a-420f-21f7b5343fc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_25eb7974-3b7b-f164-2633-c5b5794b9c17" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_25eb7974-3b7b-f164-2633-c5b5794b9c17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssetsCurrent_1cb4a384-e314-2300-ad55-c1ed289c8f7a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_Goodwill_93a64cae-271a-5e6b-8c83-5adf9f941142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_962cfc51-230d-a221-126b-1d12af7a5921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f75d01b7-d271-b07d-c4a7-6ae60293303d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_371a4d3e-148a-313f-f556-b3ca6797139e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bf3f9720-ba63-7ecd-52ae-e754a6f349db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2e0100a2-70c7-ab53-9143-6f416ad2f702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5eaab9ea-3795-2871-0d80-72b9662e37e6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_9cebbd9b-269e-5a19-54b8-1c32e2660d83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_3be9d1aa-8098-ddda-91ce-5e44ee6678ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8bd7b051-5be0-703c-6635-0cad16b52005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_a83917b5-0d97-08b8-a37b-5a651675d415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8a1490c4-32d9-5132-1fe2-2675a45abdae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_96b318db-5cfb-7c2a-3933-0632d73c101c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_e99c0df3-0a1f-1711-53bd-781647ed4275" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_e99c0df3-0a1f-1711-53bd-781647ed4275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_9c4e2a5c-e841-39a2-fcf8-f80cfa44af11" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_cc7c59d2-21ac-163e-0898-1c1f212ef02b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2652b636-1a3b-e639-2800-d9ed5b9b4fc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2a6e77d2-a694-61f8-1c68-085fd849c780" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_351eeed0-a987-88e4-c007-095f3644ffff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_499015ce-2160-aed2-85a3-080e8c4c6cdf" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dd69e307-3cf6-284a-5315-8fa7ac464283" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7908f590-67cb-1122-d422-880e24cad7ce" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_318cebec-2b05-42bf-a988-02b2e99cecfb" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_9a60f89a-212e-b51d-5cad-c5b578edd9d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_OtherSalesRevenueNet_e7cc3a47-5261-0c18-da28-7de072dc978b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_CostOfGoodsSold_23c68b7c-81fb-cba2-1814-b7ab4991d5d0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9f968bdd-178b-453d-dcf7-ca4f511341b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_29ad42f4-24c5-90ea-4492-fdb757d66249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ae796c5c-1c01-d654-6a3c-3b5dd2c89517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_fec96391-6e35-fdf3-595d-10648487b8fa" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_9e3a4c1c-d826-987b-b5de-c5b578fdbfae" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_biib_Collaborationprofitlosssharing_9e3a4c1c-d826-987b-b5de-c5b578fdbfae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d37bab5b-2ef8-8457-799f-b4fea153fb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_RestructuringCharges_78594f6e-0c1a-d6f6-6a22-c95b7bf56846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb47183-f513-314d-ceda-ee2412d9eee8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_adacf05e-7e15-bd60-3e53-87432885dc29" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c520208-bae2-1c51-b4b4-935e91f5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_baabbf0a-644b-708a-c310-1211f9af2775" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7b1369dd-f813-fe00-b292-96e275568f1b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_cee10fe8-a4bb-491c-22f6-69a723d6a718" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9684315-a9e4-a270-d882-14da209d6338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_61bb41c2-5e2c-2804-d184-f566af2acbb1" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_792de6b4-2056-4259-2de2-c302f546025c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1932fd43-f07d-5e04-493b-eca2ebb13c97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_30dc6014-97a8-c9af-5d13-c233c1983f7f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e96beffd-8ab7-62f8-402b-cfa1adccd68f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_38f7f811-0e73-faf3-e7e6-c5b578fd26c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_169d77af-5216-aa2b-07d9-c5b5792bdf8b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c92402e9-bd0b-d11c-b52e-45b5c23d49be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_4836856d-11b6-313b-8616-6a2c8b77e26f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b4cebb29-0be8-9a62-3a11-985fb541a531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_7737f022-7814-d1ba-7a34-4005044fb373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_29919d14-72a3-6197-982a-3a6269f21038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c48cf597-7f94-3186-bb2a-448703ee500e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_744a85ef-de6a-dc1b-540c-cd37e4ee0e8e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bd3fb4a2-dba4-9f41-2b9f-30441850eb67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e076fca2-751d-53ee-27b4-64a5b6f5b217" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8712fd02-171c-5995-3f18-84e885c380b9" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_d23f3a10-8672-f1d4-6f93-c5b5791c8b49" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76e8d839-867c-df13-a643-4da04e725367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_49187b45-82fd-7060-b114-79ff249a4331" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d62e128-f1a1-954f-82e2-1936cb67d793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c3ed8a56-abe0-6418-c541-e6b647d6318a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1fe06082-076b-052d-6e2e-930afe9d6b2d" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a6de665e-02e5-e3e1-f0df-a5f7155acc66" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20170930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d8866e11-7330-6a9a-9ba0-56d88707d8ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a3451b87-a72a-9fff-128b-969b95aecb3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_8ff90a51-3738-a247-ed51-c5b5792b5d90" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b077ba6e-d590-fd28-6cc4-ab52e924ed70" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_27459a92-428a-e415-bdb1-176ed2662e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_InterestExpense_7c9599ab-2a77-022c-c720-63fecff6a62c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_a2377e00-ed9e-3dc2-4fbd-c7e624463b5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_303ce027-35e0-90c6-b665-c64d3c33d4e9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1Calc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ba20f6b9-d55b-6ca6-9a65-1e800c90ae83" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_ba20f6b9-d55b-6ca6-9a65-1e800c90ae83" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d7f86d22-9204-660e-e7a4-c5b5794becca" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6cf3013c-890b-ea8a-d84d-af0ec88302d5" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_d7f86d22-9204-660e-e7a4-c5b5794becca" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>biib-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20170930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20170930.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:href="biib-20170930.xsd#HemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:href="biib-20170930.xsd#HemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:href="biib-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:href="biib-20170930.xsd#SubsequentEventsEisaiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:href="biib-20170930.xsd#SubsequentEventsNeurimmuneDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_D28826C954136E789CE75B8D218A9530_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:to="loc_us-gaap_EquityComponentDomain_D28826C954136E789CE75B8D218A9530_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:to="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:to="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:to="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3ABC101347D68DC3EB1A3B3453E13C20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3ABC101347D68DC3EB1A3B3453E13C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_74305CC684AA26B3DBF43B3453E16BED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_74305CC684AA26B3DBF43B3453E16BED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_269810CEF1BA4DE3A9413B3453E1A7C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_269810CEF1BA4DE3A9413B3453E1A7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_131E739A3D5D22C43A2F3B3453E18400" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_NetIncomeLoss_131E739A3D5D22C43A2F3B3453E18400" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5D31D080918D50A79D559A7D293EAA1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C90A3223FADB5C988BC355B288BF8C7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5D31D080918D50A79D559A7D293EAA1B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C90A3223FADB5C988BC355B288BF8C7A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_C90A3223FADB5C988BC355B288BF8C7A" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A9D1E946BF544C78BCE56FEE38DD52BF_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_A9D1E946BF544C78BCE56FEE38DD52BF_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0D11EBCFD62155E7B81B1B44D18F59BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0D11EBCFD62155E7B81B1B44D18F59BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0D11EBCFD62155E7B81B1B44D18F59BB" xlink:to="loc_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5D31D080918D50A79D559A7D293EAA1B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:to="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:to="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7D50DAE58A44524DE1A03B0BFA681C3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:to="loc_us-gaap_MinimumMember_7D50DAE58A44524DE1A03B0BFA681C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_15027E6E8A478DA16B073B0BFA6801E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:to="loc_us-gaap_MaximumMember_15027E6E8A478DA16B073B0BFA6801E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E664FCAD939C6AD01ED63B0BFA68E742" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:to="loc_biib_InLicensedPatentsMember_E664FCAD939C6AD01ED63B0BFA68E742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:to="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A5A2B0EE8A707D2EA15C3B0BFA69EF40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:to="loc_biib_SPINRAZAMember_A5A2B0EE8A707D2EA15C3B0BFA69EF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_371E33E1A5D72AF902833B0BFA69E0A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:to="loc_country_US_371E33E1A5D72AF902833B0BFA69E0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_94A7487FA4A9BB818A733B0BFA6964FC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_94A7487FA4A9BB818A733B0BFA6964FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_BF514905593A0357A0BB3B0BFA69EEB7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_OtherSalesRevenueNet_BF514905593A0357A0BB3B0BFA69EEB7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_5F36DF367EBD814D4DA23B0BFA69C4D8" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_Collaborationprofitlosssharing_5F36DF367EBD814D4DA23B0BFA69C4D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_9C7165EC239957B9C92B3B0BFA69B975" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_9C7165EC239957B9C92B3B0BFA69B975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7EFCBC80DDA511F273D43B0BFA6AA985" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7EFCBC80DDA511F273D43B0BFA6AA985" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1ABFEC1B5F65E023F420E7345B21BE9D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_Collaborationprofitlosssharing_1ABFEC1B5F65E023F420E7345B21BE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:to="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:to="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:to="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:to="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:to="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:to="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:to="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:to="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:to="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:to="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_370F29BC1FC87D4A8E365B8D217E2DCE_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_370F29BC1FC87D4A8E365B8D217E2DCE_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4771595EC7E3509EB4C3A35F3CDC3F95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4771595EC7E3509EB4C3A35F3CDC3F95" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_275B7FBBE9F05E109AFE41329CDBF99F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_MarketStockUnitsMember_275B7FBBE9F05E109AFE41329CDBF99F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:to="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:to="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86CBFBDCBACA9D8432F25B8D21DF6BEC_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86CBFBDCBACA9D8432F25B8D21DF6BEC_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0832D679F4E37DDDB2735B8D21E0F74B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0832D679F4E37DDDB2735B8D21E0F74B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_322F5C815FBDFABEB4845B8D21E035DC_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_322F5C815FBDFABEB4845B8D21E035DC_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:to="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CBE1045E92D584BD346A5B8D21D6563B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CBE1045E92D584BD346A5B8D21D6563B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5581F2A39C28529E96A592571BA7A890" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5581F2A39C28529E96A592571BA7A890" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_084B1340C9F05FB7829A138AEC3DCC85" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_084B1340C9F05FB7829A138AEC3DCC85" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_BAC150545D925160890A3B9DA5A21757" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_BAC150545D925160890A3B9DA5A21757" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BB95FE381F765D32AE138D30E5A4CCD3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BB95FE381F765D32AE138D30E5A4CCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BD18324AE1B93BBA4C045B8D21CDA4C1_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BD18324AE1B93BBA4C045B8D21CDA4C1_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9E176FE1B7FC59738E6CAF1E0BDED209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9E176FE1B7FC59738E6CAF1E0BDED209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:to="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E6F95EF0056684D17F0B5B8D21C9EA06_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E6F95EF0056684D17F0B5B8D21C9EA06_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0CDCFCDA563654E1A9A2604C3D2556A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0CDCFCDA563654E1A9A2604C3D2556A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EB0B942AC6F353898382136759A961CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EB0B942AC6F353898382136759A961CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:to="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_068FD0F2D343C04559185B8D21BBD029_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_068FD0F2D343C04559185B8D21BBD029_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_49FA984257268523D1905B8D21AF5E94_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_49FA984257268523D1905B8D21AF5E94_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:to="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:to="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F0D4E0B0E69B85C599295B8D222CF9D0_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_F0D4E0B0E69B85C599295B8D222CF9D0_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_9D2F48BC2A8757E4BA8266958D604992" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:to="loc_biib_BioverativMember_9D2F48BC2A8757E4BA8266958D604992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E65F35843BE35105B08AC20DC0327C54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E65F35843BE35105B08AC20DC0327C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21975D16EE1855C9A3082E55E55D0F86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21975D16EE1855C9A3082E55E55D0F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_735D0797EDC84CE2D6615B8D22225CED_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_735D0797EDC84CE2D6615B8D22225CED_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_FC5103295E60563A953AE36C04C3F493" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:to="loc_biib_BioverativMember_FC5103295E60563A953AE36C04C3F493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_C62A6FB83A56D658072F5B8D222203FB_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:to="loc_us-gaap_ProductsAndServicesDomain_C62A6FB83A56D658072F5B8D222203FB_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:to="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_965082D786A75827B07BB79702D60A97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_OtherSalesRevenueNet_965082D786A75827B07BB79702D60A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1B75000A44FB5E07AD4D2E9ADB7B7D98" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1B75000A44FB5E07AD4D2E9ADB7B7D98" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DF57D6C0F34E5E79078F5B8D2165C9AE_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DF57D6C0F34E5E79078F5B8D2165C9AE_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:to="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_1866E6445344E054E7C53A2289A79968" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:to="loc_biib_BioverativMember_1866E6445344E054E7C53A2289A79968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:to="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_79A559FB47A334DD90653A2289A8EC79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_TecfideraMember_79A559FB47A334DD90653A2289A8EC79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:to="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:to="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:to="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:to="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6163E1B0CCE1EFCE13085B8D21ED494B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6163E1B0CCE1EFCE13085B8D21ED494B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_B29358B3D40D5848B1D008B6C12BC427" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:to="loc_biib_BioverativMember_B29358B3D40D5848B1D008B6C12BC427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_3277CCC82AF9E5850FB45B8D21EDA562_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:to="loc_us-gaap_ProductsAndServicesDomain_3277CCC82AF9E5850FB45B8D21EDA562_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:to="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:to="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9F3D1E09105E3CCF6BFB5B8D21ED0650_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9F3D1E09105E3CCF6BFB5B8D21ED0650_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:to="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_F2D8E82BCA3D5A2D2D055B8D220376B4_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_F2D8E82BCA3D5A2D2D055B8D220376B4_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:to="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:to="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AF75ED42F8D450D73E1C5B8D2203BA5D_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AF75ED42F8D450D73E1C5B8D2203BA5D_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:to="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_7542C16304E1B8E271455B8D21540C6C_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_7542C16304E1B8E271455B8D21540C6C_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:to="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3ACB4F1865B0612F039C3B0BFA7CAC49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ACB4F1865B0612F039C3B0BFA7CAC49" xlink:to="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_CC82421B2EF5C87128D23B0BFA7C3C35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_CC82421B2EF5C87128D23B0BFA7C3C35" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_CD5BC73E33DE856531C86FDF205B1EFB_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_CD5BC73E33DE856531C86FDF205B1EFB_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:to="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_51CBD23B43C78E43E6B85B8D219A959F_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:to="loc_biib_FacilityLocationDomain_51CBD23B43C78E43E6B85B8D219A959F_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:to="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:to="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2EDAF83C692EBD18E395B8D219A12D7_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2EDAF83C692EBD18E395B8D219A12D7_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:to="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:to="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_C7A6D26FC310C9C7DEC25B8D220F1A23_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_C7A6D26FC310C9C7DEC25B8D220F1A23_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:to="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E61DBD736FE2973F72B15B8D2177E42B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E61DBD736FE2973F72B15B8D2177E42B_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_38C8BCDE125D5EDAABDA869810B6411B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_38C8BCDE125D5EDAABDA869810B6411B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5F9B54C5A80B5CCBAAA0FA4F35EB4A8F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5F9B54C5A80B5CCBAAA0FA4F35EB4A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_DB3EA57BEDA668E69F616FDF207F61FA_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:to="loc_us-gaap_PlanNameDomain_DB3EA57BEDA668E69F616FDF207F61FA_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:to="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4CBA65C053E175AF607F6FDF207FBCA2_9DD8A5EF893A53FB8D9250640404A033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4CBA65C053E175AF607F6FDF207FBCA2_9DD8A5EF893A53FB8D9250640404A033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:to="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:to="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C806C2F3871C5A25D6F44F9BB2DA0D8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:to="loc_us-gaap_SubsequentEventMember_C806C2F3871C5A25D6F44F9BB2DA0D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:to="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>biib-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_102C7B3109CC0C8016EE5B8D21692066_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8572DA76F8827ED8BAF95B8D2169AA3A_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8572DA76F8827ED8BAF95B8D2169AA3A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_CD48E2636C51BC33C7D25B8D2169A694_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_CD48E2636C51BC33C7D25B8D2169A694_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27B2EBA892BBF702CA515B8D2169BC79_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_27B2EBA892BBF702CA515B8D2169BC79_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_69E4677703E22D1D7EEF5B8D216911D4_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_69E4677703E22D1D7EEF5B8D216911D4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_B545AEF03EDF017B35AD5B8D21696566_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_B545AEF03EDF017B35AD5B8D21696566_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_A506AFBE31AAB801DAA05B8D21693823_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_A506AFBE31AAB801DAA05B8D21693823_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_4577FB5685F643CEE72B5B8D21690B05_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A39F27B980CE506384745B8D2169F20B_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_A39F27B980CE506384745B8D2169F20B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5AD0B2314C8B515F94945B8D2169A9EC_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5AD0B2314C8B515F94945B8D2169A9EC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0D60ACDEE37CF4BE17C35B8D216997D5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0D60ACDEE37CF4BE17C35B8D216997D5_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_96391F799C48ECD9847C5B8D21C58C87_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ED8949E5F182580168FC5B8D21C5B1DA_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_ED8949E5F182580168FC5B8D21C5B1DA_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_80907D7538F7A92DB2115B8D21B3C75B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_80907D7538F7A92DB2115B8D21B3C75B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_A5DD5CBD5ADC307914475B8D21B31C53_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_A5DD5CBD5ADC307914475B8D21B31C53_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_F9C879C82CDF534AB3A95B8D21B36881_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_F9C879C82CDF534AB3A95B8D21B36881_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_46451E1067B8E345B29D5B8D21AC28DD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8DD843C4CAF5C8BE6EC15B8D21AC33C8_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_8DD843C4CAF5C8BE6EC15B8D21AC33C8_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_76EEE84843C7B0DB898C5B8D21AF61D7_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9EE0E5A0B4A1776AD8D15B8D21AF0032_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Asset Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9EE0E5A0B4A1776AD8D15B8D21AF0032_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_783C46D4C21C970804715B8D21AF7D3A_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_783C46D4C21C970804715B8D21AF7D3A_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_49FA984257268523D1905B8D21AF5E94_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_49FA984257268523D1905B8D21AF5E94_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_8AFE2D1D161FE7A60CDF5B8D21AF4AEF_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_8AFE2D1D161FE7A60CDF5B8D21AF4AEF_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_8AFE2D1D161FE7A60CDF5B8D21AF4AEF_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:to="lab_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_72068F4CE980DC01902C5B8D21AF66E2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_72068F4CE980DC01902C5B8D21AF66E2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_81FE527DD03CB74059E45B8D21AFA517_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_81FE527DD03CB74059E45B8D21AFA517_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_81FE527DD03CB74059E45B8D21AFA517_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:to="lab_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:to="lab_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.900% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10_label_en-US" xlink:label="lab_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:to="lab_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="lab_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="arc" />
    <link:label id="lab_currency_EUR_40B208410E1312B2242E49C52F18AC55_verboseLabel_en-US" xlink:label="lab_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_40B208410E1312B2242E49C52F18AC55_label_en-US" xlink:label="lab_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:to="lab_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="arc" />
    <link:label id="lab_currency_GBP_6422B67508C5874164A049C52F1956D7_terseLabel_en-US" xlink:label="lab_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_6422B67508C5874164A049C52F1956D7_label_en-US" xlink:label="lab_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:to="lab_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="arc" />
    <link:label id="lab_currency_CAD_94F49E793D1435F3B7A049C52F1914E9_verboseLabel_en-US" xlink:label="lab_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_94F49E793D1435F3B7A049C52F1914E9_label_en-US" xlink:label="lab_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:to="lab_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="arc" />
    <link:label id="lab_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC_terseLabel_en-US" xlink:label="lab_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC_label_en-US" xlink:label="lab_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:to="lab_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139_label_en-US" xlink:label="lab_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:to="lab_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:to="lab_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:to="lab_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:to="lab_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:to="lab_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:to="lab_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:to="lab_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:to="lab_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:to="lab_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:to="lab_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:to="lab_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B_label_en-US" xlink:label="lab_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:to="lab_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7_label_en-US" xlink:label="lab_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:to="lab_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698_label_en-US" xlink:label="lab_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:to="lab_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F_label_en-US" xlink:label="lab_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:to="lab_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Derivatives designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value, net</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="arc" />
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8_verboseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="lab_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:to="lab_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="arc" />
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6_negatedLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_838195A2C8F55B6C62805B8D2197D315_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:to="lab_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06C0B7B3443AFFF4F4735B8D2197144D_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_06C0B7B3443AFFF4F4735B8D2197144D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_6DFCBFA62BB356100A586FED879C857E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F81239FDF1A8597D52256FED87A9524C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_F81239FDF1A8597D52256FED87A9524C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_52DDB3510DAC478AFDF55B8D2154ED97_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_52DDB3510DAC478AFDF55B8D2154ED97_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D6B734F772628C7821A85B8D2154305F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_D6B734F772628C7821A85B8D2154305F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_69E03D2C5768E52796545B8D215479F2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_69E03D2C5768E52796545B8D215479F2_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_7542C16304E1B8E271455B8D21540C6C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_7542C16304E1B8E271455B8D21540C6C_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_5E64F26F0A92FDE86BEF5B8D2154813C_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_5E64F26F0A92FDE86BEF5B8D2154813C_label_en-US" xlink:label="lab_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_5E64F26F0A92FDE86BEF5B8D2154813C_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:to="lab_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_5299676E397A7250C6635B8D21549C48_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_5299676E397A7250C6635B8D21549C48_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:type="arc" />
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_813B7DEF8C74E6C8D0B15B8D21545EDF_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost in support of collaboration agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_813B7DEF8C74E6C8D0B15B8D21545EDF_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost In Support Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_813B7DEF8C74E6C8D0B15B8D21545EDF_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development cost in support of the collaboration agreement.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:to="lab_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_A20C6E50A3A02B3719A55B8D2154A7E9_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_A20C6E50A3A02B3719A55B8D2154A7E9_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_A20C6E50A3A02B3719A55B8D2154A7E9_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_DC6EA24C6C64BC159DA15B8D2248B496_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CEEA347CAA1B27727A615B8D224888F5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_CEEA347CAA1B27727A615B8D224888F5_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0D3E31D406BF28556C085B8D21DF110F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FF93557D8D2CC600B5C65B8D21DF560C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_FF93557D8D2CC600B5C65B8D21DF560C_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A21C39167189FD965C395B8D21DF55FD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A21C39167189FD965C395B8D21DF55FD_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86CBFBDCBACA9D8432F25B8D21DF6BEC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86CBFBDCBACA9D8432F25B8D21DF6BEC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_93E7F3F59B6564B7F5C95B8D21DF5818_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_93E7F3F59B6564B7F5C95B8D21DF5818_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_38A81667D16C621F8B4C5B8D21DFFBE7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_38A81667D16C621F8B4C5B8D21DFFBE7_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_AE37932910F77A9D07915B8D21E002C1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_AE37932910F77A9D07915B8D21E002C1_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_FD9147AA47236CF4FEA15B8D21E0F52D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_FD9147AA47236CF4FEA15B8D21E0F52D_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0832D679F4E37DDDB2735B8D21E0F74B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0832D679F4E37DDDB2735B8D21E0F74B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2855542A7C59E0B788AE5B8D21E08EDA_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2855542A7C59E0B788AE5B8D21E08EDA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_407895D45C20A3FAD4E45B8D21E0B506_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_407895D45C20A3FAD4E45B8D21E0B506_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_322F5C815FBDFABEB4845B8D21E035DC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_322F5C815FBDFABEB4845B8D21E035DC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_CB9E9D700F896D42DADB5B8D21E0BDC8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_CB9E9D700F896D42DADB5B8D21E0BDC8_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1D4D1E982D884581531F5B8D21E03A5E_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1D4D1E982D884581531F5B8D21E03A5E_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_496A841E47E37AC1883D5B8D21E125A7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_496A841E47E37AC1883D5B8D21E125A7_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9AA7D373EF9FDBC3294D5B8D21E1A364_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9AA7D373EF9FDBC3294D5B8D21E1A364_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9142F50C2E34EA8A45FE5B8D21E1F2C2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_9142F50C2E34EA8A45FE5B8D21E1F2C2_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets, Liabilities and Stockholders' Equity Measured on Recurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7B928EF5EFB92F4440A85B8D21E1C5AF_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7B928EF5EFB92F4440A85B8D21E1C5AF_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F009BD067C0CA2B418A15B8D21E147CD_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_F009BD067C0CA2B418A15B8D21E147CD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_267353FE4EDFC468CBD05B8D21E11BC7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_267353FE4EDFC468CBD05B8D21E11BC7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:to="lab_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_F382CF5CC8AB0A12BCAC5B8D21E1799A_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_F382CF5CC8AB0A12BCAC5B8D21E1799A_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_6B15DCC6D90D815FBCF45B8D21E1D167_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_6B15DCC6D90D815FBCF45B8D21E1D167_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_04FFF4DAA4389BC997DC5B8D21E1A84C_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_04FFF4DAA4389BC997DC5B8D21E1A84C_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_04FFF4DAA4389BC997DC5B8D21E1A84C_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D065DC77BF3404C2956B5B8D21E1F666_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D065DC77BF3404C2956B5B8D21E1F666_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_FACCD5C73C088555F74F5B8D21E1F0A7_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_FACCD5C73C088555F74F5B8D21E1F0A7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4785EBD79698E79995215B8D21E17741_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_4785EBD79698E79995215B8D21E17741_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ABB21772C86ADA8B3E2B5B8D21E29704_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ABB21772C86ADA8B3E2B5B8D21E29704_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9C758924001BA373C3195B8D21E250AB_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9C758924001BA373C3195B8D21E250AB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5EE526C8F0063087308F5B8D217BB652_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EAEAD0FA2D2333BBFA6D5B8D217BFC1B_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EAEAD0FA2D2333BBFA6D5B8D217BFC1B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58_label_en-US" xlink:label="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:to="lab_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF_verboseLabel_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF_label_en-US" xlink:label="lab_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discount [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:to="lab_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63_verboseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:to="lab_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D_label_en-US" xlink:label="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:to="lab_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in, reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Abstract]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of the amount of, and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2016</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F_verboseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/credits relating to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of September 30, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2BC0A8D7F99E34CB1F335B8D22441B7B_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2BC0A8D7F99E34CB1F335B8D22441B7B_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_2BC0A8D7F99E34CB1F335B8D22441B7B_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D3570DAA3A1BBAE81B455B8D2244144C_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_D3570DAA3A1BBAE81B455B8D2244144C_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_CC1F1E646F9536EB0C655B8D22444B0D_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_CC1F1E646F9536EB0C655B8D22444B0D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_6F7D42D2AEB852C4BEEB5B8D224400CD_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_6F7D42D2AEB852C4BEEB5B8D224400CD_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:to="lab_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_AA24CD525C33561953515B8D2244FF12_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_AA24CD525C33561953515B8D2244FF12_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_541B02CB90B5749CA16B5B8D218E37BF_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_51B780EEF8C94FA9EDF55B8D218E3032_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_51B780EEF8C94FA9EDF55B8D218E3032_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_DA477E924CA9392512BB5B8D2165EB6D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_DA477E924CA9392512BB5B8D2165EB6D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BEA21D033B95349011755B8D21652D18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_BEA21D033B95349011755B8D21652D18_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_DF57D6C0F34E5E79078F5B8D2165C9AE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_DF57D6C0F34E5E79078F5B8D2165C9AE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_EF9F452F7BFEB24B7C8E5B8D2165EC17_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_EF9F452F7BFEB24B7C8E5B8D2165EC17_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:to="lab_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_FF3CA20D407EB183761B5B8D21657683_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_FF3CA20D407EB183761B5B8D21657683_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_191F6057700FC48C0C865B8D2165CB7E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payment, including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_191F6057700FC48C0C865B8D2165CB7E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_829BE71E5DC7BD9DECF55B8D21CDDD06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_829BE71E5DC7BD9DECF55B8D21CDDD06_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_83A83E7D20333F1EB4C65B8D21CE2F86_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_83A83E7D20333F1EB4C65B8D21CE2F86_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6AFB11330BAE18C6B0EC5B8D21CE2B05_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4BFE86DA5274B07413985B8D21CE9505_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_4BFE86DA5274B07413985B8D21CE9505_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_FABC7F605552663F27525B8D21CEF41A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_FABC7F605552663F27525B8D21CEF41A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BF76F05F904B192AE8C85B8D21CE7120_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_BF76F05F904B192AE8C85B8D21CE7120_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1A8086603E67BFEF000E5B8D21CE0E22_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_56D9397C13A73078D2185B8D2203498C_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:type="arc" />
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_2EAB36CB4179CC70FDA15B8D2203E53E_terseLabel_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_AirlineProductsAndServicesTable_2EAB36CB4179CC70FDA15B8D2203E53E_label_en-US" xlink:label="lab_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="lab_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_DDF3A9EC44AA8D64C89E5B8D2203A4FF_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_DDF3A9EC44AA8D64C89E5B8D2203A4FF_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_F2D8E82BCA3D5A2D2D055B8D220376B4_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_F2D8E82BCA3D5A2D2D055B8D220376B4_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="arc" />
    <link:label id="lab_biib_WorkinprocessMember_531F3A650F35B5902B905B8D2203284F_terseLabel_en-US" xlink:label="lab_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_biib_WorkinprocessMember_531F3A650F35B5902B905B8D2203284F_label_en-US" xlink:label="lab_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process [Member]</link:label>
    <link:label id="lab_biib_WorkinprocessMember_531F3A650F35B5902B905B8D2203284F_documentation_en-US" xlink:label="lab_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:to="lab_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="arc" />
    <link:label id="lab_biib_FinishedGoodsMember_C919AE3DB3138B201A405B8D2203298F_terseLabel_en-US" xlink:label="lab_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_C919AE3DB3138B201A405B8D2203298F_label_en-US" xlink:label="lab_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished Goods [Member]</link:label>
    <link:label id="lab_biib_FinishedGoodsMember_C919AE3DB3138B201A405B8D2203298F_documentation_en-US" xlink:label="lab_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished Goods</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:to="lab_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7C7D3ECDDFEE6EEB0F855B8D22034525_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_7C7D3ECDDFEE6EEB0F855B8D22034525_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AF75ED42F8D450D73E1C5B8D2203BA5D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_AF75ED42F8D450D73E1C5B8D2203BA5D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_15FA0B016C8363760FC15B8D22035B03_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_15FA0B016C8363760FC15B8D22035B03_label_en-US" xlink:label="lab_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_15FA0B016C8363760FC15B8D22035B03_documentation_en-US" xlink:label="lab_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:to="lab_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_6099E0CAC772D590B0365B8D2204D046_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_6099E0CAC772D590B0365B8D2204D046_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:to="lab_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_5B8B38CDA1A0505C23C95B8D2204F7A4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_5B8B38CDA1A0505C23C95B8D2204F7A4_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_402DDA1C3B983794ECDB5B8D21EC4787_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3E3F3DAF0E528736994E5B8D21ED01DB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_3E3F3DAF0E528736994E5B8D21ED01DB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_5DF33F8D96102338584B5B8D21EDB6B1_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_5DF33F8D96102338584B5B8D21EDB6B1_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:to="lab_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_3277CCC82AF9E5850FB45B8D21EDA562_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_3277CCC82AF9E5850FB45B8D21EDA562_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:to="lab_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_B6A29CAF54152662A7F65B8D21ED18EE_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_B6A29CAF54152662A7F65B8D21ED18EE_label_en-US" xlink:label="lab_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_B6A29CAF54152662A7F65B8D21ED18EE_documentation_en-US" xlink:label="lab_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:to="lab_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0E333099915AB91702865B8D21ED8C26_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0E333099915AB91702865B8D21ED8C26_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9F3D1E09105E3CCF6BFB5B8D21ED0650_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9F3D1E09105E3CCF6BFB5B8D21ED0650_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_8DE255AB14B60F4E37005B8D21ED3AE3_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_8DE255AB14B60F4E37005B8D21ED3AE3_label_en-US" xlink:label="lab_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_8DE255AB14B60F4E37005B8D21ED3AE3_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:to="lab_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_B79A936C5A39A045EDC45B8D21ED4793_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_B79A936C5A39A045EDC45B8D21ED4793_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="lab_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_DEDC591717BD436B837F5B8D21ED1886_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to our hemophilia business</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_DEDC591717BD436B837F5B8D21ED1886_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_FDE1AEAF32587ED1B1955B8D21EE816A_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_FDE1AEAF32587ED1B1955B8D21EE816A_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_C79EC58ABAFE980763E65B8D21EE1FC4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_C79EC58ABAFE980763E65B8D21EE1FC4_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_A4ED72FD2737F52737815B8D21EE25DA_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_A4ED72FD2737F52737815B8D21EE25DA_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:to="lab_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_C699E0FEBE09C276BD4D5B8D21EE430A_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_C699E0FEBE09C276BD4D5B8D21EE430A_label_en-US" xlink:label="lab_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:to="lab_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_5EFB1EBB367CAA4B109B5B8D21EE63CF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_5EFB1EBB367CAA4B109B5B8D21EE63CF_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_E105BB315019F1902CD65B8D21EE2A68_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:to="lab_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_53DAAE557BBCF48C0F795B8D21CA5BF0_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_53DAAE557BBCF48C0F795B8D21CA5BF0_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_53DAAE557BBCF48C0F795B8D21CA5BF0_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6DF16A83F4093EF5DB605B8D21CA7C46_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6DF16A83F4093EF5DB605B8D21CA7C46_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6DF16A83F4093EF5DB605B8D21CA7C46_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A362CD29B999CBA94E815B8D21CAB58C_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A362CD29B999CBA94E815B8D21CAB58C_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A362CD29B999CBA94E815B8D21CAB58C_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_415365524C1D54DD91F25B8D21CA3522_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_415365524C1D54DD91F25B8D21CA3522_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_415365524C1D54DD91F25B8D21CA3522_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_EA25042813C888A88DC45B8D21CA2EC7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_EA25042813C888A88DC45B8D21CA2EC7_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:to="lab_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B228EB8535B61C9056085B8D21CA731A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_B228EB8535B61C9056085B8D21CA731A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Changes in Valuation Techniques</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:to="lab_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8564CC11DE55A33F9DD25B8D21CA9CDB_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8564CC11DE55A33F9DD25B8D21CA9CDB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_A3425AF5360D54AF93345B8D21D52D6B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_A3425AF5360D54AF93345B8D21D52D6B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:to="lab_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_957235974572C728B1465B8D21D61E39_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_957235974572C728B1465B8D21D61E39_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_957235974572C728B1465B8D21D61E39_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:to="lab_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_36E263E01D256AA846925B8D21D604E2_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_20F7429DBC056E875DD95B8D21D66C1C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_20F7429DBC056E875DD95B8D21D66C1C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="lab_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_0B76B6E42E8AD89011A85B8D21D61567_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_0B76B6E42E8AD89011A85B8D21D61567_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_C264407D72AD3CFB44235B8D21D6A0F8_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_C264407D72AD3CFB44235B8D21D6A0F8_label_en-US" xlink:label="lab_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:to="lab_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D366DDC5ADC80081DA6E5B8D21D733F6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_D366DDC5ADC80081DA6E5B8D21D733F6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:to="lab_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI product</link:label>
    <link:label id="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381_label_en-US" xlink:label="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:to="lab_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:to="lab_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:to="lab_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD_label_en-US" xlink:label="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD_documentation_en-US" xlink:label="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:to="lab_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62_label_en-US" xlink:label="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:to="lab_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC_label_en-US" xlink:label="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:to="lab_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB_verboseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:to="lab_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48_verboseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:to="lab_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA intellectual property charges</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:to="lab_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Textual) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2017 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2018</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:to="lab_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2F693462CA76FDA36EE65B8D2259F36B_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_327F97D9948D07A0BBFC5B8D22597D5E_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_327F97D9948D07A0BBFC5B8D22597D5E_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_755EF68846D4F80F8DB75B8D2259DE39_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_755EF68846D4F80F8DB75B8D2259DE39_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:to="lab_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:to="lab_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="lab_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="arc" />
    <link:label id="lab_country_US_64FF4215281CA8D68FBE4F9338E0C2A5_terseLabel_en-US" xlink:label="lab_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_64FF4215281CA8D68FBE4F9338E0C2A5_label_en-US" xlink:label="lab_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:to="lab_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E.U.</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:to="lab_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="arc" />
    <link:label id="lab_country_JP_E9007888ED299541C2334F9338E0B41B_terseLabel_en-US" xlink:label="lab_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_E9007888ED299541C2334F9338E0B41B_label_en-US" xlink:label="lab_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:to="lab_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:to="lab_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B_label_en-US" xlink:label="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B_documentation_en-US" xlink:label="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:to="lab_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_84B132EE13F1C79F5F056FDF207E78D6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_84B132EE13F1C79F5F056FDF207E78D6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_6024C9906C47139CFAEF6FDF207E44A5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_6024C9906C47139CFAEF6FDF207E44A5_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:to="lab_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_DB3EA57BEDA668E69F616FDF207F61FA_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_DB3EA57BEDA668E69F616FDF207F61FA_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:to="lab_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="arc" />
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_05EF1E9A24FB11A291426FDF207F4C3E_terseLabel_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_05EF1E9A24FB11A291426FDF207F4C3E_label_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_05EF1E9A24FB11A291426FDF207F4C3E_documentation_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:to="lab_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_F9CBDD06EBEE158C1EDE6FDF207F702C_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_F9CBDD06EBEE158C1EDE6FDF207F702C_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:to="lab_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4CBA65C053E175AF607F6FDF207FBCA2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4CBA65C053E175AF607F6FDF207FBCA2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_04E19CEF2951159BB4E06FDF207FF225_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_04E19CEF2951159BB4E06FDF207FF225_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_04E19CEF2951159BB4E06FDF207FF225_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:to="lab_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_F1E1C1FAD7A0A0F494016FDF207F5CCF_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_F1E1C1FAD7A0A0F494016FDF207F5CCF_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_F1E1C1FAD7A0A0F494016FDF207F5CCF_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_222BE5A3AD02212FF0826FDF207FE794_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_222BE5A3AD02212FF0826FDF207FE794_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_222BE5A3AD02212FF0826FDF207FE794_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:to="lab_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_F0588CA2FC4C54C809656FDF207FA643_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_F0588CA2FC4C54C809656FDF207FA643_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:to="lab_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_DB1613FDCD134C48AEC26FDF207FB057_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_DB1613FDCD134C48AEC26FDF207FB057_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_DB1613FDCD134C48AEC26FDF207FB057_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_B88FA170ED786C49D9636FDF2080375C_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_B88FA170ED786C49D9636FDF2080375C_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20A626940DC5CB1D0BF06FDF2080DC6E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock available for grant under the 2017 Omnibus Equity Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20A626940DC5CB1D0BF06FDF2080DC6E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_3911390AEB15618984F16FDF2080DD7E_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_3911390AEB15618984F16FDF2080DD7E_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_3911390AEB15618984F16FDF2080DD7E_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E852179472A2A49955C06FDF20805C42_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_E852179472A2A49955C06FDF20805C42_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_BAA2C9F6A79F1BC911436FDF208038D0_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_BAA2C9F6A79F1BC911436FDF208038D0_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62FC5F73FCC0AA4E98BC6FDF20800E02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_62FC5F73FCC0AA4E98BC6FDF20800E02_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_323BA03F60C42785ED386FDF2080FEDF_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_323BA03F60C42785ED386FDF2080FEDF_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_323BA03F60C42785ED386FDF2080FEDF_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3094B49C566097A80A555B8D2240B180_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3094B49C566097A80A555B8D2240B180_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:to="lab_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_156DBC661194BA15CE085B8D2240F55F_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_156DBC661194BA15CE085B8D2240F55F_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_156DBC661194BA15CE085B8D2240F55F_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:to="lab_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B5E43CC50E3802F8D4DA6FDF215E1F7B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_B5E43CC50E3802F8D4DA6FDF215E1F7B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_684650C8122F0B62644E6FDF215E80B6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_684650C8122F0B62644E6FDF215E80B6_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:to="lab_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7E528D3AF7A3ABE1156A6FDF215E90A3_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_972FA0D418EC5179AF256FDF215EBB6B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_972FA0D418EC5179AF256FDF215EBB6B_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:to="lab_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_1AE890C4653138E1CEB56FDF215EE104_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_1AE890C4653138E1CEB56FDF215EE104_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_09E48DB04A7A73B2960D6FDF215E1F5D_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_09E48DB04A7A73B2960D6FDF215E1F5D_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:to="lab_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_FCD9C58449F9FA39F0D66FDF215E7EE9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_FCD9C58449F9FA39F0D66FDF215E7EE9_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:to="lab_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_0C6DF974894EEB80ED6E6FDF21631747_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_0C6DF974894EEB80ED6E6FDF21631747_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_31078C35A27677BDD4456FDF21630052_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_31078C35A27677BDD4456FDF21630052_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_DC89AAAEBDAD66F77C586FDF2163604B_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_DC89AAAEBDAD66F77C586FDF2163604B_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_A913158B2AE7B75393615B8D2207DBE4_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_A913158B2AE7B75393615B8D2207DBE4_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:to="lab_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BB66AEBF2B426C8F42D05B8D22075B9F_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_BB66AEBF2B426C8F42D05B8D22075B9F_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1887A1C52C3FDBA907D25B8D2207AB36_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_1887A1C52C3FDBA907D25B8D2207AB36_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2725426902C2CE4F27DC5B8D2207C57D_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_2725426902C2CE4F27DC5B8D2207C57D_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_EC4E01CBC77E833719AB5B8D2207EB96_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_52CE19628A4B82DB20F35B8D2207043E_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_52CE19628A4B82DB20F35B8D2207043E_label_en-US" xlink:label="lab_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:to="lab_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_4E113F9022D521C218A85B8D220702A5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_4E113F9022D521C218A85B8D220702A5_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:to="lab_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_74207FB8F6F5B272A65D5B8D210DFA15_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_54BB547E1B0325C7946B5B8D210D7C13_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_54BB547E1B0325C7946B5B8D210D7C13_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_4B5802E6FAEF67D8F6F55B8D220F1692_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_4B5802E6FAEF67D8F6F55B8D220F1692_label_en-US" xlink:label="lab_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:to="lab_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_4E5E91DE7D1FAD5676C55B8D220FDB49_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4E5E91DE7D1FAD5676C55B8D220FDB49_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:to="lab_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_379486B722F939CFC20E5B8D220F2727_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_379486B722F939CFC20E5B8D220F2727_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_AE76E4D15F29463B82025B8D220F6074_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_AE76E4D15F29463B82025B8D220F6074_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:to="lab_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_EE6FD2E709C0512E17565B8D220F77BF_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_EE6FD2E709C0512E17565B8D220F77BF_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_EE6FD2E709C0512E17565B8D220F77BF_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_D16E3BE3A7ACA16504645B8D220FC78C_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_827C6BE5A16F58293BD55B8D2235751F_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_DFDC2C2CB8F99CEE03C85B8D22352D84_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Spin Off</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_DFDC2C2CB8F99CEE03C85B8D22352D84_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_23390B4FC00CAFB6F55C5B8D221B18A7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_23390B4FC00CAFB6F55C5B8D221B18A7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:to="lab_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:to="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="lab_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases under the 2015 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity increase during the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:to="lab_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:to="lab_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to retained earnings reflecting spin-off</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_DDE15F4ED1CAC58248C25B8D2183D668_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:to="lab_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_35DCDBB53D8B7613E8745B8D2183FC14_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_35DCDBB53D8B7613E8745B8D2183FC14_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D3FDF3A9C58F970EB7BB5B8D216385DD_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D3FDF3A9C58F970EB7BB5B8D216385DD_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesAbstract_D9FCCC65210464A52F056FDF205B00D0_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:to="lab_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_D547E07230C48626BBD86FDF205BBF3E_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyTable_D547E07230C48626BBD86FDF205BBF3E_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:to="lab_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="arc" />
    <link:label id="lab_country_IT_3C79542FD69B3C0D2AD56FDF205B0739_terseLabel_en-US" xlink:label="lab_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_3C79542FD69B3C0D2AD56FDF205B0739_label_en-US" xlink:label="lab_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:to="lab_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_E48030EACD39818A5DF06FDF205C6619_terseLabel_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductLiabilityContingencyLineItems_E48030EACD39818A5DF06FDF205C6619_label_en-US" xlink:label="lab_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Liability Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="lab_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_C512C30B4EBC4F074A306FDF205C9385_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_C512C30B4EBC4F074A306FDF205C9385_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:to="lab_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_E1374348872EE20D06B16FDF205CD596_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_E1374348872EE20D06B16FDF205CD596_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5B1297F9740D9002FF375B8D22161A44_verboseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Analysis of the changes in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5B1297F9740D9002FF375B8D22161A44_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_5B1297F9740D9002FF375B8D22161A44_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D6A24A98C8817884A5515B8D22163F4A_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in condensed consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D6A24A98C8817884A5515B8D22163F4A_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_D6A24A98C8817884A5515B8D22163F4A_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6D189B89347425BA999A5B8D21C33DF5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_6D189B89347425BA999A5B8D21C33DF5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_D5D7CA5112AEF74F20FD5B8D21C39054_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_D5D7CA5112AEF74F20FD5B8D21C39054_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5CD4D2C415EE7BF1F6315B8D21C34D81_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_5CD4D2C415EE7BF1F6315B8D21C34D81_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_CCC17421EFE3E382DC985B8D21C32934_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_CCC17421EFE3E382DC985B8D21C32934_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="lab_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:to="lab_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="lab_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Neurimmune</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75_terseLabel_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential payment to Neurimmune</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75_label_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:label id="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75_documentation_en-US" xlink:label="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Potential Payments to Noncontrolling Interest</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:to="lab_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_837BB04DD737DC2F900E5B8D217ED173_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_837BB04DD737DC2F900E5B8D217ED173_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6680F4EF349CC8702F865B8D217EBC28_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6680F4EF349CC8702F865B8D217EBC28_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_370F29BC1FC87D4A8E365B8D217E2DCE_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_370F29BC1FC87D4A8E365B8D217E2DCE_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_72654EC065AB3D08D5995B8D217F852A_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_72654EC065AB3D08D5995B8D217F852A_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_72654EC065AB3D08D5995B8D217F852A_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9758095DE84D3C91C73A5B8D217F6FFB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9758095DE84D3C91C73A5B8D217F6FFB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_112F651FA0A0526E3FBB5B8D217F62A2_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_112F651FA0A0526E3FBB5B8D217F62A2_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_112F651FA0A0526E3FBB5B8D217F62A2_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_D2DCD59EC93252854C735B8D217F4EEA_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_D2DCD59EC93252854C735B8D217F4EEA_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:to="lab_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9EE33C14FF94D4DDB8485B8D217F3F13_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:to="lab_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_DD6B112E022B5CF020E75B8D217F22A9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_DD6B112E022B5CF020E75B8D217F22A9_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4771E1C001A4C856C2B65B8D217FF294_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4771E1C001A4C856C2B65B8D217FF294_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_51A0B1A98B47308270B85B8D217F2366_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_51A0B1A98B47308270B85B8D217F2366_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6F7F3E3DFF00EB271A2A5B8D217F2799_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_6F7F3E3DFF00EB271A2A5B8D217F2799_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1BFFC61C945250EE06965B8D21800FDC_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1BFFC61C945250EE06965B8D21800FDC_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5485D4A2D6C6AB968A785B8D2180E833_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5485D4A2D6C6AB968A785B8D2180E833_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="lab_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:to="lab_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A_label_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:to="lab_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5_label_en-US" xlink:label="lab_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:to="lab_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:to="lab_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:to="lab_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:to="lab_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:to="lab_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:to="lab_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:to="lab_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:to="lab_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:to="lab_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:to="lab_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:to="lab_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_E5653ED0CB7EFA362AF85B8D218AAD8B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_E5653ED0CB7EFA362AF85B8D218AAD8B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_D28826C954136E789CE75B8D218A9530_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_D28826C954136E789CE75B8D218A9530_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="lab_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B6690994E21F9A5B8D745B8D218ABD15_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Unrealized Investment Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_B6690994E21F9A5B8D745B8D218ABD15_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_874D88AB7A269DF914B35B8D218A72A2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_874D88AB7A269DF914B35B8D218A72A2_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_EE974080B18BA227E7A15B8D218AE434_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_EE974080B18BA227E7A15B8D218AE434_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_BED9887D1D27F75440185B8D218A3A40_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_BED9887D1D27F75440185B8D218A3A40_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6614E5C26FC5B95E00055B8D218B5DB7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6614E5C26FC5B95E00055B8D218B5DB7_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B6A8E87CF903D06ED4335B8D218BBB39_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_B6A8E87CF903D06ED4335B8D218BBB39_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B826D648DCB4C83D02A45B8D218BC040_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income loss before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_B826D648DCB4C83D02A45B8D218BC040_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_CEE15D2AF0F1BBD2C58A5B8D218BC04C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_CEE15D2AF0F1BBD2C58A5B8D218BC04C_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_91703201D8ED34BAFE565B8D218B73FF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_91703201D8ED34BAFE565B8D218B73FF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_FCD237E963A0E4C9BB895B8D218BAA29_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, as of the end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F32B469C29C79EF849F95B8D218DEF6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F32B469C29C79EF849F95B8D218DEF6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_982990D158B7216499A55B8D218D7189_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_982990D158B7216499A55B8D218D7189_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1D72D2DD81934E352EE65B8D2275D63C_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_865555F4D9ACF87C84F15B8D227581A7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_865555F4D9ACF87C84F15B8D227581A7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1D355BBD53F356F3531A5B8D2275A054_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1D355BBD53F356F3531A5B8D2275A054_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_C8653F0ED19EB273536C5B8D2276D7A8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_C8653F0ED19EB273536C5B8D2276D7A8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D90A537A220B55E9610B5B8D227682DA_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D90A537A220B55E9610B5B8D227682DA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EE9BAEA3D7AF1A5C60D65B8D22762D0D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EE9BAEA3D7AF1A5C60D65B8D22762D0D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_AAD500BFB5488CBA9AC35B8D227655F7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_681AC65BF8FB1FEE08135B8D2276C722_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_681AC65BF8FB1FEE08135B8D2276C722_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1273BF4339F11E3171DF5B8D227687FA_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1273BF4339F11E3171DF5B8D227687FA_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_442E279C0D07D05160BC5B8D2276CC4B_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_442E279C0D07D05160BC5B8D2276CC4B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:type="arc" />
    <link:label id="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:to="lab_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="arc" />
    <link:label id="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272_terseLabel_en-US" xlink:label="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272_label_en-US" xlink:label="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272_documentation_en-US" xlink:label="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:to="lab_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC_label_en-US" xlink:label="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC_documentation_en-US" xlink:label="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:to="lab_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:to="lab_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:to="lab_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:to="lab_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payments</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:to="lab_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4_terseLabel_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4_label_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4_documentation_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:to="lab_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF_terseLabel_en-US" xlink:label="lab_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA related assets</link:label>
    <link:label id="lab_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF_label_en-US" xlink:label="lab_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:to="lab_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A_label_en-US" xlink:label="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A_documentation_en-US" xlink:label="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:to="lab_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments per the collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3_terseLabel_en-US" xlink:label="lab_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Direct Operating Cost, Royalty Expense</link:label>
    <link:label id="lab_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3_label_en-US" xlink:label="lab_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct Operating Cost, Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:to="lab_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_AAFCF1D76EF10C25A1EB5B8D21FDC2E9_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85E58726F87F3207D6DD5B8D21FD00E0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_85E58726F87F3207D6DD5B8D21FD00E0_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0B0BABE7A247E36528995B8D21FD1364_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0B0BABE7A247E36528995B8D21FD1364_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_56429DE87A888A9F67285B8D21BBFBAA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_56429DE87A888A9F67285B8D21BBFBAA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7EAAAF162E6DEA88167E5B8D21BB485A_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7EAAAF162E6DEA88167E5B8D21BB485A_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_7EAAAF162E6DEA88167E5B8D21BB485A_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_24E4D881BC8ED696E0BA5B8D21BB7CB8_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_24E4D881BC8ED696E0BA5B8D21BB7CB8_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_24E4D881BC8ED696E0BA5B8D21BB7CB8_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_F5F8ACEC319D3EA05EFE5B8D21BB084E_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_F5F8ACEC319D3EA05EFE5B8D21BB084E_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_F5F8ACEC319D3EA05EFE5B8D21BB084E_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F3A3804C7914454B68475B8D21BB6BA3_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F3A3804C7914454B68475B8D21BB6BA3_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_F3A3804C7914454B68475B8D21BB6BA3_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_9B6669CE4D9FA2963D115B8D21BBD4CA_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_9B6669CE4D9FA2963D115B8D21BBD4CA_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_9B6669CE4D9FA2963D115B8D21BBD4CA_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7AD9EFF49630DAB339835B8D21BB20EF_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7AD9EFF49630DAB339835B8D21BB20EF_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_7AD9EFF49630DAB339835B8D21BB20EF_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_3AB7C6F173A3EFC90F875B8D21BC9ABC_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_3AB7C6F173A3EFC90F875B8D21BC9ABC_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:to="lab_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5AB451D64C4C064A4FFA5B8D21BC0D4D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5AB451D64C4C064A4FFA5B8D21BC0D4D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_7F3DBBB4FAAB25C9C9FF5B8D21BCC78C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_7F3DBBB4FAAB25C9C9FF5B8D21BCC78C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_333945D9B8BCE999DDB65B8D21BCC194_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:to="lab_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C5DA6EFBC279DC990D2E5B8D21BCE7F5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C5DA6EFBC279DC990D2E5B8D21BCE7F5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6FD651D4948B1FD7A37E5B8D21BC5029_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6FD651D4948B1FD7A37E5B8D21BC5029_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_64532F3F88EAEC5FA65C5B8D21BCCD4C_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_64532F3F88EAEC5FA65C5B8D21BCCD4C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:to="lab_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:to="lab_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ Inc.</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Bank Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Bank Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:to="lab_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F7722013744F79FB6D0F5B8D2160B5EC_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_F7722013744F79FB6D0F5B8D2160B5EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A3615D5D2BF551634F205B8D216080E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_A3615D5D2BF551634F205B8D216080E6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:to="lab_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_98B6CC2C6E66AFAC592B5B8D22881392_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_98B6CC2C6E66AFAC592B5B8D22881392_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_1E7FB7C5E49B8C842DCF5B8D22889CA3_label_en-US" xlink:label="lab_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:to="lab_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_A41DD316C582A218D44D5B8D2288FC72_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:to="lab_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7C2158058E985D7B9AC95B8D2289D493_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:to="lab_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_E0E9839AFC28F63C03435B8D22897561_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:to="lab_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_708CB1C4502B4B8E5D4D5B8D2289BE72_label_en-US" xlink:label="lab_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:to="lab_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_7735EA41E6514EFCDAAA5B8D2289032A_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:to="lab_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6404FBA098A0319BF0065B8D2289648F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:to="lab_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_B9D3EBB296D052CA72E25B8D22897FEC_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_07C95A16E2877B7AE6085B8D2289CBEA_label_en-US" xlink:label="lab_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:to="lab_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_24F4936137ED7DD2AC5C5B8D228928D6_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3E63F1F92C721498569C5B8D21821189_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3E63F1F92C721498569C5B8D21821189_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E5F7CC51F6D82E3E30755B8D2222B8A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities transferred to Bioverativ</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E5F7CC51F6D82E3E30755B8D2222B8A0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="arc" />
    <link:label id="lab_biib_HemophiliaProductsMember_C76494530F292AB2F77E5B8D22231735_terseLabel_en-US" xlink:label="lab_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia products</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_C76494530F292AB2F77E5B8D22231735_label_en-US" xlink:label="lab_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia Products [Member]</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_C76494530F292AB2F77E5B8D22231735_documentation_en-US" xlink:label="lab_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:to="lab_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_132FB21CF7D6D6B476185B8D2223D27C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Distributed to Bioverativ [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_132FB21CF7D6D6B476185B8D2223D27C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_2F0BDB3FF315182CBF9D5B8D22239CC3_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ transaction services agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_2F0BDB3FF315182CBF9D5B8D22239CC3_label_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativTransactionServicesAgreement_2F0BDB3FF315182CBF9D5B8D22239CC3_documentation_en-US" xlink:label="lab_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Transaction Services Agreement</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:to="lab_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="arc" />
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_B2D23768125C95F044FF5B8D22236F9E_terseLabel_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of Bioverativ manufacturing and supply agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_B2D23768125C95F044FF5B8D22236F9E_label_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:label id="lab_biib_TermofBioverativManufacturingandSupplyAgreement_B2D23768125C95F044FF5B8D22236F9E_documentation_en-US" xlink:label="lab_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of Bioverativ Manufacturing and Supply Agreement</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:to="lab_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7EF1D04AD8B57CB6E295B8D22235047_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7EF1D04AD8B57CB6E295B8D22235047_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_6EDF83524FFF83DF08A05B8D2223C22F_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:to="lab_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_4FC5AC1D645F735A7EFA5B8D20F3B212_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_ED38CCD428C2A995356B5B8D20F4F770_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_ED38CCD428C2A995356B5B8D20F4F770_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:to="lab_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity minimum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD_verboseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Ownership Percentage Maximum</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity method investment ownership percentage maximum.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share with Samsung Bioepis</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue related to technical development and technology transfer services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:to="lab_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_292D97ACCF94B36A983A5B8D21E6BC9F_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_292D97ACCF94B36A983A5B8D21E6BC9F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6009DD97364DC762A31A5B8D21E68756_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_6009DD97364DC762A31A5B8D21E68756_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AA32C3B3C88FD0361A4E5B8D21E6AF10_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_AA32C3B3C88FD0361A4E5B8D21E6AF10_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3E77CEB8DACF3F4485765B8D21E8417C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_3E77CEB8DACF3F4485765B8D21E8417C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A63DDA24CB56EAC43165B8D216C5989_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_3A63DDA24CB56EAC43165B8D216C5989_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0011D6D18E71F1E7EE035B8D222C0981_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0011D6D18E71F1E7EE035B8D222C0981_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_BBFD29C4C6495DBC86A25B8D222D16C9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_BBFD29C4C6495DBC86A25B8D222D16C9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_494F548B56C824D572215B8D222D56A7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_494F548B56C824D572215B8D222D56A7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_79E235270F61EC4839655B8D222D2403_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_0A0AFF8FE6E4FFED3E925B8D222D870D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_0A0AFF8FE6E4FFED3E925B8D222D870D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_D6F4C5D26276F238A1FE5B8D222DA425_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets transferred, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_D6F4C5D26276F238A1FE5B8D222DA425_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8F3D0C15791E9ABB8F185B8D222D75B9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_8F3D0C15791E9ABB8F185B8D222D75B9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_8ED150CC8CC44D38E5795B8D222D8173_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_8ED150CC8CC44D38E5795B8D222D8173_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_FEA4C6B4975EF24650DF5B8D222E0099_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities transferred, net</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_FEA4C6B4975EF24650DF5B8D222E0099_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_8B0B65456F4525CF06D25B8D21AA907B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_8B0B65456F4525CF06D25B8D21AA907B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7D22502A32441BF7FC395B8D21AA115A_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7D22502A32441BF7FC395B8D21AA115A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4920793F84FE260A071F5B8D21AA3A34_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4920793F84FE260A071F5B8D21AA3A34_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_60116D6DDE5EE0E006145B8D22096B9E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_60116D6DDE5EE0E006145B8D22096B9E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4A840B35FE876E9CA6605B8D215631A7_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_4A840B35FE876E9CA6605B8D215631A7_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0AE37FF2F09CBFC4FD815B8D2177EAC8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0AE37FF2F09CBFC4FD815B8D2177EAC8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D6C9F9F36ED9EC37D09C5B8D2177EFAE_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_D6C9F9F36ED9EC37D09C5B8D2177EFAE_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_86EAA58B34875C3082555B8D2177E597_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_86EAA58B34875C3082555B8D2177E597_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:to="lab_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_60ABD31B76F0528E49905B8D21779385_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_60ABD31B76F0528E49905B8D21779385_label_en-US" xlink:label="lab_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:to="lab_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1D42112A5AD60C2821D65B8D2177AA58_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1D42112A5AD60C2821D65B8D2177AA58_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7F6CEF1FCD6C7CC244EA5B8D21777075_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_63382C03E7F92DDC0D175B8D2177D271_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_048B8037F33A183FC5215B8D2178F33F_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_048B8037F33A183FC5215B8D2178F33F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_05E0D1D1C1BF8675A8485B8D2269245A_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_05E0D1D1C1BF8675A8485B8D2269245A_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="lab_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6FA7934EF4806872E7685B8D226969A6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6FA7934EF4806872E7685B8D226969A6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="lab_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_710901987010B8ECA7275B8D2269E4C5_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_61517C01CDE11ABCE58A5B8D2269D48A_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_61517C01CDE11ABCE58A5B8D2269D48A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_93853B9CEB267EC814CB5B8D226962FF_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_93853B9CEB267EC814CB5B8D226962FF_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:type="arc" />
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_5D5C495B9CBD23A195745B8D2269932D_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_5D5C495B9CBD23A195745B8D2269932D_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_5D5C495B9CBD23A195745B8D2269932D_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_84EFC2811BD5D502E5CE5B8D22696B8E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:to="lab_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DE6C09EDE758E98F99575B8D226AECCE_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_DE6C09EDE758E98F99575B8D226AECCE_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:to="lab_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_0B005F821EB5D63AAAA95B8D226AC8F9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_0B005F821EB5D63AAAA95B8D226AC8F9_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:to="lab_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_094E606C4DDE17E838235B8D226AAAF4_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_094E606C4DDE17E838235B8D226AAAF4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2CE9B7F4C7EF6B8FFE055B8D226A985D_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2CE9B7F4C7EF6B8FFE055B8D226A985D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6AD8E838298D96119B165B8D226AE674_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_EF74CA5873563DBD49A45B8D226ABC3B_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:to="lab_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_89CC7FF9A855D38462B65B8D226A5C27_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_89CC7FF9A855D38462B65B8D226A5C27_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_C8C9B135B721AD87E9EA5B8D226A8556_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:to="lab_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24B4ED07F16FED35222B5B8D226A7ED8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24B4ED07F16FED35222B5B8D226A7ED8_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_245E599ED148332371D55B8D226A40DE_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_245E599ED148332371D55B8D226A40DE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_FB7F733EC6411E7C2AD75B8D226BC362_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_FB7F733EC6411E7C2AD75B8D226BC362_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:to="lab_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_CA8BA362B4DE57036E575B8D226B4869_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_CA8BA362B4DE57036E575B8D226B4869_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:to="lab_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_52C74758527EA346FAAE5B8D226BDB40_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_52C74758527EA346FAAE5B8D226BDB40_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:to="lab_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_D33DA0F1D98E2835E9885B8D226B7A38_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_D33DA0F1D98E2835E9885B8D226B7A38_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_BD495E81308CBAABDECA5B8D226BFFD7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_BD495E81308CBAABDECA5B8D226BFFD7_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:to="lab_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_FB359212811BB89E23725B8D226BEE16_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable and other financing arrangements</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_FB359212811BB89E23725B8D226BEE16_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:to="lab_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_52DF8AB0586789ADBBBC5B8D226B4F33_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_52DF8AB0586789ADBBBC5B8D226B4F33_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E5FFDC69844375DDB4915B8D226B6F39_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E5FFDC69844375DDB4915B8D226B6F39_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_82BBA54809A020C646255B8D226B525D_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_82BBA54809A020C646255B8D226B525D_label_en-US" xlink:label="lab_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:to="lab_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A004FE70AF99E03D364B5B8D226CC81C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_A004FE70AF99E03D364B5B8D226CC81C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:to="lab_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7A6DA74D9AB311A994BF5B8D226CFF33_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_7A6DA74D9AB311A994BF5B8D226CFF33_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_66E893D1F0B51CB91C985B8D226C90FF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_66E893D1F0B51CB91C985B8D226C90FF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="lab_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_DD277988108DBAF9C2D25B8D226CC4AC_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_DD277988108DBAF9C2D25B8D226CC4AC_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:to="lab_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_D4CE544EEFCEAF0B3C9E5B8D226C2616_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_D4CE544EEFCEAF0B3C9E5B8D226C2616_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:to="lab_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_E6D25445E1E6F5B505E35B8D226C12E7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_E6D25445E1E6F5B505E35B8D226C12E7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:to="lab_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2715CCE8A20781D9F3F25B8D226CC2DC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_171BF8DDC90FEE346E075B8D226C40B7_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_171BF8DDC90FEE346E075B8D226C40B7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_B2BB262DA642E9976C305B8D226C7C5A_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_B2BB262DA642E9976C305B8D226C7C5A_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:to="lab_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_B38D62C149B8FB6492D75B8D226CF765_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_B38D62C149B8FB6492D75B8D226CF765_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:to="lab_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_504F0A6106DD925D2B315B8D226CECEE_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_504F0A6106DD925D2B315B8D226CECEE_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:to="lab_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74D57B5BDD2AF325ADAA5B8D226D702B_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_74D57B5BDD2AF325ADAA5B8D226D702B_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_52306DFAF821405A0D595B8D226D0EA0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_52306DFAF821405A0D595B8D226D0EA0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_F1278D34499D136EA7815B8D2231A58C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities charged against equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_F1278D34499D136EA7815B8D2231A58C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:to="lab_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_A27F49ED0CA4D1E008116FEE38DD6614_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_26CF9E636D7457D4B3A1F5C98D0642F5" xlink:type="arc" />
    <link:label id="lab_biib_RemedyPharmaceuticalMember_25017D4FBAF520F82EA26FEE38DDB25F_terseLabel_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_25017D4FBAF520F82EA26FEE38DDB25F_label_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_25017D4FBAF520F82EA26FEE38DDB25F_documentation_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:to="lab_biib_RemedyPharmaceuticalMember_0D66D6DED9745E9C9AAD0947870A92E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_B1ACC52C12073A4F4FE76FEE38DD75BD_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_B1ACC52C12073A4F4FE76FEE38DD75BD_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_85AA0C7AC4035E90BB7FC5EB48FC035F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_DA3AF6D21B65904531E25B8D219BDBB3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2424810F920CFE112CFD5B8D219B6A9D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2424810F920CFE112CFD5B8D219B6A9D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_3E72038F2D23B230BB005B8D21955E83_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to noncontrolling interests.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7801C7089BCBA42F3C5A5B8D217A8978_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7801C7089BCBA42F3C5A5B8D217A8978_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2E11DEAC0948E37374F85B8D217A86F6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2E11DEAC0948E37374F85B8D217A86F6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_28B9D3229B8BF39147625B8D21B1FD10_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:type="arc" />
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746_verboseLabel_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746_label_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Equity Attributable To Non Controlling Interests [Abstract]</link:label>
    <link:label id="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746_documentation_en-US" xlink:label="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation of equity attributable to non-controlling interests.</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="lab_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">NCI, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:to="lab_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to NCI, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of net assets and liabilities acquired and assigned to NCI</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment and other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">NCI, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:to="lab_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations and milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:to="lab_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued TECFIDERA litigation settlement and license charges</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0_label_en-US" xlink:label="lab_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:to="lab_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:to="lab_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3_label_en-US" xlink:label="lab_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:to="lab_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A4708D71D9CC24E1B89F5B8D220B468A_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_A4708D71D9CC24E1B89F5B8D220B468A_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D9E5A601BFA8D29521CC5B8D21997CA7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D9E5A601BFA8D29521CC5B8D21997CA7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_6C000B5D2A16706045F05B8D21993229_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_6C000B5D2A16706045F05B8D21993229_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_6C000B5D2A16706045F05B8D21993229_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:to="lab_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_51CBD23B43C78E43E6B85B8D219A959F_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_51CBD23B43C78E43E6B85B8D219A959F_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_51CBD23B43C78E43E6B85B8D219A959F_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:to="lab_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E2A4A6BE65E7FAF0C6805B8D219A9B25_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E2A4A6BE65E7FAF0C6805B8D219A9B25_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_E2A4A6BE65E7FAF0C6805B8D219A9B25_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:href="biib-20170930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:to="lab_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DFB1A2C17523B7681E2D5B8D219A93DB_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_DFB1A2C17523B7681E2D5B8D219A93DB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2EDAF83C692EBD18E395B8D219A12D7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_F2EDAF83C692EBD18E395B8D219A12D7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_9861DF3931283130F9135B8D219ADFC1_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_9861DF3931283130F9135B8D219ADFC1_label_en-US" xlink:label="lab_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:to="lab_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB94FAB905B397B691B35B8D219A1D03_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_AB94FAB905B397B691B35B8D219A1D03_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A716C2CA380406DC97E05B8D219AE5A2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_A716C2CA380406DC97E05B8D219AE5A2_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_C96E9183AF1E72A805B75B8D219ADB83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land purchase</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_C96E9183AF1E72A805B75B8D219ADB83_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_7792690B07734031874A5B8D219A1092_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_7792690B07734031874A5B8D219A1092_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:to="lab_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_B0D154B9FE3C8E011A9E5B8D219A656C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual commitments for the construction of the facility</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_B0D154B9FE3C8E011A9E5B8D219A656C_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:to="lab_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F44877E223AEA2B433325B8D21FFEDAE_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F44877E223AEA2B433325B8D21FFEDAE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16ED7873280E37C5FE2C5B8D216B8DDE_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16ED7873280E37C5FE2C5B8D216B8DDE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>biib-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20170930.xsd#AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20170930.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20170930.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:href="biib-20170930.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="biib-20170930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:href="biib-20170930.xsd#CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20170930.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:href="biib-20170930.xsd#DerivativeInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20170930.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20170930.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20170930.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20170930.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20170930.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20170930.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20170930.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20170930.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20170930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20170930.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20170930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20170930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:href="biib-20170930.xsd#FinancialInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:href="biib-20170930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20170930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:href="biib-20170930.xsd#HemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:href="biib-20170930.xsd#HemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:href="biib-20170930.xsd#HemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20170930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20170930.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20170930.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20170930.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20170930.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20170930.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20170930.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:href="biib-20170930.xsd#InventoryInventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20170930.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20170930.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20170930.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20170930.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:href="biib-20170930.xsd#PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowances" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:href="biib-20170930.xsd#ReservesForDiscountsAndAllowancesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20170930.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20170930.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20170930.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:href="biib-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:href="biib-20170930.xsd#SubsequentEventsEisaiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:href="biib-20170930.xsd#SubsequentEventsNeurimmuneDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20170930.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_EFBCB9A92E495C328ECE1BB438553C9B" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F085C27A780C5E8C9D8F88C08824363E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C4F989CC463A57198BF29BA7B2C3762C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_C4F989CC463A57198BF29BA7B2C3762C" xlink:to="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BAA6E75ECDE558558AA5C5A1FC1498DB" xlink:to="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_D0D0BA21E4B75179AB65F84A335FCD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_DBABBEE2274051FCB3B11347043DD71F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_B5A9764ECEC15A749AC3069B8A42184F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0226B8DB2B575600941E11B9A12B5F05" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_B0095F8211145E508BC4655D2CBC0D94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_68D4040F7DB05FA3A05DDEF0991DAE1A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A73F11037AD45FBEA6722A0F3D3440D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_FBEB4F15D99C57CEAEBE450238776DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_D34906271ACA59B0AAB5F30F832E8CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_944731D0EAA25114AAE2A8D75A11D3F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_0A3B21B2CAF65872B32C44284283564A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_AED30801A2BD57CC8E18995FFD6E2DFD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_8FAFD1A7620B284395443B3453E13363" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_8FAFD1A7620B284395443B3453E13363" xlink:to="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6554E7CAB0B3C7589DA53B3453E17AE7" xlink:to="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3ABC101347D68DC3EB1A3B3453E13C20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_3ABC101347D68DC3EB1A3B3453E13C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_74305CC684AA26B3DBF43B3453E16BED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8417EB63BB39AD1C008B3B3453E15F88" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_74305CC684AA26B3DBF43B3453E16BED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_CD0BC47383C3D4927F713B3453E13E10" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_38EA1C1C79CD313B486E3B3453E1FB59" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_471E08B47FF73F27C8F53B3453E18725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1F4D2ED323FFBCD771753B3453E10B9A" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_044743FDC77B36E007313B3453E1BD45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_269810CEF1BA4DE3A9413B3453E1A7C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_269810CEF1BA4DE3A9413B3453E1A7C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_624A8AA8FC24E3B5A1AF3B3453E1F0A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_OperatingExpenses_EA220AE7B8F6434A5E7C3B3453E1A60D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_131E739A3D5D22C43A2F3B3453E18400" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_C0DCB35D9A1B308DF9BB3B3453E1054A" xlink:to="loc_us-gaap_NetIncomeLoss_131E739A3D5D22C43A2F3B3453E18400" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_78A0AF2F06DF520294B07F393836E9E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_78A0AF2F06DF520294B07F393836E9E8" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_E9E5C307C18B58B98EBD78C562330252" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_78A0AF2F06DF520294B07F393836E9E8" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_497AE32D2CDE53E4A6CD3259BBB34FF9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_F8B47A32B09A5F01AE35D85586D985CB" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_5A1E5EC9DE1C5BD3AC4921075D5AD877" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2E511451FB145492B4D65E7FE28CCB0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DC6C1B448D7A5D838B9CAAF153AB3074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2E511451FB145492B4D65E7FE28CCB0B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DC6C1B448D7A5D838B9CAAF153AB3074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5ECC3D26B87C51A0ACE016DB70FEBBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DC6C1B448D7A5D838B9CAAF153AB3074" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5ECC3D26B87C51A0ACE016DB70FEBBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05A3AB6CD22D53578400A2335CC58E8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5ECC3D26B87C51A0ACE016DB70FEBBD0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05A3AB6CD22D53578400A2335CC58E8C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_FCDE9B033813540ABDAE55C400EE852D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05A3AB6CD22D53578400A2335CC58E8C" xlink:to="loc_biib_RemedyPharmaceuticalMember_FCDE9B033813540ABDAE55C400EE852D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3E3668CB2A1F5D50BB01EC4CC352A2CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_DC6C1B448D7A5D838B9CAAF153AB3074" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3E3668CB2A1F5D50BB01EC4CC352A2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_B47372B54A075A65902DEB72764C96C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3E3668CB2A1F5D50BB01EC4CC352A2CF" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_B47372B54A075A65902DEB72764C96C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_94AF92DA55A9560DADB304014CAD906B" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_079C4F8FA69F5E2BAE8707D4FF15919D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8354C89878BE17F8DE6A3B0BFA672132" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8354C89878BE17F8DE6A3B0BFA672132" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_1FDAC40C0FBBBAA3C1AC3B0BFA67DB28" xlink:to="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7D50DAE58A44524DE1A03B0BFA681C3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:to="loc_us-gaap_MinimumMember_7D50DAE58A44524DE1A03B0BFA681C3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_15027E6E8A478DA16B073B0BFA6801E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_88C21BA8FAEDCFF2F6473B0BFA67DFB5" xlink:to="loc_us-gaap_MaximumMember_15027E6E8A478DA16B073B0BFA6801E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EF6C10FFE2A9FD70FA573B0BFA6889DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E664FCAD939C6AD01ED63B0BFA68E742" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B04125936D56DA25F77E3B0BFA681593" xlink:to="loc_biib_InLicensedPatentsMember_E664FCAD939C6AD01ED63B0BFA68E742" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8BF279E158851F88BAEB3B0BFA68BA78" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_BristolMyersSquibbMember_21CBC20C91115D2191363B0BFA683A42" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_IPerianMember_A74E34CF7B14D1BC8CFF3B0BFA689272" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_AbbVieMember_014CC95F7D291E77AF393B0BFA68F7EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_D496AF6CFDEF63FDAA713B0BFA689BC6" xlink:to="loc_biib_IonisPharmaceuticalsMember_4F6D020DF81617828AA63B0BFA681660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_0A35DB963902C28130603B0BFA68FDAC" xlink:to="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:to="loc_biib_ZINBRYTAMember_78B379C1A16C4A3B739E3B0BFA6831F9" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A5A2B0EE8A707D2EA15C3B0BFA69EF40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_98E77045117AD8100BEB3B0BFA6811C2" xlink:to="loc_biib_SPINRAZAMember_A5A2B0EE8A707D2EA15C3B0BFA69EF40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_B936B5AE5D97F62091DC3B0BFA69E80A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_371E33E1A5D72AF902833B0BFA69E0A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:to="loc_country_US_371E33E1A5D72AF902833B0BFA69E0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_1BD1A55BE2DE94530C983B0BFA69FF63" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_3480C02F3824E8888D373B0BFA696BC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_A1EBD4F2C4559C63BE6E3B0BFA6788C9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1BE500F78CD04736A5443B0BFA69ECB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_AdditionalMilestonePayment_0A8DB20537148C96151A3B0BFA69782A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_DevelopmentalMilestonePayment_39E48DA4ACB0A3B2DE813B0BFA6945D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_Assets_522C301EFF0AC753A9293B0BFA692EBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_06AB621761AB9791B0633B0BFA692944" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_94A7487FA4A9BB818A733B0BFA6964FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_94A7487FA4A9BB818A733B0BFA6964FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_BF514905593A0357A0BB3B0BFA69EEB7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_OtherSalesRevenueNet_BF514905593A0357A0BB3B0BFA69EEB7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_5F36DF367EBD814D4DA23B0BFA69C4D8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_Collaborationprofitlosssharing_5F36DF367EBD814D4DA23B0BFA69C4D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_LicenseFee_94BC8AF57C5D3039027D3B0BFA69CB1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_9C7165EC239957B9C92B3B0BFA69B975" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_9C7165EC239957B9C92B3B0BFA69B975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_7EFCBC80DDA511F273D43B0BFA6AA985" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_7EFCBC80DDA511F273D43B0BFA6AA985" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_2A59C139A20DCC7C9B013B0BFA6AAED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DirectOperatingCostRoyaltyExpense" xlink:label="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_53A535760A100DA974C53B0BFA697CC8" xlink:to="loc_us-gaap_DirectOperatingCostRoyaltyExpense_AB7398941C213BE564A33B0BFA6A91C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5674C3F70FAF7CFBFCDBE7345B201834" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5674C3F70FAF7CFBFCDBE7345B201834" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvesteeNameDomain" xlink:label="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B85D06612FF450BA36AEE7345B21050B" xlink:to="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvesteeNameDomain_F71E229CF8D7A1FCBFD5E7345B2110AE" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5B60AF6EFC22A8A61243E7345B216135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_600AA3C93DE174FB8A35E7345B213988" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE1A8139AAAFBE2ACB9EE7345B21B27A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentOwnershipPercentageMaximum" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageMaximum_00CAAD6042158DCBE6B0E7345B215EBD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_7BFDDD563CC9672B7D42E7345B21A023" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_1ABFEC1B5F65E023F420E7345B21BE9D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_biib_Collaborationprofitlosssharing_1ABFEC1B5F65E023F420E7345B21BE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_603C3A995C38CF8A3F05E7345B2105E8" xlink:to="loc_us-gaap_OtherSalesRevenueNet_077599CE24A4404FB31CE7345B216E57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9B933FE6EAE155FFA9B8CAFC1794117C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9B933FE6EAE155FFA9B8CAFC1794117C" xlink:to="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B66B189F31A55BCA8F83FAF85A675283" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_137A2097D06856F7985E68AB222CAE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6F08028DB7A9548C8992BDA0753E38A2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DuefromantiCD20therapeuticprograms" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_499B553E69575FDBBCCB5CB529631A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_InventoryNet_665A4BB0D0025952948085768F5239D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_OtherAssetsCurrent_BF5758EDC83353BEB65D17B633603E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_E3CB63A82BCE581FA364FAE8FF72B651" xlink:to="loc_us-gaap_AssetsCurrent_3CD6C61C0E01500B840A905D1E9E0867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_117F1E9CCE53526484E341BCF41EB8FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_283DA5F1C88E53D7825F5D6D94BCF014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_D44478991790565FB3EA1B314954692E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_Goodwill_7F863E67C0A15FA4A1AC5F2D19D43540" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_C1E62BB178045F70BB75ACC4A6A5D154" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E22A884A22EA57CB92846091872B1417" xlink:to="loc_us-gaap_Assets_D6D0FDC9A36F5FAEB2BAED2FB83A091B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9B933FE6EAE155FFA9B8CAFC1794117C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="loc_us-gaap_DebtCurrent_01CBD5451B0D59309E38B6C34714A662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="loc_us-gaap_TaxesPayableCurrent_0133349C5D2F5A8A81C9B5938A6C40DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="loc_us-gaap_AccountsPayableCurrent_7906EE105A145955A619A38B387A0DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9E4A6FEC7B0B589B880127B47377E6F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F2420289234A51CA9F2B3C4918F367B2" xlink:to="loc_us-gaap_LiabilitiesCurrent_F5DAC9DDF2365D4AA9FEB1752DE2E584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_LongTermDebt_177869CAEF9B53A4A76E50573E822E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_5ECC12D6EEE95876A9849E7FD685235B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2AD15AD910955D37A9ECD548DA026C68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_Liabilities_B434C8728CBB50F4AB8E4A7917DC597C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_469281B1A383509E8C2C44359C473894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_PreferredStockValue_474C6401D4605B8992065CAB66ACC257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_CommonStockValue_47F7F99FFFCC50EB9B11B5F6A3D209C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_AdditionalPaidInCapital_F1CF0D2A6BB0516CAA299028011061DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_E6C2A717C76B55A0B98B59F863CF250D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24FF7A62A87E5D51B4565865A3419342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_TreasuryStockValue_586F6EED6FBA594595F2A67DFC904D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43CA0AF610F15A7E821757E68BFA2CA4" xlink:to="loc_us-gaap_StockholdersEquity_BCBE81B4217C517CABDB17F5522B6FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:to="loc_us-gaap_MinorityInterest_C2DBC96DCB8A59419FF558DD0F3A0B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0E6D1D8317EF5334AA36144FABB699DD" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_82CA9C4E3D505FEBAC95B61219269915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46C7317CE1285FC78D0BEB2D643C6CF4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3B400F5E0ACB5482A3F2E0A5ED4A31A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_B4408017131355648C7CB36EC0E42701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2D7B5CBC4E8257DAB4ADB05F2B2366EC" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_161223B4924956E8AFDDC6651B7F4F8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:to="loc_us-gaap_ProfitLoss_8BDE63C68553E463BFED308641A0B8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_887C56634732D51B972D308641A0D499" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3608912D1B96567C2AF5308641A004BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_ShareBasedCompensation_B511C057FB860B9B060A308641A0726A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_69A49CDC2BDF3BC9888E308641A0037E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_BA21CD7AA2E868EB3BE3308641A0C7D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97EFB0746FBA2AA7FEC2308641A0A2A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_EB5C8993F84B88354E81308641A0662E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_B815C37B5934E70B5707308641A02E94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_E4F59F62CD23AD3FB5CC308641A05AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_12135E4F2C9329A5AFFE308641A084E3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_A3CF675EE030A4D79EF5308641A066DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_955827AEFA3E0BE9CDA7308641A0353A" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2378B54EB05BAC7C42F4308641A076F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5D4EDF083145A21C33BC308641A0F489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_A2091322DFBDFF042404308641A00219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8E7201D1EB1E318441A6308641A05B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_A0086B8575DC80F3B39A308641A078DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_AD3DF51967795E5D1277308641A070D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_12C515BD803E94FEEAC8308641A02889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_91A974E907A71D5C8BB5308641A0D459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_93D23EBD4782C7CA2B16308641A06181" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_305BB02E90EA82350783308641A0120E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2E6635075C313C8D188D308641A09670" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7B4AFA35896E2091EA44308641A0FA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_28BFEF1C85BA077FF722308641A0A8CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfBankDebt" xlink:label="loc_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_RepaymentsOfBankDebt_25AC3E70FB0166150429308641A0F557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_773EB3020F06133E904F308641A04A24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_C290FD6A9DCADE1F7879308641A0D5EE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9FD57C872BE55B7953EA308641A0EBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_87D030B9FBFD2AB5A25C308641A0E298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_86F9E869FF6388A6D5F3308641A0D660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F977A9C1CC690D7FB216308641A05B96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_FE0BB2E1F11D50AD672C308641A05DB6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8AC3D1E475F9E4CABEAC308641A0C71F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BB7035478BC55C6CAF43652393C1CCC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:to="loc_us-gaap_NetIncomeLoss_BB7035478BC55C6CAF43652393C1CCC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_659CB9588BA655CCAF8ED6E22B3099A5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8637ED1E80AA5618B85F5066EE0F4877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_990A541C8ACD5C98863F318965413CA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_98205A125A9754DABFB4EF6E8B9B4E17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_32CFB84AA6F059E2A34B891E9AF7A62C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_84583C519C18507C80AD63D78870C132" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_E8D6ED122122517386C590A17AE5E070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_D21B01752E165CB5828A42CF779A6D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D80CF3D1FACD55E3BFBD4ED9175AD24F" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_EB096141BA565F27A6F0CF7BA70ABB23" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_8E028E37D7072032E2673B3454ACFDB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_8E028E37D7072032E2673B3454ACFDB7" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_RevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprograms_ABD53277C1B5BF88061C3B3454AC7FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:to="loc_us-gaap_OtherSalesRevenueNet_291482694A405E840EB33B3454AC4D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5F95E6ACB5851352C1963B3454ACECC2" xlink:to="loc_us-gaap_Revenues_41A8977C6334D7B4D8313B3454ACD9C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_CostOfGoodsSold_B82AFBA21ECC63AACB923B3454ACC70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3FAE25E1D106080A9D453B3454AC359F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_39EFE4CDBF742C64D9C63B3454AC4160" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D4552DB6A781B80E1ED23B3454ACD45F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D4552DB6A781B80E1ED23B3454ACD45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_E4DD1F8F2C27D7C66E763B3454AC89D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_biib_Collaborationprofitlosssharing_FACE924F355B28C905B03B3454AC4511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_DA4FF6A33A50BC13C68E3B3454ACBE61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_RestructuringCharges_32857B197C226939C55F3B3454AC82CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_D068D348B83CD704CBFC3B3454AC50C8" xlink:to="loc_us-gaap_CostsAndExpenses_C163BC873DA2628065D13B3454ACF26B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_OperatingIncomeLoss_993FA4577F3F5DC30BEE3B3454AC3ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_21494E812033340578D43B3454ACD0E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_842FCEC690AE642EA9A63B3454ACD5A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4F0E2C2487A89639B5FB3B3454ACD07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_09B53FFD32DD816D8CAE3B3454AC893C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_ProfitLoss_C99A09EBADC0D2C1FB743B3454ACC5F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_A4DD2DD2CD51308D97703B3454AC93E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_NetIncomeLoss_235439875106C94AF7A93B3454AC03F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:to="loc_us-gaap_EarningsPerShareBasic_F66466148B05434C3B223B3454AC124E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C1609843BC895ED11B263B3454AC592C" xlink:to="loc_us-gaap_EarningsPerShareDiluted_F7E63D36EC89DE753A623B3454AC4ECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D0229BF4D969FBDA70833B3454AC4686" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_60D21731AA992FBD91813B3454ACD650" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D0229BF4D969FBDA70833B3454AC4686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D0229BF4D969FBDA70833B3454AC4686" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_868E976ABB8675342F033B3454AC1404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_D0229BF4D969FBDA70833B3454AC4686" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4DFE0F5EF5895DF3D1FC3B3454ACB3F2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B83AFF79E38D52D78B23E81125A71DD4" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_0E8346F431A458F0A2FBBFF69711D406" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B613FD218BF5972F170449C52F0E9440" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_B613FD218BF5972F170449C52F0E9440" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F954FB7FE5BE7014B2B249C52F13B118" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C205E0D8917BA44FA57349C52F13B894" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_EC2F4C45704CBC7B0DB449C52F138CDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrencyAxis" xlink:label="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencyAxis_334C867A034771DD994F49C52F13CA10" xlink:to="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_EUR_40B208410E1312B2242E49C52F18AC55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_GBP_6422B67508C5874164A049C52F1956D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_CAD_94F49E793D1435F3B7A049C52F1914E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5E925A06A8A260058DD549C52F1301B5" xlink:to="loc_currency_CHF_5B46EE2D95912FAF997249C52F19B7BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_A5CC88EB165A1A78551249C52F19C345" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_SalesMember_8565495FA063F8CCA83549C52F197139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_OperatingExpenseMember_49C3DD671D71B60DE8E749C52F191603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2DBCC3A0C6E44B8C613649C52F197B6D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_BFD61DCC38C9153D241349C52F19D952" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_268E9F14532E0371338849C52F19CEA7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:to="loc_biib_CashflowsrevenueMember_8AD11C3EB96E26EDFECF49C52F191FA1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_292FD322B089A90C628049C52F199BB0" xlink:to="loc_biib_CashflowsoperatingexpensesMember_5EEDBC944A148028B66E49C52F19FCC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_25056832D0BC32E4A66549C52F19DA5B" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2264DAFB08F668F1A89F49C52F1ACAFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2E99F2A495AE6DD40FB749C52F19B59D" xlink:to="loc_us-gaap_InterestRateSwapMember_49BB37283FD02DEBEC0C49C52F1A27A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_083A2BC1E2EE636B428549C52F1AA14A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_E0BAC5484A93879EF2E049C52F1AE7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherInvestmentsMember_91AFCF8AF009795F91C749C52F1A1293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_BCD78A7A37421C19890749C52F1AC872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FE0F6B489916635B436F49C52F1AA0A0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_FD9A26E73A7450C02A2049C52F1AB604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_A5CF203BDD5C43E69AAE49C52F1C5A9A" xlink:to="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7CCCBC9810614C71C60549C52F1CACAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_BB51857C9445713B2BE549C52F1C7CF2" xlink:to="loc_us-gaap_NondesignatedMember_F9867A23BF6617B0C47149C52F1C6E3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_A562EE8C59366C8A445C49C52F1C4B0B" xlink:to="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:to="loc_us-gaap_MinimumMember_D01DDBB8887D2F91EB0E49C52F1D8698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9070C2FBD28C5319365249C52F1D31C7" xlink:to="loc_us-gaap_MaximumMember_746BAD1B5ECB2E8DCA9549C52F1DAA5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0A1F864AAB41C79DC57649C52F1158B0" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_AD5DFF67AF5FBCABB8D249C52F2280C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_A7F5F7D2AC0B87BAC78449C52F1DC455" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_28DB3F9FD1852F07393449C52F229DFA" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_DerivativeInstrumentsTextualAbstract" xlink:label="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_AFD4D96CA3445A5FF67F49C52F1DBDFF" xlink:to="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_4F75DCA1627E74BB651849C52F23FDFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_invest_DerivativeNotionalAmount_3437D33A18292403E5C249C52F2306D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_8C298E423C270061F64049C52F2326C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_4E2FDF0096EC2B2D0CDF49C52F231D27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_8C908FB512A80A2CE10949C52F23AC10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_C2475955F479D1ED006949C52F23B3A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeInstrumentsTextualAbstract_10F343E8A30298E89D9949C52F2255A8" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_3E856411E4A59B17BAEC49C52F230C62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E6B34B57E6AF597CB83AF2350D537057" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E6B34B57E6AF597CB83AF2350D537057" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_D1586D35A9E251DEBBBB02BDDFE45EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E6B34B57E6AF597CB83AF2350D537057" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_7804ED4D56D85BCDA95C6FBB2170BC58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_E6B34B57E6AF597CB83AF2350D537057" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_537C27BA396A5E069AA45633762C1821" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20170930.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_EntityRegistrantName_17A14104570352ACBD26145CD9551B73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_EntityCentralIndexKey_99A942842DD857239A40556D6F5D3092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_CurrentFiscalYearEndDate_8D4A1D56315E5231A768C97B291C5F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_EntityFilerCategory_8012230EF1295D2BAFC07A3623274E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:type="locator" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_DocumentType_4A8F674E93F156318CB108360EEF7642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:type="locator" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_DocumentPeriodEndDate_3D0725EA475852DFB3A7B4BAB6F626C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:type="locator" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_DocumentFiscalYearFocus_991BAFA2332D5A00B89BCCBABDB63B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:type="locator" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2885FA9CA26257399F93F3FE720E887B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:type="locator" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_AmendmentFlag_702A6AB770825135B5305D139365FB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:type="locator" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_B11D7E683BF95ED18CDE165F23852F68" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_FAFCB19648605CB08CD590F51B9FE734" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ADD09C98455655F9A16E2BAEC7143527" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_B39BFA4856525C15BABF2668FB19E436" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_531BFDDB0C6C543AA82F3D97EE90801B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_531BFDDB0C6C543AA82F3D97EE90801B" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_176B15701A995EF8BFB2F404E2858989" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_55F2417A3B8F5ECE948F8760D5849A54" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_4771595EC7E3509EB4C3A35F3CDC3F95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_4771595EC7E3509EB4C3A35F3CDC3F95" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_275B7FBBE9F05E109AFE41329CDBF99F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DDEE366B19EB5E7099604F6AB436B4BF" xlink:to="loc_biib_MarketStockUnitsMember_275B7FBBE9F05E109AFE41329CDBF99F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5D8613DFAF4B5FEB965702631FCFBAED" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0FD27E7F88AD54378D18DB12F7E51EB4" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:to="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_15146F347B8A54AAA5F26B65CCE778EF" xlink:to="loc_us-gaap_NetIncomeLoss_F3B5BE4C9AF25487BA3808C42CD1DDFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_C47B6825A72A59A8A0298BC0DE1CB898" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_C63ADFE471345263BC444C8808B562D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_92B3F745A044532F95AC2559DCBF7724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_8FEAA975DABE5BB682765C332C58070C" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_FE6A01366D975ACB96530DC3B780D40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_14B0727DF0555C738099770A2F9B59CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3DB3427B42F35EBC8ADDAF2F8BF73545" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_658B3001307B599AB7624AE69EDBD3A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_658B3001307B599AB7624AE69EDBD3A3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_785EF479DEB25EB7906769818925EAA2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7C401880D14E536BB2BACCE7F7433624" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9C1232FEBA205E8C8E7767D2A2D0C35B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_11885D4BC87248CF74843A228932050B" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_11885D4BC87248CF74843A228932050B" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="loc_us-gaap_MinorityInterest_CDCA989C42219091A9893A2289322D7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_BE6C1461CAABAB47805B3A2289320509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_CE65E9CF2F8FAA996A8C3A2289327A6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_F539F00F7252AABA144F3A228932F8E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract_97C238600A2F151B0D623A2289326746" xlink:to="loc_us-gaap_MinorityInterest_9EC0B7625CDEAC1126BF3A228932E30C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_9FD15A327422DB655F093A22892E42B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9FD15A327422DB655F093A22892E42B5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_626E5F2FCE85CC5E95313A22892E298A" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_3151CEBD978064D55AA33A22892E0736" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_C0654E1601838BC43E483A22892E3B2A" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_5F137F90DE1AC158CFDD3A22892F0AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7AA6E4B6148A3C6C673F3A22892EC868" xlink:to="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_68739E1104BCA383D0803A22892F97B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D3E669807832D68410F33A22892F86E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F647A041AB90E55F17193A22892F2E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_A47C3D96FE4684AA17223A22892F0E04" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8E54E079F8EBB1C857A13A22892FEF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9FD15A327422DB655F093A22892E42B5" xlink:to="loc_us-gaap_StockholdersEquityPeriodIncreaseDecrease_881376387EBE7D18DFF73A22892F3A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9FD15A327422DB655F093A22892E42B5" xlink:to="loc_us-gaap_NetIncomeLoss_5A7A48995A1A7A5FBE303A22892F9836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9FD15A327422DB655F093A22892E42B5" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_D0E983A8C131A8D899BF3A22892F758A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_331B8B10AB475669A30BDBD81F52B9DC" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock" xlink:label="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_331B8B10AB475669A30BDBD81F52B9DC" xlink:to="loc_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock_542A3EA9D43152DBBF613F5BECD740EE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E5BCD6DE0FEB5150B8562D97FF187158" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E5BCD6DE0FEB5150B8562D97FF187158" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_DD3964BA11425CE588944FD60EB21D1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8A360B38B182580B89B20515C15210D3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_F61AE673AF7750F6A31ED93DC4BFCCBD" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_526DEBF27E8B5F76BA76C9CB7897972A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4F5971EBCB3E5A7FAE8EEB6D56FB6D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2531FC551CC65D65A8E96D91D18B41B0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_666357ED3BE35ED594F56AA1B7FFB7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_AC295AF4874B54AABA112905C8BF5395" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_52385CCC543B5FC2916988111F04A0EA" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_000A1FAF21A359C28D3B703297941A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_3D95B4E7D0AF50D3B8E2E3F08ABC914D" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_13ED73AEF7FB5EA6BD2B02E558277FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_7960E54C4426579AAD4DEA464ACC0353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9F61A58FC3C55C1284F4ADA46E6F3D15" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5EA1425E8E885D93B655254D71E9F068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4950F0532AA35551842CEDC855E6937E" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_BFB029648F7157F992E31765667D50E5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3DD0708F51FD526E88E369826ABCFE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_AvailableForSaleSecurities_07498A5E703755F39A69E5E47C71295D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_1D97CE88049E5000AE364FBCDB593133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_C6CE50AC854E54D4ADC9A89B2FAA018A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_153BCC6D27FF53E48EB24A2EE67298B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0F45F8F8FF8D518DB0A1E774EA2BE93A" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_82BB5D081865515888B88641163D79CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisAbstract_672A0F8BFFA65BD88687FF9B51375C79" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_3A3A8E8AFAFF5DFCA34EDFE97E69850B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_00C9AC3106B452B5A42265C3520DE184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7190D06B423A56B8ADFB96D627BF7BC2" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_5FB9A4C63B32594A97D2C4309A5683BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_A8ACDF91480B5C92808D7531C60EE55C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_A8ACDF91480B5C92808D7531C60EE55C" xlink:to="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:to="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A7915E2380D453FBB63095067664E49E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_NotesPayableToFumedicaMember_D37D484490C65AFC99493ADD9D4435FB" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FD407F2FCAE05F84B0D22FC73B2F2A63" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5581F2A39C28529E96A592571BA7A890" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5581F2A39C28529E96A592571BA7A890" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_084B1340C9F05FB7829A138AEC3DCC85" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_084B1340C9F05FB7829A138AEC3DCC85" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_BAC150545D925160890A3B9DA5A21757" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_BAC150545D925160890A3B9DA5A21757" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BB95FE381F765D32AE138D30E5A4CCD3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1E51E00843B4501794E6C08C30EE9734" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BB95FE381F765D32AE138D30E5A4CCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7EAF4A38799258DC85581B60CF4673EB" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_92A80B3B4D9C511ABE75EEF536605AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_NotesPayable_E32E25BAF26A52F18150EF0907EB080D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1592444CE93D58479718D4D55E71975C" xlink:to="loc_us-gaap_DebtInstrumentFairValue_82A802356BEC5B89BB234B9B32F02812" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E70513AF148658D4B9BE9FFAEDD21831" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E70513AF148658D4B9BE9FFAEDD21831" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_A54BFE9A76D85F9C9A77B8FACF82A93F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9E176FE1B7FC59738E6CAF1E0BDED209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3E8CA3FAD0A65EA99C032FB88350689E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9E176FE1B7FC59738E6CAF1E0BDED209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_DF012CB8B765546A9B06F2BD9D9F50AE" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_A318ED18091C58808A24CC631A7EECE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_89703C6F7B5C583998478B79E939DC59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5EADCAEC77295968BC72DE20D819A5BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_46D0C84AE69F58229C02C127CCC46EC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_2965A2B9DE985F999E939FCD355257E1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_E8DD6B890502572D8667885CF32C2C86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D0813E21810758A0A9C11661B543532C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D0813E21810758A0A9C11661B543532C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:to="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_42861DAC83ED5BA3BA07D4D4D425714E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_03C8B5234B01590EB164BFDD4E8FFF15" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0CDCFCDA563654E1A9A2604C3D2556A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_0CDCFCDA563654E1A9A2604C3D2556A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_8A7800A0DC9F588F9BF9092F0FBA8D9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_A30D90C6DFD85A4A9616B3547FE619D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DA29B7D5091752BAB1591BB826CC3172" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1A81DD586EB15B3AA99C6911B89A323C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:type="locator" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_57F3912F77EC55309C86DA231C96E048" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_AssetImpairmentCharges_EA83774430C75A8FAEDE6086A1B47954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsChangesInValuationTechniques" xlink:label="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_FairValueMeasurementsChangesInValuationTechniques_44F5D3EF5E54598BA91E7154F78AAF7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EB0B942AC6F353898382136759A961CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_EB0B942AC6F353898382136759A961CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_495552615CA85FAEACCD7CA2ABF6C282" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3DD6177393F954E88BB20EC303213CDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_96818569880A54F7BA6746FAA1EFBAF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96818569880A54F7BA6746FAA1EFBAF0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8030F829FB115F5584F993A247746257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96818569880A54F7BA6746FAA1EFBAF0" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_95E5DBDDCABF5520B9055D012676AA8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_96818569880A54F7BA6746FAA1EFBAF0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6466A07B1A9559EF8695EFCF40721279" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AC6BCB99E4445AFDA8D1C1BEA7DB2C2C" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_98996168B9CA53D8A18BBF2DB78E12B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9E6134B3DFD059E499225AA8F990F0A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9E6134B3DFD059E499225AA8F990F0A5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:to="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_DB4D3CB2024E57CF9D68302D7C96192B" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_CommercialPaperMember_6EB896DF34E151E0A00D6EEDD6B5AD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_1E265442691F5E7B987A145048ED693A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B2764AE0FC5350BFA01BF1F377FDBFDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_995A9BC7D83053A786AB875922DBA51C" xlink:to="loc_us-gaap_DebtSecuritiesMember_7A22466BBB6353EE927A37E6BA7E61ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_54E8426159C3529E9740C6DC4AA60999" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_2F5039614FFA54129766B367DC57D887" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_80F5F29AF09F5639A2E5B9371990BE34" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_EF416087706F5F218C7DDF0F1A7B3026" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D59B604453B5459B115C6779E942E39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3D59B604453B5459B115C6779E942E39" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_6CC6743858465AFAA3D5EDC6C04006D9" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_EAF44B530F0551F496016A34207CFE20" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_07F75AC211E152F6B74A1F6B3906D271" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_DDE2FAB06CFF5F4C9E7511264A5C1C8F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_BE94704AD00D5D76B4E1E7231EB1D0F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_2A5D7326F1335ED8B989717F7D1E930E" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_C78117EC34805DC29DE5C5F8572D45EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2738364A5A1F5B4ABAF2A58F69F70D64" xlink:to="loc_us-gaap_EquitySecuritiesMember_0549600BE9C25B95AF2FC8B97598829A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_C9D9D6A889CC5D2EA23EFAE584A03082" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DD22F92CE2D65678BBC632EC6168806E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecurities_C8758A3B8C5751C5BBC679B398BC2D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3998708FF8BA54A4853A8F8740417AFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_91DC34F35F135211A8EC3AB86EC69069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_D17DD39DDA89550082E68EE328C20674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_2E5FBA14315356BA94C2FC87B1A1F508" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A3028AC4648317CFA33F3A22895F67A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A3028AC4648317CFA33F3A22895F67A5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_154DE13E191B8F7F88753A22895F0219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_AA96E78D084845C84ADF3A22895F29E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_E7A1FCD612E843F76E1A3A22895FC3BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_462F26481AC44F5D263A3A22895F923B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_11E811ACDC9C056D45BF3A228960DD39" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_F82735B6500CDF6416013A2289605536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9575BF0F5AC6BB5D94A03A2289608E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_AEC489EB04EB14B8F2ED3A22895F033F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8F2E7D7C771CF80A64113A22896060EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7CF00CF85BA85F5B9F317979FA927B07" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7CF00CF85BA85F5B9F317979FA927B07" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_A781D84CBFB6585BBE484D65E596496D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7CF00CF85BA85F5B9F317979FA927B07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_C26C9281B3B65109A8B4CDB45FBF8EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7CF00CF85BA85F5B9F317979FA927B07" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_CB8767F9E9C2508BA0A77DA84F5E7F95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97945783A3F15B0183144BA936AC7D1B" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_97945783A3F15B0183144BA936AC7D1B" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_FABC2AB322885AAA993A532A192F1E45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_3F01C17A3EFF55B98A5E11944D217B9E" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_BC1DACD03AAD5644A6E600EE72B43185" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_5BF079BD40815A308ACAEF14F1F6CDEE" xlink:to="loc_biib_StrategicInvestmentsMember_35E4976DC1085420ACBCAFC73E5E5E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_AAA952E2A7295273BF3CA504157269B6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2C5C28F1E5D85A94A710751562039B08" xlink:to="loc_biib_StrategicInvestmentPortfolio_4C3FE7D107AA52E68286A386150EB201" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_33D225DB8EA35B869EFA87A9A89EF9EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_33D225DB8EA35B869EFA87A9A89EF9EE" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_86D1EBBF25EB5132B5F8AFE3A559982A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_33D225DB8EA35B869EFA87A9A89EF9EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_BE0178DC8ED756D49677DA913B7A987E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_33D225DB8EA35B869EFA87A9A89EF9EE" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_280903C59AEC5110B38B67B320399A9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_33D225DB8EA35B869EFA87A9A89EF9EE" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_02359BAF80395DFE9F36879352ACA640" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOff" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8DB0F7D789BE5550AC79A8AAE389CCB9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_E6ACC8F471EF5C7DAD4BEDD43F87A23A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_644C38138B5A53C4888C85514493D788" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_644C38138B5A53C4888C85514493D788" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_CE300C92540A53D9A737A03976741B5C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_9D2F48BC2A8757E4BA8266958D604992" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_D96F38ADDEC75C798E5EF1FF8BB06A88" xlink:to="loc_biib_BioverativMember_9D2F48BC2A8757E4BA8266958D604992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_4176EC7803795E9B8E9F2ACCC408708A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E65F35843BE35105B08AC20DC0327C54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E65F35843BE35105B08AC20DC0327C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E9D55BDBC11E5A80B1270A59328D3015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21975D16EE1855C9A3082E55E55D0F86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_21975D16EE1855C9A3082E55E55D0F86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_C770AF9CF9C056DA819756F6A49934DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_4227B147BE8752698E5AB516798C0E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_1393E07238E4524CAAF2073795EF5E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_AE58D70403DC53649A5A55A57583D406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_E41C12FBAE9652CEB7F4BBE89714CA7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_A3DF3FCC84115BB5B88157FC2D4BE662" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_63FFBAC1E2D95EA9B929F2C03162EC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_46D31B72745858F5A98540A282547A3E" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_E43C4923A85459268C2B8944CD53E802" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5892C1CD90B5523DBE57A4C04B8B1FBB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5892C1CD90B5523DBE57A4C04B8B1FBB" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_79D70B86C2C3528BA130357DEFB506DE" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_FC5103295E60563A953AE36C04C3F493" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_B272279277DB55A6909274497A592356" xlink:to="loc_biib_BioverativMember_FC5103295E60563A953AE36C04C3F493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_C65C562067D45D8F96A422CC99982351" xlink:to="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_EC259182421C5825B82B8DA8608471E8" xlink:to="loc_biib_HemophiliaProductsMember_9D46619A05DC53C0A904B43606EC0348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_BE714EDF1307523BA0DEED714AFC542C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativTransactionServicesAgreement" xlink:label="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_biib_TermofBioverativTransactionServicesAgreement_6115E693918C51699C3E5F6EA77C3370" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TermofBioverativManufacturingandSupplyAgreement" xlink:label="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_biib_TermofBioverativManufacturingandSupplyAgreement_A66AE8E175D05B0DA2CD66941ED5D49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_EED8D881A6A4540494BEE518C027518F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="loc_us-gaap_OtherSalesRevenueNet_965082D786A75827B07BB79702D60A97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_OtherSalesRevenueNet_965082D786A75827B07BB79702D60A97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_CostOfGoodsSold_7E87CC4C9ECD5DE98A78C7C1D477616B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1B75000A44FB5E07AD4D2E9ADB7B7D98" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ED873542A26859239EC58305E8FBA6B2" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1B75000A44FB5E07AD4D2E9ADB7B7D98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B18CFF905267559AACB38EE00039EA33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B18CFF905267559AACB38EE00039EA33" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_57DD911DE0EA514CA02747163B6829A7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2F446F5BF1695D5192E74ACB6A7B37DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2F446F5BF1695D5192E74ACB6A7B37DB" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_C24EABC0E159509E8BF91FF12BFBF6FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94FC3B08AD4C59D1A1409930505C6008" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_65B12A574A7A58BDA4B8B8721DC15AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_40B989F2460C5E74B3BF37D94B3D7DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FF1F1E9067555D0FB10BC5A32F40414B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5DDF358DB6BC5DF2A1E59207EC01A94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_9A923B6BBF50586AA4A9CEB0E461263A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_09B84594F04059859333D5067E2DCB03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_8D020A9795E95CC48B53999DC2F38F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_E85D315A51DB5B6A9EE913224A4BC29B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_E196B37B0F0456408028434647E6B7AD" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02A5CD3E615450E798A5AF26B30C9C8B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_69933A4A9AA55F44812EE90161407C7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69933A4A9AA55F44812EE90161407C7A" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_C446BDE280C5550BB32048EB1F39A5C2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DFB5AE4DCE0D5B7AB3926FB46EACA761" xlink:to="loc_us-gaap_ForeignCountryMember_A995B5C3DEFF584DAB88C2DEA639AD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_D2B1CE7E9FAA53EA8D849FC5BA880614" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_2D9E9AC04BBE53BBA7ED04ECFA3578C1" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_4D6B2EDDFCEF571FB71D159D517D1DD3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43B4115C420D563E8C7B791D5F6028EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43B4115C420D563E8C7B791D5F6028EB" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_EC5D5DD89A7F55DBA5B0AFB85A880121" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64E761462B5858FB8E5F56512C60AFF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_64E761462B5858FB8E5F56512C60AFF3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_DC2EE67D6FA75A97911F1DFC956AEC3F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_63F81E6AFBCAFEE46A593A2289A7A7F7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_1866E6445344E054E7C53A2289A79968" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4B627C8F2F174DD3896B3A2289A79754" xlink:to="loc_biib_BioverativMember_1866E6445344E054E7C53A2289A79968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_31B0B795C1F497E745E03A2289A7C352" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FB28C5739A126D6E3BA63A2289A7B813" xlink:to="loc_biib_TysabriProductMember_B31263A51EC501F217363A2289A71381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7E91F9E9A834EBFCB4333A2289A7F079" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2FBB5906D746D8FA72883A2289A74341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_7318AB924840F1E052843A2289A78338" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_FF250D4D979EC4FECD4A3A2289A7C7A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C42D675EF9BD80A6F7573A2289A74C8F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_biib_OutLicensedPatentsMember_2047E8E58FBA98FCEFC93A2289A88C44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7C2BA281D8B9030FBCFD3A2289A85533" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638011386DA22B1BB9A63A2289A79775" xlink:to="loc_biib_InLicensedPatentsMember_AD1B2CF75ACF9268FA003A2289A809F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_4D689C897ECBF7D269483A2289A8999B" xlink:to="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_AVONEXMember_B3DBAA34D43E7611888B3A2289A8F2AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_SPINRAZAMember_03FC2D4057D4CF57071D3A2289A83F62" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_BiosimilarsMember_ECE085F0E87A18926EE83A2289A84FBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_79A559FB47A334DD90653A2289A8EC79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_F28C4368896E7F1E90B93A2289A8F9CF" xlink:to="loc_biib_TecfideraMember_79A559FB47A334DD90653A2289A8EC79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_D8B6EEFDCE8182A011CD3A2289A81B86" xlink:to="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:to="loc_us-gaap_MinimumMember_7285763C4F6918928C7D3A2289A8DECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3DAFCE923FA2124BC0D73A2289A864F8" xlink:to="loc_us-gaap_MaximumMember_66916CFD42E2ACF750F33A2289A80B48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_506D6547764AA8C0365C3A2289A74F6F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_B82C5BF070BD0B7BF4893A2289A8B70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_04312F4B73BDC57A56A73A2289A9AFBC" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_273F463A6391C81BF7153A2289A9D64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_E0CE1E5F3D1B169B0C023A2289A92F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_162F546F29BA27218D333A2289A9E867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_EB5A0C8ADC69D92141C63A2289A95902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6DD67C6EAA5BFD127D7B3A2289A9AC46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_F534CD4B274F0046B0873A2289A9A0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_EB1D5C8EF7E1E97A87D43A2289A88A02" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37EDE4DDC20348AAB4C23A2289A98BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_C485DF24872780B764123A2289A93172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_LitigationSettlementExpense_504B5C2ECFEC4A6F00953A2289A9B116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_70BB24DF024D6E3670CD3A2289A8FDC1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_87FEE0AD6E9817EAACC53A2289A9F8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract_01E60E2902359409F6CB3A2289A9445E" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3E8D8DD8FC51367137E63A2289A9EABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2950EE2DE0F6117B3BC93A2289A927A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_81B97284C9C3D0FA8C9C3A2289A91009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1A759FD0537454D3F6F73A2289A9A7D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_C83BF7B26B8ADF7863F93A2289A932B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0F938A73F2061CB9B84B3A2289A96AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0F1CCF04AC8B2292A91E3A2289A6C834" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C75FB9843D859787CB9A3A2289AA254A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_5C5DE017E08C54128BA7EBDC13898854" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_B29358B3D40D5848B1D008B6C12BC427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1D7BBA8027B05852B0251FAB685E7E39" xlink:to="loc_biib_BioverativMember_B29358B3D40D5848B1D008B6C12BC427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_6B353E9E7CBA597EB1BEE3C38FB05986" xlink:to="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_BBA39250EDA850639D30B0AF48A12674" xlink:to="loc_biib_TecfideraMember_B5403D2669F55F068D04A06966D818C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F744E2D340F15E128EA0BE943A79ECC2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_065D41EE800E566E89FB8917D4E23296" xlink:to="loc_biib_FumapharmAgMember_D77E7521EC2C5676ABDC9D16E753F4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_21CFC08873DD5CE9B3DE597DDF140CA2" xlink:to="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_BFBE656A273D5B7AAFF60E2E6821BE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E0AF96B1085853E9AA39FD78D1CD63FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_A1B4104A07235936982BD7E146EFB5E2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2904E9518CE156B4A161937778E8383B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7625375DB18A570EB3F3A37ACC314E4A" xlink:to="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:to="loc_us-gaap_Goodwill_122A58D240F95C4185C3E1B16BB46443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_9BA8B7B2E87F5C8EB3A70A13CB3C5E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_928484B7E3455D339CA3829143958217" xlink:to="loc_us-gaap_Goodwill_B4C041EBEAAE5C1B944ABC7FCE7D47FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74BBC6F98D4A5027AE00503E5D1172D9" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74BBC6F98D4A5027AE00503E5D1172D9" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_296F180481F45FDFA24A8BFA15568C82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74BBC6F98D4A5027AE00503E5D1172D9" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5029F1F8F10F54C9BFD6E15C0D86B336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_74BBC6F98D4A5027AE00503E5D1172D9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_A8725DC86D535E72A6F2EADD35FA48A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_DB93C54BDC975718B0F45628458D2F89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_DB93C54BDC975718B0F45628458D2F89" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_62EBE76B6D7959FFA5A233B4658D2066" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_CD115D8F95F058189ABA834A3292CEA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CD115D8F95F058189ABA834A3292CEA2" xlink:to="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4BD7391528CB5B8AA250F8A46FF9255F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_A5C368BA15DB502F83E7880A256ACD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_C9CABE4B63365C9D9F007647D5F1A753" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_8636C302E24551959381F5B13A7D79BA" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_35B9AE08BFCC500C8108EC4B2570DD92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CD115D8F95F058189ABA834A3292CEA2" xlink:to="loc_us-gaap_InventoryNet_D09428E163DD57A1AF89E8810666DFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_CD115D8F95F058189ABA834A3292CEA2" xlink:to="loc_us-gaap_InventoryNoncurrent_3E3634386EE158749BE78BE6C282E5D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryInventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AirlineProductsAndServicesTable" xlink:label="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_83BBD277CE5B566C8BB0A8B4E00DE695" xlink:to="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_39779084E8135893A9A8E70E76FF7A05" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_WorkinprocessMember" xlink:label="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:to="loc_biib_WorkinprocessMember_CACC6E1FDD48593980CE57542901489F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FinishedGoodsMember" xlink:label="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_621F345E44AB51C4A6F399BD561D9860" xlink:to="loc_biib_FinishedGoodsMember_35F8501E4C915BB882852700B3B26ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4F839B0700C45170BB9FE4CEE77085D2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_926D48741AD659D3A551022D761883ED" xlink:to="loc_biib_BioverativMember_47F1706D373259C69A780BC7DD4C55BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AirlineProductsAndServicesTable_836DEE4638645647B95DEE3DF7E80B9E" xlink:to="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_441A1E01A9BC570AAECAC9259E399306" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_79274627D6855F618FA688E321E7548E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_AB1950A7C0B35BF7A9FB4BC2CFE93E06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_AB1950A7C0B35BF7A9FB4BC2CFE93E06" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ADDE33D90F045C1DADFBAFC4109DDFB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_30033CCC7D3D5A0B982E0CD17C885F87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_30033CCC7D3D5A0B982E0CD17C885F87" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_ADE4D0AD40DB5EE7BC31BEB81D47B0E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_67390C66C9D05F3D854C62CBF0AA543D" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_C652DEDF3D0955BA880B3B47D7775D28" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_B05DC47403485FE58FDF432879D03D23" xlink:to="loc_biib_NeurimmuneMember_F459E8CEFCDC5972908C9FF813259651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_E02BAD9D192759A191DC407E3A7354CA" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement" xlink:label="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="loc_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement_E37C43E085EE57B7BD97E99C380F9D28" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_015C0F01CE5658278450727F05BDD550" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_5F3CE978B2AE58AB967BD4845E3B4A5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_E98DBDB496195E68BE4B0F27492BB80D" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_8257A842A48B5482BC9CFAA34D05CAFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F7908C8F5432599ABFA41F0799F11284" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F7908C8F5432599ABFA41F0799F11284" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_F2BAD56A902355B49903B439DF222257" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65959337F502A2B316273B0BFA7BB720" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65959337F502A2B316273B0BFA7BB720" xlink:to="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BBE7949CF8B3C4BDE7083B0BFA7B2AED" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_CC82421B2EF5C87128D23B0BFA7C3C35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7855AA7CD0F9CB611BE73B0BFA7CAC91" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_CC82421B2EF5C87128D23B0BFA7C3C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_3ACB4F1865B0612F039C3B0BFA7CAC49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_FA0ACB104E23E69410523B0BFA7B2A8B" xlink:to="loc_us-gaap_StatementLineItems_3ACB4F1865B0612F039C3B0BFA7CAC49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65959337F502A2B316273B0BFA7BB720" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_1EA0B9765D74AE49925E3B0BFA7C2BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1623A251B89F9A98547D3B0BFA7C1BB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_CB9847830D7933FB7EF93B0BFA7CF2FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_biib_Collaborationexpensesaccrual_EB21C7A71791B324BC9F3B0BFA7C6F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_6EE308D06626392CD63C3B0BFA7CD0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_B750435046112CB1ED023B0BFA7C55D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationReserve" xlink:label="loc_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_LitigationReserve_B8C55DF7A9051C2F1A3A3B0BFA7C3AC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75C95B2C39A8950A82C93B0BFA7C31C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6DA9BBA2DF44E0EB27AD3B0BFA7C0126" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5F1146EF9D19BD6B51003B0BFA7CE1B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65959337F502A2B316273B0BFA7BB720" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_InvestmentIncomeInterest_F68AFA6B467197ACBA353B0BFA7DD553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_InterestExpense_349143F3D456692E551E3B0BFA7D7EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_2EE4C47028016A559E9E3B0BFA7DD80D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1EA05696AFBF5D166A323B0BFA7D9D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25A63215A7A894A526943B0BFA7DC5AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_66758F34034EEE11BE933B0BFA7D5211" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_69FE554BD0DCACE2B7E63B0BFA7D7010" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyTable" xlink:label="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesAbstract_5BDC9FEC3DC95FB1B99461EA57C30ADF" xlink:to="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:to="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_BEA71EAA909E519096259F19C4C504A7" xlink:to="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_IT" xlink:label="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_525F3A18A91E5E0CBFAE2904896266FD" xlink:to="loc_country_IT_4D4DA964F45F50709DA77D577C906D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductLiabilityContingencyLineItems" xlink:label="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyTable_8D2663149FF856F29B7B25C5F04BE7C9" xlink:to="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="loc_us-gaap_PrepaidTaxes_4AB67E9F552D5CF293AEDCC746924855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductLiabilityContingencyLineItems_59C352A75AB95B3D94CBA7FA0FD54058" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_16945C39937E52AB8A809CD7530EC4FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7A18B542894752F58F18A175CD235C23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7A18B542894752F58F18A175CD235C23" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_C54366885B97542B9586814D49DC9E52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7A18B542894752F58F18A175CD235C23" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_912F26CD3EAF5859B316593862FC1352" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6C1D95F14D2E5F2E916B680038E68825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1C318614374354B6B766E0EBF101FD2E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48A2C75C829A56D4B5C491A908633806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_48A2C75C829A56D4B5C491A908633806" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_BB93F294DF0A5391AB9B346FA855512F" xlink:to="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SolothurnSwitzerlandMember" xlink:label="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_0A6553C6BBD25466A032FE55A61249A8" xlink:to="loc_biib_SolothurnSwitzerlandMember_13FD84D077B35EC1BD3382DCAB63F94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_EEF2FCDF2C7F54338C96E105C3B3A047" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_34CA3B74D69D5AADB86B177725F7E715" xlink:to="loc_us-gaap_LandMember_1F6F1FD34AA851C9B17E1B8852730D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3E68AA3F782F5FDFB33F7B269BD788E1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1D174122C05C5D2EB75BEEC0F91AE97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_5A1862E38A215B119C96FA42576E4663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_ConstructionInProgressGross_10B768E9C48A5FB1A506E7564DC4FC78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D305EF425685F59B244C394FEF430C9" xlink:to="loc_us-gaap_OtherCommitment_B4720F43F11858CE81A554D1F801C6B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_CFE88BF1A3B55EF3966EAB3E24219B84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_CFE88BF1A3B55EF3966EAB3E24219B84" xlink:to="loc_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_FCC72AD3CA225819AD80C8613B64C845" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_337EDFA5735D7C1DCE233A2289C1AD58" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_D55E0C948333E41152EB3A2289C185D0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReserveForCashDiscountMember" xlink:label="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_us-gaap_ReserveForCashDiscountMember_DFC29058C1169E7F03603A2289C294DF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_biib_ContractualAdjustmentsMember_B8CCEF1210E99879F8843A2289C2FB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8C7C3FCEC6EA406F25943A2289C124CE" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_33A98F05ABE2D32A23CC3A2289C2CC22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureTable_5E8902CD2F30D050A64C3A2289C102FF" xlink:to="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_61964DCC5D77040937983A2289C2021D" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6F6DA6107735B37E86BC3A2289C250E6" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_688A74893126A41955CE3A2289C2863F" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_3F8912806F88100643453A2289C24430" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_06AC60356B3A4A25D2623A2289C2E262" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_623D83930E52505CFBB73A2289C21319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract_CFA08C888900DB84C8C73A2289C2867B" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_04D0E5A6B4ACFFDC56A53A2289C2D3DD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_B0438FEEE3AB50F39804A8AC2BA941A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_B0438FEEE3AB50F39804A8AC2BA941A8" xlink:to="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D39D128A62125BCEABA8F4640D974EA7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:to="loc_us-gaap_AccountsReceivableMember_B77544A2C48C53C2B3740D2AE8DDC257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_7098CB1374B1590FA5376B247BAFA940" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_2FF9608F13E153BF8278F1DBE8807BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3390C904334B547B96F47503D6BB42B6" xlink:to="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4EABFCB0EC9455C6926F470866A700CF" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract_63489617E18B54D8B0CF1365F8EECEFA" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_245FB1286CF15319A226FF394E808177" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_78E1F5124E05561EA51BEA7E290EBC17" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_78E1F5124E05561EA51BEA7E290EBC17" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_1993E772557D5C36893ECD244C1F4291" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract_78E1F5124E05561EA51BEA7E290EBC17" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_7813839DDB165387BAF53554E6CD3013" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9AE5A2CB57FA5E3B80EF2C736A2DBE1A" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_EA9F267C04F958F3A2B4526C9FF1F2D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5FCE5D29D10C5B19A6CBE0F68CD97485" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5FCE5D29D10C5B19A6CBE0F68CD97485" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CF670FBFF8405F44AF3773A2EAF6DD19" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0C6FB9F08FA3561B9D2AC219453D5523" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_C3445C8D1E0052CBA4B24E2E0D932FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_RestructuringChargesMember_25D5B18A827C54288EFFB05804D96921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97A2414F6169545B817A84DAF2DE1CF6" xlink:to="loc_us-gaap_ParentMember_DAA713152A6953109C6128E3E2ECB34D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_D4CAFC12CFCF5F2F80726AC089DCBBC8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_99EF7784EB5C57A3B4820AFDA8DAE56B" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_866E37A7FCB5573CA837EF693CF1709E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_5CE6A54E770D5CB4868FB91899CFF3D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_38C8BCDE125D5EDAABDA869810B6411B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_38C8BCDE125D5EDAABDA869810B6411B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5F9B54C5A80B5CCBAAA0FA4F35EB4A8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_5F9B54C5A80B5CCBAAA0FA4F35EB4A8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_DC1ED89D7792585CB53B7C29E371F549" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99073771D74A5E2AB8B82A9862C48943" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79A884C21FF452A2AD3185F63EA682B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_79A884C21FF452A2AD3185F63EA682B5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_60087A97F39154229EB252A204035D76" xlink:to="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_63291DC06EF75087A381420C695E659C" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_86DD920DB462593384C5D0D2A4C5CEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5CACB0BE9CAD575AA7864B9E427AC78A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_MarketStockUnitsMember_66A6DFBEA6875A56887981AA71045F6A" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_A4A8A839DB5A5708A2BD84FF356BE312" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_CashSettledPerformanceSharesMember_7194E402BFC65B3381A5662755A0771D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_us-gaap_PerformanceSharesMember_98A9F1E4ADE05174887AA7FEC0B7E398" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D6EBB01E929454028EFC2FC7FEC0B61B" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_914F522FF5DD5D0B8EE7ED646100DA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5D8A91B6083A55B5987F0A2782B6556B" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9C5F042FA858574CA046FC21E8AA1B9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2181724140225544B1E7531A7DDD953A" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5EA8D9CA664B5BA3957FB94286D4208D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FF1A97A6D27154BA828913749426ED09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_E20EBBC0D59251D8A6C76E1A6AFFA4D5" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_FB3BBFBD028159F7ADD116074E5788E2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_CFEA2B74DD775FA797C805BF80A9A03E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_977C4F7AF18052738274F3E1F19B362E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_977C4F7AF18052738274F3E1F19B362E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E893A8EBDC0E5AC499DAD78C44C88932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_977C4F7AF18052738274F3E1F19B362E" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1EB9515781F05720931C73936678D0C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B4F51DBC448740747C154F92F4D94289" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_F81DF4C2AF72FBAE916F4F92F4E2640F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsEisaiDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_88C4967756175465760A4F9338DE4CAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_88C4967756175465760A4F9338DE4CAF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_687CDFF143ABAB0574504F9338DF2DF5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_536FFD2010751E4480414F9338DF4313" xlink:to="loc_us-gaap_SubsequentEventMember_ABAC0845E1C32DA7B4974F9338DF3331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_13985A88EFE9BAECE90D4F9338E0686A" xlink:to="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_country_US_64FF4215281CA8D68FBE4F9338E0C2A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_us-gaap_EuropeanUnionMember_F166FFECFD3CBC6A9C794F9338E03E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_0CED30AF3392689D35994F9338E0A34E" xlink:to="loc_country_JP_E9007888ED299541C2334F9338E0B41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A5C717221B3853EF54334F9338E1F2A8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A8DEF1DF64E2030C74F44F9338E665FD" xlink:to="loc_biib_EisaiMember_49AE9A78CC7308DEE8AB4F9338E6711B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1408A2C19326DA73FEB24F9338DE49FE" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_3ED21B9803F798FB43774F9338E64294" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3F131F2A15BCF31379F84F9338E6D9CD" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_A91EC2D39E1473CE91C64F9338E7FDAE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_575D0F939274746993D94F9BB2DA68CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_575D0F939274746993D94F9BB2DA68CB" xlink:to="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_026F1DE8952D4FC76CCA4F9BB2DA2FBE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_C806C2F3871C5A25D6F44F9BB2DA0D8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_00B608D2978D650150E24F9BB2DA8A10" xlink:to="loc_us-gaap_SubsequentEventMember_C806C2F3871C5A25D6F44F9BB2DA0D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_12EB4E1A0E6DFE2CB59E4F9BB2DB06D2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806975612CF542E6D9714F9BB2DB239B" xlink:to="loc_biib_NeurimmuneMember_A432E31815B5290166804F9BB2DBB78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_FC09A3DAB924A55F03C14F9BB2DAA774" xlink:to="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_7727B309507DD05C624A4F9BB2DB3B89" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_E4EC7EF0F38D21D0ECD54F9BB2DBAF92" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_C55CA71E39F67CE32E984F9BB2DB9C01" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_AdditionalPotentialPaymentstoNoncontrollingInterest" xlink:label="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_D5EAD3A7CD6A76F642EB4F9BB2DBC9A1" xlink:to="loc_biib_AdditionalPotentialPaymentstoNoncontrollingInterest_55884D689E2C8CD632B74F9BB2DB2D75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E182B736F36054A9B27F68EA6A4DCA82" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_54B24E6CD099578A9BACA078EF64965C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9EB13628138B53F381CF0100C6D25DB8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9EB13628138B53F381CF0100C6D25DB8" xlink:to="loc_us-gaap_NumberOfReportableSegments_28284B7FF7C752CEA270645FE5B95F2D" xlink:type="arc" />
    <link:loc xlink:href="biib-20170930.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9EB13628138B53F381CF0100C6D25DB8" xlink:to="loc_biib_InterestInSubsidiary_B05EC2CC828B5329B2121D2FF7FC09CC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:type="locator" />
    <link:loc xlink:href="biib-20170930.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_5E1574DBE41453A996006F2767C9EF43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_41CF05CB35C158CF8A456531F99FD915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_DC10BC550E8B5B0B8DBF665D9DF06128" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:to="loc_us-gaap_UseOfEstimates_388D589B17365A9688ED83055C8EBE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_63BACC359BD65AE4A3A79AB9EF6CE87B" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395E83D11B855C15A5291A652E5076BD" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-2017930acquirediprd.jpg
<TEXT>
begin 644 biib-2017930acquirediprd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%_VD/BZ?V?OV>/CS\>1H!\5GX)_!CXI?%P>%QJ7]CGQ(?AMX&UWQF- &K_
M &'4_P"RCK']B_V<-1_LW4/L/VG[5]BN_*\B3X[^$O\ P41\%:G\.K'XB?&+
MQ9\ +FS\3B>X\(:?^R#\1_B3^V%?BQ\-^#](\9_$NX\96'@;X+:/J_A>+X<:
M3XD\,WOB>_&EZCI&DZ?KVD3ZSJ&EW6M:%8:I]H_'[X2:=\??@3\:O@5K&K7V
M@:1\:?A+\1_A+JNNZ9!;W.I:+IWQ'\&ZUX.OM6T^WO/]$GOM.MM9EO+2&Z_T
M>6XACCG_ '3-7AGQ2_9"3QC+\*->^'OQ2\1?![Q]\+/AIXX^"]IXQ\.>%O!?
MB ZS\+_B=IG@.Q\<:-?:#XGTR[TN'6GU#X9>!O$WA7Q# 6/A[7] A2^TSQ'X
M<OM6\.WX!ZI\./VF?@O\7O%/C?PC\,O%LGC?4OAU%H\OB^_\.^'?$^H^%],;
MQ'X.\%?$+PU;0^,H-&;PGJU_XG\"?$+PEXO\-:;HVLZAJ&O>'M575=,M;BSM
M[B5/S]^'O_!8?X)>-1\+_$NL_#[XI_#[X9^/_A;^V!\2=6\2>+?A]\2Y/%G@
MZ+]D3XY?#/X/>)FO_AYH7P^U36[[PAJ&F^/=1\=Z]X_M95\/?#[3?"VH:+XE
MD&L6VN1:%]I?LL_LE^ ?V2=(^)7AKX<:AJTOA;QWXR\">)],T35/)E'A+3OA
MW^SO\#OV<_#_ (=L;Y,W6JP#PS\#-#UF\U'4,7MSK&L:H"J6R6R+\N^'_P#@
ME]X/T&V\6Z'#\6_%UQX1U#X*?MP? 7P/HLGAWP_'?>"? W[<OQ%\&_%CQTMQ
MK:2^;XIU7P9XV\-:D_@^\O[+3FDT'6H=)UY-1O-)76=0 /L/PY^U9\"O%WQ+
M'PI\-^,Y=8\32ZI>^'K#4K+PQXOE\ :WXLTOPJ/'.K>"?#OQ3.@+\-?$?CK2
M/!I?Q1JO@S0_%=_XCT_1+34[VYTY%T?6$T_P7XW?M/?M#?#+]JWX6? 3PQ\'
M/@WXG\#_ !7^'GQ<^*.C^.]<^-7CGPWXLTSPS\!/^%/Q?$JQU'P-I_P-\2:/
M)KU_=?%ZP3P-#:^.9-.U.'1KN37[_P /RW,,"<A^SY_P3$^#G[._Q<T7XH^%
M7\,7TF@7NH^*K*34?@Q\(Y/B$WC[Q%X&B\#>*M8E^-,_AN\^)D'AG5(WU?Q%
M8^$-,U?3I-&UGQ!JVEQ>)+OP']A\%V?U3\1OV>-$^(_QN^%'QOO?$.J:=JOP
MI^%/[07PKTW1;2ULIM.U73OV@9OA%/K.JWMQ/_I4-YH!^$>FKI<-O_H]T-7O
MC>?ZBVH ^8O@E_P5'_9I^*'P0^%'Q5\6:QK'PX\1_$?X<?LV>-KKX>7?@WXF
M:WJ-MJG[3^G/#\.]#\#7\7@'3Y/BYI>J^.;'7/AKI/B[P#IFJ:/JWC;2E\/8
ML]:U+3=-N?<X?VX?V9FF\8K??$*?0+'P-H7CSQ!K?B#Q1X,\>>&?"5U:_"JY
MAL/BE8>%_&&N>&+'PQXW\0_#35KA-"\>^%_!>JZ_XB\+^(8[S0-3TR+6-.U*
MRL_F+2O^"6/P^TJ3]F&2/XH^,YO^&8OA'^Q;\)- 5]'T!1XFT[]B_P"*"_$_
MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M?_)M;]% &!_:FK?]"Y=_^#'2/_DVC^U-6_Z%R[_\&.D?_)M;]% &!_:FK?\
M0N7?_@QTC_Y-H_M35O\ H7+O_P &.D?_ ";6_10!@?VIJW_0N7?_ (,=(_\
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MX>U/6--\0CP]<^+H[:&\\26/@5];O?#5M_:*>;'R][\;/C/KWB/_ ()Z^(O
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M-_R5F2?]A-7_ -1,0-;2]/U1]0T445_4H@HHHH **** "BBB@ HHHH ****
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M@5K_ /X)KS_XBK]CJ"7WF[;74+;RMF?MUE-:;]^['E^:H\S;M^?;]W*Y^\*
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M3F/_ *AUAQW7JOS/B-NI^I_G24K=3]3_ #I*_D404444 %>[_ ;_ )#FN_\
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MZ#_IQK\8O^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H P_\
MA)M(_P">US_X+-5_^0:/^$FTC_GM<_\ @LU7_P"0:WZ* ,#_ (2;2/\ GM<_
M^"S5?_D&C_A)M(_Y[7/_ (+-5_\ D&M^B@# _P"$FTC_ )[7/_@LU7_Y!H_X
M2;2/^>US_P""S5?_ )!K?HH P/\ A)M(_P">US_X+-5_^0:/^$FTC_GM<_\
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M -+6KZO@;_DK,D_[":O_ *B8@:VEZ?JCZAHHHK^I1!111D9QGGKCOCUH **
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M;1_D+_\ $TH((R""#T(.0?Q%+0 W:/\ (7_XFC:/\A?_ (FG4$@#)( ]3P*
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MPR:CJ,UM8VBE()"9KF>*($ %@Q6OJ$N@."R@^A8 _EG-*&5L[6!QUP0<?7%
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M?$GPNU'P+\/?%GQD^(NH?$'Q)\+/A_X,UIA\/->\,Z/8>-_%^I>$](DC\/\
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MCPWH^O:E\._%1\<>!K[5+&&\N?"GB\^&O$?@X^(]"EE!;3]8/A;Q?XGT#[=
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-2017930amortization.jpg
<TEXT>
begin 644 biib-2017930amortization.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
MLZW]J#_UCGX@U^WD?^KC_P!Q?_010 ^BBB@ HHHH **** "BBB@ HHHH ***
M* "LK6]8M- TJ]UB^69K2PB\Z=;=!),4+K'^[C9XPS;G'!=>,G-:M<)\3?\
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MK5*<'.<IN$(X3$\D(\S?+"-](*T8INR0_P";T_5'T_\ ;K+_ )_+7_P(B_\
MBZ/MUE_S^6O_ ($1?_%U4_L+1?\ H$Z9_P""^S_^,4?V%HO_ $"=,_\ !?9_
M_&*_J(1;^W67_/Y:_P#@1%_\71]NLO\ G\M?_ B+_P"+JI_86B_] G3/_!?9
M_P#QBC^PM%_Z!.F?^"^S_P#C% %O[=9?\_EK_P"!$7_Q='VZR_Y_+7_P(B_^
M+JI_86B_] G3/_!?9_\ QBC^PM%_Z!.F?^"^S_\ C% %O[=9?\_EK_X$1?\
MQ=2Q3P3;O)FBEVXW>5(DFW.<;MI.,X.,]<''2L_^PM%_Z!.F?^"^S_\ C%6K
M:QLK+?\ 8[2UM?,V^9]FMX8-^W.W?Y2)NV[FV[LXR<8R<@%NBBB@ HHHH **
M** "BBB@ HHHH _$#_@I/_RDD_X(4_\ 9UO[4'_K'/Q!K]O(_P#5Q_[B_P#H
M(K\0_P#@I/\ \I)/^"%/_9UO[4'_ *QS\0:_;R/_ %<?^XO_ *"* 'T444 %
M%%% !1110 4444 %%%% !1110 5PGQ-_Y$/Q-_UX+_Z4P5W=<)\3?^1#\3?]
M>"_^E,%>3G__ "(LZ_[%.8_^H=8<=UZK\SXC;J?J?YTE*W4_4_SI*_D40444
M4 %>[_ ;_D.:[_V"+?\ ]+6KPBO=_@-_R'-=_P"P1;_^EK5]7P-_R5F2?]A-
M7_U$Q UM+T_5'U#1117]2B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHKCKCXB> ;3Q)#X-NO&WA&V\6W(4V_A>X\2Z)!XCG#@%3#H4M^FK2[MR[=EF
MV=PQG(KL?\^G\Z /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\
MZ"*_$/\ X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@B@!]%%%
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M3_P$T+_Y44 ;E%8?]EZE_P!#)JG_ (":%_\ *BC^R]2_Z&35/_ 30O\ Y44
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MJ_\ J)B!KKZ?JCZMHK#_ ++U+_H9-4_\!-"_^5%']EZE_P!#)JG_ (":%_\
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M^7I[=: /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\ Z"*_$/\
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M?M)4W5IU9U(8G%1KN_\ PWY_?_PUK*WQ!!\-?VE5_;3T[XXWF@?!G4OA?9?
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M3 **** "BBB@ HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
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MN$W_ *+:OSM7H/H/Y5]SXN_Q<@_PYK_[S!"T445^-@%%%% '=_#+_D?/#?\
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MQ_WB_P"]KT:M.*:4H<CG7C2IVFRUMW^'IY^?H^CU/Z=_^%B^!O\ H9])_P#
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M5/#_ (HT&XMM5T35M.U/3K.\L[RWDDB+P_9K^TU#3+B]T^Z^._BS_P %^?\
M@D)XHTK2;72/VU?!L\UMJ;W$RGX;?'O"Q&SFC#93X2R'EW Y 'H2>*\*_P"'
MX?\ P2C_ .CS/!?_ (;CX_\ _P Z"O*X_P JS?$<4XK$X++<RQ%/V6!=/$87
M!8FM3YZ>'I*\:M*E*/-":UM*\9+6UA'O/PR_83\#_"KX4:#\-_#'Q8^.%EK]
MAJ&@:MXF^*]MXE\+7'C/Q]?^%?#-MX,\+)XET7Q=X,\;?#V/2O!?AJPTVT^'
M=AIOA&WN_AUJNGP>*O".K:=XGFOM4O.N\1?L:?"CQ!X5\%?#E=:^)NB?"?P=
MX)L/AW-\*=(\8V<WA#Q;X1LKV6_O+#Q-?^(O#GB#QY::AXQFN+JU^*?B+P/X
MU\%>(/BYHUW=Z#\1=2\0Z7.T ^6/^'X?_!*/_H\SP7_X;CX__P#SH*;_ ,/Q
MO^"4.XI_PV?X(\P*',?_  KKX^^8$)*B0Q_\*AWB,LK*LA78SJRABRL!\N\%
MQ9*?M'EN>.?M'5YO[,QB?M+-1FK8=6=)2:H6M]7N_8^SU'=GWSKGP7TGQ7I5
M_HWB_P 9?$+Q;IUU\=_"_P >[&WU[6])FC\/ZEX*\;>&?B!X3^&F@QV/AZPA
MM?A!H'B/PKITVG>$KN._U6.WFO89/$TK26TUI[']22>Y)R2>Y)[DGDGN:_*7
M_A^'_P $H_\ H\SP7_X;CX__ /SH*/\ A^'_ ,$H_P#H\SP7_P"&X^/_ /\
M.@KDEDG$,XQC+)LX<8RE*,?[,QBBI34(R:2H))R4()_X5V8K_P!?U_6_=G]
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M)1_]'F>"_P#PW'Q__P#G04O[ S[_ *$F;_\ ALQOE_TX\U_28'ZM5[O\!O\
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MCTI"R@9+* >A) !_$T -\M?0?]\K_P#$TNT?Y"__ !-*"",@@@]"#D'\12T
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M[0OPTLKR&WN9(I]2EE\7^/O"^GFTT])[J.&]EU"2);*RNYX?HSRU]!_WRO\
M\33@01D$$>H.1^8HR,9R,9QG/&<XQ]<\?7B@!OEKZ#_OE?\ XFC8HZ #_@*_
M_$TI90<%E!]"0#STX)S3J &[1_D+_P#$TGEKZ#_OE?\ XFGT4 ,\M?0?]\K_
M /$U\O?MI?##Q=\8OV6OC;\,O &G0:KXQ\:>![W1/#^G3W]AI4-WJ,U[831P
MR:CJ,MM8VBE+>0F6YGCB!4 L&*U]1%T!P64'T+ '\LYI0RMG:P..N"#CZXH
MC2( '(&2\C=%/#2,PYQW!'OZ\T[RU]!_WRO_ ,33\CIGD=1Z9Z4F1C.1CUSQ
MSTYH ;L7T'_?*_\ Q-. Q_\ J _D!2T4 %%%% !1110 4444 %%%% !1110
M4444 ?CO^TK\=/C?::O_ ,%"?'_A?XQ:O\+(?V"?AMX+\7_#'X;V&D> [OPG
M\7]4O/@M-\:M0U'XIQ^)M(U'Q/KOAOXD:W++\"_"]AX<\0^!&T74/#'B35-"
MO+WQ?/;7FF=7\1?BK\:/ G[2WP"\3P_$_P"(<WPB^+'QUTCX9^+9-2L?@;J?
M[//@X>(_#/C#0-/_ &=?^$?\)3:E^T+;_'NW^)VBZ&!\2]3>#P+I^MWNI:%X
MJU33M)CM/!Z?7_Q[_9+^$W[0.N>!?&OB33(M$^)?PW\0^'-?\(?$G1] \%ZI
MXGLHO#>HWNIVGAW4X?&GACQ7X?\ $OA4W>IZAJ-KH/B31=4M?#_B26T\;>%#
MH'C?2-(\0V786W[-GP#L_BB_QJM?A!\/;?XJR7ESJ;>.X?"VE1^(?[9O;"32
M;[Q MXMN GB6]T>:71;WQ/'$GB*\T:1])N=4ET]FMB 4/&/@WXVW?CS6O%W@
M3XLZ7HF@7_PMTKP;H/@CQ/X17Q+X3T3Q])X[?4]1^*-W9Z9>>&?$NM7J>#KK
M^PK7P[_PF6E:/<3V-I)<BU$MW=M^9WPQ^+_Q.^(O_!)[X/\ [07Q1^-OQH/Q
M7TWPU>ZG>^)/A=J/@7X>^+/C)\1=0^(/B3X6?#_P9K3#X>:]X9T>P\;^+]2\
M)Z1)'X?\-Z7#I=Y=6U];YM[,VL_Z_>/_  #X0^*'@_7/ 7CS1+;Q'X1\26L=
MEK>BW<MW#;W]M%=6]Y'%)+87-I=QA+JUMYE:WN87#Q+AL9!\?^&'[(7[-'P9
M\%7GPX^&'P7\#>#/ 5]XI\+>-IO!^CZ7(OAQ/%7@G7=*\3^$]<M=)NKFYM+&
M^\/^)-#TG7],>QCMDMM9L8-36,W@:9@#T+X,>#_%O@#X4^ /!GCWX@:[\5/&
M_ASPMI6F>+OB)XD&EKJ_B_Q)#;AM:UJXCT;1]!TZ&&YU%[@:?!!I5JT.FQV<
M5QYUTD]Q-Z=110 5\.?M"^)?B!XG_:1_9[_9L\-_$OQ3\&/"?Q(^&O[0'Q4\
M3>.O UOX.'CCQ!JWP?U7X*:!X:^&WAC5/&NB^+-,TA+Y/BUK/CSQ'+:^%+W5
MK[2_ UMIUO?V.CS^(4NON.O%OCU^S[\*OVD_A]JGPW^+7A>S\0Z)?07W]FWX
M2&W\1^$M6O=,O=(7Q-X,U[R9+_PSXFL['4;RWMM6TYXY'M;JZTZ^CO=*O;ZP
MN@#\B?&7[0?[4/BC]C&#]HGPQ\6?'MUXY^%_@3XQ'75^$6E_L[Z;X-AM_A%\
M4OC/X,T#]KSXX^'/'T^J^+O%OP3^(GA/X2_\)6WPR^!FG7&MZOI[^,8_AYH^
MJ:VWAV3PE^OVN6'BOX@Q?!'Q5X!^)#^'_#FE^,M,\>^,H]+TJUEL_BI\/M0^
M&OC73;7P@XU>RO[[1],O?%'B;P;XWBNK.:QUF+_A%+;3Y+\P7=_:7G 2_L>?
M #Q#X?\ AKI/Q.^&O@/XM:M\+_">B>#-"\4>,OAY\/;+4)_#^@ MIVCW6A^#
M/"WA7P7!X<MKC%Y:>"],\,6/@C3;M5N-+\.64JJP^GF575D<;E92K ]PP*D<
M8Z@D<8ZT ?B#KO[5/[4'P8^&?_!476O'?C^Q^(WCGX$?M%_L]?#GX;W_ (:^
M'.EZ1X;^&>A?'GX+_LE7.I3>%_"&H:E<7.O:/\-=>^-7B;QQ&_Q$\7:O=:[/
MIEQ)XDUG3O#]PNE:3]F?L6?$+QKJ/B#]H7X-_$[Q-\5=9^('P<\=>$WN]*^+
M<OPJ\1:YH?A7XB>"++Q)X3?3/B+\'M&\+^&_%^DZY]CUG5GL-;\*Z'XO\%:Q
M)JOAF;^VO!T'@GQ#JGH/P\_85_9%^%6K^-=<\!? +X>:!J7Q)\/:OX4^(<T>
ME3ZA%X[\.Z]::?IVL:3XQLM9O-2L/$UGJ&EZ5IND7":S:WK-HUC:Z0'73(4M
M![1\+/@Y\+?@CX>N/"GPE\!>&/A_H%[JEQKFH:=X8TJWTV/4]:NK>ULY]7U6
M:-3=ZKJ;V-AI^G"_U&XNKJ/3=.T[38I4L+"SMX #TNBBB@#\W?VO_B-^T1\)
MOC-\&=#^%_B2&Y\+?M@W$G[+'A^#4[31)H_@+\<++0?'?Q;TKX\:;%=B"[\1
MZ/=_!OPE\6[3Q'X3O9M2M[KQ[X$^"]OINFV6E>(O'FHK^=W[6OB[]HWX*>(_
M^"E]_P""/VO/VCA;? #]E[]E?XC?"?2-9U7X8ZIIGAOQ=^TC\0/C_P"#?&VI
MM WPK2XU3^P]+^'GAN?P3::G>7UEX?U*&ZNI;?4A=M$G]!'B3P-X/\8:AX,U
M7Q1X;T?7M2^'?BH^./ U]JEC#>7/A3Q>?#7B/P<?$>A2R@MI^L'PMXO\3Z!]
MN@(F_LK7M4L\^5=R@\-XY_9Z^"'Q,M/B?8^/OA;X)\6VGQI\'^&OA_\ %:'7
M-"M;U?'_ (+\&W/B.\\*>&O%#. ^J:1X=N_%WB:ZT:UF;;I]QKFI36Q22Y=J
M /F?X+^)?B/\._VM?'/[,&K?$CQQ\:O =I^SUX*^-FF^*/B./"=[XZ^'7B'5
M?B;XS^'LOA77/$/A/PSX236O#WQ!TWP^WB;P6NO:+/KFFWW@_P >1IXAU;1;
MG2].T#R']N?Q!^U5^SQ^RKKOCGP9\?K>+6]+_:/\.:YJWB.\\!:)J_BN;X8?
M%C]LGX?:+X-^$'AJ6:&T\+Z!I'ACX8>.Y_ .M^*-3\,>)O%6H:/H]O)I%[I_
MB*^F\767W]\(_@-\'?@/I>JZ1\(?AUX6\ VFO7T6I^()- TU(-0\0ZC;VXL[
M6^\0:Q.USK&NW5G9*EC8SZOJ%[)8V*)969@M46$87QV_9A^ ?[3>EZ'HGQ[^
M%WA;XIZ-X<O)]0T;2?%MM=7VFV=[<2Z?.]S]ABN[:VN)DN=)TR\MGNX[@V=]
MI]G>VGD7=O%,H!\T_M-^'/&^N?M$?L[^%OA_\?OCW\/_ !%\2O$%WJVM>%O!
MFO\ @JU^'.E?"'X&RV7B;XG^(KS0M<^'?B+4M2UKQA?>(_ ?PFP=>MX(#\0(
M?$%LEM-X;6&\_0X9 Y.3R3^)S@<#@=!WP!GFO.?"?PB^&O@9?!7_  BW@[1=
M(E^'7@W5?A[X)NXH);C4/#G@K7;[PYJ6M>&].U*]FNM032]6U#PAX8O=1@EN
M93>76@Z7/<.\EI$P]'H *^'_ -OCXL?$+]F_X*R?M4>"KZ_U/P]^S=J$_P 2
MOC%\*K5-&4?%_P""\>DW^B>/?#6F7^KFU&C^-_#-KJ=I\1?A]>IJVDV.H>)O
M"$'A77[E=!\37\]K]P5R?COP)X-^)_@[Q+\/OB%X9T;QEX(\8Z/>^'_%/A7Q
M%8PZGH>OZ)J,1AO]*U73[@-!>6-W$3'<6\JE)$)5@10!^1GQ'\-_M+:)^U'_
M ,$]O!7C3]JKXS:%??'N_P#CK>?'CP=\-=3\"Z;\.&U?X<?#B\^+>B^&/!<6
MK?#K5/$&G>%]%UR^3P3+?-K$>K^*_!^B6,^J26^KWM[<GA/V,/C3^T%;?"O_
M ()M_&'QC\>?B)\:-;_;7\7:]X4^+'PU\>6WP]N-.TVVU#X6_&?XG#Q_\+O^
M$=\(>$O$'A.T^&=_\,-%TW5],?4/$?AV^\(^)[Z'4;%/$2Z!KD?[5:U\/_!/
MB+Q5X+\<:[X6T/5O%_PZF\03^!?$E]I\-QK'A.;Q7I']@>))="OG4S:>^MZ+
M_P 2O4F@*FZLO]'DRG%>.?!W]CS]F#]G[6I_$?P:^!WPZ^'>NRV6I:7%JWAS
MP_!;WVFZ1K-_%JFL:-HEQ<-<R>']%U;4K>UO]4T?06TW3-1O+2SN+RTGEM+9
MH@"?QGX,^.PU;XQ^(/!'QBT_1K7Q?X,^&.B_#C1?$_@RU\4Z'\)]:\-ZCXUD
M^)?C*QTJQG\.:AXGUKQCH6NZ FF:9KWB2?0=.USPCI%S<V$FE3:QIFL?E1X2
M_:@_:>^*'[-7_!*OP;HVN_$36_BG^UE^R/JOQM^)/Q!\#77PL\$>-_&/C#X<
M?"OX/:O<^'XO%OC?PKK'P[^'_P#PF6M?%'4?&FL7FE_#W4+VZM_!3^'?#FDZ
M7HNIZW=Z;^T_Q+^&7@3XP^#-7^'OQ)\.67BSP;KIL3JV@ZC)>1V=]_9NH6VJ
M67G/875G= 07UG;W"B.X0,T060/&61O#-$_89_9&\.?"VW^">C?L_?#2R^%-
MAXCB\6Z5X#701-X=T+Q##HT7AR/4_#MG<SSMX<F7P[$?#XCT&;3K<Z%/>:.T
M+:;?7UK<@'1_LC_%:#XW?LU?!7XHP^(-?\52^+/ .B7>H^(?%?AG0?!_B?5=
M;L4DT?7[KQ%X<\)WNI>$-,UPZYINHQZK%X-U&^\&S7L<UWX1N[CPY<:9*WT9
M65H>AZ+X8T72/#?AO2-,\/\ A[P_I=AHF@Z%HFGVFE:-HNC:5:Q6.EZ3I.EV
M$-O8Z;IFFV4$%G86%G!#:V=K#%;V\4<4:(-6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-2017930anticd.jpg
<TEXT>
begin 644 biib-2017930anticd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %4 3T# 2(  A$! Q$!_\0
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MEJ'@;3O@3XGTF3Q#?7/Q?LQX&MK;QP^F:K!HEW)X@U+PY+>00)Q'[/'_  3
M^#O[.?Q:T/XG^%KGP[J4OA^[U#Q18RZI\&_A+)\0!X]\0>"3X*\5:N/C'+X>
MN_B)9^&-76[UWQ':>$=*U'3IM(UGQ%JFE0^)KGP(;;P;!]5?$C]G;1_B1\<?
MA+\<;OQ-JVF:E\*/A/\ M#?"G3]!L[/3I],UBP_:$G^#\^K:Q?75PIO8+[PX
M?A#IZZ3!:,MI>#6K\Z@&-O:;0#YI^"G_  5'_9C^)OP1^$WQ6\7^(=0^&?B#
MXD?#7]FWQW>?#Z^\(_$K6]0L-0_:>TZ6'X=Z)X-OX/ -A)\6-+U7QWIVO_#+
M2/%W@+2]4T;6/&^C'0$^RZMJ.FZ?=>XP_MP?LRNWBYKWXBRZ%8>"- \?>(M;
MU_Q1X,\>^&/"<]I\*;N'3OBG8^&_%^O>%]/\,>-/$/PTU6>/0_'OACP;JNO>
M(?"WB%+OP_JFFPZSIVHV-G\KZ7_P2K\#:9+^RY*/B]XZN#^R]\'_ -B?X0Z&
MLNB>&0/%6G_L5_%&/XG^&M9UDK'FQO\ QS>1II'B*WTS99Z;8*LVC*ERJD9+
M?\$=_P!FJY3XT>'[JWTA/ WQ8LOBREM:Z;\)_A'8?$GP[JOQD\;/\1?$=]??
M&B?PGJ'CKQKI_ASQ?+/<>"/#OB&7^Q8M#F'AGQW#\0M'M;""T /T7^'/QM^'
MGQ3T7Q+K?A;4=:MU\&:G)HWC+1/&'@[QE\//&/A'4TT33O$T=GXH\#>/=!\.
M>,-!EO?#6L:3XBTPZGHEO'JVA:G8:MIKW5E=12GPD_\ !0']E>W65=7\=>)/
M#5\FN_"OP_;:#XK^$?QB\+>+-4NOC?KFL>&/A%>Z'X.\0> M.\5ZYH?Q#\3Z
M#JOAKPQKNDZ-=Z7?>(+8:,]Q#J%Q:V\]WX"?L?\ A/X&?"GXD?#?0M2TCP[>
M?%2ZUJ\\1^)O@M\-?A]^SS+I-WJ?A2T\&VFH^$--^&>D6_\ 9>NZ-IME#J6F
M^)-;U/Q/K]MK[O=6VH6NCVNCZ#I7QKX&_P""/OPY\&>-?!/Q!'Q3U9O%'A._
M_9EGU"Y\.?"WX8>"(?&L7[+7Q@U'XL>#M5\;#PSI<%_XE\=^,)-3N=$^(_Q
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MBN!O$@TV#7QX(\0Q^+M7\46WA6#[.OAWQ;?7T^F7[^&QHWA?0_T74;55>NT
M9^@Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"G_!0
MM=0E^!.E6MA\;-$^!YO/BS\,(+W5?&.N^.? _P //'NF)KS76H?"+XC?%3X<
MM;^+/A)X0^)=O;MX?G\>V&HV$,&L/HWAN_37;'Q-<>%=?_*R7_@H;\6OA1X4
M\*?#WX0^%-+TK2M(UK]IU]5^(WQ"_: ^'7QY^"^J^)?A!<_![5/"WPU^#?[0
MGQU^,G[-B^,?A)JVG_%:]?4[]M0\2?%KX>0^"?&/P^\/>![_ /X0;6=1\/\
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MN]"2UUK5P#]&Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^9?C-^UA\+_@7\9?V7?@9XUM_%<WC3]KGQWXW^'GPKET/1K;4-#MM?\  'P\
MU7XF:Z_BW49M4LIM%T]_#FCW:6%Q:66JRW.HF.V>W@A,EU'],@A@&'0@$?0C
M-?B!_P %*65/^"D7_!"IF954?M6_M099B% S^QU\00,DD 9. /4D <U^VT=S
M;>6G^D0?<7_EM&>P[AL4 6J*@^U6W_/Q!_W^C_\ BJ/M5M_S\0?]_H__ (J@
M">BH/M5M_P _$'_?Z/\ ^*H^U6W_ #\0?]_H_P#XJ@">BH/M5M_S\0?]_H__
M (JC[5;?\_$'_?Z/_P"*H GHJ#[5;?\ /Q!_W^C_ /BJ/M5M_P _$'_?Z/\
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M ,8H_L#0_P#H#:5_X+;+_P",5KT4 9']@:'_ - ;2O\ P6V7_P 8H_L#0_\
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M>5Y:L97C1OO.TL+"RWFRL[2T\X*9#:VT%OY@7.S?Y,<>_;N;;NSMW'&,G/\
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M$_\ X*3_ /*23_@A3_V=;^U!_P"L<_$&OV\C_P!7'_N+_P"@BOQ#_P""D_\
MRDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(H ?1110 4444 %%%% !1110 4
M444 %%%% !7YE_\ !9'_ )1D_M@_]DOB_P#4N\,5^FE?F7_P61_Y1D_M@_\
M9+XO_4N\,5['#W_(_P C_P"QQEG_ *FT#P>*O^28XB_[$>;?^H%<_P Y:3_6
M2?[[?^A&F4^3_62?[[?^A&F5_8\=EZ+\C^#0HHHI@%?TO?\ !LE_R<G^TO\
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MGZ!96%HE_J'H7[/'P%\._$;P7XM\<>,4\4W>FZK\/OCC<_!Z#P@LCPZ_XO\
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M8NM;LIM0\ 7NN>$-1\ ZQ=>%+EK/S-&GU+P7J^I^&+R2U*--HM_=6#YAF8'
M^&?PW^ GP9U'Q-J_PH\#_L]_#O5/&$\,WB34/!TVB:#>:LEK-=75G97,]AID
M4@TJQO-0U&]L-'@,.DV-]J>IWMG8P7>I7TUP?5<3_P! ]?\ \$U/_D0^NX/_
M *"\+_X44O\ Y/S7WGU%7YE_\%D?^49/[8/_ &2^+_U+O#%?H1I^M:EJT3SZ
M5-X3U.".0PR3:=KMQ>Q1RA5<Q/);:=*B2!'1RC,&VNK8PP)_.'_@L1)KC?\
M!,_]KX7=MI,=N?AA%YCV][?2SA?^$M\,_P"K273H8V.<</*O..<9KTN'XRAQ
M#DD91<9+.,L3C)-23^NT-&G9KYGD\3SC4X7XAG"49PED6;.,HR4HR7U#$:J2
M;37HS_.LD)\R3GJS@^XW'@^H]J:2203R0203R06&&()Y!8<,01D<'(ITG^LD
M_P!]O_0C3*_L:.R]%^1_!X=R>Y 4G')4'(4GJ5!Y )P#R!FC@YR =QW-D [F
M_O-Q\S=.3D\#GBBBF W8F=WEQ[L[MVQ-V[^]NQG=[YS[U_3!_P &R7_)R?[2
M_P#V0OP=_P"K(FK^:&OZ4_\ @V>:_7]H_P#:5-A%9RR?\*,\'[Q>SW$"!?\
MA8TV"C6]M<LS$\89%4';\Q!./D>/?^20SS_L'H?^IN%/NO#3_DNN'?/%5_\
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MQ?\ =7^0K_.0_P"".G_*3+]D7_L?_$O_ *JKXAU_HWI]Q?\ =7^0K^=_%_\
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MZ ,'_P"$U'R_N>2/YWQ_P:__ /!*L'(\,?M( CD$?M:?''(/K_R,E>W>'O\
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M_P!"O^TA_P"):?''_P":2OZ(**/K^._Z#,7_ .%%;_Y/R7W!_9N7?] &#_\
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M (*-_M<R1R1R*4DCD1_B25='1F1T8%64E6!!(KY\_P"(7[_@E4, >%_VD
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MG&UV48_XJ3IQQG)QU+')+O\ B%^_X)5?]"O^TA_XEI\<?_FDK^B"BCZ_CO\
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M/%'A*Z\=Z%I5U'<V\CW&I^$[+Q5X(NM;A>UCN(%MX/%6BO'--%="Z80&WF^
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MM&T$:: ?5WBKXU>,?"/B'XN64_P*^(_B7PY\/_"GPJUGP/K?@A;#Q!J7Q?\
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M";2?C'<6_P '=!T3P;J7B?XE6=AX/N=>UC4H_#NAW.L:3X9\*:EX^UK2=+\
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MQI^),/QW\&:SXV_:L^!VE?MC?$7]E#XK_L\_$'4M=A\)W?A/PG=_MO\ P7^
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M^(O$'B#Q'XIUJ3Q#K&IZI>_;E%% !1110 4444 %%%% !1110 4444 %%%%
M!69J>BZ1K26<>L:5INJQZ?J6GZS8)J5C:7Z66KZ5<+=Z7JEHMW#,MMJ.G72)
M<V%] ([JSN%6:VFBD4,-.B@#C#\.? #'Q*S>"/"#-XSOK#4_%[-X8T-CXIU'
M2GBETR_\2$V!.O7NG200R6-WJQO+FS>*-[:6)D4CH;S1])U&ZTJ^O],T^]O=
M"O9]1T2[N[&UN;K2-0N=.O=(N+[2[B>*2;3[R?2M2U'39KJS>">6POKRRDD:
MVNIXI-*B@#EX?!'@VWN[R_@\)^&H;[4;?6[34+V+0-(CN[ZU\2WL.I>(K:\N
M4LUFNH-=U"W@OM9AG>2/5;R"&ZU!;BXC21:FL?#GX?\ B'1M$\.:]X'\'ZUX
M?\-3:9<^'=#U;PQH6I:/H-QHL(MM'GT72[[3Y[#2IM*MU6#39=/M[>2QA58K
M5H8P%'9T4 <]?>$O"VIV6JZ;J/AO0;_3M=OX-4UJPO=&TV[LM7U*V-@UOJ&J
M6MQ:R6^HWT#:5IC0WEY'/<Q-IU@4E4V=L8DN_"'A2_.D&^\->'[PZ 83H9NM
M%TRX.C&WGT^YMSI1FM7_ +-,%QI.ESPFR\CRIM.L)8]LEG;-%T5% &;;Z-I-
MKJ>HZS;:7IUOJ^KQ6$&JZI!8VL.HZE!I2W*Z9#J%]'"MW>Q:<M[>+8QW4TJ6
M:W5R+98A/*'Y.W^%7PRM3=M:_#OP+;M?ZM<Z]?-!X/\ #D)O-;O-8T7Q!=ZQ
M=&/3%-QJEUKOASP_K-QJ,V^\GU;0]'U*6=[[2[&>W[ZB@#BK[X;?#W4V+ZEX
M%\':@YU^Y\5EKWPMH-VQ\3WNG?V1>>(R;C3Y#_;UUI7_ !+;G6,_VE<:>!93
M73VH\JM;5/"GAC6_#L_A'6?#NA:MX5NM/CTJY\-:EH^G7_A^YTN)(XH].N-%
MN[:;3)K"..*)$LI;5[9$BC58@(T"[]% '/:/X2\+>'FWZ%X;T#17^QVFG[M)
MT73--;[!80QV]C9;K&U@/V2S@AB@M;;/D6\,4<4,:(BJ/.+#]G']GW2O$]EX
MUTSX&_!W3O&.FWD.HZ=XKL?A?X$L_$MA?V^?(OK+7K;P_%JUK>0Y/E7-O>1S
MQY.R1<U[110!B0>&?#MK9:MIMMH.BV^GZ]=:K?:Y8P:5I\-GK%[KI=M:N]5M
M8[=8-1NM7:21M4N+V.>;4#(YO'F+MDB\->'8(;BWAT'1HK>[TNST2Y@BTJPC
MAN-&T^"YMK#29XDMUCFTRRMKV\@M+"57M+:&ZN8H(8XYY5?;HH KV=G::?:6
MUA86UO965E;P6EG9VD$5M:VMK;1)!;VUM;P)'#!;P0QI%##$B111(L<:JB@"
MQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44A.!GW
M _,@?UK^?CQ5_P %Z_"OA?Q1XE\,R?LS^)KQ_#GB'7?#[W:_$_0X$NWT35KS
M2GNDA;PC(T*W#6AF6)I',8<(7?;O;[#A+@+BWCJICJ7"N43S:IET*$\;&&+P
M&%]C'$RJQH-O'8K"J?.Z-56I.;CR>\HWC?\ ._$#Q7\/_"RCEF(X]XBI</T<
MYJXJCELZN S7'?6JF#C0GB8I97@<=*G[*.)H-NLJ:ES^XY.,DOZ"**_%/]F+
M_@LKX<_:5^._P\^!]E\ M?\ "-U\0-1U33X?$5W\0M(UBVTLZ9X<UGQ"TLNF
MV_AFQFNA,FCM:A$NX2C3K*698S&_[5@Y /J ?SKFXKX-XEX(Q]#+.*,LEE6.
MQ.$ACZ%">)P6*=3"5*U:A&JIX'$XFE%.MAZT.24XU%R<SCRRC*79P%XD<%>)
MV58K.^!<\IY]E>#Q]3*\3BZ>#S'!1I8^EAL+BZF'=/,\'@JTG'#XS#5'.%.5
M)^U45-RC.,5I"0!DY_ $G\  2?P%+7P/_P %"#J ^'/PA_M<:U_PHL_M&_#
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MX+_: OKCPQXS2Z\=S?L_:]X*^-6B>#OA7/JO@'X5?!>^\?Z%H>J_#VZUB_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-2017930biosimilars.jpg
<TEXT>
begin 644 biib-2017930biosimilars.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
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M4?\ "0P_] O7_P#P2WW_ ,:K>P/0?D*,#T'Y"@#!_P"$AA_Z!>O_ /@EOO\
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M10 ^BBB@ HHHH **** "BBB@ HHHH **** "OA3_ (*8_P#)BG[27_8A1_\
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M_@7:?_*^@#H**Y_^PYO^@]KW_@7:?_*^C^PYO^@]KW_@7:?_ "OH Z"BN?\
M[#F_Z#VO?^!=I_\ *^C^PYO^@]KW_@7:?_*^@#H**Y_^PYO^@]KW_@7:?_*^
MC^PYO^@]KW_@7:?_ "OH Z"BN?\ [#F_Z#VO?^!=I_\ *^C^PYO^@]KW_@7:
M?_*^@#H*^%/^"F/_ "8I^TE_V(4?_J2:!7V7_8<W_0>U[_P+M/\ Y7U\._\
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M*^/_ /P$\%__ #)U\544?V7EG_0NP'_A)A__ )7Y+[@_MK./^AMF?_A?BO\
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MU\%?\%NO^3L/ W_9!?"G3@_\CK\0N]?6\%?\CN'_ &#5_P X'PGB+_R3D_\
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M;BY>R@FTVHVL?9E%%%?F)^R!1110 4444 %?"G_!3'_DQ3]I+_L0H_\ U)-
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M.E:AJ^B:IXNGU6QBLO#6NZXDMG%J%R]F\CSZ5#"XN%*"&64CYPE?OTIR ?4
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MQRQ2H4DCD1M"*LCHS(ZD$,I(/!KYP_XACOV)Q@#]IG_@I*   !_PV5X@X X
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M]G8_$+]H+]EGXXP^*8M$@_9LO_C)>'PJNA?;!XKC^*WPT_X5[%;PZJFIVB:
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MY+*;0QX>FT[5M3F< _4;X?>+7\>>!O"/C27PYKWA"7Q5X<T?Q!+X5\4?V/\
M\)%X<EU:P@O9-%UM_#VKZ_X?EU+37F-K=W&@Z[K6B7,D9N=)U;4=/EM[R;L*
M\,_9H^!FD?LT_ ;X5_ C0=<U3Q)I7PO\'Z9X4M-:U>*VM;F_6S\V:62WTRR_
MT#0M)CN+F:#0O#>FYTSPUH46F^']-+6.F6['W.@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.TNI+?\ <23PR/%^[*UZ30 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-2017930collaborationps.jpg
<TEXT>
begin 644 biib-2017930collaborationps.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MW^SO\#OV<_#_ (>LKY#]IU6W'AGX&:'K-YJ.HXO;G6-8U0%4MDMD7Y<\/_\
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M (6#XV_Z&?5_^_\ '_\ &:/^%@^-O^AGU?\ [_Q__&:7_$6LG_Z%>:??A/\
MYH]?Z>A9?S+[G_EZ_P!/3[GHKX8_X6#XV_Z&?5_^_P#'_P#&:]6^$WBWQ-J>
MJZM'J-QJ_B&.+3H9(K?[1IX^SR&ZV--F\N+%/G7Y/D>1^.4 .ZO3R?Q'RS.<
MSPF64<OQ]&KC)RIPJ57AO9P<:4ZK<^2O*5FJ<DN6+=VM-79671IVWW\O+NSZ
M1HK$_M34/^A;U?\ \"?#_P#\NZ/[4U#_ *%O5_\ P)\/_P#R[K]$$;=%8G]J
M:A_T+>K_ /@3X?\ _EW1_:FH?]"WJ_\ X$^'_P#Y=T ;=%8G]J:A_P!"WJ__
M ($^'_\ Y=T?VIJ'_0MZO_X$^'__ )=T ;=%8G]J:A_T+>K_ /@3X?\ _EW5
MVSNKBY\SS]-O-/V;=OVJ73Y/-W;MVS[#?7F-F!N\WR\[UV;L-M +U%%% !11
M10 4444 %%%% !1110!^('_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W
M%_\ 017XA_\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% #Z***
M "BBB@ HHHH **** "BBB@ HHHH *X3XF_\ (A^)O^O!?_2F"N[KA/B;_P B
M'XF_Z\%_]*8*\G/_ /D19U_V*<Q_]0ZPX[KU7YGQ&W4_4_SI*5NI^I_G25_(
MH@HHHH *]W^ W_(<UW_L$6__ *6M7A%>[_ ;_D.:[_V"+?\ ]+6KZO@;_DK,
MD_[":O\ ZB8@:VEZ?JCZAHHHK^I1!1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH *X3XF_\B'XF_P"O!?\ TI@KNZX3XF_\B'XF_P"O!?\
MTI@KR<__ .1%G7_8IS'_ -0ZPX[KU7YGQ&W4_4_SI*5NI^I_G25_(H@HHHH
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MP04444 %%%% !7"?$W_D0_$W_7@O_I3!7=UPGQ-_Y$/Q-_UX+_Z4P5Y.?_\
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MTV>TL_&%Q)+K,4VBVPGU2&6T6GXX_:1^"?PW\6KX(\:^.H-%UZ*/PI+K3_\
M"/\ B[5/#W@J+QYJCZ)X#F^)/C/1?#VI>#/AC#XYUB-].\(3?$'7_#<>O7"B
M2R9K-XKITL+B935*.'KNHX*HJ:HU'-TVTE-04>;D;:2E;E;:5[M#MK;^O3U_
M4]Q7J/J/YU]Q_#K_ )$;PQ_V";?^35\.E6C=D=61XW9)$8%61T8JZ.I *LC
MJRD JP((!&*^RO 6O:;:^#?#EO-)<"6+2X$<+8:C*H8;@=LD-I)&XR/O([*>
MQK]-\)O^1UF/_8K?_J7A@Z+U?Z'IE%8'_"3:1_SVN?\ P6:K_P#(-'_"3:1_
MSVN?_!9JO_R#7[X(WZ*P/^$FTC_GM<_^"S5?_D&C_A)M(_Y[7/\ X+-5_P#D
M&@#?HK _X2;2/^>US_X+-5_^0:/^$FTC_GM<_P#@LU7_ .0: -^N$^)O_(A^
M)O\ KP7_ -*8*W/^$FTC_GM<_P#@LU7_ .0:XOXB:[IUWX)\16\$D[2RV(5
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M<_\ @LU7_P"0:/\ A)M(_P">US_X+-5_^0: -^BL#_A)M(_Y[7/_ (+-5_\
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M_H]'PS_X:SX__P#SI*;_ ,1#/_!'7>8Q^VIX5,H02&(?##X^F58V8JLK1?\
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MMH)GN+6XCC^H<@8R0,]/?Z4$@8R0,G SW/H/4\&@ HHR.>>G7V^M (/0Y^E
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MQSTYH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\=_VE?CI\;[35_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-2017930cos.jpg
<TEXT>
begin 644 biib-2017930cos.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $D 3T# 2(  A$! Q$!_\0
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MEJ'@;3O@3XGTF3Q#?7/Q?LQX&MK;QP^F:K!HEW)X@U+PY+>00)Q'[/'_  3
M^#O[.?Q:T/XG^%KGP[J4OA^[U#Q18RZI\&_A+)\0!X]\0>"3X*\5:N/C'+X>
MN_B)9^&-76[UWQ':>$=*U'3IM(UGQ%JFE0^)KGP(;;P;!]5?$C]G;1_B1\<?
MA+\<;OQ-JVF:E\*/A/\ M#?"G3]!L[/3I],UBP_:$G^#\^K:Q?75PIO8+[PX
M?A#IZZ3!:,MI>#6K\Z@&-O:;0#YI^"G_  5'_9C^)OP1^$WQ6\7^(=0^&?B#
MXD?#7]FWQW>?#Z^\(_$K6]0L-0_:>TZ6'X=Z)X-OX/ -A)\6-+U7QWIVO_#+
M2/%W@+2]4T;6/&^C'0$^RZMJ.FZ?=>XP_MP?LRNWBYKWXBRZ%8>"- \?>(M;
MU_Q1X,\>^&/"<]I\*;N'3OBG8^&_%^O>%]/\,>-/$/PTU6>/0_'OACP;JNO>
M(?"WB%+OP_JFFPZSIVHV-G\KZ7_P2K\#:9+^RY*/B]XZN#^R]\'_ -B?X0Z&
MLNB>&0/%6G_L5_%&/XG^&M9UDK'FQO\ QS>1II'B*WTS99Z;8*LVC*ERJD9+
M?\$=_P!FJY3XT>'[JWTA/ WQ8LOBREM:Z;\)_A'8?$GP[JOQD\;/\1?$=]??
M&B?PGJ'CKQKI_ASQ?+/<>"/#OB&7^Q8M#F'AGQW#\0M'M;""T /T7^'/QM^'
MGQ3T7Q+K?A;4=:MU\&:G)HWC+1/&'@[QE\//&/A'4TT33O$T=GXH\#>/=!\.
M>,-!EO?#6L:3XBTPZGHEO'JVA:G8:MIKW5E=12GPD_\ !0']E>W65=7\=>)/
M#5\FN_"OP_;:#XK^$?QB\+>+-4NOC?KFL>&/A%>Z'X.\0> M.\5ZYH?Q#\3Z
M#JOAKPQKNDZ-=Z7?>(+8:,]Q#J%Q:V\]WX"?L?\ A/X&?"GXD?#?0M2TCP[>
M?%2ZUJ\\1^)O@M\-?A]^SS+I-WJ?A2T\&VFH^$--^&>D6_\ 9>NZ-IME#J6F
M^)-;U/Q/K]MK[O=6VH6NCVNCZ#I7QKX&_P""/OPY\&>-?!/Q!'Q3U9O%'A._
M_9EGU"Y\.?"WX8>"(?&L7[+7Q@U'XL>#M5\;#PSI<%_XE\=^,)-3N=$^(_Q
MUO4=2UK7U$6I:?'HK1K8  ]D_:!_X*A_L[_!_P" ?Q+^,7@^]UCXI>(O ?PB
M^)GQ4B^'%AX1^)NB7]H/AIK_ (L\"ZEH'Q7U8_#W5A\ [NY^)W@GQ/\ #-'^
M+&F>'KE?&7A_Q%I%OI]Y<>'=92R]B^/G[6L7P$^/'[./PKUGP%<ZOX'^-MC\
M0;GQG\4H/$$5G%\'CX?\5?!KX?>!=1UKPN^DW$VN^&?&OQ&^-/A;P5J^O0ZQ
MI2>!KW5-%U?4[6^T*ZU>_P!"^5O%/_!*7P]K'A?]I;P?X;^/_P 1?!>C_M?V
MWQZT;X__ -F>%? FJ77BCPW\7OC%\<?C-X6TS1;O6=/NW\+7WPUU;]H+Q]X3
MM-7L#+-XN\%7MO9ZU:6NOV6F>)-.^\OB/^SUX-^*OQ!T'QIXX:36]'T[X(_&
MWX%:YX'NK:W;0?%?A;XY:W\(-6\1RZI.C)J,$]G'\)+33[*&RFBC>+7;ZX=T
MN[/3Y8P#Y5\&?\%)_A9=ZA=+\4FT#X7:?;6BPO8'4/'OB_QBFNZU^V5\1OV,
M_ %HVA:)\,!H\FF^//'W@G3K72Y++Q/>>(K'Q%KSZ%J/A>'2;&U\4ZM[(W[>
MO[+2:=HVJ-\0]2$&IQ^,Y]8@'PY^*$FI_#BR^'7C*[^'?CO5OC1I$7@R35/@
MAH?A'QU8WWA;Q#KOQ:M/!VD:9JEAJ)GO19:7J=[9_)W@O_@DUX1\)#X?S7?Q
M]^*GB[4O <?P%1M>\3Z3X1N?$/BJY^!'[>6O?MW6&K>)[^SL;,7FN>,/%.NS
M>"/%6I6]K;//HT<GB.UBB\074SU5\0?\$?/@IX@^(OC+XDZGX@TSQ#KOQ)^(
M7Q;\3>-6^(/P7^#WQ5B;PE\5/BEK7Q7_ .$6\(6_Q$\.>(M/\':QX1UGQ/XF
MT?1?&D&GZF^I^'_$%U9^*?#NMW>G^'K[1@#ZM_:?_:_@_9H^)7[+O@_4O DG
MB7PK\??B=JG@/QGXVA\1Q:2OPBT.'2K"TT?QU>Z1-I-XGB/1KKXA>)O _A#6
MXO[5T(>']+\1W/BN2[O+?1IM.N/,O#7_  4<^']S\>?VKOA/XW\,7G@_PI^S
MQKGP&\(^!/&FFS^(/'OBCX^>,_C%J'QA\+:KX7\#_"?PGX/O?%LFK>$?B#\%
M/''@ZUL=$;Q7?>(CX>\1^()+70M&T.ZG/M_[1W[)_A#]I2Y\.)XJ\0Z[HNF:
M%X#^./P_ET_0[33O].T[XW> K?P+>ZA'>WEO,^FZKX32TM=>\-75HA\G6[2T
MN)1_HT6/FNP_X)D^'_#^M:/XX\-?'#XB67Q0\'^%/V7;'P3\0-7T/P=X@O[3
MQ]^SAI7[36BZQ\2?%^F7=A;Z?XXUCXZZ?^UA\6U^*]C>#2DDO]=FUOPIJ'A_
M6_L^HV8![9+_ ,%$/V/XKK2K4_%L.-4\.>"_%]Q=1>!OB1+8>%O#/C_XD^,_
M@YX>UKXAWT?@]K;X964?Q8^'_BSX<>)F^(4GAF3P1XSTF70?&<>@WLD:-\R^
M&_\ @KY\&-:\7:!8:U\-_C!X#\#75Y^WGIGB7Q7XR^&?Q.A\0:)=_L*_%SX8
M_#'Q3J6D_#W0_ &M>(O$_A37['QYK7C#7_$%F(!\*K3P9JOA_P =6MKXDCU3
M3]&U-9_X)3> ]6\(?'_PR_QA^(0O?VCO@_X4^'7Q"\2SZ/X/EU2Y\7:=^TS\
M=_VJ/&GQ0M[2TT[3]'AUCQY\0_C_ .*K2X\-V^GVWAGPWX?T[1]/T*VC,=P\
MO3V?_!-K0K+X@>-O%$7QC\7?\(QKV@?MYZ-X9\(_\(OX6CF\)W/_  4-\>^"
M?BO\:M0E\3QA+WQ,-$^(?A&75? -MJ5A;_V/I&L2^']4NM9ATW3[N( ^IO!?
M[6GP(^(WQ#N?AGX#\7:CXPUNSU&/0[C7?#G@?Q_J_P -8_$DG@33?B>/"9^+
MMEX7F^%H\7#X?:UHWB__ (1@^+QK3:)JEI<QV<DCO#'H:_\ M0_!'PS\4H?@
M[J_C"XA\;-J/A#1+\6OA3QEJ?A3PWXC^(<BQ?#WPIXS^(6F>'KSP!X)\6^/7
M>%?!?A?Q9XET?7?$SWVCQZ58W$OB#0$U3Y1^%'_!.71OA7\2O@QX\L/B]KTT
M7P7\/^!=%L!HGP]^'/@+QOXVM? OP7M_@K8>$/B9\3/!6E:/XD^(_P )I+"!
M/&-O\/O&\'B.[TSQG::'-8^,ET#PWH>@672^*/\ @G;\)/$?[5EU^U0?^$='
MB+Q!XQ^&/Q&\7VFO?"/X5^./$MUXZ^#NB>&_#W@C5?!GQ)\8^&M7\8?#>Q?2
MO!GA"+Q#IGAMVGGO/#EEK?A74_!FO7FLZIJ8!UVE?\%%/V/]:T2Y\1Z?\5YW
MT6/P]K/B33-0N?AY\4;&+Q?9^'/B=I/P6\0Z?\.DO/!<,WQ,\2:'\6O$7AGX
M;ZKX3^'T?B7Q/:>,_%/A;P^^DG4/$>D0W7GGP^_X*9_ SQ-J'QOM?%]OXH\#
MQ_";XS>./AM86H\"_%7Q)XJU7P=\-?A3\"OB/\0/BSXW\#:;\.(_%?PA\(>!
M=0^-^G>$_&NH>.M,LM"\,7]A9SZCXA677;6Q@\^C_P""5'@.#PM^SWH,7Q@\
M?0ZM^S/H?QI/PT\3QZ'X2>^LO'_Q._:<^#_[5/A;X@W^GW-E=:1>7'PX\>?!
MG0](L_#ES:2Z%XK\+:OKNGZ^B7,]M=VW*^)?^"/WPV\:^+_%?Q1\<_$2'XA?
M%?X@>+_'&O\ C/Q3\2?@A\&/B'H3:1\2?!/P2\*>)-'\(> ?&&@:OX7\):CH
M5[\$-%UCX?>)?(UJ[T*#7=?T'Q79>/\ 39X64 ^E_B=^W[\+/!_Q5^#OPC\$
M6UW\2]=^)'[3/A+]FWQ)K&EV?BG3_!/@O7/$WPE\<?%RYDL_B'_PB6H?#[QC
MXKT#0/"^BS:Q\/\ 1_%46N6&G^*K34K^:S:SFLY/O%3N56QC<H..N,C.*_.A
M?^">'ARP^(7@G7/#WQ7\8:!\,?A_^T_9_M=>&_@]9^'?!KZ):_%NX\%^*_!7
MBN!O$@TV#7QX(\0Q^+M7\46WA6#[.OAWQ;?7T^F7[^&QHWA?0_T74;55>NT
M9^@Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?"G_!0
MM=0E^!.E6MA\;-$^!YO/BS\,(+W5?&.N^.? _P //'NF)KS76H?"+XC?%3X<
MM;^+/A)X0^)=O;MX?G\>V&HV$,&L/HWAN_37;'Q-<>%=?_*R7_@H;\6OA1X4
M\*?#WX0^%-+TK2M(UK]IU]5^(WQ"_: ^'7QY^"^J^)?A!<_![5/"WPU^#?[0
MGQU^,G[-B^,?A)JVG_%:]?4[]M0\2?%KX>0^"?&/P^\/>![_ /X0;6=1\/\
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M\-+@O%_6*U:="E0CF]"=:I4I2E"HX4X8&4Y4XRA47MDG1?))QJ-*[_??P_\
ML&?LT:!X7\6>#_\ A$?$>NZ+XI\+^$/ </\ PE?Q%^(GB75_!7P_^'6N?\)1
M\-_ _P ,?$6J^))_$'PT\/\ P[\4K#XH\$IX+U/1]3T#Q'8:-K5MJ;:AX>T"
M?3-S1_V/OA=X=T^PM- \1?&O1;^+6/B%XF\0^)=,^.OQ7L_%7Q!\6_$GX>#X
M8ZSXL^)FOP^)EO?'^OZ'X6M])B^'UWXD:\A^&E]X:\)ZAX"M?#\_A?0_L/X
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M/ZSR<CBVG!OF=[):***^6/N@HHHH **** "BBB@ HHHH _$#_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_#[_@I;,D'_!1__@A7*XE9$_:M
M_:>R(8)KF4[OV._B HVPV\<LS\D$[(VVKEFPJL1^U$>NV/EI^XUG[B_\RYXA
M]!_U"Z -RBL;^W;'_GAK/_A.>(?_ )5T?V[8_P#/#6?_  G/$/\ \JZ -FBL
M;^W;'_GAK/\ X3GB'_Y5T?V[8_\ /#6?_"<\0_\ RKH V:*QO[=L?^>&L_\
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MQM.[RM^S*[]NY<_B'BY_R/<M_P"Q/3\_^8['=S^FOH_._"V<-[OB'$-Z)?\
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M#W_0=T;_ ,&EC_\ 'Z/^$C\/?]!W1O\ P:6/_P ?H V:*QO^$C\/?]!W1O\
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M@> M5\3VVMCPCHOQ(T72?''@#QM\.=1\8?"WQ-=S6/AOXG^";3QOH6AS^*?
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M5?%'QB\'_MD?#'X%_!#Q'#X/\/\ A2UMM>^*7PI_9)UO1OA'\/=(>VUOP_\
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MPW<_ KPO?6_C?XO?#6"?2/"G[.$;76A7OP3^'MYJ&F>&-*^)6M>%O#/BW6-
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M 3QN8(BGQ!_PX"_X(X#_ )Q]?L__ /@H\2'^?B:OV&HH _'G_AP%_P $</\
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ML.C3O!!;7,3W']$=&.<_AU./RZ?CUH _'G_AP%_P1P_Z1]?L_P#_ (*/$?\
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MX1.MMX;&IG4-3U'S!I!\1ZV;3RO)VG4KG?YFY=GV+10 4444 %%%% !1110
M4444 %%%% !1110!^;?QS_;/^)?@?7_VHM7^&WP[\$^)?AC^PWX4T3Q;^T)-
MXK\5:QHOC;Q:;WX:0?&SQ/X9^%%IINEWVAZ=JG@OX/W^B>*;;4_&EP^F>-?$
MVNV_@BWB\+V]C?>,$L^)/VQOB%X7_:L^$7P4N/#OPDUGP[\:O$AT_P )>&=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM<\5^,_#GCOPQ<ZMX%\%_#_4=/T3PYX/U>Z\=?%KPK:>%(=<>&?2Y_T*TO\
MX*!?!PZSK?A?QOX5^+7PE\7>&O#WB/Q3XB\*_$SP98Z-K.C:)HOPZO/BOI-W
M=?V/XD\0:;+_ ,)QX$\/^/M7\'Q6.I7<MQ>?"WXF>'-=30/$_A&]T=P#[IHK
M\B/VF/\ @K%\/OA)X'_: TOPGX:U#2?C[\,_@/\ &3XP^ / GQ=/AG3;+Q?<
M_!G1;?6O%.EZYX:\'?$#6/BCX1ATRRN/[2W>,_"O@E?%&BVU[J?@:_\ $-K
MLTOH?PD_X*5>%_%_B7]H#0?BI\(?B'\&++X-_&O]HKX5:!XFUAO#?B/P]X^L
M_P!G'P)H/Q%\47MM=>'-?O[O1?%.H^$-1U;Q)I7A2_L/*O=$T.]EL-:O+^UU
M/3]/ /TTHK/TF_;5-+T[4VL;_2VU"PL[YM-U6&.VU/3VN[:*X:QU&WBFN(H+
M^T,AM[R&.XGCBN8I8TFE50[:% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>5_&#2M2UCPK!::58W6H7(UFRF:"TB::40I!>*\I1>0B,Z!FZ
ML!WKU2BO/S7+Z>:Y=C,NJU)TJ>,H2H3J4U%S@I6O**DG%M6TNF@/A/\ X0/Q
MI_T*^M?^ 4O^%?3?PATO4M(\)M::I8W.GW7]K7\HM[N)H93$X@"2;&YV/M;:
M>AP<5ZC17R?#O 6!X=S'^T</CL7B*GL*E#V=945#EJNE)R_=TXRNG3TUM9_<
M?J%(1D$'H01^=+17W@'BG@?X">"/A_J/Q^U/0I_$,EQ^TA\3+CXK?$)-0U5+
MJ"#Q/=?"7X;_  9EC\-Q)9P#2=)/A'X6^&918S-?O_;3ZGJ!N3'=QVMM\U1_
M\$WO@);>#OAI\/\ 3]<^+&F>"_ OP"^#_P"S#XL\/:?XZCMK'XZ?!'X$^:WP
MV\%?&H+H;3>((-';4O$R7>I^%9O!6KZUIOC/Q?X<U:^N_"VN3Z(GZ 44 ?G'
MXB_X)>?LW>+%?2O$-_\ %+4? ]CX8_:!\%^#?AH?&UO:^!?AUX4_:9-O=_%#
M0O!&GV.@6NK:;:-KME8>(O!DVI:WK%[\/KVPL=*\'76D>%+*V\.1[-C_ ,$Y
M_A/I6K^(/&6C?$[]H+1?BGXP\6>,_%/C/XPZ-\2K+2?B1XIA^)/PZ^#7PT^(
M_A>^U;3_  I;Z5I?A?QEI/P!^%6M26GAC0]!U/P?XL\+67B'X;:OX*N4C2+]
M Z* /#/AO\ ?"7PH^(OQ?^(7@W6O%UHGQNUSP]XO\;>"[W5-/U/P>_CSP_X%
M\'_#1O'>F+>:/)XJLO$>N>!OA]X*T'Q DOBJ\T*__P"$>@UF/1+7Q#J.MZMJ
MGN=%% !7YV?MV_#SQWXZOOAG)X,\(>(?%*:;:>*TU!]#TZ6_6R>[F\/M;+<F
M+_5&<6\YB#??$,F/NFOT3H(!Z@'ZU[&0YQ6R#-<-FM"C2KU<,JZC2K.:IR]O
MAZN'ES.#C+W8U7)6:]Y*^ET?.\5\.8;BS(L9D6+Q%?"T,:\,YU\.J;JP^JXO
M#XR/*JD90?-/#QA*Z?NRE;6S7\]Z_L_?''(S\)/'_4?\R[=>OUK]LO@%I&J:
M#\&/AGHVMZ?=Z3JVF^#]&L]0TV_A:WO+*ZAM]LMO<P/\T4T;<.C<J>#7KN!Z
M#\A2U[_$_'&-XHPF'PF)P6$PL,/B/K$9X>59RE+V<Z?*_:SDN6TV]%>Z1\KP
M1X99;P/C\7C\%F6/QL\7A/JDZ>+AAXPA#VU*MSQ=&G"7-S4DK-M6;TO:Q2,H
M88/JK?BK!A^H&?:EHKX@_3#X0MO^"='[.,?PN^'?P?O;7QMJ_@KX=Z-^T1X2
MAMM1\73K?^+/A_\ M1Q>*3\8/AWXRU#3K+3YM3\(:WJ?B+3?$6G6FG#1]2T3
MQ)X#^'VM:?JL=WX<W7G$>*_^"?>C:KK'@1F\3^(?B'=77QJ^#OQ5^,'Q>^,/
MC;5-9^+VJZ)^SG::C)\*_AQX:M?"GAGPWX-O/".K'6_%?@_QSIFL6^EV6J^#
M_B%\2[S7+;QIXE\;ZC=Q_I-10!^7_C+_ ()+?LR^/-$UOPOX@U_XR/X6U"R_
M:9TW0] L_'&E6UKX-L/VN;#Q):_&R#0[Y?"+:[K%SKE[XIU/6=(UKQ_J_C;Q
M!X<OOL]EI.K0>'HFT27I_B)^P+X<\0>-C)X6OY[3X=?$']JCP;^UC\6_#VN^
M);^1-#^(7@/3+:/49?A5I&E>&X+MK?X\KI]EX.^-^C>-O'-]X.E\"S:_;>&_
M"L=]XGUB.?\ 1FB@!%& !W[D#&2>2<=LG)_&EHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-2017930glfvcc.jpg
<TEXT>
begin 644 biib-2017930glfvcc.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #I 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%_VD?BZ?V?OV>/CU\>1H!\5GX)_!CXI?%P>%QJ7]C'Q(?AMX&UWQF- &KB
MQU,Z4=8_L7^SAJ7]FZA]A^T_:OL-WY7V>3X[^$O_  41\%:I\.K'XB?&'Q;\
M +JS\3B>X\(:=^R#\1_B3^V%?BQ\->#](\9?$NX\8V'@;X+:/J_A>+X;Z3XE
M\,WGB>_72]1TC2K#7M'GUC4-+N];T&PU3[1^/WPETWX^_ GXU? K6=6OM!TC
MXT_"7XC_  EU37=+AMKG4M%T[XC^#M9\'7VK:?;WG^B3WVG6NLRWEI#=?Z/+
M<0QI/^Z9J\-^*7[(2>,9?A3K_P /OBEXC^#WC[X6?#3QQ\&+3QEX<\+^"_$#
M:S\+_B=IG@.R\<:+?Z#XGTN\TN'67U#X9>!O$WA;Q#!N;P]K^@0I?:9XC\.7
MVK>';\ ]3^''[3/P7^+WBGQOX1^&7BV7QOJ7PZBT>7Q??^'?#OB?4?"VF-XC
M\'>"OB'X9MH/&4&CMX4U>_\ $_@3XA>$O%_AK3=&UC4+_7?#VJKJNF6UQ9P3
MRQ_GY\/?^"Q'P3\:CX7^)=9^'OQ4^'OPS^('PM_; ^).K>(_%GP^^)<OBWP=
M%^R+\<OAG\'O$K7_ ,/-"^'VJ:W?^$-0TWQ[J7CO7O']K*OA_P"'^G>%M0T7
MQ))_;-OK<6A?:?[+/[)G@']DK2/B5X:^'%_JTOA;QYXR\">)],T34_)D'A+3
MOAW^SO\  []G/P_X=L;Z/_2M5@'ACX&:'K-YJ.H8OKG6-8U0%5MDMD7Y=\/_
M /!+[P?H5OXMT2'XM^+[CPCJ'P4_;?\ @+X'T1_#WAZ.^\$>!OVY?B+X-^+'
MCI;C6TD\WQ3JG@SQMX:U)_!]YJ%EI[/H.M0Z3KR:C>:2NLZ@ ?8?AS]JWX%>
M+OB6/A1X;\9RZQXFFU2]\/:?J=EX8\7R_#_6_%FE^%1XYU?P1X=^*?\ 8*_#
M7Q'XZTCP:9/%&J^#-#\5W_B/3]$M-3O;G3D&C:RFG^"_&W]I[]H7X9?M6_"S
MX">&?@Y\&_$_@?XK_#SXN?%'2/'>N?&GQQX<\6:9X9^ A^#\7Q)L=0\#:?\
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MFM>*-=\06/E1?"Z#P?J&@^-(H=<&J6VC;NJ?\$I_AQJ7@WX[>%7^*OCY[O\
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M$^*7@W1])\7?$'X0R:5:1>,8_AQXS_X2&:T\=6ND7]OXO?1M T;0K3HO%/\
MP3R^$7B3]JFY_:F:/PP/$FO^,?A=\1?%L&O_  ?^$WCCQ5<^.?@WHFA>'O ^
MI>"_B=XR\+ZQXV^&VGR:3X5\*Q>(]*\,S?:+F]\.:?K7A;5/!FMWFO:CK !U
M&E?\%%OV1=:T2^\16'Q,U)M%@\.:QXGTK4+GX:_%.Q@\:6/A[XH:;\$]>L/A
MM]K\%Q/\3?$NB_%W7/#GPVU/PCX 7Q'XHL_&?BCPMH4ND"]\1:3'=>>^ O\
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M;>2>'#HOAC0/T34;55>NT 9^@Q0 M%%% !1110 4444 %%%% !1110 4444
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M7'C7P?HWPDUK6OB3\4_#5C#X6%K#X(^UZ7XCT?3FURZD^H?V)/B)K7C'7O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^7_C5^UK\,O@/\:/V5O@5XST_P 87?C+]K[X@>.?AO\
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MA^&-EXW?1O"4C>+/@YXV\-:SX>^&;6?B*^TWXO\ Q,U>7QGJ6CS^"O#6G?M
MW4_4_P Z2OY3P698O+_:O"5(TW6]ES2<(3:="K&M3:YTU=3@G9IK[22G&$HJ
M_P#7]>A^6_Q _8V^-NI?LQ?M:?!3X<0?LW>!M0_:^U+7K?4O >B:E\3/"GP(
M^ GAO5_AGX9\"SS_  PT_1/AY?ZMXG\3^)=;\+IXY\>Q77A'X<>&-9\0ZM<7
MMAI]K?VEQ?Z]]4^,7_;7U+P5XH3P.G[*?A'XA:EX$T.V\,76K:Q\9O%WAOP]
M\1KOQOJ\'C*_U&:7P7I$GB/P;9?"\Z)>^";"Y\*6U]>_$YM5T_QG97?@&"V.
MH_3]%54S&M5Y/:TZ%5PK>V3J4W.\G##TW&:E)J<'2PM"G)34I3C!N<I3J5)3
M=_SO_5MOD?._[,_PU\7_  M\!:MH?CO2?!MKXLUCQGK7B_Q'XF\+_$#QI\3M
M:^)/B+Q#;:8VN_$+XC^+_'/P_P#AMJ%YXYUF[LTL'T_1_#=IX2\/^&-(\-^'
M/"-IHGA[2-.\/:5]_P#P&_Y#FN_]@BW_ /2UJ\(KW?X#?\AS7?\ L$6__I:U
M?0<&U95^,<GK3MSU,75E*W,U=X3$;<SD[=DV[+1:)(-^;T6WJCZAHHHK^H!!
M1110 4444 %%%% !1110 4444 %%%% !4<WF&*7RG6*3RW\N1XS*D;[3L=HP
M\1D5&PS()(RX!4.F=PDI#T/?@^I_ED_D,T ?D?\ $;X]^"O!OQ0M/#5U\6/V
MP?$/BBP^)US\.O&/C?PIJ_PGT7X<> H]*N/@1HWB#QG<^ M9MK'0-?\ !'AS
MQU^TC\(_ %[9Z7X(\8^,WU;6=?EMK/7-+\(:_K\7ZQ:5!>VVFZ?;:E?#5-0M
M[*V@OM26TBL!J%Y#"D5S>BQA>2&S^U3*\_V:&1XH"YCB8QJM?B5XT\,VNL_M
MQ_$[6-?TGQ#\/[^Z^,GP+M[>7P9_P3=^-_Q;T+XL^'?AXGP\\4>"O$_C#]IC
M_A#;_P &)J6@>.$GBOM?TJXTOPE\-)_#7@_5=7GU75?!]EXCM_W#' _/KGU]
M^3]>_7O0!^(/_!2?_E))_P $*?\ LZW]J#_UCGX@U^WD?^KC_P!Q?_017XA_
M\%)_^4DG_!"G_LZW]J#_ -8Y^(-?MY'_ *N/_<7_ -!% #Z*** "BBB@ HHH
MH **** "BBB@ HHHH *X3XF_\B'XF_Z\%_\ 2F"N[KA/B;_R(?B;_KP7_P!*
M8*\G/_\ D19U_P!BG,?_ %#K#CNO5?F?$;=3]3_.DI6ZGZG^=)7\BB"BBB@
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M6T5R7_">^"O^AIT+_P &5K_\<H_X3WP5_P!#3H7_ (,K7_XY1]?P/_0;A/\
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M^(VZGZG^=)2MU/U/\Z2OY6$%%%% !7N_P&_Y#FN_]@BW_P#2UJ\(KW?X#?\
M(<UW_L$6_P#Z6M7U? W_ "5F2?\ 835_]1,0-;2]/U1]-77_ ![7'_7";_T6
MU?G:O0?0?RK]$KK_ (]KC_KA-_Z+:OSM7H/H/Y5]SXN_Q<@_PYK_ .\P0O3!
M'4-N'LV,;AZ-@ 9ZX&,XJ62>>4 2SS2@,' EEDD <=' =F <8&&^][U%17XV
M XLS%RSNQE.92S,3(>QD))WD8&-V<8XI"2Q!8EBJA%+$L50=$7).U!V484=A
M244 =W\,O^1\\-_]?=Q_Z07=?;M?$7PR_P"1\\-_]?=Q_P"D%W7V[7[[X3?\
MB/,/^QO6_P#4++P"BBBOU, HHHH **** "BBB@ HHHH ^&?VH?V-KC]H;]H#
M]A_]H'3OB)#X/U;]BWXL?$GXGV'AB]\)R>(=.^(@^(WP@\0_":YT.[U2W\1Z
M'=>%O[*BUX:[!J<-EKXNY+,Z;+I\"W OK?VCQ/\ ##Q?XMOX-1U36?"R3P6<
M5B@M-)U^*,Q1232J2K:XYWEIGR<X( XSDGWZBN+'Y=@LTP[PN88:GBL.YQJ.
ME5ORN<+N$O=:=XMNVH'R[_PH?7?^@YX?_P#!;KO_ ,NJ0_ C70"?[<\/\ G_
M )!NN]A_V&J^HZ",@@]#P:\3_4KA7_H28/[JG_RP=_3[E_73\^[/SF^#.@>+
M_B9XI_:.T'4+WPE90?!KX_W_ ,*-"EM-)\1)+J6@6_PA^#7Q#M[_ %0R>([A
M9-5.I_$;5[.:2V2VM?L5GIZ)!YR3S3>[_P#"A]=_Z#GA_P#\%NN__+JO<O"W
M@'PCX*U#QMJOAC1H=)O_ (C>+Y/'GC2YBN+V=M=\6R^&_#7A"369TN[FXCMI
MF\.>#_#>F&WL$M+(1Z7%,+874UU//V%'^I7"O_0DP?W5/_E@K_U9?U_7FSY=
M_P"%#Z\/^8YX?_\ !;KO_P NJ]2T?1/B+H>EV.D6>J>"FM=/MTMH&FT7Q$\K
M1QYP9&7Q H9CGDA0/:O4**]#+L@R;**LZ^6Y?0PE6K3]E4G24N:5/FC/D?-*
M6G-&+TZI!?\ K[O\CQ?Q9X(\<^,;6TL]5U?PA'%9W+741M-'\01N9&A>$AR^
MO2979(Q &"&P<UPO_"A]=/77/#__ (+==_\ EU7U%166.X9R',L3/%X_+,-B
M<3-0C.M44^>2IQ4()\LTO=BDEIL@O_5E_7]>;/SEF_X)T_!VX^-DW[1-QX#^
M%<_QCN?"]UX2N?&4_A/49I[K3[Z<O>ZI=Z;+JCZ5=>+;RQ+^'KOQE<6<GB2Z
M\*R2^&KC4)=)E>W;YPT']BSX,0_'CXM_LJ6/PH^%-A\.];_9H^#_ (Z\0K;6
M?Q)74M4CF^-_Q)L-%\!6NJR?$>74/#?PT\*3?#K1O$'AKP-X/E\.>'-)UV>]
M>WTH64_D#]J:XV#X?>#[;Q_J7Q1AT2&/Q[J_A#1? 6H^(A<WQN+GPCX>US7_
M !)H^C-:-='3DAL=;\4:]?I<16:7LCZC)%/<RV\5O##/^J^0VBO[/A:,:48K
MV^*M&-"7-0BE[>RC1E[U)6M3EK!1>H7_ ,_Z^X^-K7]A'X=V?Q.O?C-;>%_A
M[%\4+^_U?6+CQ?\ V7XODNDU[Q#I<>A>(O$UAH\_BN7PMH_BWQ%H4,6A^(?&
M&BZ!IWBK7=$3^R-7UF]TYY;:3UG_ (4/KO\ T'/#_P#X+==_^75?45%8SX/X
M:J\KJ91AZCA"-.#J2K3Y*<;\M.'-5?+"-WRPC:,;NR5PO_5E_7]>;/&O"O@S
MQWX/L;C3]+U?P?)!<W;7DAN]'\0RR"5H88"%9->0!-D"'&#\Q)STK2UO0?B'
MK^DWVCWNJ^"DM;^'R9V@T7Q"DP0.DF8V;Q P5MR#DJ>,\5ZG17LTLOP5' _V
M;2P].&!]C/#_ %:-_9^PJ*4:E/?FY91G)/6]F]0/EW_A0^O'_F.>'_\ P6Z[
M_P#+JC_A0^N_]!SP_P#^"W7?_EU7U%17A_ZE<*_]"3!_=4_^6#OZ?<OZZ?GW
M9^=?Q6\,^,_ 7Q!_9G\(:=?>$+NS^-GQD\2?#C7[B\TKQ&]QIFE:-^S[\;/B
MY;WNE-%XAACBOI-:^&6EZ?*]U'=0'3;V^C2%;AXKBW]R_P"%#Z[_ -!SP_\
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-2017930highlights.jpg
<TEXT>
begin 644 biib-2017930highlights.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &J 3T# 2(  A$! Q$!_\0
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M_'+]G*[N/V6? 7A7]GS6_ L7C#5OBS^TQ=^#?C)XH\':[\"-!^/OC/QW\/\
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MO5/!_B/Q5K^F^ _'5C#<7]EI>NZS_;FBZ[=2:-/H(!Z1\2?^"D_[+WP^\/\
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MNOM%?:7:W&BV'@A-6CUVYN=%M[*\>T6YN/EKX2_L">(?!/[-?C7]F#Q]\?\
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M7PC8CPI)Q;?\$V_$WA?PEXH\+?#+XWZ7HTWQU^"GBGX'?M1^(/$WPML]8O\
MQS9>./B=\:OB]XF^(_PWL](\4Z#9> _'"^+?VCOC;;:'IOB0^/\ PI8Z3XH\
M-I?V.JS>"0OB4 _5'3-3L-9TZPU?2KNWU#3-4L[74=.OK25)[6]L+Z".ZL[R
MVFC)26WNK:6*>"125DBD1QP:NDXYY_ $_H 36'X8\-Z/X.\.:!X3\/6::?H/
MAC1=*\/:)81L[1V6D:)I]MI>F6:,Y9V6UL;2W@5G8LPC#,<DUE>.O 7AKXCZ
M$WASQ7;ZE<Z4UY:7YCTKQ%XE\+W7VFR9WMV&J>%-8T/51&K.QDMQ?"VN!A;B
M&554  [$$'IG\58?S I:_"K[%J'PQ_X+E?!/X%^#/&/Q+TWX.>+?^"9_QZ^)
M'B7X9WGQ6^)OB#P5K/C_ ,._M&?#'P]H/C.\\/\ B3Q=K&GOXET?0M5U+2-.
MUE8EO[33[ZZM8)TAF=#^VW_",Z3_ ,\[O_P:ZO\ _)] &_16!_PC.D_\\[O_
M ,&NK_\ R?1_PC.D_P#/.[_\&NK_ /R?0!OT5@?\(SI/_/.[_P#!KJ__ ,GT
M?\(SI/\ SSN__!KJ_P#\GT ;]%8'_",Z3_SSN_\ P:ZO_P#)]'_",Z3_ ,\[
MO_P:ZO\ _)] &_16!_PC.D_\\[O_ ,&NK_\ R?1_PC.D_P#/.[_\&NK_ /R?
M0!OT5@?\(SI/_/.[_P#!KJ__ ,GT?\(SI/\ SSN__!KJ_P#\GT ;]%8'_",Z
M3_SSN_\ P:ZO_P#)]'_",Z3_ ,\[O_P:ZO\ _)] &_16!_PC.D_\\[O_ ,&N
MK_\ R?1_PC.D_P#/.[_\&NK_ /R?0!OT5@?\(SI/_/.[_P#!KJ__ ,GT?\(S
MI/\ SSN__!KJ_P#\GT ;]%8'_",Z3_SSN_\ P:ZO_P#)]'_",Z3_ ,\[O_P:
MZO\ _)] &_16!_PC.D_\\[O_ ,&NK_\ R?1_PC.D_P#/.[_\&NK_ /R?0!OT
M5@?\(SI/_/.[_P#!KJ__ ,GU?L=,M-.\W[*LR^=LW^;=WESG9NV[?M5Q/L^^
MV=FW=QNSA< &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AWX_
M_P"5B#]G#_M$W^TE_P"M2?"&OW$K\._'_P#RL0?LX?\ :)O]I+_UJ3X0U^XE
M !1110 4444 %%("#T(..N#G%+0 4444 %%%% !1110 44W<O]Y?S'^-*3CU
M_ $_R!H"Z[BT4W</?\58<G@#) ')XK^87]KC_@NO\5/ OQS\;_#O]GCX?_#2
M\\#_  Z\2ZQX.NO%7Q!M?$>OZEXRUKPYJ,VEZWJ6E6FA^(?#-KH?A]-1M;NP
MTQ)FU34+^*V.JRS6D=U#8P_9<%\!<2<?8[$X#AW"4J]3!X=8G%UL37AAL-AZ
M4Y^SI>TJSNW4K3O&E3IQG.2C4GRJG2J3A\CQ?QQP]P/@L/CL_P 54HT\97>'
MPM'#T)XG$8BI&//4<*<-%3I0:E5JU)0IQYH0YG4J4X2_I\HKX8_X)]?MHZ5^
MW#\!XOB<OAV+P=XO\/>(;WP3\0?"EO?OJ5CIOB73['3]22^T:]FB@NI]!U[2
MM3L=5TM;R(7ED)KC2[N6YN+"2[G^YZ^?SC*,PR'-,=DV:X>6%S'+L14PN+H2
ME"?LZM-Z\M2G*=.K3G%J=*K3G*G5IRC4IRE"2;][*<UP&>9;@LWRRNL5@,PP
M\,3A:ZC.'/2J+3FIU(QJ4YQ:<*E*I&-2G4C*$XQG%I%%%%>:>@%%%% !1110
M 4444 %%%% !1110 4444 %%?/\ ^T'KWQ3\/>&[#5/ 'C;X._"?PQI)USQ!
M\5_B_P#&6TU'7M"^'W@;P_H%[J3W]EX5M?$W@#3-1EO-22U35M;\1_$+PWHO
MA3P];:IJCVVN7TEC9Q?,&M_M=_&+1_\ @G7;_M7ZC\-_#WA_XN77@K0M9M_!
M6MQZ[::3J,^N>.K'PKI>O^'O!NK7^@^.-9U#Q=X6O;;X@?#OX'3:MIOQ)\6Z
MMK'AWX.0ZQ!XUU5-2 !^C]%?CM\./VX/C'\6=7\'?!+P/XF\&1_$CQG^T%\3
M/A9#\5?'G[.OQ:^&5SX8\'_"3X$>'OC!XJOO&_[+7CWQKX=^(7@WQUJ>O>*-
M%\)>"](\9>,_"UOXL\$W4OQ@TO29M!&AZ?XDQK7]OO\ :'^('@SXE>)/ N@?
M"?PKJW[*O[/'C'XU?'K2/$N@^.M?TWXJ^+_ 'QH_:7^"VL_#[X5:I%KOAF?P
M-X8U>]_9,^)GB#3?'&IV_P 1M3TU?%O@*RN/#^HQZ3X@;6@#]HJ*YKP9XIT[
MQQX1\+^,](CO(M)\6^'=#\3Z9'J%LUG?QZ=X@TJTUBQ2]M'+-;7B6M[$EU;L
M2T,ZR1DY6J_C7Q]X(^&^BGQ)\0/%WASP5X?6[M;!M:\4:Q8:'I8OKUF2SM#?
M:C/;VXN;IT=;>'S/,E96"*Q!H _&CQ__ ,K$'[.'_:)O]I+_ -:D^$-?N)7\
M_E_\5OAC\0?^#@[]GG6? GQ"\%^,=)LO^"4?[2-I>ZCX9\3:/K=E9W;?M0?"
M:=;6[N-.O+B*VNF@@EN$MYVCF:W7SU0Q,KG]Z/\ A)?#W_0;TK_P/MO_ (Y0
M!MT5B?\ "2^'O^@WI7_@?;?_ !RC_A)?#W_0;TK_ ,#[;_XY0!MU^7__  5<
M_;0\;_L9?L^:+K_POM-/;XD_$CQK!X%\,:WK-C%JFD^$XHM&U/Q#K7B*72IW
M6#5M0@L-+%AH]A=@V O]034+^.[MM/?3[W])?^$E\/?]!O2O_ ^V_P#CE?*7
M[8_[-'P6_;3^#MW\)/B)XD71OL^K6?B;PCXOT*]TMM=\'^*M.ANK6VU:QBOA
M-97UM<V%]?Z5J^DWL9MM2TR^N(EDM+U+*_M/I^"\7D&!XJR+%\485XS(,/F%
M&IF>'5-UHSH*]I5*"UQ%&E5=.K7PZ4G7HPG1Y*G/R2^;XOPN>8WAG.L+PUB5
MA,\KX&K3R[$>T5&4*[Y6XTZ[5J%:I252E0Q#<50K3A5<X<G/'^9#]D3_ (+#
M_M<>$_CEX(L_C3\0=5^-'PP\8^+=&\/>+?#FH^%- F\2:=;>(;^+2(M8\"2^
M$= TO5?[7TJ[OK>[A\-)!J5KXAAA?1;6RM]1N[.\@_J(G_:RT=Y7AT3X&?M4
M^(V$BQ1-;?L[^/O#D-PXYF"S^/[7P;#;K;J"7EOGM(96'E6DEU.5C;\I_P!E
M7_@BC\(/@9\8O#'Q:^)WQ^MOB^O@'7K3Q-X.\'6?A;3O!NA2>(-)G%UH6K>*
MY9_$WB>]UA-&OX[;5;/1[%]+L9=3L[6349=0LDDT^;]ZO^$C\.'KK6DD^IOK
M7/\ Z,K].\7>(O"[-<]P&(X+R6C6HTL![/'U\NH5.'\MKU_:\U"/U!X##UJM
M>C34HUL1&&&]I"<*?/5=)2I_F_A1D'B7EF2XZCQAF]:C5J8Y3P5#,*U//LQH
MT53BJT_KZQV(HPHUI\KHT)3Q/).%2?+2564:GSI'^T1\1M26,Z#^Q[^TC=[T
M:;S-:NO@!X1C:W!V(ZQ^(/CG;WB3RL018W=G:WD<>9)HHMI4TE^+W[4EZX73
MOV1(]/!\M-WC']H3X>:4%ED8X9QX1T7Q\_V2!-INY4#W:/N2SL;U565_ID>)
M/#HZ:WI(^E]:C_VI2_\ "2^'O^@WI7_@?;?_ !ROR59IE\;J/#>4371UL3G\
MIK7K*CG5"#?I3BO):W_4O[,Q\K.7$6:QEU5+#Y'&#VV57)ZTTM.M1[ZWU3^<
M9?$?[:6I1E['X2_LV^&%>4!5UKX[?$KQ-=0118#M);:-\!-$MIS=,"8#'J<)
MMHR'GCF<&(UX++]N&]9FN/$_[*OAI65W6&'P+\8?&[1L[X2V-U-\0_ "R""/
MYFOQ9Q&[?Y!IMFHWGZ6_X27P]_T&]*_\#[;_ ..4?\)+X>_Z#>E?^!]M_P#'
M*%G48)JADV2T.S>$K8QK9?\ ,RQ..3T26J>R>]VW_8\YM.OF^<5^Z^M4<(GM
M_P!"[#8)K:]DTM;?"DCYKN?AG^UMJ!47?[4?@#28RB1.?"/[-%I9W 4MNFFB
MF\7?&#QK MYC]W;R264UG&G,^GW,AWB6#X%?&^["+K_[97QA,9D9YH?"?P\_
M9W\,)A ?(2WFOOA+XHOX%W;9+H27MR+EMRH+:)O*7Z/_ .$E\/?]!O2O_ ^V
M_P#CE'_"2^'O^@WI7_@?;?\ QRC_ %@Q_*H^QR96U4H\.</1FM$M)QRM35K:
M-236Z%_8.!O=ULX=]T^(<^E%K31P>9.#3MJK6:NMCYG?]E6\O&+:U^TY^U?K
M.?,)"?%72?"J^;,<S3!? /@GPEM\Q<I';J?L=F#NL+>UE"R+<?\ 8\^$E['+
M'X@U[X]>*Q*%C9?$O[3_ .T9J,)ME^;[%):)\3[:SN+-Y"TLL%U;SB5V(D9D
MP@^C/^$E\/?]!O2O_ ^V_P#CE'_"2^'O^@WI7_@?;?\ QRA\29XK>RS+$X6V
MRP,HX!*UGI'!1H):J^B6K?=C_P!7LE=_:9=A\3?=XR+QK?K+&.O)_??[E;YJ
MA_8<_94259[[X-^'?$4P=I6E\97_ (F\<O/,PVK-=MXQU[7#>30KB.VENC-)
M:Q 16SPQ@*/Y^/VL?^"%GQNOOC1XK\4?LR:A\,[[X6>--?U#Q!IGA?Q+K]_X
M-U/X=/JUT]Y>>&XHUT;7++6/#>G7$\O]A7MG<07\&FF+3+G2B]BE[??U.?\
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M(:_<2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?PI<C&<C'KV_.@ HI,C /8].#D]^!U/'/ Z<T;E&.1S^/'K[#W/'O0 M%%%
M'X=^/_\ E8@_9P_[1-_M)?\ K4GPAK]Q*_#OQ_\ \K$'[.'_ &B;_:2_]:D^
M$-?N)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR7XU^.=>^%?C;7?C/\>OB7X1O/AY^Q=X_P#B)^PGXE'Q0\4>!M7^-OCOP_\
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M;9D)&04BV9)V@ XK2MO#OAZS(-KH>E0,.CQZ;;+)SUS((?,)/<EB3W->4S_
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M7M2TR/1K+3KO5@#[^HIJ.DB+)&RNC@,CJ0RNI&596&0RL"&5@2&4A@2"#3J
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M9?\ /QK7_A1:_P#_ "SK:HH Q?[!LO\ GXUK_P *+7__ )9T?V#9?\_&M?\
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M'K_H[^+_ ,,+^U!_\Y*C_B(?_P""/7_1W\7_ (87]J#_ .<E7[48'O\ F?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS0 ZBBC(& 2,GH/7OQZ\<T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ1KNKV&G-I+6T5_KNDL=)UR<H[:SI>W3=3^UV4<4":O@W]E_]G+X>7WA_5/
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M7S>,I4\'&E.I0K4<MC&I[>M)P=&KCG*<N649.HM&FH;QL.]K6T\]^W3U5_\
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M/X+_ +2GB+0['XA^'-=AT5-?^"&G^,9+?Q=#X2UZ&R\5V.G^(M-\-#Q'X?\
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M/@;7];BCU?6?"IB.B:EJ4:7MY937*+(.AT'X*?![PMX^\2?%7PU\+/AYX?\
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MZ'X>\.Z%I4%KIFC:)H^FVUMI^EZ7I]M;V5A900VUK#%#$B  Z6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-2017930incometax.jpg
<TEXT>
begin 644 biib-2017930incometax.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%OVD?BZ?V?OV=_CU\>1X?/BP_!+X+_ !2^+@\++J7]C-XE/PV\#:[XS&@#
M5_L6I?V4=9.B_P!G#4O[.O\ [";G[5]BNO*\B3Y ^%/_  40\":A\/K+X@?&
M#QC^S]<VGB07=QX3T[]D3XD?$C]L+45L?#'A?3/%WQ*N/&6G>!/@KI&L>%8?
MAQHWB'PSJ'BJ_.EW^D:-9:[I;ZQJ&FW>L:#9:M]E_M _"/3_ (__  &^-OP(
MU;6=0\.Z5\:_A%\2?A)J?B#28+2ZU70M/^)'@S6O!M[K.F6U^KV%QJ&F6VM2
MWME!>HUI-<P11W*M"S@^'?$S]D)?%4_PJ\0_#?XJ^)/@Q\0?A=\-_&WP<MO&
M?A?PIX$UYM<^&7Q-M?AZOCG2-0\/>*=%OM%@UR?6/A7X#\4>&O$EM%Y_A[7-
M"$5S8Z[X>U'5M O@#U+X=?M.?!;XN>)?''A3X8^+)_'6I?#F#2)O%]YX:\-^
M*-2\-:8?$7@WP3\1/#-K!XQBT;_A$]6U'Q3X$^(?A+Q?X9TS1]9O]1U[P]JJ
MZKIMK<6EO<2Q_G]\.?\ @L3\%/&[_#CQ#KWPZ^*_PR^&?C?X8?MA?$C5O$WC
MCP#\0_\ A*O"=M^R'\;?A=\)/$\UW\/O#O@76M8OO!U]I?Q!U3QUK_CV&XAT
M/X?6/A#5O#_B7&NVVL0:-]G_ +*O[)/@/]D;1OB7X8^'.IZS<^$_'?C3P'XH
MTG0M6^SRKX-TWX=?LY_ K]F_P_X<T^^A47FKV_\ PC'P(T+7+[5-69]2N]:U
MG50S)9QV<4?R[H'_  2\\*:!;^+]$MOC'XU?PAJ7P0_;B^ ?@G0SX<\+Q7O@
MGP3^W/\ $3P/\6/&SW&N(@N/%FK^!O&OA749?!=YJEG9"70]=33/$46JWNDP
MZQ>@'V1X<_:L^!'B[XD'X6>&_&SZQXDDU>[\-V&IV?AGQ=)X!UOQ=IWA5?'.
MJ^"/#WQ2.@K\-?$7CO2/!K-XGU3P7HGBN_\ $MCHMKJ=[/IJKHNMKIW@OQM_
M:>_:#^&7[5?PL^ GACX.?!OQ/X*^*_P\^+GQ2TCQUKGQJ\<^&_%6F^&/@*WP
M<@^)-C?^!]-^!?B?2)?$%]<_%^S_ .$'M[;QNVFZG;Z)=R>(-1\.RWD$"<;^
MSS_P3!^#?[.?Q:T3XH>%;CP]J,V@7=_XGL9-3^#?PAD\??\ ">^(/!1\%^*M
M7_X7)+X8NOB1:>&=76ZUSQ':^$-+U?3GT?6O$.JZ7!XBN/ IM/!MM]4?$C]G
M;1OB1\<?A-\<+SQ+J^F:G\*/A/\ M"_"K3]!LK33IM+UC3_VA)_@_/J^KWUS
M<(U[!?>'#\(=.72(+1UM+L:SJ!U!7-O9[0#YF^"G_!4?]F7XF_!'X3?%7QAK
M^I?#3Q%\2/AK^S9X[O/A]>>#_B9KFH6.H?M/Z;)#\.]%\%ZA!X!L)?BQI>J^
M/-.U_P"&6D>+O >E:GH^L>-]'_L%!:ZKJ>EV-W[C#^W'^S(S>+FO?B+-H.G^
M"=!\?>(=:\0>)_!GCWPQX3N+7X47<6G?%.P\,^+]=\+V'AGQKXA^&FK3QZ'X
M\\,>#=5U[Q#X8\0I=^']2TV/6=.U*RL_EO2O^"5G@33)?V795^+GCRX/[+WP
M?_8I^$.A"71O"X'BK3OV+/BC'\3_  SK.M%8,V6H>.+V--(\26^EF.ST^P59
M=&6*Y52,H_\ !'C]FBY3XT>'[JUTA/ WQ8LOBO';V>F_";X/Z?\ $?P[JGQC
M\:O\1?$=_>_&B;P=?^/?&UAX=\7RSW/@CP[XEN9-#@T2;_A&?'-O\0-&M=/M
M[, _1/X<?&[X>?%31?$NM^%M0UNV'@O4Y-&\9:%XP\&^,?A[XR\(:HFAZ=XG
MBL_%'@;QWH/AWQ?H4M[X:UC2?$6EG4=%@CU;0M3L-5TV2ZL[J*4^$M_P4#_9
M7MEF35_'/B;PUJ":]\*_#]OX?\5_"+XP^%O%VJ77QPUS6/"_PAO=$\&:_P"
M]/\ %FMZ)\0_%&@ZKX:\,ZWI>C76FWGB"U&CR3P7]Q:P3W_@+^R!X2^!GPI^
M(_PVT+4M)\/W?Q4NM:O/$GB7X+_#7X=_L\2Z3=ZIX4M?!MKJ/A#3/A=HEBFD
MZYH^FV4.I:;XDUG4/$OB"V\0/)=VVI6VD6ND:%I7QMX&_P""/OPU\%^-/!7Q
M!7XI:RWBCPE?_LS3WUSX=^&'PN\$0>-(OV6_C!J/Q7\&:IXU3POHUM>^)?'/
MBZ74[G1/B/X_UN_U'6]?01ZC8+HK1I8  ]A_:!_X*B?L\_"#X!_$SXP^#KK6
MOBEXC\!?"+XF?%1/AS8^#_B=HE]8_P#"L]?\7>!=2T#XLZO_ ,*]U<? .[N?
MB?X'\4?#1'^*VF>'[D>,?#WB+2K:PO)O#VLBS]B^/G[6L?P$^/'[./PLUGP%
M/J_@;XV6'Q!N?&OQ1@\0QV2?![_A'_%?P9^'W@74M8\+OI-Q+KOACQI\1OC3
MX6\%:SKT.L:4O@6\U31=8U.UOM!N=8O]"^6?%7_!*7PWK/AC]I7PAX<^/WQ(
M\%Z/^U];?'K1_C]_9?ACP'J=UXI\-_%[XP_''XS>%],T>[UK2[Q_"U[\-=7_
M &@O'WA2RU?3B\_BWP5>P66N6L&O6>F>(].^\?B-^SWX,^*GQ"T'QIXW:36]
M'T[X)?&SX%ZWX'N[:W;P_P"*_"OQRUOX0ZMXDDU69=FHPSVD?PDL]/LH;*:*
M-X==OYY&6[M-/EC /E/P9_P4G^%MUJ%ROQ3;0?A?86UH('T\7WC_ ,8^,5U[
M6_VR_B-^QG\/[1M#T3X8+H\NG>//'W@G3;73'LO$MYXCL/$6O/H6H^%X=)LK
M3Q3JWL;?M[_LM)INCZH_Q"U00:C'XSN-:MQ\./B@^I_#:Q^'7C*[^'?CO5OC
M3I$7@R34_@CH?A'QU87WA;Q!KOQ8M/"&D:=J=AJ3RWOV#2M3OK/Y2\%?\$FO
M!OA$?#^:Z^/?Q6\6ZCX"B^ J'7?$^F>$+KQ#XIN?@1^WCKO[=NGZKXHU"TTZ
MS^VZYXO\5Z[-X)\5ZG!;6TEQHL;^(K:.'Q%=32FKK_\ P1]^"6O_ !%\8_$G
M4]?T[7]?^)'Q#^+?B?QJ_P 0/@O\&OBJC>$_BI\4M:^*Y\+>$(/B/X7\2V'@
MS5_".M>)O$VD:)XTM+"_FU+P_P"(+NS\4Z#KEWI_AV^T4 ^JOVH/VOX/V:/B
M5^RYX0U'P))XE\*?'SXG:KX#\:>-H?$<>DCX1:%#I6GVFC^.KS2)=)O(_$FC
M7/Q!\3>!_"6N1'5="_L#2O$5UXK>[O;?1IM.N?,O#7_!1SP#<_'K]J[X3^-_
M#%YX0\*?L\ZY\!O"/@+QGI<WB'Q[XJ^/GC3XPW_QB\+:MX8\$?"?PGX/O?%D
MFJ^$?B#\$O'/@^ULM$;Q5>>(!X=\1^(IK?0M%T.[GKW']HW]E#P?^TG<>'$\
M5^(->T;3="\!_'#X?RZ?H=KIP%]IOQN\!6_@6^OTO;RVGDT[5/"D=I:Z]X:N
MK-?W&MVEI<S BVBQ\V6'_!,GPYH&M:/XW\-?&[XC67Q/\'^%/V7;#P1\0-6T
M;P=X@U&R\>?LWZ5^TQHNJ_$GQ9IMYIL.G>-]:^.FG?M7?%Q/BS97RZ9'->Z]
M/K7A6^\/:X8-2M #VF7_ (*)?L?Q7>EVI^+3/_:7ASP9XON;J+P'\2I;#PKX
M9\??$GQK\'/#^M?$2^3P>;;X8V</Q8^'OBSX<>)S\0W\,R>!_&6E2Z'XSCT&
M[>-3\R^&_P#@KY\&M:\7>'[#6OAK\8? ?@:[O/V]-,\2^*_&/PS^)L?B'1+K
M]A7XN_#'X8>)]3TCX>Z#X!UOQ%XG\*:_8^/-:\7^(-?LQ;CX56O@S5/#WC>U
MM_$B:GI^D:^L?\$IOA_JWA'X_>&'^,'Q%^V?M&_"#PI\.OB%XEGTGP=+JEUX
MMTW]ICX[_M3^,_BC;VMKI>GZ/#K?CWXB?'_Q7:W7AVWTZV\,>'?#^GZ/IV@V
MD/E3O+TUG_P3:T"R^('C;Q1%\8O&'_",Z_H'[>.C>&O"!\,>%8Y/"=S_ ,%#
M/'O@GXK_ !KU"3Q-'''?^)AHWQ#\(2:MX!MM3LH1HVDZQ-X?U.YUF#3M.NH0
M#ZE\%?M:? CXC_$.Z^&G@+Q;J?C#6K/48]#N=?\ #G@;Q_J_PTB\2R>!-,^)
MX\)M\7;'PO-\+E\6_P#"OM:T;Q>/#+^+EUA]%U6SGBM9)7>"._K_ .U'\$/#
M/Q2A^#NL>+[F'QLVH^#]#U#[+X4\9:GX3\-^)?B)(L7P\\)^,_B%IGAZ\\ ^
M"O%WCYG@7P7X7\5^)=(USQ(]_HT>F6,\OB'P\FJ_*GPJ_P""<NA_"WXE?!CQ
M[8_%OQ!/%\%?#W@71--&C_#[X;^!/&WC.T\"_!BW^"MAX0^)7Q.\$Z+HWBGX
MC_"633HD\80?#KQNGB.?3O&EKHD]CXN70/#FA:!8])XG_P""=WPB\1_M67/[
M5)'AX>)/$'C#X9?$7Q?::]\(OA/XW\27?CKX/:)X<\/>"-6\'?$KQGX6UGQK
M\-K)])\&^$(?$.F>&)UFN+KPY9:UX7U+P;KUWK.JZF =9I7_  46_9 UK1+C
MQ%8?%6Z;15\/ZSXCTJ_N?AU\4K&/QC:^'/B?I'P5\0Z=\.([OP7%-\3?$VA_
M%OQ%X9^&^J>$OA_'XD\3VOC+Q5X6T%M*-]XBTF*Y\Z^'W_!37X&>)M0^-]KX
MPMO%/@>/X2_&7QS\.+"T7P+\5?$GBO4_!?PT^%/P*^(_Q ^+7CGP-IWPYB\5
M?"'PAX%U'XWZ=X3\:ZAXYTVTT/PW?6%E/?>(/-UZUL8.#C_X)4^ (/"W[/F@
MQ?%[Q_%JW[-&A_&G_A6?BB/1?"+W]CX^^)W[3?P?_:I\+_$*^T^YT^ZT>\NO
MAOX\^#.AZ18^';JSET#Q5X6U;7=.\00_:)[:ZMN6\2?\$?\ X9>-/%_BGXH>
M./B&GQ"^*_C_ ,7^-_$'C3Q7\2O@E\$_B+HKZ1\2/!/P2\*>)='\(^ O&7AG
M6?"OA'4-#O/@AHNL?#[Q*EMJ][H$.NZ_H7BBT\>Z;<1%0#Z3^)W[?OPM\(?%
M7X._"3P/:WGQ+USXC_M->$OV;/$FM:99>*M/\#^#-<\3?"7QQ\7+I[+XB#PE
MJ'P^\8^*_#^@>%]%FUCP!I'BF+6K"P\56NH7T]I)8SV3_>2G<JMC&Y0<=<9&
M<5^=2_\ !/'PU8?$+P3KOA[XJ^,O#_PR^'_[3MG^UQX;^#UGX?\ !;:%:_%R
MX\&>*_!7BN)O$7]E0^(1X)\11>+]7\46_A6![=/#WBZ_OKG3+]O#O]C^&-#_
M $54;551T4 ?D,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'PG_ ,%#4O9_@/I=K9?&S1?@>+KXL?#&*]U;QAK/CKP;\.O'>FQZ^UU?
M_"/XE_%#X</:^+/A-X+^)5O;MX?NO'EEJFFVUOK#Z+X<U%==T_Q)<^$_$/Y5
M3?\ !0KXN?"CPEX3^'WPB\*Z/HVC:5K7[3C:E\2?'O[0'P]^._P2UGQ/\([C
MX/:EX4^&WP8_:"^//Q>_9Q_X3#X0ZO8_%74'U.X%[XB^+/P_B\#>,OA[X6\&
M7R>!=8U/0?Z.KJVM[VVN+.\@ANK2[@EMKJUN8HY[>YMYXVBG@N()5>*:&:)V
MCEBE1XY$9D=64D'./A[0FL=.TQM&THZ=I$ME/I-@=.LC9:9/II5M.FTZT,'V
M>QET\JILI+6*)[0@&W:,\T ?B7+^W=^T7XL^,GCKX5:#XM^$?AGQ9:_M0^!O
MV:-*^#>D^$_^$S^+NC>&OBU^QC\&?CKJ?QMTO4)_'&EV/BBS^ ?CSX@>(=2U
M"1_",7@[Q=X#\(ZOIVLWVA:]J6CSZ=\R?LV?\%&/VLK#X;?L8>!]1\0>#/B]
MXAO?V5_V/?&GC;Q]\0-?^"7@[5?C7\3OC)KFK^&?BK\.]2O_ !3\>_"'BO3O
M'?P7AT:T\*>(C\.?AO\ %3QU>_&#5+6X^(OA#PO9ZMI7A_7/Z'/!?P?^''P]
M\3?$CQCX1\,6FD^)OBYXVD^(GC_6?M%]?7FN>+IO!7@'X>3ZDCZC<W8TB"?P
MC\+_  )I=QI6B#3M'N)/#]OJ4UA)JMQ>WMSV$7AKP]!<P7D&A:/#=VVH:EJM
MO<Q:78QW%OJFLK(NKZE!,ENLL.H:HLLJZE>Q.EU?K(ZW<LP8@@'X*^+/^"A7
M[6MAX9UW7]#UWX)PQZK\./\ @K7X]\,1ZG\,/$%[)X?D_P""8/[3EU\-M LM
M0^S_ !-T^/Q#;_&GP9J6F6'C,XT67P3J&ER:EX<FU"XU"2"#Q'X6?\% ?V@/
MA7X/^,?Q(\'7VB?'C7?&/[6/[7.K:+^R+??V]K?QJM/ 1^"GC'X[^%/%_A/Q
M/=>,&U"T^'/@WQ'X5TOP;]CTOP(? EQX4UF?3?#^J0_$1]*TF[_I>.A:(4$9
MTC2S&L6J0A#IUF4$.MS"XUF(*8"HCU6<";4HP-E_,!+>"9QNIT&BZ1:W4=];
M:7I]O>163:=%=P65K#<QZ>UP;MK&.XBB29+,W1^TFU5Q;FY_?^7YWST ?A7\
M//V^?VJO'O\ PICPC9:Q\##>?%_]J?X>_!&V^*%C)\+?'MM9:/XZ_9@_:8^-
M/BB*/P1\#/VB_C%X:L=5\(:]\'O"USX'N->^)UEJOB3PMXGBA\5^%[)].EUS
M7_I#_@I=J_A!?"$M@GQ<\-^"?BWI7PS\<^)/ OA[XC_M._%#]E[P7':+;/#=
M?$_PKK/P_L8[;QY\7_ 6O66@0>$/#^JZM%;Z-::Y>W,]QX>BUN+4[_\ 4&VT
M+1+.."&TTC3+6*UU"XU6VBM]/LX(K?5+PW1N]1@CB@1(;^Z-]>&YO8U6YG-W
M<^;*_GR[YM0TG3-6%HNIZ=8ZBMA?6^IV*W]G;7@L]1M"YM;^U%S%*+:]MC(Y
MM[N$)<0EF\N1=QR ?SUO\7/%FJS:MXVO/B=\7(_VM['XH?\ !/O3OV4_A;\2
M?&'B#X;^,O'/P'^)_P /OV5]2^)-SXH^ &A7&G^"=:O?''B'Q)^U%!^T'>Q>
M%_%%MX U7P-JJ_\ "0>'K3X3^&-1T?\ 7_X\_%3X"W7[-/Q(^(_C7]HBS^&'
MP-T(:O8>.OC;X$^(]CX;'A^#P1X^_P"$2\:^&++Q_I7VZ[T/7[KQ1H>J_"?5
MX?#4EOX^L/$-[J/A[PE=Z1\0(]*NK+Z8ETW3YKVTU&:RM9=0L8KJ"ROI;>&2
M\LX+TVYO8;6[=&N+>*\-K;&[BAD2.Y-O#YZR>6F,:#P9X4M]"N/#$?AW1SX>
MNKS4-0NM%GT^UNM,NK[5M9N?$6I7EU97<<]O<W5]KUY=:Q=3SQR23:E/)>.Q
MG;> #\ /!'C/1->U3X:6_BKXM7/A#]@OXJ_M)_$N^_X1._\ VH+_ %34OA!I
M?AW]FG0(?A!\,_C'\5_#OQ%U?6_AW9?%_P")&B_$SXXV?PFUCXIPVOA;Q#'\
M/O!E_<1^(M4U+P'!E>+_ (_:YX9\!?\ !*[QO\7/VL]?\'W&J_M?Z?HT?A'Q
MG\5/#7@'_A:/[.4.L?M3:5\,OC5\6?[8;PYXX^(4'C/X3^'_ (2:G=77BV\_
MX0N?Q%>'Q-?Z/?\ C2^M]2L/Z"]-^'W@31M*O]"TGP9X3TO1=4D2;4M(T[PW
MHECI>H2QB,1R7VGVEC#9WCH(H@CW,$K+Y<>TCRTVN\0> O!'BNYCO/$_@_PM
MXBNX;0V,5UKOAW1M9N8[)I6F:SCGU*QNI4M6F9I3;JXA,K-(4+DL0#\_+SX1
M?#/QY_P4#\.ZSX;TW6[;5?AM\+M#_:.^(GBW2?B=\2C8>+?$/Q+OO%7PK^"G
MAX^'K3QPW@2?P>FD^ /BGXRUW3$\-M:ZMK6@_#N[B/V:WU>/4O"_^"@'_!1+
MXA_LP?%'6-!^&S^&M=B^$_A?X+>-_'7P\\2^'O#F@WGBKP_\4_B%K7A34FT#
MQ=XH^+&@^,/%TECX?T6]N[6+X/?"?Q?;^!M:M/MGQ!U^]L[\>&]/_9J"RL[9
MS);6EM!(;:VLR\-O#$_V2S,QM+;=&BM]GM3<3_9X,^5!YTOE(GF/NKWFC:3J
M%Q%=WVF:?>74%M>64%S=V-K<SPV>HB$7]K%-/#))';7PMX!>6Z,L-T(8O/23
MRTP ?@5XB_X*3_M0^"-$\-^)-07X0:]I_P 6?$?[??@;PZP\"Z_I^G?!BR_8
M[_;ATG]G:#XT^.[VV^($ESXV\'Z%\)M=UCXE?%OPYIT'A4VR>"1-H_B'1M.;
M7+QOJ']B?XB:QXQ\0_\ !334/&G[1FE>,?#OAOX_>#=-T?XV^$K^PT3P+X9\
M,6W[!_[,FH:OXJ\%6GB+7O'?@3PI8:%KUQXB\1:W+I]]J7@*7QA;^(=>N[0_
M:M8LT_51=&TA&A9-+TY&MFU%K=DL;56@;5YFN-5:$B$&(ZE.S3:@4*F]E9I+
MKSG8L60:'HUK8RZ9;:3IEOIL]K'8S:?!I]G#92V45FFGQVDEI' MO):QV,:6
M:6[QM"EHB6RH(%6, '\Y-I\5/"NO:/XT\;_LU_M#^)KW]CW6_$'[(G@7XF:O
MJG[4FL^.?B-XQ^'VI?M#V-M\?OVOY+E_&WB/XB_!/P%XH\ ZCI7PYUOXA-<?
M#G4?&OA;6O%GQ7DTKP9X9\(_#[QMK=?]K#XKCPC^P=^V?J'A#]K#Q5X!^#_P
MZ_:)70_V3O$UC\;K/3=2^*_@[3O#O[.VK^+/!'A_XM^*+J7Q]XQ^'/PY^,VM
M_&CPQ:6?@KQK.^HZ#X?;P!J6O7O@309-#O?Z)-$^'W@7PW-?7'A[P9X4T*XU
M2!K;4I]&\-Z)I4VH6[N9'@OI=/L+:2[@=R7>&X:2-V)+(22:FU/P/X,UJQTO
M2]8\)^&=4TW0U1-&L-2T#2+^RTE([=;1$TRTN[*:WT]$MD6W5;.*%5@585 C
M 6@#\%?VTOV@]4O?C9\8/%:^-?#^K?#'X6_ ?X&_%K]EW2?"_P"T]\0?A=K7
MQ^U/6/$GQEM_BCIO[,C?""_GT;XI_'^X\3>&O _@32;#Q;8?$?PG8M>^!O ]
MYX.L]#^+?B_5;G^@Z"0RPQR&.2(R*',4N!+&7&XQR!6=0Z$['57=592JNR@,
M<:T\+>&K"VT:SLO#^B6=KX==Y- MK72=/MK?0Y)8IH))-'@@MHXM+>2"XGA=
M[!+=WBFEC8E)'!WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH?XUD?\ ".>'O^@%HW_@KL?_ (Q1_P (YX>_Z 6C?^"NQ_\ C% &OO3^\O\
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MYRE*I1PM7FE3DU5CB*E_94J=.G%N6)<Y1C*E"O[TI2E7CS5)SC>#.;T^Y?\
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MQ!K]%/CI_P C#H?_ & $_P#2ZZKX#Q,_Y)3$_P#87@?_ %(B!^&'[2OPA_:
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M;ZKXFTWX=^![_P",]YJGPW^'#_!67P[J/BGX;>'?$/[1_AP_!/\ X0.>TL_
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M?\7IJ/Q*A7X:_&'Q[\%_BY\?/A[%\.]+^T_$#XH?!>P^'-M#J7AGQ>?$8E\
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M?D&GG]__  /7^EK];8/H?R->W_ C(\2:QD'_ ) 9['_G_M?:OS:_X<2_#?\
MZ2+?\%@__%@OCO\ ^9BK^G_\$.O!6DRO/I?_  4F_P""Q^G32Q^5)+9?\%#/
M']O(\6X/Y;O%X94LF]5;:3C<H/45[&0>&^/R?.,!F=7,L'6IX2LZDZ5.G7C.
M:=.<+1<H\M[SOJTK)]T+3^G_ ,#U_I:_M]17S;^RS^S=;_LL_#2Y^&MM\;OV
MD/C['<^*=6\4GQQ^U)\8=8^-WQ*@;5K32K,Z!;>,=;L[&\A\+Z>-*%SI.B"
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M ^HZ*** "BOC_P"(?[87A;X9?$[QE\'O$G@[Q,GQ M]"^&VO?!S0[>[T(O\
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M#O5_AIXPAU;Q/H?QH\'Z9:64&C:Q+J/AU++PQYUMJ<$0U274K5I8WXWX5_\
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M-WXU?P_XHAU/QQ=ZCI/ZB 8 &<__ %^?P'H.PX' I:* "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-2017930interferon.jpg
<TEXT>
begin 644 biib-2017930interferon.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%_VD/BZ?V?OV>/CS\>1H!\5GX)_!CXI?%P>%QJ7]CGQ(?AMX&UWQF- &K_
M &'4_P"RCK']B_V<-1_LW4/L/VG[5]BN_*\B3X[^$O\ P41\%:G\.K'XB?&+
MQ9\ +FS\3B>X\(:?^R#\1_B3^V%?BQ\-^#](\9_$NX\96'@;X+:/J_A>+X<:
M3XD\,WOB>_&EZCI&DZ?KVD3ZSJ&EW6M:%8:I]H_'[X2:=\??@3\:O@5K&K7V
M@:1\:?A+\1_A+JNNZ9!;W.I:+IWQ'\&ZUX.OM6T^WO/]$GOM.MM9EO+2&Z_T
M>6XACCG_ '3-7AGQ2_9"3QC+\*->^'OQ2\1?![Q]\+/AIXX^"]IXQ\.>%O!?
MB ZS\+_B=IG@.Q\<:-?:#XGTR[TN'6GU#X9>!O$WA7Q# 6/A[7] A2^TSQ'X
M<OM6\.WX!ZI\./VF?@O\7O%/C?PC\,O%LGC?4OAU%H\OB^_\.^'?$^H^%],;
MQ'X.\%?$+PU;0^,H-&;PGJU_XG\"?$+PEXO\-:;HVLZAJ&O>'M575=,M;BSM
M[B5/S]^'O_!8?X)>-1\+_$NL_#[XI_#[X9^/_A;^V!\2=6\2>+?A]\2Y/%G@
MZ+]D3XY?#/X/>)FO_AYH7P^U36[[PAJ&F^/=1\=Z]X_M95\/?#[3?"VH:+XE
MD&L6VN1:%]I?LL_LE^ ?V2=(^)7AKX<:AJTOA;QWXR\">)],T35/)E'A+3OA
MW^SO\#OV<_#_ (=L;Y,W6JP#PS\#-#UF\U'4,7MSK&L:H"J6R6R+\N^'_P#@
ME]X/T&V\6Z'#\6_%UQX1U#X*?MP? 7P/HLGAWP_'?>"? W[<OQ%\&_%CQTMQ
MK:2^;XIU7P9XV\-:D_@^\O[+3FDT'6H=)UY-1O-)76=0 /L/PY^U9\"O%WQ+
M'PI\-^,Y=8\32ZI>^'K#4K+PQXOE\ :WXLTOPJ/'.K>"?#OQ3.@+\-?$?CK2
M/!I?Q1JO@S0_%=_XCT_1+34[VYTY%T?6$T_P7XW?M/?M#?#+]JWX6? 3PQ\'
M/@WXG\#_ !7^'GQ<^*.C^.]<^-7CGPWXLTSPS\!/^%/Q?$JQU'P-I_P-\2:/
M)KU_=?%ZP3P-#:^.9-.U.'1KN37[_P /RW,,"<A^SY_P3$^#G[._Q<T7XH^%
M7\,7TF@7NH^*K*34?@Q\(Y/B$WC[Q%X&B\#>*M8E^-,_AN\^)D'AG5(WU?Q%
M8^$-,U?3I-&UGQ!JVEQ>)+OP']A\%V?U3\1OV>-$^(_QN^%'QOO?$.J:=JOP
MI^%/[07PKTW1;2ULIM.U73OV@9OA%/K.JWMQ/_I4-YH!^$>FKI<-O_H]T-7O
MC>?ZBVH ^8O@E_P5'_9I^*'P0^%'Q5\6:QK'PX\1_$?X<?LV>-KKX>7?@WXF
M:WJ-MJG[3^G/#\.]#\#7\7@'3Y/BYI>J^.;'7/AKI/B[P#IFJ:/JWC;2E\/8
ML]:U+3=-N?<X?VX?V9FF\8K??$*?0+'P-H7CSQ!K?B#Q1X,\>>&?"5U:_"JY
MAL/BE8>%_&&N>&+'PQXW\0_#35KA-"\>^%_!>JZ_XB\+^(8[S0-3TR+6-.U*
MRL_F+2O^"6/P^TJ3]F&2/XH^,YO^&8OA'^Q;\)- 5]'T!1XFT[]B_P"*"_$_
MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
MA!?BUIGQ@L[:TT_X._!NR^)'AR]^-OCH?$KQ3<W_ ,:KCP=J'C_QQI^@>,M]
MUX,T#Q-<2:2NB3R^%O'T?Q%T"#3K.P /T/\ AK\;OA[\5]$\1ZYX5O\ 7+4>
M#=3DT;QCH7C/P;XQ^'7C/PAJB:)IWB:*S\4^!O'N@^'/%^@2WOAK6-(\1:6=
M3T6WCU70M4L-5TU[JSNHY3X7)^W_ /LO6JR+JWC'Q;X<U'^WOA5X?LO#OBOX
M/?&/PKXOUJY^..NZMX6^$-]X>\&^(? 6F^*O$&A?$/Q/H6J^&O#.O:1H]YIE
M[XAM?[%>XAU*XM;:?0^ O[(?A3X'?"SXD_#O1=1T?0-0^*][K=_XG\3_  7^
M&?P[_9WETR\U3PI9^#+34?".E?"W1;&+2-;T;2[&#4--\1ZO?^)?$-MKS/=6
M^IVVD6VCZ#I/QOX%_P""07PR\&>-?!OQ";XDW\GBKPK>_LSS7MYX<^%OPS\"
M0^,8?V6OC'JOQ<\%:IXSC\*:9:W?B3QQXKO-8O-.^(OCS6[[4=5UZ>635-.@
MT)&32D /7/C_ /\ !4/]GOX1? #XD_&3P=/KOQ/\0^!O@Y\2?BU#\.;;P9\4
M/#VH6:?#CQ%XG\!ZAX?^+&IR?#S56^ EY<?$OP;XI^'0;XK:7X?ND\6>&?$V
MEV^GWMSX>U:*V]@_:!_:XB^ 'QW_ &</A=K?@.?5? GQKLOB#<^./BE#X@CL
MH_@XOA_Q5\&OA[X&U36?#4FDW#:WX7\8_$?XT^%?!NM:\FM:2O@>YU/2-7U"
MUU#1+K5KW0_EWQ;_ ,$I?"NM>'/VD/"7ASXZ?$#P9HW[7-I\=M%^/T>F^&?!
M6J7'BOPW\7/C+\:/C9X;TW2+O5[*XE\+W_PZUSX[>.O#-GJU@\S^*?!FH+9:
MI966O6NE^)=,^\?B/^SYX*^*OC[1/&/CE6US1[#X)_&OX&:WX*N[>(Z%XH\*
M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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MLT4C6ES<6[/&58PSS1YV2N&^B_U+XP_Z);B+_P ,V8__ #/YK[SP?];N%?\
MHI,AZ?\ ,WR_K;_J(_O+\3\3;+P'J5S\-OA)I_P?^&'Q(TO3_#7[.'P8T3_@
MJ1H-C\._B9H_BSXC^*M%_:6_9;UOXK^&_%5N(=-U?XK?&RY^&VF_M?WWC6\T
MH^-/$WBSX;>*KFV.HZWIGQ"\"1:S[1;>'?!47Q$L/&6N_#^WNO\ @E[%^UC\
M1-9\.^"+GX2^*M2^%=E<ZI^R+\-M!T;QQ)\*I]#N;4? RY_:"M_C-'X7NV\$
M'P-!\6]=L_&VEPV[:MX9\22?JC_PW9^RT,_\7%FY]?"/C4X'HN= .T#C 7 !
M (Z4?\-V?LMXQ_PL:?Z_\(EXVW>F=_\ 8&[..,YZ<=*/]2^,/^B6XB_\,V8_
M_,_FOO#_ %NX5_Z*3(>G_,WR_K;_ *B/[R_$_/H/KNN?\$\[?]GWQSJWC/P]
M\3/!/AOP%\=KGP)X\^&WQM\06>K_ +*UG^USKNI?"'X1?&"[\(^#/&/BDZ5X
MV^"/@'3/A/\ &WP]I0\3?$CP)X5GUGQ!\0/ U[X?2]TG6_HO_@FGI'BZVM/V
MIO$B^&_#?@7X&^./VA;/Q)^SYX"\$:/XITCX=>&O#<?P2^$VB?$>7X6#Q?X:
M\#ZKJ7PX\0?&'2?&VN:3X@MOA_\ #_0?%OB*Z\6^+_#7A2+0]?L=9UGWO_AN
MW]EOG_BXT_(Q_P BCXU QSR!_8'!Y^\,-TYX&/3_ (6?M%?"#XS:GJFB_#CQ
M1+KVH:+I\&J:C ^B>(-,\BRN+DV<,WG:OIME'.6N!Y92*2250-S*$^:N?%<+
M<38'#U<7C>'L[PF%HI2K8G$Y7C:%"E&4HPC*I5J4(P@G.<(IRDDY2BMVC?#<
M2\/8VO2PN$SW*,5B:S<:.'P^98.M6JR47-QITJ5:4YM03DU&+M&,F]%<]O)
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M--TO:4*DH*M"52,DJE-P4TVX^1U^DW_!-"PL]0^(_P 38KR!9XU\#:.55BX
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MQLK)99'%K9VT C@0 _$[_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\
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M^BE^!O\ PIM*_P#DFC_A;_PG_P"BE^!O_"FTK_Y)J99-2F^:>4PG)SJU'*6
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MDW_R@H_X;GN/^B96W_A63?\ R@H_U=SC_H$7_A1AO_EW]6?E<_UBRC_H*?\
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M-H__ #\2_P#@#J7_ ,AUOT4 8'_"3:/_ ,_$O_@#J7_R'1_PDVC_ //Q+_X
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M_!Y_P2K_ .4A'[+W_8[>(/\ U6WCFO[TD^XO^ZO\A7\(_2F_Y+?(O^R5P_\
MZM\W/[9^C-_R1V=_]E/B?_53DXZBBBOYE/Z/"BBB@ HHHH *Q/$B>9X>UR/[
M,UYOT?5$^R)IYU9KG=87*_9UTL7-F=1:?/E"P%W;&\+BV^T0>;YJ;=(WW6ST
MVGV[>HY'X4 ?S8^$_P!G;3/A[\;_ (8Z9=_ ;X?PW6F^,_A3J\&OZ-_P2VM_
M"-I;"^O/"^NQW.G>,;W]M74;GPU=^'Y+PZ=J/B"+PSKR^$O$&DZD5TW7)-%:
MVNOZ3A_4]L=S]?S[]>.E?@_XJT7X?VW[='Q/O_$WAC]GG3_$NI_M!_#*]TN]
M^)7_  3K_:*_:>^)FLQVWA/X6Z=INN^&_P!JZPO_  ]X!^'*-=V3Z;X6T&SL
M->\._!2^TD>(;_6+Z'4[G2],_> ?U/;'<_Y)[GGO0!^(/_!2?_E))_P0I_[.
MM_:@_P#6.?B#7[>1_P"KC_W%_P#017XA_P#!2?\ Y22?\$*?^SK?VH/_ %CG
MX@U^WD?^K3_<7_T$4 /HKYDN/VP?V>[7]HVT_94G^(%C'\9K[P]+K]OH366I
M?V29(I;<?\(P_BS[)_PC$7CF2SNH=7A\$2:JOB:71775$TXV\D1DH:!^VW^R
M]XDT_P ;:QI_Q9TBVT3P!X+D^)&MZ_K^C>+/"OAW4OAU'JEYHG_"P? WB#Q1
MX>T?1OB;X#DUJQET>W\8_#:]\6>'KO5I;'3K34)[O5-+BO0#ZJHKY1?]MK]G
M*/2(M3;Q;XI_M&7QAKG@(> 5^$'QG?XQ1>*O#/A72O'/B+3+OX'I\/6^,5FF
MA^"M>T#QAJVHW?@:'2K#PKK^@>(;F^CTO6]*N;SU2Z^._P '[3X.)^T#+\1/
M"S?!F;PC9>.[7XBV^I)>>&[_ ,+:G;V]SI>J:9=VBSRZI_:PN[2VTBQT^"YU
M/5=1N[32=/L;C5+F"SD /6J*\T^%GQ?\ ?&?0=0\1?#[6+O4K31?$&H^$_$.
MG:QX>\3>#?%7A7Q3I,5G<ZAX:\8>"O&NC>'?&/A'Q!;66I:9J3:-XET+2]0?
M2M4TO5H8)=,U.PN[GTN@ HHK\N?VX?VXOB5^S)\>?V7?AGX=\-?"S2/!7Q<\
M:PZ3XE^(OQR\2>+_  )X&U[[5X,^,&JCX?>%?B+I/A/7/!W@CQM8ZKX$\*7,
MM_XXN;G^U!XU\-Z/H7A?4K&Z\4>)_!X!^HU%?G?XY^/WQ_\ A9^T%XFTGQ7K
MGP1U_P"!'@+X5?%']H;XFV/AOX>_$S3_ (I?#[X+>&=+UZV\ FX\4:C\2M2\
M$^(/''C?Q9H.NVMCIL/A'1=/O-"\#>.M1ADL+FQTRWO_ )]\6?\ !13XT_"C
MX;2^*/BE\-_A=%K_ ,0/V=O O[4?PPB\+:[XVO\ 0O!7PX\0?%SX2?#/XFZ;
M\3(ET[4/%'C36/@?HOQM\#^/I)?AEH]MK'QEBB\0^"_!'@?0?$-GHT^O '[)
M45\>?L>_M'ZE^TG\)/%/CN&X\#^+&\-?$/QK\/\ 1?%?@+_A)/#OA7XB2^#K
M72UO=5M/"WC@77C?X=SVGB6[UCP7JGAWQ>U_?PW_ (9NO$FF7>J^%M;T&^NO
M.?V8/VJOB;\4OC[\6/@1\0M*^%%]JGPT\%:#XH\3:O\ "G4O&T-G\//&6J>*
M]<\,:E\'];@^)&G:-J?Q$N--&C7&IZ=\6_ ^EZ7X3UB.TO[#5?#'A.^DT)-;
M /T)K\]/^"K?_*//]J;_ +)U%_ZE/AROT+K\]/\ @JW_ ,H\_P!J;_LG47_J
M4^'*^JX%_P"2WX-_[*KA[_U;X,^8XV_Y(WBW_LFL]_\ 59BC^#1_OM_O-_,T
MVG/]]O\ >;^9IM?ZNQV7HOR/\O@HHHI@%?T#_P#!O/\ \G!?M"?]D:\+?^IX
M]?S\5_0/_P &\_\ R<%^T)_V1KPM_P"IX]?EOC7_ ,FMXP_[ <)_ZM<O/TSP
M<_Y.;PC_ -AV)_\ 59CC^K'Q9_R*_B/_ + .L_\ IMNJ_P T2/\ U47_ %RB
M_P#1:U_I=^+/^17\1_\ 8!UG_P!-MU7^:)'_ *J+_KE%_P"BUK\1^B?_  N.
MO^OG#G_I.=G[%]*+^/P3_P!>^(__ $K(1]%%%?V ?RB%%%% 'Z"?\$J_^4A'
M[+W_ &.WB#_U6WCFO[TD^XO^ZO\ (5_!;_P2K_Y2$?LO?]CMX@_]5MXYK^])
M/N+_ +J_R%?PC]*;_DM\B_[)7#_^K?-S^V?HS?\ )'9W_P!E/B?_ %4Y..HH
MHK^93^CPHHHH **** "D)P"?0$]0.GN>!]3Q2U4U"":YL;RWMII;:XGM+F&"
MX@E2":":6"2.*:*>2UO8X98I&62.62SNTC=5=K:X53"X!^6WBC]NC7H_VJ/%
MWP/L_C!^PO\ #"R\#_%/P)\.I? ?QC^-6I0_'WQM;^)=)\(:TVL^&?"&A:E8
MZ/IUYXD?Q-=^'O WAR[_ +9U&YU32H;C77LIM670[']5!^'4]/8_S]?>ORJT
M3X;?'+PUXDT*+4/B-_P4Q\5:SH]_IVI3:3/XQ_8IU3X8^)#I5[!<2V&I^,(O
M /A6]/AC61 ]OJ)D@\,^*7TJ>X^S:5I^I&WA7]2-,EOY].L9]4LX-/U*:SMI
M=0L+:].I6UE>R0H]U:6^H-:6+7T%M.SPQ7;65H;E$68VT&_RU /Q-_X*3_\
M*23_ ((4_P#9UO[4'_K'/Q!K]NT&8D& <QJ,'H?E'!]O7VK\0/\ @I:95_X*
M0?\ !"HP1QRR_P##5W[3H5)96A0@_L>>/PY,BQ3L-J%G4")M[*$RH;>OV/\
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MU2S4G!1U/GMO#?[??PST+QBGPH^#WC*\T7XO?%?5I/"5IXH^//PY^+_QI_9
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MW\%(/@_'>_%B73[GQ]IFJ7WB'Q3XX^'_ (DT+X5_8=+U/QFMWXQ^'?CSP_\
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M_P#(^_$OOBOVWZ/^!AF'B'0PTZDJ<7E&9SYHI2=XPI65FTK.^I^.>.N.GEW
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M(HTZ])RCK&3IU8R@W%[-JZZ'\VG_ !"Z_L'_ /1P?_!1'_Q+K5/_ )B:1O\
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M_P#B76J?_,37])=%'^L?$/\ T/LZ_P##KC_+_I_Y(/[ R+_H291_X;<%Y?\
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MG_X*:?\ !9N:":.2&:&7_@HU\39(I8I4:.2*1&T(JZ2(S(ZL"&5B",&OE_\
MXA=?V#Q@#]H+_@HB   !_P -=:IP!P /^*)Z <"OZ2Z*PPF99CE_M/J&/QN!
M]KR>U^IXNOAO:^SYN3VGL*D.?DYI<G-?EYI6MS.^V*R_ 8YP>-P.#QCI<WLG
MBL-0Q'L^=Q<_9^VA/DYG"'-RVYN6-[V1_-I_Q"Z_L'_]'!_\%$?_ !+K5/\
MYB:^;?VO_P#@W-_8X^!O[-'QE^+/@K]H#]OQ_%7@7P7>:]H2ZW^U;JVHZ4;^
M"]L(4^W62^$K,W$'EW$H:/[1'DE3N! (_K=K.U;2-*U[3KO2-<TS3]8TF_A-
MO?:9JME;:CI][ Q5F@N[*\BGM;F%F56,4T3H2JDKD#'9_K'Q"O\ F?9UI_U-
M<?TM_P!1'DON.3^P,B_Z$F4=O^1;@O+_ *<>2/YQ%_X-=_V#WW-_PT%_P40
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MG^+=OXE&MI%J3#_A&UTP6 ?48]0L/FG]IC]@'4OCY%^VY+IGQ6L?".H?M;_
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M^T%^RS\<8?%,6B0?LV7_ ,9+P^%5T+[8/%<?Q6^&G_"O8K>'54U.T30%\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME>$\9VJV,]L]<&OUYJ-XHI,>9'')C.-Z*^,XSC<#C.!G'7 KZ;@_B+_53B'
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K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-2017930oie.jpg
<TEXT>
begin 644 biib-2017930oie.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M[7'_ %PF_P#1;5^=J]!]!_*ON?%W^+D'^'-?_>8(6BBBOQL HHHH [OX9?\
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MJ$>KMI*WC1&X&E/JT46JOIGF_8)-2BCOWMVNT289V@? KX,>%M%TOPYX=?\
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M&MEM'"05"M*I-U::PBG4E%TX)*HZ-2I)\TGS2L[MMB;OWW;U\TO\CRSX]?\
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M9X;R8VV'U>M[*-;V<U2G[7DFU93]A[+VKC?62I^VI\S2:5WK[D^5'V?\"/\
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M^ADU7_P%T'_Y3T?V7J/_ $,FJ_\ @+H/_P IZ -NBL3^R]1_Z&35?_ 70?\
MY3T?V7J/_0R:K_X"Z#_\IZ -NBL3^R]1_P"ADU7_ ,!=!_\ E/1_9>H_]#)J
MO_@+H/\ \IZ -NBL3^R]1_Z&35?_  %T'_Y3T?V7J/\ T,FJ_P#@+H/_ ,IZ
M -NN$^)O_(A^)O\ KP7_ -*8*Z#^R]1_Z&35?_ 70?\ Y3UQ7Q%L+V'P1XBD
MEUS4;N-+$%K>:WTA(I!]H@&UVMM,@G [_NYHVR!\V,@^3G__ "(LZ_[%.8_^
MH=8:W7JOS/CANI^I_G24IZGZFDK^11!1110 5[O\!O\ D.:[_P!@BW_]+6KP
MBO;/@C;SW&LZVL%_<V#+I5NQDMH[*1G!O"-C"]M;M HY(**CY/+%?EKZO@;_
M )*S)/\ L)J_^HF(&MI>GZH^I;K_ (]KC_KA-_Z+:OSM7H/H/Y5]\7.F:@+>
M<GQ'JK 0RD@VNA ']VW!(T<'![X(/H0>:^!QT'T%?<^+O\7(/\.:_P#O,$+1
M117XV 4444 =W\,O^1\\-_\ 7W<?^D%W7V[7P[\.8WE\;^'HXYY;9VNIPL\*
MPM+'BRNB2BW$4\)) *GS(7 #$@!@"/M2SM;FV\S[1J5WJ&_;L^U16$7E;=V[
M9]BL[3=OR-WF>9C8-FW+;OWWPF_Y$>8?]C>M_P"H67@7J***_4P"BBB@ HHH
MH *0]#CDX.!^'OQ^=+2'@$CK@XXS^@Y/TH _(77?A#^T-IW[6_Q \5VG@K]K
M&\^'OBCXS>!/$^C:S\'_ -H7]GWX3_!E?#5IH'@32M7NO%_PFO?%47CCQ7<0
M7VC:O-XWUK4+.;Q9X^T@0:7;6EO:Z;H5@GZ]#^IZ_4_Y'H.*_*CQ/X__ &@G
M_:F\7:#KNJ_MZ:)X(T[XL^"-,\!6WP0^ 7[/>H_LY:Q\/[G1_!4ER_BOQOX^
M\#>,?BO<L?$<WBJ#XE>)+'Q#X;M;/1I((O MIITFE3:C+^K _'J>OU_EZ>W6
M@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(K\0_\ @I/_
M ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"* 'T444 %%%% !1110 4444
M%%%% !1110 5PGQ-_P"1#\3?]>"_^E,%=W7"?$W_ )$/Q-_UX+_Z4P5Y.?\
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M 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7_P!!%?B'_P %)_\
ME))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 /HHHH **** "BBB@ HHHH
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MXF5-*FL/#%-7DYJE.=6%YI1<:<DJ,YN-24.:-HP<JJG3@-6M?2_^2?XIJW_
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M3RJ4ZCG.C3J-3E**JTZ52,8SI4G!W^?W_P!=_O9^.L/_  3JF_X79H_QDO\
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M6/<P('[0QZ]HGEI_Q-]+^XO_ #$;+T'_ $WH V:*R?[>T3_H+Z7_ .#&R_\
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M &]HG_07TO\ \&-E_P#'Z/[>T3_H+Z7_ .#&R_\ C] &M163_;VB?]!?2_\
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M>&?$NM7J>#KK^PK7P[_PF6E:/<3V-I)<BU$MW=M^9WPQ^+_Q.^(O_!)[X/\
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M(-0\0ZC;VXL[6^\0:Q.USK&NW5G9*EC8SZOJ%[)8V*)969@M46$87QV_9A^
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M5:Q6.EZ3I.EV$-O8Z;IFFV4$%G86%G!#:V=K#%;V\4<4:(-6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-2017930otherrevenues.jpg
<TEXT>
begin 644 biib-2017930otherrevenues.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M)-MI)*[;T22W;?1(#\PO^"MOQ!^,_P //V2O%.I_ SQ_>>!O%SQ:[->KX/\
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MZ2XUO[(;V6ZO]$":)J-^TIO]1T:*+2;ZYN-.BCM5XZV_9&_9 L_#_C7PG;?
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M?^7K4O0?].%?C%_P4G_Y22?\$*?^SK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$4
M8?F>)_\ GWT+_P "M2_^0*/,\3_\^^A?^!6I?_(%;]% &!YGB?\ Y]]"_P#
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M)^1>IZ*,?AQ2;$_NK_WR/\*>W4_4_P Z2OY$LNR^Y!=]W]_]=E]PW8G]U?\
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M>\ _#E&N[)]-\+:#9V&O>'?@I?:2/$-_K%]#J=SI>F?O /ZGMCN?\D]SSWH
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M9>!>HHHK]3 **** "BBB@ HHHH 3 SG STSCG'IFEHHH _$#_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_$/_@I/_RDD_X(4_\ 9UO[4'_K
M'/Q!K]:_&'Q.MO!FHVNES:/<W[3:=!?">&Z@@55EEGA$>R5&8LIMRQ;(&&
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M'IO_ $WZ=79_$W_D0_$W_7@O_I3!7&? C_D6-5_[#TW_ *;].JE^U!?7NF_
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MO,_2:BOS8_X6%X[X_P"*R\3\]/\ B=7W/&>/WO/'/TYH_P"%A^.CT\9>)_\
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M$SR\XSK*L@P;S#.,93P&"C4IT98BI"M4BJE5M4X<M"E5J7FTTGR6[M'Y5?\
M!7SPY8:_^R7J5QJC:\MAX>UI-6<-\)]:^,_POFN;I]-T.UA^,'@[PU=V_B"S
MTH?VI-<^!_%UC!=V_A[QG:PVMYY$^NZ;YWA'QYT*R\4?!OP'9R?L_2?#+]HR
MT\&?#F#2_A=>?!3XU>./B3XTT#P5\2YM:\$?#S]D;]H;4+K6U_9C\6)%INH:
MOKFM^,]"N/%?PNM?&&A:;\5M,MX?"A\26GMG[='[<_Q#^$/P&UGQA\%O!5Y;
MZS;7<$6N^-=:\&7'Q2L?A_HYFM?LVK3?#OP]J.G7^OIKNJO;>&6OYIY]-\.?
MVBNHW>G7ES+IS6M?4_\ @HAX^3QU^QOI_AWPW\--;^%7Q[\6>*/"_P 2?&GA
M+Q#XDU0^)M4TGX-_&3QW:6OPJT/5H]-G\+Z#IFO?#K2SKFH_$:\UWQ2'O]0\
M%+H-CJ6B:MXCN?B,)X5>*>#HX3!2X0Q2KX/%3Q/L7FN64JO+B/91H1J4HUZE
M.=#%8A?5XU.>K)8CDA&>!G:K5\&GXA\%U,/#%4\_PLL/4^LQC6^KX]0<L)1>
M(Q%/F>%3C6I8=2KNBTJLZ"=6$)T[R,SP]H-SHWQQ\/WD_@_5[3]I[P[^W;^T
M/\5/CE\2K;X;^,,ZQ^Q;JMG\:KW2'E^(UOIEQHWBCX8:[\*;OX&> _AA\/\
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MMN_\%60/,D  _;N\:X"K(RJ/F\,L?N@=68^I/6G?\0\?[.__ $>]_P %6O\
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M:5J<.B:[X?\ %NC:SID^FW6F)I.NZQ\+7'_!/+XS_$VV_;2\._'_ .-'P?\
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M^/G[1?Q;^#OC_P  >'/#O[/0^)'A3XA^,/!'@'0O$ME\8/"7A?7[[Q7XHO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BO*/CCXNUGP'\)?'GB_P\]K%K6@:#/J&F
MR7ML+RU2YCF@13/;&2(3)MD;*&1,G!SQ7Y4']N7X^@D#4/"'!(_Y%1/_ )95
M];P_P7F_$N%K8O+YX.-*AB'AIK$UJE.?M%3IU6XQA1J)QY:D=7).]U:VI\!Q
M;XD</\&8[#Y?F]/,9U\3A8XNF\'AZ-:FJ4JU2BN:53$T6I\U*;:46E&SOK9?
MM=17PU^R!\>OB'\9M1\>6WCBYT:>+0++PY/IHTK2%TQDDU*YUF*Z,[+=7'G
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MQ>V?A234]7TK0I=:A\17,FCP?>>0>ASU'X@X(_ \'WH **** "BBB@ HHHH
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MGX4^&FI:9X3\6^)/BDWACPS\+OB)JW@71O%4GPXUK1IKBRO[N_\ !3_$FR\
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MJ222>3R:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-2017930rd.jpg
<TEXT>
begin 644 biib-2017930rd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +J 3T# 2(  A$! Q$!_\0
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M4?R[H'_!+OPKH%OXOT2V^,GC23PAJ7P0_;B^ ?@C0SX;\+Q7W@GP3^W/\1?
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M)'PT_9L\=WGP^O/!_P 2]<U"QU#]I_39(?AWHO@O4(/ -A+\6-+U7QYIVO\
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MQ?<Q>-FU'P?H>H?9?"GC/4_"?AOQ)\1)%B^'OA/QG\0M,\/7G@'P3XN\>M)
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MQ_";XR^.?AO86J^!?BKXD\5:IX,^&GPH^!7Q'^('Q:\<>!M.^',7BKX0>$/
MNH?&_3O"?C74/'.FVFA^&KZPLI[_ ,0"77;:QM^"B_X)4> (/"W[/>@Q_%_Q
M_%JW[-&A_&@_#/Q1'HOA%[^Q\??$[]ISX/\ [5/A?X@WVGW-A=:/>7/PX\>?
M!G0](L?#MU9RZ!XJ\+:OKNG>((OM$]M=VW+>)/\ @C_\,_&GB_Q3\4/''Q#3
MXA?%?Q_XO\;Z_P",_%?Q*^"/P4^(NBMI'Q(\%?!+PIXDT?PCX"\9>&=9\*^$
M=1T.\^"&BZQ\/O$J6VKWN@0Z[K^A>*+3Q[IMQ%M /I/XG?M^_"WPA\5?@[\)
M/ ]K>?$O7/B/^TUX2_9L\2:UI=EXJT_P1X+USQ-\)?''Q<N7LOB(/"6H?#WQ
MCXKT#0/"^BS:QX TCQ5%K5A8>*K74+Z:TDL9[)_O)3N56QC<H..N,C.*_.E?
M^">/AJP^(7@G7?#WQ5\9>'_AE\/_ -IVS_:Y\-_!ZS\/^#&T*U^+EQX,\5^"
MO%<3>(_[+A\0CP3XBC\7ZOXHM_"L#VZ>'O%U_?7.F7S>'?[&\,:'^BRC:JJ.
MB@#\AB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^$_^
M"AB7L_P'TNULOC9HOP/%W\6/AC#>ZMXPUCQUX-^'7CO38]?-U?\ PC^)7Q0^
M'#VOBSX3>#/B5!;GP]=>/++5--MK?5Y-%\.:BNNV'B6X\)^(?RJF_P""A?Q;
M^%/A+PG\/OA#X5TC1]&TK6_VG&U+XD^/OV@/A[\=_@EK/B?X17/P>U+PK\-?
M@S^T%\>/B]^SC_PF'PBU>Q^*NHR:E<B]\1?%GX?Q>!O&/P]\+^#+Y/ NL:GH
M/]'5U:VU[;7%G>00W5I=P36UU:W,4<]O<VT\;13V]Q!*KQ3P31.T<L,J/'(C
M,CJRD@YQ\/:"UCIVF'1=).G:/-97&DV!TVR-EI<^F%6TZ;3K0P?9K&;3V538
MRVL43VA -NT9YH _$N7]N[]HOQ9\8_'/PJT'Q;\(O#/BRV_:A\"_LTZ5\&])
M\)_\)G\7=&\-?%K]C'X,_'74_C;IFH3^.=+L?%%E\ _'GQ!\0ZEJ$C^$8O!W
MB[P'X1U?3M9O]"U[4M(GT[YD_9L_X*,_M96'PU_8P\#ZCK_@SXO>(KW]E?\
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M32]1NO#UWX9BUM+_ %RVU+6=3 /M.BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %?.'[77_)M_Q9_P"Q:3_T[:97T?7SA^UU_P FW_%G_L6D_P#3MIE
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MPB^@?] V+_OY/_\ ':/^$7T#_H&Q?]_)_P#X[6_10!@?\(OH'_0-B_[^3_\
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M_J0-0!^N.K\:7J."0187N"#@C_19N01R#[U_,&FI:D50#4=2)(4 ?VA?$DG
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MO_R"]2_Z\+W_ -)9J_EXB=X_*DC=XY(S')')&S))'(A#))&ZD,CHP#(ZD,K
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M8:A=2VETE_JTK0R/I6H0,PCGOY87S%+(F)(W #$@!@"/TAZ4 %%%% !1110
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M_.DH **** "O<O@7_P AS7/^P3;?^E]>&U[E\"_^0YKG_8)MO_2^@#Z7NO\
MCVN/^N$W_HMJ_/5>@^@_E7Z%77_'M<?]<)O_ $6U?GJO0?0?RH 6BBB@ HHH
MH [CX:_\CWX;_P"OR?\ ]-]Y7VQ7Q/\ #7_D>_#?_7Y/_P"F^\K[8H ****
M"BBB@ HHHH **** "BBB@#\0/^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\
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M;4;Z"TU/2[\VNHVH!\3:1^WQ9:G\&?A?\6+KX!?$KPS?_%#Q%XIT*P\(>/\
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M*OT*NO\ CVN/^N$W_HMJ_/5>@^@_E0 M%%% !1110!W'PU_Y'OPW_P!?D_\
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MX3XF?\B+XD_Z\!_Z56U=W7"?$S_D1?$G_7@/_2JVH ^*VZGZG^=)2MU/U/\
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M"]5\(^$]'\'_  T\<V5Y%<>-/W47.!GKS[=^I [GJ?<F@#\._P#@I=/%;?\
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M=OVJ"#?]TYV;MO&[&1GXW^&O_(]^&_\ K\G_ %T^\!_,5]L4 %%%% !1110
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M]@.Y]/Y]3U/- 'X@_P#!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\
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M,"TA5069G(55!9F.3P  23[ $TP?-]WYN"QQSA00"QQT ) R>,D#.2*^%_\
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MAX?;;;U;;W9]UPG_ +CB/^PN7_IFB+1117]CGU(4444 %%%% !1110 4444
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MDU='A$7[9'P C^"E[\?=<\5ZKX1\!:;-<V>H6WB[PAXGT+QK!JEL9I/['M?
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MX"T7X@6S77AVU^'W]O7Q\8Z3I<=QX%F\6^%;^?1]7U:/5-;:'VKXX^ /A?\
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MS0=E_P!U?_017],.JJSZ;J"("S-8WBJH&26:VE  ]R2 /<U_.H/AK\0B%/\
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M#/\ V"+7^3U^-_[)GQG\8_%VQ^,=EXTNH-1N_A?\7/\ A!M#U;4OAOKGP/\
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M2OY%$%%%% !7N_P&_P"0YKO_ &"+?_TM:O"*]W^ W_(<UW_L$6__ *6M7U?
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MQR=;U0#N3X<U< >Y)AP![FOC,Y\1N >'<?4RK/\ C3A?)LRHQI3JX#-,]RW
MXRE"M"-6C*IA\3B:=6$:M.<:E-R@E.#4HW33.2KC\%0FZ=;%X:E45FX5*U.$
MTG9IN,I)JZ::NM4[['N5%>&G]HSX3J2&UO5%(."#X;U<$'T(,.0?8X/M2?\
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MW=O/[QX3?\B+,/+-ZOXX+ ?Y 7Z***_4P"BBB@ HHHH **** "BBB@#\0/\
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MY;X-?^%E9_\ Q%'_  VG^R'_ -'+?!K_ ,+*S_\ B*_,O^(=^(/_ $0?&O\
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MPE/A7_H:_"G_ (5&@?\ RQK^%;[-;?\ /M;_ /?B+_XBC[-;?\^UO_WXB_\
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M_P#U;YN?VS]&;_DCL[_[*?$?^JG)QU%%%?S*?T>%%%% !1110 4444 %%%%
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M<GR;+\MKUJ;H5:N#PU.C.='FIS]G*4$FX<\(2L]+Q3W1YY\>O^0%H7_89?\
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MXH_&#Q!)??%G1-$\':?H-GJ7CSPKX1A^+WASX1?'_P 9V5_#_P (-H'AIXM
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M[#FE*;2LG.4IN\I2;_JQ\6?\BOXC_P"P#K/_ *;;JO\ -$C_ -5%_P!<HO\
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MCS\%O$G_  4OO_ O[67[3L,?P%_9?_90^(GPNTK5?'?A;6=+\->+?VCOB/\
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M<ND^(_B)KE]X1U'PEJZZKJWC/5O%/@#X32--J-N;>+XA'Q';LL_A>&TO?T2
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MO#5[I<C?2% !1110 4444 %%%% !1110 4444 %%%% 'S;\<?V5/A'\>M>\
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MOH9\+^+O$NEW-A8036>N>(O#&SPUJNI0NMW=>'8;;0GE_LJUMK2( _,+3O\
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M^*OC#Q[;_!_]G3XD^,_A?K/B?7;G1_ $7@WX?:'XYUOP'XCNM$\9>+O% M-
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M'1U)5T92&5E)5@002"#3ZRVW-TTU=.Z>J:V:[A1135=&.%=6(Y(5@3CUX)H
M=102 "2< <DGH!ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _(7_ (*&1QO\5/!1
M>.-R/AZH!=$8@?\ "2:N< L"0,\XZ9KX!FAA\F;]S#_J9NL,9_Y9MZK7[$_M
M4_LS>/\ XV^-O#OB+PEJ'A:TL-*\*C1+E-=U#4K2Y:[&KW]_OACLM(U&-H/)
MN8UWO*C^8''E[0&;Y>D_X)__ !I:.11K?P\R\;J,ZUKV,LC*,_\ %,=,GFOZ
M0X0XJX>P/#>387%9Q@\/B*&&<*U&I4<9TY>WJRM)*+2?+)/?;Y'\:^(/ G%V
M9\9\08[ <.YAB\'B<9"=#$4J,94ZT%A<-3<HR<U=<Z:^3/U9^&8 ^''@
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M/PGI_P 1_"6JVEOI45O?>'?'EEX#\%VWC#2+B.2R\1Q>%?#ZZO#=_P!E69B
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M:AK^AZ3*D&J:QI6G321^='#?ZC96<KQ;BGF)'<SQ.T>]63>JE=P*YR"*H?\
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MY1;:6L6?G6;Y5F%?,<75I8.K4ISJ)QG&*<9+D@KK7:ZM\C]<?A: /AG\/
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MJ^'?#_Z$7_[(7[*NJ>%?"_@;4OV;_@9J'@WP5>ZAJ/A/PM>_"KP1=:%X>O\
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M_M8UY?V<OV?Y]2^(FL7'P2^$USJGQ<L9]+^*=_<_#SPG<77Q&TV[DCFO-/\
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M]7ZSP-_P5/\ C3XS^%?ASXEC]F6XT"'XJ:O^QM<_"S_A,U^('@/PVND_M?\
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M)&>.V01]01VI: "BBB@ HHHH *** 00"""",@CD$'H0>X- !112 @D@$$CJ
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M-W<02]1-\$_@[<7=W?S_  K^'<U]?^,_!GQ&OKR3P9X>>YO/B!\.M(T7P_X
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-2017930rdpie2016.jpg
<TEXT>
begin 644 biib-2017930rdpie2016.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
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MH6E7P\1^%)-?Q/BI_P %"_@EX#_8H\<?MV^$M.^('Q8^#?A3PGI?C'16\'>
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MEM/#*?"BZ\!0_$2/4=>^&/AK6_&/A83>&XX/$^EZ?=#19KN[M[FV@\J^+?\
MP4P^ G@[P;X6\1_"V]NOC3J'B[Q'^R;IVGP^'=%\=6?A#3="_:R^-/PX^%W@
MZ^\5?$>+P3JOA'P7XI&@>.KSQWI'P\\7WVB>+=<M-"73;BPT;^U[*^IWPG_X
M)U^ /AAXE^#OC&RUKP[8^(OA/\<O$'QQD3X;_!#X/_!3PWXMU;5_V=_B1^SC
M9:5K'AWX8^'-%MW2Q\.?$G5_$\^L7UYK.LW/B?SX;&;1/"MS;^'-/\=\'_\
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M2?4/'^JR'PQX6M]3\3(=)/S5X]_X)._"_P :>+?$/BF;Q9I^IK-\7_C%\8/
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M? WB^^#^-+WX??#S0(K/P[:^)O'FES>,M,DM>5^,/_!//Q1\7?@A\>_A??\
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M% OV@OB5^SE\&O"_BSX::#!>7/BCXO\ P]^'7BWQC?3^$+72_A1X(\5RZO\
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M+^%/'>H?$BQ^)GB[3-,;6_ 7[C?#?]N+P)\4?B!+\.O"WA3Q+>:[>^*8]/\
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M3BJ6$SGV<;RBJ:]W#9ARQE4E1C:A7Y92PZI.V&7T+=_LJ>/?$?Q-\'Z_XO\
MB5X F^'/@CX[+^TCH^@>$O@K9>#?B/>_$K_A#]?\*)IVO_$:P\8S:/JWA6V7
MQ#>B;4_^%?6WQ)\2>';;2?"/BOQQJMG!KFI>)/&_C[_P3^\<?M.Z'X2L_C!\
M2/@IJGB74_@G>_!#XV^.-!_9XUK1O$/B?P_K]UK#^*Y/ARD_QMO]+T'3=2L=
M:O$\.>$?C%I_QW\,?#_Q2;;XB^%K*#Q1#>#5?U(HK^<3^@S\^/C%^PL/BAKN
MH>(=)^(LG@:^@FT/PWX,AT+0)8[3P7\-M+^'EWX3\FQ%IKFG75_\3-*\87]M
M\3O"OQ"O[N5=)\1> OA-I]]H>J:=X$M7N/T& Q^9/YDG^O\ ^KI2T4 %%%%
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M^*WB_P"'&B_!CQ/X8FT[QY\6;[P!X@TCQ;J.H:=+H5M>Z_?:?X$ /TJ\??\
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MZ>[6_BKP%HWQKL+OPAK(UL)<^#_$"(]QJ5EHNNRS1:)JMD]]+I7Y;:!^S?\
MM'_#?X.^'M$\*?"O]H/PK^T!+\$IO"'PM\7_  A^-GP[\,?##PSXYT7XT_'S
MQS\-?$/[4GAJ+QG:6?B#Q?%I?Q)TKQ?\>F@M/C1\&_&GB'Q/\1-*^'?@RSU&
MQT"+5_WI(!&" 1Z'D48!QD XZ>WTH _/[]H2R\1_$YO#6I:Y\!/VGKJS^"WQ
MMU[2/M/P:^)O@+X:>,_&VA:M\&9M,D^)/@6;2_B5I/BJ[^%NJ:IXYU'P9<V=
MKX_^%OQ;TKQ#X<O-6_L74?!D,DVN?(^M_LI_M ZYX&^&NMZ]X1\0Z]\8-.T_
M5_B-\3-2\4>+_#'B=-?B\*>);GP#\)O ?B'3M-N]-\*^/?CF?V=M=@T/XD>)
M6:3P#XOG^'EUX4U'4-9L_B+=>(A^W&!SP.3D\#D\<GU/ _(4N!Z>WX>E 'F'
MP8O/B1?_  O\%WGQ=L+'3?B)/HT<GB>TL! B)>&XN!;27<%G+<6%IJUSIHL;
MK7;'3+FYTNPUN?4;+2[B?3[>VF?T^BB@#Y*^-&GM:^,!>8)CU33+2<-V\VTW
MV4J^Q5(K=L9XW^IKR2OJ?XV:$]_H%IK,",TNB7)\_:N?] OMD4SMCD+!/';2
M,>BQF5CTKY8H **** "BBB@#&\0Z[I_AG0]5\0:J_EZ?I%E-?7." \BQ !+>
M+. 9[J9H[:!<C=-,@]:_*3Q+K]_XIU_5O$.IMNOM7OIKR9<Y6$.0L%K'Z0VE
MND5K"!P(X5QU-?5?[47CG)TSX?V$W"^1KGB'8W\7S?V+I\F/0>9JDR'N; L.
ME?'%?YB?2[\27Q+QC0X&R[$<^3<&N3QZIRO3Q7$N)I)8IRM[LO[)PLXY?!22
MJ4,95S:E+22/S[B?'_6,5'!TW>EA+\[6TJ\TN;U]E&T%I>,W56QT&FR[[<H3
MS$Y _P!U\LHSZ [@!V]^:V+2[NK&Y@O+*YN+.[MG$MO=6LTEO<02#H\,T3+)
M&WJ589'# @D5R^FR%+@)VE4H><?,,LOMU&!]?QKH*_U5^A!X@0\0_H[\+X7&
M5(8G,>"I8OP_S6G5Y9J>'R:E0GDL94Y\W/1?#&/R?#3<TXU:]#$IWM(_D;CW
M+Y95Q1BJM+FIPQKIYIAYQ;C*-2K*7MI1E&SC..,I5IQ::<5*#5M#ZC\"?M#3
MP>3IOCN%KJ$8C3Q%8Q#[9&"0 VJ6$85+M1_'=62QW &6>UN'RQ^I]-U/3M9L
MH=2TF^M=2L+A=T-W9S+-"_JI93F.1>CPRA)HSQ(BGBORUKI_"_C'Q%X.OOMV
M@:E+9LY4W-JW[ZPOE7^"]LG/DSC' DPEQ'UBFC/->YXD?1FX?XB^L9KP5.AP
MSG$N:I/+91G_ *OXVH];0I4HSJY14ETE@Z=7!)1C&.7TY3G77W_!?C=F^4>R
MP'$\*V=Y='EA''1E%YOA8*RO*=24:>8PBDW;$3IXEMN3Q<U&-(_3&BO#O GQ
MR\.^*/)T_7!%X:UM]L:B>;.CWTIXQ:7TI'V61V^[:WY0Y(6*YN&(KW'_  !'
MN",@CU!!!!Z$'(K^'.)^$>(^#<RGE/$N4XK*L9'FE35>*E0Q5*+M[?!8NDYX
M;&4&VE[;#5:D(RO3FXU(R@OZBR/B#)N),%',,EQ]#'X:5E/V4FJU";5_98G#
MS4:^&JVU]G6IPDU[T5*#4F5]E?"#3FT_P/I\CY#ZG/=ZF5.?E2>7RH,9 X:W
MMX7]#OSGFOD+3=/N-5O[/3+12]S?W,-I" "</.X3><?PQ@M*Y. $1F/ -??V
MFV,.F:?8Z;; B"PM+>SASU,=M$D*%O\ :*H"QYRQ)S7VWA/ETJN99CFDH_NL
M+A8X2G)[.MBJD*DN5]73I4+3715H?S'L_K_7]>A<(!!!Y!!!'L>M<'X.^&'@
M/X?ZG\0=8\'^'+/0]3^*GCBY^)'C^[MI;R63Q+XVN_"WA/P5<Z_>"\N;F.&Y
MF\+^!O">D/;V*6EB8-%M9?LGVIKB>;O:*_=P*T]E:74307-M!<0O#);O#/$D
ML+P31F*:%XG4QM%-$3%-&5*2Q$QR*R?+7SY\)?V4?@A\$-6TS6/AYX=\06,_
MAWPG/X"\&6?B#XC_ !,\<Z'\.? ES)X>DN?!'PO\.>.O&'B30/AGX1G/A/PQ
M'-X=\#:;H6F/:^'=!L# +#1M,M;7Z,HH B,$1+DQH3(27)527RAC^?(.["$H
M-V<(2@PGRTXQQDY*+DLKD[5SN4 *V<9W*  K?>4< @4^B@")88D#!(T4,_F,
M H :3=N,C#&&D+<M(<NQ +,2 1%<65G=E&NK6VN&C614:>"&8HLH"RJAE1RJ
MR* L@7 <<,"*M44 1QQ11*B11QQI%&(HTC145(U "QHJ@!$4  (H"@ 8' PC
M0Q.%5HT8*XD4%1A9%?>K@8P'5_F5P-ZM\RL&)-2T4 1/!!(LBO%&ZRJJ2AD5
MA(B9VK)D'>HR<!LCDCN:E_SZ_P Z** "BBB@ HHHH **** "BBB@ HHHH **
M** *M]9V^HV=W87:"2UO;>:UN(S_ !0SQM'( ><':QVMU4X(Y KX5\1Z#=^&
MM9O='O Q>UE(AF((6ZM7RUM=(3P5FBP6P?DE66,X9"*^]*\P^)O@?_A*],6\
ML(T_MW348VN2$^VVQ)>6P=R,!F),MHS$*EP-C%8YI& !\?44YD>-F2161T9D
M='4JZ.C%'1U."KHP*LI *L"" 0:;0 5A>)_$-AX4\/ZOXBU-L66D64UY*F0&
MG= %M[2,GK+>7+PVL0Z[YE/0&MVOB[]J+QSYMQIO@"PF^2U\G6O$&QN#<.C?
MV1I\F".8(7DU&:,YP\]D6 *"OS7Q<X_P_AIP%GG%$W3ECJ-#ZED>'J6:Q>>8
MU2I9?3=-M>UI4)\^/QE--2>!P>*E'WHI'!F>-C@,%6Q#MSI<E&+^U6G=05NJ
M3O.2WY(R/E?7M;U#Q)K.IZ]JTOG:CJUY-?7;_P *R3-\L,8Z+#;1+';0(.$A
MAC4<"LBBBO\ %C%8K$8[%8G&XRO5Q.+QE>MBL5B:\W4K8C$XBI*K7KUJDO>J
M5:U6<JE2<O>G.4I-MMGY/*4IRE.3<I2DY2DW=RE)W;;>K;;;;ZL<C%'5QU5@
MP^JD$?GC'XUUJL'577[KJ''T89_3I^%<A70Z;+OM]AZPL5]]C?,GX#D?4=!T
MK_2/]FMXAO)_$7BWPXQ==1P?&N10SC*Z4Y;Y]PM.K4J4,/#93Q>18_-,5B9+
M65/):"=^2-ORSQ2RSV^5X+-(1O4P&(="JTO^8;&**4IOM3Q%*C""Z.O)]2_1
M117^TQ^$AZ@\@\$'D$>A!X(]C7KO@3XR>)_!GDV,[G7= 3:G]EW\S^=:QYY_
MLN_822VFT?=MY1/9G&!#$3OKR*O7/@M\(=?^,_C:S\+:1OM=.A\J^\3ZYL!B
MT'0A,(Y[SYQY<M_<$/;Z39GFZO,LX6TMKR:'YOBO).&<^R3%X3BW 8''Y-3I
MRKUXXZ%UAW&+C]8PU>#CB,+BDI.%*OA*E+%7GR4I\T^5_0<,8SB'!YU@O]5Z
M^+HYQB*T,/AH827O8B4Y)^QK4I7HUL.[<]:&)A/#J$'4JI0@Y+]5?V9#IOCN
MR;XD6<-Y'IL#W.EZ9%J%J]M.-30"+4Y%SNAN([-)#9I=6LDUM)-+<HD@EMY$
M3Z_KY%\ _M0?LHZ/X^M_V6_ 7Q)\/W'COP7KL_PUE\#Z-8^)-3ET7Q3HVB0^
M(=1\.:OK5IH<^@6OB"VTF[@U;5H+_6H[I6OX9;K;<7L*2_6XD4@')P2 ,JPY
M;A>H'!/ /0G@'/%?Q[@,FR?(H8C!9%2Q-'+98W%8C#QQE6%?%^SK56Z2Q%:G
M3I1J3IT52HIJ%U"G",I5))U)?Z"9=''0P&#CF=2A6S&.&H+'5<+3E2PU3%*G
M'V\J%.<I2C2=3FY%)IN-GRPOR1?17(>!O'_@SXE^'E\5^ O$FD^+/#CZUXI\
M.KK.B72WNGMKG@GQ5K7@?Q9I8G0!?MGA_P 7>'=<\/:K#C-KJFEWEL_S0DUU
MI8 X.<GT!(]LD @9[9(SVKN.P=16)H/B7P]XJTT:QX8US2/$6DF_U?2QJFA:
MC::OIQU+0-6O=!UW3_MNG37-M]MT37=,U+1=7M?-\_3-7T^^TR]2"]L[B"/5
MDN((FB26:.-IY!# )'5/.F,<DHABW$>;+Y<4DGE1[G\N-WV[48@ FHI 0W3\
MB""/J" 1^(Y'/2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQO\ "CQ3J_@S57B\=:IK'PM_:-\'?%SP]I7@[P5_PA\ TK6-(U?J]'_X*@?
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M\*>%]1\):3X@\0VOQ(\)SZ5I&H^/;>WN_!%E>7D>J&..Y\8V]Q%+X7A4LWB
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-2017930rdpie2017.jpg
<TEXT>
begin 644 biib-2017930rdpie2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX@_;F_:X
MN_V1?"GP4UFRTWX637'QF_: \-? Q/$7QL^*\OP8^%W@8:]\/_B=X];Q7XM\
M;P^$/&LEO;*OPW/A[3].&DQ#4-9\0Z=$;^VV;)OM^O!/C;\ ]"^-^O?L^Z[K
M>LZAI;_L^_'?2_COHMI96MC=6_B#6M*^&OQ1^&T&B:M]M5VM]-:R^*%_JIN+
M+%XE]I5BB,(9)\@'DG@;]MWX2W<W@7P?\0/&O@8?$GQ3;^$8+^^^#DWQ"^*_
MP'L_$?Q&TBX\5_#/PMI_Q\'P[\/>"Y/$'Q'\''3->\#:!KTGA[7_ !4FL:-#
MH6E7P\1^%)-?Q/BI_P %"_@EX#_8H\<?MV^$M.^('Q8^#?A3PGI?C'16\'>
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MEM/#*?"BZ\!0_$2/4=>^&/AK6_&/A83>&XX/$^EZ?=#19KN[M[FV@\J^+?\
MP4P^ G@[P;X6\1_"V]NOC3J'B[Q'^R;IVGP^'=%\=6?A#3="_:R^-/PX^%W@
MZ^\5?$>+P3JOA'P7XI&@>.KSQWI'P\\7WVB>+=<M-"73;BPT;^U[*^IWPG_X
M)U^ /AAXE^#OC&RUKP[8^(OA/\<O$'QQD3X;_!#X/_!3PWXMU;5_V=_B1^SC
M9:5K'AWX8^'-%MW2Q\.?$G5_$\^L7UYK.LW/B?SX;&;1/"MS;^'-/\=\'_\
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M2?4/'^JR'PQX6M]3\3(=)/S5X]_X)._"_P :>+?$/BF;Q9I^IK-\7_C%\8/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9Z7HEYILFK_"JVU_XJ?!>>/P9K%[+JNJZMH.B7ESXKT/PM%JEAH^H_4FM?\
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M;_"[PU!=>'M:O_A-X8^.OC-?#6E^+O%^K:U?> M5^-6M^*;1['PS\"[#3;4
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MACQ!XFDT70[8WFM:O'H&D7NKOI>D6@(-SJFH+9&ST^W!S->3P1_Q5U5!&>M
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MN(B"^\6ZE")+66YL[G'G67AN-6EBM8X7CFUQ':ZOC]A:VM*^%OT X '  '
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MWOM:U_4KS5M4NW8L9KV^F::8IDG;#&6$%M&/EAMHH84 2-0 #'HHHH ****
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M/@%;>"_BS\/OC+J/P2\.6'A70]'_ &HOB-=>&M$^).FZIH7PMT._T=?"/PF
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MQ]:G4J0PU3+\QH2<*,?:5'[6KA8X>/+%7]ZLK_#&\FD_L&BBBOT4^Y"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2OC1I[
M6OC 7F"8]4TRTG#=O-M-]E*OL52*W;&>-_J:\DKZG^-FA/?Z!::S C-+HER?
M/VKG_0+[9%,[8Y"P3QVTC'HL9E8]*^6* "BBB@ HHHH *.M%% 'YR_M%^'_[
M%^)FH7D<92V\2V5GKL1 PAN74V&H@'NWVNS,S=,&X!.=P)\:M+YH2(Y,O$2
M,<M'[IZJ>Z'ZJ1G%?:_[5'A_[7X9T#Q+%'F71-5?3;IP.18ZU'F(L<?=CU"S
MB49( -R>I-?"]?Y8>(G$'&7T?/I$Y_Q1P'FE;),=B<;'B+!N"<\!FF6\0>SS
M#,LKS+ MQH8_**N:1QN$J86JK1E@Z6(P\J&,P^'Q%'\>XPR+ X_$8[+\?AU6
MPN)DL1"_NSIRJIR]K0GK*E4IU'4C&<>BE"2E"4X2Z]65U#(P96Y#*<@_0^W<
M=0>" >*6N;M;R2W;'WHV/SQDXR>FY2?NN/7H>C9ZUT,4L<R!XV#*21Z%2.JL
M.JL/0_@2*_V%^C;]*3@WZ062K#TW1X>\0<LPL:N?\(5ZZE*I"'+"IG'#U:HU
M/,LEJ5''VL;/'915J0PV8TW3JX''YC_+O%/"..X;K\SYL3EM65L-CHQLDWM0
MQ,5I1KI;?\NZT4YTG=5*=)]%%%?U$?) .2!ZU^X/[%?AF7PY\ O#=Q.6$WBK
M4=:\5M&P(V0:A>?8M/P"!A9=,TVSG&.#YV[J37XM^&/#FI>+_$>A^%M'C:75
M/$6JV.C6**I8K/?SI )F Z16L;27<[G"QP02.S*JDC^C;PQH%CX4\.:#X8TP
M%=.\/:/INBV(;&XVNF6<-G"SX)R[I"'=LDEV8DDG-?D?BWF,:66Y=E<9+VN+
MQ4L94BFKJAA:<J<>96NHU*M>\'I>5"?\K/Z"^C_D\Z^=9QGLX/V. P$<OHS=
MU&6)QU:G6GR/[4J-#"M5%JHQQ--M>\F>>?'WXX^ OV;/@_X\^.'Q/NM5M/ O
MPZT7^W/$$NA:)J'B366MGOK+3+:WTK0M+CDU#5=0O-0U"SL[2SM4,DLTZ#*J
M&88WP[_: \-^./#.K^*_$/A7XB?!?3=(\0V_AHK\>?"G_"J;G4;ZZ@MI;:;1
MTU_4FAU*QN9[D:?;W4%QBXU&*>T@21X\MY)_P42^ 7C?]J+]B[]H'X"_#@:&
M_C;XD>"HM%\/P^)/$&I^$]%NKRV\1Z#K4EE>^)]&T[5M6\.K>VFE7-I#K>FZ
M?=7NEW4\%Y;(LL*R)\9>.OV2?V@OBCX/^&G@^'X,^!/A[X.\+^,OBS_PDOAS
MQ9^TO?\ QZ^(=];?$W0O#MIIGCGP[\;OC;\"_C%K_A[3-(N3XPT[Q=\.=(TG
M3=;UVRN?#LOA[Q]I&CZ=J_A/7?P,_JX_3WXJ_'OX7?!FV\.7/CSQ+!IW_"4_
M$KX;?";2K:TB?5+\^,OBOXL\.^"_!]I>6%B9;O3["?6_%6@_VEJMY%%8Z-IV
MH0ZKJ,L-@RS-ZQ;:C87C*EK>VER[V=KJ*)!<PS,UA?&86=XJQ.[-:W9MYQ;7
M !AG,,HA=S&^W^?KX3?\$M_CYX0\!^'X_B7JOPL\7?$'1?B7_P $E?$.N>,9
MM9UW7+_5? O[$G@7]GG1/VA;%+N_\)R:DT_CC6?A1XDU30]'"/%XT:70YO$]
MW871 LOO_P#8#^%?B7PY\&_$VL^)&U%QKUU=_#+X.W'B'1?%W@_7H_V7/@W<
M^(?!'[-T/B?PUXAM-!\5Z#KFH>$KK4/%^M17=KI.K2W7BM[YH+"]FVQ 'U3\
M0OVB_@;\*=$T[Q)\0OBGX*\+Z%JOQ,\+?!NRU74->L6LG^*'C36K7P_X;\$3
MSVDMREEKU_JUY!!-:WQMAID!EU#5Y+#3;:YNX?2[?Q1X;N]4U?1+77]%N=9T
M""WNM<TFWU73Y]3T:VO(VFM+C5M/BN'N]-@NHD>6VEOH8(YXT9XF=5)'X&:;
M_P $POC7#\-KCPC+\-OV<1H7PU\>_L7_ !)^&_PWUW6?#7C*\\7ZY^RA\;CX
M[U?PM>?&ZP_9L^'OC&+P#XI^&%[K7@;PM>?&S1?CA\4HM<U:\O?%OC@Z1?Z^
M=>\F_:3_ &#_ -KFRTCXC?%S5M!\*ZM-?>$?VNO /CCPK\"]0>&/XAZ'^U7J
M&B6W@K7K/X;?#SX#:%XMBT?X5:Q)I/BKXNQ^+/$_Q\\6^)+3PYXMU^QT3XC+
M<KX1\3@']%6D_%?X8Z]#<W.B?$+P3J]M9^(['P?<W.F^*=#O;:'Q9J>FV&LZ
M=X9-U;WTEN^OWVDZIIVHVFCQ2R:A<65]:W$-N\<Z$^@5_,+X+_80^+_QZ\/?
MV[X0TF[TGP[9WO[0?@WQ#X?GU?0?A)\+O$.O_M$1_"+Q=JWQH^!FD_%?]AO4
M]5\%Z#H47AF\^'&OZ;X1^"'PQ\9:?K]GJWB[P/\ %;Q5KNM^*KZ]_IA\.:5+
MH?A_0]%FO[[5)=(T?2],EU+4[R?4-2U"33["WLWOM0O[G_2+V]NWA:XN[N?]
M]<W$LD\O[R1J -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JWU
MG;ZC9W=A=H)+6]MYK6XC/\4,\;1R 'G!VL=K=5.".0*^%?$>@W?AK6;W1[P,
M7M92(9B"%NK5\M;72$\%9HL%L'Y)5EC.&0BOO2O,/B;X'_X2O3%O+"-/[=TU
M&-KDA/MML27EL'<C 9B3+:,Q"I<#8Q6.:1@ ?'U%.9'C9DD5D=&9'1U*NCHQ
M1T=3@JZ,"K*0"K @@$&FT %%%% !1110!Q7Q'\/_ /"4^!?%.A*F^>\T>ZDL
MUQDC4+%1?V!7D88W5K$@((X<CH2#^4@.0"1C(!QZ9&<?49P?>OV0!P00,X(.
M/7!S@^QZ'VK\J_B=X=_X17Q]XJT14*6]OJUQ<60Q@'3]2QJ5D5[%5@NEB&">
M8F&<@X_@7Z;7"UX\%\:T:>SQO"^855'6SYLUR>#?9-9XVWUE!=CXOBW#_P"Z
M8M+^?#U'_P"5*2_]._@<'4\%Q);N'1N. RG)5EXX8 ^W!'*]1GH8**_AC(,_
MSOA7.<MXBX<S3&Y+GF48JGC<LS3+J\\-C,'B:=^6I1JP::O%RIU*<N:E6I3J
M4:T)TJDX2^%Q.&H8NA5PV*HTZ^'K0<*M&K%2A4@]U)/SLTU:49)2BU))KJ8+
MB.X3<APP WH3\R$_S4_PL.#['BIZY..1XG62-BK+T(YZC!!'1E/=3P?;K7OO
MP*^%>N_'+QK9^%-'62SM+<0WWBG6@@:#0M"\\0S7J&0;)K^Z8/;:18M\]S>Y
M9L6EM=S0_P"X?T6OIJ9!XM8*CPAXB5\#PWXDX'"59T\0K8?)N,\/@Z$JU?&9
M7'X<%GE.A2J5L=D2O'$1A/&Y*ZE!XG+LJ_"^(?#C,L-CJ/\ 8&'KYCA,;B*=
M"CAX+GQ.$K5IJ$*=5M^_AKR5L7)J-*":Q4HJ*K5?LC]@KX0S:AK>I?&#6;4K
MI^BI=:#X0,JX%UK%RAAUS5801\\6FV3MI4,H!0W=[?HI$EFV/U7K \*^&-%\
M&>'='\*^'+)-.T30K&'3M.M(\GRK>$?>D<Y>:>:0O/<SR%I+BXEEGD8O(Q._
M7W_%&?5>(\YQ.934H47:C@Z,FFZ.$I75*#M=<\VY5JMFU[:K4Y7RV/ZTX'X6
MH\'\.8+)J<H5,1%/$YAB()J.(S"NHO$5(W2;IPY88>@Y14OJ]&ESKGYF_GS]
MJC]H+1OV6/@)\1?CWX@\/:MXKT?X<Z9INJ7_ (>T*XLK76-4AU#Q'HOAX6^G
M3:BR6*W8EUF.:)+N6""8Q>3)<VRR>?'\9>)/^"G&F^!?B+JWPD\?_!3Q%X:\
M>>"=6^-4OQ0AA\:Z!KGASP7X"^"GPJ^#OQ^UCXA0:YINF-=>(]-UKX,?%ZSU
M;2M"LM%L_$2>.=!U#P/=6*6%S:>,Z^POVM_V=-'_ &L_V=OBC^SQX@U^Z\,Z
M)\4=#L] U36K/3;;5[BTLK?7]&UN=$TZ[N;.WNEO$TG[!-')<PA8;J216WHJ
MM2\/_L<_LY^'?$VG^-+?X>?VMXMTZ^^*^H?\))XO\6>.?'6LZM<_&W1/!GA;
MXDMXJOO&OB;Q!/XS77O"7PZ\">#[>/Q:^M1>'_"'A/0_"_AJ/1]!LH]/'SQ]
M<?'>O?\ !3^/PC9:9IOC?X$ZMX%\=^,+'X'>+O FE^+_ (K?#O1_ )^&7Q_M
M/B?=>#/&7Q-^++F7PU\++C2KSX1>*?"?BG0K^R\0*/'>K>!_#G@W6O&MOXJ7
M6-.I>$_^"G%_K'A@ZCJ?P4_LO5=)^ _[,GQL\72:]\1=$\ :)H$_[7.H>/-,
M^$_P_A3QIID?BG7?%-IJ?@;4-/\ $%OH?A[4M7U:.,7W@+PWXMU+6/"_AC6^
MX^+?_!,7X1^)_"WA'0/A+>M\.9/"OBSPSX@FM?&&H?%GXG:)XCT3P-X%\=>
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MYENYRX\D+>\7> -#\7QF2ZC-GJ:+M@U6U51<* /ECN$.$O( 0,13$/&,B":
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MI>@ZC-J$6C3:I%X377+*SU2XTRVO=6CT6&]FC&I2Z=:W6HKIT5R]G!-=^6C
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MS]H/PEKG[2'QM3QA^U)X-TKX5?&OXM0:+\#1XO\ $'P9T;PI\2/"&G_"_1M
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-2017930reserves.jpg
<TEXT>
begin 644 biib-2017930reserves.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %U 3T# 2(  A$! Q$!_\0
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M4?R[H'_!+OPKH%OXOT2V^,GC23PAJ7P0_;B^ ?@C0SX;\+Q7W@GP3^W/\1?
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M)'PT_9L\=WGP^O/!_P 2]<U"QU#]I_39(?AWHO@O4(/ -A+\6-+U7QYIVO\
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MQ?<Q>-FU'P?H>H?9?"GC/4_"?AOQ)\1)%B^'OA/QG\0M,\/7G@'P3XN\>M)
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MQ_";XR^.?AO86J^!?BKXD\5:IX,^&GPH^!7Q'^('Q:\<>!M.^',7BKX0>$/
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MB[P'X1U?3M9O]"U[4M(GT[YD_9L_X*,_M96'PU_8P\#ZCK_@SXO>(KW]E?\
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MR 'UY115<7=L;DV8N(3=+"MP;82Q^>(&D:)9C#N\T0M*CQ"4IY9E5HPQ=2H
M+%%("",CD>O.#[CU'H1D'L:7/Z>O'^?K0 44@8'U'&>05X_$#IW].^*4'/\
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MBBB@ HHHH **** "O!/VH_\ DWKXO_\ 8C:S_P"BDKWNO!/VH_\ DWKXO_\
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MV5IJ5C>:=?V\5U8WUI<V=Y:SKNAN+6ZA>WN()E_BBFAD>.1>Z,P[U;H.,'/
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M  AOO"U[X_\ A/\ LY_%>T\$?%WX@:1\+OCOXL@_:(O+NTM? _P*^"UQX?\
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MO4(;3PYI3W6E:58^+-3TZTNS!9P-< 'V_P#L9X'[2WPWV$E?-\4A6(V,R?\
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MAE5*TFNZ+#;:O>RZMID5IH#7":Y=2:A9I;Z,UI9PZA=+JL[SB+33;6%Q!>W
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MKR^G$CQ6ZVU]&SK AFE.^:UCC&R-68[G!.,*"<"OYK->_P"0]KW_ &'=;_\
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MJ^ _B=\5?%'B.'2OVH?$WQ2\6ZC\5O&"^++JPU'6_#5QX1U3Q;X1UG3?AO\
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M<U_]YH'HWPI6Z;QQI0LY+>*X,&I;)+F"2XA"BPGWAHHKBU=B4R%(F4*Q#$,
M5/XG:[G^W-=S@M_;FM;MH(!;^U;S.T$D@$YP"Q('!8]:_;CX0?\ (_:1_P!>
M^J?^FZXK\2->_P"0]KW_ &'=;_\ 3K>5]!X4_P#).8K_ +'&)_\ 4/  ?$_P
MJ\->)[+_ (*^_LT>(_ OPEU+XG>)=6&KWFH6?CGP)=KHWASPO9ZK\!/#GB7X
MH?#+XV:'J]I'X>TKX<>$(]=\6W7@7Q5-+'?^)M(\7^"+/PZ)OC!INH2?=_A[
M1KOQ##_P5M^%O[/OAOXQWES\9/&7P/\ B#X7C\4_!_\ :3TG7?COX#\$_"#X
M':'^TG8:3\1OBYI/A\^*?%WC?3](^(/PTM+35O&B:QK>IW2:5HWEZ)#9FU]S
M_8R _P"&E?AMP/\ 6^)ST[CP=KX!^H!(!ZCM7[[X4=_8@L2/Q!)'Z5^F ?DO
M^SYJ<W@WXL_M Z[\,?"?B?X9? K]H'QM\(/AW\ M)MOV:_BQX5\.K\<-"^#7
MCW4?B?\ $_4_A\VC:-??"WX<WFF>'?A[X.U/Q]XX\/>"O".N^.O 4NB0W=YK
M6NZ)>:]Y?^P3\,O%/ASXD_LMIH_PJ\2?##Q)\)_V/_''PT_;@U[7OA#XE^'J
M_$/X^7^K? RZ\/+JGC76Q%IGQT\53^.="^.'Q-LOB3X=O_&MA%X=\9W^L2^)
M;0_%&W@U3]N!M['OG@\DX[\\\>N>@]!2@ =![?0<<#T' X&.E "T444 %%%%
M !1110 4444 %%%% 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[&ZWX$\,>)
M[B"_UK3WNKJ*TBM4D6\O;<"!&DE5-EO<1(2'FD.XJ6.<$X  _'+_ (*3_P#*
M23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BN;%X+"8^B\/C<+A\70<HS='$T:
M=>DYP=XR=.K&4>:.MG:ZOHT!YO\ \*A\ G_F#2_^#35/_DRN:^(7[.?PC^*,
M^A7/C7PU/JTWAO2?[#T=H]>U[31;:;YB2^0RZ;J-JMPWF1JWG7 DFXQOP2*]
MPHK#!93E>72G/ 9=@L%.I%1J3PN%H8>4XIW49NE3@Y13U2=TGJ@/DS_AB']F
MW_H1+O\ \+#QA_\ +NOHK1/"&D^&] T+PSH+7^E:+X<TNTT;2K.WO[B3R;"R
MAC@M8I9[II[BY>*&)4$T\KRN,F1V8YKJ:*]%-Q=T[-?\-U)E%33C)73M=;;-
M/IKT,?\ L?\ ZBFL?^!O_P!JK4AC\F*.+S)9=BA?,F??*^/XI'P-S'N<#-24
M4Y3E)6D[K?9+\DB84H4VW%6;5GJWI\V<_P"(?"^B^*;>WM=;M&NX;6<W$"+<
M7-L4F,;1%BUM+$S?([#:Q*\YQD CE/\ A4/@'_H#2_\ @TU3_P"3*]+HKR<5
MD>38ZM+$8S*LNQ5>2BI5L1@L-6JR4$HQ4JE2G*;48I1BF](Z+96T/(O&'P,^
M&?CSPOI_@WQ/H$VH>'M+U=M=LK)-9UFR>+4W@N[9K@W=E?07<@,-]<KY,DS0
M@R!A'N1"OE/_  Q#^S;_ -")=_\ A8>,/_EW7UG7FGQC\7>*_ ?PO\<>,/ W
M@N^^(?BSP[X=O]4T+P;IIN#>:[?6R*4M88;*WO-2O/*0R7DFG:/9WNN:G#;2
M:=H=E>:O=6-K+WT:-'#TJ="A2IT:-&$:=*E2A&G3ITX)1C"$(*,81C%)1C%)
M))))("KX4^#_ (4\ >$5\%_#^;6_!>CKJ]SK1.DZHU]>O=WB@7:-=^(X-=8V
M]P5B=X0B['A3RGC7>KZ?_"#:E_T4?X@?^!GA?_YDJ_,C]A_]O;XC_M"_#KX5
MVWB#5_@EX^^*GC+QK\7[76D^'%OXU\$?V1X0^%.D7FI7UGXK^'7Q"2#Q+\.O
M'%[J^L?#W1-.M-2U'7=.O/#?B=?'$B6TD$V@#Z)^"/QX^/&I_M$:S\ _C#9_
M!SQ!J>G? [2?B[XQO?@I#XSBLO@)XLUGQ/I^D:!\&?B%JOBK5M9M?&>J>.=#
MOM;\4> ?&=C:?#S4=8T7X=^*]6U?X9Z#I&L>%;NZ[:6*K48\D/9\MV_>H4:C
MN[7]Z=.4K:;7LDW;<Y*V!P^(G[2HJW-9+W,3B:4;+;W*56$+]WRW?5[6^UM#
MTB?1[:6WN-<UG7GDG,PNM;DT^6YB4QQI]GB;3M-TR$0 H9 'A>3S))"92I5$
MM:KI=EK6GW6EZC$9[*]C$5Q$LDD1= ZOM$D+)(GS*IRCJ>,9YKXETC]I/XOW
M?[?&L?LMZ[X!\%^&?A@_[-7B/XQ^#/% U^^\0?$'Q%K?ASXK^"OA[<:AJFGV
M(M/#/AOPC=6_BV9]*T+[1K'BN\N=*EO]7O/#D$]MI,OT=\#/B3=?%?X:Z1XN
MU*RLM.UV'5_&?@SQ78Z9.USI=IXV^&?CCQ)\-O&\&ERR22SMI:>+/"6L'3!=
M2-=I8-;)=DW2S5S5U'$QJPKPIU85X2IU:<J</9U(3BX3A*FHJ#A*+<91Y>62
M;33NSHI4XTH1IPYN6"M'FG.<N^LYRE.3\Y2;^1H_\*B\ G_F#2_^#35/_DRG
MW7PE\"7GAWQ+X5N-'E?0_%NG'2M>M!J>IHUY8D2#R5N4NQ<VI_>O^]M989>?
MO\#'I%%>5ALAR7!UH8G"93EN&Q%+F]G7H8'#4:L.:#A)PJ4Z49QYH2E&5FKQ
ME*+T=BSY,_X8A_9N/_,B7?\ X6'C#_Y=UZ/\/?V>OA9\*_\ A(6\!:)J'AV;
MQ/I\&F:K=6WB3Q#<7;6UJ]S);FTN+W4KB2PGADNYGCN;,PSAF!WG8F/;**]=
M-Q:DG9IIIK=-.Z:]&*45*+C))QDG&2>J::LTUV:T9Y[_ ,*XT[_H9?B%_P"%
M_P"*O_EG6YH7A:UT">>>#5O$VH-/$L+1Z[XEUC6X(PK^8'@@U*[N(X)2?E:6
M-5=D^0L5XKIJ*Z)XS%5(.%2O4G"2M*,I-II--77JE]R..EEV!HSC5I86C"I!
MWC.,(J46U:Z:6CM?[WY#7571D895U96&2,JP((R.1D$\CFO-O^%0^ 1_S!I?
M_!IJG_R97I=%>/C<KRW,73>88#!XUT>?V3Q>&HXAT_:<GM.1U83Y.?V<.;EM
MS<L;WY5;M.(T;X=^$O#^HPZKI6FR6]];K*D4S7U_.%6>)H91Y<]S)$VZ-V7+
M(2,Y7! ->$W'[%'[.5U<7%U-X&NWFNKB>ZF?_A+O%Z[YKF9YYGVKK05=TLCM
MM4!5SM4!0 /JVBM<'@<%E])T,#A,-@Z,INI*EA:%.A3E4E&,95'"E&$7-QA"
M+E:[48J]D@/G?P1^RO\ !#X=>*-+\9>$O"5QIOB'1C=G3[U_$GB6_2 WME<Z
M?<YM+_5+BTE\RTNIXQYL+["XD3:ZJP]<D\(P2222'7O%B&1W<I'XBU!(TWL6
MVQHK@(BYVHHX50%' %=917=3JU*3;IS<&[7M;6VWW7,JM"E7455@IJ+;C>^E
M[7V[V.:LO#,5C=0W2ZSXEN3"Q807NNWMU:R91DQ-;RN4E4!MP5A@.%;JHKI:
M**52I4JM.I)R:5DW;;MH%*C3HQ<:4%"+?,TNKLE?[D@HHHJ#4**** "BBB@
MHHHH **** /Y_O\ @KY\6OA=\#/VY?\ @B;\5?C/\1/!?PI^&G@_]J/]I>]\
M4^/?B%XDTOPGX1\/6M[^R9XST:RGUC7M9N+73M/BO-8U33=*MI+F>..74-0L
M[8,)+B,'[73_ (+'_P#!* (@/_!2#]B7(51_R<I\*NP [^)0?S /M7WYXN\
M>!O']M:67CGP;X4\96EA.]S8VOBOPWHOB.VL[B2/RI)[6#6K&^BMYI(OW;RP
MHDCQ_(S%>*X+_AFW]GO_ *(7\'/_  UO@+_YGJ /D+_A\A_P2?\ ^DD'[$O_
M (DK\*?_ )I:/^'R'_!)_P#Z20?L2_\ B2OPI_\ FEKZ]_X9M_9[_P"B%_!S
M_P -;X"_^9ZD;]FW]GO:V/@7\',X./\ BUO@+KCC_F7J /D/_A\A_P $G_\
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MX9M_9[_Z(7\'/_#6^ O_ )GJ/^&;?V>_^B%_!S_PUO@+_P"9Z@#Y"_X?(?\
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MX9M_9[_Z(7\'/_#6^ O_ )GJ/^&;?V>_^B%_!S_PUO@+_P"9Z@#Y"_X?(?\
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MXA3PQJ>HMI":VVA:TNE->B$7S:5J*VYD-G.$ZS_AFW]GO_HA?P<_\-;X"_\
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M\->$K5+'0+WQ59?";QQ9^%O%/C[Q%JCG3M2T6XUZQ\-^)]4U5+C20#]1J*^
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M)'C/3[W3O&5OI/A2[MM-T34_$WC]+WP3:>OZ3^P/^R=H5CX.T?1_A0NG>'/
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MH **** "BBB@ HHHH **** "BBB@ HHHH **"<>OY$_RI,CW_(_X4 +1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-2017930sga.jpg
<TEXT>
begin 644 biib-2017930sga.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%_VD/BZ?V?OV>/CS\>1H!\5GX)_!CXI?%P>%QJ7]CGQ(?AMX&UWQF- &K_
M &'4_P"RCK']B_V<-1_LW4/L/VG[5]BN_*\B3X[^$O\ P41\%:G\.K'XB?&+
MQ9\ +FS\3B>X\(:?^R#\1_B3^V%?BQ\-^#](\9_$NX\96'@;X+:/J_A>+X<:
M3XD\,WOB>_&EZCI&DZ?KVD3ZSJ&EW6M:%8:I]H_'[X2:=\??@3\:O@5K&K7V
M@:1\:?A+\1_A+JNNZ9!;W.I:+IWQ'\&ZUX.OM6T^WO/]$GOM.MM9EO+2&Z_T
M>6XACCG_ '3-7AGQ2_9"3QC+\*->^'OQ2\1?![Q]\+/AIXX^"]IXQ\.>%O!?
MB ZS\+_B=IG@.Q\<:-?:#XGTR[TN'6GU#X9>!O$WA7Q# 6/A[7] A2^TSQ'X
M<OM6\.WX!ZI\./VF?@O\7O%/C?PC\,O%LGC?4OAU%H\OB^_\.^'?$^H^%],;
MQ'X.\%?$+PU;0^,H-&;PGJU_XG\"?$+PEXO\-:;HVLZAJ&O>'M575=,M;BSM
M[B5/S]^'O_!8?X)>-1\+_$NL_#[XI_#[X9^/_A;^V!\2=6\2>+?A]\2Y/%G@
MZ+]D3XY?#/X/>)FO_AYH7P^U36[[PAJ&F^/=1\=Z]X_M95\/?#[3?"VH:+XE
MD&L6VN1:%]I?LL_LE^ ?V2=(^)7AKX<:AJTOA;QWXR\">)],T35/)E'A+3OA
MW^SO\#OV<_#_ (=L;Y,W6JP#PS\#-#UF\U'4,7MSK&L:H"J6R6R+\N^'_P#@
ME]X/T&V\6Z'#\6_%UQX1U#X*?MP? 7P/HLGAWP_'?>"? W[<OQ%\&_%CQTMQ
MK:2^;XIU7P9XV\-:D_@^\O[+3FDT'6H=)UY-1O-)76=0 /L/PY^U9\"O%WQ+
M'PI\-^,Y=8\32ZI>^'K#4K+PQXOE\ :WXLTOPJ/'.K>"?#OQ3.@+\-?$?CK2
M/!I?Q1JO@S0_%=_XCT_1+34[VYTY%T?6$T_P7XW?M/?M#?#+]JWX6? 3PQ\'
M/@WXG\#_ !7^'GQ<^*.C^.]<^-7CGPWXLTSPS\!/^%/Q?$JQU'P-I_P-\2:/
M)KU_=?%ZP3P-#:^.9-.U.'1KN37[_P /RW,,"<A^SY_P3$^#G[._Q<T7XH^%
M7\,7TF@7NH^*K*34?@Q\(Y/B$WC[Q%X&B\#>*M8E^-,_AN\^)D'AG5(WU?Q%
M8^$-,U?3I-&UGQ!JVEQ>)+OP']A\%V?U3\1OV>-$^(_QN^%'QOO?$.J:=JOP
MI^%/[07PKTW1;2ULIM.U73OV@9OA%/K.JWMQ/_I4-YH!^$>FKI<-O_H]T-7O
MC>?ZBVH ^8O@E_P5'_9I^*'P0^%'Q5\6:QK'PX\1_$?X<?LV>-KKX>7?@WXF
M:WJ-MJG[3^G/#\.]#\#7\7@'3Y/BYI>J^.;'7/AKI/B[P#IFJ:/JWC;2E\/8
ML]:U+3=-N?<X?VX?V9FF\8K??$*?0+'P-H7CSQ!K?B#Q1X,\>>&?"5U:_"JY
MAL/BE8>%_&&N>&+'PQXW\0_#35KA-"\>^%_!>JZ_XB\+^(8[S0-3TR+6-.U*
MRL_F+2O^"6/P^TJ3]F&2/XH^,YO^&8OA'^Q;\)- 5]'T!1XFT[]B_P"*"_$_
MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
M!*KX>1>%/@#X?@^+'CJTU;]FW0_C0/AGXI@T?PN^I:=X[^)_[3/PB_:G\-_$
M"ZL;VUOM(N[KX=^/_@YH6G6>@WEI/HOB;PYJFM6.LK#<SVUU;\KXG_X) _#'
MQMXL\6?$WQOXZL?'_P 5/B+XM^(&N^._%/Q(^!OP7^)&B7.C?%+PA\$_#/BK
M1/"?@/QSX=U_POX/U#1KSX(:'J_@#Q-#!JU]H<6L:UHGBVT^(.FS)D ^C_B;
M^W]\+O"'Q7^#WPC\$6=]\2M;^(_[3'@_]F[Q)KNF6'BW3_ G@S7/%7PE\>_%
MR=K'XD?\(?J'PZ\9^+=!T#PEH\NL?#[1O%D>N:=8>*K34-1EL6LIK.3[T4[E
M5L8W*#CKC(SBOSL_X=Z>&[/XD>$/$>A?%+Q3H/PR\"_M/VG[7GAKX.V/AGP8
MFA6/QAN?!'BGP-XL(\11:=;:ZG@SQ#;>*]4\1VGA.V%M!X<\3WU_+IM[+X;_
M +%\,:!^B:C:JKUV@#/T&* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#X4_X*&I>3_ 73K2T^,VB?!1;SXK?#"&]U;QCK'CKP;\.?&^F
MQ>(?MM_\)OB7\4?AP]MXK^$G@OXEV]JWANZ\?6>HV-K:ZO/HOA_48M?L?$4_
MA/Q!^5=Q_P %!OBU\)O!OACP!\)/"^E:'HFC:U^U,;[XC>,/CY\./CS\&=>\
M5_!^Y^$NJ>$OAE\%/C]^T!\7OV:)/&/PCURT^*.I7.IWLDNO_%GX?VG@7QI\
M/_"_@R]7P+J6I:/_ $;W=I:W]M<65[;P7=G=0R6]U:W,4<]M<P3(8Y8+B"57
MBGAE1F22*5'CD0E75E)%9K>&_#[V&GZ4VB:0VF:3+9SZ7IS:;9&QTV?3F#:?
M-I]F8/LUC+8L UE+:Q0R6C#=;M&W- 'XDWW[=7[1GB[XU?$+X1^'?%GPG\,>
M++']IWP7^S-I7P5TWPR/%_Q;TSPY\6?V,/@_\=-5^-NF:NWC31X?$6G_ +/_
M (Z\?Z[?:I<)X0'A7Q5X)\,ZG::K=:'K6H:/<:9\V_LT_P#!13]JRS^&W[%O
M@?4/$?A'XP>(K[]F#]CSQ=XU\=>,_$/P1\*ZE\;_ (I_&3Q/J7A/XO\ PZU#
M5O&7Q_\ "7C#2_&/P+32K?P;XIE^'/PV^+OCJ[^,FI6C?$'PGX=MM3L?#FK?
MT+>#?@[\-OA_XH^(_C3PGX6M-+\4_%KQJ_Q#\?:T;B^O[W6_%LG@GP)\.Y=2
MB?4;J[&CPS>#_AGX'TF?2M#73M'N&T&#49K"35+B]O;GKXO"_AN"XM[J'0-%
MANK34=1U>UN8M*L(Y[;5=7WC5=3MYH[=9(=0U,22#4;Z)ENKX.PNYI@S9 /P
M4\7?\% /VO+7P]X@\0:%X@^#=I;ZM\.?^"LGCCPM;ZC\+->U"?P[)_P3%_:7
MO/ASH=KJ,EM\2],3Q#!\;_!VI:7IWB>-8]%G\$7^E3:OH%WJ-QJ,EO;^/?"W
M]OWX_?##PM\8/B+X/OM$^.&M>,/VM/VO]5T']D34?[9UGXVV_P .V^"GB?X[
M>$/&7A?Q1<^,H;RW^&W@CQ'X6TWP6]MIOP]/@^[\.^()].T34K7QR='TVY_I
M4.A:*RA#I.F%!'JL(0Z?9%1%KDPN-9B"F# CU6<";4D VZA*!+>">0;J6WT3
M1[2Z2^M=*TZVO4LVT]+RWLK6&Z2P>?[4UDEQ%$DR6;77^DFU5Q ;C]^8S-\]
M 'X7?#K]O?\ :F^($?P9\):=J?P=^V?%[]J?X9_!.#XHQ#X4^-H;#1O'W[+7
M[1?QN\6K'X'^!G[0WQD\,VE[X0U_X2^&9_ EQKWQ-T_6O$7A7Q/!#XM\,6EQ
MI\^L:]](?\%+]6\'_P#"'OIX^*WAKP=\6=+^&OCKQ%X#\.?$G]IOXG_LN^"8
M[06Y@OOB?X8U_P"'NEB#Q_\ %[X?ZY9>'X_"'AG5-4C@TJVUN\GEN/"\.O1Z
MQ=_I]:^']"L8H(++1]*LX;;4+C5K>&UTZR@B@U2[^T_:]2ACB@1(;^Z^VWAN
M;V)4NI_M5QYLK^?+OEU'1])U@6BZKIMAJ2V%Y!J-D+^SMKT6>H6Q)MKZU%S%
M*+:]MRS&"[A"7$)),<BY.0#^?&Y^+?BC6-1UCQO=?$CXLVW[6EC\5/\ @GQI
MW[*/PM^)'BW7?ASXQ\;_  '^)W@#]F#4OB1+XI^!6A7%CX-U:?QSKOB7]J*+
M]H.[A\.^*;3P'JO@74%;Q/HEO\*?#6HZ/^O?Q[^*'P&O?V:?B7\1/&G[0]C\
M,?@=H8UG3O'GQL\#?$?3O#J^'[?P3X^/A'QQX9L?'^F&_N-%UZZ\3Z'JWPGU
M:+PU+#X^L?$%[J/A[PE<Z5X_32[FS^EI=+TV:_M-4FL+.74K"&YM[+4);:"2
M^L[>\,1O(+6\>-KFWANS;P&ZBAE2.X,,1F5S&F,>#P9X4M]!G\+Q^'M(;P[=
M7FHZA=:+<:?:WFFW5]J^M77B/4[NZL[R*>WN;B^UV]NM7NIIXY'EU">2[8^<
MV\ 'X!>"O&?A_7=5^&]GXN^+4O@[]@SXH?M,?$VYG\(WG[46HZCJ/P=T[P[^
MS7H(^$'PS^,GQ7\._$+5M9^&]G\7_B/I/Q'^-UC\(=5^*4-EX3UT?#[P7>.O
MB'5=3\"VN/XN^/\ KGAGP#_P2J\;?%W]K'Q#X,N=0_:^TO1U\(^,?B;X>\"C
MXG_LY+J?[5.B?#3XU?%O^U(_#OC?Q[:>+?A1H/PEU.]OO%UZW@J3Q#>KXHU'
M2=0\9WEGK%C_ $&:;\/? FCZ5?Z%I/@OPGI>BZK+'-JFD:=X;T2QTO49HEC6
M.6_T^TL(;.]DC6&%4>Y@E9!%$%(\M-J^(/A_X%\67$5WXH\&^%/$=U#9OIT5
MSKWAS1=9N(["24S/91SZG8W<J6CS$RO;*X@:0F1D+G- 'Y]WGP=^&?CS_@H+
MX9\0>&]-URUU3X<?##1_VD/B'XKTKXE?$AM.\7^)/B5=>)OA1\%?#_\ 8%IX
MU_X0D^%+?1O ?Q3\8:YI,6@-8ZSJ^D?#^\\GRK2_-_XM^W__ ,%"?B!^S#\3
M]5T3X<7'A[78_A9X4^"OCCQK\-?$&A>%=#U#Q?H?Q.^)VI>$-8;0?%/BKXK:
M%XU\4'3_  MI>HZE:Q_"#X2^+K;P;K6FFY\<^([^&_'A6Q_9*"RL[9_,MK6V
M@<VUM9[X8(8F^R6?FFTMMT:*WV>V\^;[/!GRH/.E\I$\Q]U6]T31]1N8KR_T
MK3;V[@MKJR@NKNPM+JX@M+XPF]M89IX9)8K:\-O ;J!&6&Y,,1F1_+3: ?@9
MXB_X*/\ [4W@G1=%\4:@GPJU_3OBOKW[?O@CPO#'X#URRL?@O9_L=?MM:7^S
M]#\;/'>HV_CW[1XT\&Z-\)=;UKXE?%/PU8P>%?LD'@@W>E^)-(TY]<NG^HOV
M)?B+KGC#7_\ @IG?^-/VBM+\8^'/#/[0/A/2]!^.'A2[TS1? OA_PI:_L*?L
MSZAJOB[P5;>(=;\;^!/#6G:)KUQXC\1:Q+:7FH>!7\6V_B#6KNR"7&JV2?JD
M-%T@>5C2].!@.I&$BQM%,)UB9I]5\HB$&/\ M.9FEU#9M^W2,TEWYSL6++;0
M=$L["72[31]+M=,GM4LIM.M].LX+&6SCLTT^.TDLXH%MY+9+&..S2W>-H4M$
M2V5! JQ@ _G*L_BIX.US0O'?C']FS]H;Q%>?LAZUKO['W@;XF:MJ'[4&M>.?
MB/XP^'.K_M!V5O\ 'W]L/[0WCCQ#\0O@KX"\3^ ]1TOX;ZIX^#?#Z[\=>&M9
M\9_%:33/!OAOP=\/O&>N5OVKOBPG@[]@O]M"]\(?M5>+/ /PD^''[1XT?]DS
MQ%IWQDM++4?BOX/TK1_V<M9\5^!O#WQ1\1O<>//&'P[^'7QDUOXS^'+.S\$^
M-IWU#0?#[>!M4UZ]\ ^'KKPY?_T1Z)\// ?AJ6_N/#W@OPEH4^JVS6>IS:+X
M:T329M0M&<R-;7TNGV%M)=V[.S.T%PTL3,S,4)))FU+P)X*UBPTK2]6\(^&-
M3TW0@!HFGZCX?T>^LM' @^R@:7:7=E-;Z<%MO]'46<4 $'[D#R_EH _!C]M;
MX_:KJ7QL^+GBR'QOX=U;X9_"OX%? ;XL_LOZ7X3_ &E_'GPTUGX_W^L>,OBU
M;?%.Q_9JF^%-[<:1\1OCW<>)O#?@7P'IL7B.P^(WAFR@OO!W@"Z\$6^D_&+Q
M3K)_H-A<R1([1O$74,8I"IDC+#<8WV,Z!T)V.$=T5E*H[J QQ+7PGX7L;;1+
M*R\.Z%9VGAIG?P[:VFD:=;6V@N\4T#OHL$%M'#I3O#//"[Z>ELS132QL2DCJ
MW04 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'RS\<OVN/AO\ _C%^RQ\#?%ND>,
MM4\;?M??$'QM\-OA;)X<T[1[G0=/UWP#\.-9^*&NW7C34=3U[2KG2-)?PYH=
MW;V$^DZ=K]Y<ZO+:VLEA;VK37T'T,-6U5@&'AR[P0"/^)CI'0C/_ #^U^,'_
M  4G_P"4DG_!"G_LZW]J#_UCGX@U^WD?^KC_ -Q?_010!A_VIJW_ $+EW_X,
M=(_^3:/[4U;_ *%R[_\ !CI'_P FUOT4 8']J:M_T+EW_P"#'2/_ )-H_M35
MO^A<N_\ P8Z1_P#)M;]% &!_:FK?]"Y=_P#@QTC_ .3:/[4U;_H7+O\ \&.D
M?_)M;]% &!_:FK?]"Y=_^#'2/_DVC^U-6_Z%R[_\&.D?_)M;]% &!_:FK?\
M0N7?_@QTC_Y-H_M35O\ H7+O_P &.D?_ ";6_10!@?VIJW_0N7?_ (,=(_\
MDVC^U-6_Z%R[_P#!CI'_ ,FUOT4 8']J:M_T+EW_ .#'2/\ Y-H_M35O^A<N
M_P#P8Z1_\FUOT4 8']J:M_T+EW_X,=(_^3:/[4U;_H7+O_P8Z1_\FUOT4 8'
M]J:M_P!"Y=_^#'2/_DVC^U-6_P"A<N__  8Z1_\ )M;]% &!_:FK?]"Y=_\
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M% !1110 4444 %%%% 'X@?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\
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M,/[0?[0G[/7B3Q!X='Q ^+OBS3/B-\._AF?AMXY\<2? #QQ;>.KWQO\ M2?
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M*OT2NO\ CVN/^N$W_HMJ_.U>@^@_E7W/B[_%R#_#FO\ [S!"T445^-@%%%%
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M/>H_LY:Q\/[G1_!4ER_BOQOX^\#>,?BO<L?$<WBJ#XE>)+'Q#X;M;/1I((O
MMIITFE3:C+^K _'J>OU_EZ>W6@#\0/\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]
MO(_]7'_N+_Z"*_$/_@I/_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z
M"* 'T444 %%%% !1110 4444 %%%% !1110 5PGQ-_Y$/Q-_UX+_ .E,%=W7
M"?$W_D0_$W_7@O\ Z4P5Y.?_ /(BSK_L4YC_ .H=8<=UZK\SXC;J?J?YTE*W
M4_4_SI*_D404444 %>[_  &_Y#FN_P#8(M__ $M:O"*]W^ W_(<UW_L$6_\
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M?$T:THQNES2C3G)J-VE=I*[2O=B,K_A)M(_Y[7/_ (+-5_\ D&C_ (2;2/\
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MR5F2?]A-7_U$Q UU]/U1[Y<>)-):WN );G)@F _XENJCGRV[FQ 'U)XKX+'
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M)VM;_91_: E_:&\)^.-?75_ _BFP\%?$G4?A[8^.?AYI'CKPCX<\92Z5X?\
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M_P!>"_\ I3!7&? C_D6-5_[#TW_IOTZNS^)O_(A^)O\ KP7_ -*8*_H')_\
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M]7^43SSX]?\ ("T+_L,O_P"D%S7R]7U#\>O^0%H7_89?_P!(+FOEZO&\2/\
MDK,=_P!>,#_ZB4A!1117P@!1110!]5? C_D6-5_[#TW_ *;].KL_B;_R(?B;
M_KP7_P!*8*XSX$?\BQJO_8>F_P#3?IU=G\3?^1#\3?\ 7@O_ *4P5_2&3_\
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M[Q&65E60KL9U90Q96 ^*_L#/O^A)G'_ALQO_ ,H\_P ^S _5RBORE_X?A_\
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M ,TX^/\ _P#.@I/^'X?_  2C_P"CS/!?_AN/C_\ _.@K^?\ _5_/O^A)F_\
MX;,;_P#*//\ JS$?JU17Y1G_ (+C?\$H5*AOVS_!"LY*HK?#KX^JTC!6<K&K
M?"$&1PBNY1 S"-'D(V([*[_A^'_P2C_Z/,\%_P#AN/C_ /\ SH*7]@9]_P!"
M3-__  V8WR_Z<>:_I,#]6J]W^ W_ "'-=_[!%O\ ^EK5^%W_  _#_P""4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-2017930spinraza.jpg
<TEXT>
begin 644 biib-2017930spinraza.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M_P#%U4_L+1?^@3IG_@OL_P#XQ1_86B_] G3/_!?9_P#QB@"W]NLO^?RU_P#
MB+_XNC[=9?\ /Y:_^!$7_P 753^PM%_Z!.F?^"^S_P#C%']A:+_T"=,_\%]G
M_P#&* +?VZR_Y_+7_P "(O\ XNI8IX)MWDS12[<;O*D23;G.-VTG&<'&>N#C
MI6?_ &%HO_0)TS_P7V?_ ,8JU;6-E9;_ +':6MKYFWS/LUO#!OVYV[_*1-VW
M<VW=G&3C&3D MT444 %%%% !1110 445',K-#*JR-"S1N%E14=XF*D+(J2*\
M;,A(8*Z,C$ .K*2I 'Y&"<C ."<C (.""?7/'UI:_&WXH?'KX:^#_BM_PA,%
MO^U%XQ\1:-\6'\ _$+XH6W[27B3PE'X2TB/6/V=_"VH^/M%^%FE>*(O"7B"Q
MM?B;^TU\-O!^F^!Q\,=#A\0VVE?$#6M&L]2TC0M'M?%W[":9;7%GIUC9W6H7
M.K75I:6]K<ZI>QV<5YJ4]O$D,U_=Q:=:6&GQW-W(C7$Z6%C962RR.+6SMH!'
M @!^)W_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^WD?^KC_W%_\ 017XA_\ !2?_
M )22?\$*?^SK?VH/_6.?B#7[>1_ZN/\ W%_]!% #Z*** "BBB@ HHHH ****
M "BBB@ HHHH *^'/^"D__)CG[1O_ &(B?^I'H-?<=?#G_!2?_DQS]HW_ +$1
M/_4CT&O)S[_D1YS_ -BO'_\ J+5./,?^1?CO^P/%?^F)G\8C_?;_ 'F_F:;3
MG^^W^\W\S3:_DT_&PHHHH *_;O\ X(;_ /);?CA_V2KPW_ZF;U^(E?MW_P $
M-_\ DMOQP_[)5X;_ /4S>OJN"/\ DJLF_P"PBI_ZC5SV,@_Y'&!_Z^3_ /3-
M0_IEHHHK^GC]8"BBB@ HHHH **** "BBB@ HHHH **** "D/ )'7!QQG]!R?
MI2U4O[I+&RO+V2*[G2TM;BZ>&QM9[V]E2WA>9HK2SMDDN;NZD5"EO;6\;SW$
MS)#$C2.JD _%/QI:3W'[='CX>+] _:#T+Q!KGQ?^"^H^%)OA%^RK^R?K/@/X
MC>!/AIIW@ZY\%^(_&OQ"^(OPX\9?'[Q2?AWXMU+QA%KOCNQ\0Z/I'P]L;J%O
MANGA^_TB;6#^VP_Q_G[=O3VK\&_B)X'LO$_[4VJ7EI\/O'0TWXE_';X!?&.\
M^+NN?\$^?VD-?^/WP]U#P]8?"B\TWP/X$_:%MM%C\ >&/!,5MX>AT34-?UNZ
MTS_A3ND^(?B7X4UGPSXCG74+N#]Y!T[]3U^IZ>WI[8H _$'_ (*3_P#*23_@
MA3_V=;^U!_ZQS\0:_;M"!$A/01J3WX"@]N:_$#_@I:)C_P %(/\ @A4('BCE
M_P"&KOVG</-&TL87_ACSQ^9,QI+"S$Q[@F)%"N59MR@J?VDCA\2F-,:AH8^1
M<'^Q[_(^4>NMXR/<8]J /BA/V\=!O?VN_%/[+&@_"+XB^)[3P)X)UGQ)XX^*
M?AR;PSJMGX8US1FT*:?0+SX:0:S_ ,+3N],N++Q#I,&G^*--\+WD.KZ_J-AI
MNA:5JVC3S^)K2WX:_;%\8>)]8\3?#Y?V9_B3X6^-2?"C3_C?\-_A9XW\6?#?
M1[WQ]\/;_P 6V7@VY74O$>DZ_P")-&^'/C/P[J]_9Q>)O!WC#R[BU:]MH-$U
M+Q#<6NO)H?A'Q+_X)^?%SX@_MQ>'/VL6^,?PYLK/P+X.=/ MU!\*)-+^+^D^
M)-.\01Z[HOP]U3X@>&_$FBMKWP'U&X:ZM_&^BW%O#XP\3^$+V_\ AY<:T+6\
M@\5:;Z9^S?\ LS_M0_#*?XM^(/BS\7O@EX^^*GQ5\'QV.L?&SPW\+?B-HWCJ
M\\7Z7#JL/A!3IGB;XN>*/"_AGX1^ VUK4KGP9\(/!.GZ'I.CW=[JFK7>J:OX
MK\2>+/%>O $?A/\ ;Q\3>)]!\.6EO^S=XPO/BQX\^)_Q8\ _#CX:>'OB1\--
M=L_&GA[X&66G'XJ_%"T^),VI:-X+TWP-X8\37DOP[BFOIQJNL>/A8Z=IUC)H
M.I1^);?VC4OVQ/AG!^S-X:_:?T32_%OB3PUXUN/ 'A_PCX+LK#2]/\>:O\1?
MB;\0=$^$GA3X8W-CK6L:?H6B>+3\4M?L_ ^O/JVOV^@>'=3MM3N]1UH:5I\M
M\WER_L;^-/!_AG]DFY^$GQ'\$^'_ (G_ +(_PVO?A7X;\0>,?AOJWBGPAXU\
M)^+_  )X1\*?$BT\4>'='\?>$]>MKGQ'XC\"^$?B%9:II'BNVO[;7= 2PU5]
M9L=7U.:LS3/V*/&F@_L^WO[+=AX\^$/B3X/2_"6QT9;+XD? O4O%FK:Y\<-1
M^*6L?$SXA_$_Q:NF_%;PSH\WACQCJ&J/>Z1X-\*67A7Q3X \6.WBSPU\2/ME
MAHMO8 'T=\!/V@[#XTW7Q2\*:GX2U?X<_%/X'>-M.\ ?%CX=:YJOAW7[KPYK
M>O>"/"_Q)\,7^F^(/"NHZEHVO>'/%/@CQEH.NZ+J4;6%^GG7NEZUHVCZQIE[
M8Q?1%?%'[)W[)MW^S3:?%#69-?\ "&M_$#XT^-=(\:>/=8T;PMXJT[2E/ACP
M'X7^'/A/0[*7Q7\0O&OC;Q#)I7A_PNE[K7C+Q[XR\3>,/%WB;6]<UC4;^RL9
M=,T/2OKOR?$O_00T/_P3W_\ \O* -RBL/R?$O_00T/\ \$]__P#+RCR?$O\
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M3W__ ,O*_IX_6#<HK#\GQ+_T$-#_ /!/?_\ R\H\GQ+_ -!#0_\ P3W_ /\
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MO;GPOILL$VG>%KSQ)_9O_"67WA:QDM;5K7PW>:]/H<*VMK$E@(+:"*/];?\
M@AOS\;?CAG_HE7AO_P!3-Z_$2OVP_P""(=]::?\ &GXWS7DZ6\9^%7AP!GW8
M)'C4K@!023EU[=\] 2/I>#*M6KQ5DGM:M2JX5IPA[2<I\D(X:NU"/,WRP6K4
M8VBKMVU9ZV13E+.,!SSE*TYQCS2<K)4JKY8\S=DM6DK):Z'].%%8'_"4Z!_T
M$X/^^9?_ (W1_P )3H'_ $$X/^^9?_C=?TT?JQOT5@?\)3H'_03@_P"^9?\
MXW1_PE.@?]!.#_OF7_XW0!OT5@?\)3H'_03@_P"^9?\ XW1_PE.@?]!.#_OF
M7_XW0!OT5@?\)3H'_03@_P"^9?\ XW5^QU33]2\W[#=1W/D[/-V!QLW[MF=R
MK][8V,9Z&@#0HHHH **** "BBB@ HHHH 3 SG STSCG'IFEHHH _$#_@I/\
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M[TQQVTEO97-\)!I\?VL_8&E?$'X57G[)+^&/%GC72-2\9Z9/%HW@G3-,\/\
MBOPK\3/#&MQ:)JCZ+I>M:MI5[+X/\=?"'3K_ %"^N-0U?Q);WL[:#>-H%KI%
MMXML-(4:&K?$;0+/Q=^SWXNU+XY_#7XA:GH?PO\ &WPG^+=[JE]\7-?GU!?B
M'XB^-<_B&\U+48?!FD>*'T2^\*>/=-TIO%GAZXN]=\,ZG>QW=EX?U*RT::SF
M_%/[-P#5"7UN,5/#X*K5_P!IPLG"=;$PHXF,DG[DH4Y2JPIIUI4X0<ZTHO\
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MX14>>,E&Z2;^EX4C&&98N,'S16#33YHSTE4H2LY148N46^65DES)I75F_L7
M]_S/^-&![_F?\:6BOV\^_$P/?\S_ (T8'O\ F?\ &EHH 3 ]_P S_C1@>_YG
M_&EHH 3 ]_S/^-?#G_!2<8_8<_:-Z_\ (B)U)/\ S,>@^IK[DKX<_P""D_\
MR8Y^T;_V(B?^I'H->3GW_(CSG_L5X_\ ]1:IQYC_ ,B_'?\ 8'BO_3$S^,1_
MOM_O-_,TVG/]]O\ >;^9IM?R:?C84444 %?MW_P0W'_%[?CA_P!DJ\-]R/\
MF<W]*_$2OV[_ ."&_P#R6WXX?]DJ\-_^IF]?5<$?\E5DW_814_\ 4:N>QD'_
M ".,#_U\G_Z9J'],F![_ )G_ !HP/?\ ,_XTM%?T\?K F![_ )G_ !HP/?\
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M%/!MHOA*V/ASP?I7]J:@J_;>1[_D?\* %HI,CW_(_P"%+G/K^((_G0 4444
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M4=1DMXHWOK\V&G:?9&\NFFN3:6-G;&7R+6"./0H_LW+O^@#!?^$F'_\ E?\
M7S8_JN%_Z!J'_@FG_P#(^2^X_G,_XAE_V+QT_:?_ ."E/_B9OB'_ .9"O<O#
MG_!#3P!X/T/2_#'A/_@HW_P6)\,^&]#LXM/T70-!_P""AOQ%TO1])L(,^39:
M=I]GX?BMK.UAW$1P01I&@)VJ,U^X-%;4L+A<.W*AAL/0E)<LI4:-*E)QT=FX
M1BVKI.S=KZ[EPHT:3;ITJ=-M6;A3C!M=FXI76BT\C\6/^'+&A?\ 23C_ (+/
M_P#BQWXG?_*.C_ARQH7_ $DX_P""S_\ XL=^)W_RCK]IZ*W-#\6/^'+&A?\
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M_P#,A1_Q#+?L7_\ 1S__  4I_P#$S?$/_P R%?T9T5Q_V;EW_0!@?_"3#_\
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M\YG_ !#+?L7_ /1S_P#P4I_\3-\0_P#S(5W?@+_@WH_9Z^%=_?ZI\,?VW_\
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M-_\ @L\!YD@ '_!1SXGX"K(RJ/FT1C]T#JS'U)ZT[_ARQH7_ $DX_P""S_\
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M\V:62WTRR_T#0M)CN+F:#0O#>FYTSPUH46F^']-+6.F6['W.@ HHHH ****
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MK#??.7Q0_P""7NJ?$_P-\3/A-??'2WT[X8ZEHW[=DWP:TZ#X;3S^+O 7C?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-2017930tecfidera.jpg
<TEXT>
begin 644 biib-2017930tecfidera.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M1M<;QYJ2^&?$7P-\6:C;R:5KT5CJG_">Z/#]DU32O#^J+%K0_?B'POX;M_M
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M\"KK^H^(;CQCJM_\/=<?7+C]O;J/7K2VN+I]:MG2V@FN&5-$3<RPQ/*RKG5
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M^T7\0_B7J/P<^&UU\5?A?\+=(_:L^-G[5GA_XD>(;/X11>'_  WXI^*_PO\
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M9(R-3\->(+62WUSP[?SP1RZ;=WVC7EI-?:3=7^DW;S6%[<V\GYA_\%+$=_\
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MQ"RS&7K*I*$JT:E3DA[6<:BE6Y5[5SL?U>>*CCPQXB/3&A:P<XSC&FW7;O\
M2OXC?"WQ+^'=[^QAX7T'6OC3X7T3XB:#JV@>'OAI?>&M2^)WP^^(?A#Q+I6G
M>&[WPUH?Q3TBTAU?X?\ C#X1^%-1.H:QJOQ"-LI&BZ9H.IZ5:7OQ)TDZ*_\
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M)2J-2Q>*=>M5<\1C98B4\?6Q52GAYT?I/]HWXRZ3\8]2^&T]E>>*_$^K>!_
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M^S=\>?BM:-H\X\(Q"PU#_A*?AOX>6:Z:*Y#Z4=1LO*4W@G@^@/\ B%U_8/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOB:/^"C'A#XAP#P5J5OJ,WPH_P""A'QS\+?'[5])\(:GI_CVQ.@^//A?XN\
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M;NFGGDTK2?&]WJ<5OJ$]A%:3_,7AW_@GEXL^&EC\/M8^%'QZMM/^)WP^U/\
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-2017930tysabri.jpg
<TEXT>
begin 644 biib-2017930tysabri.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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MT3\<-?\ VB](^"GQ#UOXR>-M'\3_ +'GAOX\>+]4^.OP@T3X,^*_AI\<M/\
MB/8^!?'/P]\->'M+\%?#V\O_ (=:RNNR7/A>_N=)\:>'_M7@O5O^$-^+7C>P
MGU+^S?URH **** "BBB@ HHHH **** "BBB@#Y<^-_[7/PO^ /QD_97^!WC:
MP\877C#]K[XA>-?AK\+KKP]I&GZAH.G:_P"!/AUK'Q-UB?QE>76M:??:5I<^
M@Z+<VFGW&DZ9KUS/J\]M!<6=I9&XU"W^@QXHT9@&%T^" 1_H>H=",_\ /I7X
MP?\ !2?_ )22?\$*?^SK?VH/_6.?B#7[=Q@>7'U^XO<_W1[T 8G_  DVC?\
M/T__ (!ZA_\ (E'_  DVC?\ /T__ (!ZA_\ (E;V![_F?\:,#W_,_P"- &#_
M ,)-HW_/T_\ X!ZA_P#(E'_"3:-_S]/_ . >H?\ R)6]@>_YG_&C ]_S/^-
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M  0I_P"SK?VH/_6.?B#7[>1_ZN/_ '%_]!%?B'_P4G_Y22?\$*?^SK?VH/\
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M]+*ZW"2J4JE7VU//;<CBN7V<LGO?F:W]HK6[.Y^W-%?B3_PN7XM_]%-\=?\
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M8_\ B-XTT+X=0?&]]5\':_K/A[1?BK\2?[-\7?%0ZS>:E*6ULZ!&+;1O!=B
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M7=O;W4>FV7[Q?LE_\FV_!C_L0]&_]!EK^.9/VV?AL"H'A3QR!D  1>'0!SV
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MO^R5P_\ ZM\W/[3^C-_R1V=_]E/B?_53DXZBBBOYE/Z/"BBB@ HHHH ****
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M1/!OQB\+Z+H?ASQ]I\UEI5G=ZP-+@O&\):]<7OAC4=3NKVT:*V_M:_X)F?\
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MS+\36DHJ5;$8+#5ZLE%)13J5:4IM144HINR2LM#^;3_B%U_8/_Z.#_X*(_\
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M=?:1-?:;--&\MA>2Z5J>I:;)=6CPSR:??WMD\AMKNXBDO4?ZQ\0_]#[.M/\
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M/V?MH3Y.9PAS<MN;EC>]D?S:?\0NO[!__1P?_!1'_P 2ZU3_ .8FOFW]K_\
MX-S?V./@;^S1\9?BSX*_: _;\?Q5X%\%WFO:$NM_M6ZMJ.E&_@O;"%/MUDOA
M*S-Q!Y=Q*&C^T1Y)4[@0"/ZW:SM6TC2M>TZ[TC7-,T_6-)OX3;WVF:K96VHZ
M?>P,59H+NRO(I[6YA9E5C%-$Z$JI*Y QV?ZQ\0K_ )GV=:?]37']+?\ 41Y+
M[CD_L#(O^A)E';_D6X+R_P"G'DC^<1?^#7?]@]]S?\-!?\%$ /,E  _:ZU4
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M=_$/P1^S?X<\/>+?VF_B#X:N_#=G8?"?0_$FAS>+HTT_0-;U*RU[XBZUX8\
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MZ;%XC\!-JNFZAI]AINA:XMS<Z+JTUO/!> 'WC\%?'?B/XG_"?X??$/Q;\/\
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MAOBI8Z]XI^&!L=$OO+M=;TKXBV>LZ?>_V?X5\9S:)\D_%;_@I?\ $?X,:_\
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M3%HD'[-E_P#&2\/A5="^V#Q7'\5OAI_PKV*WAU5-3M$T!?#_ !J>3INJC4$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTKP=):P>-;F]U_4([;09V\#7=_I^G^.;73]3O;SP5J>H6&E^*K;2-1O;6UF
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MXFT#XB_M*^.?B-J.I6FB11:QX.\01?%NTM/!M_ N@Z=X>N/"UYK5EJ_ZGT4
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M\3ZC/X\\7#4_'%Q8:-%IGBEM)LM \+WMWY>H^'O#OAN'[5I]U^B-% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-2017930zinbryta.jpg
<TEXT>
begin 644 biib-2017930zinbryta.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /%_VD/BZ?V?OV>/CS\>1H!\5GX)_!CXI?%P>%QJ7]CGQ(?AMX&UWQF- &K_
M &'4_P"RCK']B_V<-1_LW4/L/VG[5]BN_*\B3X[^$O\ P41\%:G\.K'XB?&+
MQ9\ +FS\3B>X\(:?^R#\1_B3^V%?BQ\-^#](\9_$NX\96'@;X+:/J_A>+X<:
M3XD\,WOB>_&EZCI&DZ?KVD3ZSJ&EW6M:%8:I]H_'[X2:=\??@3\:O@5K&K7V
M@:1\:?A+\1_A+JNNZ9!;W.I:+IWQ'\&ZUX.OM6T^WO/]$GOM.MM9EO+2&Z_T
M>6XACCG_ '3-7AGQ2_9"3QC+\*->^'OQ2\1?![Q]\+/AIXX^"]IXQ\.>%O!?
MB ZS\+_B=IG@.Q\<:-?:#XGTR[TN'6GU#X9>!O$WA7Q# 6/A[7] A2^TSQ'X
M<OM6\.WX!ZI\./VF?@O\7O%/C?PC\,O%LGC?4OAU%H\OB^_\.^'?$^H^%],;
MQ'X.\%?$+PU;0^,H-&;PGJU_XG\"?$+PEXO\-:;HVLZAJ&O>'M575=,M;BSM
M[B5/S]^'O_!8?X)>-1\+_$NL_#[XI_#[X9^/_A;^V!\2=6\2>+?A]\2Y/%G@
MZ+]D3XY?#/X/>)FO_AYH7P^U36[[PAJ&F^/=1\=Z]X_M95\/?#[3?"VH:+XE
MD&L6VN1:%]I?LL_LE^ ?V2=(^)7AKX<:AJTOA;QWXR\">)],T35/)E'A+3OA
MW^SO\#OV<_#_ (=L;Y,W6JP#PS\#-#UF\U'4,7MSK&L:H"J6R6R+\N^'_P#@
ME]X/T&V\6Z'#\6_%UQX1U#X*?MP? 7P/HLGAWP_'?>"? W[<OQ%\&_%CQTMQ
MK:2^;XIU7P9XV\-:D_@^\O[+3FDT'6H=)UY-1O-)76=0 /L/PY^U9\"O%WQ+
M'PI\-^,Y=8\32ZI>^'K#4K+PQXOE\ :WXLTOPJ/'.K>"?#OQ3.@+\-?$?CK2
M/!I?Q1JO@S0_%=_XCT_1+34[VYTY%T?6$T_P7XW?M/?M#?#+]JWX6? 3PQ\'
M/@WXG\#_ !7^'GQ<^*.C^.]<^-7CGPWXLTSPS\!/^%/Q?$JQU'P-I_P-\2:/
M)KU_=?%ZP3P-#:^.9-.U.'1KN37[_P /RW,,"<A^SY_P3$^#G[._Q<T7XH^%
M7\,7TF@7NH^*K*34?@Q\(Y/B$WC[Q%X&B\#>*M8E^-,_AN\^)D'AG5(WU?Q%
M8^$-,U?3I-&UGQ!JVEQ>)+OP']A\%V?U3\1OV>-$^(_QN^%'QOO?$.J:=JOP
MI^%/[07PKTW1;2ULIM.U73OV@9OA%/K.JWMQ/_I4-YH!^$>FKI<-O_H]T-7O
MC>?ZBVH ^8O@E_P5'_9I^*'P0^%'Q5\6:QK'PX\1_$?X<?LV>-KKX>7?@WXF
M:WJ-MJG[3^G/#\.]#\#7\7@'3Y/BYI>J^.;'7/AKI/B[P#IFJ:/JWC;2E\/8
ML]:U+3=-N?<X?VX?V9FF\8K??$*?0+'P-H7CSQ!K?B#Q1X,\>>&?"5U:_"JY
MAL/BE8>%_&&N>&+'PQXW\0_#35KA-"\>^%_!>JZ_XB\+^(8[S0-3TR+6-.U*
MRL_F+2O^"6/P^TJ3]F&2/XH^,YO^&8OA'^Q;\)- 5]'T!1XFT[]B_P"*"_$_
MPMJ^L;>;._\ &6H*-,\006'^C6-G^^TS_2 *QF_X(^_LTW4?QI\/7VG^'?\
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M_''6OA'JWB5]3GC>._@FM5^$MC964=G+&OEZS>W'F1W5I92* ?*7@[_@I/\
M"ZYO[O\ X6B=!^&6G6UJD+6*WWC_ ,8>,!KNM_MF?$7]C/P!:G1=$^%PT:73
MO'?CSP5IMOICV7B:[\16/B'7GT/4?#$.D65GXIU?V!OV^?V6TTK1-7?Q]K"6
M^J1>+[K6+9OAI\4AJOPVT_X?^,;KX>^.=8^->B_\(6=6^!VA^$?&]E>^&=?U
MKXM6?@[3-/U&QU$R71LM,U*\M/EKP3_P2=\#^$(_A\UW\</B=XMU'P%;_ :
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M<>"--^'$7BKX0^#?!.H?&W3?"WC'4O'.F6>B>&KNSL+G4M>CGUVWT^VX0?\
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M5KIT^E:=KUU<:O-;6TUE:VC3W\'T\"& 8=" 1]",U^(/_!2?_E))_P $*?\
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M-N'XRJU)1>*KIQE.33_V'%;IMI[+TLNR/V'^Q^(?^@Y:?^"1?_EI1]C\0_\
M0<M/_!(O_P M*WZ*_B _L8P/L?B'_H.6G_@D7_Y:4?8_$/\ T'+3_P $B_\
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MX(4R2$A?^&K_ -IQ/E1W8M+^Q[X_B0!8U=SEW4<*0,Y8A02/VAC\3:/Y<?\
MI$OW%_Y<=2_NC_ISH Z*BL#_ (2;1_\ GXE_\ =2_P#D.C_A)M'_ .?B7_P!
MU+_Y#H WZ*P/^$FT?_GXE_\  '4O_D.C_A)M'_Y^)?\ P!U+_P"0Z -^BL#_
M (2;1_\ GXE_\ =2_P#D.C_A)M'_ .?B7_P!U+_Y#H WZ*P/^$FT?_GXE_\
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M#K0L=3L]1\W[)(\GD[/,W07,&-^[;C[1##NSL;.S=C'S8R,@%^BBB@ HHHH
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M[8H _$'_ (*3_P#*23_@A3_V=;^U!_ZQS\0:_;R/_5Q_[B_^@BOQ#_X*3_\
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M$^&_XC#P=_/F?_A#_P#=C]UJ*_"G_AY)\??^@+\,?_"=U[_YK*/^'DGQ]_Z
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M4'_K'/Q!K._X*3_\ET\,?]DMT+_U(O%5?K?@I_R7%'_L69C_ .D4S\N\7_\
MDC:O_8QP'_I50_/>BO=?V?= \$>(/' M?'-O:75H+=%TJ#6Y=<LO"D^J3&<O
M!XBU/0;.[N;'=IT%Y-HRW3V6G76H6["[NU,$,,UR?P7X.T[1OCG8ZGX>U?2_
M&/@S1=$\0:-'<>+;+6M"\/:1J7B_P)IUD++4=/@MI/%\NLZ3XGNKF'7-02VL
M%TA]-EMK"XU.ZN;RU_JVMG6'HX^KE\L/BG6IK+WSQC15.I',,73P<)T^>O"I
M4IX>K5IO%58TW3I<\::E+$3I4:G\RTLIKUL%3QT:^&5*H\<N64JW/!X#"RQ<
MX5'"A.G"I7I4ZGU:E*HIU.5U&HT8U*M/Y^HKZ;G^"\VC? _Q/XGU/PCXAG\5
MV]G\/O&,&OB#5$T70O"WB;5-0@;2(O* TO4;U]"BM/$?B6^F,_\ 8$6HZ-I<
M;6UW%JI;EOAEI7@76]+N5\2^%6_L33+77+[QY\2[[Q%J.G)X8@FL)QX-L/!U
ME9W,.DWWB&_U&&&.+0M7L=>U#Q1<W4D%I;Z9H]E<ZA!"S[!U,/C<3AX5L52P
M.,>"K>P>'E*=3V%&O&=!2Q$/;0J_6*5'#PC^_P 37G&%"C44Z<IMY-BX5\)A
MZTZ.'J8W"+&4O;K$14*?MJM"4:[CAYNE.DZ-2K7DTZ&'H1E.O6IN$X1\.7J/
MJ/YU_1U^RGK-E;?LY?!N&5-1+IX$T<$Q:-K%Q&<"924FM[&6&1<@X:.1E(Y!
M((-?SAQ[L1[P%?:F]1R%? W@')R V0#D\#J>M?TH_LE_\FV_!C_L0]&_]!EK
M\F\>_P#DF\H_['2_]0L6?J/@CKQ!FKUUR:6^G_,;@]UW_(]M_P"$@T[^YJO_
M ((->_\ E;1_PD&G?W-5_P#!!KW_ ,K:VZ*_E,_IDQ/^$@T[^YJO_@@U[_Y6
MT?\ "0:=_<U7_P $&O?_ "MK'/Q%\!CQ^OPJ/C'PR/B4_A-O':^ CK>G#Q>W
M@M-670G\5CP[]H_M4^'EUEETMM8%K]A%^1;&?S3MK<TO7]#UN?6K71]9TK5;
MGPYJQT'Q!;:;J-G?7&A:V-.T[5SH^LPVL\LNEZJ-*U?2M3.G7Z6]X-/U+3[T
MP?9;VVEE (_^$@T[^YJO_@@U[_Y6T?\ "0:=_<U7_P $&O?_ "MK(B^(G@&X
M\:W7PV@\;>$9OB'8Z3%KU[X$B\3:))XSL]#G*+#K-UX62_;7K?29FEC6+4IM
M/2RD+H$G.]-W94 8G_"0:=_<U7_P0:]_\K:^:OVP]8LKK]FCXOPQ)J =_"Z
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MG_!"G_LZW]J#_P!8Y^(-9W_!2?\ Y+IX8_[);H7_ *D7BJM'_@I/_P I)/\
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MV\'?'WPWJ?BGP79>(;+3M)UR7P_<Q^(]/M+"[:]AT^QU)GABL]0U*-[8P:A
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M7G.5YU1J8G*L=0Q]"E5=&I5P\G*,*JA"HX-M+WE"I"37:2%HHHKRCTPHHHH
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M=^(O@.#0OA1\0[#QKX&UKPS\%-+\*?M$Z=X2T>#68]*^ -W\<M'\6Q65[\#
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M7OBCXTBO;OQ[IL7B/P$VJZ;J&GV&FZ%KBW-SHNK36\\%X ?>/P5\=^(_B?\
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MXL_LCQ#X1\1:$]SXQ^%_@#6M!\5Z3XBC31+O3;VWU/2=6TO5[I;4 \C\9?\
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M!H6DQW%S-!H7AO3<Z9X:T*+3?#^FEK'3+=C[G0 4444 %%%% !1110 4444
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M'\1^)6F6WA36?"<O[3OBWP/XNEU.'Q-IWC72]+TKQ!I>G>#O$$<DLO[3T4
MSCGKWP,#/TR<?3)^M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7%%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biogenlogostandarda10.jpg
<TEXT>
begin 644 biogenlogostandarda10.jpg
M_]C_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T      ! !+     $  0$L
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M86-K970@96YD/2)W(C\^_^)]$$E#0U]04D]&24Q%  $2  B <$%$0D4"$
M<')T<D--64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M                 /;6  $     TRU!1$)%
M                                       *9&5S8P   /P   !T8W!R
M=    7     K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&
M03)",0  H[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@
M CBT9V%M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,@
M                                                      !T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B
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MW%_,8+UAK&*;8XED>&5F9E1G0F@P:1YJ"VKX:^5LTFV^;JIOEG""<6QR5G-
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M_P"  (  Y;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&&
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MY"^#B\#:S:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V
M=)Y8$52! XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-
M4\: "*A6-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z
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MJWDZ?=&P_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(
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MT9^2>OJM#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H
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M\W_X<<*YD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H
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M*J30<!:UJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8
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M?(9!9D/"A83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X
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M5*EV9DJ^**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(
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M0Z@L<+-X%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT
MH1EU^;9VB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT
M><\,N#IT]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$
MX>.$+G?ES#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"
MF7O3$]^$G7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8!
M5!Z!,( >-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2
M,H>,;(: +H:!4PR 0(6.-N> C83B$3R!LH1SW.> *IB7QZ1_Q975L:I_=I,Z
MFNI_1I#4@WQ_/([":UA_2(S>4@A_9(LD-?I_K(GA$"N =8?!VV!_/:.2QB1^
MV)_JL#)^D)QKF8%^:9DD@B]^8987:CI^?I-H415^HY#S-2%^XH]*#T!_98I0
MV@U^A:ZMQ-I^(*HDKNU]U:6]F$M]L:&/@15]L)VI:3)]RYH;4#A]^9<+-%Y^
M,I5?#GM^@(G*V/-]\[GJP\A]CK2!K=I]/J\QESQ]&*H@@"-]'J5O:&%]/Z$G
M3WQ]9YV,,[A]F9MF#=A]PXE<V!!]A<59PNM]'[\.K/)\R+C7EE!\F;+C?T1\
MH*UM9YU\RZB53MI\]Z39,RQ]&Z!8#5-]*(D"UV1]-=$7PCQ\T,GGK#!\;L+&
ME8)\-+OW?H1\.+7-9O=\9;"73E1\EZR6,KI\MZ),#.A\K8BZT<&-47:2O;6+
MZW<&J0.*J7=^DWZ)CG@)?3&(EWBR9@6'Q7EZ39Z'*'I),CB')7LQ#-:))'QY
MT#R+\8#'O'R*F8 ^I]J)8W_.DFB(57]^?!^';G]79/N&KG]13)2&'G]<,36&
M&G^8"^R'BX!:SN**J8L;NR&)7XF<IJR(*X@WD2^',(<->O*&6(838^*%J85&
M2X^%)H26,$2%(81$"QZ&)(/"S7Z)CY5UN;&(29,7I2:')9#:C\V&+H[/>;&%
M;(T+8L>$S(MV2IR$48H5+VZ$1HE9"FN$[(:WS":(L)_:N%>';)RKH\Z&3IF>
MCH&%79;">(2$F)0>8<*$")'12<"#DX_0+J^#?H[Q"=*#X8:DRO:( *IHMR^&
MO:9JHJJ%GJ*(C6B$L)[:=X*#[YMO8-.#6)A>2/N"ZI7C+@>"T)4-"5&# (9,
MR?F'<K49MC>&,;!.H;&%#ZN7C'6$(*<:=J>#9J+W8!>"TI]'2%6"6)QU+7N"
M.)I)".:"1H8$R2R' [__M6V%Q;IGH-^$G[3>BZ&#J:^2==Z"[ZK"7V>"9J:D
M1\>![:/Y+02!NIYP"(^!KH7)R)&&KLL]M,V%=,38H"^$2;YZBNJ#2[AH=36"
MCK, 7M6"!JZU1TJ!DZK6+)>!7IXF"$J!-86;P@>6O76$KUF4BG8+G V2@W:7
MA_"0KG<V<OB/!W?S70:-E'C+1;F,<GFF*P.,3GJ,!JF,_WR<P+R5?7\LKE.3
M4'[+FQ214WY^AP&/B'Y3<@F-[7Y/7!R,B'YM1,Z+;WZ9*B>+0W[Z!BR+;( 7
MOXZ45XC8K1B2-(>=F?N0-H9UA>2.>(6)</^,ZH3&6RB+DH0O0_&*@8.Z*6.*
M38.Y!;Z*"H,FOF^309*GJ^21*)"9F+F/-XZAA,B-<(SC;^N+](MF6C"*J(H<
M0QF)GHD1**J)98CG!5^(UX.AO4>29YR%JL^03IFREYF.89<#@Y6,JI2%;MF+
M*))!64")ZY!20E.(Y(['* B(H([*!0V'T(-JO#R1OZ:&J<6/J:+XEI"-O)^'
M@I>,!YQ*;?"*AYE16&V)0):[0:>(/)3?)WR'\)0[!,B&\X,\NUN1.;"GJ.F/
M):Q?E;2--:@L@<"+?J0T;2R*!*"85\:(O9V#01F'J9N5)PN'59B^!(^&/(,5
MNJ20S[L!J#:.O;8 E/F,RK$/@02+#JQ>;'F)E*@P5RB(5Z370)V'0*+<)JJ&
MUIHD!&"%IH+VNAJ0?,6ZIZ>.;< #E%N,>+I2@&"*MK3R:^*)-[!.5J>'^ZT2
M0"V&[*C$)DB&@9GB!#N%+X+=LL.@>G3#H4B=B'5.CSR:QW7B?&B8/7:,:+&5
MZ7=34^B3VG@R/:&217D,(V>227G4 4J067RZL;"?8'WFH'V<:WV8CGR9K'UC
M>ZJ7)'U19^R4V'UF4R22TGV=/-N10'WA(KF1,WY4 2R.S'_=L+N>1H<.GWF;
M7(7TC8^8FX3Y>K:6((0S9P63W8.<4E"1X8,Q/!V04X+N(AZ0-8,[ 1&-;X"Y
MK[R=4Y QGFB:;8Y@C&Z7M(RV>;>5,(LS9A.2^HGZ47Z1!8CS.VZ/>(@Y(96/
M2HBS /J,0("IKM6<<)F*G7:9DY<$BW*6XI2G>+.499)S93&2&Y""4+:0,X[N
M.LJ.IXW<(1>.;8XO .:+/8"<K?.;S*,(G*R8[I_1BJF6.)R^=^"3O)GE9&.1
M?9=73_^/BI4].CB-_I02(*F-MY+@ -:*8X"1K3*;3:R@F^R8;ZC!B>B5MZ3^
M=R63.J%^8[J0_YYF3VZ/"IOQ.<*-:IL"(%6-%I7< ,B)KH"'K)":Z[9JFU"8
M#;'CB4B54:UU=H62SJE68R"0DZ7+3N:.IZ-*.5F- *%;( R,D)6K +V)&X"
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M]HR#@'V@@(K^;MN=1(FR7%6:68BK2,N7Q8?A,Z&5T8=X&A.6&H@X  "*=X
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M5+<A?82=T+*+:]>:@ZYZ69"7AJN#1FR4[ZE",<Z2V*&L&/>2M9#A  "'L(
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M!))P=%FHW)"(8[*DZ8[?4DJA0(V$/\B>'XRA*X&;VXRH$AN<[HKB  "'&8
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M]7.M:MFV0W0K6R>QRG3,2HJMGG6'.).J%'9&)%*H*W:W"EBJ!W<7  "&#(
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M9Y?6:36QB)6<676LWY.]2/FHC))5-UVDTY'&(\.B:Y'H"W2BE(>_  "$PH
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MPGH17UZ_:WG94'"Z27G:0)FUAWH-+U*QJ'I6&T>P,7I?! NN+WQ&  "#(H
M>W+)$H'9;9?#GH#87T>^/8 /4$ZY"W^@0'VT.G]M+U"P1W]W&WVNDG^K!)>L
M28!U  "#(8  >W#'Z(D4;7W"<X>>7Q>]$89G4"6WU(6%0%ZS 84"+TJO H3?
M&ZVM'86$!1*JFX-N  "#'X  >UO&[)!E;67!<(Z 7OZ\!(SH4 *VPHNE0$^Q
MWXK/+U"MW(JL&]^KT(LP!8&I)(.Y  "#'H  >SG&)9?D;53 FI607O>['Y..
M4 .UU9'V0$^P[I#L+V&LTI$!'!6JII +!>2GX8/[  "#'8  >Q?%A)]U;4>_
MZIRS7O>Z8)I'4 JU#)AF0%NP)9==+WFL )=Y'$NIHY,A!CNFSH0W  "#'8
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MGJ,9@DJ0>I_Z<&B.@9S\7<F,PYI32C:+1I@_-26*%I>4&]&*+)+/  "#E8
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M?7]>>@J<EG\-:1^9[7[@5T:7>G[01#N59G[9+V*4!W[H%525>'\(  "$!(
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MO:A.=I*8TJ3Y9;:6#J'75!Z3E9]108>1@IX0+5B/Z9O@%#F0A(VL  " X(
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M.H5W;<.DJX2B7>NA38/Y31&>0X.!.P";M(,V)N":-8,M#3^;M8,1  " DX
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M,ZTJ:Y6A@JG 6Z.=]J:]2O^:Q:3Z.4Z8'Z+$)<B649F,#4.6H(CW  "  (
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M<HKA8ENM/HFP4U6I-XBM0W2EAH?P,C&BDX>>'I"A-(@K!O&?^H2Q  "  (
M??"T_I0&<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>
MHX32  "  (  ?9^T:9OF< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z
M'GZ?+I*G!TZ=>(3Q  "  (  ?6JSZ:/E;]BOCJ%089"K/9[-4H:G&YRI0JRC
M7)MP,9R@2IKB'F:>?)2-!WF<=H4.  "  (  ?3:SFZQ';]"O*ZE6882JP:9=
M4F2F@J/K0I"BK:+#,92?CY_S'G:=R929!Z";Q84H  "  (  <J_%2&S>9:7
MK&VT6!V\.6Z?2=.W[&^5.G6T 7"!*5.Q-'$M%):QZ7"X  "K*71[  "  (
M<J+$=W1P9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^I
MZ7CG  "  (  <J/#.GNX9:J^<GM%6":YM7K]2=:U)'KW.HBQ WL2*9ZM\GLX
M%6ZMWGL$ *.GTWTN  "  (  <I7![8+:98"])H'X5^>X:H%"2:BSTH#,.F:O
MK8"6*9RLBH"0%:^L,(#, 2&E^(#$  "  (  <G; THH+95^\!XC(5\"W18>V
M276RJ(;:.E&N<X91*9ZK1X9)%>VJKX:0 9&D58$/  "  (  <E&_^9%H94J[
M'X_+5[*V3HY426>QJ(TB.D&M;(Q>*:BJ(8R%%B>I6(N# ?&BZH%0  "  (
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M0X"!W71'*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6
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M-'U&4"F$N'UU.E&$<GV9(%6$]'V0  "#YGZ*J=&&]H9:F:2&#X6WB)"%/H4
M=HN$AH138WF#[8/#3UR#>8-).::#.(+C'\:#F(*X  "";X  J*6%PX_;F)B$
MX(Z*AX.$%XTB=6*#9XNV8F^"UHID3FN"=8E*..&",HAN'S*"9HA[  "!+H
MIZN$UYE^EY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!
M6(W=  " ((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R
M-\> =I2Z'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!*
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M!I28>S>+?I+$:C6*%)#P6%Z(U8]&16V'U(WQ,,N'*8U-%TF'K(P%  "  (
MF:2-[Y^"BH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&
MLH^-  "  (  F1R-:*C,B?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)
M+^:%O9HI%KZ%X8]A  "  (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>05I&'
M!J240]6&!*+V+X:%.)\=%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^: FPT
M8\27[VW%4H>6"V])/^R4AG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C@DB;
M$')1<SR8PW,Z8R:6HW0B4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (
MCYB<(7G9@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3
M+WLE  "  (  CL^:S((]@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"
M*=Z/XH"I#]*1DH"J  "  (  C@"9M(JH?\:768FY<+25'8C'8+23!X?>3]:1
M'(<,/9N/H(9Z*7>.P88^#ZV0%H5[  "  (  C568QI-'?Q>6>)'+< &4/)!
M8 J2'XZZ3S.0,XU@/26.GXQJ*2*-MHQ=#XN.P(F1  "  (  C,:8&)OW?IJ5
MSYGX;X*3B9?47WJ18)6Y3IZ/=9/Q/*6-XI+-*,^,V)+%#VF-G8IK  "  (
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MB'BB9R*@DWCE5^^=TGD]1[";5'F@-@"99WG^(>N8S'H5")V99WJG  "  (
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M&YZY9'Z<%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (
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M?7X66W>H\WW=332EE'W#/<>BF7W&+-"@:GW1&.>@6GV\ JR;^GZO  "  (
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MOJ,96BZD_*#02[BA79[)/'N>*9WS*^N;OIN3&-&:\I#( ZR5C()\  "  (
M:C*_ V:T7<Z[0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?
M!'.P  "  (  :>V^/6XR7<^Z.6[84/6V0F^<0T6R=W!N-%NO+G$Q(W.M2G&<
M#K6NZ'#F  "=P'@I  "  (  :<V\YW5D79VXVG6 4-6TSW6X0R:P[789-%&M
MD'9\(Y&KB':N#QRLR'8F  "<B7PB  "  (  ::B[<GQK76&W9GP>4(>S77OI
M0O*O=WO>-"VL%'OP(Y.I\GOX#V>JXGO8  ";:'^A  "  (  :7JZ,8-_736V
M(X+:4%:R%8)+0K2N*X'7-!2JMX&:(Y2HA8&>#ZFI,(&N  ":;(    "  (
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MW8 B@!=_IX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (
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M8JQN>_Q[(:C9:MYZY*4\6/YZTJ(=1AEZX* :,:]ZQIV?&+AY\I"W  "  (
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M4X97<_R&:X7#8_6%DH4=4O6$V82!0)R$7(0,+%N$((._$G>$Z(.&  "  (
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MJ(OO:#^.#XKT61B,B8GK20:++HC]-YR*)8A;(^N)P(AK"MF)9X84  "  (
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MS&OB8#2<?VU!4;F:76Z50@&8@&_2,*.72G#4'&:7SW$'!""6$''2  "  (
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MGI#$71666(^&3KJ4*XY(/VV20(U.+L20RHST&X:098RD!,>-*8,[  "  (
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MDW%S5)BDM'(W1MZB W,!-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (
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M)I3U4IR?,Y.?1/.<7Y)9-D"9])&S)>F889&\$H*8K8R#  "0)X    "  (
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M&G892/VMT'9A/ 2JJW:Z+:JH('<+'1>G,G<&":BG>G<X  "/OW\6  "  (
M8&BR]7S25.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".
MP8    "  (  8"ZQVH/Q5,>N@8.72*.K)(,J.YNG\8+!+6^E2(*#'26D$(*@
M"B>CS((Y  "-XX    "  (  7_VP_(L45+6MC8I]2)BJ'XF\.XNFX8D(+5VD
M,8BV'2NBWHD@"F6B2H:(  "-,X    "  (  7]FP5Y)&5+*LRY%^2)BI2)!V
M.X6E^8^)+4NC08]E'1BA[(Z\"GRA'X<7  ",G(    "  (  7\&OW9F@5+NL
M+)B]2*.HD9>!.X>E-):$+5*B;98M'3.A 9-."I*@(H<F  ", (    "  (
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M?HFQ!\%RY84^MUQ:>:!CI<Q=5IV>DVI?]9JZ@#%B<)?>;#UDWI4Q5VIG&I+
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MR)='?Q1M[I4_;?!O"Y,G6^YP+I$T2-QQ-X^(-%EQQ8YQ&Y!P78U8  "  (
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M,)S*= MTGIIX8^=U")@34M=UAI7S0*%V )1F+-IV!Y/^$_5U=XU^  "  (
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MQ7B7;+B!>'DJ782!,GFH30"!#7H>.R.!!WJ!)RR!,GJK#6:!T7I=  "  (
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M8*&L:2]\$Y\X6?9[O)RQ2=9[AYJL.'9[:YG@)29[#)<C#(I[7XAZ  "  (
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M6'Y$81F(:WYD4K"'CGYJ0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (
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MUH,^5=R02(+[2#N.RH*A.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (
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MCF3Q39.@;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (
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M&(=Y2R28\(;X/BB6W(9F+_J5,H8.'^:4;89$#*R4=(4-  "%SH    "  (
M8=6<7H\K5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%
M(8    "  (  896;RY;-5K^9KI8D2L67;)3O/;V5*).L+ZN32I-G'[&26Y'O
M#+^1[(B?  "$G(    "  (  62.QK5ID3AJO4ER-0F2M&5ZJ-9RK&&">)RRI
MXV(C%9.K86)H T6IMF-:  "(YW']  "  (  6'"P9V%]3;JMXF,;0B.K:F2Y
M-7^I+F8Z)SJGO6=@%>JHSV=P ]*FOVA1  "'H':R  "  (  6 BNDFAH34JL
M"VF00="IB6JT-3BG.&O.)QBEK&R:%@JF<VQ\!#FC\VUX  "&9WK=  "  (
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M,HK]0*JB@XIG-#*?_HG/)EV>(8G*%?^>$8DV!4V9JX.6  ""%H    "  (
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MWX@*=R9GIH=69O=I4X:,5=9J[87,0W]L3H4K+XALYX2_%NEL<H3   "  (
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M>8W>;$%MG(S#70)NJXN13,9OL(I[.TAP?HFF)_IP<(EI#RYR68=P  "  (
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M5FLI9<U\EVS85QE\W&YF1S)]+6_8-;Y]EG$3(>9^&'&V",5_AG&;  "  (
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M^Y+@87-T<Y%_4Q-TU9 $0Z-U.8[,,LMU>HXK']QTX(X-"&-WSH6K  "  (
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M"'$96?:"QW(X3$J"C',^/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (
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M8)="5M-\+)6_23M[UI0B.I=[C9,2*EM[29+_%U%Z=8^/ I!\H(&\  "  (
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MO'853IN)\7;"09Z)+G=0,V:(GW?((P.(HG?]#PR)4W>4  "!3GSE  "  (
M9/>)XGSP6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PO_XGT024-#
M7U!23T9)3$4  A*'$GVU  " &X    "  (  9%J(B(2+65*'YH1W36B'((0O
M0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "  (  8]Z'@(Q%60V&
M[XOE32^&'XLD0#^%+(H[,B^$9XFP(C:$!HH!#N6#H(?R  "  (    "  (
M8WR&L9096*V&(9-\3,N%39)3/^&$3Y$&,>.#<Y!N(@*"[9 J#MN"78H+  "
M (    "  (  7.">\57?4D*=65B?1L"<"%M%.?F:^UVX*XF:?5^^&DF;S6"X
M!H2<2F$$  "#HVU)  "  (  7 :<W5T=4:R;65]51C>9]&%Y.968P&-R*U&8
M%&4,&E"9$66T!M^8W67C  ""$'(Q  "  (  6U^:A61#4/69&V7\19^7O6>B
M.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "  (  6K:80&M:4#B6
MYVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4,V_.!RZ2L7 C  "  'ME  "  (
M6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W*@*1JW4M&922''4A!S&0*G7>  "
M '\N  "  (  67.4MWG(3P:3?7I#0[&2+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,
M!SN-^'O1  "  (    "  (  6/"3:X$33I:2/H$[0TR0ZH$C-NV/EX#L*2Z.
MI8#.&2".J8#K!U",'(#@  "  (    "  (  6(B27(A@3B^1.H@[0N>/YH?$
M-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "  (  6#>1CH_E3@F0
M<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,"(RA!W*)5(4)  "  (    "  (
M4*:J851-1F*HF%;2.TVG#5D]+NREY%MI((:EV5SW#I>HHUT(  "@"&!\  "
M '$N  "  (  3\:HE%LJ1<2FS%TW.K^E'E\R+H6CP6#W(%NC;6(K#L>ELF('
M  "=;&45  "  '7X  "  (  3SVF4V'O12VDEF...D&BZV48+A&A?F9Y(!.A
M!V=6#M&BX6<*  ":WFGN  "  'H\  "  (  3L>D"VBG1*.B66G>.:2@MFL!
M+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "  (  3DNB"V]Q1"N@
M:W!..3.>Q7$1+2N=3'&D'XR<I7'V#L"=V7&. #66 '4)  "  (    "  (
M3=>@:G9@0\J>TW;P..2=*'=5+.N;GG>1'UB:UW><#MB;J7=> '&3VGI4  "
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M!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2&/Q@38A)  "  (
MDX%-N)@:A7M1;99$=HA4Q91)9I%7VY)259U:MY"30XQ<^H\M,"Q=>(Y\&+E?
M.8SM  "  (  DO1,=Z&7A.U0-Y\$=?=3DYQ$9@=6JYF95259B)=)0RQ;QI6-
M+\E<$Y3[&%E>9I!V  "  (  D5AIK%-B@YYK3%<O=/-L\%K,91MND%XW5!!P
M(V%X0:QQF&2 +75RI6<)$]%SQF?'  "  ''DC\IEPUR^@E-GP%^W<[9IH6*)
M9 -K;V4W4QEM)V? 0-ANKFH:+,=ODFP"$V%PYVQ2  "  ':5CDMB*F8@@-UD
M<FA)<H]FC&I78NAH@6Q#4BEJ5FX70!9KZV_%+#ELI7$5$Q)N77$/  "  'JS
MC+=>Z&]N?U-A:'#7</YCJW(E8:%EQG-84/YGPW1X/QMI8W6 *W%IZW9%$I)L
M1W8,  "  'Y'BT5<#'BX??)>M7EI;ZUA('G\8&!C67IU4!!E;'KF/D=G%WM1
M*M!G:'N=$C1J>GMO  "  (  BA%9H(((?-)<:H(';J)>\H'?7V5A1H&@3R=C
M9X%D/9UE"X$[*DUE)($L$>9H]X$[  "  (  B1E7F8M/>^=:?8J>;<5=&(F\
M7I9??XC(3F1AKH?M//IC2X="*>EC)X;_$;-GL(9#  "  (  B%Q5]I2">S%8
M[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)$8)FJHIB  "  (
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M#&\W9P!JMG"A6)5L0''R2+UMKG,B-WUNS'0K)!=NX73+"TYS7G2S  "  (
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MJ)@@8MMAI99*5(1C9)1A12EDY9+6-'AEOI(;(<ED8I%1"FMN9(<+  "  (
M>/UY[E+^;01Z8E:/8 U[ %GV4==[L%TI0D=\:& ?,/]]06*N'.)^;&0C!(2
MZ63M  "  'D@=[-V8%M(:_5W*%XO7PYW\F#O4/]XN&.%091Y?67F,'1Z1V?J
M'(A[!6CQ!)M^*6FR  "  'S =GUS#6.7:K!T%V747?QU"6?S3_QUZFGK0+EV
MOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "  '_O=41P!6O?:7-Q.FU]7+IR3V[^
M3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "  (  =!-M5W0W:$MN
ML'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER>W@2&UAQ[G@B!*UX&7FS  "  (
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M>'IB4(AV'GK50YIVG7LE-7]V_WMD)7UW'WN2$==WN7M@  "  'X)  "  (
M9JYRR(&S6\MSO8';3_9T:X'%0PMTXX&,-.EU.8%C)/=U+X%D$:EUVH&)  "
M (    "  (  9A)Q28F:6S1R38E53V)S 8B]0H)S=(@%-&=SNX>+)')SB8>;
M$4MT:H;!  "  (    "  (  99AP%I&&6KYQ*)#J3NMQX(_;0A-R2XZS- MR
M?HX")"]R(8XV$1%S/XKP  "  (    "  (  8*:,;U&85@>+[53<2G>+J5?]
M/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "  'YP7X^)4EC^52N)
M$5N[2:J(WEY5//6(Q&"\+J&([F+&'<F)^6/X":2*J&/]  "  &XI  "  (
M7I^&06!C5"V&,6*82->&%V2O/"^&!&:6+@6&)&@I'6*&]6C]":.'46CK  "
M '-D  "  (  7;"#:&?)4S*#=VEZ1]6#<6L-.V>#:FQZ+56#B6V<'..$)&X8
M"8:$9VX,  "  'A;  "  (  7,: Z&\]4DZ!$G!Q1O2!''&%.HN!%7)O+,"!
M)W,M'&>!CG-C"6&!XW.*  "  'RL  "  (  6_1^QW;$48A_"G>%1CU_'W@<
M.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "  (  6SQ\\'X]4-=]
M3WZ219E];WZT.4=]9'ZW*YM]3WZZ&]%])'[$"8U]TG\S  "  (    "  (
M6JQ[>87+4'1[^87.149\&X5X.09[\83]*V][MH3#&XU[6H4;"5)\7(/?  "
M (    "  (  6CMZ2HUL4 5ZUXTK1-EZ_XQM.*=ZS8N2*R=Z=8M(&V)YV8LR
M"4Q[*H9)  "  (    "  (  5*66W% ]2HR5\5-5/XF53U9*,R:5 ECZ),^5
M=UL6$N^84ENH 8*4I5V-  "  &T4  "  (  4YZ3_5<_2;R31%G@/L62IUQ=
M,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "  (  4LN1#%X_2-R0
M>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1I&6. @:-RV=G  "  ';D  "  (
M4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA(U2- 6K0$DJ.DVJ= A^*\&RD  "
M 'L\  "  (  43F+R&Q51T2+:6V6/&N*]VZU,'2*CV^>(N.*BG ]$?Z+OF_F
M BV(>'):  "  '\&  "  (  4(*)JW. 1IF)9W1<.]*(_74-+^J(C'6/(FF(
M:'77$>*)'W6( D6&57A*  "  (    "  (  3^*'XGJI1@R'N'LM.UB'5'MU
M+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "  (  3V"&8X'$18B&
M4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%&('# F&#$8%U  "  (    "  (
M3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4(>V#@X@:$>2#'8<D M>!M('L  "
M (    "  (  2%BB<4Y?/M^A/%%"-&F@9U/V*%F@*%9.&<.A<U>_"*.C&UAE
M  "1E%_D  "  '!Z  "  (  1T>?YE3^/?B>[%=W,WB>&EG%)X^=KUN\&46>
MH5S8"*>?<UU9  ".W&1^  "  '51  "  (  1IN=#5N=/32<+5VL,L*;;U^.
M)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "  (  1@>:/&(Z/(29
M;V/<,?:8O&56)D"81V:+&$>8[6<&"("83&=?  ")WFY\  "  'V   "  (
M1627N&CH.]V7#&HI,5Z66&M ):B5TFP*%_N63&Q+"'65#VRO  "'QG0O  "
M (    "  (  1,65DV^^.TJ5"G"G,.246W%?)4R3OG'3%[B4 ''0")*2*7)D
M  "&$'EG  "  (    "  (  1#N3PG:<.L^36G<Y,(*2KG>6)/B2 7>\%VB2
M'G>9"(*/TGB;  "$LGW*  "  (    "  (  0\F207V0.FV1]GWM,#*13WWX
M),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "  (  0X"1!(3&.B60
MSH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8    "  (    "  (
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MN'Y-;WI-Q'YR8&91=GZ,4$Y4OWZI/O17'7[4*_56P'\)%(=>9']8  "  (
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M/(1X95M1RH095QA4^(.P1\!7I8-9-QE9)H,I)*98D8-$#3QIH8,3  "  (
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MHXFY6S96GHCX3;-9*H@G/P=;%H>&+MY;?(=!')U<Y(?%!M-T>(2=  "  (
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MQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI /-^97&6  "  (
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M (XS4/=<7HTV1")>,HPB-B!?/XMJ)F=>88N)$[!D.(GS 0]^-8"X  "  (
M9.-Z#$U:6=QZN%#X3@=[B%2"00-\9%?=,G1]3%K;(91^@%T-#,R H%UX  "
M &6=  "  'NT8T5UPE3?6*AVP5@"3/UWNEL%0"IXI%W8,<AY@F!3(1QZ9V(1
M#+1\K&(]  "  &I(  "  '[T8?%QIUR#5UUR[E\72^YT$F&0/R]U#V/7,/IU
MYF70((%V>&<>#'QY06<:  "  &]6  "  (  8+!MU60R5AMO468T2K!PEV@=
M/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "  (  7X1J7&OH50-L
M!&U?2:1M:6Z\/2QNBV_S+WAO3W#Y'TMO'7&("_YST'%N  "  'FR  "  (
M7G9G1G.R5 9I&72D2+YJG'5T/&IKQW8B+L]L=':P'P-KVW;]"_1QF7<?  "
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M5WA_3E-\381_U5:*0GF 8%EQ-BR \5P;*!.!L5Y)%O&#,U]#!(V$"&!N  "
M &WQ  "  (  5DA[6EJS3%1\'UU 07M\R5^J-3Y]7V'7)U-^ F.1%FM^^V0O
M!(J MF56  "  ',D  "  (  52MWHF'U2S%XDF/]0%9Y567D-%AY]V>:)HAZ
M?VCF%=-Z^&DO!'-]W&IO  "  '@@  "  (  5!IT.6E'2BEU4FK./U5V+VPV
M,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "  (  4R9Q+'"K24-R
M;W&[/H1S9'*F,J%T!G-G)3=T/7/K%05TAW/3!&)Y0W7?  "  (    "  (
M4E%N=W@*2'-OYWBI/<1P]GD:,?5QEGEK)*%QFWF?%*)R)GF !)!X2GMS  "
M (    "  (  4:9L)W]T1^]MS'^X/5AN]W^Q,:AOB7^-)&5O4G^)%$)P.G^P
M!%QXHH G  "  (    "  (  425J/X;R1V]L 8;I/-QM089X,3EMSH7S)!%M
M9(7;%!!NI(6X!%%XM8+K  "  (    "  (  3.^-H$K70V"-:DXV.-6-@U%I
M++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "  (  2Y.)RU&40CB)
MYE2+-[6*%U=0*\6*?UF^'9F+F%ML##F-%5O6  "&3F#?  "  '&.  "  (
M2H6%^EAG01R&2UKI-KR&E%T\*M>&\U\['-R'U&"$"^2(GF"_  "#5&6Z  "
M ':(  "  (  28V"5%]'0!>"R&%/-:N#(V,K*@&#@62_'""$,66K"XB$MV7"
M  " JFK>  "  'KK  "  (  2)M^\68\/R=_CV?.-,)__FDW*1Z 3VI7&Y6
MP6KX"SN!8&K]  "  '!Y  "  'Z^  "  (  1[I[XFU,/DU\L&YP,_Y]-F]H
M*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "  (  1OAY,71=/95Z
M+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\-G9L  "  'M'  "  (    "  (
M1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P &?IXA'O["FUZ;WRM  "  ']X  "
M (    "  (  1=-TVX*\/(=V1(+@,F]W((*?)SIW.8)+&B1V<H);"LYXM8(&
M  "  (    "  (    "  (  0)F914BK-[*8K4OE+:.8E$[4(:J945$[$GF<
M,E)3 U*9OE1@  "$LE^*  "  ' -  "  (  /S>5O$\$-E25CE'9+"R5F51B
M($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "  (  /D&2%E5X-3J2
M&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0SUXN  "  &DC  "  'ET  "  (
M/6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H#_^0UV$J JJ-!F,Z  "  &Y6  "
M 'U8  "  (  /)J+%&*:,W2+:60F*42+K65T'9F,(F9+#Z>-$&9G IF)Q6B'
M  "  '0$  "  (    "  (  .\N'\FE=,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)
MI&O6 J:' VXP  "  'D[  "  (    "  (  .Q6%*7 I,?2%_G#O)_B&=W%Y
M'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "  (  .GR"NW<*,5V#
MSW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (    "  (    "  (
M.@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!B'[_  "  (    "
M (    "  (    #__P  __\  /__  !M9G0R      0#"0   0
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MC,HHO(8?AMF9K+)L=&F+/*W'=/I\G:DZ=:UMOJ2S=HQ>L* :=YU/HIM@>.)
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MDGYGJK4$D E;#:Z!C<).H*?6BYA"E*#\B8,W2IGFAW4M!Y*,A7LD:(L6@ZJ
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MCGDTH91_)WG+G*9JP7J$EZ56F'M6DFU"JWQ7C-DO5WV!AI_..7>\NFBZ[W@
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M!'64E;9YIW:GDGYF.G?=CT-3&'DUB_! .GJZB%4N(7QUA$;#W7(:J3*QUW,
MI3J?,W/AH0N,%G38G,=XT77XF(1EB7<^E#!2CGBBCZX_WGH^BN M]'P+A8W#
M)W&)LP6Q'7)OKBB>:W-+J/B+3'0_HY]X$'5FGD9DY7:]F-I2%'@QDS$_CWG8
MC2HMSGNTAJ;"KG$JO*6PEG(,MMF=S7+<L)R*H7/&JB=W;W3MHZYD779,G2%1
MHG?.EE,_/7F%CR0ML7MNAY"]8()[:U*LW8(>;3^;B8'<;PN)7H&N<,AVK8&,
M<I1CR(%X=']1$8%R=HL^AX&->-TLLX'8>YN\28"V=1NKR8"'=@":8X!?=MJ(
M2X!&=[9ULH [>*)B[H!$>:=06X!=>L$^!(":? 0L>8$&?8"[)G\7?MFJC'\&
M?L:96'[Q?K"'-G[O?J-TN7[[?JMB''\@?L5/M']:?N8]D'^\?Q0L1H!)?TFY
MTWVMB'2I-GVEAX67YGVDAHJ%]WVTA9%SG7WAA*]A,'XE@]1._WY[@O0]&G[Z
M@@0L&7^B@/*XDGQ_D?RG]GQ_D#F6JWR+CF"$S'RJC'MRHGSDBIQ@7GU%B,A.
M8GVUAMX\MGY/A,PK\G\1@G:WAGN3FX&F['N:F.J5IGNIEB>#TGO0DT]QP7P6
MD'-?HWR C9)-V'T*BIL\77V\AV,KTGZ5@]"VKWK8I.ZF$GKDH7^4R7KRG<V"
M^WL;F?=Q 'MNEAU?!GOFDC%-97QXCAX\%7U B<(KMWXMA/ZV#'I+KCBE9GI:
MJ>V4$7IDI42"0WJ(H&9P4WKAFX)><'MKEHI,]GP*D6 [UGS;B^ KH'W7A@&U
MH7GLMU>DYGG\LBJ3>GGZK'V!I'H4IHQOPGIKH)1=^7K[FHA,EGNJE$8[DWR+
MC;$KCWV3AM>O9HL[:K*@3HGT;*B068C@;GY_@X?N<$=N*8<'<B-<H(8I="-+
M5X51=DDZ0(20>+LI^X/L>YRNBHF2<^J?:HA_=.F/78>$==Q^E(:?=M1M3X7(
M=^%;XX4 >0E*N81!>DHYV8.=>[LIYX,3?6VMDX@*?/^>2(<3?2..6X8E?3Y]
MD856?6)L;X24?9E;+(/F?>5*+8-$?CLY@H*_?J0IUH)2?R"L@H:EA@N=*(6Z
MA6"-*83AA*%\F(0>@^=KEH-Q@T1:A(+;@JE)L8)8@@TY-8'V@6DIQH&H@+&K
M8X5_COZ<+(2:C92,+X/-C M[C(,6BG%JK8)ZB-Q9OX(#AU5)(X&6A;PXYH%*
MA 0IN8$6@ARJ=H2=E_&;.8/ E<"+/X+UDUYZKX)#D-UIZ(&QCEA9(H$^B]-(
MLX#IB3TXI("VAF\IKH"8@U^IMH/JH,>:=H,5G<V*>X)(FHIY[H&7EQEI.8$.
MDZ-8F("GD")(68!4C(,X;X XB*(II8 PA'>I)8-DJ8"9VX*5I;B)U('#H8IY
M2($)G1QHGX"#F*I8#( NE"A'\W_ICX8X07_2BI<IGG_;A66HQ(,&LA>99((\
MK7V)18%@J%5XLX"8HMQH'H .G6)7J'^^E]U'J'^)DC0X$G^#C$,IF'^6ABFA
MY904:DZ3[Y(";#^%+9 M;AAUG(YV;^QEEXS!<=55;8L)<^9%EHE,=AXV"8>7
M>*8G=H7I>YNA-9*:<P&3/I"U= B$98[N=0MTX(TZ=AEDZHN-=S]4VHGF>(5%
M'X@]>>8UQX:?>WXGB(4(?5F@;)$I>XV228]@>\6#AHVC>_YT 8O_?$5D*(ID
M?*-4/(C5?1A$JH=$?9PUC(7 ?CPGEX1 ?O>?>H_;@^^12(X9@W*"=(QN@NYS
M)(K2@FIC9(E0@?M3I8?8@99$0X9?@30U683W@-4GI(.1@'*>E8ZTC%B07(S_
MBR.!BXM?B=MR0(G/B(5BM8A0AS93&8;QA?-#Y(61A*0U+(1#@T,GL(+Z@<B=
MS8W:E+^/J(PNDM. VHJ.D+UQA8D CHYB!8>+C%Q2D(8PBBI#A83DA^HT_8.L
MA8(GNH)Z@O6=*8TOG0*._(N*FEN +8GHEW)PWHA9E&)A<(;LD4Q2&H69CBM#
M/(1-BO(TVX,KAXDGPH(0@_B<J8ROI1R.=8L0H;9_G8EHG?1P4H?1F?E@[89F
ME?51IH4BD>)"[(/?C;8TOH+!B5,GR(&YA-.<3XQ3K1..#(JWJ.Q_(XD'I$%O
MU8=EGTQ@@87TFE%14X2TE4E"K8. D"8TF()SBM8GS8%SA8>4XYTD:?V'VYI=
M:^1Z+9?(;;]KUY5#;YY=()*R<99.59 0<[@_\8U;=@$Q^8J9>)LE*X?)>Y>4
M59O=<C.'6)DP<SUYF9:<=$YK3902=7!<I)&#=J]-[X[M>!(_IHQ&>9(QXHF7
M>TPE88;;?463MYJ!>CB&E9?K>H)X[I5;>M-JH)+<>SM<$)!;>[Y-?(W9?%P_
M6HM'?0PQS(BO?=\ED(8*?M"2^YDZ@A>%Q):N@;5X#90M@5-IZY&U@/];<(]*
M@,!- XS=@)$_#8IA@&@QM8?@@$PEN854@#B2.I@LB>"%"96FB-IW4I,MA\II
M+)"]AK9:Z(Y0A:9,F(OYA*8^S8F1@YXQI(<H@H\EVX2W@7F1FI=(D;.$9Y30
MD -VL9)9CC1HF(_IC%!:8XV!BFM,08LGB(H^F8C4AJ(QE8:&A*(E^80S@I.1
M%9:AF6.#]90PEPMV/Y&RE'1H'(\ZD;E9Z8S9COU+XHJ+C#T^9X@XB6\QAH7^
MAH F$8/&@X20JY8GH.:#AI.XG=]URI$TFGQGJHZREN19@(Q2DTI+A(H0CZ<^
M*8?$B_8Q>860B"(F)(-LA$^0797.J#^#+Y->I(9U9Y#1H$MG1HY%F\M9*HO@
METE+1(FADL$]^X=CCBTQ8X5 B8 F-(,EA/2(@*9L::=\4:+X:X%OHY^E;5UB
M=IQ);T=5!9C*<5!'E94I<X4ZH9%F=>(N.XU_>) C(8F >Y.($J57<6Q[_*'H
M<G-O1YZ"<XUB(YL6=,-4O)>4=AQ'7Y/[=YTZA)!#>3XN3XQO>QPC>8B$?3&'
MH*0*>/)[:Z"J>45NS)U$>:MAJ)G=>C)45Y9F>ME'%Y+>>Z(Z8(\X?( N7(MZ
M?8<CQH>H?JR'%J+$@$IZS9]L@ !N()P2?[]A()BR?Y93XI5-?XA&QI'8?X\Z
M-XY'?Z,N98J@?\LD"(;I@ *&A:&SAY%Z/)YCAJ]MBYL0A<M@C)>SA.M3>911
MA!Y&=Y#P@UXZ$(UQ@J N;(G@@>8D0(9&@3*&!:#ACLYYPIV7C51M%9I!B\-@
M&);DBBA3$I.#B)!&/9 <AOXY]XROA6TN<XDX@](D;X6\@CN%HJ ME>9Y7)SK
MD\]LK)F4D8E?LY8VCRI2O)+9C,E&!8]XBF4YZHP"A_TN?HBEA8@DEH5+@QR%
M4)^VG-=Y+)QTFBEL>ID.ER!?=)68D^52>I(VD+!%PX[IC7\YOXN%BDTN@8@P
MAP@DM83O@]F%$I]AHYQX[IP5H$ML-)BCG'=?*Y4DF&)2/9&^E%=%F(YSD%(Y
MIXL?C$\N?H?;B$8DSH2EA')\OJ_K:3]Q2ZO7:PMEBZ?";.A9?*.";M]-2)\$
M</Q!+YI,<TDUIY5C=;\JSI!$>(0A5XL,>XU\;:\#<)UQ):K8<9UE:*:=<L%9
M8J)"= M--YV[=8%!+9D*=R4UNY0L>.LK"X\?>NXASHH!?1]\):V_=ZQPR*F9
M> 5E'Z58>'Q9&J#\>21- IQ]>?)!$I?<>N@UP),/>_DK/8X:?34B-HD9?HM[
MSJQQ?H1P7JA1?DUDJ*09?BI8PI_$?BQ,N9M5?E- Z9;&?I,UO9(-?N4K9HTR
M?U0BCXA0?])[<*M5A4EP *<\A(ID1Z,(@]-879ZV@R=,>II*@IA P)7/@A\U
MMY$I@:PKAXQG@4DBVX>E@/-[&:I^C 9OLZ9EBKYC_J(LB618%IW8B E,.YEO
MAKM H93RA7TULY!>A$4KHXNV@Q$C&H<6@>UZT*G7DI9O>:6[D,-CQJ%ZCL%7
MW)T?C*U,!)B[BJ- @Y1%B*(UMX^LAJ4KO8L=A*8C3H:A@L%ZGZE/F.]O2Z4O
MEHICDZ#HD]U7J9R(D0Q+U9@DCD) 5Y.\BWPUJ(\EB, KUXJ<A@4C>(9!@W%Z
M=*CYGR9O3:3)G#ECCZ!LF,=7CIORE1=+PY>"D8) 5I,?C@ ULXZHBI$KZ8I
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M@9,F;H&F@,B4:X;)CH^'8X71C5IYH(3>B^QK28/VBE9<SX,IB+Q.6H)\ARE
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M'VKYDO!L+&UAD!9;-V_^C31*K'+*BCHZAG7CAQ,K>WD[@ZBLT&-XI$"=3V7
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M?JDQ0HOZ?OLJ7(CX?V D(H8^?\(?)H/9@!98M9DO@WI0YY;G@UM(WI0X@NY
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M)E,!C7"+ E</C#Q]/UK[BN)NY5[WB71@/F,PB A1E6>NAIU#;FQLA3 UQW&
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M>#PG$WN8>U.1!V%T<&&$GV1 <>-WE&;T<U=I^6FT=,);W&RH=C5-MV_3=[]
M"7,T>6(RZW;C>S$G*GK!?2Z/K5[I>2Z#6V'J>>MV9F35>I!HXV?,>R5;&&KW
M>\!-&6YG?&P_I'()?28RPW7U??@G/GH(?MZ.CUS&@>2"4E_R@=MU=V,)@:QH
M"68Q@6=:66F,@2),F6TK@.D_4G$&@+DRH'4I@(LG3WEK@%V-J5K^BFF!>UY-
MB9ATL6&&B)%G5V34AVU9NFA=ADE,(6PHA2D_%' JA PRBG1]@N(G77CH@:N,
M^5F0DJR U%SZD1)T$&!,CR]FQ&.UC2=9,V=@BR%+JVM5B1P^R6]]AQ0R='/O
MA/4G:7A]@L:,?UA\FI6 65OYF#=SD%]9E79F2F+2DH98T&:2CYM+9&JBC+(^
MBF[LB< R2W."AK8G<G@G@[&*!W*V58!^3'/>67%QYW4I74]DT':.82-71G@+
M90A)IGFL:1D\>GMU;6$OUWV%<A$D@7_4=T>(N6]/7@5]-7#982]PY7)L9$IC
M]70.9V)6EG7-:HI)(W>W;=<\)WG+<5(OPGPF=2(DMWZU>5:'?6PT9GM[\&X.
M:.-OWF_>:S]C!W&^;9=5VG.^;_U(FW7N<H([V'A*=2HOKWKL>!,DYGVX>T"&
M-FEB;N-ZL&M]<(UNKFV(<B=B-&^><[Y5+''?=5I()711=PX[FG;Q>-TOI'G5
M>MHE#WS<?0*$_6;U=S%YI&E">"5MK6M_>/]A+VW&><E4<' \>IE'BW+P>WP[
M.77,?&XOA'CH?7HE,GP=?IF#^F3J?V=XKF=>?Z1LS&G"?[=@9&PW?[)3PV[9
M?ZY'''&W?[<Z]G3*?\LO<'@;?^4E3WM]@ "#*6,VAVEWZV7*AN]L&6A-ACA?
MPFKDA5]3,VVOA(=&LG"W@[0ZR'/M@N@O9W=L@A0E:'KW@3>"AF'5CRMW462$
MC?MK@V<>C'9?.FG-BL12MVRXB1-&1F_GAV8ZAG- A;TO6W;<A $E>WJ*@C^"
M$6#'EIMVW6.*E+QK"V8RDF=>R&COC]=26VOMC4I&!F\VBL(Z3G*PB#@O.79O
MA: EBWHS@QA^TGI\59]T!'L!67UHFWNP75%<CWQS8250('U#91!#J'XL:2HW
ML7\T;7LL5X!U<C0B6('G=U]]IG=*79US$W@K8,=GOWD68^A;W7H-9PU/EWL6
M:D=#2WQ ;:DWA'V+<3HL8G\1=1\BI("]>5A\C'1298]Q\G6 : 9FTG:F:G=;
M"'?3;.A.\'D8;VU"UGJ$<A,W1WP1=-XL8WW5=^DBYW^W>RQ[<'&D;6=PV',*
M;S-EO71E</1:1G7#<K).37=(='Q":GCQ=E\W$GJ^>%XL9'R^>HHC(7[3?-=Z
M7&],=35OTG#B=E1DSG)J=V!9;'/V>%Y-T'6H>6="$7>->H,VZWF2>[$L;'O)
M?/LC4WX/?E=Y<6U9?.]O$&\7?6AD(W#!?;I8P')S??--,W1-?C%!K79:?H$V
ML7B0?MTL87KZ?T(C?'UJ?ZAXL6NWA'1N6FV3A$5C?&]:@]E8*G$L@TM,KW,I
M@L!!3W5<@D VC7>R@<@L8GI(@4PCGGSA@,MX&FIDB[5MS6Q:BN%B]6XVB;57
MLG =B%M,0W(WAP- \'2.A;(V6'<$A&HL8GFU@Q8CNGQR@<%WJ6E<DJYM8&MF
MD3MBAVU1CTU73&]%C2!+\W%PBO5 O'/>B-0V+'9UAK<L2WE'A)4CSWP9@HIS
MS(*,59IIWX)Q66=?;()[7314;(*/80U)&X*A900]T8*_:3 S%H+Q;9$I"X-/
M<E0@8X/4=W-ROG^271QI#'_*8$9>KX &8V]3V8!#9J5(LH"$:?8]E(#;;70S
M"H%)<1\I-('C=1L@QH*=>5EQRGR^9)!H$GT\9Q9=YWVL:9U3)WX9;"Q(+GZ0
M;M(]07\B<9XR[7_,=) I4("@=[\A&X&->QAPTWHM:^YG&7K>;=5<]'M];[=2
M=7P;<9Y'GGS+<Y8\XWV7=:LRQ7Y[=]PI8'^&>CHA98"A?*YOZ'?R<SAF07C-
M=(-<*GF4=<!1LWI;=O9','LS>#D\EGPW>90RIWU0>P$I<GZ.?(DAI'_6?AEO
M%'8+>G-E?7<.>R%;>W?W>[!1)GC>?"Q&O7G;?+ \:7L ?4LRFGQ(??,IA'VX
M?J4AV7\L?U=N9G1X@7YD\'6@@95; G:B@7)0MW>=@2]&5'BZ@/4\''H#@,PR
MAGMH@*\ID'T"@(TB!'Z?@&AMW',RB$ID;W1SA\E:B76*AO%03G:7A>Q%^G?,
MA/$[SWDVA ,R7'JV@R(IF7QL@C@B)WXM@4UM<G(PCM)D"G.%C<!:)W2LC#!/
M^'7&BF-%NG<)B*$[J'B'ANTR0WHEA44IDWO[@YLB0WW1@@AI((KD55Q@#(HC
M61Q6C8E]7.E,F8C08,U"98@/9-HX28=-:2 NR8:6;9LF"87_<F\>J(61=X-H
M+H@@7&U?5(>J7YE5Z8<J8M%,'8:;9AY"%H8!:8XX*85O;2\NVX3K</TF382*
M=14?'X1->5AG7X5L8VM>?X4S9@-5083B:*-+BX1]:U=!L802;B8W\X.V<2 N
MVH-I=#TF@8,_=Y4?AH,R>P1FD8+P:E-=KX+D;%A4=(*];F!*^(*%<'=!/H)/
M<J,WLH(I=/ NS((2=UDFIX(<>>P?WX(]?(AEQX#'<2Q<\8#C<J!3PH#@= U*
M5X#*=7I WX"^=P W<X#+>)XNNX#F>DXFQ8$@?!D@*H%L?>%E$W[U=_)<37\U
M>-93,W]/>:-)V7]8>F9 >W]J>S<W4G^4?!\NMW_<?14FX8!%?A8@:8"\?PUD
M=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q% )'Y0?S W*'Z8?U\NT'[T?Y\G!'^)
M?]P@G8 K@ YC^WPHA-];:GRTA*]2<7S[A"I)/GT<@WM "'U5@N$W!GV_@ELN
MM'X]@>HG%W[O@6L@QW^U@.5CFGLJBP5;#WO*BD]2'7PCB1I(^7Q1AZP_VWR5
MAE4V\'T.A18NL7VF@^HG)'YX@K<@Z']7@91>XY.(5-E6GI(56)-."I"J7&9%
M'8\E8&$\!(U^9(XS%(O(:/HJRXH6;9@C38A_<H4=)H<<=Y!>")#[6X-5]X_&
M7K=-=XYV8@-$L8T&97 [R(MY:0DS"HGJ;-@J]HAD<-(CJH;^=0P=KX7+>55=
M6(YG8A5518UD9,-,ZXP]9X-$.HKO:F([?8F-;60R\(@N<)4K$(;9<^<C]86G
M=VP>)H2E>O)<L8O[:))4FXL@:KA,0XH>;.M#R(C[;S8[*X?(<:$RS(:;="XK
M'85Z=M8D,(1[>:,>C8.H?&5<#8G:;P-4 HDF<*)+MXA%<D5#2X=!<_$ZZX8U
M=;XRJX4X=Z<K)(1&>: D88-W>[ >XX+0?:Y;=8@+=6%3>X=^=GQ+1X:Z=XA"
M[X70>)4ZIH3@>;8RGX/_>O8K,8,W?$ DB8*7?9 ?*X(;?LQ:\H:'>XU3#88?
M?"=*[85S?)A"J82;?/XZ;H/#?7<RA8+^?@@K1X)-?J<DL('8?SP?9X&%?[]:
MAX5&@7!2I83]@8%*CX1H@51"7(.B@1(Z-(+=@.4R4((W@,HK/X&3@,0DVX$R
M@+ ?EX$,@(I:,X1(ATA2@80GANM*>8.FA@E"7X+/A/0Z8H'[A XRH(%:@TTK
M?(#?@J4D_8"R@>H?O8"L@2]4W)R&5"--BYI:5]=%^Y@@6Z\^'Y6N7\ V)I+^
M9!8N8) U:+$G18UM;7P@[XK,<HH;THA^=YI4!)H\6FI,WIA37:=%598J80H]
MI).Y9)XUZ9$/:&@N88Y=;&PGA8NU<)4A88D_=/<<;8<@>5)3?9>_8)1,3)7\
M8UI$V9/]9CT].9&G:5(UK(\A;(TN6HR9;_LGMXH?<X4APH?<=SL<\H7O>N%3
M")529J-+R9.O:.Q$3I'0:U$\W(^H;=HU<HU0<(LN3HKZ<U\GVXBS=DHB$(:F
M>54=9(3I?$92B9,I;*5+3I&S;G1#YX_N<%,\@XW><D4U3HNS=&0N28F+=J(G
M]X=W>.LB4(6:>T8=Q80*?8%2#9%4<J-*XI +<_A#EHYC=4H\38QI=J8U+XI4
M>!\N5XA)>;TH&(9A>V0BA82T?0T>%H-0?I)1H8_*>'5*B(ZL>5%#5(T;>A \
M'(LT>L\U"XDV>ZHN4(=&?*$H.X5S?:8BM8/R?J >6(*W?WE12HZ'?AE*08V-
M?GI#'XP2?J$[_8HU?KHT^8A%?O0N.(9U?T4H.(2Z?ZHBW8-0?_\>CH(Z@#E1
M$8U_@YM*#8R@@WU"](L]@P [Y8EK@FLT_8=_@?PN486\@:DH5(0;@6DB_8+1
M@2 >N8'7@-6B-5:;3ZJ3Y%HI5".%0EV_6)AV'6%X70MFAV5H88=6QFF:9B-'
M9FX*:O8X=W+:<"TJQW?[=@2@*%'*69^2357:73"#X5GL8+IT[%X89$-E?6)\
M9]15ZF<C:X5&OFP-;V<X&G%8<Z<JSW;J>&R>34UQ8XN0DU'Y9BB";59W:,-S
MEUL+:V)D7E_5;@Y5!F3J<-A&'6I$<\HWR'  =PLJUW7X>K&<=TF#;56.XDY\
M;P6 UE-8<+IR5%A(<G)C2%UY=#A4+V+R=A=%C&BS>!4W@&[4>D\JWG4B?,Z:
MM$7^=ON-8$M@=\E_@E"<>)MQ&E7@>6UB;5MF>DM3?6$_>SQ%$V=;?#\W1&W3
M?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y @%1P/%/7@$)AJ%FG@#12_%_)@#1$
MMV8W@#PW%6SZ@%,JZ'/-@'F7XD!,B;V+#49AB,)]I$P^A\EOD5(;AM%A#U@Q
MA=Q2@UZ5A.I$=&5!@_<V\VQ#@OPJ['-*@?Z6WSX?DK.*.41ZD,9\_4J6CN!O
M#U"KC0-@HE;ZBRM2'UV9B4Q$+&1]AV(VV&NMA5XJ[W+>@TN6*#QUFR&)GD,
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M?[<HGG8A@!F.#T@4APN"!DUCAFAU;5*0A;)H.U?-A/5:L5U'A#U-)F,*@XU
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M<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/ ='I;#&<F==9/26K
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
M>:N]OWBRO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO?^<.!K_FD8M_Y=10?^:4T_^G%5>]9Q:;.R;7WKDF6>'W)9Q
MDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS >:N]
MOWBRO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO?^<.!K_FD8M_Y=10?^:4T_^G%5>]9Q:;.R;7WKDF6>'W)9QDM63
M>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS >:N]OWBR
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO?^=.!K_FD4N_Y=00?^;44__G51=]9Y8:^R=77GDFV2&W)ANDM65>)S0
MDH&DRX^)J\>-C['%B9.UPX67N,*"FKK!?YZ[P'VBO;][I[Z_>:V^NWBQOK9Y
MLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFR
MOO^=.!K_FD4N_YA/0/^=4$[_GU)<]J!5:NV@6GCEGV"%W9QJD=:8<YO0E7VD
MRY*%J\>/C;'$C)&VPH>5N<&#F;N_?YV^OGVBO[UZJ,"\>:_!M'FPP;!ZL,"P
M>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP/^=
M-QK_FT4N_YE.0/^>3D[_H5!;]Z)3:>ZC5W?FHEV#WI]FC]><;YK1F'FCRY6"
MJ\>2B;'$CH^VPHF3NK^$F+V]@)W O'VCPKM[JL2T>JW$K7NNPZI[K\&J>Z_!
MJGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP:I[K\&J>Z_!JGNOP?^>-QK_
MFT0N_YI-0/^?34W_HDY;]Z11:.^E577GI5J"WZ-BC=B@:YC2G'6AS)E^J<B5
MAK#$DHVVP8R1N[Z&EK^\@9S#NGZDQ;=\J\>M>ZO&IWRMQ*1]KL.D?:[#I'VN
MPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNPZ1]KL.D?:[#I'VNP_^>-QK_FT0N
M_YM,0/^@3$W_I$U:^*9/9_"H4W3HJ%> X*=>C-JD:);3H7&?SIUZI\F9@Z_%
ME8JUP8^/N[V)E<&ZA9W$MH*DQ[" JLBG?:K(HGZLQ9]_KL.??Z[#GW^NPY]_
MKL.??Z[#GW^NPY]_KL.??Z[#GW^NPY]_KL.??Z[#GW^NP_^>-QK_FT0N_YQ+
M/_^A2DS_I4M9^:A.9O&J47/IJU5_XJM;BMNI9935IFZ=SZ-WI<J?@*S%F8:T
MOY.,O+B-D\&RB9G%KH:AR*J$J<FA@*G*G(&LQIN!K<2;@:W$FX&MQ)N!K<2;
M@:W$FX&MQ)N!K<2;@:W$FX&MQ)N!K<2;@:W$FX&MQ/^>-AK_G$0N_YQ*/_^B
M24S_IDI9^:E,9?&L3W'JKE1]XZ]9B-VN8I'6K6N:T:IUHLNE?:O!G8.TN9:)
MO+*1D,&LC);&IXF=R*.'ILJ;@ZC+F(.KQY:$K<66A*W%EH2MQ9:$K<66A*W%
MEH2MQ9:$K<66A*W%EH2MQ9:$K<66A*W%EH2MQ?^>-AK_G$,N_YU)/_^C2$O_
MITE8^JM+9/*N3G#KL5)[Y+-7A=^T8([9LVJ6T;%UGL:H>ZN\H(&TLYJ'O*R4
MC<*FD)3&H(V;R9R+I,N6AZC+DX>KR)*'K,62AZS%DH>LQ9*'K,62AZS%DH>L
MQ9*'K,62AZS%DH>LQ9*'K,62AZS%DH>LQ?^?-AK_G$,N_YY(/_^C1TO_J$A7
M^ZU)8_.P3&_LM%!YYKA6@^&[7HO:NVJ2S;1SGL&K>:JWI'^TKIV$O*:8BL&@
ME)'&FI&8R9:/H<N1C*C,CXJJR(Z*K,:.BJS&CHJLQHZ*K,:.BJS&CHJLQHZ*
MK,:.BJS&CHJLQHZ*K,:.BJS&CHJLQO^?-AK_G$,N_YY'/O^D1DK_JD96_*Y(
M8O2S2VWNN$]WZ+U5?^'!7H;6P&R.R+=QG;VN=ZJRIWVTJ:&"NZ&<B,&:F(_&
ME):6R9"4G\N,DJC,BH^JR8J.K,:*CJS&BHZLQHJ.K,:*CJS&BHZLQHJ.K,:*
MCJS&BHZLQHJ.K,:*CJS&BHZLQO^?-AK_G$,N_Y]&/O^E14K_JT55_+!&8?:V
M26OPO$YTY\)5>]_(88#1PVJ-Q+IPG;BR=:FMJWNSHZ6 NYNAAL&4G8W%CIN4
MR(J9G<J&F:C+AI2JR8:2J\:&DJO&AI*KQH:2J\:&DJO&AI*KQH:2J\:&DJO&
MAI*KQH:2J\:&DJO&AI*KQO^?-1K_G4(N_Z!%/?^G1$G_K4-4_K-$7_>Z1VCO
MP4UPY<E6==S.9'K,QFF-OKYNG+*V=*BGL'FRGJM^NI6FA,".HXO$B*&2QX2?
MFLF GZ?*@9JJR(*8J\:"F*O&@IBKQH*8J\:"F*O&@IBKQH*8J\:"F*O&@IBK
MQH*8J\:"F*O&@IBKQO^@-1K_G4(N_Z%$/?^H0DC_KT%3_[9"7?>^1F7LQTUK
MX])8;=;387K'RF>,N<)MFZR\<J>AMG>QF+%]N8^M@KZ(JHG#@JB0QGVGF<AZ
MIZ7)>Z*KR'V>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>K,9]GJS&?9ZLQGV>
MK,9]GJS&?9ZLQO^@-1K_G4(N_Z)"//^J0$?_LCY1_;I 6?/#1&#HSTYCW]Q9
M9\_88'G SV:*LLAKFJ;"<*:;O':OD;A[MXFU@;R"LH? ?;".PWBNEL5VK:'&
M=:RLQG>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5WIJW%=Z:MQ7>FK<5W
MIJW%=Z:MQ?^@-!K_GD$N_Z1 ._^L/47_M3M.][\^5>S+1%GAVD]:U-]1;,;:
M6GVXTV*+J\YIF)_&<:25P'>MCKM^M(>W@[F!M(>]?+*,OWFQD\%VL)O"=+"F
MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"<K"MPG*PK<)RL*W"
M<K"MPO^A,QK_GD$O_Z<].O^P.D/]NCA*\,8[3^/514[5X49?R.)+<;K=4H&L
MU5N/G\QFFY;&<*2/P'BKBKQ_L82Y@[6 MX>X?+:+NWFTD+QWM)>]=K2AO72S
MI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.EOG2SI;YTLZ6^=+.E
MOO^B,QK_H#XN_ZHY-_^T-3_VP#5$Y\\Y1=??/%#)YT%DN^5&=JS<3H6?TUJ2
ME<QGG([&<:2*PGFJA;]^KH"\@K)]NH:T>KF*MG>XCKAUMY.Y<[>:N7.WH+ES
MMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N7.WH+ESMZ"Y<[>@N?^C
M,AK_HSHL_ZXT-/ZZ,3KMRC [VMTR/\KG.%6\[#UIK>5$>9_;3H>4TUR2C<QH
MFXC(<J&$Q'FF@,)]JGS @:UYOH6O=[V(L'2\B[)RNY"S<+N5M&^ZFK1ONIJT
M;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M&^ZFK1ONIJT;[J:M/^D,!K_
MIS4J_[0O,/3#*C'>V"LMS.8N1;WR-5JM[CMLG^1$>Y/;48>+U%Z0AL]JF(++
M<YU^R'BA>L9\I'?$@*9UPX.H<\*&J7'!B:MOP(VL;<"2K6R_E:ULOY6M;+^5
MK6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K6R_E:ULOY6M;+^5K?^E+QK_K2TE
M_+PG*.70(23.Y"0SOO$L2J[X,UV@[3UMD^1'>HK=5(6#UV&,?])LDGO/<I=W
MS7>:=,M[G'+*?IYPR8&@;LB$H6W'AZ)KQHJC:<:.I&C%D:5HQ9&E:,61I6C%
MD:5HQ9&E:,61I6C%D:5HQ9&E:,61I6C%D:5HQ9&E:,61I?^G+!K_M24?[,D:
M'-#B&2&_\"(XK_TK3:#X-5Z3[D%LB>9-=X'@6(!]W&2&>-AKBW/5<8YPTW61
M;M)YDVS1?)1JT'^6:<^"EVC/A9AFSHB99<V,FF3-CIIDS8Z:9,V.FF3-CIID
MS8Z:9,V.FF3-CIIDS8Z:9,V.FF3-CIIDS8Z:9,V.FO^N)!;UP1<4U-\.$,#O
M&":P_2,\H?\M3I3Y.EV)\4=H@>M2<7KF77ATXF1]<-]K@6W=<(1JW'2&:-MX
MB&;:>XEEV7V*9-B BV+8@XQAUH6-8-:)CE_5BXY?U8N.7]6+CE_5BXY?U8N.
M7]6+CE_5BXY?U8N.7]6+CE_5BXY?U8N.7]6+COZY%@W4T@L&PNX.%K'\&2JB
M_R4]E/\R3(G\0%F!]DUB>O!8:7/L7V]LZ61S:.=J=F;E;WEDY'-Z8N-V?&'C
M>7U@XGM^7^%^?E[A@']=X(. 7."%@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(
M@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@=3("0/$UPH'LOL0&:/_'"N5_R@[
MBO\X2('_15)Z_%):<O=98&OT7F1F\F1H8O!I:F#N;6Q>[7%M7.UT;EOL=F]:
M['EP6>M[<5CK?7%8ZG]R5^J"<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;I
MA'-6Z81S5NF$<U;IA'-6Z81S5NF$<\3-" &TW0@+I/\2&I?_'RJ+_RXV@?\]
M07G_2DEQ_U)0:?]856/]75A?^V-;7/EG75KX:U]8]VY@5_=Q85;V=&%5]G9B
M5/5W8U/U>6-3]'QD4O1^9%'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51
M](!E4?2 95'T@&51](!E4?2 9?^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/68
M86WME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>E
MK\AUJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WM
ME6AYY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AU
MJ;#'=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AY
MY9)RA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'
M=*ZQQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)R
MA-^/?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQ
MQW.SLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/
M?([:C(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.S
MLL9SNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LO^6,Q3_E4,E_Y)1-_^74T7_F5=3_9E;8/6886WME6AYY9)RA-^/?([:
MC(66U8>+G-&#D*'/@)6FS7V:J<M[GJO*>:&MR7>EK\AUJ;#'=*ZQQW.SLL9S
MNK+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLO^6,Q3_E4,E_Y-1-_^74T7_F592_9E;8/688&WMEF=YY9-QA-^0>X[:C826
MU8B*G-&$D*+/@)6FS'V9J<M[G:S)>:&NR'>EK\AVJK''=*ZRQW.TLL1TNK*_
M=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLO^6
M,Q3_ED,E_Y50-_^9443_FU12_IQ87_6;76SMF61XYI9L@]^3=HW:CX"6U(R(
MG=&'CJ/-@Y.HRX"8J\E]G*[(>J&QQGBELL9WJK3%=;"UQ72XM;UWN+6X=[BU
MN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM?^7,Q3_
MED,E_Y9.-_^:3T3_G5)1_IY57O:>6FKNG&!VYYIG@N"6<HS:DGN5U(Z$G="*
MBZ/-AI&IRH*6K<A^F[#&>Z"SQ7FFM<1WK+;#=K.WOG>WM[=XMKBR>;:XLGFV
MN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN/^8,Q3_ET,E
M_Y=--_^;34/_GU!0_Z!37?>@6&GOGUUUZ)UD@.&:;HO;EG>4U9& G-".B:/,
MB8^IR825KL> FK+%?:"UPWJGM\)XKKG =[6YN'BUN;%YM;FL>K6YK'JUN:QZ
MM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN?^8,Q3_F$,E_YA,
M-O^<3$/_H$Y/_Z)17/BC56CPHEMTZ:%A?^*>:HG<FG.3UI5\F]&1A:/,C(RI
MR8>3K\:"F;/#?J"WPGJHN<%XL;NY>+.\L7FSNZMZM+NG>[6ZIWNUNJ=[M;JG
M>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNO^9,Q3_F$,E_YE+-O^>
M2T+_H4Q._Z1/6_FE4V;QI5ARZJ1>?>.B9H?=GG"1UYEXF=*5@:'-CXFIR8J1
MK\6#F+3"?Y^XO7RGN[IZL+VR>K*^JWNRO:9\L[RC?;2ZHWVTNJ-]M+JC?;2Z
MHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNO^9,Q3_F$,F_YE*-O^?2D+_
MHTM._Z9.6?JH467RJ%9PZZA<>^6G8H7?HVR.V9]UE].:?I_-DX:HQ8V-K[^'
ME+6Y@YRYM7^CO+%]K+ZL?+&_I7RQOZ%^L[V>?K2[GGZTNYY^M+N>?K2[GGZT
MNYY^M+N>?K2[GGZTNYY^M+N>?K2[GGZTN_^9,Q3_F4,F_YI)-?^@2$'_I$E-
M_Z=,6/JJ4&3SJU1N[:Q:>>:L8(+@JFF+VJ9SE,^??)W&EX.HOI"*L+B+D;:R
MAIBZK8.@O:F!J+^E@+# GW^PP)R LKV:@;.[FH&SNYJ!L[N:@;.[FH&SNYJ!
ML[N:@;.[FH&SNYJ!L[N:@;.[FH&SN_^:,Q3_F4,F_YM(-?^A1T'_I4A,_ZE*
M5_NL3F+UKU)L[K!8=NBQ7G_?L&B(U:QTD,JC>IW FX&HN)2'L+&/CK:KBI6[
MIH>=OJ*%I<"?A*_!F8&OP9>"LKZ5@[.\E8.SO)6#L[R5@[.\E8.SO)6#L[R5
M@[.\E8.SO)6#L[R5@[.\E8.SO/^:,Q3_F4,F_YQ'-?^B1D#_IT=+_ZM)5OVO
M3&#VLE%J[K17<^6W7GS=MFJ#SZ]RD,6F>)V[GGZGLIB%L*N3B[:ECI.[GXN:
MOIN)HL&8B*S"DX6OPI*&L;^1AK.\D8:SO)&&L[R1AK.\D8:SO)&&L[R1AK.\
MD8:SO)&&L[R1AK.\D8:SO/^:,Q3_F4(F_YQ&-/^C14#_J$5*_ZU'5?ZQ2E_U
MM5!HZ[E6<..]7G?9NVJ R[)PD,"I=IVVHGRGK9R"KZ67B;:>DY"[F8^8OI2-
MH,&1C*G"C8JNPHV)L;^-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-B;*]C8FR
MO8V)LKV-B;*]C8FRO?^;,Q3_FD(F_YU%-/^D1#__JD1)_Z]%4_RT25WRN4]E
MZ;Y6;.'#8'+3OFF QK5NC[NM=)RPIGJGIZ" KY^;AK68EXZ[DY65OHZ2G<&*
MDJ?"B)"NPHB.L,"(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-
MLKV(C;*]B(VRO?^;,Q3_FD(F_YY$,_^E0C[_JT)(_[%$4OJW2%KPO4YAYL16
M9][)8FW.P6=_P;EMCK:Q<INKJGBFHJ5^KIF@A+62G8NZC)J3OH>8F\"$EZ3"
M@I:OPH.3L,"$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$
MD;*^A)&ROO^;,Q3_FD$F_Y]",_^F0#W_K4!'_[1"3_>[1U?MPTU=Y,Q88-G-
M8&S)Q69^O+UKC;"U<9JEKW:EG*I\K9.F@K2,HHFYAJ"0O8&>F;]]GJ+!>YZO
MP7V9L,!_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^
M?Y:ROO^<,Q3_FD$F_Z!!,O^H/SS_L#Y%_[=!3?3 15/JR4Y6XM5:5]+17FO$
MR61]ML%JC*J[;YF?M72DEK!ZK(VL@+*&J8>W?Z>.NWJFEKYWI:"_=*:MOW>A
ML;]ZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVR
MOO^=,Q3_FT$F_Z(_,?^J/#K_LSQ"^[L^2?#&1$WFTD]-W-Q75LS576J^S6-[
ML,=HBZ3!;9>9O'.BC[AXJH:T?K!_LH6U>;",N'2OE;MQKI^\;J^KO7&JL[QT
MI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO/^=
M,Q3_FT F_Z0\,/^M.3C_MCD_]<$\0^G.1$3>W4U'TN!36,7;7&BWTV%ZJ<UF
MB9S(:Y61Q'&?B,!VIW^]?:UXNX2Q<[J+M&^XE+=LMYVX:K>HN6FVMKAMK[6Y
M;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN?^>,A3_
MG3XE_Z<Y+O^Q-C7[O#8Z[<DZ/.#:1#K2XD=,Q^)-7KG>5&ZLV5M\G]1BB)30
M:).*S&^;@L=WHGS#?JAVP(2L<KZ*KV^\D;%MO)BR:[NALVJ[K;)GNK:T9[JV
MM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM/^?,A3_H#HD
M_ZHT+/^U,C'SPS(SX]0X,-/A/#_&Z$)2N>5(8ZSB37*?WU1_D]E=BHG29Y.#
MS7":?<EWGWC&?:1TQ(.G<,*(J6[!CJMLP)2L:K^;K6F_I:UHOZZM:+^NK6B_
MKJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK?^@,!3_HS8B_Z\P
M*/N\+2OHS2PHU> P,,?I.$2Y[#Y7K.E%9Y[G2W62X%. B=E>B8+4:)%\T'&6
M>,QWFW3*?9YPR(*A;L>'HVO%BZ5IQ)"F:,26IV;#GJAEPZ6H9<.EJ&7#I:AE
MPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ/^A+Q3_J"\?_[4J(O#&
M)"'8W2,@R.DM-;KR-4FL\3Q:GO!#:9+H3'6(X55_@=MAAWO7:HUVTW&1<M%W
ME6_/?)=LS8"::LR%FVC+B9UFRHV>9<F2GV/)F*!BR)ZA8LB>H6+(GJ%BR)ZA
M8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H?^C+13_KBD:^+\@&M[6&!/)
MZ"(ENO0K.JSX-$V>]SQ<DO%&:8CI4'-_XUE[>M]D@G3<:X9PV7&*;=9VC6K5
M>X]HTW^19M*#DF31AY1CT8J58="/EF#/E)=>SYF87L^9F%[/F9A>SYF87L^9
MF%[/F9A>SYF87L^9F%[/F9A>SYF87L^9F/^G*!+_MQ\2YLX1#<OF%1:[]"$J
MK/XK/I[_-$Z2^C]<B/)*9G_L56]YZ%YU<N1D>V[A:WYJWW"!:-YUA&7<>85C
MVWV'8MJ!B&#:A(E?V8>*7=B+BUS7D(Q;UI2-6]:4C5O6E(U;UI2-6]:4C5O6
ME(U;UI2-6]:4C5O6E(U;UI2-6]:4C?^P'@OMQ@X(S=L+"+OS%1JL_R$NGO\L
M/Y+_-TV'_418?_9/87CQ66AQ[5]M:NMD<6?H:G1DYV]W8N5T>6#D>'I?XWM[
M7>-^?%SB@7U;X81^6N&(?UG@C(!8X(^!6."/@5C@CX%8X(^!6."/@5C@CX%8
MX(^!6."/@5C@CX%8X(^!6."/@?.]#03,SPD!O>4,#*S_%QZ>_R0ODO\O/8?_
M/4E__TE2>/Q46G#X6E]I]%]D9/)E9V'P:FE>[VYK7.YR;5OM=FY:['EO6.Q\
M<%?K?G!6ZX%Q5>J$<E3JB'-3Z8MT4^F+=%/IBW13Z8MT4^F+=%/IBW13Z8MT
M4^F+=%/IBW13Z8MT4^F+=,S&" "]U @#K?4.#Y__&A^3_R<MB/\T.7[_0D-W
M_TU*;O]34&?_655B_%Y87OMD6UOY:%U9^&Q>5_=P8%;W<V%5]G9B5/5X8E/U
M>V-2]'UD4?2 9%#S@V5/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&
M9D_SAF9/\X9F3_.&9KW+!@"NVP8$G_\0$)/_'1V(_RHH?O\X,G;_1#IM_TM!
M9?]11E__5TE;_UU,6/]B3E7_9E!3_VI14O]M4E#_<%-/_W)43O]U5$W_=U5-
M_WE53/Y[5DO^?E=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]
M@5=*_8%72OV!5_^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR
M=NF)?'_DA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.A
MT6RYHM%KP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:BR&[&HO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)
M?'_DA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RY
MHM%KP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
MR&[&HO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_D
MA82&X("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%K
MP*/-;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHO^-+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&
MX("+C=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-
M;,6CR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-
M+0[_C#X=_XI,+O^24SO_E%=(_Y5<5/V38F#UD6IK[XUR=NF)?'_DA82&X("+
MC=Q\D9+:>9>6V':<F=5SH)O4<:6=TV^IG])NKJ#2;;.AT6RYHM%KP*/-;,6C
MR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HO^-+0[_
MC3X=_XQ,+O^44SO_E59'_Y9;5/V586#VDFAK[X]P=>F+>G_DAX.'WX**C=Q^
MD)+9>I:7UG>;FM5TH)W3<J6?TG"IH=%NKJ+0;;2CT&RZI-!LPJ3*;L2DQ&_$
MI,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I/^.+0[_CCX=
M_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN CI38
M?)28U7F:G--VGY_1<Z2BT'&JI,]OKZ7.;K:FSFV]I\INPJ?#<,*GO7'"I[UQ
MPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I_^/+0[_CCX>_Y!*
M+?^73SK_F5%&_YM64OZ:6U[WF&%I\)5H=.J1<7[DCGR&WXF$CMN#BY37?Y*:
MU'N8GM)WGJ'0=*2DSG*JILUPL:C-;[FIRV_!J<-QP:F\<L"JMW/ JK=SP*JW
M<\"JMW/ JK=SP*JW<\"JMW/ JK=SP*JW<\"JMW/ JO^/+0[_CSX>_Y)*+?^8
M33G_FT]%_YU34?^=6%SXFUYH\9EE<NJ5;7SDD7>&WXR!CMN'B976@9":TWV6
MG]!YG:/.=:.FS7*KJ<QPLZK+;[VKQ7*_J[USOZRV=+ZLL76^K;%UOJVQ=;ZM
ML76^K;%UOJVQ=;ZML76^K;%UOJVQ=;ZML76^K?^0+0[_D#X>_Y-)+?^93#G_
MG4Y$_Y]14/^?5EOYGEQF\IQB<>N8:7OEE'.$X(]]C=N*AI36A(V;TG^5H,]Z
MG*7-=J.HRW.KJ\IQM:W&<;ZMOG2]KK9UO:ZP=KVNK'>]KJQWO:ZL=[VNK'>]
MKJQWO:ZL=[VNK'>]KJQWO:ZL=[VNK'>]KO^0+0[_D#X>_Y5)+/^;2CC_GDQ#
M_Z%/3_^B5%KZH5EE\Z!?;^R=9GGFF&^#X)-YC-N.@I/6AXJ;TH&2H<]\FJ;*
M>**JQW6KK<-SM*^_<[RPMW6\L+!WN["J>+NPIWF\L*=YO+"G>;RPIWF\L*=Y
MO+"G>;RPIWF\L*=YO+"G>;RPIWF\L/^1+0[_D3X>_Y9(+/^<2#?_H$I"_Z--
M3?^D4EC[I5=C]*1=;>ZA8W?HGFN XIAUB=R2?I+3C(>:S(:/H<: EZ?!?)ZL
MO7FFK[EVK[&W=KJRKW>ZLJIYNK*E>KJRHGN[L:)[N[&B>[NQHGN[L:)[N[&B
M>[NQHGN[L:)[N[&B>[NQHGN[L?^1+0[_D3X>_YA'+/^=1S?_H4A!_Z5+3/^G
M4%;\J%5A]:A;:^VG873EI&E^WI]SA]28?9#+D82:Q(J,HKZ$DZBX@)JMM'RB
ML+!ZJ[.M>;6TJ'JYM*1[N;2@?;FSG7VZLYU]NK.=?;JSG7VZLYU]NK.=?;JS
MG7VZLYU]NK.=?;JSG7VZL_^2+0[_DCX>_YA&*_^>1C;_HT=!_Z=)2_^J3E7Z
MJU->\JQ9:.FL8''BJ6AZV:5S@\V<>H_%E8&:O8Z(HK>(D*FQA)>NK("?L:A^
MI[2E?;&UH7VXMIU^N+6:?[FTF8"ZLYF NK.9@+JSF8"ZLYF NK.9@+JSF8"Z
MLYF NK.9@+JSF8"ZL_^2+0[_DCX>_YE%*_^?1#7_I$5 _ZE(2?^L3%/XKE)<
M[[!89>:Q7VW>L&EVTJEQ@LB@>(^_F'Z:MY*%HK",C*FJB)2NI(6<LJ""I+6=
M@:ZVFH"WMY>!M[:5@KFTE(*YLY2"N;.4@KFSE(*YLY2"N;.4@KFSE(*YLY2"
MN;.4@KFSE(*YL_^3+0[_DCT>_YI$*O^@0S7_ID0^_ZM&2/^N2U'ULE!9[+57
M8>2W7FG:M&ESS:QO@L*D=H^YG'R9L9:#HJJ1BJFCC)&NGHF9LIF'H;66A:NW
MDX6VMY&$M[>0A;BUD(6YM)"%N;20A;FTD(6YM)"%N;20A;FTD(6YM)"%N;20
MA;FTD(6YM/^3+0[_DST>_YM#*O^B0C3_J$(]_ZU%1ORQ2D_RM4]6Z;I67>&]
M8&34N&=RR*]M@;VG=(ZTH'J9JYJ HJ25AZF=D8ZNEXZ6LI*+G[6/BJBWC(JS
MN(N)M[>+B+BUBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FTBXBYM(N(N;2+B+FT
MBXBYM/^3+0[_DST>_YQ!*O^C0#/_J4$\_Z]$1?JT2$SPNDY3Y[]66=["8&#/
MNV9QP[-L@;BK<HZNI'B8I9Y^H9Z:A*B7EHRND9.4LHR1G+6(CZ:WA8^QN(6.
MMK>&C;BVAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRXM8>,N+6'C+BUAXRX
MM?^4+ [_E#T>_YU *?^D/C+_JS\[_[%"0OBX1TGMODY/Y<974]K&7E_+OF1Q
MOK9J@+.O<(VIJ7:8H*-\H9B?@JB1FXFMBIF2LH66FK6!E:2W?Y6NMWZ4M[>!
MD;>V@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM8*0N+6"D+BU@I"XM?^4
M+ [_E#T>_YX_*/^F/3'_K3XY_[1!0/2\1D7KQ$U)XLY82]/*7%[&PF-PN;IH
M?ZZT;HRCKG27FJEZGY*E@*>*H8>LA)^/L7^=E[1[G*&V>)NLMW>;M[9ZE[BU
M?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM'R5N;1\E;FT?)6YM/^5+ [_
ME3T>_Z ])_^H.S#_L#PW_;@_//'!1$#HRTY"WM-52L[-6UW QF%NM+]G?JBY
M;8J=M'*5E*]XGHNK?J6$J(6J?::,KWBDE;)THY^T<:.JM7"CN+5SGKFT=INY
MLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYLW:;N;-VF[FS=INYL_^6+ [_ESP>
M_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*' :XF7
MNG"3C;9VG(2S?*)]L(.H=ZZ*K'*MDZ]NK)VQ:ZRHLFFMMK)LJ+NQ;Z.[L6^C
MN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L6^CN[%OH[NQ;Z.[L?^7+ [_FCL=_Z0W
M)?^M-BO_MS<P\\,Z,>;00S#<WTHUS]]21\'86%JST5YKILMC>IK':8:/PFZ0
MAK]TF'V\>I]VNH&D<+B)J&NWDJMHMYRM9;>GKF2WM*YEL[VN:*V]KFBMO:YH
MK;VN:*V]KFBMO:YHK;VN:*V]KFBMO:YHK;VN:*V]KO^8+ [_G3D<_Z<T(_^Q
M,RCYO3(JZLLW*=S=/BG0XT8ZQ>)-2[C>55JLV5QHGM-B=Y+/9X*(RVV,?LES
ME';'>9IPQ8&?:L2)HF;#DJ5BPYRG8,.FJ%_#M*A?P<*H8;K!J6&ZP:EANL&I
M8;K!J6&ZP:EANL&I8;K!J6&ZP:EANL&I8;K!J?^9+ [_H#4:_ZHQ(/^V+B/P
MQ2TBW]@S'-#C.B[$Z$) N.5)4*OA3E^>WE5LDMM<=X?88X%^U6J)=M1QCV_1
M>91KSH"89\R(FV3*D)UBR9B?8,FAH%_)JZ!?R;F?7,C#HES(PZ)<R,.B7,C#
MHES(PZ)<R,.B7,C#HES(PZ)<R,.B7,C#HO^;+ [_I# 8_Z\L&_B^)QODT287
MT>(M(,3K-S.WZSY%JNE%5)[G3&*2Y5)NAN-8>'W@8']VW&F&<-AQBVO5>(]H
MTW^29=&&E&+/C99@SI287LZ;F5W-HYI<S:V:6\VWFEO-MYI;S;>:6\VWFEO-
MMYI;S;>:6\VWFEO-MYI;S;>:6\VWFO^=+ [_J"L4_[<D%>O*'!'3X!X3Q.LK
M)K?Q-#BJ\#Q)G>]$5Y'N2V.&[5)M?>A;=77C8GQPX&N!:]URA6C:>(ADV7Z+
M8M>$C5_5BHY>U)"07-.5D5K3G))9TJ236-*LDUC2K)-8TJR36-*LDUC2K)-8
MTJR36-*LDUC2K)-8TJR36-*LD_^A*PW_KR,/],(7#-;=$ ?%ZQX8M_8I*ZGW
M,SR=]CQ+D?=$6(;V36)]\%9J=NM><6[G9'9JY&MZ9N)R?63@=X!AWWV"7]Z"
MA%W=AX5;W(R&6MN1AUC:EHA7V9V)5MFCBE;9HXI6V:.*5MFCBE;9HXI6V:.*
M5MFCBE;9HXI6V:.*5MFCBO^H(PG]N18'UM$+ \;J$ NV]QX=J?TI+IS^-#Z0
M_SY+AOY'5GWX45YV\UEE;O!?:FCM96YDZFMR8>EQ=%_G=G9=YGMX6^5_>5GD
MA'I8XXA\5^.,?5;BD7Y4X9=_4^&<?U/AG']3X9Q_4^&<?U/AG']3X9Q_4^&<
M?U/AG']3X9Q_4^&<?_^Q%0/4QPD!QM8* [;W$@^H_Q\@F_\K,)#_-CV%_T!(
M??]+477]5%AM^5I=9_9@8F/S9F5?\FMG7/!P:5KO=&M8[GAL5^U\;E7L@&]4
M[(1P4^N(<5+KC'%1ZI%R4.F5<U#IE7-0Z95S4.F5<U#IE7-0Z95S4.F5<U#I
ME7-0Z95S4.F5<]:^!P#%RP@ M]L)!:C_%!*;_R(AD/\N+H7_.3I\_T1#=/].
M2FS_5%!E_UI48/U?6%W[95I:^FI<5_EN7E7X<E]4]W9@4O9Y85'V?6)0]8!C
M3_2$9$[TAV1-\XQE3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,
M\Y!F3/.09L3"!@"VT0< J.T+!IO_%Q.0_R4?A?\Q*GS_/#1S_T8[:O],06/_
M4T9>_UE)6O]>3%;_8TY4_VA04O]L45#_;U)/_W)33O]V5$S_>55+_WQ52OY_
M5DG^@E=(_8981_V*6$?]BEA'_8I81_V*6$?]BEA'_8I81_V*6$?]BEA'_8I8
M1_V*6+;)! "HV00!F_\.!X__&A&%_R<;>_\S)''_/"QH_T,R8?]*-UO_4#M6
M_U8]4_]<0%#_8$%._V1#3/]H1$K_:T5)_VY&2/]Q1D?_=$=&_W9(1?]Y2$3_
M?$E#_X!)0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*0O^#
M2O^"* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-W
MZGB+?>=TDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<
M9<V2U&;1DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"
M* G_@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+
M?>=TDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2
MU&;1DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_
M@CD6_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+?>=T
MDH+D<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2U&;1
MDL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_@CD6
M_X%()?^*3S'_CE8]_X]<2?^.8U3^BFI>^(5Q:/* >G#N?(-WZGB+?>=TDH+D
M<9B%XF^=B.%MHHO@:Z>-WVFLCMYHL9#=9[>1W6:]D=QEQ9+<9<V2U&;1DL]H
MTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DO^"* G_@SD6_X-'
M)?^,3C'_D%4]_Y%;2/^085/^C6A>^(AO:/*#>'#M?H)XZ7J*?N9VD8/D<Y>'
MXG"=BN!NHHS?:Z>.W6JLD-UHLI'<9[B3VV:_D]MFQY399M"4SVC0D\MIT)3+
M:="4RVG0E,MIT)3+:="4RVG0E,MIT)3+:="4RVG0E/^#* G_@SD7_X9&)/^.
M33#_DU0\_Y181_^27E/_D&5=^(QM9_*&=7#M@7]XZ7V'?N5YCX3B=96(X'*;
MC-YOH8_=;*>1W&NLD]MILY3::+J6V6?#EMEFS9?0:<Z6R&K.E\1KS9?$:\V7
MQ&O-E\1KS9?$:\V7Q&O-E\1KS9?$:\V7Q&O-E_^$* G_A#D7_XA%)/^13##_
ME5$[_Y961_^57%+_DV)<^8]J9O.*<G#MA7MXZ8"$?^5[C(7B=Y.*WW.:CMUP
MH)';;::4VFNMEMEIM)?8:+V8V&?(F=%IS)G):\R9PFS,FKUMRYJ];<N:O6W+
MFKUMRYJ];<N:O6W+FKUMRYJ];<N:O6W+FO^%* G_A3D7_XI$)/^32R__ET\Z
M_YA41O^765#_EF!;^9)G9?..;V_NB7AWZ8.!?^1^BH7A>9&+WG68C]QQGY/:
M;J:6V&RNF-=JMIK6:,&;TVG+F\IKRYO";<J<NV[*G;AORIVX;\J=N&_*G;AO
MRIVX;\J=N&_*G;AORIVX;\J=N&_*G?^%* G_ACD7_XQ$(_^52B__F4TZ_YI1
M1/^:5D__F5U:^I9D9/22:V[NC71VZ8=^?N2!AX7@?(^+W7>7D-MSGI78;Z:8
MUFROFM5JN9S4:<:=RVS)G<-MR9Z\;\B?M7#(G[)QR)^R<<B?LG'(G[)QR)^R
M<<B?LG'(G[)QR)^R<<B?LG'(G_^&)PG_ACD7_XY#(_^722[_FDLY_YQ/0_^=
M5$[_G%I8^YI@8O66:&SOD6]UZHMY?N6%@X7@?XR,W7F5D=ETG9;4<*6:T&ZN
MG<ULMY_+:\.@PV['H+MOQZ&U<<:AKW+&H:QSQJ&L<\:AK'/&H:QSQJ&L<\:A
MK'/&H:QSQJ&L<\:AK'/&H?^')PG_ASD7_Y!"(_^81RW_G$DX_Y],0O^@44S_
MH%=6^YY>8/2;96KMEFQSYY!V?.&*@(3;A(F+TWZ1DLYXF9C)=*&<QG&IG\)P
MLJ+ ;[VCNG#%H[-RQ:2N<\6DJ73%HZ9UQ:.F=<6CIG7%HZ9UQ:.F=<6CIG7%
MHZ9UQ:.F=<6CIG7%H_^')PG_B#@7_Y%!(O^:12S_GD<V_Z%*0/^C4$K^HU54
M]J)<7>^@8F?HG&EPX99T>=J0?8+1B8:+RH*-D\5]E9G >9V>O':EH;ASK:2U
M<KBELG+#IJQTPZ:G=L.FHW?$I:%XQ*6A>,2EH7C$I:%XQ*6A>,2EH7C$I:%X
MQ*6A>,2EH7C$I?^()PG_B#@7_Y-!(O^;1"S_H$4U_Z-)/_^E3DC[IU11\Z9:
M6^NE8&3CHFAMW)US=M&5>H+)C8*+PH>*D[R"D9JW?9F?LGJAHZ]WJ::K=K.G
MJ7; J*1WPJBA><*GG7K#IYMZPZ:;>L.FFWK#IIMZPZ:;>L.FFWK#IIMZPZ:;
M>L.FFWK#IO^()PG_B3@7_Y5 (?^=0BO_HD0T_Z5(/?^H3$;XJE)/[ZM85^>K
M7V#@J&EIU*%P=<N9>('"DG^+NXN&E+6&CIJO@I6@JGZ=I*9[IJ>C>K"IH'F\
MJIUZP:F:?,&IF'W"J)9]PJ>6?<*GEGW"IY9]PJ>6?<*GEGW"IY9]PJ>6?<*G
MEGW"I_^))PG_B3@7_Y8_(?^>02K_HT(S_Z=&._ZK2T3UKE%,[+!75.2Q7ES;
MK6AFSZ5N=<6==8&\EGR+M9"#E*Z*BYNHAI*@HX*:I9Z HJB;?JRJF'ZXJY9^
MP*N4?\"JDX#!J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"
MJ/^))PG_BC@7_Y@_(/^?/RG_I4$R_ZI%.ORN24'RL4])Z;564.&W7U?5L65E
MRJAL=,"A<X"WFGJ+KY2!E*B/B)NBBH^@G(>7I9>$H*B4@JFJD8*UJX^"OZN.
M@\"JC8/!J8V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J/^*
M)PG_BS@7_YD^(/^A/BC_ID P_ZQ#./FQ2#_PM4Y%Y[I52]Z[7E30M&1EQ:QK
M<[ND<8"QGGB*J9A^DZ*3A9J;CXV@EHR5I9&)G:B-AZ>KBH>RK(B'OZR(A\"K
MB(; J8B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J/^*)PG_
MC#<7_YL]'_^B/2?_J#\O_ZY"-O>T1SSMNDU!Y,!61MF_7%/+MV-DP*]I<[:H
M;W^LHG6*I)Q\DYR8@YJ5E(J@CY&2I8J.FZB&C:2K@XROK(&-O:R"C+^K@XK
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M8]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@?]U) ;_=C40_W=#'/^
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MEW=\K)%^A::,AHR@B(V1FH65EI:"GIJ2@*>=CW^RGHV P9Z,@,F>BX#*G8J
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M5T#]IEA _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E80/RI6,:X! "VQ 0
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M7NAQV%[H<=A>Z''87NAQV%[H<?]K(P3_:C$*_W$\%/]Z0QW_@$LH_X%3,O^
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M?=1BX7W*8^!^PV3@?[UFWX"W9]^ MV??@+=GWX"W9]^ MV??@+=GWX"W9]^
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M9TCFWV=*X.QG2M_L9TK?[&=*W^QG2M_L9TK?[&=*W^QG2M_L9_^<#0#;L08
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M=%.UY'14L.=U5JSG=5:LYW56K.=U5JSG=5:LYW56K.=U5JSG=?^#$@'_EA$
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M44#M\5% [?%10.WQ44#M\5% [?%10.WQ4=2E  #$L@, MKP# *O)!0"@V @
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M3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*J0(
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M)RG_OB<I_[XG*?^^)RG_OB<I_[XG*?^^)Z:V  "8P@  B\X  '[;  !U^0<
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M5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<__T+
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M(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(N7&
M3K5NB%*R:X]6KVF76JQGGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:9O5A
MF&?V8)9H]F"6:/9@EFCV8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"(0+_
MBRD$^9$Q!^^5. OFEC\0W91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\3JYR
MA%.J;XM7IFV36Z-KFUZ@:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1CD6OU
M8I!K]6&0:_5AD&OU89!K]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_CB<#
M]94N!>N9-0CAG#L,UIA#%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W@%.C
M=(A8GW&06YMOF%^8;J%BE6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T8XIN
M]&**;O1BBF[T8HIN]&**;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"\IDK
M!.>>,07=H#8)T9Q!%<>732&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<>(58
MF':-7)1TE5^1<IYBCG&H98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R]&.$
M<O1CA'+T8X1R]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG N.B
M+ /8I#((S)] %,.:2R"ZE54LLY!=-ZR+93^EAVQ'H(-S39N >U.6?8)7DGJ*
M7(YXDF"*=IMCAW6E9H1TL6>"=,!H@'35:(!U[&=_=O)F?W7S97]U\V1_=?-D
M?W7S9']U\V1_=?-D?W7S9/]E&0+_=!0!_X$7 ?^-&@'YEQX!ZZ C =^F)@+2
MIS 'R*,^$[^>21^VF5,KKI1;-J>/8S^@BVI&FX=Q396$>%*0@7]7C'^'7(A]
MD&"$>YEC@'JC9GYYKVA[>;UI>GG1:7EZZFAZ>O)F>GGR97IY\V1Z>?-D>GGS
M9'IY\V1Z>?-D>GGS9/]G%P+_=A0!_X06 ?^0%P'UFQH!YZ0= =NK'P'.JB\&
MQ*8]$KJA2!ZRG5$JJIA9-**483Z<D&A%EHQO3)")=E*+AGU7AH2%6X*"C5]^
M@)=C>G^A9G=^K&AU?;MI<W[.:7-^Z&AT?O%F='WR975\\V1U?/-D=7SS9'5\
M\V1U?/-D=7SS9/]I%@'_>!,!_X<4 /^3%0#QGA4 XZ@6 -6N&P'*K2T&P*D[
M$;:E1AVMH5 II9Q8,YZ87SR7E&9$D)%M2XN.=%&&C'M6@8F#6WR'BU]XAI1B
M=(2?97&#JF=O@[AI;8/+:6V#YFAN@_)F;X+R97"!\V1P@?-D<('S9'"!\V1P
M@?-D<('S9/]K% '_>Q(!_XH2 /^6$@#MHA  WJT. -"Q&0#%L"L%NZTY#[*I
M1!NII4XGH*%6,IF=7CN2FF1#BY=K2H:4<E" DGE5>X^ 6G>-B5YRC))A;HJ<
M9&N)J&=IB;9H9XG(:&>)XV=HB?)F:8?S96J&\V1JAO-D:H;S9&J&\V1JAO-D
M:H;S9/]N$@'_?A  _XT0 />:#@#;IPH T[ + ,JT%@# M"D$MK$W#JVN0QJD
MJDPEFZ95,).C7#F,H&-!AIUI2(":<$Y[F'=3=I9^6'&4AEQLDI!@:)&:8V60
MIF5CD+1F89#&9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C9(ST
M8_]Q$ '_@@\ _Y$- -Z?"0#3J@D S+,) ,2X$P"ZN"8#L;8U#*>S01B>KTHC
MEJQ3+HZI6C>'IF$_@*1G1GJA;DQUGW51<)U\56N<A%IFFHY=8YF88%^8I&)=
MF+)D6YC#9%N8WF-;F/!C7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U8O]U
M#@#_A@T ZY8( -6C!P#,K0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@D+-1
M*XBP6#2 KE\\>JMF0W2I;$AOJ'-.:J9Z4F6E@E9AHXQ:7:*67%JBHE]7H;!@
M5J'!8%6BW&!5H>]@5I_W7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z# #]
MBPD VIL$ ,ZG!@#$L 8 O+D$ +7!#@"LPB !I,$P")J_/!.1O48=B;I/)X&X
M5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];4*S
M6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#AD@$
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M*EO49R]7U&XS4]-V-E#3?SE,TX@[2M.4/D?3H#]%U*Y 1-2_04/5V$!$T^Q
M0M+V0D'1_D1!T?Y$0='^1$'1_D1!T?Y$0='^1-&8  ##I0  M:X  *FX  ">
MPP( E,T& (K9"@"$XQ@!?>0F W7D,@ANXSP/9^-%%6'C31M<XU4@5^-=)%3C
M9"=0XFLJ3>)S+4KC?#!(XX8R1>.0-$/CG#5!Y*DV0.2X-S_ERS<_Y>0W/^/S
M-CWB^S@]XOLX/>+[.#WB^S@]XOLX/>+[.,:A  "WJP  JK0  )Z^  "3R0(
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M2WTI_TB(+/]&DB[_19LP_T2B,O]#J3/_0K T_T*W-?]!OS;_0<DV_T#7-_]
MY3?]0/ W^D#X-_=!_S;V0?\W\D'_..Q#_SGJ1/\YZD3_.>I$_SGJ1/\YZD3_
M.?]%*P/_22P#_U L!/]5+P7_63<(_UQ"#O];317_6%<;_U9C(/]2;R7_3WHJ
M_TR%+?]*CS#_2)@R_T>?-/]&IC7_1:TV_T6T-_]$O#C^1,8X_$32.?E#XCGV
M1.XY\T3W.?%$_SGO1/\ZZT7_.^1&_SSC1O\\XT;_/.-&_SSC1O\\XT;_//]&
M*P/_32D#_U0I!/]9+ 7_7C4'_V% #?]A2A3_7E0:_UI?(/]7:R;_5'8J_U&!
M+O].BS'^3)0T_$N<-?M*HS?Z2:HX^$BQ.?=(N3KV1\([]4?-._)'WSON1^P[
MZTCV.^E'_SWG1_\^X4C_/]I*_T#82O] V$K_0-A*_T#82O] V$K_0/]'*@/_
M4"<#_U@F _]>*@3_8S,'_V8]#?]F1Q/_9%$:_V!;(/]<9R;]67(K^E9]+_A3
MAS/V49 U]%"8-_).GSGQ3:8[[TRM/.Y,M3WL2[X]ZTO*/NE+W#[E3.H]XDOU
M/]]+_D'<2O]"U$S_0\U-_T/+3O]#RT[_0\M._T/+3O]#RT[_0_]** /_5"0#
M_UPC _]C* 3_:# &_VP["_]L1!+_:DX9_F98'_EA8B7U7FTK\EMX,.]8@C3L
M5HLWZE24.>A3FSOF4:,]Y5&J/N-0LC_A3[M X$_'0-Y/V$'93^A!U$_T0]!.
M_D7.3O]&R%#_1L)1_T? 4?]'P%'_1\!1_T? 4?]'P%'_1_]-)0+_5R$"_V @
M _]H)@/_;BX%_W(X"O]R01#]<$L7]VU4'?)H7B3M9&DJZ6%T,.5>?C3B6X<X
MX%F/.]U7ES[;59] V%2F0M53KD/24K=$T%+"1<Y2T$;+4N5&R%+R2,52_4G"
M4O]*O%3_2K=5_TJV5?]*ME7_2K95_TJV5?]*ME7_2O]0(P+_6QX"_V0> O]M
M) /_<RL$_W<U"/YX/@[V=T<4\'10&^IO6B+D:V4IX&=O+]MC>3768((ZTEV*
M/L];DD',69I#REBA1<A7J4?&5K))Q%:\2L)5R4N_5=]+O%;N3+E6^DVW5O]-
MLEC_3:Y9_TVL6?]-K%G_3:Q9_TVL6?]-K%G_3?]3( +_7AP"_V@< O]Q(@+_
M>"@#_WPQ!_A^.@OP?4,1Z7I,&.)V5Q_<<F$HU&UK+\]I=#;+97T[QV*%0,1@
MC4/!7I5&OUV<2+Q;I$NZ6JU,N%FW3K99PT^T6=5/L5KJ4*Y:]U"L6O]0J%O_
M4*1<_U"D7?]/I%W_3Z1=_T^D7?]/I%W_3_]6'@+_81D"_VP: O]U( +_?"4#
M_8$N!?.$-PGJA#\.XH%(%=M]4QW1=UTGRW)G,,9N<#?":G@\OF> 0;IEB$6W
M8Y!(M&&82[)?GTVO7JA/K5VR4:M=OE*I7<Y3IEWE4Z1>]%.B7O]3GU__4IQ@
M_U*;8/]2FV#_4IM@_U*;8/]2FV#_4O]8' +_9!<!_W 9 ?]Y'0'_@","^(8J
M ^V),@;DBCL*W(A%$M&"4!S*?5HFQ'AC+[YS;#>Y;W0]M6Q\0K)JA$:N9XQ*
MJV633:ADFT^E8J12HV&N5*%AN56?8<A6G6'A5IMB\5698OU5EV/_5)5D_U24
M9/]3E&3_4Y1D_U.49/]3E&3_4_]:&@+_9Q4!_W,7 ?]]&P'_A" !\XHF NB.
M+@3?D#8'U(Q!$<N'31O$@E<FO7U@+[=X:3:R='$]KG%X0JIN@$>F;(A*HVJ/
M3J!HF%&=9Z!3FF:J59AEM5>59<18E&7;6))F[U>19OQ7CV?^5HYG_E6-:/Y5
MC6C^58UH_E6-:/Y5C6C^5?]<& '_:1,!_W86 ?^ &0']B!T![XXB >23*0+:
ME#$&SI _#\:+2QJ^AE4EMX%>+K%]9C:L>6X\IW9U0J-S?4>?<(1+G&Z,3IAL
ME%*5:YU4DFJG5Y!ILEF-:<!:C&G56HIJ[%F*:OI8B6O]5X=K_5:':_Y6AVO^
M5H=K_E:':_Y6AVO^5O]>%P'_;!(!_W@4 ?^#%P#YBQH ZY(= >"8(P'3F"\%
MRI0]#L&/21FYBE,DLH9;+:R!9#6F?FL\H7IR0IUW>D>9=8%+E7.)3Y%QD5*.
M;YI5BVZD6(AMKUJ&;;U;A&W06X-NZ5J#;OA9@F_\6()O_5>";_U7@F_]5X)O
M_5>";_U7@F_]5_]@%0'_;A$!_WL3 /^&% #VCQ8 YY88 -N<' #/FRT$Q9<[
M#;R31QBTCE$CK8I9+*>&832A@FD[G']P09=\=T:3>7Y+CW>&3XMUCE*(<Y=5
MA'*A6()QK%I_<;I<?G',7'URYUM]<O9:?'+\67QR_%=\<OU7?'+]5WQR_5=\
M<OU7?'+]5_]B% '_<1$!_WT1 /^($@#RDA( XYH2 -6?&0#*GBL$P9LY#+B7
M11>PDD\BJ8Y8*Z**7S.<AF<ZEX-N0)* =46-?GQ*B7R$3H5ZC%*">)56?G>?
M6'MVJEMY=;A<=W7*7'=VY5QW=_5:=W;[67=V_%AW=OQ7=W;\5W=V_%=W=OQ7
M=W;\5_]D$@'_<Q  _X 0 /^+$ #OE0X WYX- -"B%P#&H2D#O9XW"[2:0Q:L
MEDT@I))6*IV.7C*7BV4YDHAL0(V%<T6(@WI*A("!3H!_BE)\?9-5>'R=6'5[
MJ%MS>K9<<7K'7'%ZXEQQ>_-:<7O[67)Z_%AR>OQ8<GK\6')Z_%AR>OQ8<GK\
M6/]G$0'_=0\ _X,. /2.#0#;F0H U*$+ ,RD%0#"I"<#N*(V"K">0A6GFDP?
MH)=4*9F37#&3D&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^ IEIM
M?[1<:W_%7&N WUQK@/)::X#[66Q^_%AM?OQ8;7[\6&U^_%AM?OQ8;7[\6/]I
M$ '_> X _X4, .*2" #5FPD SJ,) ,>H$@"]J"4"M*8T":NB0!.CGTH>FYM2
M)Y286C".E6$WB))H/8*0;T-^CG9(>8Q]3'6*A5!QB(Y4;8>95VJ&I%EGA;%;
M987"6V6%W%MEA?!:9H7[66>#_%AG@_Q79X/\5V>#_%=G@_Q79X/\5_]L#@#_
M>PP \HD) -F5!@#/G@@ R:8( ,&K$ "XJR("KZHR"*:G/A*>I$@<EJ%1)8^>
M6"Z(FU\U@IEF/'V6;4%XE'1&<Y)[2V^0@T]KCXQ29XZ6562-HEAAC*]97XS
M6E^,V5E?C.Y97XS[6&&*_5=AB?U788G]5V&)_5=AB?U788G]5_]O# #_?PD
MWXT# -*8!@#*H@8 PJD& +JO#@"RL" !J:XO!J&L/!"8J48:D:=/(XFD5BR#
MHETS?9]D.7>=:S]RFW%$;IIY2&F8@4QEEXI089644UZ5H%5;E*U76I2]6%F4
MU%=9E.Q769/Y5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0 V)$#
M ,R<!0##I04 NZT$ +.S# "KM1P!H[0L!9NR.0Z2L$07BJU-((.K5"E]J5PP
M=Z=B-G&E:3QLI&]!:*)W162A?TE?GXA,7)Z23UB>GE)6G:M35)V\5%.=T513
MG>M34YSX4U2:_U-4F?]35)G_4U29_U-4F?]35)G_4_]X!@#AB0  T)8" ,:A
M P"\J0, L[ ! *NX" "DNA@ G+HI Y2Y-@N,MT$4A+5*'7RS4B5VL5HL<*]@
M,FNN9SAFK6X\8JMU0%ZJ?41:J89(5JB12E.HG4U1IZI.3ZBZ3TZHST].I^E/
M3:;W3TVE_T].I/]/3J3_3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE @"T
MK0$ J[4  *&_! ";P10 E,$E HS ,PB$OSX1?+U(&76\4"%ONE@G:KE?+66X
M93)@MVPV7+9T.EBU?#Y5M(5!4;201$ZSG$9,LZE(2K.Y2$FTSDA)L^E(2+'V
M24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0
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M(S3K^",TZ_@C-.OX([.E  "FK0  F;<  (W!  " RP  ==4! &GA!@!D\Q$
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M4&YWV5!N=^]/;G?\3FYW_TUO=_],;W?_3&]W_TQO=_],;W?_3/]D#0#_<@H
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M2E>._TI8CO])6([_25B._TE8CO])6([_2?]Q 0#@@   SXP  ,26 @"[G@(
MLJ0  *FJ!0"BK!4 FZPF I2K- >,JC\/A:A(%WZF4!YXI%@E<Z)>*VZA93!J
MGVPT99YS.6&=>SQ>FX1 6IJ.0U>9FD54F:='4IFV2%&9RDA1F.9(49?U2%&7
M_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@  JZ@
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M-T"W_S= M_\W0+?_-\Z+  "_F   LJ$  *>I  "<L   D;@  (;  @![R <
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M&P!6XR<!4N0R D[D/ 1*Y$0&1^5-"$7E50I"Y5P,0.5D#C[F;! [YG82.>:
M%#?GC!4UYYD6-.>H%S+HN!@RZ,P8,>CE&#'F]!@QY?P8,>7\&#'E_!@QY?P8
M,>7\&*ZB  "AJ@  E+,  (B]  ![Q@  ;\X  &/6 0!8W@4 5.X0 %'O&P!-
M[R8!2? O D7P. -!\3\$/O%'!3SR3@8Z\E4'-_)<"#7S9 DS\VT*,?1W#"_T
M@@TM](\.*_6=#RKVJQ I]KP0*/;.$2?WYA$G]?$1)_7Q$2?U\1$G]?$1)_7Q
M$:.H  "6L@  B+L  'O%  !OS@  8M<  %;>  !.\ < 2OH0 $;[&0!"^R(!
M/_PJ 3O],@(X_3D"-?X_ S+^1@,P_TP$+O]3!2O_6@4I_V(&)_]K!B3_=@<C
M_X(((?^0""#_G0D?_ZL)'O^Z"1W_R0D<_]T)'/_="1S_W0D<_]T)'/_="9BP
M  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP -/\D
M 3'_*P$M_S$!*O\V B?_/ (E_T("(_]( B#_3@,>_U4#'/]= QG_9P07_W($
M%?]_!!3_C 43_YH%$O^F!1'_L@41_[P%$?^\!1'_O 41_[P%$?^\!8RX  !]
MP@  ;\P  &+8  !4WP  1^4  #[Q   Y_P$ -/\+ ##_$  L_Q8 *?\< ";_
M(@ B_R<!'_\L 1S_,0$:_S8!&/\\ 17_00$3_T@"$?]/ A#_5P(-_V$"#/]L
M @K_>0()_X8#"/^2 P?_G0,&_Z4#!O^E P;_I0,&_Z4#!O^E _\Q,0+_-BX"
M_SHO O\[,@/_.SD$_SM#!?\Y3P?_.%P*_S9H#?\T=!#_,H 2_S&+%/\PE!;_
M,)L7_R^B%_\OJ!C_+J\9_RZU&?\NO!G_+L4:_R[/&O\NX!K_+NL:_R[T&O\N
M_!K\+_\9^R__&OHN_QOZ+O\<^B[_'/HN_QSZ+O\<^B[_'/\S+P+_.2P"_STM
M O\^, /_/S8$_S]!!?\]30?_/%D*_SIE#O\X<A'_-GT3_S6(%?\TD1?_,YD8
M_S.@&?\RIAG_,JP:_S&S&O\QNAO_,<(;_S',&_\QW1O_,>D;_3'S&_HR^QOX
M,O\;]S+_'/8Q_QWU,?\>]3'_'O4Q_Q[U,?\>]3'_'O\U+ +_/"H"_T J O]"
M+0/_0S0$_T0_!?]"2@?_058*_S]B#O\];A'_.WH4_SF$%O\XCAC_-Y89_S:=
M&O\VI!O_-:H<_S6P'/\UMQW_-;\=_S7)'?PUV!WZ-><=]S7Q'?0U^AWR-?\>
M\37_'_ U_R#O-/\A[S3_(>\T_R'O-/\A[S3_(?\X*@+_/R<"_T,F O]&*0+_
M23(#_TD\!?](1P?_1E,+_T1?#_]":A+_0'85_SZ &/\\BAG_/)(;_SN:'/TZ
MH!W\.J<=^SFM'OHYM!_Y.;P?^#G&'_8YTQ_R.>0?[SGP'^PZ^A_J.?\AZ3G_
M(^@Y_R3G.?\DYSG_)><Y_R7G.?\EYSG_)?\\)P+_0R,"_T@B O],)@+_3R\#
M_U Y!?].0P?_3$\+_TI;#_](9A/_17$6_$-\&?I"AAOX08X<]D"6'O4_G1_S
M/Z,@\CZJ(/$^L2'P/KDA[C[#(>T^SR'J/N(AYC_O(>,^^2/A/?\EWSW_)]X]
M_RC</?\HW#W_*-P]_RC</?\HW#W_*/\_(P'_1R !_TP> ?]1) +_52P#_U8U
M!/]5/P;_4TH*_E!6#_I.8A/V2VT7\TEW&O!'@1SN1HH>[$62(.M$F2'I0Z B
MZ$.G(^9#KB/E0K8DY$+ ).)#S"3?0^ DVT/M)=9"^"C30O\JT4+_*\]!_RO.
M0?\LSD'_+,Y!_RS.0?\LSD'_+/]#( '_2AP!_U ; ?]7(0'_6R@"_UPR _];
M.P;\648)]E91#O%471/M46@7Z4]R&N9-?!WD2X4@XDJ.(>!)E2/>2)PDW$>C
M)MI'JR?81K,HU4:\*--&R"G11MPJS4?L*LE&]RS'1O\NQ$;_+\-&_R_"1O\O
MP4;_+\%&_R_!1O\OP4;_+_]&'0'_3A@!_U88 ?]<'@'_8"4"_V(M _QB-P7T
M8$$([EU,#>A:6!+C6&,7WU5N&]M2=Q_84( BU$^))-%-D"?/3)<HS4R>*LM+
MIBO)2JTLQTJW+<9*PB[$2M$OP4OG+[U*]#&[2O\RN$K_,K=+_S.V2_\SMDO_
M,[9+_S.V2_\SMDO_,_]*&@'_4A4!_UH6 ?]A&P'_9B$!_F@I O1H,@/L9SP&
MY61("]]A5!#97EX7TEMI',Y8<B#+5GLDR%2#)\52BRK#49(LP5"9+K]/H2^]
M3Z@QNTZQ,KE.O#.W3LHTM4[A-+).\36O3_TVK4__-JQ/_S:K3_\VJT__-JM/
M_S:K3_\VJT__-O]-%P'_51(!_U\4 /]F& #_:QT!^&TD >UN+ +E;38$W6M#
M"-1G3Q#-9%H7R&!D'<1=;2+!6W8FO5E^*;M7A2RX5HTOME64,;14G#.R4Z0T
ML%*M-JU2MS>L4L4XJE+:.*=2[3FE4_HYHU/_.:)3_SFA5/\XH53_.*%4_SBA
M5/\XH53_./]/% '_61  _V,2 /]J% #_;QD \G(? .9T)@'==#$"TW$_",MM
M2P_%:587P&9@';MC:2*W8'$GM%YY*[%<@"ZN6X@QK%F/,ZI8ES6G5Y\WI5>H
M.:-6LSJA5L [GU;2/)U6Z3R;5_@\FE?_/)E8_SN86/\[F%C_.IA8_SJ86/\Z
MF%C_.O]2$@'_7 X _V80 /]M$0#Z<Q0 ZW<8 .!Y'P#4>2T"RW8\!\1R2 Z^
M;U,6N&M<';-H92*O96TGK&-U*ZEA?"^F7X0RHUZ+-:%=DS>>7)LYG%ND.YE:
MKSV76KL^EEK,/Y1:Y3^26_4^D5O_/I!<_SV07/\\CUS_/(]<_SR/7/\\CUS_
M//]5$0#_7PT _VD. /]Q#@#U=Q  YGL1 -E]& #.?2H"Q7LY!KYW10ZW=% 5
ML7!9'*UM8B*H:FDGI6AQ+*%F>"^>9( SFV*'-IAACSB68)@[DU^A/9%>JS^/
M7KA C5[(08M>X4&*7_- B5__/XE@_SZ(8/\^B&#_/8A@_SV(8/\]B&#_/?]7
M#P#_8@P _VP, /AT# #I>@P WGX, -*!%0#(@2<!P'\V!KA\0@VR>$T5K'56
M&Z=R7R*B;V8GGFQN+)MJ=3"7:'PSE&>$-I%EC#F.9)4\C&.>/HEBJ$"'8K5"
MA6+%0H1BWD.#8_%"@F/]08)D_T""9/\_@F3_/X)D_S^"9/\_@F3_/_]9#@#_
M9 L _VX* .IW" #;?0@ U((* ,R$$@##A20!NX,T!;. 0 RM?$L4IGE4&Z%V
M7"&<<V0FF'%K*Y1O<B^1;7DSCFN!-HMJB3F(:)(\A6>;/X)FID& 9K)#?F;!
M1'UFV41\9^]#?&?\07QH_T!\:/] ?&C_/WQH_S]\:/\_?&C_/_];# #_9PD
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M0V9X_T)F>/]!9GC_0&9X_T!F>/] 9GC_0/]D P#N<0  V'P  ,N% @##C ,
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M/$^1_SQ/D?\\3Y'_/.1T  #/@0  PHP  +B6  "MG   HZ$  )BH  "0J@T
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M)+V1  "PFP  I*(  )BJ  ",L0  @+D  '6_  !JQ@0 7LP( %G/$@!7T"$
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M!R7PIP@D\;@((_',""+RY0@B\/,((N_U""+O]0@B[_4((N_U")ZF  "1KP
MA+@  '?!  !JR0  7=   %'7  !&W0  /^H% #SV#@ Y]A< -O<@ #/W*  Q
M^#  +ODV 2OY/0$I^D0!)_I* B7[4@(C^UH"(/QC Q[\;@,<_7L#&_Z)!!G^
MF 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP  >,
M &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F_R<
M(_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_AP(.
M_Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D  %[3
M  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX &/\C
M !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$ _X$!
M /^/ 0#_FP$ _Z<! /^I 0#_J0$ _ZD! /^I ?\L+P'_,"P!_S(L O\S, +_
M,38#_S!! _\O303_+5H&_RMF!_\I<PC_*'X*_R>("_\GD0S_)YD-_R:?#?\F
MI0[_)JL._R:Q#_\FN __)L /_R;)#_\FUP__)N8/_R;P#_XF^0_[)_\/^2?_
M#_DF_Q'X)O\1^";_$O@F_Q+X)O\2^";_$O\N+ '_,RD!_S4J O\V+0+_-C0"
M_S4_ _\S2P3_,E<&_S!D!_\N< G_+'L*_RR%#/\KC@W_*Y8._RJ=#_\JHP__
M*JD0_RJO$/\IMA#_*;T1_RG'$?\ITQ'^*>,1^RKO$?@J^!#V*_\0]"K_$O0J
M_Q/S*O\4\RG_%/,I_Q3S*?\4\RG_%/\Q*0'_-B8!_SDF ?\Z*0+_.S("_SL]
M _\Y2 7_-U0&_S5@!_\S; G_,G<,_S""#?\PBP[_+Y,/_R^:$/\NH!'_+J81
M_RZL$O\NLQ+^+KH2_2[$$OLNSQ/X+N$2]2[M$O$O]Q+O+_\3[B[_%>TN_Q;L
M+O\7["[_%^PN_Q?L+O\7["[_%_\T)@'_.2,!_STC ?\^)@+_02\"_T$Y _\_
M103_/5 &_SM<"/\Y: K_-W,-_S9^#O\UAQ#]-(\1_#26$OHSG1/Y,Z,3^#.I
M%/<SL!3V,[<4]#/ %/,SS!3P,]X4[3/K%.DT]A7G,_\7YC/_&.0R_QGD,_\:
MXS+_&N,R_QKC,O\:XS+_&O\X(P'_/2 !_T$? ?]%(P'_1RP"_T<V _]&0 3_
M1$P&_T%8"/\_9 O[/F\.^3QY$/8[@Q'T.HL3\SF3%/$YF13P.* 5[CBF%NTX
MK1;L.+06ZCB]%NDXR1;G.-L6XSGJ%N X]1C=./\:VS?_'-DW_QW7-_\=UC?_
M'M8W_Q[6-_\>UC?_'O\[( '_01P!_T4: ?]+( '_32@!_TXR O]-/ 3_2D<&
M^DA3"/9&7POR1&H.[T)T$>Q!?A/J0(<4Z#^.%>8^EA;E/IP7XSVC&.(]JAC@
M/;(8WSV[&=T]QAG;/=@:UCWI&M(]]1W./?X?S#S_(,L\_R')//\AR3S_(<D\
M_R')//\AR3S_(?\_' '_11<!_TL7 ?]0'0'_4R0!_U0M O]3-P/W44(%\4Y-
M".Q,6@OH2F4/Y4AO$>)'>13?18(6W42*%]I#D1G80ID:U4*?&]-!IAS10:X=
MST&W'LY!P1[,0= ?R4+E'\5"\R'"0?XCP$'_)+Y!_R2]0?\EO4'_);U!_R6]
M0?\EO4'_)?]"& '_21, _U 4 /]6&0#_62 !_UHH ?=:,@+O6#T$Z%5)!^-3
M50K>46 .V4YJ$M1,=!;02WP8SDF$&\Q(C!S*1Y,>R$>:'\9&H2'$1JDBPD6Q
M(\%%O"._1<DDO4;?);E&[R:V1OLGM$;_*+-&_RBR1O\HL4;_*+%&_RBQ1O\H
ML4;_*/]&%0#_31$ _U42 /];%@#_7AL ^6 C >]@+ 'F7C8#WUQ$!=A94 K1
M5UL/S%1E%,A2;AC%4'<;PT]_'<!.AA^^38XAO$R5([I+G"2X2J0FMDJL)[1*
MMBBS2<,IL4G6*:Y*ZBJK2O@KJ4K_*ZA+_RNG2_\KITO_*Z=+_RNG2_\KITO_
M*_])$@#_4 X _UD0 /]?$@#_8Q8 \F4= .=E)0#>9#$!U&(_!<U@2PK'758/
MPEI@%;Y8:1F[5G$<N%1Y'[93@2*S4H@DL5"0)J]0ERBM3Y\IJTZH*ZE.LBRG
M3KXMID[.+J-.YBZA3_4NGT__+IY/_RZ=3_\NG5#_+IU0_RZ=4/\NG5#_+O],
M$ #_5 T _UT. /]C#P#Y9Q$ ZVD5 -]J' #3:BP!RV@[!,5E1PF_8E(/NF!<
M%;9=91FR6VT=KUEU(:Q8?".J5H,FIU6+**54DRJC4YLLH5.C+I]2K2^=4KDP
MFU+),9E2XC&74_(QEE/_,954_S&45/\PE%3_,)14_S"45/\PE%3_,/]/#@#_
M6 L _V + /MF# #P:PT Y&T. -9N%@#,;R@!Q&TW!+UK1 FW:$\/LF58%:YB
M81JJ8&D>IUYP(:1=>"6A6W\GGUJ'*IQ9CBR:6)<NF%>@,)56JC*35K4SD5;%
M-)!6W32.5_ TC5?],XQ8_S.,6/\RC%C_,8Q8_S&,6/\QC%C_,?]1# #_6PD
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M.')G_S=R:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P,
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M-5YX_S5>>/\U7GC_-?5D  #<<   RGH  ,"#  "VB0  KHT  *2/  "=D1
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M%S>]M1@VO<H8-[SG%S6[]ADUNO\:-+G_&S2Y_QLTN?\;-+G_&[B/  "JF
MGY\  ).F  "'K   >[,  &^Y  !CO@  6,0$ %#(# !-R!< 3,DE $K*,0!'
MRCL!1<I$ D/*3 -!RE0$/LI<!CS*9 <ZRVX).,MX"C;+A0PTRY(-,LNB#C'+
ML@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@  E:4
M (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [US$
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M A#[Q@(0^]T"$/OI A#[Z0(0^^D"$/OI H^K  "!M   <[T  &;&  !9S0
M2],  $#9   UW@  +.,  ";Q   D_@H (?\0 !__%@ <_QP &?\B !?_*  5
M_RX $_\U !+_/  0_T, #O],  W_5@ +_V( "?]O  C_?P$'_Y !!?^@ 03_
MK@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0  /]P
M #/A   IY0  (>P  ![]   :_P4 %_\, !7_$  2_Q0 $/\9  [_'@ -_R,
M"_\H  C_+@ &_S4  _\]  #_1@  _U$  /]=  #_:P  _WL  /^+  #_F0
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M'ZI%XR"G1O,AI4;_(:-&_R*B1O\AHD;_(:)&_R&B1O\AHD;_(?]%#@#_2PH
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M*X!8_RJ 6/\J@%C_*8!8_RF 6/\I@%C_*?]/ @#]60  XF   -5G  #,:@,
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M*VIG_RMJ9_\K:F?_*_Y8  #A8P  SVP  ,1S  "[>   LWH  *MZ! "D>Q(
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M(T24LR-#E,@C0Y3E(T.2]21#D?\D0Y#_)$.0_R1#D/\D0Y#_),IU  "[@0
ML(L  *21  ":E0  CYD  (.=  !TH@  ;J,+ &JD%P!FI24 8Z4Q 5^D.P-;
MI$0%6*1+"%6C4PM2HUH-3Z)A$$VB:!-*H7$51Z![&$2@AAI"GY,<0)^B'3Z?
MLAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB   J9
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M""K$\ @IPOL)*,'_"BC!_PLHP?\+*,'_"ZB5  "=FP  D:(  (2I  !XKP
M:[4  %^[  !4OP  2<,  #_(!  VS0D ,\X1 #+/'  QSR< ,- Q "_0.@ N
MT4, +=%, "O250 JTE\!*--I 2?3=@$ETX0")-24 B+4I@(AU;D"(=72 B#3
MZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN   8+X
M %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @X#<
M'^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13GW0$3
MY>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*
M   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U
M !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD
M"/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   Q
MV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^
M,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.
M  #_SP  _\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0
M'.4  !3I   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P
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M"<DQZ@K&,?<,PS'_#L$Q_P_ ,?\/OS'_#[\Q_Q"_,?\0OS'_$/\V$P#_.0\
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M')5&_QN41O\;DT;_&Y-'_QN31_\;DT?_&_]"!0#_2@$ \E   .%4 0#95@4
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M)6I?^R1J7_\C:E__(FI?_R)J7_\B:E__(O!2  #=70  RV4  ,!K  "W;@
MKV\  *=N 0"@;Q  FG ? )1P+ &/;S@#BFU"!H9L2PF":E(,?FE9#WMH8!)W
M9F84=69N%W)E=1IP9'X=;6.('VMCDB)I8IXD9V*K)65BNB9D8L\F9&+J)F5B
M^B1E8_\C96/_(F5C_R)E8_\B96/_(NM5  #88   R&@  +QN  "S<0  JW,
M *)Q  ";<@X E7,< )!T*@&*<S8"A7) !8%P2 A];U +>6U7#G9L7A%S:V04
M<&IL%VUI<QIK:7P<:&B&'V9GD"%D9YPC8F:I)6!FN29?9LTF7V;H)F!F^21@
M9O\C8&;_(V%F_R)A9O\B86;_(NA8  #38P  Q&L  +EQ  "P=0  IW<  )YU
M  "6=@T D'<9 (MX)P"&=S,"@78]!'QU1@=X<TX+=7)5#G%Q7!%N<&,4:V]J
M%FEN<1EF;GH<8VV#'F%LCB%?:YHC76NG)5MKMR9::\HF6FOG)5MK]R1;:O\C
M7&K_(EQJ_R)<:O\B7&K_(N-;  #.9@  P&X  +9T  "L>0  HWL  )AY  "0
M>@L BGL6 (5\) "!?#$!?'L[!'=Z1 9S>4P*<'A3#6QW6A!I=F$39W5H%F1T
M;QAA<W@;7G*!'5QQC"!:<9@B6'"F)%9PM255<,@E57#E)55P]B16;_\C5F__
M(E=O_R)7;_\B5V__(M]?  #*:0  O'(  +)X  "I?0  GW\  ))^  "*?P<
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M&\)S  "U?@  JH<  )^,  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T
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M""ZRI@@MLK@)+++0""RP[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@
ME9@  (F=  !]HP  <:@  &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ U
MO"D -+TR #.].P RO40 ,;Y, "^^50$NOEX!++YH 2J^= (IOH(")[^1 R:_
MH@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[_P4BN_\%(KO_!:22  "8F   C)X
M ("E  !SJP  9[   %NU  !/N0  1+P  #K    PQ 0 *L<+ "C($P GR1T
M)LDG "7),  DRCD (\I" "++2P ARU4 (,Q? !_,;  =S7H ',V* !O-G  9
MSJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8RO\"&,K_ IN9  "/GP  @J8  '6M
M  !HLP  7+D  %"]  !$P0  .<0  ##(   HS $ (- & !G5"P 6UQ  %=@9
M !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3 !'=7P 0W6T $-Y^  [?D0 .X*0
M#>"X  S@T@ +W^T #-[W  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=
MO   4,$  $3%   XR0  +LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH
M&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG
M  #KO   Z](  .OI  #L[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0
M0\D  #?-   MT0  (]8  !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #
M]A@  /4>  #U)0  ]2X  /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #W
MIP  ][<  /C'  #XT   ^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$
M "O7   AW   &.   !'D   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A
M /X4  #_&@  _R$  /\I  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@
M_Z$  /^M  #_LP  _[,  /^S /\<)@#_'"0 _QHE /\5)P#_$2X _Q Z /\.
M1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*AP'_"HX!_PJ5 ?\*FP'_": !_PFE
M /\)JP#_";$ _PFX /\)P0#^"<P _ G> /D)ZP#U"?8 \PG_ /(*_P#Q"O\!
M\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$ _QXA /\9) #_%RP _Q4W /\31 #_
M$5 !_Q!< ?\.9P'_#G(!_PY[ ?\.A '_#HL!_PZ2 ?\.F '_#IT!_PZC ?X.
MJ '\#JX!^PZU /H.O@#X#LD ]0[; /(.Z@#N#O4 [ [_ >L/_P'J#_\!ZA#_
M >D0_P'I$/\!Z1#_ ?\B'P#_(AP _R$< /\?( #_'RD _QPT /\:0 #_%TP!
M_Q58 ?\48P'_$VX!_Q-W ?X3@ '\$X@!^A*. ?D2E0'X$IH!]A*@ ?42I@'T
M$JP!\Q*S ?$2O 'P$L<![1+8 >D3Z 'F$_4!Y!3_ >(4_P+A%?\"X17_ N 5
M_P+@%?\"X!7_ O\E&P#_)A< _R06 /\E' #_)B4 _R0P /\A.P#_'T@ _QU4
M ?T;7P'Y&FD!]QIS ?09? 'R&80!\1F+ >\9D0'N&9<![!F= >L9HP'I&:H!
MZ!FQ ><9N@'E&<4!XQG5 =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32
M'/\$TAS_!/\I%P#_*A, _RD2 /\L& #_+"$ _RPK /\I-P#])T, ]R5/ ?,C
M6@'O(F0!["%N >DA=P'G(7\!Y2&& >0AC0'B()0!X2": =\@H '>(*<!W"&O
M =HAN +8(<,"U2'3 M$BYP+-(O0#RB/_!,@C_P7'(_\&QB/_!L8C_P;&(_\&
MQB/_!O\L$@#_+@\ _S 0 /\S% #_,QL _S(E /HP, #R+CP ["Q) .<J50'C
M*E\!X"EI =TI<@':*'H!URB" M4HB0+3*) "T2B6 \\HG /.**,#S"BK \HH
MLP/)*+X$QRC,!,4IX@3!*O$&OBK^![PJ_PBZ*O\(NBK_"+DJ_PFY*O\)N2K_
M"?\P#P#_,@L _S8- /\X$ #_.14 ^3<> .\U* #G,S4 X#)" -LR3P#5,5H!
MT#%D LTP;0++,'4#R3!\ \<O@P3%+XH$Q"^1!<(OEP7!+YX&OR^F!KTOKP:\
M+[D'NB_'![@PW0>U,.X)LC#["K P_PNN,/\+KC#_"ZTP_PNM,/\+K3#_"_\S
M# #_-@8 _SP) /\^# #]/1  [SP5 .0Y'P#;.2T TCH\ ,TZ20'(.50!Q#E>
M L$X9P._-V\$O3=V!;LV?0:Y-H0'MS:+![8UD@BT-9H)LS6A";$UJ@JO-;0+
MKC7!"ZPUU NI-NH,IC;X#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_
M.P( _T # /)"!0#I0@D Y3\. -@^%@#.0"< QT$V ,)!1 &]04\"N4!9 [8_
M802T/FD&L3UQ!Z\]> BN/'\)K#R&"JH[C0NI.Y4,ISN=#:4[I@VC.K .HCN\
M#Z [S0^>.^80FSSU$9H\_Q&9//\1F#S_$9@\_Q&8//\1F#S_$?\Z 0#_0
M[T4  .%(  #92 4 TT8) ,Q%$@#$1R( O4@Q +A(/P&S1TH"L$94!*Q%706J
M1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>0) /G$"8$)I H1&80*P2ET"X$I5
MR!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"_Q..0O\3CD+_$_\\  #Y1   Y$H
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M?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  #
M60  NE@! +16"0"L5Q8 IE@E *%8,@&=5SX"F%9(!)5540:25%@(CU)?"HQ2
M9@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].EQ=]3J$8>TVN&7I.O1IX3M$:=T[K
M&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__%_A&  #B4   T%<  ,1<  "[7@
MM%T  *Y:!@"F6Q, H%PB )M<+P"76SL"DEI% X]930:+6%4(B%=<"H968PR#
M56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV4I\9=%*K&G)2NAMQ4LT<<%+H&W!3
M^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])  #=4P  RUH  ,!?  "W8@  KV$
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M&F%>_QIA7O\:85[_&N12  #/7   P&0  +9I  "L;   HVP  )EI  "2:@L
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M&<Y@  "^:@  LG(  *AX  "=>P  D'H  (1Z  !Z>P  ='P, &]^%P!L?B0
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M$3R*IQ([BK@2.HK/$CN(ZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P
MI8,  )F'  ",B   ?XD  '.,  !ED   7),  %>5# !4EA8 4I8B %"7+0!-
MES8 2Y<_ 4F71P)'ETX#1995!$.6705!EF4&/I5O"#R5>@DZE8<+.)65##:4
MI0TUE+8.-)3,#323Z0TTDO@.-)#_#S20_P\TD/\/-)#_#[5X  "J@@  GH@
M ).-  "&C@  >9   &V3  !AEP  59L  $V>!@!)GQ  1Y\; $:@)@!$H#
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M,@ IMSH *+=# ">W3  FN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G
M 1RXWP$<MO(!&[7\ ANT_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@
M8JL  %:P  !*LP  /[8  #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :
MPR\ &<0X !C$00 7Q$H %L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'
MU  0QNX $,3Z !##_P 0P_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0
M $NX  ! NP  -;X  "O!   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$
M#-$J  S1-  +TCX "M))  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !
MU=P  =7M  '5]@ !U?8  =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_
M   TPP  *L<  "'*   9S@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@
M  #>*   WS$  . \  #A1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$
M .75  #FYP  YN<  .;G (.D  !UK   :+,  %J[  !-P0  0,0  #/(   H
MS   ']   !?4   0V0  "]T   7A    Y    .4'  #F#0  YQ$  .@6  #I
M'0  ZB4  .LN  #M.0  [T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[
M  #TR   ],@  /3( '>M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@
M%-P   [@   (XP   >8   #J    [@   .X   #O!   \ H  /$.  #S$@
M]!@  /8@  #X*@  ^C4  /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_
ML   _[   /^P /\6(P#_%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!=
M /\ : #_ '( _P![ /\ @P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P
M^0"S /< NP#U ,4 \P#1 /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M
M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$
M9 #_!&X _P-W /\#@ #_ X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P
M /$!N #O <( [0'/ .L!XP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\
MY@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_
M"VH _0MS /L+? #Y"H, ]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)
MM@#H"<  Y@G- .0)X@#B"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_
M ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8
M\Q!O / 0=P#N$'\ [!"& .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@
M#[X W@_, -H0X0#5$?  TA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B
M$@#_(@\ _R$/ /\B% #_(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J
M .06<@#B%GH X!:" -X6B #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L
MSA?) ,P8W@#(&>X!Q1K[ <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_
M)0L _R@, /\I$ #_*!8 _B8@ /0D*P#L(3@ YB!$ .$?4 #='UL V1YE -4>
M;0#2'W4 T!]] ,X?@P#,'XH!RQ^0 <D?EP'('YX!QA^E <4@K0'#(+<!P2#$
M < AU@&\(NH"N2+X [8B_P.U(_\#M"/_!+,C_P2S(_\$LR/_!/\I"P#_*@4
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M#8H\^PV)//\-B3S_#(@\_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20
MOT8" +I## "S1!D K44G *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:4
M07 'DD%V")! ?@F.0(8*C4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!
M^0^ 0?\/@$+_#H!"_PZ 0O\.@$+_#OH[  #E1   TTL  ,=.  "^3P  N$P
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M$FM._Q%K3O\1:T[_$>A&  #34   Q%8  +E:  "P7   IEH  )]6  "85@T
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M$M93  #$7   MV,  *QH  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R<
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M$4ELIQ)(;+@31VS-$T=LZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P
MK&X  *%R  "3<@  AW$  'IQ  !Q<@  :W0' &9U$0!C=AT 8'<H %YW,P!;
M>#P!67=# E9W2P-4=U($4G99!5!V8 =.=6@(2W5Q"DET? Q'=(@.17.6#T-S
MI1!"<[8107/+$4)RZ!%"<O@10G'_$$-P_Q!#</\00W#_$,%C  "S;   J',
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M!R^.X0<OC/0(+XO_""^*_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0
M<(<  &6*  !:C@  3Y(  $:5  !!F P /I@4 #V9'P [F2@ .IHQ #F:.@ W
MFD( -II* #6:4@$SFEH!,9ID 2^:;P(MFGL"+)J* RJ:F@,IFJP$*)K !">9
MW@,GE_($)Y;]!2>5_P4GE?\%)Y7_!:E^  ">A0  DHD  (2*  !VC   :H\
M %Z3  !4EP  29L  $"?   WH@0 ,J,. #&C%P PI"$ +J0J "VD,@ LI3H
M*Z5# "JE2P II50 **5> ":E:0 EI78!(Z6% 2*EE@$@IJ@!'Z6[ 1ZEUP$>
MI.\!'J+[ AZA_P(>H?\"'J'_ J*&  "7C   BX\  'V1  !OE   8Y@  %>=
M  !-H0  0Z4  #BH   PJP  **X' "2O$  CKQ< (:\A ""P*0 ?L#$ 'K Z
M !VQ0@ <L4P &[%6 !JQ80 9LF\ &+)^ !:RD  5LJ( %+*V !.RS@ 3L>L
M$Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%
MK   .[   #&R   GM0  (+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]
M-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P
M  B]^@ (O?P "+W\ ).4  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@
M,;@  ">[   ?O@  %\$  !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #
MRC8  LI   #+3   RUD  ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,
M[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$
M !W$   5R   #\L   K.   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH
M -DT  #:/P  W$L  -Q:  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@
MWN(  -[B '^B  !QJ0  9+   %:W  !)O   /,   "_$   DQP  &\L  !//
M   -T@  !]8   #;    W@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G
M  #H,0  ZCT  .Q+  #L6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8
M .[& '2J  !FL@  6+D  $O    ]Q0  +\D  "3-   9T0  $=8   O;   #
MW@   .$   #E    Z    .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T
M(P  ]RX  /D[  #[2@  _%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO
M /\0'P#_#AT _PH= /\!( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X
M_P!W /\ ?P#^ (8 _ ", /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R
M +T \0#) .\ W #N .L [0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3
M' #_$1D _PT9 /\&' #_ R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S
M /H >P#W (, ]0") /0 CP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H
MZ #& .< U@#E .@ Y #U ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_
M$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /(
M=P#O 'X [0"% .L BP#J )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP##
M -T T0#; .8 V0#S -< _0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1
M_Q(/ /\2%0#_$1T _PXH /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F
M!7H Y 6! .(%AP#@!HT WP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - '
MSP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@-
M /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74
MV U\ -4-@@#3#8D T0V/ - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##
M$.8 P!'U +T2_P"\$O\ NQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?
M#0#_'1( ^!H; .X6)@#F%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W
M ,<5?0#&%80 Q!6* ,,5D0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.(
MLQGR ;$:_P&O&_\!KAO_ :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W
M(0P [!T2 .$:' #8&BH T!LX ,L=10#''5  PQY: , >8@"^'FH O!]Q +H?
M> "Y'WX MQ^% +8?C "T'Y, LQ^: ;$@HP&P(*P!KB"W :PAQ@&K(=T!IR+O
M J4B_0*C(_\"HB/_ J(C_P*A(_\"H2/_ O\E  #_*   \BH  .4K  #?* 4
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M"'H\_PAZ//\(>CS_".XW  #=00  RT8  +])  "V20  KD8  *E!! "C01$
MG4(> )A#*P"50S< D4-! (Y"2@&,0E(!B4%9 H=!7P.%068#@T!M!(% = 6
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M"]Q'  #'4   N58  *Y9  "B6   F%8  )!1  ")4@8 @U,1 ']3'0![5"D
M>%0T '54/0%R4T4!<%-, FU24P)K4ED#:5)@!&=19P9E46\'8U%X"&)1@PI@
M48\+7E";#5U0J0Y;4;D.6U'.#UI1Z@Y;4?H-6U'_#%M1_PQ;4?\+6U'_"]9*
M  ##4P  MED  *M<  ">6@  DUD  (M4  "$5@, ?E80 'I7&@!V5R8 <U@Q
M '!7.@!M5T(!:E=) FA64 )F5E<#9%9>!&)5905@56T'7E5V"%U5@0I;58T+
M652:#5A4IPY65;@/5E7,#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  #
M5@  LUP  *=>  ":70  CUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;
M-P!H6T !95M' 6-:3@)A6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8
M#5-8I@Y26;8.45G*#U%9YPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60
ML%\  *-A  "68   BU\  (%;  !Y70  <UX, &]>%0!K7R  :%\K &9@-0!C
M8#T!85]% 5]?3 )=7U,#6U]:!%E>80577FD&55YR"%->?0E178D+4%V6#$Y=
MI U-7;0.3%W(#DQ=Y@Y-7?<-35S_#$U<_PQ.7/\,3ES_#,E4  "Y7   K6,
M )]C  "28P  AV(  'Q@  !T80  ;F() &EC$@!F8QT 8V0H &%D,@!>9#L
M7&1# 5ID2@)89%$"5F18 U1D7P128V<%4&-P!TYC>@A,8H8*2V*4"TEBH@Q(
M8K(-1V+'#4=BY U(8?8,2&'_#$A@_PM)8/\+26#_"\18  "U8   JF8  )MF
M  "-9@  @F4  '9D  !N90  :&8% &-G$ !@:!H 76DE %MJ+P!9:C@ 5VI
M 55J1P%3:DX"46I5 T]I701-:60%2VEM!DEH> =':(0)1FB2"D1GH0M#9[$,
M0F?%#$)GX@Q"9O4,0V;_"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  ")
M:0  ?6D  '%I  !G:@  8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P
M10%.<$P!3'!3 DIP6@-(<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6["
M"CQNX H];?0*/6S_"CUK_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0
M>&T  &QN  !A<   6W(  %9T"@!2=1( 4'8= $YW)P!,=S$ 2W@Y $EX00!(
M>$D!1GA0 41W5P)"=U\#0'=H SYW<P0\=G\&.G:-!SEVG @W=:T(-W7 "#9U
MW@@W=/((-W/^"#=R_P@W<O\(-W+_"+5F  "I;P  FG$  (MQ  !^<0  <W(
M &AS  !<=@  5'D  $Y[!0!*?0\ 2'X8 $9_(P!%?RP 0X U $* /0!!@$4
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M B"/_P(@C_\"((__ J1\  "7@   AW\  'N   !N@@  8H4  %>)  !-C@
M0I(  #J6   RF0  *IP) "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @
MGDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;
M_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P
M #.@   KHP  (Z8  !RH"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD,
M$ZM- !*K6  1JV4 $*MT  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -
MJ/\ #:C_ ):*  ")C   >HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ
M   CK@  &[   !2S 0 /M0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#
M  :W3P $MUL  [=J  *W>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<
M +7W (^1  "!E   <I<  &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :
MN   $[L   Z]   )P 4  \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$
M1   Q%   ,1>  #%;P  Q8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N
M (:8  !YG@  :Z,  %VI  !0K@  1+,  #>V   LN0  (KP  !F_   1P@
M#,4   ;(    RP   ,P'  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.
MU$0  -12  #580  U7,  -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@
M  !NI@  8*T  %.S  !%N   .+P  "N_   AP@  %\8  !#)   *S    M
M  #4    UP   -@   #:!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38
M .=#  #G4P  Z&0  .EW  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !B
MKP  5;8  $>\   YP   +,0  "#(   6S   #M    ?4    V0   -T   #A
M    XP   .0   #F    YP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S
M  #W0P  ^%0  /EF  #Y>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD
M_P 9 /\ ' #_ "4 _P R /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[
M (( ^@"( /@ C0#W )( ]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P
MT0#K .8 Z0#S .@ _@#H /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4
M /\ & #_ "( _P N /\ .P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X
M\@"$ /  B0#O (\ [@"4 .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A
M .( WP#P -X ^P#> /\ W0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"
M%0#_ !X _P I /\ -@#_ $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_
M .< A0#E (L Y "0 .( E@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T
MT0#M -  ^0#/ /\ S@#_ ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_
M!QD _P(D /\ , #V #P [P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L
M@0#9 (8 U@", -0 D@#2 )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J
M ,, ]P#" /\ P0'_ , "_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0
M_PH> /4&*0#K!#8 XP-" -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*
M!8( R06( ,<%C@#&!90 Q 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+
M^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5
M .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T
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M 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X  ,\O  #'+0  P2<# +TB#0"V(QH
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M!>(Y  #,0@  OD<  +%(  "E1@  G4,  )<_  "2/@L C3\5 (D_(0"%0"T
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M!UU(I0A;2+0(6TC'"5I(Y A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3
MLE(  *-1  "74   C4X  (9*  " 2@$ >DL. '9,%P!R3", ;TPM &U--@!J
M3#\ :$Q& &9,30%D3%,!8DQ: F%,80)?3&D#7DQR!%Q,? 5:3(@&64R5!U=,
MHPA63+((54S&"55,X@E53/4(54S_!U5,_P=63/\&5DS_!LQ(  "\4   KU4
M *!4  "34P  B5$  (%-  !Z3@  =4\, '!/%0!M4"  :E J &=0,P!E4#P
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M1@!664T!5%E4 5-96P)166,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC
M"$=8W0A'6/((1U?_!TA7_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P
M?5H  ')8  !K60  95H# &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !1
M7DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=
MV@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T
M &U<  !E70  7U\  %I@# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@
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M!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@  (%H  !U:0  :VD  &!K  !5;@
M37$  $9S  !"=0L /W82 #UW'  \=R4 .G@M #EX-0 X>3T -WE% #9Y30 U
M>54 ,WE> #%Y: $P>70!+GF# BUYD@(K>*,"*GBU BIXS (J=^H"*G;Y RIU
M_P,J=/\#*G3_ ZIJ  ":;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@
M $%[   Z?@4 -G\. #2 %@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E
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M )5]  "%?   >'P  &M^  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@
M'IT  !>@ P 2H@P $*,2 !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *
MI%P ":1J  >D>P &HXX !*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#
M  !_@@  <80  &2'  !8C   39$  $*6   XF@  +YX  ":B   >I0  %Z@
M !&K   ,K@< !Z\-  .O$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,
M +!A  "P<0  L(,  *^7  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !X
MB@  :HX  %V3  !1F   19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV
M   %N0,  +H*  "Z#@  NA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6
M  "^90  OG<  +Z,  "^GP  O;,  +['  "^W@  O>L  +WK '^2  !PE0
M8IH  %6?  !)I0  /:L  #*O   HM   'K8  !6Y   .O   ";\   +"
MQ    ,4$  #&"@  Q@X  ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/
M60  SVH  ,]^  #/DP  SZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<
M $ZN  !!M   -+<  "BZ   =O0  $\    W$   &QP   ,H   #.    T
M -$   #2 @  TP@  -4,  #6$   V14  -L<  #=)   X"\  .(\  #C2P
MY%P  .1O  #E@P  Y9@  .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y
M   UO   *,   !S$   2R   #,L   //    TP   -@   #<    WP   -\
M  #A    XP   .0#  #F"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T
M /5?  #V<P  ]X<  />9  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_
M ", _P O /\ / #_ $@ _P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8
MB #U (X ] "3 /( F #Q )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q
M .8 _0#E /\ Y #_ .0 _P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\
M_P K /\ -P#_ $0 _@!/ /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K
M (H Z@"/ .@ E #G )H Y0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@
M^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F
M /P ,@#W #\ ] !* /$ 50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4
MW@"+ -P D #; )8 V "< -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#(
M /\ R #_ ,@ _P#( /\ R #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$
M+ #L #D Z0!% .4 3P#A %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"&
M ,P C #+ )( R0"8 ,< H #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T
MNP#_ +H _P"Z /\ N@#_ /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A
M #( W  _ -8 20#1 %, S@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,
MAP"^ (X O "4 +L G "Y *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_
M *T#_P"M _\ K0/_ /\0  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL
MS ,W ,@$0P#$!$T P016 +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R
M!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-
M_P"A#?\ H W_ /\1  #\$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP
M +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4
MI0^- *0/E@"B$)\ H!"I )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5
M%/\ E!3_ /\5  #M&P  X!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4
M-0"L%4  J15) *854@"D%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>(
M )@7D0"6&)L E!BF ),9L@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\
MB1S_ /0=  #D)0  TRD  ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A
M'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@
MC0"*()< B2&B (<AK@"&(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_
M >PE  #;+0  R3$  +PQ  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4
MDR8_ )$F1P"/)D\ C296 (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0&
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M FHUI0)I-;,#:#7& V<VX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@
MM4(  *9!  ";/P  DSP  (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U
M.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K.6L!:3ET 6@Y?@)F.8D"9#F5 V,Z
MH@-B.K$#83K# V [X 1?._,#7SO_ U\[_P-?._\"7SO_ M$[  # 0@  L$4
M *%$  "50P  C4   (<]  "".P( ?3L. 'D\& !U/2, <STM ' ]-@!N/3\
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M!$]'U@5/1^\$3T?]!$]'_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P
M?TH  'A&  !Q1P  ;$<' &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !7
M24H 5DE1 %5*60%42F$!4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+
MTP5*2^X$2TO]!$M*_P-+2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT
M '-)  !L2@  9TL$ &),#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@
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M SU6_P,]5O\#/5;_ [93  "E5P  E%<  (56  !Y5@  ;U8  &55  !<5@
M5U@  %)9!P!.6A  3%H8 $I;(0!(7"H 1UPR $5<.@!$74$ 0UU( $)=4 !
M75@ /UUA 3U=:P$\778".EV$ CE=DP(X7:,#-UVU S9=RP,V7.@#-USY S=;
M_P,X6_\#.%K_ [)7  "@6@  CUD  (%9  !U60  :UD  &!:  !66P  45T
M $Q> @!(8 T 16 4 $1A'@!"8B8 0&(N #]B-@ ^8SX /6-% #QC30 [8U4
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M :%E  ".9   ?V0  ')D  !H90  7F8  %1I  !);   0F\  #MR   T=0
M+G@* "MY$0 J>1@ *7HA "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @
M>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI
M  "(:0  >6D  &UI  !C:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$#
M "*##0 @A!( 'X0: !V$(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF,
M%89Q !2&@0 2AI, $8:F !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!
M;0  =&X  &EN  !=<   4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-
M!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J
M  N1>@ *D8T ")"?  >0LP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P
M;W,  &-U  !7>   37T  $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .
MF@@ "YP.  F<$P (G!H !YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<
M<@  G(0  )R7  ";J@  F[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H
M %Q^  !1@@  1H<  #R,   RD0  *94  "&9   9G0  $J    ZC   )I@4
M Z<,  "G$   IQ4  *@<  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:
MJ7H  *F.  "IH0  J+4  *C+  "GY   I^\  *?S 'V   !O@0  880  %6)
M  !)C@  /I0  #29   JG@  (:(  !FF   2J0  #:P   >O    L@   +,'
M  "S#   LQ   +05  "T&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X
M +B"  "XEP  N*H  +>^  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"
MG   -Z(  "RG   BJP  &:\  !&S   +M@  !+D   "\    O@   +X   "_
M!@  P L  ,$/  #"$P  PQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU
M  #)B@  R9\  ,JQ  #*P0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP
M+[   "2U   9N   $+P   J_   !P0   ,0   #(    R@   ,H   #,
MS0,  ,X(  #0#0  T1   -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@
M?   X)$  ."D  #@L@  X+X  .## &:?  !9I@  3*T  #^T   RN   )+P
M !B_   0PP  ",<   #*    S0   -$   #5    V    -D   #;    W0
M -\   #A!   XPH  .4.  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P
M\X   /24  #THP  ]*X  /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\
M.0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0".
M /  DP#N )D [0"? .P I@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\
MX0#_ .$ _P#A /\ X0#_ /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^
M $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4
MCP#C )4 X0"; .  H@#> *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_
M -  _P#0 /\ T #_ /\ #0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L
M\ !' .T 40#I %H Y0!B .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3
M )$ T0"7 ,\ G@#- *8 RP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$
M_P#" /\ P@#_ /\#!@#_  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!!
M -\ 2P#; %0 U0!< -( 8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P
MPP"3 ,$ F@"_ *( O0"K +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T
M /\ M #_ /\$  #_    _P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T
M10#* $X Q@!7 ,0 7@#! &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0".
M +, E0"R )X L "G *X L@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\
MI@#_ /\&  #_!0  \0,  .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\
M $@ N0!1 +8 6 "T %\ L@!E +  :@"O '  K0!V *P ? "J (( J0") *<
MD0"E )H HP"D *$ K@"@ +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_
M /\*  #Q#@  Y!   -D/  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4(
MK09* *H&4@"H!UD I@=? *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":
M"9< F JA )8*K "5"[H DPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81
M  #F%P  UAL  ,<9  "^%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$
M )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90
MC1&? (L1J@"*$K@ B!++ (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<
M(0  RB4  +LB  "Q'P  JQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )06
M1P"2%DX D!95 (X76P",%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F;
M ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0
MORP  + J  "G)P  H",  )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"'
M'TD A1]0 (,?5@""'UP @!]B '\?:0!]('  ?"!X 'H@@0!Y(8P =R&7 '4B
MI !T(K( <R/# '(CWP!P)/, ;R3_ &\D_P!N)/\ ;B3_ -TI  #(,   MS(
M *@P  ">+@  ERH  ),G  "0(PH C",3 (@D'P"$)2H @B4T ( F/0!])D0
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M 5HUT@%9->T!637\ 5@U_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/
M@SH  'TW  !X-   =#0+ ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A
M-DT 8#93 %XW6@!=-V( 7#=J %HX= %9.'\!5SB, 58YF0%5.:@"5#FY E,Z
MSP)3.NL"4SK[ 5,Z_P%3.?\!4SG_ <0\  "R00  H$   ))   "&/P  ?CT
M '@Z  !S.   ;CD( &HY$0!G.1H 9#HD &(Z+ !@.C0 7CH\ %T[0P!;.TH
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M D1%_P)%1?\"147_ ;I&  "F2   E$@  (9(  ![1P  <D8  &I"  !C0P
M7D0  %I%"P!611( 5$8; %%&(P!/1BL 3D8S $Q'.@!+1T$ 2D=) $E(4 !(
M2%@ 1TAA $9):P!$278!0TF# 4))D@%!2:("0$FS C]*QP(_2N4"/TGW D!)
M_P) 2/\"0$C_ ;9)  "B2@  D4H  (-*  !W2@  ;DD  &5%  !>1P  64@
M %5)" !12A  3TH8 $Q*(0!*2RD 24LQ $=+. !&3#\ 14Q& $1,3@!#358
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M :A2  "54@  A%(  '=2  !L4@  8E(  %A3  !/5   258  $17  ! 60@
M/5H0 #M:%P Y6R  .%LG #=<+P V7#8 -5P^ #1<1@ S74X ,5U7 #!=80 O
M76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I7=X!*ESR 2I;_@$K6_\!*UK_ :-5
M  "/50  ?U4  ')5  !G5@  7E8  %17  !,60  15L  #]=   Z7P0 -F -
M #1A$P R8AP ,6(C #!B*P O8S( +F,Z "UC0@ L8TH *F13 "ED70 H9&D
M)V1V "9DA@ E9)< )&2I "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")
M6   >ED  &Y9  !C60  6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI
M$  J:1< *6H? "AJ)@ G:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR
M !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7
M=5P  &E=  !?70  5EX  $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A
M<A( (',: !]S(0 ><R@ '70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U
M?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$
M &5A  !;8@  460  $AG   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X
M%GT3 !5]&P 4?B( $WXJ !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,
M?XH "WZ=  I^L  )?<8 "GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F
M  !6:   3&L  $)O   Y<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.
M  R)%  ,B1L "XDC  J)*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,
M (F6  "(J0  A[X  (?:  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0
M<   1G0  #QX   S?0  *H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3
M$0  E!8  )0=  "4)   E2P  )4U  "50   E4P  )99  "6:0  E7H  )6.
M  "4H0  E+4  )/,  "2Y@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0
M/WX  #6#   LB   (XT  !N1   4E   #Y<   J:   $G0,  )X)  "?#@
MGQ(  * 7  "@'0  H24  *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "B
MF0  HJT  *'"  "AW   H>L  *#R '-V  !F=P  67L  $V   !"A0  .(L
M "Z0   DE0  &YH  !2>   .H0  ":0   *G    J@   *L$  "K"@  K T
M *T1  "M%@  KAP  *\D  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@
ML:,  +*W  "QR@  L>   +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>
M   <HP  $Z<   VK   'K@   +(   "U    MP   +@   "Y @  N0@  +H,
M  "[$   O!0  +T;  "_(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<
M ,2K  #$O   Q,L  ,3: &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4
ML0  #;8   :Y    O    +\   ##    Q    ,4   #&    QP   ,D$  #*
M"0  RPT  ,T1  #/&   TB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>
M  #;K@  V[H  -S# %Z6  !1G   1*,  #BJ   LL0  (+<  !6[   -O@
M!,(   #%    R0   ,T   #0    T@   -(   #5    U@   -D   #;
MW@4  . *  #B#P  Y18  .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #P
MGP  \*L  /"S /\ $ #_  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!-
M /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4
MZ@"; .@ H@#F *H Y0"S ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#>
M /\ W@#_ /\ #0#_  H _P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0
M4@#P %H [0!B .L :0#I &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6
M -H G0#8 *4 U0"O -( N@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\
MRP#_ /\ " #_  , _P % /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D
M %4 X != -T 9 #: &H V !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D
MF0#' *$ Q0"J ,, M0#! ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_
M /\   #_    _P   /D !P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %
MS@!7 ,L 7@#) &4 Q@!J ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y
M )P MP"E +4 L "S +T L0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\
M  #_    _0   .X  0#C  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2
M +P 60"Z %\ N !E +8 :@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@
MJ0"A *< JP"E +@ HP#( *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V
M    Z@   .    #3  8 R0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X
M4P"L %D J@!? *D 9 "G &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "=
M )H IP"8 +0 E@## )4 W "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P
MW T  ,L*  #"!0  O  * +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@
M %, G@!9 )P 7P"; &0 F@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"
MI ", K$ BP/  (D%U@"(!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4
M +P2  "S$   K@P  *L&#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X
MDPE4 )$*6@"0"E\ C@IE (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!
M#;  @ W  '\-V !]#N\ ? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<
M  "F&0  H14  )X0! "=#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/
M (<050"%$%L A!%A ((19P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX
M=1.^ '04U0!S%>X <1;] '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<
M(0  EAX  )(9  "1% L C104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P7
M4 !Z%U8 >1A< '<88@!V&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[
M &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*
MC24  (@B  "&'08 @QL0 '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q
M'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$C
MS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H
M ( H  !])   >B(- '8C%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T
M9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9
M*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM
M  !U*@  <B@* &\H$@!K*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0
M %XK5P!<*UX 6RQF %DL;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4
M4B_W %(O_P!2+_\ 4B__ ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O
M+P  :RX& &@M$ !D+A@ 8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P
M4P!6,%L 5#%C %,Q; !2,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V
M $PT_P!,-/\ 3#/_ +LY  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P
M93(" &$R#0!>,A0 7#,> %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0
M-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X
M_P%'./\!1SC_ ;<[  "B/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8
M %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54
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M :I"  "60P  AD,  'A#  !N0P  94,  %U   !60   44(  $U" @!)0PP
M1D,2 $1$&@!"1"( 040J #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X
M1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$
M  "210  @D8  '5&  !J1@  844  %E$  !11   3$8  $A'  !$1PH 04@0
M #])&  ]22  /$DG #I*+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H
M,DQW #%,A@ P3)< +TVH "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".
M2   ?D@  '%(  !F20  74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.
M%0 W3AT -D\D #5/*P S3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U
M "M1A  J4I4 *5*F "E2N0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@
M>DL  &U+  !C3   6DP  %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q
M5!D ,%4A "Y5*  M52\ +%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57
M@0 D5Y( (U>D ")7MP B5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X
M &E.  !?3P  5D\  $U0  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4
M*%P= "=<)  F7"L )5PS "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =
M7H\ '%ZA !M>M  :7<P &UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12
M  !;4@  4E,  $I4  !!5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8
M !]D(  >9"< '60N !QD-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L
M%&6> !-EL0 29<@ $F3G !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !7
M5@  3U<  $99   ]7   -E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M
M&@ 5;2$ %&TI !1M,  3;3D _^)]$$E#0U]04D]&24Q%  <2$FY" !%N3  0
M;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_ ()9
M  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;   '6\
M !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (=U(
M!W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=  !M
M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD  !)\
M   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP  ()9
M  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H8@
M7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&   (
MB00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1  ".
M8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P  6&D
M $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2    E0
M )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<5P
MG&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(  $9W
M   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@   *,!
M  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30  K%T
M *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$   T
MB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +    "Q
M    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(  +UD
M  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   LF0
M(9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
MP0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7  #2
M:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ   &JX
M !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/    T
M -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I70
MZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F /\
M,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\ ZP"$
M .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8 /\
MV #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H + #W
M #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_ -L
MA0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\ Q@#_
M ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I #(
MY@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D ?P#'
M (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_ +8
M_P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T T0 W
M ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W (
MM@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *< _P"G
M /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q +P
M.P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H IP"!
M *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8 /\
MF #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T -0"K
M #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![ )@
M@P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\ C #_
M /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@"> #<
MG !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L ?@"*
M (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_ .@-
M  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$ D  Y
M (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^!(0
M?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5  #$
M%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS (,+
M.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8  <@V,
M ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y'@
MJ!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0-@!W
M$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.) &83
ME@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P  GR0
M )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N%S@
M;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;D@!<
M&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@  (LH
M  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3, 8QXZ
M &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4(IX
M4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M  !\
M+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V %HC
M/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P 3"BL
M $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W+P
M;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H.0!2
M*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ $4N
MO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P  :S$
M &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,+3P
M2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ RNP _
M,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4  &$R
M  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D 1#%
M $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z-M$
M.C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV  !7
M,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8] #XV
M1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\ -CKL
M #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3-@
M3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[0@ X
M.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J #$^
M^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@  23L
M $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S0$@
M,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"^0 M
M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\  $!
M   \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144 +45.
M "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H1?\
M*$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%   W
M1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+ "9+
M50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\ (DK_
M )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R2P
M+DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!04@ ?
M45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__ (I&
M  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4   *%,"
M "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 85UD
M%UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)  !T
M2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D  !Y;
M!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4 $%]B
M  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N3@
M8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB 0 3
M90D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==  =G
M;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@  75(
M %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /;08
M"W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P90
M<'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658  %%7
M  !'6   /EL  #9?   N8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+
M  %X#P  >1,  'D9  !Y'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G
M 'J#  !ZF   >JP  'G"  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"
M8   .6,  #!H   H;   ('   !ET   3=P  #GL   E^   $@0(  (((  "#
M#0  @Q   (04  "%&0  AB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[
M  "'D   AJ4  (6Z  "%TP  A.H  (3T &5@  !<8   46$  $9D   \:0
M,FT  "ER   A=P  &7L  !*    -@P  "(<   **    C0   (X$  "."0
MCPT  ) 0  "1%   DAD  ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5
MB   E9T  )2R  "4R   D^(  )/N &%E  !69@  2FH  #]N   U=   *WD
M "%_   9A   $8D   R-   &D0   )0   "8    F@   )L   "< @  G0<
M )X+  "?#@  H1(  *(8  "C(   I2D  *8V  "F1   IE4  *9H  "F?0
MII0  *6I  "DO0  I-$  *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-
M   1D@  "Y<   2<    H    *,   "F    J    *D   "J    K    *T$
M  "N"0  L T  +$1  "S%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@
M +B=  "XL0  M\(  +?0 %1V  !(?   /((  #&)   FD   &Y<  !*=   ,
MH@   Z<   "K    K@   +(   "V    N    +@   "Z    NP   +T   "^
M    P 4  ,$+  ##$   QA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1
M  #-I   S;0  ,W  $V#  !!B@  -9$  "F9   >H   $Z8   RL   #L0
M +8   "Z    O@   ,(   #&    R    ,@   #*    RP   ,T   #.
MT    -(!  #5"   V0X  -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #G
ME@  YZ4  .:P /\ "0#_  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!#
M /D 30#U %4 \@!= /  8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L
MXP"1 .$ F0#? *$ W "J -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/
M /\ R@#_ /\  0#_    _P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P
M2 #H %  Y0!8 .( 7@#? &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ",
M ,X DP#, )P R0"E ,< L #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\
MO@#_ /\   #_    _P   /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5
M $L T0!2 ,X 60#+ %\ R0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T
MC@"[ )8 N0"@ +< J@"V +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_
M /\   #_    ]P   .H  @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4
MOP!- +P 4P"Z %D N !? +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L
M )$ J@": *@ I0"F +$ I #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\
M  #W    Z    -D   #+  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!'
M *P 30"K %0 J0!9 *< 7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L
MFP"5 )D GP"8 *P E@"Z )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G
M    TP   ,8   "[  ( LP , *T $@"J !P IP F *0 , "C #@ H !  )X
M1P"< $X F@!3 )D 6 "7 %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/
M (L F@"* *< B "U (8 QP"% .0 A #U (0 _P"# /\ @P#_ .P   #3
MP0$  +0   "L    I@ ' *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/
M $@ C0!- (P 4P"+ %@ B0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X
ME@!] *, >P"P 'H P@!Y -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P
M *8+  "="   F00  )4 "@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $(
M@@!( (  3@!_ %, ?0!8 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q
M )\ < "M &X O@!M =8 ;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1
M  "1$   BPX  (D+ P"'!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1#
M '4%2 !T!4X <P54 '$%60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T
M90FL &0)O !C"M0 8POL &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'
M%@  @10  'T1  !\#@8 ? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,
M1 !K#4H :0U/ &@-50!G#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K
M %L0O0!:$-8 61'P %D1_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0
M>!L  '08  !Q%0  <1$) &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B
M$44 8!)+ %\240!=$E@ 7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6
MN@!1%M( 41?M %$7_0!1%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$
M &P>  !I&P  9Q@$ &85#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$
M6!A' %8830!5&%0 4QA< %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*
M'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C
M  !B(0  8!X  %X<"P!;&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U#
M $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP
M0R/I $,C^@!#(_\ 0R+_ *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<
M)0  62,  %<A!P!5(0\ 4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B
M1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH
M #TH^0 ])_\ /B?_ *(J  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*
M5"8  %$F! !.)0T 3"43 $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P!
M)TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L
M^  X+/\ ."S_ )TL  "*+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H
M $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@
M.BQ0 #DM60 X+F0 -RYP #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S
M,/\ -"__ )DO  "',0  =S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N
M  !$+@@ 02X. #\N%  ]+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%.
M #0Q5P S,F( ,C)N #$S?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\
M+S/_ )4Q  "#,P  =#0  &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _
M,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V
M50 N-F  +3=L "PW>P K-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_
M )(T  !_-0  <38  &4W  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@(
M-S<+ #0W$  R-Q8 ,3@= "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I
M.UX *#MJ "<[>0 F/(D )3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV
M  !\.   ;3D  &(Y  !8.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL(
M "\\#@ M/10 +#T: "H](0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L
M(D!H "% =@ @0(< 'T&9 !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X
M.@  :3L  %X\  !5/   33P  $<\  ! /   .#T  #0^   P0   +4$% "I"
M#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E
M !M%=  :184 &4:7 !E&J0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0
M9CX  %L_  !2/P  2C\  $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A
M2 \ ($D4 !Y)&P =22( '$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+
M<0 42X( $TN4 !)+IP 22[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$
M %="  !.0@  1T(  $%"   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT
M&% 1 !=0%P 64!X %5 E !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .
M4GX #5&1  U1I  ,4;@ #%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%
M  !+10  1$4  #Y&   V2   +TH  "E,   D3P  'U$  !I3   45@D $5<.
M !!8$P 06!D #U@@  Y8*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D
M!EB,  58GP $6+, !%?*  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(
M2   04D  #I*   R30  *U   "52   @50  &E@  !5:   0708 #& ,  I@
M$  )8!4 "& <  =@(P %8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&
M  !?F@  7ZX  %_$  !>X@  7O   %[X &Q*  !?2P  54L  $Q,  !%3
M/4X  #50   N4P  )U8  "!9   :7   %5\  !!B   -900 "&<+  -G#@
M:!,  &@8  !H'P  :28  &DN  !I.   :4,  &E/  !I70  :6T  &F   !I
ME   :*D  &B_  !GW   9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0
M #!7   H6P  (5X  !IB   490  $&@   QK   ';@,  7 )  !P#0  <1
M '$4  !R&@  <R$  ',H  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@
M<Z,  '*Y  !QT@  <>L  '#T &%3  !64P  3U,  $55   [6   ,EP  "I@
M   B9   &V@  !1L   /;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1
M  !]%0  ?AL  '\B  " *@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T
M '^R  !^R@  ?N4  'WQ %Q8  !46   25H  #]=   U80  +&4  "-J   ;
M;P  %',   YW   )>P   W\   ""    A    (8!  "&!@  B H  (D-  "*
M$   BQ4  (P;  ".(@  CRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK
M  "-P0  C=P  (SK %E=  !.7P  0V(  #AF   N;   )'$  !QW   4?
M#H$   B%    B0   (T   "0    D@   ),   "4    E@,  )<(  "8#
MF@\  )L3  "=&@  GR,  * N  "@/   H$P  *!>  "@=   GXP  )^B  "?
MMP  GLL  )[@ %-D  !':   /&T  #%S   G>0  '7\  !2%   -BP  !I
M  "4    F    )P   "?    H0   *(   "D    I0   *<   "H!   J@D
M *P-  "M$@  L!D  +(C  "R,0  LD(  +)4  "R:0  LH   +*8  "QK
MLK\  +'. $QN  ! <P  -7H  "J!   ?B   %8X   Z5   &F@   )\   "D
M    J    *P   "O    L0   +$   "S    M0   +8   "X    N@   +P&
M  "^#   P!$  ,,9  #%)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\
M ,B\ $9Z   Y@0  +HD  "*0   7F   #Y\   >E    J@   *\   "S
MMP   +P   "_    P0   ,(   #$    Q0   ,<   #)    RP   ,T   #/
M P  T@H  -80  #<&@  W2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M
M /\  @#_    _P # /\ # #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %
M\ !7 .T 7@#K &0 Z !I .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9
M )P U@"F -, L0#1 ,  SP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\
M  #_    _P   /\ " #[ !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2
M -T 60#9 %\ U@!D -, :0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8
MQ "@ ,( JP#  +D O@#- +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_
M    _@   /0 ! #K  T Y  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,<
M4P#% %D PP!? ,$ 9 "_ &D O0!N +L <P"Z 'D N "  +8 B "T )  L@":
M +$ I0"O +( K0#$ *P X0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]
M[@   .(   #5  H S0 1 ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R
M %, L !9 *\ 7@"M &, K !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$
MGP"? *P G@"[ )P T@"; .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@
M ,L   #!  4 N0 - +0 % "Q !X K@ G *L , "J #D IP!! *0 2 "B $T
MH0!3 )\ 6 "> %T G0!B )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0
M *8 C@"T (T R ", .8 BP#Y (H _P"* /\ BP#_ /    #;    QP   +H
M  "P    J  * *0 $ "@ !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!-
M )$ 4@"/ %< C@!< (P 80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *
M@ "O '\ P !^ -T ?0#R 'T _P!] /\ ?0#_ .    #&    M0   *H   "B
M    FP % )4 #0"2 !, D  < (T ) "+ "T B@ T (@ .P"& $( A0!' (,
M30"" %( @0!7 '\ 7 !^ &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J
M '( N@!Q -$ < #L '  ^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!
MC@   (H " "&  \ A  6 ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V
M $P =0!2 ', 5P!R %T <0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &<
MM@!F ,L 90#G &4 ]P!E /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L
M 'X' 0!\ 0L >0 1 '< & !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $<
M:@!- &D 4@!H %@ 9@!? &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!<
M \< 6P3D %L%] !;!OX 6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.
M  !R# 0 <0<- &X$$@!L!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=)
M %\'3@!>"%4 70A< %L)8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,<
M4@SD %$-]0!1#?\ 40W_ *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G
M$0  9PX' &8,#@!C#!4 80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-
M2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E
M $D1]P!)$O\ 21'_ *49  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P
M7A0! %X1"@!;$!$ 61$8 %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.
M$DX 3!)5 $L37@!)$V< 2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7
M]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD
M %46!@!4%0X 4144 $\6' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH
M11A2 $,86@!"&60 01EP #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 [
M'/\ /!S_ )HA  "'(P  >"0  &PE  !C)0  7"0  %<C  !3(   41X  $\<
M @!-&PP 2QH1 $@;& !'&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/
M #T>6  \'F( .A]M #D?>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\
M-B'_ )8C  "#)@  ="<  &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'
M( D 1!\/ $(?%0! (!P /R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B
M50 V(U\ -"-K #,D>0 R)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_
M )$F  !_*   <2H  &4J  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4
M/R0- #TD$@ [)!D .20? #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P
M)UT +RAI "XI=P M*8< +"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH
M  !\*@  ;2P  &(M  !9+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+
M #<H$  U*!8 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L
M*BQG "DM=0 H+84 )RV7 "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X
M+0  :BX  %\O  !6+P  3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L
M#@ P+1, +BT: "TM(  K+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E
M "0Q<P C,8, (C*5 "$RIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P
M9S   %PQ  !3,0  2S$  $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K
M,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U
M<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,
M %DT  !0-   230  $(S   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q
M)#<5 "(W&P A."( (#@H !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8
M.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V
M  !--@  1C8  $ V   Z-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2
M !T]&  </1\ &SXE !H^+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P
M$D"/ !% H@ 10+8 $$#. !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*
M.0  0SD  #TY   W.0  ,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#
M%0 51!L %$0B !-$*0 31#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,
M  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/
M0#P  #H\   T/   +CX  "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 0
M2A@ #TL>  Y+)0 -2RT #4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+
MF@ $2ZX !$K$  5*X  %2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X
M #<_   Q0   *D(  "1%   ?1P  &DD  !5,   13@4 #E$+  M1$  *410
M"5$;  A1(@ '42D !5$R  12.P #4D8  5)2  !27P  4F\  %*!  !1E@
M4:D  %&_  !0W   4.X  %#W &A   !;00  4$$  $A!  !!00  .T(  #1#
M   M10  )D@  "!+   ;30  %E   !%3   .500 "E@*  98#@ "6!(  %D7
M  !9'0  624  %DM  !9-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4
M %BZ  !8U0  5^P  %?V &-$  !610  344  $5%   _10  -T<  "])   H
M3   (D\  !M2   650  $5@   U:   )70, !%\)  !@#0  8!   &$4  !A
M&0  8B   &(G  !B,0  8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V
M  !ASP  8.H  &#U %U(  !220  2D@  $-(   Z2@  ,DT  "I0   C4P
M'%<  !9:   170  #6    AC   #9@$  &<&  !H"P  :0X  &H1  !K%0
M;!L  &TB  !M*@  ;30  &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !K
MR   :^8  &KS %A-  !.30  2$P  #Y.   U40  +%0  "18   =7   %F
M !!D   ,9P  !VL   %N    <    '(#  !R!P  <PL  '4.  !V$0  =Q8
M '@<  !Y(P  >BT  'HY  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0
M=]\  '?O %11  !,40  0E(  #A5   O60  )EX  !YB   69P  $&L   MO
M   %<P   '<   !Z    ?    'X   !_ @  @ 8  ($*  "##0  A!$  (85
M  "('   B24  (HP  "*/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$
M (;H %)6  !'5P  /%H  #)?   H9   'VD  !9O   0=   "GD   )]
M@0   (4   "(    B@   (P   "-    CP   ) $  "2"   DPP  )40  "7
M%0  F1T  )LG  ";-   FT0  )I6  "::@  F8(  )J:  "8L   F,<  )?>
M $M<  ! 8   -64  "MJ   A<0  %W<  !!]   )@P   8@   ",    D0
M )4   "8    F@   )L   "=    GP   *    "B    I 4  *8*  "H#@
MJA0  *T=  "M*@  K3D  *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F
M   Y:P  +G$  "-X   9?P  $(8   F-    DP   )@   "=    H0   *4
M  "H    JP   *L   "N    KP   +$   "S    M0   +<!  "Y!P  O T
M +\3  #"'P  PBX  ,)   #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R
M>   )X   !R(   2D   "I<   "=    HP   *@   "M    L@   +8   "Y
M    NP   +P   "^    P    ,(   #$    Q@   ,@   #+    S@4  -$-
M  #6%   UR,  -@U  #920  VEX  -MU  #;C   W)\  -RK /\   #_
M_P   /\ "0#_ !  _P 9 /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G
M %\ Y !D .( :0#@ &X W@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P
MK #* +L R #2 ,8 [@#& /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P
M /X !0#W  X \@ 5 .X 'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D
MS@!> ,P 8P#* &@ R0!M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y
M +0 MP#( +8 Y@"U /L M #_ +0 _P"S /\ K@#_ /\   #_    ^    .T
M  #E  L W0 1 -< &@#2 "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9
M +H 7@"X &, M@!H +4 ;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T
MI@"^ *4 VP"D /0 I #_ *, _P"C /\ H@#_ /\   #V    Y@   -<   #+
M  8 Q  . +X %0"[ !\ N0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *<
M6 "F %P I !A *, 9P"A &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V
M )4 S "4 .L DP#] ), _P"3 /\ DP#_ /<   #D    T    ,$   "W  (
MKP + *L $0"G !D I0 B *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6
M %< E0!; ), 80"2 &8 D !M (\ = "- 'T C "' (H DP"( *  AP"O (4
MP@"% .( A #W (0 _P"$ /\ A #_ .4   #-    O    *\   "F    G@ '
M )H #@"6 !0 E  = )( )0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$
MA@!6 (0 6P"# &  @0!G (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V
M -, =@#O '8 _@!U /\ =0#_ -    "[    JP   )\   "7    D  " (L
M"P"( !  A@ 7 (0 ( "" "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0
M '< 50!V %L = !A ', :0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D
M:0#H &D ^0!I /\ :0#_ ,    "L    G (  ) "  "(    @P   '\ !@![
M  T >0 2 '< &@!V "( =  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L
M4 !J %8 : !< &< 9 !E &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A
M %X ] != /\ 70#_ +0'  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D
M;P / &T %0!K !P :0 C &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !?
M %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %,
M[P!4 /L 5 #_ *D-  "6#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+
M &0 $ !B !< 8  > %X )0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X
M50)4 %,"7 !2 V4 40-O $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*
M!_D 2@?_ *$0  ".$@  ?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)
M#0!:!A( 6 <9 %8'( !5!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1
M $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L
M0@W_ )H4  "'%@  >!@  &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3
M#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.
M5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_
M ),8  "!&@  <QP  &<=  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L
M2A 0 $@1%P!&$1X 11$D $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [
M$UX .11I #@4=@ W%84 -A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;
M  !\'0  ;A\  &,@  !:(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4.
M $$5$P _%1H /A4@ #T5)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L
M,QEF #(9<P P&H, +QJ4 "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X
M(   :B(  %\C  !6(P  3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9
M$0 Y&18 -QH= #8:(P U&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD
M "P><0 K'X$ *A^2 "D?I  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P
M9R0  %PE  !3)0  3"4  $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S
M'A, ,1X: # >(  O'B8 +A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B
M;P E(W\ )".0 ",CH@ B)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8
M %DG  !0*   22<  $,G   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$
M+"(7 "HB'0 I(B, *",J "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @
M)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I
M  !-*@  1BH  $$I   \*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4
M "4G&@ D)R$ (R@G "(H+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL
M&BR- !DLGP 8++( &"S) !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*
M+   0RP  #XK   Y*P  -"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L
M&  ?+!X 'BTE !TM+  <+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+
M !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@
M02X  #LN   V+0  ,2T  "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :
M,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! U
MG  0-;  #C7&  \TY  0-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C
M #@P   S,   +S   "DQ   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D
M$S@? !(X)@ 2."X $3DV ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +
M.:P "CG!  HYW@ +.?$ ##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S
M   Q,@  +#,  "<T   A-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<
M  X^(P -/BH ##XS  P^/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@
M SZ\  0^UP %/NP !3[W &DS  !;-   4#4  $<U   _-0  .34  #0U   N
M-0  *3<  ",X   >.P  &CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$
M(  '1"< !D0O  5$.  #14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y
M  !$T0  1.H  $/U &0V  !7-P  3#@  $,X   \.   -S@  #$X   K.0
M)3L  " ]   :0   %D(  !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'
M2R,  $LK  !+-   2SX  $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*
MS@  2ND  $KU %\Z  !2.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$
M !Q#   61@  $DD   Y+   +3@, !U (  )1#   41   %(3  !3&   4Q\
M %,F  !3+P  4SD  %-%  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@
M4><  %'T %D^  !./@  13X  #X^   X/@  ,$   "E"   C1   '4<  !=*
M   230  #E    M3   &50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA
M  !<*@  7#0  %P_  !<30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0
M %GS %1"  !*0@  0D(  #Q"   T0P  +$8  "5)   >3   %T\  !)3   .
M5@  "ED   5;    7@   & $  !A"   8@P  &,.  !D$0  918  &8<  !G
M(P  9RT  &<Y  !G1@  9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P
M $]&  !'1@  0$4  #='   O2@  )DT  !]1   850  $ED   U<   (8
M F,   !F    :    &H   !K!   ; @  &T,  !O#@  <!(  '(7  !S'0
M="8  '0R  !T/P  =$X  '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*
M  !%2@  .TL  #).   I4@  (%8  !A;   27P  #60   =H    :P   &\
M  !R    =0   '8   !W    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X
M (0I  "$-@  A$4  (16  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _
M4   -5,  "M7   B7   &6(  !)G   ,;   !7$   !U    >0   'T   "!
M    @P   (4   "&    B    (D   "+!   C0@  (\-  "2$   E!8  )8@
M  "6+   ECL  )9,  "58   E78  )20  "3IP  DKT  )+5 $15   Y60
M+UT  "1C   ::0  $F\   QU   $>P   (    "%    B0   (T   "1
MDP   )0   "6    F    )H   "<    G@   * &  "B"P  I1   *@7  "I
M(P  J3$  *E#  "I5@  J&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH
M !UP   3>   #'\   .%    BP   )$   "6    FP   )\   "B    I
M *4   "G    J0   *L   "M    L    +(   "U @  MPD  +L0  "^&
MOB8  +XX  "^2P  O6$  +QZ  "[E   NJD  +JY #=J   K<   ('@  !:
M   -B   !8\   "6    G    *(   "G    K    +    "S    M@   +<
M  "Y    NP   +T   "_    P@   ,4   #(    R@   ,X(  #2$   U1L
M -4L  #40   U%<  --N  #4A@  U)L  -.K /\   #_    _P   /\ !0#_
M  X _P 5 /P ( #Y "H ]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X
M8P#< &@ V0!N -4 <P#3 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#,
M ,  [ "_ /\ O@#_ +T _P"W /\ L@#_ /\   #_    _P   /H  0#S  L
M[0 2 .@ &P#E "4 Y  N -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$
M &, P@!G ,  ;0"_ ', O0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X
MXP"N /H K #_ *T _P"I /\ I@#_ /\   #_    \@   .8   #=  < T@ .
M ,T %@#* "  R  I ,4 ,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T
ML !B *X 9P"L &P J@!S *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"=
M /( G #_ )T _P"< /\ F0#_ /P   #N    W0   ,P   #!  ( N@ , +8
M$@"R !H L  C *\ + "M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!;
M )P 8 ": &8 F0!L )< = "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@
MBP#] (P _P", /\ C #_ .T   #8    Q0   +<   "L    I@ ( *$ #@"?
M !4 G0 > )L )@": "X EP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L
M6@"* &  B0!F (< ;0"% '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U
M 'P _P!\ /\ ? #_ -D   #!    L0   *0   "<    E  # )  # "- !$
MBP 8 (D ( ") "@ AP O (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![
M %H >0!@ '@ 9P!V '  =0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X
M_@!N /\ ;@#_ ,0   "O    H    )0   ",    A@   ($ " !^  X ?  4
M 'L &P!Y "( >  I '< , !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0
M; !; &L 8@!I &H : !T &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A
M /\ 80#_ +0   "@    D0   (8   !^    >0   '4  P!Q  L ;P 0 &T
M%@!L !T :P D &L *@!I #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6
M %\ 70!= &4 7 !O %H >@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\
M5@#_ *@!  "4!0  A0<  'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A
M !@ 8  ? %\ )0!> "L 70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4
M6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_
M )T)  "+"P  ? T  ' -  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !,
M5P 9 %8 ( !5 "8 4P K %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!*
M %T 20!G $< <P!& (  10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-
M  "##P  =!   &D1  !@$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5
M $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H
M0 5D #\%<  ^!GX /0:. #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\
M$@  ;A0  &(5  !:%0  5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(
M%@!%"!T 1 @C $((* !!"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC
M #@,;P V#'X -0R. #0-GP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0
M:1<  %X8  !5&   3Q@  $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _
M#1@ /0T? #P-)  [#2H .0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0
M;@ O$'T +A". "T1H  L$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H
M %D;  !1&P  2QL  $8:  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4
M-Q ; #41(0 T$2< ,Q$M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I
M%'L *!2, "<5G@ F%;  )17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>
M  !-'@  1QX  $(=   ^'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07
M "\4'0 M%", +!4J "L5,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D
M(AF* "$9G  @&:\ 'QG$ !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*
M(   1"   #X?   Z'@  -QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8
M&@ G&"  )ADF "49+0 D&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V(
M !P>FP ;'JT &A[# !H>X  :'?, &QW_ '<=  !G(   6B$  % B  !((@
M02(  #LB   W(0  ,R   # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A
M'1T (1TD " >*@ ?'C( 'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<B
MF0 6(JP %2+! !4BWP 5(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0
M #DD   T(P  ,"(  "PB   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL
M&R(A !LB*  :(R\ &2,X !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1
M)JL $2;  ! FW0 1)?$ $B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F
M   Q)0  +24  "DD   F)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<?
M !8G)0 5*"T %"@U !,I/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD
M#2J]  TJUP -*NX #BG[ &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O
M*   *R<  "<G   B*   'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M
M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY
M  @NT  )+ND "B[W &@G  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@
M*2H  "0J   @*P  &RT  !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -
M,B< ##(O  LS.  *,T( "3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (S
MS0 #,^< !#+S &0J  !6+   2RT  $(M   Z+0  -"T  "\L   K+   )BP
M "(M   =+P  &3$  !4R   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0
M!C@L  0X-  #.#X  CE*   Y5P  .64  #EW   YBP  .)\  #BS   XR@
M..8  #?R %\M  !2+@  2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q
M   :,P  %34  !(W   /.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH
M   ^,0  /SL  #]&   _4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0
M #WR %HP  !.,@  1#(  #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6
M.   $CL   \]   ,/P, "$$(  1##   0PX  $02  !%%@  11T  $4D  !%
M+0  1C8  $9"  !&3@  1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R
M %4T  !*-0  034  #DU   S-   +C0  "@U   B-P  '3H  !<\   2/P
M#T$   Q$   (1@$  T@&  !)"@  2@T  $L0  !,%   31D  $X@  !.*
M3C(  $T]  !.2@  3E@  $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X
M  !&.   /3@  #<X   Q-P  *CD  "0[   >/0  &$   !-#   /1@  "TD
M  =+   "3@   % $  !1"   4@L  %,.  !4$0  514  %8;  !7(P  5RP
M %<X  !71   5U(  %9C  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"
M/   .SL  #4[   M/   )C\  !]"   910  $T@   Y+   +3P  !5$   !4
M    5P   %@!  !:!0  6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q
M  !B/@  84P  &%=  !A<   8(@  &"@  !?MP  7M0  %WN $=    _/P
M.C\  #%    I0P  (48  !I*   33@  #E$   I5   $6    %L   !>
M80   &,   !D 0  900  &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O
M-@  ;D4  &Y5  !N:   ;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40
M "M'   C2P  &T\  !-4   .6   "%P   )@    9    &<   !K    ;0
M &\   !P    <@   '0"  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@
M?ST  'Y-  !]80  ?7<  'R0  ![J   >L   'G? $-'   Y20  +TP  "50
M   <50  %%L   Y@   '90   &H   !N    <@   '8   !Y    ?    'X
M  !_    @0   (,   "%    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,
M ))$  "15P  D&T  (^&  ".GP  C;4  (S- #U.   R40  *%8  !Y<   5
M8@  #F@   =N    =    'D   !^    @@   (8   ")    C    (X   "0
M    D@   )0   "6    F    )L   ">!@  H0P  *01  "F&P  IBD  *8Z
M  "E30  I6(  *1[  "CE   H:L  *&_ #97   L7   (6(  !=I   /<
M!W<   !^    A    (H   "/    E    )@   ";    G@   )\   "B
MI    *8   "H    JP   *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[
M0P  NE@  +EP  "WBP  MZ$  +>S #!B   E:0  &G   !!X   )@    (@
M  "/    E@   )L   "A    I@   *H   "N    L    +$   "T    M@
M +@   "[    O0   ,    ##    QP   ,L#  #/#   TQ4  -(E  #2.
MT4X  -!E  #/?@  S98  ,RI /\   #_    _P   /\  P#_  L _  1 /D
M&P#W "4 \P O .X . #I $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H
M -  ;0#. ', RP!Z ,@ @@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\
MN #_ +$ _P"J /\ IP#_ /\   #_    ^P   /8   #M  < YP / .( %@#?
M "  W@ I -D ,P#1 #L S !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H
M9P"Y &T MP!T +4 >P"R (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_
M *, _P"= /\ FP#_ /T   #V    ZP   -\   #1  , R@ , ,4 $@## !L
MP  D +X + "Y #4 M@ \ +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F
M &< I !M *( = "@ 'T G@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4
M_P"0 /\ C@#_ /,   #F    T0   ,(   "X    L0 ( *T #P"J !8 J  >
M *@ )P"F "\ H@ V )\ / "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &
MD0!F )  ;@". '8 C "! (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"#
M /\ @0#_ .0   #+    N@   *P   "B    G  $ )@ # "6 !$ E  9 ),
M(0"2 "@ CP P (T -@"+ #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@
M '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\
M= #_ ,L   "V    I@   )H   "2    B@   (8 " "#  X @0 4 ($ &P"
M ", ?P J 'T , ![ #8 >@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '
M80!N &D ;0!S &L ?P!I (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_
M +@   "D    E0   (H   "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T
M<  D &X *@!M #  :P U &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A
M &, 8 !M %X >0!= (< 6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@
M  "5    AP   'L   !S    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ?
M &( )0!A "H 7P P %X -0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X
M5 !H %, <P!1 ($ 4 "1 $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")
M    >P,  ' #  !H P  8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %<
M( !6 "4 50 J %, , !2 #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C
M $D ;P!' 'P 1@", $4 G0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P
M<0H  &8*  !>"@  60D  %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!,
M "  2P F $H *P!) #  2  U $< .@!& $  10!& $, 3@!" %8 00!? $
M:P ^ '@ /0"( #P F0 \ *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X
M %\.  !7#@  40X  $T,  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P
M0P A $( )@!! "L /P Q #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V
M '4 -0"% #0 E@ T *@ ,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1
M  !1$0  2Q$  $<0  !$#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(=
M #H#(@ Y R@ . ,M #<#,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W,
M+@># "T'E0 L!Z< *P>Z "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,
M%   1A0  $(3   ^$@  /!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)
M'P R"20 ,0DI # )+P O"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR#
M "8-E0 E#:< ) V[ ",-T@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P
M0A8  #T6   Y%0  -Q,  #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L
M#2$ *PTG "H-+0 I#C0 * X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0
ME@ >$*D '1"] !P0V  =$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD
M #H8   U%P  ,A8  # 5   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X
M)1 D "00*@ C$3$ (A$Y "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8
M%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;
M   R&@  +QD  "P8   J%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A
M !X4)P =%"X '!4V !L5/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8
M$ABZ !(7T@ 2%^P $Q?Z &P9  !=&P  41T  $<=   _'@  .1T  #0=   O
M'   *QL  "@:   F&0  )!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8
M)  8&2P %QDT !8:/0 5&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY
M  X<T  .&^H #QOX &D;  !:'0  3A\  $4?   ](   -A\  #$?   M'@
M*1T  "4=   C'   (!L  !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3
M'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@
MR@ +(.4 #!_T &4=  !7'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\
M ",?   @'@  '1X  !D@   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8
M#B,O  XC-P -(T$ #"1-  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &
M(^, !R/Q &(?  !4(0  22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A
M   >(0  &B$  !8C   3) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K
M  DH-  (*#X !RA)  8H50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$
M 2?P %XB  !1)   1B4  #TE   U)0  +R4  "HD   F)   (B,  !\C   ;
M)   &"4  !0F   1* , #RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M
M,  "+3H  2U%   M4@  +F   "YQ   MA   +9D  "VM   LP@  +.   "SP
M %HD  !-)@  0R<  #HG   S)P  +2<  "@F   D)@  (28  !TF   9)P
M%2D  !$K   /+ , #2X'  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0
M,C8  #-"   S3@  ,UT  #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G
M  !**0  /RH  #<J   P*@  *RD  "<H   C*   'BD  !HJ   6+   $BX
M  \P   -,0( "C0'  4U"P "-@X  #<0   X%   .!H  #@B   X*@  .3,
M #D^   Y2@  .5D  #EI   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&
M+   /"P  #0L   N+   *BL  "4K   @+   &RT  !<O   3,0  $#,   TU
M   )-P( !3H&  $["@  / T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z
M  ! 1@  0%0  $!E   _>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P
M.2\  #(O   M+@  *"X  "(O   =,   &#(  !,U   0-P  ##H   D\   %
M/@   $$$  !""   0PL  $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(
M00  2$\  $A@  !'<P  1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(
M # Q   K,0  )3(  !\T   9-@  $SD  ! \   ,/P  "$(   -$    1@
M $@"  !*!0  2P@  $P+  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/
M44H  %%:  !1;0  4(0  $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T
M   G-0  (3@  !H[   4/@  $$$   Q$   '1P   DH   !-    3P   %$
M  !3 @  5 4  %4(  !7"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0
M %Q4  !;9P  6WX  %J7  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C
M/   '#\  !5#   01P  "TH   5.    40   %0   !7    6@   %P   !=
M    7P   & $  !B!P  9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-
M  !I7P  :'4  &>/  !FJ   9<(  &3C #T]   W/   +CT  "5    =1
M%DD  !!-   *40  !%4   !:    70   &    !C    9@   &@   !J
M:P   &T   !O @  <08  '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X
M60  >&T  '>&  !VGP  =;<  '32 #Q!   R0@  *$4  "!*   73@  $%0
M  I9   "7@   &,   !G    :P   &\   !R    =0   '<   !Y    >P
M 'T   !_    @@   (0#  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@
MBV,  (I\  "*E0  B*T  (?% #9'   L2P  (D\  !E5   06P  "F$   %G
M    ;0   '(   !W    >P   '\   "#    A@   (@   "*    C0   (\
M  "1    E    )<   ": 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED
M *!P  "?BP  G:(  )VW #!0   E50  &UL  !)B   +:0   7    !W
M?0   (,   "(    C0   )$   "5    F    )H   "<    GP   *$   "C
M    I@   *D   "L    L    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E
M  "V?@  M98  +.K "E;   >8@  %&D   QQ   ">0   ($   ")    CP
M )8   ";    H    *0   "H    JP   *P   "O    L@   +0   "V
MN0   +P   #     Q    ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-
M<P  RXT  ,JA /\   #_    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J
M .L ,P#F #L X@!# -X 20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X
MQ@!U ,, ?0#! (8 O@"2 +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P">
M /\ FP#_ /T   #W    \@   /    #G  , X0 , -P $@#8 !L U@ D -(
M+0#, #8 Q@ ] ,( 0P"_ $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N
M *\ =@"L '\ J@"* *@ EP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\
MCP#_ /,   #L    XP   -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S
M "\ KP W *P /0"J $, J !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P
M;P": '@ EP"# )4 D "3 )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_
M .<   #=    Q@   +@   "N    J  $ *4 # "A !( H0 9 *  (@"? "D
MFP P )@ -P"6 #T DP!" )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "'
M '  A0![ (, B "! )8 ?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8
M  #     KP   *,   "9    DP   (\ "0"-  X BP 4 (H ' "* ", B  J
M (4 , "# #8 @@ [ (  0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D
M=0!S ', @ !Q (X ;P"? &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K
M    FP   (\   "'    @    'P ! !Z  P >  1 '@ %P!X !X =P D '4
M*@!S #  <0 U '  .@!N #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M
M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9
MB@   '\   !W    <0   &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E
M "H 8P O &( - !A #D 8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %<
M<@!5 ($ 5 "1 %, HP!2 +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?
M '$   !I    9    &    !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4
M5P J %8 +P!5 #0 5  X %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!*
M 'H 20"+ $@ G0!' +$ 1P#, $8 \ !' /\ 1P#_ )    !^    <    &8
M  !>    60   %8   !3  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E
M $P *@!* "X 20 S $@ . !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4
M/P"% #X EP ] *L /0## #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5
M!@  4 8  $P$  !* 0  20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $(
M)0!! "H 0  O #\ -  ^ #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"!
M #4 DP T *8 - "[ #0 W0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#
M2 L  $0*  !""   0 4! #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y
M "4 -P J #8 ,  U #4 -  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T
MCP L *( + "V "P T  L .X + #\ '<*  !G#   6@X  % .  !)#@  0PX
M #X-   [#   .0L  #@) P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "(
M,  G "\ +  N #( +0 X "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E
M )\ )0"R "4 R@ E .@ )0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0
M   V#P  ,PX  #$- 0 P"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C
M "@$*0 G!"\ )@4U "4%/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT
M'@>P !T&Q@ =!N, '07S &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q
M$0  +A   "P/   J#@, *@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "()
M)@ A"2P ( HS !\*.P >"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP
M !8,Q0 6#.$ %@OP &D0  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P
M*A(  "@1   F$ $ )! $ ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <
M#2H &PTR !H..@ 8#D0 %PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /
MR0 0#^0 $0_R &42  !7%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0
M "03   B$P  (!(# !X1!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@
M%1$P !01.0 3$4, $A). !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,
M$N$ #1+Q &(4  !4%@  21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6
M   ?%0  '!0" !H3!  9$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M
M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT
M"17N %\6  !1&   1AH  #T:   U&P  +QH  "H:   E&0  (A@  !\8   <
M%P  &18! !<6 P 5%@0 $Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9
M,P ,&3P "QI'  H:4P )&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL
M %P8  !.&@  0QP  #H<   S'   +!P  "<<   C&P  (!H  !T9   :&0
M%Q@! !48 @ 2&00 $!L'  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P '
M'CD !AY#  0>4  #'UX  A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:
M  !+'   01X  #@>   P'@  *AX  "4=   A'   'AP  !L;   8&P  %AL!
M !,; @ 1' 0 #AX'  P?"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4
M ")    C30  (UH  "-K   C?@  (Y,  "*G   BO   (=<  "'M %4=  !(
M'P  /B   #4@   N(   *"   ",?   @'@  '1T  !H=   6'0  $QX  !$?
M @ .( 0 #2('  HD"P &)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]
M   G20  *%<  "AG   G>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0
M.R(  #(B   L(@  )B$  "(A   >(   &Q\  !@@   4(   $2(   \C   -
M)0, "B8&  8H"@ #*0T  "L/   L$@  +!<  "P>   L)@  +2\  "TY   M
M1@  +50  "UD   M=P  +(T  "RD   KN@  *]8  "KN $TB  !!)   ."0
M # D   I)   )",  "$B   =(@  &2(  !4C   2)   #R8   TH   **@(
M!BP%  (N"0  +PL  # .   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@
M,U   #-@   S<P  ,HH  #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG
M   H)@  (R4  !\D   ;)0  %B8  !(H   0*@  #2P   HN   &, $  C($
M   T!P  -0H  #<,   X#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP
M #I<   Z;P  .88  #B>   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F
M*   (B<  !TH   8*0  $RL  ! N   -,   "3(   4U   !-P   #D"   [
M!0  / @  #X+   _#0  01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7
M  !":@  08$  $":   _L@  /L\  #[O #\L   V+   +RP  "HK   E*@
M'RL  !DM   4+P  $#(   TU   (.   !#H    \    /P   $$   !# @
M104  $8(  !("P  2@X  $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+
M9   2WL  $J4  !)K0  2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$
M !4T   0-P  #3H   @]   "0    $,   !&    2    $H   !,    3@$
M $\$  !1!P  4PL  %4.  !8$@  61D  %@B  !8+@  5SP  %=+  !67@
M5G,  %6-  !4IP  4L(  %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\
M   ,0   !T0   !'    2@   $T   !0    4P   %4   !7    60   %H
M  !< P  7@<  &$+  !D#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L
M &*%  !AGP  8+D  %[< #4W   P-0  *#<  " Z   8/0  $4(   Q&   &
M2@   $\   !3    5@   %D   !<    7P   &$   !D    90   &<   !I
M    ; $  &X&  !Q"P  = \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[
M  !RE0  <*\  &_) #4Z   K.P  (C\  !I#   22   #$T   52    5P
M %P   !@    9    &@   !K    ;@   '$   !S    =0   '<   !Z
M?    '\   ""!   A@H  (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%
MBP  @Z4  (*\ "]    E1   '$D  !-.   -5   !%H   !A    9@   &L
M  !O    =    'D   !]    @    (,   "%    AP   (H   ",    CP
M )(   "6    F0(  )X)  "B$   HAH  *$I  "@.P  GU   )UG  ":@0
MFID  )FO "E)   ?3@  %50   Y;   %8@   &D   !P    =P   'T   ""
M    A@   (L   "/    DP   )4   "7    F@   )T   "@    HP   *8
M  "J    K@   +(   "W"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X
M *^D ")4   86P  $&(   =J    <P   'L   ""    B0   )    "5
MF@   )\   "C    I@   *@   "K    K@   +    "S    M@   +H   "]
M    P@   ,<   #, 0  TPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6
M /P   #V    \@   /$   #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8
MW@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\
M ($ N0"- +8 F@"S *L L0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0
M  #L    Z    .<   #?    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W
M +P /@"Y $0 MP!) +4 3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H
MI0"% *( DP"@ *( G0"V )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?
M    V0   ,D   "_    N  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8
M. "D #T H@!# *  2 "> $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!]
M (\ BP"- )H BP"L (D Q0"( .X A@#_ '\ _P!Z /\ > #_ -D   #_XGT0
M24-#7U!23T9)3$4 "!+-    NP   *X   "E    GP   )P "0"9  \ F0 5
M )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "% %4
M@P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '( _P!N
M /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1 ((
M%P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\ <@!5
M '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A /\
M8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\ $@!O
M !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!. &$
M50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\ 5 #_
M *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!? !,
M7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %, 4 !2
M %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_ )(
M  "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !  4@ 4
M %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!& %(
M10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4   !T
M    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1 $8
M%0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X .P!7
M #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P $0 \
M !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3 #$
M7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0  5P<
M $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T !(
M,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D 6@ H
M &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L  $@,
M  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !  *P 3
M "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A &0
M( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.   \
M#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0 "0!
M%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$ &@%P
M !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X$
M,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%$0 <
M!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N !,'
M@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0  +Q$
M "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7"1(
M%@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,@  .
M#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,  "<2
M   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!  $@P4
M !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )#Y,
M"0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44   A
M$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2  T0
M&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I  !!*D
M  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >%
M&Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2%0 )
M$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C   4
MMP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@  &14
M !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %%AD
M!!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8MP
M%\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8  !45
M @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8  !L=
M   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@  &]
M !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07 P 2
M%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:   A
M(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$  !_M
M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1&0$
M#AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G'P
M)R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N $0=
M   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0  #1\
M  HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'   +20
M "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @   V
M(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0   8F
M   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2   #4J
M   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R)
M*B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF   ^
M,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P  *"8
M ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U    .
M #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(+
M1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@  "(G
M   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00   $,
M  !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P  4S0
M %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L   8
M+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X   !1
M    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP  &$\
M  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3-P
M#CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T  !R
M10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00  !T<
M  !,    40   %4   !9    70   &$   !E    :    &L   !M    ;P
M '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&/0
MA%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0   !:
M    8    &0   !I    ;@   '(   !V    >@   'T   "     @@   (4
M  "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P  G4<
M )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M<0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D   "<
M    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP  +12
M  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\    @P
M (D   "/    E    )H   "?    H@   *0   "G    J@   *X   "Q
MM    +@   "\    P0   ,<   #-    U 4  -@0  #5'@  TS$  -!(  #-
M7P  RW8  ,B.                       ! P0%!@@)"@L-#@\1$A,4%A<8
M&AL<'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!2
M4U155UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+
MC(Z/D)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$
MQL?(R<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^
M______________________________________________________\
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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MDYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]WTP@T4]<,4,/;
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MT;!^I-'_N!0._[@>)_^T*D;WKS9IWJ="C\>;8K'$FW*VPIM_N<";B+V^F8G
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MI:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"EC]*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MBI>DT8J7I-'_MA((_[<<'?^T*#G_L#1:ZJE ?=6D29S(I%6PQJI;L\.O8[?
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M_ZHG%_^G-2__HT1*^IU19>F77G[;E&V4SY)WIL62@;3$DXBVPY*-N,&/C[K
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M1,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(LH?
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MJE=L[JE==^>H8X'AI&V+UIYYELN5@Z+ BXZMMH.:MJY^JKND?+.\GGZUNIJ
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M23G_ITHX_[%*-_^^2S?_PDLW_\)+-__"2S?_PDLW_\)+-__"2S?_PDN_LP
MKKX  *#-  "2W@  B?\- 8'_&@5W_R,,;?\J$V3_,1E<_S@>5?] (E#_2"9,
M_T\I2/]5*T3_6RU"_V$O/_]G,3W_;3([_W,S.?]Z-3?_@C8U_XLW,_^4.#+_
MG#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN   H,<
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M_X-I5_U\<F#X=G]G]'&*;O!LE73M:)]YZF2J?>AAMX#F7\B"W6';@\QDW(3
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MD8""F8R*BY&'E9&+A**6AH.RF8.$RYB$@\Z6A(/0E(2"TI*$@=.0A('4CH2
MUHR$@-:,A(#6C(2 UHR$@-:,A(#6C(2 UHS_=Q(!_W0; _^"'@3_E"<(_Z R
M#?^G-!/ZKC@8[[4]'.:\1B'<OTPLSKE4/\.Q75"WJF5?K:1L;*.=='>9F'R!
MD9.&BHF/DI&"C)^6?8JOF'J+QYA\B<Z6?8C0E'Z&TI)_A=.0?X34CH"#UHR
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M8$/N[&!'X_%?2-OQ84G2\F-)TO)C2=+R8TG2\F-)TO)C2=+R8TG2\F/^E0
MU*D  ,*U P"UP0, JL\% *#G"P&8_1H&C_XI$(;_-1M^_T E=/]&+6O_3#5C
M_U(Z7/]9/U;_8$-0_VA'3/]Q2D?_>TQ#_X=.0/^44#[_H5(]_[!4.__#53O^
MX54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0  Q;
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M+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]X@
M=?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_21$P
M_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E'!W_
ML!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0  9?\
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M!M:_-@_*ND0@O[1/,;2N6$"JJ&!.H:-G6IB>;V2/FG=MB): =8"2BWMZCY:
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M\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH [98
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M1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP  O:P  *ZU  "BP@
ME<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7_TH@4?]1)$S_6"=(
M_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__T#@N_^\Y+?__.3'_
M_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@  A]@
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M$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP  7/T  %3_  !+_P4
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MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72 \&ET@/!I=(#P:72
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M64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P  W),  ,JB  "\K $
ML;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=QW4T@:MQ6*&/;7R]=
MVF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38]$E"T_]-1,G_3T7"
M_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL   I[L
M )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5YV0M
M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7_T1
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M*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0  @=$  '7>  !M^@D
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M,_](GC;_1Z8X_T:O.?]%N#O_1<0\_T32//Q$Y3WX1/(]]47^//%%_S[F2/]
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M6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H _WP  -R,  #-F
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M1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+R ,
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M$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP  3O\$ $G_#@!#_Q0
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M285G_TF%9_])A6?_285G_TG_4A0!_U\. /]K"P#_=0P ^7X- /"%#@#CBQ
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M4EJ.WE);C?A07(O_3UZ(_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4
M]70  -J"  #+C@  P9<  +B> 0"QI0  J:L' *.M&@"<K"P$E:LZ#(VH11:&
MID\??Z17*'FB7R]SH&8U;9YN.VB<=T!CFH%%7YF,25N8F4Q7EZA.59>[3U27
MW$Y4EO9.593_35B0_TQ9C?]+6XK_2EN*_TI;BO]*6XK_2EN*_TK_:   Y7D
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M/4*S_SY$KO\^1:G_/D6I_SY%J?\^1:G_/D6I_S[@?0  R8T  +N:  "NH@
MHZD  )BQ  ".N0  A,$" 'G)!P!TRQ0 <,PF 6O+-05ERT *8,I+$%O*5!97
MR5T:4LEE'T[(;R-+R'HF1\B&*43(E"Q"R*0N0,BX+S_)UR\_Q_4P/<3_,SO#
M_S4\OO\V/;C_-SVX_S<]N/\W/;C_-SVX_S?1A@  P)4  +*?  "EIP  FJ\
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M$R7Q_Q,E\?\3)?'_$R7Q_Q.MH0  H*D  )*S  "$O   =L8  &G/  !=V
M4=\  $GN! !&_ X 0OT7 #[^(0 [_BH!-_\S C3_.@(P_T(#+?]* RO_4P0H
M_UP%)?]F!2+_<P8@_X,''_^4"!W_I@@<_[P(&__B"1K_^0D:__\)&?__"1G_
M_PD9__\)&?__"1G__PFBIP  D[$  (6[  !VQ@  :=   %O:  !.X   0^4
M #[[ 0 Z_PP -O\3 #+_&P O_R, *_\J 2C_,0$D_S<!(?\_ A__1@(<_TX"
M&?]8 Q;_8P,3_W #$O^!!!'_DP00_Z<$#_^]!0[_X 4.__8%#O__!0[__P4.
M__\%#O__!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_
M   N_P< *O\. ";_$P C_QH '_\@ !O_)@ 8_RL!%?\R 1+_. $0_T !#O](
M 0S_4@$)_UT"!O]K @3_?0("_Y " ?^C @#_M@( _\T# /_L P#_[ , _^P#
M /_L P#_[ .(N0  >,0  &G0  !;W0  2^,  #[I   R[@  *_\  ";_   A
M_P  '?\( !K_#0 6_Q$ $_\6 !#_&@ ._Q\ "_\D  G_*@ &_S   O\W 0#_
M0 $ _TH! /]6 0#_9 $ _W4! /^( 0#_F@$ _ZH! /^[ 0#_NP$ _[L! /^[
M 0#_NP'_+RL!_RLR O\O,0+_,#0"_R\Y _\K00/_)TP$_R-8!?\A9@;_('0'
M_QZ""?\>C@O_'I@,_QZA#?\>J0[_'K /_QVX#_\=P1#_'<L0_QW;$?\=Z!'_
M'?(1_QW\$?\>_Q'_'O\0_Q[_$/\?_Q'_'_\2_R'_$_\B_Q/_(O\3_R+_$_\B
M_Q/_+RL!_RXP O\R+P+_,S$"_S(V _\O/@/_*TD%_RE6!O\G8P?_)7$(_R1^
M"_\CB@S_(Y4._R*>#_\BIA#_(JT1_R*U$?\BO1+_(L<2_R+4$_\BY1/_(O 3
M_R+Z$_\B_Q/_(_\2_R/_$O\C_Q3_)/\5_B;_%OPG_Q;\)_\6_"?_%OPG_Q;_
M,"H!_S$M O\U*P+_-RT"_S8R _\T.@/_,D4%_R]2!O\M8 ?_+&T*_RIZ#/\I
MA@[_*)$0_RB:$?\HHA+_)ZH3_R>Q%/\GN13_)\,5_R?/%?\GX17_)^T5_R?X
M%?\H_Q7_*/\5_RC_%O\G_Q?\*?\8]BO_&?0L_QGT+/\9]"S_&?0L_QG_,2D!
M_S0I ?\Y* +_.RH"_SPN O\Z-@/_.4(%_S=/!O\U7 C_,VD+_S%V#O\P@A#_
M+XT2_RZ6%/\NGA7_+:86_RVM%O\MM1?_+;X8_RW*&/\MW!C_+>H8_RWU&/TN
M_QCZ+O\8^2W_&ODM_QSS+_\<[3'_'>HR_QWJ,O\=ZC+_'>HR_QW_,RD!_S@F
M ?\]) '_0"4"_T$I O]",P/_03X%_S]*!O\]5PG_.V0,_SEP#_\W?1+_-H@4
M_S61%O\UFA?_-*(9_S2I&?\SL1K_,[H;_S/%&_TSTQOZ,^8;]S3S&_,U_AOQ
M-/\=\#/_'^XS_R#G-O\AX3?_(=XX_R'>./\AWCC_(=XX_R'_-2<!_STB ?]"
M( '_1B !_T@E O]*+P/_23H$_T=&!O]%4@G_0U\-_T%K$?\_=Q3_/8(7_CR,
M&?P\E1K[.YT<^3NE'?@ZK1[V.K8>]3K '_,ZSA_P.N,?ZSOQ'^@Z_2'F.O\C
MY#K_)>$Z_R78//\FT#W_)LT^_R;-/O\FS3[_)LT^_R;_.20!_T$> ?]'&P'_
M2QL!_T\B ?]1*P+_438$_T]!!O],30G_2UH._$EF$OA'<A;U17T9\T.'&_%"
MD1WO0ID?[4&A(.Q!J2'J0+(BZ$"\(N= RB/D0=\CX$'O)-Q _"?80/\IU#__
M*L] _RK'0O\JPD/_*L!#_RK 0_\JP$/_*L!#_RK_/" !_T4: ?]+%P'_41<!
M_U8? ?]8)P+_6#$#_U<\!?Q52 GV4E0.\E!A$^Y.;1?J3'@;YTJ"'N5)C"#B
M2)4BX$>=)-Y'I27<1JXFVD6Y)]A%QBC41=PIST;N*LM%^RW(1?\NQ47_+\!&
M_R^Z2/\OM4G_+K1)_RZT2?\NM$G_+K1)_R[_0!T!_TD6 ?]0$P'_5A0 _UP;
M ?]?(P'_8"P"^E\W!/-=0@CM6D\-YUA<$^)6:!C>4W(<VE%](-9/AB323H\G
MT$V8*<U,H"O+2ZDMR4JS+L=*OR_%2M PPDOH,+U+^#*Z2O\SN$O_,[-,_S.N
M3?\SJD[_,JE._S*I3O\RJ4[_,JE._S+_0QH!_TP3 /]4$ #_7!( _V$7 /]E
M'@'[9B<!\F8Q ^IE/0;C8TH+W&!7$M5=8AG06FT?S%=W(\A5@"?%5(DKPE*2
M+L!1FC"^4*,RNT^M-+E/N36W3\@VM$_B-K%/]#>N4/\XK%#_.*=1_S>C4O\V
MH%/_-9]3_S6?4_\UGU/_-9]3_S7_1A<!_U 1 /]8#0#_8!  _V83 /]J&0#T
M;"$!ZFTK N%L-P39:D4*T&=2$LIC7AK%8&@@P5YR)KU<>RJZ6H0NMUB,,;17
ME32Q59XVKU2H.*U4LSJJ4\([J%/:.Z54\#RB5?\\H57_.YU6_SJ:5_\YEU?_
M.)=7_S>75_\WEU?_-Y=7_S?_210 _U,. /]<# #_90T _VL/ /IO$P#L<AD
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M26MUU$EK=?)':W7_16QU_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60<
M_V4  .)R  #1?   QX0  ,"* @"YCP( LY(, *R4'0"FDR\$GI$\"YB/2!21
MC%$<BXE:)(:'8BJ!A6DP?()Q-7B!>CIT?X,^<'V.0FQ\FD5I>Z='9GJX2&1[
MT$AD>_!'97O_1&9Z_T-G>/]!:';_/VAV_S]H=O\_:';_/VAV_S__6P0 ]VD
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M0%*/_S]5B_\^5HC_/5>'_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0
MLY4  *F;  "@H   EJ<  (^I#P"+JB$!A:DP!'^H/ IXIT<2<Z50&&VC6!YH
MHF D9*%G*5^@<"Y;GGDR5YV$-E.<D3E0G)\[3INP/4R<QSU,F^H\3)G_/$R8
M_SQ-E?\\3Y'_.U"/_SM0C_\[4(__.U"/_SOK;0  TWP  ,.)  "WDP  K)H
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M*CBV_RLXMO\K.+;_*SBV_RO)A0  N9,  *R<  "@H@  E*H  (BQ  !\N
M<;X  &;% P!;RP@ 5\T3 %;.(P!3SC(!4,X^ TW/2 5)SU((1L];"T//90Y
MSV\0/L][$SO/B14YSYD7-\^K&#;0PQ@VS^@8-,W[&S++_QTQRO\?,,G_(2_(
M_R$OR/\A+\C_(2_(_R&^CP  KYH  **A  "6J0  BK   'VX  !QOP  9L8
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M Q/Y_P.=I0  CZX  ("X  !RP@  9,L  %;3  !)V@  /M\  #3D   N]
M*_\* "C_$  E_Q< (O\? !__)@ <_RT &?\T !?_/  4_T0!$O]. 1#_60$.
M_V<!#/]W 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?_
M_P*1K0  @K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$
M !S_#  9_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0
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M4"P!_4XW O9+0P3P25 'ZTA="N=&:0WC1700X$1^$]U#AQ7;0I 7V$&8&-5
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M.GMBSSMZ8NXY>F/_.'IC_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P<
M_UD  .9D  #7;   S',  ,1W @"_>00 N7H. +)\( "L?#$#I7H^"9]X2A":
M=5,7E7-<'9%Q9"*-;VPGB6UT*X5L?"^":H4R?VF/-7QHFSAY9Z<Z=F:V.W1F
MS#QS9^L[<V?_.'-H_S9S:/\U<V?_,W-F_S)S9O\R<V;_,G-F_S+_400 _UP
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M=@  OWT  +>"  "PA0  J(<& **)%P"<BBD!EHDW!I"'0PR+A4T3A8)5&8"
M71]\?V4D>'UM*71[=2UP>GXQ;7F(-&EWE#=F=J$Z8W:P.V%VQ#QA=N4[87;[
M.6)V_S=C=?\U8W/_-&1R_S-D<O\S9'+_,V1R_S/_6   YF8  -)Q  #%>@
MNX$  +*'  "KB@  HHP" )R.% "7CR8!D8XT!8N,0 N%BDH1@(A3&'N&6QUV
MA6,B<H-J)VZ"<BMJ@'LO9W^&,V-^D39@?9XY77RN.EM\P3M;?.,Z6WSZ.%Q[
M_S==>_\U7GG_-%]W_S-?=_\S7W?_,U]W_S/^7   X6H  ,UU  # ?@  MH8
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M+TN-_R]+C?\O2XW_+TN-_R_B:P  RGD  +R%  "QCP  II0  )N9  "1G0
MAJ(  'JF P!VIQ, <Z@D &ZH,@-JJ#T&9:='"V&F4 ]=I5@46:1@&%6C:!Q2
MHW$?3J)\(TNAB"9(H98H1:"F*D2ANBM#H=HJ0Y_U*T*=_RM"G/\L0IO_+$27
M_RM$E_\K1)?_*T27_RO7<@  PX   +:,  "JE   GYD  )2>  ")HP  ?J@
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M%RO _Q>XC0  JI<  )Z>  "1I0  A*P  'BR  !KN0  8+\  %3#  !*R (
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M"0 C\!$ (?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>
M 1#XE $/^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP
MBZP  'RU  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9
M_PX %_\3 !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_
M@  !_Y8  /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4
M &Z_  !@R   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@
M#O\.  S_$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0
M_WX  /^5  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')
M  !2TP  0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&
M  #_"@  _PX  /\1  #_%0  _QL  /\C  #_*P  _S8  /]#  #_4P  _V4
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M248"U4=3!-!&7PC,16D+R41S#<9#?!##0H02P4*,$[]!E16]09T6NT"F%[I
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M*)%0T"B.4.PHC5'^)XM1_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10<
M_TL  /!5  #?6P  TV   ,QA P#(808 PV$1 +MD) "U9#0"KV-"!:IA3@JE
M7U</H5U@%)Y<:!B;6W ;F%EX'I58@2&35XHDD%:3)HY5GBB+5:DJB52W*X=4
MRRN%5>DKA%7\*H-6_RB#5O\G@E;_)8%6_R2!5O\D@5;_)(%6_R3_1P, _T\
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M+F]C_RQO8_\J;V/_*&]B_R=O8O\G;V+_)V]B_R?_30  ZU@  -EC  #):@
MOW   +=S  "P=   J70' *-V%P">=R@!F'8W!)-U0@B.<TP.B7%5$X5P71B!
M;F4<?FUL'WML="-X:GTF=&F'*7%HDBQN9YXN;&>L,&IGOC%I9]PP:6?U+FEG
M_RQI9_\J:F?_*6IF_RAJ9O\G:F;_)VIF_R?_4   YUL  --F  #%;@  NW,
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M*5IT_RA:=/\G6G3_)UIT_R?M60  UV8  ,5Q  "Y>@  KX   *:$  "=A@
MD8<  (J)# "&BAL @HLK 7V*. 1XB4((=(A,#6^'5!)LA5L6:(1C&F2#:QYA
M@G0A78%])%J B2A7?Y8J57ZD+%)^MBU1?LXM47WO+%)]_RM2?/\I4WO_*%1Z
M_R=4>O\G5'K_)U1Z_R?H7@  T&L  ,!V  "T?@  JX4  *&)  "7BP  B8T
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M(3^4_R'-<   O'T  +"(  "DCP  F90  (Z8  "#G0  =Z   &FD  !@IP@
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M!RO J@@JP<((*L#G!RF]_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC
MI90  )F:  "-H0  ?Z<  '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  N
MRA$ +<H= "S+*0 KRS4 *\Q  "K-2@ HS58 )\YA ";.;P$DSG\!(\^1 B'/
MI0(@T+T"(,_D A_-^@,>R_\$'LK_!1W)_P8=R?\&'<G_!AW)_P:HE   G)H
M )"A  ""J   =*\  &>V  !;O   3L   $/#   YQP  +\P  "?0!  ?U@H
M&]H0 !O;&@ :VR8 &MPQ !G=/  8W4@ &-Y5 !??8@ 6X'( %>"% !3AF@ 3
MXK$ $N// !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I
M  !VL0  :+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D.
M !+J%  1ZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J
M!?*Z  3QY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !I
MN@  6\(  $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ
M#P )^Q4 !_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD
M  #\P0  _.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q
M3LP  #_1   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0
M_PX  /\2  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_
MI@  _\(  /_G  #__   __\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8
M #'=   EX@  &N8  !'J   ,[@  !?(   #_    _P   /\   #_    _P4
M /\*  #_#@  _Q(  /\8  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C
M_Z0  /^Y  #_U   _]X  /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+
M. '_ T0!_P!1 ?\ 7@'_ &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H
M /\ KP#_ +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\
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M$:XZV1&J.^\2ISO_$Z4[_Q2D._\3HSO_$Z([_Q.B._\2HCO_$J([_Q+_. H
M_SP  /]!  #U10  YD8" .%%!P#C0@T U4,9 ,Q%+ #&1SP!P4=) KQ&502Y
M15\&M41H";-#<0NP0WD-KD*!#ZQ"B1"J09$2J$&:$Z= I!2E0*\5HT"\%J%
MT!:>0>H7G$'\%YI!_Q>80?\7F$'_%I=!_Q670?\5ET'_%9=!_Q7_.P8 _S\
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M('U1_Q]]4?\=?5'_''U1_QM]4?\:?5'_&GU1_QK_0@  \$H  -]4  #.6@
MQ%X  +Q?  "V7@  L5P+ *M>&@"E8"L H& Z IQ?10677E )E%Q8#)!;8!"-
M6F@3BUEP%HA8=QB%5X ;@U:)'8!6E!]^59\A>U6M(GE4O2-X5=<C=U7R(G96
M_R!V5O\?=E;_'796_QQV5O\;=E;_&W96_QO_10  [$X  -I8  #)7@  OV(
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M'V5B_QYE8O\=96+_'65B_QWR3   WU@  ,IB  "]:0  LVX  *MP  "B<
MF6X  )-P$ "/<A\ BG(N 89R.P."<44'?7!."WIN5@YV;5X2<VQE%7!K;1AM
M:G4;:FE_'F=IBB%E:)8C8F>D)6!GM"9?9\DF7F?J)5YG_B-?9_\A7V;_'V!F
M_QY@9O\>8&;_'F!F_Q[O3P  VEP  ,9E  "Z;0  L'(  *=U  "==   E',
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M'4]U_QW?7   R&@  +ER  "N>@  I8   )J"  ".@@  @(,  'F% @!TAA$
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M%3V4J!8[E+T6.Y3?%CJ2^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@
MMGL  *J%  ">BP  E(\  (B2  ![E   ;I<  &*;  !7G@  4J . %&@&P!/
MH2@ 3:$T $NA/@%)H4<"1Z%0 T2A6 5"H6$'/Z!K"3V@=PLZH(4-.*"4#C:@
MI@\UH+L0-*#=#S2=]Q SG/\2,YK_$C.9_Q,SF?\3,YG_$S.9_Q.]=P  KX,
M *.+  "8D0  C94  (&9  !SG   9Y\  %NB  !/I@  1ZD( $2J$@!#JA\
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M !?&\0$7Q/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0
M<*L  &*Q  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0
MTAH $-,E  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9
MY@ *UOX "]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0
M %>Z  !)OP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$
M!=\:  3@)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR
MY_   .C_  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#
M   \QP  ,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1
M  #J&   ZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M
M /?S  #W_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   N
MT0  (]8  !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V
M#P  ]A0  /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/
M  #_[0  __D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0
M%N(   [F   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@
M_PP  /\0  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_
MPP  _]4  /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/
M /\ 7 #_ &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +
M_P"W /\ P #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\
M6 #_ &0 _P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T
M /\ O #^ ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\
M^0#_ /D _P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_
M &  _P!K /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H
MN0#W ,0 ]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_
M /  _P#_'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L
M_P=F /\&<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P
M!<  [07. .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+
M_P'_(1@ _R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA
M /D.:P#V#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T
MY0_, .$/XP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_
M)1, _R40 /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P7
M9@#I%W  YA=Y .07@0#B%XD X!>1 -\7F #=%Y\ VQ>G -D8L0#6&+L U!G*
M - :X0',&_,!R1S_ L8<_P+$'/\#PQS_ \,<_P/#'/\#PQS_ \,<_P/_*!
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M#Y0\_P^2//\/DCS_#I$\_PV1//\-D3S_#9$\_PW_-0  _SD  .I!  #=1@
MT$<  ,E&  #&004 P$ 1 +E"(0"S1#( KT5  :M%2P*G154#I$1>!:%$9@>?
M0VX(G4-V"IM"?@N90H8-ET&/#I5!F0^30:01D4&P$I!!P!*.0=D2BT'Q$HE"
M_Q*(0O\1B$+_$(="_Q"'0O\/AT+_#X="_P__.   \ST  .-'  #23   R$X
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M%7!1_Q1Q4/\3<5#_$W%0_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P
MH5@# )M9$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y
M5W<3=E: %716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5
M_Q5K5?\4:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP
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M%5MA_Q7G30  SUD  +]B  "S:   J6T  )YM  "3:P  B6D  (-K"0!_;14
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M%TMSIAA)<[D92'/5&4ER\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@
MP&8  +-O  "H=@  G7D  (]X  "$>   =WD  &]\  !J?0T 9WX9 &1_)@!B
M@#(!7X ] ER 1@-:?TX%5W]5!U1^70E2?64,3WUO#DQ\>1%*?(831WN4%45[
MI!9$>[<60WO2%D-Z\A9#>?\50WC_%$1W_Q1$=O\31';_$T1V_Q/-7P  NVL
M *YT  "D?   EWX  (I]  !_?@  <G\  &:#  !AA @ 7H83 %R'(0!:ARX
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M""Z8[0@NEO\*+93_"BV3_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0
MAHX  'B/  !KD@  7Y4  %29  !)G0  0*   #JB#0 XHQ< -Z,B #:D+0 U
MI#< -*1! #.E2P QI50!,*5> 2ZE:@$LI7@"*J6( RBEF@,GI:T$)J7& R:D
MZP0EHO\%):#_!B2?_P8DGO\'))[_!R2>_P>O?@  HX@  )>.  "-DP  ?I4
M '"8  !CFP  5Y\  $RB  !"I@  .*D  "^L P JK@X *:X8 "BO(P GKRT
M)K W "6P00 DL$L ([%6 "*Q8P AL7$ '[&" !ZRE $<LJD!&[+! 1NQYP$;
MK_X"&JW_ AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB
M  !;I0  3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ
M !6]-0 4O4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L
M#[S_ !"Z_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2
ML0  1;0  #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*
M)P 'RC( !LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_
M  #+_P !RO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0
M.;P  "Z_   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@
MV"<  -DQ  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?
M_P  W_\  -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8
M "')   8S0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L
M .<D  #I+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0
M\/\  /#_  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75
M   .V@  !]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7
M  #U(   ^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4
M /_U  #_]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #
MY@   .D   #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_
M$@  _QL  /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1
M  #_T0#_#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4
M_P!P /\ >@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_
M ,4 _P#3 /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X
M_P#_$2$ _Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L
M /\ =@#_ '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,
M^P#- /D X@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_
M%1T _Q,: /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\
M<0#_ 'H _@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#(
M .\ W #N .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D
M_Q85 /\3$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X
M '4 ]0!^ /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0
MU #B .D X0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0
M /\6#@#_$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G
MZ@)X .<"@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3
M!N< T CX ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:
M!P#_&0L _Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US
M -L->P#9#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D
MPA+Y +\3_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_
M(04 _Q\, /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6
M=0#)%WT QQ>% ,48C #$&)0 PAF< , 9I0"^&:\ O1J[ +L:RP"X&^4!M!SV
M ;(=_P*P'?\"KQW_ JX=_P*N'?\"KAW_ JX=_P+_)@8 _R4  /\F  #[)P
M\24# / A"P#H'!( WAD= -0;+0#-'3P R!]) ,4@50#!(5\ OR)H +PB< "Z
M(W@ N2-_ ;<CAP&U(X\!M"27 ;(DH &Q)*H"KR2V JTEQ@*K)=\"J";S Z4F
M_P.C)O\#HB;_!*$F_P.A)O\#H2;_ Z$F_P/_*0  _R@  /8M  #G,   WR\
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M"H$\_PF!//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@
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M#&5/_PSL00  U$P  ,-4  "V60  K%P  *!:  "75P  D50  (M5# "&5QD
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M$E==I1-57;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3
MQU8  +A?  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L
M9S<!:F=  F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)B
MHQ-08K033V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH
M +1C  "I:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0
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M#CUUZ X^<_T-/G+_#3YQ_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0
MC70  (!T  !U=   :78  %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,
M@$,!2H!+ DA_5 )&?UP$0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]
MY@LW>_P+-WK_"S=Y_PHX>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD
M 'MY  !P>@  9'P  %B   !0@P  2X4* $B&% !'AR  18@K $2(-0!#B#X
M08E' 4")3P$^B%@"/(AA SJ(; 0WB'@%-8B'!C.(F <RAZH',(C !S"'Y <P
MA?L(,(/_"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_
M  !J@   7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)
M #:220 TDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$
M)X[_!2>-_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !C
MB   6(L  $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=
M00 HG4L )YY5 ":>80 EGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_
M AZ9_P,>E_\#'I?_ QZ7_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0
M4)4  $:9   [G0  ,J   "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :
MJ4$ &:E, !BI6  7JF8 %JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E
M_P$3I?\!$Z3_ 1.D_P&CA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*
M #ZD   TIP  *JL  "&N   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38
M#+9!  NV3@ *MEP ";9L  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (
ML_\ ";+_  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P
M   JLP  (;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V
M  ##0@  PU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\
M ,/_  ##_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?
MO0  %L   !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1
M-0  TT,  -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_
M  #6_P"*FP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP
M#<L   ;.    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P
MY3,  .="  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K
M_P!]HP  ;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@
M  #=    X0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0
M /<Q  #Y00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !Q
MK   8;4  %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H
M    [    .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A
M  #_+P  _T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R
M_P<> /\ '0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\
MX0#_ /  _@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL:
M /\$&0#_ !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H
M_P"" /\ B0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U
M .L ] #Y /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(
M% #_ !0 _P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!]
M /D A #W (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8
MZ #U .8 _P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_
M Q  _P 5 /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T
M?P#K (8 Z@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P
M -< _@#5 /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP
M_PD2 /\#&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#>
M (  W "' -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,<
M^P#% /\ Q '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\-
M /\,% #\!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L
MRP2" ,H$B0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V
M#/\ M0W_ +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0
M#@#N#!8 XPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^
M +T/A0"\#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\
MIQ7_ *<5_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>
M#@T TPX8 ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:
M@ "N&H@ K!N0 *L;F0"I&Z, IQRN *8<O "D'<\ H1[J 9X>_ &<'_\!FQ__
M 9H?_P&:'O\!F1[_ 9D>_P'_(@  _R$  .PG  #@*@  U"D  ,TD  #*' @
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M!7([_P7Q,@  WCT  ,E$  "\2   L$D  *9&  "?00  FST! )4]$ "1/QT
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M"F)+I MA2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P
MRTD  +Q1  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T
M4CD <E)" 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/
MH0Q;3[(-64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT
M +A4  "L60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8
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M#$E=XPQ)7/H*25O_"4I;_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80
MD6   (5?  ![7P  <%T  &I?  !E80H 8F(4 &!C(0!>9"T 7&0W %ID0 %8
M9$@!5F10 E1D5P-29%\$4&1G!4YC<09,8WT(26*+"4=BF@I&8JH+1&*_"T1B
MX0M$8?D*1&#_"41@_PA%7_\'15__!T5?_P?(4@  N%P  *MD  ";9   C&,
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M!3%S_P4Q<O\%,G+_!3)R_P6W8P  JFT  )QQ  "+<   ?7   ')P  !G<0
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M 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@  H7P  (][  " >@
M<WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   FDPP ))03 ".4'  B
ME28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7A@ 8EYD %Y>N !67
MR0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,  (F!  ![@   ;((
M %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$ %J , !2A$@ 4H1L
M$Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -HY( #*.G  JBP  +
MHN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(  !SB   98L  %B.
M  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$  JN#  'K1( !JT;
M  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<  *Z=  "NM   KM4
M *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !KD@  798  %":  !$
MGP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X"0  N X  +D4  "Y
M'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1  "\J0  O,0  +SK
M  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP  5:,  $>H   [K0
M,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @  Q0H  ,4.  #&%
MQQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.FP  S;4  ,[:  #.
M]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(  #ZV   PN0  )+P
M !F_   1P@  "L4   +)    S    -    #1    T@$  -,(  #5#0  UQ$
M -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP  Y:4  .7   #EY@
MY?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_   CPP  %\<   _*
M   'S@   -$   #6    W    -\   #@    X@   .0   #F P  Z D  .D.
M  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),  /BM  #YQ@  ^>0
M /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6S@  #=(   38
MW0   .$   #D    Z    .L   #M    [P   /$   #S    ]@   /@#  #Z
M"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9  #_KP  _\,  /_6
M  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@ _P!& /\ 4P#_ %X
M_P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_ *$ _P"H /\ KP#_
M +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H _P#T /\ \ #_ /
M_P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!" /\ 3@#_ %H _P!D
M /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T ^0"C /@ JP#W +0
M]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N /\ Z@#_ .H _P#_
M"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\ 20#_ %0 _@!? /L
M: #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"? .P I@#J *X Z "Y
M .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\ X0#_ .$ _P#_#1
M_PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V $X \@!9 .\ 8@#L
M &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T H0#; *H V "T -4
MP #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_ ,P _P#_$ P _PP'
M /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@ Y0!3 .$ 7 #> &4
MVP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#( *4 Q@"O ,0 NP#"
M ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P _P#_$04 _PX  /\*
M  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!, ,\ 5@#+ %\ R0!F
M ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$ N "K +8 MP"T ,<
ML@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_%   _Q   /\/  #R
M#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #4 "]!%D NP5A +D%
M: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH *H*M0"H"L4 I@O?
M *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P  _Q,  .\8  #D&0
MVQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q#E, KQ!; *T08P"K
M$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3LP"<$\, FQ3> )<6
M] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T  .4C  #5)0  RB0
M ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T HAE6 * :70">&V4
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M G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P  K#P  *(X  "<,P
MF"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40" -5@ ?C5? 7TU9@%[
M-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TVYP1L-OP#:S;_ VLV
M_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$  )L^  "5.@  D#8
M (PU#0"(-Q@ A#@E ($Z,0!_.SP ?#M% 'H\30!X/%4!=SQ< 74\8P%S/&H"
M<3QS G \? -N.X<#;#N4!&H[H01H.[$%9SS%!64\Y05D//H$9#S_ V,[_P-C
M._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#  ".0   B3P  (0\
M"@" /10 ?3XB 'H_+@!X0#@ =4%" '-!2@!R05$!<$%9 6Y!8 )L06<":D%P
M VA!>0-G080$94&1!6-!GP5A0:X&8$'"!EY!X@9>0?D%74'_!%U _P-=0/\#
M74#_ UU _P/?.0  R$,  +E*  "I2P  FTD  )!'  "(1   @T$  'Y!!@!Z
M0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K1D\!:D96 6A&70)F1F4"9$9M V)&
M=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&WP981O<%5T7_!%=%_P171/\#6$3_
M UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20  ?44  'A& @!T1Q
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M!4Q3EP9+4Z<'25.Z!TA3U0=(4O,&2%+_!4A1_P1)4?\$25#_ TE0_P/*2
MN5(  *I7  "85@  BE4  ']4  !V4P  ;%$  &=3  !B5 @ 7U82 %U7'@!;
M5RD 65@S %A8/ !6640 55E, 5-94P%165L"3UAD DU8;0-+6'@$25B&!4=7
ME09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5_P1$5?\$1%3_ T14_P/&3   M58
M *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600 65H0 %=;&P!57"8
M4UTP %)=.0!17D$ 3UY) $U>40%,7E@!2EYA DA=:P-&778#1%V#!$)=D@5
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M S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P  J60  )9D  "&8P
M>&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^;Q@ /6\B #QP*P Z
M<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]QB@(M<9P"*W&O BIQ
MR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D  )!H  " 9P  =&<
M &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q( ,W@< #)X)0 Q>2X
M,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E>ID!(WJL 2)ZQ0$B
M>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM  ![;   ;VP  &5L
M  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4 ":"'@ E@B< )((O
M ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4 &H2I !B$P0 8@^8
M&('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V<0  :W$  %YS  !4
M=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-%0 9C1X &(XG !>.
M,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D  Z/NP -C^  #HWZ
M  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P  9'@  %A[  !-?@
M0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -FA0 #)H=  N:)@ +
MFC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":L0 !F<\  IGP  *8
M_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$  %"%  !%B0  .XT
M #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1   *46  "F'P  IB@
M *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ   IL,  *7I  "E_
MI?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1   ]E@  ,IH  "B>
M   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1  "R%P  LQ\  +,H
M  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8  +7<  "T]P  M/\
M +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   UI   *J@  ""L   6
ML   #[0   FW   !N0   +T   "^    O@8  +\,  # $   P18  ,(=  ##
M)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'  #'[   Q_X  ,?_
M  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP  (+<  !:Z   .O0
M!L    ##    QP   ,D   #*    S    ,T#  #."0  T X  -(3  #4&P
MV"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?V0  W_,  -__  #?
M_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(   S&   #R0   ,P
M  #0    U0   -D   #:    W    -X   #@    X@4  .0+  #G$   ZA@
M .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP  ]-\  /3S  #T] !J
MJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2    UP   -P   #@
M    Y0   .<   #I    ZP   .T   #O    \0   /,   #V!P  ^0X  /P6
M  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X  /_8  #_VP#_ !@
M_P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_ %H _P!D /\ ;0#_
M '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\ JP#_ +0 _@"_ /T
MSP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_ .< _P#_ !0 _P 1
M /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8 _P!@ /\ : #_ '
M_P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T *X \@"Y /$ QP#O
M .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X _P#_ Q  _P . /\
M#0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!: /@ 8P#U &L \P!R
M /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D Y "S .$ P #@ -,
MW@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_!PT _P ) /\ !@#_
M  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H 70#G &4 Y !L .(
M<P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M ,T N0#+ ,D R0#D
M ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8 _P$  /\   #_  0
M_P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4 %\ T0!G ,X ;0#,
M '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T LP"Z ,( N0#; +<
M\ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0  /\   #^    ]@ #
M .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D P !@ +X 9P"\ &X
MN@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L +T J@#0 *@ ZP"G
M /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)  #J"0  X@0  -H
M!P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!; +  8@"N &@ K !O
M *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D G0/, )P$Z ":!OD
MF0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<%0  SA$  ,8-  #"
M! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)7 "B"F, H IJ )\+
M<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W, ) .Z@".$/P C!#_
M (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0  OQT  +<7  "S$0
ML@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6$EX E1-E ),3; "2
M$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07YP""&/L @!G_ '\9
M_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8  *HB  "E'   I!4(
M * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D B1U@ (@=9P"&'F\
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M 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P  AC   (,N"0!_+Q,
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M E9 E0)40*0#4T"V U) SP-10.\#4$#_ E __P)0/_\"43[_ 5$^_P'/.P
MO44  *I'  "91@  BT4  (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C
M0RL 84,U %]$/@!>1$4 745- %M%5 !915P!6$5D 59%;0%417@"4D6% E%$
MDP-/1*,#346T TQ%S -+1>T#2T3_ DM$_P)+0_\"3$+_ DQ"_P+*/P  N4@
M *9*  "520  AT@  'U'  !U10  ;D(  &E#  !E1 D 8D43 %]&'@!=1R@
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M SU2Q@,\4ND"/%'^ CQ0_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40
M?%$  '%0  !H4   7DX  %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(
M5CH 1U=" $972@!$5U( 0U=: $%79 % 5VX!/E=[ CQ7BP(Z5YL".%>M C=7
MQ (W5^<"-U;] C=5_P(W5/\"-U/_ CA3_P*Z3P  J58  )55  "%5   >%0
M &U4  !D5   6%0  %)6  !.5P  2ED) $=:$0!&6AL 1%LE $-;+@!"7#8
M05P^ #]<1@ ^74\ /5U7 #M=80 Z76P!.%UY 39=B $T79D",UVK C%=P@(Q
M7.4",5O\ C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7
M  !@6   5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z
M #AC0@ W8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!
M*F+[ 2I@_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<
M7   45X  $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J
M/0 N:D8 +6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY
M 2-G_P$C9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78
M36,  $1F   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E
M<D  )')* ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP
M_P ;;_\ &V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D
M #]L   W;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D
M&'Q# !=\3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1
M>/\ $G?_ !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET
M   Q>   *7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[
M  V'1@ ,AU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\
M"8+_  F"_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J
M@0  (H4  !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3
M/@  DTL  )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__
M  "/_P"-=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0
M&I$  !.4   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0
MH$(  *!0  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<
M_P"&?0  >'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX
M  VA   &I    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<
M *]%  "O5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!
MA   <80  &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O
M    L@   +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X
M  # 2   P%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0
M:)   %F4  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^
MP0   ,0   #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5
M.@  U4P  -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X
M %&D  !#J@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP
M -(   #3    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@
M[3P  .U1  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT
M   ZN@  *KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,
M  #D    Y@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP
M /\_  #_50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_
M !0 _P 9 /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\
M?P#_ (4 _P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T
M /< _P#V /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \
M_P 4 /\ ( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y
M (  ]P"& /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D
M_@#G /\ YP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0
M /\ &P#_ "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H
MZ0"  .< A@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2
M /\ T@#_ -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P
M%@#W "( \P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z
M -, @ #1 (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\
MOP#_ +X _P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G
M !L X0 G -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,
M>@"_ (  O0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_
M *T _P"N /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4
MS  A ,@ + #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O
M 'H K0"" *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X
M_P"> /\ G@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9
M +@ )0"T #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4
MGP!\ )X A0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0
M /\ CP#_ (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P
M'@"H "D I0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X
M )$#@ "0!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\
M@PO_ (,+_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=
M!R( F0DN )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.
M?0"%#H< @PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_
M '<2_P#O%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L
MCQ$G (P2,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y
M%X, >!>/ '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:
M_P#G(   T"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB
M ($;+0!^'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\
M;B&+ &PAF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@
M)@  R"\  +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C
M*0!U)#, <R4\ '$E0P!P)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B(
M &0IE0!B*:0 8"FU %\IRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+
MPS4  *TU  "=-   D#,  (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M
M*R\ :RPX &HL0 !H+4< 9RU. &4N50!D+ET 8RYE &$O;@!?+W@ 7B^$ %PO
MD@!:+Z$!62^R 5@PR %6,.D!53#^ 54O_P!5+_\ 52[_ %4N_P#0,0  O3H
M *@Y  "7.   BC<  ( V  !Z,@  =3   '(N  !N+@T :R\6 &DP(0!F,2L
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M 44_P0%$/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@
M?4$  '-   !K/P  93P  & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !0
M0CP 3T)# $Y"2P!-0U( 2T-: $I#9 !(0VX 1T-[ 45#B0%#0YD!0D.K 4!#
MP $_0^$!/T/Y 3]"_P$_0?\!0$'_ 4! _P&_00  JD4  )9%  "&10  >40
M &]$  !G0@  8#\  %M!  !70@  5$,- %%$%0!/11\ 3D4H $Q&,0!+1CD
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M 2]/_P$P3O\!,$[_ 3!-_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30
M44T  $M/  !&4   0E(# #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V
M5D< -590 #-660 R5V0 ,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5
M_P J5/\!*E/_ 2I2_P&O40  F%$  (51  !V4   :E   &!0  !840  3E(
M $=3  !!50  .U@  #A9"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$,
M+5Q, "Q<5@ K76  *5UM "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C
M6O\ (UG_ "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8
M   \6P  -ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-'
M "-C40 B9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\
M'&#_ !Q?_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W
M8   ,6,  "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL
M3  9;%@ %VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_
M !-G_P"970  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P
M*VH  "1M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /
M=5( #G5?  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP
M_P"18@  ?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(
M !UV   7>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL
M G]8  %_9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")
M9P  >&<  &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:
M   0@P  #(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0
M  "+7P  BW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0
M<VP  &AL  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +
MCP  !)(   "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "9
M5@  F6@  )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,
M &%S  !3=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G
M *    "A    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3
MJ5X  *ER  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^
M  !+@@  /H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X
M  "O    L    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(
M +ME  "[?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#
MD   -I<  "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_
M    P    ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8
M  #0;@  T8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0
M+J<  "&M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.
MT    -$   #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I
M7P  ZG@  .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD
M !F^   .P@  !,4   #*    S0   -$   #8    VP   -\   #@    X@
M .0   #F    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P
M_V<  /^"  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\
M(@#_ "\ _P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"&
M /\ C #^ ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\
M\P#_ .D _P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_
M "H _P V /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /(
MA@#P (T [P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_
M -X _P#1 /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0
M_0 P /L .P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@
M (< W@". -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L
M_P#% /\ OP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J
M .H -0#G $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (
MR "' ,8 CP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W
M /\ LP#_ +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -(
M+@#/ #D RP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"!
M +0 B0"R )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\
MI0#_ *0 _P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[
M #, N0 ] +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0
M@@"B (P H "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_
M )< _P#_    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P
MJ  V *8 /P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4
M (8 D@"1 )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@
M_P#Y!@  Z0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P
M )@ .0"6 $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($
MA0", (0 F "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q
M#@  WA4  ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T"
M,P"* SP B 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F)
M '@)E@!W"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@
MT!X  +D=  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0"
M#38 ?@X^ 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1
ME !L$:( :Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0
M + D  "@(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$
M=!4Z '(600!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C
M&I\ 81JO & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I
M  "8*0  C"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU
M &D>/0!H'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP
M62*L %<BP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2
M+@  A2T  'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E
M.0!@)D$ 7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ
M % IO@!/*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@
M@#$  '8P  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9
M+#T 6"Q$ %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DO
MNP!(+]L 2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4
M '(T  !K,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H
M4C)" %$R20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"
M--8 0C3T $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW
M  !F-@  83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_
M $LW1@!*-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=,
M/#GS #PX_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B
M.0  73<  %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\
M1 !%/$L 1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR
M #<\_P X._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0
M6#L  %,Z  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00!
M0$D /D%1 #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #)
M_P S0/\ ,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\
M $X_  !*0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148
M.45. #A&6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N
M1/\ +D/_ "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#
M  !$10  048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI,
M #)*50 P2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\
M*$C_ "E'_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _
M2@  .TL  #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M0
M4@ J4%P *%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_
M "--_P"A20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@
M-5   #%2!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B
M5ED (59E !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2
M_P";30  ADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54
M "M8   F6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754
M&%UA !==<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"4
M40  @%$  '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>
M   ?80, &F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=
M  ]E:P .97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50
M>E4  &M5  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9
M:   $VL% !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N
M90 $;G8  FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H
M &9:  !<60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0
M#G0#  IW"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@
M>&\  'B$  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>
M  !97@  35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X
M  * "   @0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@
M (1\  "$DP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !2
M9   1V<  #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ",
M P  C D  (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S
M  "2BP  D:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0
M/W$  #1V   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9
MF@,  )L(  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B
M@   HIH  *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX
M "R$   AB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0
M *H   "L!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P
MM8X  +6H  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4
M   8F@  $)\   FD    J0   *T   "P    M    +<   "X    N0   +L
M  "\    O@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\
M ,J;  #*N   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1
MJP  ";    "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.
M    T    -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,
M  #FJ   Y<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O
M ,$   #%    R0   ,T   #2    U@   -H   #;    W@   .    #B
MY    .<   #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]
MEP  _:\  /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V
M /\ 0@#_ $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T
M^@"4 /D G #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7
M /\ S@#_ ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\
M/0#_ $< _@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ".
M .H E@#H )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\
MP@#_ +X _P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S
M $$ [P!+ .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0
MD #2 )@ SP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_
M +, _P#_    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L
MW !% -4 30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"]
M )( NP"< +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *<
M_P#_    _P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^
M ,  1P"\ $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L
MJ "5 *< H "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_
M    _    .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T
M0 "J $@ J !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ".
M )8 F@"5 *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\
M[P   -L   #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@":
M $( F !) )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@
ME0"& *( A0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D
M ,<(  "W!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P
MBP!# (D 20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y
M )T > "L '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0
M  "I$   G@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^
M 'T 1 !\ $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH
M; .J &L#NP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">
M%@  DQ4  (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)
M0 !R"48 < I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI
M &$-NP!@#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0
MB1P  ($:  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I
M$$( 9Q%) &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4
MN@!6%-4 517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(
M 'DA  !S'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX
M7AA% %T82P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.
M&]  31SQ $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F
M  !L)   :"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]!
M %8@2 !4($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT
M1B/O $4C_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F
M*0  8B8  %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F
M10!.)DP 3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM
M #\H_P _*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0
M72L  %HH  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(
M+$D 1BQ1 $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM
M_P Z+?\ .BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\
M %4L  !1+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4<
M03%/ $ Q5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U
M,?\ -3'_ #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P
M  !,,0  23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9,
M #HV50 Y-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\
M,#7_ # T_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'
M-0  1#8# $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z
M4P T.UT ,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_
M "PX_P"D.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@
M/SL  #P\"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N
M/UH +4!F "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]
M_P"?.P  BCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\
M #9!"  T00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@
M)T5C "5%<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":
M/@  A3\  '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!&
M P M1PT *T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA
M !]*;P =2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@
M@$(  '!#  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F
M30D )$X0 ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0
M:P 64'P %%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8
M &M&  !?1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P,
M'%4, !I6$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /
M5WD #E>,  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*
M  !;2@  44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P'
M !%>#0 07A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G,
M!5Z&  ->FP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !7
M3@  3DX  $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF
M"P (9Q  !F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>
M  !FE0  9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@
M2U(  $)3   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0
M;PX  &\2  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !Q
MCP  <*<  &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<
M #Q:   R70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L
M 'D.  !Z$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B
M?*$  'RZ  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C
M   K9P  (VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+
M  "&#P  B!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD
M (JS  ")V   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D
M<P  &G@  !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5
M"@  EPX  )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK
M  ":R0  FO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0
M$H<   R,   $D0   )4   "9    G0   *    "A    H@   *0   "E 0
MIP<  *D,  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "N
MO@  K>8  *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@
M  .=    H@   *8   "J    K@   +    "Q    LP   +0   "V    N
M +H$  "\"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP
MQ=$  ,/R  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N
M    L@   +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T
M  #/    T@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T
M .'B  #@] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_
MQ    ,@   #.    T0   -0   #5    V    -H   #=    WP   .(   #D
M    YP   .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$
M  #XX0#_  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@
M_P!2 /\ 6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U
M *  \P"J /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,(
M_P#_  0 _P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!,
M /D 5 #W %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H
MX@"D .  L #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_
M    _P   /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@
M3@#D %8 X0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "=
M ,8 J #$ +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_
M_P   /\   #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #*
M $\ QP!6 ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +(
MH0"P *\ K@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P
M /<   #H    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@
ML@!/ +  50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"=
M *< FP"X )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0
M  #2    Q0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !)
M )X 3P"< %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$
MBP"P (H Q0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]
M    LP   *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X
M20", $\ B@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J
M 'L O !Z -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0
MH@   )L   "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^
M $D ?0!/ 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X
MM@!M ,X ; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL
M (P'  "( @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0
M<0!* '  4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A
M ,D 8 #I &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /
M  !\#0  >0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-&
M &8$3 !E!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8
M5@GG %8*^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q
M$P  ;A   &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-
M2 !<#4\ 6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J
M $T0_0!-$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@
M9A<  &04  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4
M$DP 4Q-3 %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46
M_@!%%O\ 117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT
M %P:  !;%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@
M2QI0 $H:6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^
M'/\ /AO_ #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?
M  !4'0  4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!-
M $,@50!"(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\
M."'_ #@A_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/
M(@  3"(' $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF
M4P \)EP .B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_
M #,E_P"E*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@
M1R<$ $0G#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V
M*UH -2ME #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ
M_P"A+   BRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L
M #\L"P ]+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@
M,#!C "XP<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<
M+@  AS   '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ
M"0 W,1  -C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A
M "DU;@ G-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0
M@S,  '(T  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R
M-@X ,#<3 "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y
M;  A.GP (#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8
M &XW  !A-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL
M*CP1 "D\&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;
M/WD &C^, !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY
M  !>.@  4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(.
M ")"%  A0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'<
M$T2* !)$G@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:
M/0  4#T  $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)
M$0 921< &$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'
M  U*FP ,2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60
M34   $5    _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 2
M4!, $5 9 !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50
ME@ #4*L  E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0
M $-#   \1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!
M"E@5  A8'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0
M5Z<  %?   !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'
M   X2   ,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2
M  !?&   8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(
M %^[  !?X@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R
M3@  *U$  "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H
M$P  :1D  &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV
M  !HW0  :/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@
M)%D  !U=   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$
M=!0  '4;  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !T
MTP  <_4  '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,
M !5G   0;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1
M ((4  "$&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0
M@O$  ('_  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU
M   )>0   7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/
M  "3%   E1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H
M )+_  "2_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$
MB0   (X   "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E
M#0  IQ,  *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X
M  "F_P!6:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@
M )\   "C    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0
MN@P  +T2  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\
M_@!.=   0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +
M  "U    N0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(
M - +  #5$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&
M@@  .(D  "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(
M    RP   ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8
M  #J"@  [Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8
M_P # /\ !0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_
M %T _P!D /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X
MLP#K ,0 Z0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P
M /\   #_  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %<
M\0!= .X 8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5
M +L T@#4 ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\
M  #_    _P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7
M -< 70#4 &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +(
MNP#& +D Z "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U
M    ZP ! .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T
M5@"[ %P N0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[
M *4 V@"C /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?
MT    ,< !P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F
M %4 I !: *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )(
MR0"1 .L D0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@
M +$  @"K  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\
MD@!4 )  6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"
M .  @ #Y '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *
M  "9  < E0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!.
M ($ 5 !_ %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\
M<0#Q '  _P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+
M  ( A@ + (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ',
M3@!R %0 < !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H
M &0 _0!C /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^
M>P & '< #@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F
M $\ 90!6 &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@
M^ !8 /\ 6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8
M &T "@!K !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L
M6P!2 %H 60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !.
M _\ 3@3_ $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+
M P!C!@P 8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/
M %$(5@!0"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\
M10S_ $4,_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:
M#@8 6@P- %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.
M50!(#UX 1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_
M #X0_P"I&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P
M4A$* % 0$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!
M%%L /Q1E #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5
M_P"C'   C1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8&
M $D6#@!'%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@
M.1IC #<;;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"=
M'P  B"(  '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<
M# !!'!( /QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@
M #$@;0 O('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@
MA"4  ',F  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [
M(1  .2(6 #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE
M:P J)7H *"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<
M &\I  !B*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X
M-"<4 #(G&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D
M*G@ (RJ* "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK
M  !?+   5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1
M "TL&  L+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8
M'2^( !POFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;
M+P  42\  $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q
M%0 F,1P )3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2&
M !8TF@ 4,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0
M3C(  $8R  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @
M-QD 'S<@ !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$Y
MF  0.:T #CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0
M $0T   ]-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14
M&#T< !<](P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +
M/JD "C[!  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W
M   [-P  -3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8
M !%#'P 01"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4
M D.]  -#X  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X
M.@  ,SH  "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*
M&P )2B, "$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY
M  !)W0  2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0
M+SX  "E    C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P
M41X  %$F  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0
MV   4/4  $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,
M "1&   >2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D
M %HA  !:*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0
M6/0  %?_  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-
M   84   $E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;
M  !D(P  9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(
M &'_  !@_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   2
M60  #5T   A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P
M'0  <28  '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_
M  !L_P!:3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9
M!F@   !K    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@
M?QX  ( H  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z
M_P!65   3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8
M  !Z    ?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8
M )(?  "2+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!5
M60  2%H  #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+
M    C@   )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06
M  "F(0  IC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80
M0&0  #-I   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=
MH0   *0   "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\
M%@  O"4  +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7
M "MW   ??P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP
M +<   "W    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@
MU!D  -0K  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(
M   7D0  #9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H
M  #*    S0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\
M .P?  #M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_
M  D _P . /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\
M90#] &L ^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@
M ., ^ #B /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_
M_P ) /\ $ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I
M &0 Y@!J .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. /_B
M?1!)0T-?4%)/1DE,10 ,$LD \ #' /\ Q0#_ +L _P"T /\ K0#_ *D _P#_
M    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P * #I #( XP [ -T
M1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V ,( ?@"_ (< O "2
M +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\ H #_ )P _P#_
M_P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#) "L Q@ T ,$ /0"]
M $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H =@"H '\ I@"* *,
ME@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_ )  _P#_    ]@
M .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4 K@ N *D -@"F #T
MHP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4 '< D@"! )  C@".
M )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ (( _P#S    XP   ,P
M  "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G )8 +P"3 #< D0 ]
M (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\ @ !Z 'X A@!\ )0
M>@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F    RP   +<   "H
M    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0 *0"" #  ?P W 'T
M/0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S &\ ?P!M (T ; "=
M &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2    N    *4   "7
MC0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S "L <0 Q &\ -P!N
M #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &( > !@ (< 7P"6 %T
MJ != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$  )@#  ")!   ?P(
M '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4 90 L &, ,@!B #@
M8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5 ($ 5 "1 %( HP!1
M +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+  !^#   <PL  &P*
M  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G %D +0!8 #, 5@ Y
M %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T 2@"- $D GP!( +(
M1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U$   :Q   &,/  !>
M#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$ *0!/ "\ 3@ U $T!
M.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+ $ #G  _ Z\ /@/(
M #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%   9!0  %P3  !6$@
M4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!("2L 1PDQ $8). !$
M"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,G  W#*\ -0S' #4,
MZ0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@  %88  !0%P  314
M $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@ 0 XN #\.-0 ^#SP
M/0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O$+  +1#) "T1[  M
M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<  !,&P  1QH  $08
M  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K #@3,@ W$SD -A1
M #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X )Q7' "85Z@ G%?\
M*!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !('@  0QT  $ <   ^
M&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8+P Q&38 ,!D] "X9
M1@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K% " :Z  A&OX (AK_
M ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0  /R$  #P@   Y'@
M.!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K'C, *AX[ "D?0P G
M'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?YP ;'_T '1__ !X>
M_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",  #@C   U(@  ,R
M # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S  )2,X ",C00 B)$H
M(215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6)/P %R/_ !DC_P"%
M(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F   Q)0  +B0  "LE
M   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V !XH/@ =*$@ &RE3
M !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L $RC_ !0G_P" )0
M;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N*   *B@  "8I   D
M*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M/  7+44 %BY0 !0N
M70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_ ! L_P!\*   :BH
M %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P  )BP  "(N   ?+P
M'# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2,T, $3-. ! S6P .
M,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ_P!W*P  9BT  %@N
M  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S   !\R   ;,P  %S4%
M !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\ ##A*  LX5P ).&4
M!SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S+@  8C   %0Q  !)
M,0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV   7.   $SH" ! \
M"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&  ,^4@ !/F$  #YR
M   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@  73,  % T  !&-
M/C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4/0  $#\"  U!"  )
M0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$3@  1%P  $1M  !$
M@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<  $PX  !#.   .S<
M #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@  #44!  A'!P #20P
M $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20  3%<  $MH  !+?0
M2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[  ! .P  .3H  #,Y
M   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P   )/!0  4 H  % -
M  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(  %1C  !4=P  5(\
M %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^/@  -ST  "\^   G
M0   ($,  !E&   320  #TP   M/   &4@   %0   !7 @  6 <  %D+  !:
M#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=  !><0  78D  %VC
M  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00  ,D(  "E%   A2
M&DL  !-.   .4@  "E4   -9    6P   %X   !@    8@(  &,&  !E"@
M9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J:@  :H(  &F=  !H
MNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H  "--   ;40  $U4
M  Y9   (70   6$   !D    9P   &H   !L    ;@   '    !R!0  <PD
M '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@  >7D  'B6  !WLP
M=>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8   37   #6$   9F
M    :@   &\   !R    =@   'D   !\    ?0   '\   "!    @P(  (8'
M  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\  (J,  ")J@  B,\
M (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -:@  !7    !V
M>P   '\   "#    AP   (H   "-    C@   )$   "3    E0   )@   ":
M!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!  ">H   G<$  )ON
M  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P   ($   "'    C0
M )(   "6    F@   )T   "?    H0   *0   "F    J    *L   "N
ML0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "TEP  M+4  +'B  "P
M_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0   ":    H    *4
M  "J    K@   +$   "R    M0   +<   "Z    O    +\   ##    Q@
M ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@  RJL  ,O+  #+[P W
M<0  *7@  !V    1B0  ")$   ":    H0   *<   "M    LP   +D   "^
M    P@   ,4   #&    R0   ,P   #.    T@   -4   #:    W@   .$
M  #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD  .NU  #KU0#_
M_P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_ #H _P!# /\ 2P#_
M %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$ B0#O )( [ "= .D
MJ@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_ *T _P#_    _P
M /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #, ]P ] /, 10#O $T
M[ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2 (H SP"5 ,P H@#(
M +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$ _P#_    _P   /T
M  #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V -8 /@#1 $8 S0!,
M ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($ MP"- +0 F@"Q *D
MK@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_    ^0   /(   #G
M    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L -P"W #\ M !% +$
M2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$ )T D0": *  F "Q
M )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W    [    -X   #)
MO    +0   "O  H JP 0 *D %P"H "  IP H *( , "? #@ G  ^ )H 1 "8
M $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D B "' )< A0"H (,
MO@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP   ,$   "Q    I@
M )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$ B0 X (< /@"% $,
M@P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U (X <P"? '$ LP!P
M -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P   ">    DP   (P
M  "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q '4 -P!T #T <@!"
M '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8 9 "7 &( J@!A ,(
M8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-    @P   'P   !W
M    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &< ,0!F #< 9  ] &,
M0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0 %8 HP!5 +D 5 #>
M %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_    =0   &X   !I
M9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !: #( 6  W %< /0!6
M $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L G !* +$ 20#. $D
M\P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@  &,&  !>!   6P
M %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T 3@ S $T . !, #X
M2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !  *L 0 #% #\ Z@ _
M /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-  !5"P  4@D  % &
M  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O $4 - !$ #H 0@!!
M $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *< -P"^ #8 XP V /D
M-@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.$   2@X  $@-  !'
M"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$,0 \!#< .P0^ #H%
M10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[ "X%W0 N!O4 +0?_
M "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P  1!(  $$0  ! #@
M0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V"S4 -0L[ #,+0P R
M#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,W0 E#?4 )@W_ "<-
M_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4  #P4   Z$@  .1$!
M #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S( +Q Z "T00@ L$$L
M*A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >$?< 'Q#_ " 0_P"&
M%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8   U%@  -!0  #,2
M!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W "<4/P F%$@ )!13
M "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@ &13_ !H4_P""%P
M;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q&@  +QD  "X6   L
M%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9/0 @&48 'AE1 !T9
M70 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_ !48_P!]&@  :QT
M %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0  *QP  "D;   G&P4
M)1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;'D0 &1Y. !<>6P 6
M'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=_P!Z'0  9Q\  %DA
M  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R   "0?   B( ( (" *
M !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$ %"-, !(C6  1(V<
M$"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V'P  9"(  %8C  !+
M)   020  #HD   T)   +R,  "LC   H(P  )",  " C   =)   &R4' !DF
M#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*  XH5@ -*&0 #"AT
M  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@  8"0  %,F  !()P
M/R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9*   %BH$ !0K"P 2
M+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM4@ (+6  !BUP  0M
M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<  $\H  !%*0  /"D
M #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+   $RX" ! P"  .,0T
M#3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !,EP  #)L   R?P
M,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK  !!+   .2P  #(K
M   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("  XT!P *-PP !S<0
M  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@  #AH   X?   -Y(
M #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^+P  -BX  # N   K
M+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ!P &.PL  CP.   ]
M$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=P  /H\  #VG
M   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@  -#$  "XP   I+P
M)#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0  00H  $(-  !#$
M1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&<P  18H  $6D  !$
MP   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0  "TS   F-   (#4
M !HX   4.@  $#T   U    )0@  !$4   !' P  2 <  $H+  !+#@  3!$
M $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0  3H4  $V@  !,O
M2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW   A.0  &SP  !4_
M   00@  #$4   =(   "2@   $T   !/    400  %('  !4"P  50X  %<1
M  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\  %>:  !6MP  5>,
M %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <00  %40  !!(   +
M2P  !4X   !1    5    %<   !9    6P   %T"  !>!@  8 L  &(.  !D
M$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23  !CL0  8=T  &#\
M  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@  $$X   I2   #5@
M %H   !=    8    &,   !E    9P   &D   !K 0  ;04  &\*  !R#@
M=1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !RJ0  <,T  &_W  !N
M_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H   %?    8P   &@
M  !K    ;P   '(   !U    =P   'D   ![    ?0   ( #  "#"   A@T
M (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H   @L(  ('P  !__P!&
M2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O    =    '@   !\
M    @0   (0   "'    B    (L   ".    D    ),   "6    F0<  )T-
M  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4  );E  "5_@ _4@
M,E4  "9:   ;8   $6<   EM    =    'L   "!    A@   (L   "0
ME    )<   "9    G    )\   "A    I    *<   "J    K0   +$&  "U
M#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/  "M]0 W7   *V$
M !YH   3<   "W@   "     AP   (X   "5    F@   )\   "D    J
M *P   "M    L    +,   "U    N    +L   "_    PP   ,<   #+!0
MT0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%Z0 O:0  (W   !9Y
M   -@0   8L   "3    FP   *(   "H    K@   +0   "X    O0   ,
M  #"    Q0   ,@   #+    S@   -$   #6    VP   -\   #D    Z 8
M .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_    _P   /\   #_
M  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\ 1P#_ $X _P!5 /P
M6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9 .8 IP#C +D WP#5
M -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_    _P   /X   #\
M_  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L $@ Z0!. .8 5 #B
M %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,< G@## *X P #% +T
MZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@   /0   #Q    \@
M .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $  R !' ,4 30#" %,
MOP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K *0 J "X *8 W "C
M /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<   #?    SP   ,@
M  #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!  *L 1@"H $P I@!1
M *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L D@"M )  QP". /
MC0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_    LP   *H   "F
M  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ), /P"1 $0 CP!* (X
M3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C 'P N@!Z .$ >0#_
M '< _P!R /\ < #_ &\ _P#=    RP   +8   "G    G0   )0   ".  $
MBP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !] #T >P!# 'D 2 !X
M $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H K@!I ,P : #V &<
M_P!E /\ 9 #_ &, _P#*    M    *$   "3    B0   ((   ![    >  %
M '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #< :@ \ &D 0@!H $@
M9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!: +X 60#I %D _P!9
M /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$   !M    :0 ! &8
M"0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W %L / !: $( 6 !(
M %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0 30#: $T ^P!- /\
M30#_ $T _P"J    E    ((   !U    :P   &0   !@    70   %H !0!8
M  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\ -P!. #T 30!# $P
M2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#) $( \0!" /\ 0P#_
M $, _P">    B0   '@#  !J!   800  %H#  !5 0  4@   %   @!.  D
M30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$ #@ 0P ^ $( 10!!
M $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@ Z  X /\ .0#_ #D
M_P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208  $<#  !&  8 1  +
M $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0 .@ Z #D 00 X $D
M-P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O /D +P#_ #  _P",
M"0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*   ^" ( /00( #P!
M#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W #( /@ Q $8 +P!0
M "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /( )P#_ "< _P"&#
M<@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W#0  -@L$ #8("@ U
M!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&/  J!D0 *0=. "<'
M60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^ !\'_P" #@  ;1$
M %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$   , \! # -!@ P"PL
M+PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D#$, (PQ- "$-6  @
M#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,_P![$0  :1,  %H5
M  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(  "H0 P J#P@ *0X-
M "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$( '1!, !L06  9$&8
M%Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W$P  914  %<7  !+
M&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84 0 E$@0 (Q(+ "(2
M#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1* !845@ 4%&0 $A1T
M !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0  81@  %,:  !(&P
M/QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @%@$ 'A8( !T6#0 ;
M%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$95  0&6( #AER  T9
MA  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH  % <  !%'0  /!T
M #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@  &AL% !@;#  6'!
M%1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,'EX "AYM  D>@  '
M'I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>  !"'P  .A\  #(?
M   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\" !,@"0 2(0X $"$2
M ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH !2)I  ,B?  !(I$
M "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  ! (0  -R(  # A   J
M(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D!P .)@P #"80  LF
M%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F   G>0  )X\  ":F
M   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])   -"0  "XC   H(P
M)"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +*@L ""L.  8K$P $
M*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L=@  +(P  "ND   K
MO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8  "LF   F)0  (R0
M !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL !# .   P$0  ,14
M #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@  ,8D  #&B   PO
M,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH   E)P  (28  !PG
M   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,   V#P  -Q(  #@8
M   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4  #>?   WN@  -N0
M #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D*0  'BH  !DK   4
M+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]#0  /A   $ 4  !
M&P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;   ^MP  />,  #S\
M   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0  &B\  !4Q   1,P
M#38   DX   %.P   #T   !  0  000  $,'  !%"P  1@X  $@1  !*%@
M2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'M   1N   $7\  !$
M_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4  !$X   -.P  "#X
M  -!    0P   $8   !(    2@   $P$  !.!P  3PL  %$.  !4$@  51D
M %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@  4-<  $_[  !._P!%
M-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!   '1    $@   !*
M    30   %    !3    50   %<   !8 @  6P8  %T+  !?#@  8A,  &(;
M  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P  %KX  !9_P!!/
M.CL  #0Y   J.@  (3P  !A    10P  #$<   9+    3P   %,   !6
M60   %P   !?    80   &,   !E    9P$  &H%  !M"@  < X  ',5  !R
M(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ  !H_P _0   .3X
M "X_   D0@  &D8  !)*   ,3P  !%0   !8    70   &$   !E    :
M &L   !N    <0   ',   !U    >    'L   !^ P  @0H  (4/  "'%P
MAB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z_P _1   ,T4  "A(
M   =3   $U(   Q7   #70   &,   !H    ;0   '$   !V    >@   'X
M  "!    @P   (8   ")    BP   (X   "2    E0$  )D)  ">$   GAH
M )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X2P  +$X  "!3   5
M60  #6    -G    ;@   '0   !Z    @    (0   "*    C@   )(   "5
M    EP   )H   "=    H    *,   "G    JP   *\   "T"0  N!   +<>
M  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50  )%L  !AA   .:0
M!7$   !Y    @0   (@   "/    E    )H   "?    I    *@   "I
MK    *\   "S    M0   +D   "]    P0   ,8   #+    T0H  -,4  #1
M)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D  !%Q   '>P   (0
M  "-    E0   )T   "C    J0   *\   "T    N0   +P   "^    P@
M ,4   #(    S    -    #4    V@   -\   #D    Z@   .X,  #M&@
M["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\   #\  $ _  ( /X
M#@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0 /L 5@#Y %P ]@!B
M /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4 VP#0 -4 ]@#* /\
MM@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S    \P   /8 "0#Z
M  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .( 3P#> %4 VP!; -8
M8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#! +@ Z0"V /\ IP#_
M )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G    YP   .0  0#@  L
MVP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\ $X N@!3 +@ 60"V
M %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *  V "> /L E0#_ (L
M_P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@   +\   "Y  8 MP .
M +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8 GP!, )T 40"; %<
MF0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "( .\ A0#_ 'P _P!V
M /\ <P#_ '( _P#@    T    ,8   "V    J0   *$   "=  $ F0 * )@
M$ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !% (< 2@"% %  @P!6
M ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\ <@#_ &X _P!I /\
M9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%    @@ % (  #0!_
M !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '( 0P!P $D ;P!/ &T
M5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V &  _P!< /\ 6P#_
M %H _P"]    J0   )<   ")    ?@   '@   !S    ;P ! &T "0!L  X
M:P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@ $( 7P!( %T 3P!<
M %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %( _P!0 /\ 3P#_ $\
M_P"M    F    (8   !X    ;@   &<   !C    8    %T !0!<  L 6P 0
M %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P 40!" $\ 20!. %$
M30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !% /\ 10#_ $4 _P"?
M    B0   '@   !L    8@   %L   !6    4P   %$  @!/  @ 3P - $X
M$0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ] $0 1 !# $P 0@!5
M $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\ .P#_ #P _P"3
M?@   &X   !A    6    %$   !,    20   $<   !%  4 1  + $, #@!#
M !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H /P Y $< . !0 #<
M6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_ #, _P")    =@,
M &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  , .P ( #H #0 Z !
M.0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P $, +P!, "X 5P M
M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H _P"!!   ;@@  %\*
M  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (& #, "@ R  X ,0 1
M #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\ * !) "< 5  F &
M) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P!["0  : P  %H-  !.
M#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&"  L! P *P(/ "H!
M$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%& "$!40 ? 5T '@%L
M !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#   9 X  %4/  !*$
M0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G"@H )@@- "4'$  D
M!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(3P 9"%P %PAK !8(
M?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q   %$1  !&$@  /1(
M #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0< (0P+ " +#@ ?"Q(
M'0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3#5P $@UK ! -?@ /
M#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3  !#%   .A0  #(4
M   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \( !L/#  :#A  &0\4
M !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T #1!K  P0?  +$)
M"1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  ! %@  -Q8  # 6   J
M%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82"@ 5$@X %!(2 !(2
M&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G  <4>  &%(T !!2C
M  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&   -!@  "T8   H&
M(Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1%@T $!<0  X7%0 .
M%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8=0 !&(L  !>A   7
MN0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH  "L:   E&@  (1D
M !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL #!L/  L;$P *&Q@
M"!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@  '(@  !R@   ;N0
M&]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<   C'   'QL  !P:
M   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.  8@$0 %(!8  R <
M  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88  "">   @N   ']X
M ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B'0  'AT  !L<   8
M&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D$   )1,  "49   F
M(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<   EMP  )-\  "/Y
M   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P  '1X  !H=   6'@
M$QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@  *Q$  "P6   L'0
M+"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   JM0  *=\  "G[   H
M_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"   !<@   3(0  $",
M  XD   +)@  ""@   0J!   + <  "X)   P#   ,0\  #,3   S&0  ,R$
M #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP  ,-X  "_[   N_P!,
M)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D   1)@  #B@   LJ
M   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0   [%0  .QT  #LF
M   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L  #;\   U_P!'*0
M.RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .+   "B\   8Q   !
M-    #8    X    .P$  #T$   _!P  00H  $,.  !%$0  11@  $4A  !%
M+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z   ^_P!"+0  ."X
M "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-   !#<    Z    /
M #\   !!    1    $8   !( P  2@<  $P+  !.#@  4!,  % <  !0)P
M3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(_P ^,@  -3$  "XO
M   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $    !$    1P   $D
M  !,    3P   %$   !3    50$  %@&  !:"P  70X  %\5  !>(   7BP
M %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z-@  ,S0  "TR   D
M,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0    4P   %8   !9
M    6P   %T   !@    8@   &4   !H!0  :PL  &\0  !O&   ;B4  &TT
M  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0  ,C<  "@Y   >.P
M%3\   Y$   '20   $T   !2    5@   %H   !>    8@   &4   !H
M:P   &T   !P    <P   '8   !Y    ?00  ($+  "%$0  A!T  ((L  "
M/@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X  ")!   71@  #TL
M  =1    5P   %P   !B    9@   &L   !O    =    '@   ![    ?@
M (    "#    A@   (H   "-    D0   )8#  ";#   G1,  )LA  ":,P
METD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-   04P  "%H   !A
M    :    &X   !T    >0   '\   "$    B0   (T   "1    DP   )8
M  "9    G0   *    "D    J    *P   "R P  MPT  +<7  "U*   LCX
M +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *8@   &H   !S
M>P   ((   ")    C@   )0   ":    GP   *0   "F    J0   *T   "P
M    LP   +<   "[    P    ,4   #+    T00  -4.  #3'0  T#(  ,U+
M  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=    'T   "'    D
M )<   ">    I    *L   "Q    M@   +H   "\    P    ,0   #(
MRP   ,\   #4    V@   .    #F    ZP   /$&  #P$P  [B<  .P_  #J
M6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  % /8 # #Z !$ _P 9
M /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@ ]0!> /, 9 #Q &H
M[@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#! /\ K0#_ )X _P"6
M /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P !0#R  P ^  2 /<
M&P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6 -  7 #- &( R@!J
M ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\ G0#_ )  _P"( /\
M@P#_ (  _P#P    Y0   -X   #:    VP   -P   #8  < T0 . -$ %0#2
M !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +( 50"P %L K@!A *P
M:0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_ (( _P![ /\ =@#_
M '0 _P#B    TP   ,H   #'    O    +8   "P  $ KP + *P $0"M !@
MK0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5 %, DP!9 )$ 80"/
M &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ', _P!M /\ :@#_ &@
M_P#/    P0   +D   "M    H    )@   "4    D0 & )  #0"0 !( CP 9
M (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L ? !2 'H 60!X &(
M=@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@ /\ 7@#_ %P _P"^
M    L0   *    "2    B0   ((   !\    >@ ! '@ "0!W  X >  4 '<
M&@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !* &8 40!D %H 8P!D
M &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\ 4@#_ %$ _P"P
MGP   (T   !_    =    &X   !J    9@   &4 ! !C  L 8P 0 &, %0!C
M !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8 2P!5 %, 4P!< %(
M: !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_ $< _P"B    C0
M 'P   !N    90   %X   !9    5P   %4  0!4  < 4P - %, $0!4 !8
M4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !' $P 1@!6 $0 80!#
M '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X _P"4    ?P   &\
M  !C    60   %$   !-    2@   $@   !'  0 1P * $8 #@!& !$ 1P 6
M $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $< .@!0 #D 6P X &D
M-P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(    =    &4   !8
M    3P   $@   !#    /P   #T    \  ( /  ' #L #  [  \ .P 2 #H
M%P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+ "\ 5@ N &, +0!S
M "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_    ;    %T!  !1 @
M2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R  T ,0 0 #$ $P P
M !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "< 40 F %X )0!N "0
M@@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900  %8&  !+!P  0@@
M #H(   U!P  , 8  "T%   L P  *P # "H !P I  L *0 . "D $0 H !4
M)P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ? %H '@!I !T ?  <
M ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*  !&"P  /0L  #4+
M   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$, "( #P A !( (  6
M !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %< %P!F !8 >  5 (\
M%0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"#0  .0T  #$-   L
M#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%#0 <!!  &P04 !D$
M&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C !$#=0 0 HH $ &B
M  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P  -0\  "X/   H#P
M) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7"0X %@D2 !4)%@ 4
M"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)<P ,"(@ "PB?  H'
MMP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$  "L1   E$   (1
M !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T $@P0 !$,%  0#!D
M$ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &#88 !0V=  0,M  #
M#-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2   C$@  'A$  !L1
M   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.  X/$@ -#Q< #! =
M  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0  !"<   /M   #M0
M  [S   ._P!<$   31(  $ 3   V%   +10  "84   A$P  '!,  !D2   6
M$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2$0 *$A4 "1(:  @2
M(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;   2M   $=<  !'U
M   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0  &A0  !<4   4$P$
M$Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &%A, !!88  ,6'P "
M%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5M   %=D  !3W   3
M_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18  !85   3% , $A,&
M ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$  !H6   ;'   &R0
M !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP  &=L  !CY   7_P!1
M%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46 0 3%04 $14$  \5
M!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3   @&0  ("$  "$J
M   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML  !WZ   <_P!-&0
M/QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2%P( $!@!  T9 0 +
M&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F%@  )AX  "<G   G
M,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[   A_P!('0  /!X
M #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P  #1P   L=   ('P
M!"$   $C @  )00  "<&   I"0  + P  "X/   N$P  +AH  "XC   N+@
M+CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H_P!$(   ."$  "XA
M   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$   <C   #)0   "<
M   I    + $  "X#   P!@  ,PH  #4-   V$0  -A<  #8?   V*0  -C8
M #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _)   -"0  "LD   D
M(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J    +0   "\    R
M    -    #<    Y P  .P8  #X*  ! #@  01(  $$:  ! )0  0#$  $!
M   _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*   ,"@  "DG   C)0
M'R,  !@D   2)0  #B@   HJ   %+0   #     S    -@   #@    [
M/@   $    !"    10(  $<&  !*"@  30X  $T5  !,'P  3"L  $LZ  !*
M3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L  "<I   C)P  &R@
M !0J   .+0  "C    0S    -P   #H    ]    0    $,   !&    2
M $L   !-    4    %,!  !6!@  60L  %L0  !;&0  6B4  %DT  !81@
M5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L   >+0  %B\  ! R
M   *-@   SH    _    0@   $8   !)    3    $\   !2    50   %@
M  !:    70   &    !C    9P8  &L,  !L$@  :QX  &LL  !I/0  9U(
M &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9-0  $3D   H]   "
M0@   $<   !,    4    %0   !8    6P   %\   !B    90   &@   !K
M    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D  !^-0  ?$D  'MA
M  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20   "T4   )+    40
M %8   !;    8    &4   !I    ;@   '(   !V    >0   'P   !^
M@@   (4   ")    C@   ),   "8!@  G X  )L:  "8*P  ED   ))9  "1
M<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0   !;    80   &@
M  !N    <P   'D   !^    @P   (@   ",    CP   )(   "5    F0
M )T   "A    I0   *H   "P    MP<  +@1  "U(0  LC4  *]-  "J:0
MJ(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M    =0   'P   "#
M    B0   (\   "5    FP   *    "C    I@   *D   "M    L0   +4
M  "Y    O@   ,0   #*    T@   -H*  #6%@  TBD  ,Y!  #*7   Q7P
M ,*=  #!O0 <50  $5P   =E    ;@   '<   !_    B    )    "8
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M________________________________________________
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MV=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0
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MG]B5CI_8E8Z?V)6.G]B5CI_8E8Z?V)6.G]B5CI_8_Z B!?^?+0S_HS<4_ZY
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M ,;4"0"X]Q0$J_\I#I[_-!B0_SHAA/]!*7K_23!R_U(V;/]>.FC_:#UD_V]
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>^KD. ,W+"0#
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MQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
M:<>A_XT< _^*)PC_BC$-_Y8W$_^>0!O_I4DG_Z=3-/^G74/_I&A3_*!R8O*:
M?'#JE(5]XXN+B-V$DI'8?IB8TWJ>G]!UI*3-<JJHRV^PJ\EMN*[":;RPO&O
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MAYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6 D;BU@)&XM8"1N+6
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M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X_Z(5 ?^W%0#8SPL
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M@\2EC8/$I8V#Q*6-@\2E_XD9 _^') ;_DRD)_Y\Q#?^I.1/_L4$<_[E)*?;
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M-Q=E_S\;7O]''EC_3B%4_U<C4?]?)4[_929-_VPG2_]Q*$K_=BE)_WLJ2/^
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ME)%_T)21?]"4_X$9 _]^) ;_C28'_YHM"O^D-0__K#T7_K)%(O:X3##MO%1
MY+A=4=>R9&/+J6QSP*%S@+>:>HNOE("3J(^(FZ**CZ"<AY>EEX2@J)2"J:J1
M@K6KC8&_JXV!Q:2,@LN;C(+/E8R"SY6,@L^5C(+/E8R"SY6,@L^5C(+/E8R"
MSY6,@L^5_X(9 _]_) ;_CR4'_YPM"?^F-0[_KCT6_+5%(?.\2R[JP5(_X+Q;
M4=&U8V/&K6IRNZ5Q?[*>=XJIF'Z3HI.%FIN/C:"6C)6ED8F=J(V'IZN*A[*L
MAX>_K(:&Q*6'ALJ<AX;.EX>&SI>'ALZ7AX;.EX>&SI>'ALZ7AX;.EX>&SI>'
MALZ7_X(9 _^ (P7_D24&_YXL"?^H- W_L3P5^KA$'_"_2RWGQ5$]W,!:4,VX
M86+!L&AQMJEO?JRB=8FDG7R2G)B"FI64BJ"/D9*EBHZ;J(:-I:N#C+"L@8V^
MK("+PZ:!B\F=@8O-F(&+S9B!B\V8@8O-F(&+S9B!B\V8@8O-F(&+S9B!B\V8
M_X,9 _^"(@7_DR0&_Z L"/^K,PW_M#P4][Q#'N[$2BODR5$[U<183\B\8&&\
MM&=PL:UM?:>G<XF>HGF2EIV F8^:B)^)EY"D@Y28J'^3HJI\DJVK>I*[K'J1
MPZ9[D,F>?(_-F'R/S9A\C\V8?(_-F'R/S9A\C\V8?(_-F'R/S9A\C\V8_X,8
M O^$(07_E20&_Z(K"/^M,PO^MSL2],!"'.K)22C@S4\YT,=73L/ 7F"WN&5O
MJ[)K?*&L<8>8IWB0D*-^F(F@A9Z"G8VC?9N6IWB9H*EUF:NJ<YFXJW.8PZ9U
MELF>=I7-F7:5S9EVE<V9=I7-F7:5S9EVE<V9=I7-F7:5S9EVE<V9_X08 O^'
M( 7_ER,%_Z4J!_^Q,@K[NSH0\<5!&>?/2"7;TDTXR\M53+W$75ZQOF-NI;AJ
M>YNR;X:2KG:/B:I\EH*G@YQ[I(NA=J*4I7&AG:=NH*FI;*&VJ6VAPZ9OG<F>
M<)S-F'"<S9APG,V8<)S-F'"<S9APG,V8<)S-F'"<S9APG,V8_X48 O^*'@3_
MFB($_Z@I!O^U, CVP#@.Z\M %>'81B#3V$LVQ=!42[?)6URKPV)LG[YH>)2Y
M;H.+M7.,@[)ZDWNO@9EUK8F>;ZN2HFNJG*1HJJ>E9JJTIF:KQ:1HILJ<::3-
MEVFDS9=II,V7::3-EVFDS9=II,V7::3-EVFDS9=II,V7_X87 O^-' 3_GB$$
M_ZPG!?VZ+P;OQS8*X]0^$-C?0Q_+WDHTOM922+#06EJDRF!IF,9F=HW!;("$
MOG*)>[MXD'2Y?Y5NMX>::;:0G66UFZ!BM*:A8+6SH5^VQ:!AL<R:8J[/E6*N
MSY5BKL^58J[/E6*NSY5BKL^58J[/E6*NSY5BKL^5_X<7 O^1&@/_HB #_[(E
M _7 *P3FSS$&V-XX#\SE0R##XDDSMMY11JG86%><TEYED,YD<H;+:GQ\R'"$
M=,9WBF[$?H]HPX>48\*0EU_!FYE<P:::6\*SFUK#Q9I;OL^57+K2D5RZTI%<
MNM*17+K2D5RZTI%<NM*17+K2D5RZTI%<NM*1_XD6 O^6&0+_J!T"_K@A NS)
M(@+9W24$S.4W$<+J0R*WYT@SK.1/1*#@5E.4W5U@B-IC:W[6:G5UU'!];M)W
M@V?1?XABT(>+7M"1CEK0G)!8T*>15M"UDE72QY%6S=2.5LC6BU;(UHM6R-:+
M5LC6BU;(UHM6R-:+5LC6BU;(UHM6R-:+_XL5 O^=%P'_KQD!],$8 =W8$0#,
MY28%P>XW$[;O0B.K[4<RH>M,0);I54V+YUU8@N9E87GD;&ERY'1O;.-\=&?B
MA'ABXHU[7N*5?EO@GH!8WZ>"5=ZQ@U/>OH-2WM*#4=G<@E'9W()1V=R"4=G<
M@E'9W()1V=R"4=G<@E'9W()1V=R"_X\3 O^D$P'^N!( ULP+ ,SD$0' [R8'
MM?4X%:KT0"*?\T8PE?)+/(SQ5$:"\%U/>O!F5G3P;EQN[W9A:>]^9&7OAFAA
M[XYJ7NZ6;5OMGF]8ZZ5P5NNN<53JN')2ZL=S4>G5<U'IU7-1Z=5S4>G5<U'I
MU7-1Z=5S4>G5<U'IU7-1Z=5S_Y@0 ?^N#@#4P0D R<\) +[P$@*S^2<*J?LX
M%9[[/B&3^T0LB?I*-8'Z4SYY^EU%<OIF2FWZ;TYH^G929/I^56'ZAE=?^XY:
M7/J66UKYG5U7^*5>5?>L8%/WM6%2]L%A4/;*8E#VRF)0]LIB4/;*8E#VRF)0
M]LIB4/;*8E#VRF)0]LIB_Z,+ -:X!@#&Q < N]0) +#\% .F_RD+G/\U%9#_
M.QZ&_T(F??])+G7_431O_ULZ:?]E/F7_;D%B_W5$7_]\1ES_@TA:_XM)6/^3
M2U;_FTQ5_Z)-4_^I3E'_L4]0_[M03__#44__PU%/_\-13__#44__PU%/_\-1
M3__#44__PU%/_\-1VJ\" ,:\!0"YR04 K=L( */_%P2:_RL+CO\Q$H/_.!IY
M_T @</]')FG_3RMC_U@O7_]B,ES_:S1:_W(V6/]X.%;_?SE4_X8[4O^-/%'_
ME3U/_YP^3O^C/DW_JC]+_[- 2O^Y04K_N4%*_[E!2O^Y04K_N4%*_[E!2O^Y
M04K_N4%*_[E!R+4" +C!! "KT , G^L) 9;_&@6+_R8*?_\M#W7_-15L_ST:
M9?]$'E[_3")8_U0E5?]=)U+_92E0_VPJ3O]S*TW_>2Q,_W\M2O^%+DG_C"](
M_Y(P1_^9,$7_H#%$_ZDR0_^N,D/_KC)#_ZXR0_^N,D/_KC)#_ZXR0_^N,D/_
MKC)#_ZXRN+H" *K(  "=V0  DO\, HG_&@1]_R$(<O\H#&C_,!!@_S@46O]
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MI6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[.>C8#"GHN
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M!/^O+ ;WNC,)[,0[#^+.0AC3SD@LQL=20+G 6E&MNF%?H[1G;)FP;7>0JW2
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M4"7_B5TO_X5I.OV!=43Z?(!-]WB+5?1SE5SQ;YUB[VRE9^UIK6OK9K9OZ&/
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M ]31,@W'S$$?NL=,,:[!5$*CO%Q0F;=B7)"S:6:'L&]N@*UV=7FJ?7MSJ(2
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MN4Q*]\A-2?C@34CW\TU(]_1-2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-VJ,
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M(S7_N",U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2,U_[DCK;8  )_$  "2T@
MA.$  'W_#0%R_Q,":/\;!%__(P98_RL)4?\S"TS_.@U'_T$/0_]($4#_3A(]
M_U03._]:%#G_7Q0W_V45-?]K%C/_<A8Q_WH7+_^"%R[_BQ@L_Y,8*_^<&2K_
MIQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\  )+,  "$W   >/<
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M8?Y5_V(? _]C)03_;R0%_WDH!O^!, K_A3D/_XA"%O^)2Q[_B58H^H5B,_6
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M,=*:7D#(DV=-P(QO6+F'=V&S@G]HKGV';JEZCG.D=Y9XH'2?>YUSJ'Z:<;2
MF''"@99RV(&5=.5XDW3J<9)U[VN1=?)FD77R9I%U\F:1=?)FD77R9I%U\F:1
M=?)F_V8= O]Q&P/_@!L#_XPA _^6* 7_GB\(]J0W#>RH/Q7CJT@@V*92,,R>
M7$##EV5-NY%M5[.+=&&MAGQHIX*#;J)^BW2=>Y-XF7F<?)5WI7^2=K"!D'6^
M@HYVT8*.>.-ZC7CH<XQX[6R+>/%HBWCQ:(MX\6B+>/%HBWCQ:(MX\6B+>/%H
M_V<< O]S&@+_@AH"_X\@ _^9)@3^HBX&\Z@U"^FM/1/?KT8>TJE1+\>B6C^^
MFV-,M95J5ZZ/<F"GBWEHH8>!;IR#B'27@)!XDGV9?(Y\HH"+>JV"B'J[@X=Z
MS8.'?.)\AWSG=89\[&Z&?/!IAGSP:89\\&F&?/!IAGSP:89\\&F&?/!I_V<<
M O]U&0+_A1D"_Y(? O^<)0/[I2P%\*PT">:R.Q#;LT0=S:U/+L.F63ZYGV%+
ML)EH5JB4<%^ACW=GFXM^;I:(AG.0A8YXC(*6?(B H("$?ZN"@7^X@W]_RH2!
M@>%]@8'F=H& ZV^ @.]J@(#O:H" [VJ @.]J@(#O:H" [VJ @.]J_V@< O]X
M%P+_AQ@"_Y0= O^?(P/XJ2H$[+$Q!^*W.0W5MT(<R;!.+;ZJ5SVTHU]*JYYG
M5:.8;E^<E'5FEI!\;9"-@W.+BHMXAHB4?(&&GH!]A*B">X2UA'F$QX1ZAN!_
M>X7F=WN%ZW![A.YK>X3N:WN$[FM[A.YK>X3N:WN$[FM[A.YK_VD; O]Z%@+_
MBA<"_Y<< O^C(0+TK2<#Z+4N!=Z]-0K0ND ;Q+1,++JN5CNOJ%Y)IJ)E5)Z=
M;%V7F7-FD)5Y;(J2@7*%D(EW?XV2?'N+FW]WBJ:"=(FS@W**Q(-TC.!_=(OE
M>'6)ZG%VB.UL=HCM;':([6QVB.UL=HCM;':([6QVB.UL_VL: O]]% +_C18!
M_YH: ?^F'@'PL2,"Y+LI ]G", G+O3\9P+A**K6R5#JJK%Q'H:=C4IFC:ER1
MGW%DBIMW:X28?W%^EH9V>9./>W22F7YPD*2!;9"Q@FN0P8)MDMU_;I'E>&^/
MZG%PCNUL<([M;'".[6QPCNUL<([M;'".[6QPCNUL_VX8 O^ $@'_D!4!_YX7
M ?NK&@'LMQX!X,,A =+&+0C&P3T8NKQ)**^W4CBELEI%G*UA49.I:%J+I6]B
MA*)U:7Z??&]XG81T<YN->6Z9EGQJF*)_9Y>N@&68OX%EF=A_:)CE>&F6ZG%J
ME.UL:I3M;&J4[6QJE.UL:I3M;&J4[6QJE.UL_W$6 O^#$0'_E!,!_Z(4 /6P
M% #FOA0 V<P5 ,S**P? QCL6M<%')JJ\43:?N%A#EK-@3HVP9EB%K&U@?JIS
M9W>G>FQRI8)R;*.+=FBBE'EDH:!\8*"M?5^AO7Y>HM1]8:'F=F*=ZW!CF^YL
M8YON;&.;[FQCF^YL8YON;&.;[FQCF^YL_W03 ?^'$ '_F!  _J<0 .>W#0#6
MQ0L T- 1 ,7/* 6YRSD4KL=%(Z/#3S.9OU= C[M>2X:X9%1^M6M<=[)Q8W&P
M>&EKKH!M9JV)<F&KDW5=JYYX6ZJL>5FKO'E8K-)Y6JOH<URG[&Y=I.]J7:3O
M:EVD[VI=I.]J7:3O:EVD[VI=I.]J_WD1 ?^,#@#_G@T W*X( -*["0#,R D
MQ]8. +W5)02RTC81I\Y"()S*3"^2QU0\B,-<1W_!8E!WOFE7<+QP7FJ[=V-E
MN7]H8+B(;%RWDF]8MIYQ5;:K<U.WNW-2M])S5+?K;U:R[VI7K_%G5Z_Q9U>O
M\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@ O-T.
M +3=(P.JVC,-G]9 ')332BJ*T%(W@,U:07C+84IPR6A1:LAO5V3&=EQ?Q7]@
M6L6(9%;$DF=3Q)YI4,2L:D_$O&M.Q=-J3\7M:%# \V11O?5A4;WU85&]]6%1
MO?5A4;WU85&]]6%1O?5A_X8* /":! #4J@0 R+8& +[!!0"WSPD L.,1 *CC
M)02?XC4-E> ^&8O>2"6!W% P>-I8.G#87T)IUF=)8]5N3U[4=E-9TW]75=.)
M6E+3DUU/TZ!?3=.M8$O4OF!*U=A@2]3M7DS1]UQ,S/E:3,SY6DS,^5I,S/E:
M3,SY6DS,^5I,S/E:_X\# -JB  #*KP, O;D$ +3&!0"KU D I.H4 9SI* :3
MZ30.B>@]&'_G1")WYDXJ;^97,FGE7SACY6<]7^1O0EKD=T56Y(!)4^2*2U#D
ME$Y-Y)]02^6L44GENU)(YL]22.;H4DCD^%%(X?Q/2.'\3TCA_$](X?Q/2.'\
M3TCA_$](X?Q/X9D  ,VI  "^LP( L[X# *C+!0"?V@D F/(8 I#R*@>&\C,.
M?/$[%G3Q0QUL\4LC9O%4*6'Q72U=\68Q6?%N-5;Q=C=3\7\Z4/*(/$WRDCY+
M\IU 2?.I04?SMD)&],=#1?3?0T3T\$-$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R
M^D)$\OI"T:(  ,"N  "RN $ I\0" )S2! "2[0P C/L< X+[* =Y^S$,</PY
M$FG\01=B_$D<7/Q0(%?\62-4_6(F4?UJ*$_]<RI,_GLL2OZ#+DC^C2]&_Y@Q
M1/^B,D/_KC-!_[LT0/_+-#__XS0__^\U/__O-3__[S4__^\U/__O-3__[S4_
M_^\UQ*H  +.S  "GOP  FLL  (_: @"&_P\!?O\< W7_)09L_RT*9/\V#EW_
M/A)8_T454O]-&$__51I,_UP<2?]D'D?_:Q]$_W,@0O]\(D'_A2,__X\D/?^:
M)3O_I"8Z_Z\F.?^Z)SC_RB<X_]PH./_<*#C_W"@X_]PH./_<*#C_W"@X_]PH
MM:\  *>Z  ":Q@  C=0  ('F 0!Z_Q !</\8 F?_(05?_RD'6/\Q"E+_.0U-
M_T$/2?]($47_3Q-"_U440/]<%3W_8A8[_VD7.?]P&#?_>1DU_X(9,_^,&C+_
MEQLP_Z$;+_^J'"__M1PN_[\<+O^_'"[_OQPN_[\<+O^_'"[_OQPN_[\<J;4
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M7VZ,]U]NC/=?;HSW7VZ,]U]NC/=?_VP3 ?]]#P'_C1  _YL0 /2H#P#EM0T
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MLSA"\,0X0?#?.4'O[SA [?TX0.S_.$#L_SA [/\X0.S_.$#L_SA [/\XRZ
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M%BC_LQ8G_\(6)__'%B?_QQ8G_\<6)__'%B?_QQ8G_\<6I+0  );   "'S
M>MH  &WK  !D_P4 7/\. 53_% %-_QP"2/\D!$+_+ 4^_S,&.O\Y!S;_0 @S
M_T4(,/]+"2[_40HK_U<**?]="R?_9 LD_VP,(O]V#2#_@ T>_XP.'?^7#AS_
MH0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@  :^,
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M5L57[%7#6_E/PE[_2L!?_T:]8/]"NF#_0+I@_T"Z8/] NF#_0+I@_T"Z8/]
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M47Y]_U%^??]1?GW_47Y]_U%^??]1_V,4 ?]R#P'_@1  _XT1 /R8$@#LH1,
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MH?]0_W<' /")  #6F   RZ0# ,&M! "YM@, LL $ *O%% "CQ2@$F\(W#I'
M0QF)O4PD@+I5+GFX7#9RMF,];;1J0V>S<4ABL7E,7K"!4%JOBU16KY=64ZZC
M6%"NLEE/KL993Z[D6%&N]E13KO]05*S_352L_TU4K/]-5*S_352L_TU4K/]-
M_WT  -^/  #.G0  PZ@" +FP @"PN@( J,0% *',#P";S","DLHS"HG(/Q6!
MQDD?><12*'+"6C!KP6$W9K]H/&&^<$%<O7A%6+R!252\BTQ1NY9/3KNC44R[
MLU)*N\922KOD44R[]DY-NO]+3KG_24ZY_TE.N?])3KG_24ZY_TE.N?])[X4
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M+CWJ[RX]Z/PN/>?_+3WG_RT]Y_\M/>?_+3WG_RT]Y_\MQ9\  +6I  "HL0
MG+P  )#'  "$T@$ >M\& '3T$P!M]" "9O0J!%_T- A:]3T+5/5%#T_U3!),
M]5442?9=%T;V91A$]FX:0?9W'#_W@1T]]XT?._>9(#GXIB$X^+4B-_G((C;Y
MXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0  D,0
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M"A3_LPH4_[,*%/^S"A3_LPH4_[,*D[L  (3'  !UTP  9^$  %CH  !.^P
M2/\  $'_"@ [_Q !-O\5 3'_' $M_R("*?\H B7_+0(B_S(#'_\X QS_/0,:
M_T(#%_](!!7_3@03_U4$$?]=!0__9P4-_W(%#/]]!0K_B08*_Y,&"?^<!@G_
MG 8)_YP&"?^<!@G_G 8)_YP&_S\J O\_, /_1# #_T@S!/]).0;_2$((_T9-
M"_]%6P[_0VD1_T%W$_] A17_/Y$6_SZ;&/\^I!C_/:L9_SVS&O\]NAK_/<,:
M_SS,&_\\VQO_/.<;_SSP&_\\^!O_/?\;_SW_&_\]_QO_/?\:_SW_&?\]_QG_
M/?\9_SW_&?\]_QG_/?\9_T J O]!+@/_1RX#_THQ!/],-P;_2T (_TI+"_](
M60__1F<1_T1U%/]#@A;_0H\8_T&9&?]!HAK_0*D;_T"Q&_\_N!S_/\ <_S_)
M'?\_UAW_/^4=_S_O'?\_]Q[_/_X=_S__'?\__QW_0/\<_D#_&_Y _QO^0/\;
M_D#_&_Y _QO^0/\;_T J O]#+ /_22P#_TTO!/]/-0;_4#X(_TY)#/],5@__
M2F02_TAR%?]'?QC_1HL9_T66&_]$GQS_1*<=_T.N'O]#M1__0KT?_T+&(/]"
MT2#_0N(A_T+M(?]"]2'_0OTA_4+_(?M#_R#Z0_\?^4/_'OE#_Q[Y0_\>^4/_
M'OE#_Q[Y0_\>_T$I O]&*@/_3"D#_U$L!/]3,@;_5#P(_U1'#/]14@__3V 3
M_TUO%_],?!G_2H@<_TF2'O](FQ__1Z,A_T>K(O]&LB/_1KHC_T;#)/]%S27_
M1=XE_T7J)OQ%]";Y1?PF]D7_)O5&_R3T1O\C\T?_(?-'_R'S1_\A\T?_(?-'
M_R'S1_\A_T(H O]))P+_4"8#_U4H!/]8+P7_6CD(_UI$#/]73Q#_55P4_U-J
M&/]1=QO_3X,?_TZ.(?]-ER/_3)\E_TNG)O]*KB?_2K8I_DF^*OU)R2KZ2-DK
M]TCG+/1(\BSQ2/LL[TG_*NU*_RCL2O\GZTO_)>M,_R7K3/\EZTS_)>M,_R7K
M3/\E_T,H O]-) +_5",#_UHE _]>+ 7_8#8'_V!!"_]>3!#_6U<5_UEF&?]7
M<A[_57XB_E.))?Q1DRCZ4)LJ^4^C+/=.JB[V3;(O]$RZ,/-,Q#+R2]$S[DOD
M-.I*\#3G2_HSY4W_,.1._RWB3_\KX5#_*>%0_RGA4/\IX5#_*>%0_RGA4/\I
M_T8E O]0(0+_6" "_U\A _]D*@3_9C,'_V8]"_]E2!#_8E,5_V!A&_Q=;2#X
M6GDE]5B$*?-6C2WP5)8P[E*>,^U1I37K4*TWZ4ZU.>=.OSOF3<P\XTS@/=]-
M[CS<3_DYV5'_-=92_S+44_\PTU3_+=-5_RW35?\MTU7_+=-5_RW35?\M_THC
M O]4'@+_7!P"_V0? O]I)P3_;# &_VTZ"O]L1 _]:D\5^&=<'/-C:"+O8'0H
MZUU^+NA:B#/E5Y$WXU69.N!3H#[>4JA W%&Q0=E0NT+64,A#TU#<1,]0[$/,
M4O@_RU7_.\E7_S?(6/\TQUG_,L99_S'&6?\QQEG_,<99_S'&6?\Q_TT@ O]7
M&P+_8!D"_VD= O]O)0/_<BT%_W0W"/US00[V<4L4\&Y8'.IJ9"3E96XKX&%Y
M,]Q>@CC87(L\TUJ4/]!8G$+.5Z-$RU6L1LE5M4?'5,!)Q5302<)3YDG 5O5%
MOEG_0+U;_SR\7/\YNUW_-;I=_S6Z7?\UNEW_-;I=_S6Z7?\U_U > O];&0'_
M9!8!_VT; O]T(@+_>"H$_WHS!_9Z/0SO>$<3YW54&^%P7R7::VHMTV=T-,YD
M?3K*888_QU^.0L1=ED7!6YY(OUJF2KQ9KTRZ6+I-N%C(3K98WTZT6?!+LUS]
M1;)?_T"R8/\\L&'_.;!A_SBP8?\XL&'_.+!A_SBP8?\X_U(; ?]>%@'_:!0!
M_W(9 ?]Y'P+_?B<#^8 P!?"!.0KG@$,1X'Q0&M9W6R3/<F8NR6UO-<1J>#O
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M&0'[AR ![XPG N2., 7:C3T,SX=*&,>"52._?5\MN7AH-;-T<#RO<7A"JVZ
M1J=LB$JD:9!.H&B849UFH5.;9:M5F&2X5Y9DR%B49.%8E6CT4)9K_TJ7;/]%
MEFW_099M_T"6;?] EFW_0)9M_T"6;?] _UD5 ?]F$ '_<A  _WT2 /^%%@#V
MC!L!ZI$B =^4*P/3D3H+R8Q'%\"'4R*Y@EPLLGUE-:UY;3RH=75"HW-]1Z!P
MA$N<;HQ.F6R54I5KGE22::A7D&FT68YHPUF,:-Q:C6SR4X]N_TR0</]'CW'_
M0X]Q_T&/<?]!CW'_08]Q_T&/<?]!_UL4 ?]H#P#_=0\ _X 1 /^)$P#RD!<
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M14FV\D-*M?]!2[7_/DNT_SU+M/\]2[3_/4NT_SU+M/\]XH,  ,V2  #!GP
MM*<  *JO  "@N   EL # (S*!P"&S10 @<TF GK,-0ASRT$/;,I*%V;)4QUA
MR%LC7,=B*%C&:BQ4QG(P4,5\,TW%AC9*Q)(Y1\2?.T7$KCQ$Q<$\0\7?/$3$
M\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI   JZP
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M&3'Q_QDQ\?\9,?'_&3'Q_QDQ\?\9LJ0  *6K  "8M@  B\   '[*  !QU0
M9=X  %[U"@!9_!, 4_P> 4[\)P)*_3 #1?TY!4']0 8^_D@'._Y/"3C_5PHV
M_UX+,_]G##'_< TN_WP.+/^)#RO_EA I_Z00*/^T$2?_QQ$G_^$1)O_R$2;_
M]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@  6.<
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M2U>2[T=:DOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP
MQ)4  +J=  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-R
MI%TJ;:)D+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;
M[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH
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M+D&\_RU!O/\M0;S_+4&\_RU!O/\MSHH  +^8  "QH   IJ@  )NP  "0N
MA;\  'K'! !OSPD :]$5 &?1)@%CT30$7M! "%G02@Q5SU,04<];%$[/8QA+
MSFL;2,YU'D7.?R!"SHPB0,Z9)#[.J"8\SKHF/,_4)CS-[R4[S/LE.\O_)3O*
M_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP  ><<
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M"B#\_ H@_/P*HJ<  )6Q  "'NP  ><8  &S/  !?V0  4M\  $CH  !#_P@
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M169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9>@
MS(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+62%_
MB6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/1&!_
M[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@  QX<
M +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]ZCUXE
M=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%ZC]<
MAOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3
M  "PF0  J)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,%WF85!UTEUPB<)5C
M)VN3:BQGDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9 4XW+0%2-Z3U6C?HY
M5XW_-5F._S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "J
MG0  H:$  )>F! "1IQ4 C*<G H6F-09_I$ ->:)*%'.@4AINGUD?:9U@)&6<
M9RAAFV\L7IIW,%J8@#-6EXLV4Y>7.5&6I3M/EK0\3I;)/$Z6Z#I/EODV49;_
M,U*6_S!2EO\P4I;_,%*6_S!2EO\PYG(  -"   #"C   N)8  *V<  "CH0
MF:8  (ZM  "(KA$ @ZXB 7VM,01WK#T*<JI'$&RI3Q9GJ%<;8Z=>'U^F921;
MI&TG6*1U*U2C?RY1HHDQ3J&6-$NAI#9)H;0V2*'(-TB@YS5)H/DR2I__,$N?
M_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@  D:P
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M'#;$_QPVQ/\<OI$  +";  "DHP  F*H  (RR  " N0  =,   &C'  !=S04
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M> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #DZX
M (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C_Q$
M(/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_90$%
M_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!
M  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP %/\0
M !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@  _UX
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M.G-G[39T:?TP=6K_+'9K_REW:_\G=VO_)W=K_R=W:_\G_U<  /9C  #?;0
MT74  ,A[  #!?P( NX # +2!$ "L@B,!I8$R!)Y^/PF8>TH0DGE3%HUV6QN)
M=&(@A7)I)(%Q<"=^;W<K>VY_+GAMB#%U;)(T<VN>-W!JJCEN:KDZ;6K..FUK
MZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<   S7@
M ,1^  "\@@$ MH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$>6 ?
M@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=PZ3=I
M<?HR:W+_+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L  ,""
M  "XA@  L8@  *F)#0"BBAT G(DN I6'.P>/A44.B8)/%(2 5QE_?EX>>WQE
M(GA[;"9T>7,J<7A[+6YWA#!K=HXS:'6:-F5TICAC=+4Y873).F%TYSAC=ODR
M97;_+F9W_RMG=_\I9W?_*6=W_REG=_\I_U\  .-L  #0=@  Q7\  +R%  "T
MB@  K(P  *.."@"=CAH EXXK I",. :*BD,,A(=,$G^%51AZA%P==H)C(7.
M:B5O?W$I;'YY+&A]@B]E?(PR8GN8-5]ZI#==>K,X7'K'.5QZY3=>>_@R7WO_
M+F!\_RMA?/\I87S_*6%\_REA?/\I]6(  -YO  #,>@  P(,  +>)  "OC@
MII$  )V2!@"7DQ< D9,H 8N2-@6%D$$+?XY*$7J,4A9UBEH;<8AA'VV':"-J
MAF\G9H1W*V.#@"Y@@HHQ78&6-%J!HS98@+(W5H#%-U: XS98@?<Q68'_+5N"
M_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@  H)4
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M)$>:_R1'FO\DU'<  ,*$  "VCP  JY8  *&<  "6H   BZ4  '^J  !TK@4
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MF DMTZD)+-.^"BS3WPDKT?,**L_^"RG._PPIS?\-*<W_#2G-_PTIS?\-KI@
M **?  "6I@  B:X  'RV  !OO0  8\,  %?(  !,S0  0M(# #G9"0 UWQ
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M 0G_I@$(_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP
M8\D  %;1  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1
M_QD #_\>  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_
MD   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0  5M,
M $?;   ZX   +N4  "/I   :[0  %?T  !+_   0_P( #O\)  O_#0 (_Q
M!/\3  '_&   _QX  /\D  #_*P  _S,  /\]  #_20  _U8  /]F  #_>
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M+(-7[RF#6/XD@UG_((1:_QZ$6O\<A%K_'(1:_QR$6O\<_TX! /]7  #E7P
MV&8  ,YJ  #'; , PVL% +QL$@"T;24 K6PU Z=J0@>A9TT,G&56$9AC7A64
M8F48D6!L&XY?=!Z,7GLAB5V#)(9<C":$6Y4H@5J@*G]:K"Q]6KLM?%K/+GM;
M["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P  TFH
M ,EN  #"< $ O7 # +9P$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.9F(8
MBV5I&XAC<!Z%8G@A@F& )(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>Z2UU
M8/HG=F'_(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT  ,1R
M  "]=   MW0! +!T#@"I=1\ HG0O IQR/067<$<*D6Y1#XUL612):F 7A6EG
M&X)H;AY_9G4A?65])'IDAB=W8Y I=6.;+')BIRYP8K8O;V+)+VYBYBYO9/DH
M<&7_)'%F_R%Q9O\?<6;_'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U  "Y
M>   LG@  *MX#0"D>1T GG@M 9=W.@62=44*C').#HAP5A.$;UX7@&UD&GUL
M:QUZ:W,@=VI[(W1I@R9R:(TI;V>9+&QFI2YJ9K,O:6;&,&AFY"]J:/<I:VG_
M)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U>P
MK7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP:1UU
M;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_)F9M
M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P  J8
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M(%=\_R!7?/\@Y60  ,]P  #!>@  MH,  *V)  "CC   F8X  (V/  "&D X
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M(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X  ,-[  "WA0  K(T  **2  "7E@
MC)D  '^<  !UG@4 <)\3 &V?(P!IGS !99X[!&&>10==G4T*6IQ4#5>;7!%4
MFF,449IK%TZ9=!E+F'\<2)B+'D67F2!#EZ@A0I>Z(D&7TR)!EN\@0I7^'D*5
M_QU#E/\<0Y3_'$.4_QQ#E/\<S'4  +R!  "QC   II(  )N7  "1FP  A9\
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M#BRX_PXLN/\.LX\  *:7  ";G0  CZ,  (.J  !VL   :K4  %ZZ  !2O@
M1\(! #W'!@ XR1  -\D; #;*)P URC, -,L] #/+1P QRU$!,,M; 2[,90(L
MS'$"*LQ_ RG,D 0GS*$$)LVT!"7-S@0ER^X$),G\!B/(_P<CQ_\'(\?_!R/'
M_P<CQ_\'J98  )Z=  "2HP  A:L  'BR  !KN   7[X  %+"  !'Q@  /<H
M #3/!  KU D )MD/ "79&0 EVB4 )-HP "/;.P CVT4 (MQ0 "'=6P @W6@
M'MYV !W>AP$<WYD!&M^L 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7
MVO\"H)P  )2C  "'JP  >;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9
M   AW@4 'N@. !WH%0 ;Z1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG
M !#N=P 0[HH #N^>  [PLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\
MEZ,  (FK  ![M   ;;P  %_$  !2R@  1<X  #G3   OV   )=T  !WA   8
M[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]
M9@ "_G<  /V+  #]GP  _+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL
M 'VT  !NO0  8,8  %+-  !$T@  -]@  "S=   BX0  &>4  !/J   0^@
M#O\&  W_#  *_Q  !_\4  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P
M_V(  /]U  #_B@  _Y\  /^S  #_QP  _^4  /_E  #_Y0  _^4 ?[0  '"]
M  !AQP  4]   $/6   VW0  *N(  !_F   6Z@  $.T   SZ   )_P  !O\
M  +_!   _PD  /\-  #_$   _Q0  /\:  #_(0  _RD  /\T  #_0   _TX
M /]>  #_<@  _X<  /^:  #_J@  _[D  /^Y  #_N0  _[D _R I ?\B)P'_
M(B<!_Q\J ?\9, '_$CD!_Q!% ?\-4P'_#& !_PIM O\)>0+_"80"_PF. ?\)
ME@'_"9T!_PFC ?\)J0'_"; !_PBW ?\(O@'_",@!_PC6 ?\(Y@'_"/$!_PC[
M /\(_P#_"/\ _PG_ ?\)_P'_"?\!_PG_ ?\)_P'_"?\!_R,F ?\E) #_)20
M_R,G ?\=+ '_&#4!_Q5" ?\24 '_$%T"_PYJ O\.=@+_#H "_PZ* O\.D@+_
M#IH"_PZ@ O\.I@'_#:T!_PVS ?\-NP'_#<4!_PW1 ?\-XP'_#>\!_@WZ ?H-
M_P'Y#O\!^0[_ ?D._P'X#O\!^ [_ ?@._P'X#O\!_R8C /\H( #_*"  _R8B
M /\B* '_(#(!_QP_ ?\93 '_%UD"_Q5E O\3<0+_$WP"_Q.& O\3C@+_$I8"
M_Q*= O\2HP+_$JD"_Q*P O\2MP+_$L$"_Q+, ?T2WP'Y$^T!]1/X ?,3_P'R
M$_\!\1/_ O 4_P+P%/\"\!3_ O 4_P+P%/\"_RH? /\L' #_+!L _RL= /\I
M) #_*"\!_R4[ ?\B2 '_'U0"_QUA O\;;0+_&G<"_QJ! O\:B@+_&I("_QJ9
M OT:GP+\&J8"^QJL OD:M +X&KT"]AK( O,:VP+O&NH"[!OW ND;_P+H&_\#
MYQS_ ^8<_P/E'/\#Y1O_ ^4;_P/E&_\#_RT; /\P%P#_,14 _S 6 /\Q( #_
M,"H _RXV ?\K0P'_*$\"_R9< O\D9P+\(W(#^2-\ _<BA0/U(HT#\R*5 _(B
MFP/P(J(#[R*I ^TBL0/L(KD#ZB+% ^@BU0/D(^D#X"/V!-XC_P3;)/\$V23_
M!-@D_P37)/\$UB3_!-8D_P36)/\$_S$6 /\T$@#_-A$ _S<3 /\Y&P#_."4
M_S8Q ?\S/0'],4H!^"Y6 O0M8@/P+&T#[2MW ^HK@ 3H*H@$YBJ0!.4JEP3C
M*IX%X2JE!> JK07>*K8%W"K"!=HJT@;5*^<&T"OU!\TL_P?++/\'R2S_!\@L
M_P?'+/\&QRS_!L<L_P;'+/\&_S42 /\Y#@#_.@T _SX0 /] %@#_/R  _STJ
M /D[-P'R.$0![#91 N<U7 /C-&<#X#-R!-TS>P7:,H,&UC*+!M0RDP?2,9H(
MT#&A",XQJ0G,,;()RS&\"LDQR@K&,N$+PC+Q"[\S_@N],_\*NS/_"KHS_PFZ
M,_\)NC/_";HS_PFZ,_\)_SD0 /\]"P#_0 D _T0- /]&$0#_11D ]T0C .Y!
M+P#F/SP!X#Y* =H]5P+3/&($SSML!LPZ=0?).GT)QSF%"L4YC O#.)0,P3B;
M#< XHPV^.*P.O#BV#[HXPP^Y.-<0M3CL$+(Y^P^P.O\.KSK_#:XZ_PRM.O\+
MK3K_"ZTZ_PNM.O\+_SP- /] !@#_100 _TD) /]+#0#Y2A$ [4D: .-&)@#:
M1C8 T49% <M%40/&1%P%PD)F"+]";PJ\07<+ND!_#;@_A@ZV/XX0M#Z5$;(^
MG1*P/J83KSZP%*T^O12K/LT5J3[F%:8_]Q.D0/\2HT#_$*) _P^B0/\.HD'_
M#J)!_PZB0?\._S\) /]$  #_2@  ]TX" .Q0!@#J3PL XTP0 -9,'@#-33
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MJB&!4;@B?U'+(GY2YR%^4_D=?E3_&GY5_Q=^5?\6?E7_%7Y5_Q5^5?\5_TH
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M)FE>WB9J7_0A:V#_'6MA_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90
MPVL  +EO  "Q<0  JG$  *)O" ";;Q< EG G )!O-0*+;D %AFQ)"()J4@Q^
M:5D/>VA@$G=F9A1U9FX7<F5V&G!D?AUM8X@?:V.3(FEBH"1F8JXE96*_)F1B
MVB9D8_(B963_'F9D_QMG9/\99V7_&&=E_QAG9?\8\%,  -U?  #+:   OV\
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M'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX  ,UI  "_<P  M'H  *M_  "B@@
MF(,  (N!  "$@0T ?X(: 'N"*0%V@38"<H% !6Y_20AJ?E +9WU7#F1\7A%A
M>V847GIM%UMZ=AE9>8 <5GB+'U-XF"%1=Z8B4'>W(T]WSB-/=^PA4'?]'E%W
M_QM2=_\94G?_&5)W_QE2=_\9WF(  ,AN  "[=P  L'\  *>$  "=AP  DH<
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M%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\  ):3  "+E@  ?YD  '.<  !DGP
M7* ) %F@% !7H2( 5:$O %*A.0%0H4,"3:!+!$J@4P5(H%H'19]C"4.?; M
MGG8./IZ#$#N>D1$YG: 2.)VR$S>>R!,WG>@2-IOZ$C::_Q(VF?\1-YG_$3>9
M_Q$WF?\1OGL  +&'  "ECP  FY0  )"8  "$G   =Z   &ND  !?IP  4JH
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MA@$@QI@!'\:K 1['P0$>QN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90
M )J:  ".H0  @:<  '.N  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0
M'M * !O1$0 :TAH &=(E !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2
MUX\ $=BD !#9NP 0V=X $-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A
M  "#J   =;   &BW  !;O0  3L$  $+%   WR   +<P  "30   <U0  %=H%
M !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH
M!>:5  3FJP "YL0  >;F  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !W
ML0  :;D  %O   !.Q@  0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ
M"  )\PX !_,3  3R&@ "\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"
M  #RF   \ZT  //&  #TY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@
M7,(  $[)  ! S@  ,],  "C8   >W0  %>$   _D   *Z   !?,   /] 0
M_ @  /L-  #[$0  ^Q8  /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_
M@@  _Y@  /^L  #_P   _]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T
M $#2   RV0  )MX  !OB   2Y@  #.H   7M    ]    /\   #_    _P
M /\$  #_"0  _PX  /\2  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P
M_X   /^5  #_I@  _[,  /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0
M+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@
M /\ I@#_ *P _P"R /\ N0#_ ,( _P#- /\ WP#_ .P _P#X /\ _P#] /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _Q\C /\?(0#_'B$ _QDC /\3*0#_
M#C( _PQ  /\)30'_!UH!_P1G ?\#<P'_ WT!_P.' ?\#CP#_ I8 _P*< /\"
MH@#_ J@ _P*O /\!M@#_ ;X _P') /\!VP#_ .H _ #V /@ _P#W O\ ]P/_
M /8$_P#V!/\ ]@7_ /8%_P#V!?\ _R(? /\B' #_(1P _QX? /\8) #_%2\
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M \$D_P/!)/\#_S / /\R"P#_,P@ _S8- /\V$@#_-1H _3(E /0P,@#M+3\
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ML1&:/K\1F#[4$I8_[1&4/_P/DT#_#I) _PR20?\+DD'_"Y)!_PN20?\+_ST
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M&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P
MR%P  +]?  "W7P  L5P  *I9# "D6AH GELJ )E;. &46D,#D%E,!8Q850B)
M5UP*AE9C#(-5:@Z!5'$0?U-Y$GU3@11Z4HL6>%*5&'91H1ET4:\;<U' &W%1
MVQQQ4O(9<5/_%7%4_Q-R5/\1<E3_$')4_Q!R5/\0\T@  .-3  #06P  Q&
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M&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$  -1<  #$9   N6H  +!N  "G<
MGFX  )1K  "-:A  AVL> (-K+ !^:S@">FI" W9I2@9S:%((<&=9"FUF8 UK
M96</:&1N$69D=Q1D8X$686.,&%]BF!I=8J8<6V*V'5IBS!U:8NH<6V/\&%QC
M_Q9<8_\476/_$UUC_Q-=8_\3YE4  ,]?  #!:   MFX  *QR  "D=   FG,
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M$DUR_Q)-<O\2U&   ,)K  "U=   JWL  *)_  "7@0  C($  'I^  !S?P(
M;G\1 &N '@!H@"P 98 W 6* 0 -??T@$7'Y0!EE^5PA7?5X+5'QF#5%\;@]/
M>W@13'N#%$IZD19(>I\71GJO&$5ZQ!A$>N0817GX%D9Y_Q1&>/\21WC_$4=X
M_Q%'>/\1S64  +UP  "Q>0  IX   )R$  "2A@  AH8  '>&  !KA@  9H<-
M &.'&0!@B"< 7H@S 5N(/ )8AT4#5H=-!%.&5 90AEL(3H5C"DN$; Q)A'8/
M1H.!$42#CQ-"@YT40(*N%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q!
M@/\0QFL  +=V  "L?P  HH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0
M% !8D"$ 5I$M %.0. %1D$$"3I!) TR04 1*CU@%1X]@!T6.:0E"CG,+0(U_
M#3Z-C0\\C9P0.HVL$3F-P1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.
MOW(  +)]  "GA@  G(H  )&.  "&D0  >I,  &V5  !?EP  5)D! $^9#P!.
MFAH 3)HG $J:,@!(FCP!1II$ 42:3 )"FE0#0)E<!#Z99@4[F7 '.9A\"#>8
MB@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5_PLQE/\+,9/_"S&3_PLQD_\+N'H
M *R%  "ABP  EI   (N4  !_EP  <IL  &:=  !:H   3J(  $6D"0!"I!,
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M !; M@ 4P-, %;[Q !6\_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@
M?:0  &^J  !BKP  5K0  $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1
MS!( $<P; !#,)0 /S2\ #LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.
MK  (SL8 ",[H  C-^P )R_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P
M &2S  !7N0  2KT  #[    RPP  *,8  !_*   7S0  $=$   S6!0 (V0P
M!MD2  7:&P $VB0  ]LN  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0
MW[,  -_.  #@[@  W_H  -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]
M  !*P@  /<4  #')   FS   '=   !34   .V0  "=T   /A    XP<  .,-
M  #D$@  Y1D  .8B  #G*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$
M .^W  #OT0  [^L  /#V  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \
MR@  +\X  "32   :V   $MP   S@   %XP   .<   #K    ZP   .T%  #N
M"P  \!   /$5  #S'@  ]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC
M  #^M@  _LD  /_?  #_WP  _]\ =[   &BY  !:P0  3,H  #S/   NU
M(MH  !?>   0X@  ">8   #I    [    /    #V    ]@   /<   #X
M^@<  /L-  #]$0  _QD  /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_
MGP  _ZX  /^Z  #_N@  _[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!!
M /\ 3@#_ %P _P!H /\ = #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@
M_P"N /\ M0#_ +T _P#' /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[
M /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\
M2P#_ %@ _P!D /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J
M /\ L0#] +D ^P## /H T #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\
M\P#_ /, _P#S /\ _QT< /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_
M E, _P!? /\ :P#_ '4 _P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@
MK@#U +4 \P"_ /$ RP#P -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_
M .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X
M_PE: /\(9@#_"'  _@=Y /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M
M!K( Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,
M_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5
M /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\
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M /\O  #_,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED
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M"Y$YY0N/.O<*C3K_"8P[_PB,._\'C#O_!XP[_P>,._\'_S@  /$^  #C10
MU$D  ,M*  #%1P  P4$$ +H_$0"S02$ K4(Q *A#/@"D0TD!H$)3 IU!6P.;
M06($F$!J!99 <0:4/W@'DC]_") _B J//I$+C3Z;#(L^I@V)/K,-B#[$#H8_
MX Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@  S$\
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M$&Q/_PYL3_\,;$__"VQ/_PML3_\+[D4  -Q0  #)5P  O5P  +1>  "L7@
MI%L  )Q6! "55A( D%<A (M8+P"'5SL!@U9$ G]630-\550%>E1;!G=48@AU
M4V@)<U-P"W%2> UO4H(/;5&-$6M1F1)I4:849U&V%691RQ5E4ND495+[$693
M_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@  GU\
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M#5=>_PU77O\-WE,  ,A=  "[9   L&H  *9M  "=;@  DVT  (5G  !^9PD
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M' !F<B@ 8W(T &!R/0%><D4"6W%- UEQ5 57<%L&5'!C"%)O:PI0;W0,36Z
M#DMNC1!);IL11VVK$D9NOA-%;MP21FWT$49M_P]';?\.1VS_#4=L_PU';/\-
MS%\  +QI  "P<0  I7<  )Q[  "1?   AGL  '5X  !K=P  97<, &%X%P!?
M>"0 77DP %IY.@%8>4("5GA* E-X4011=U@%3W=@!TQV: A*=G(*2'5]#$5U
MB@Y#=9D/0G6I$$!UO!! ==D00'3S#T!T_PY!<_\-07/_#$%S_PQ!<_\,QF0
M +=N  "K=@  HGP  )=_  ",@0  @8$  '*   !E?P  77\( %E_$P!7@"
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M!BV2MP8LDM$&+)'O!BN/_P8KCO\&*XW_!RN-_P<KC?\'LW@  *>"  "<B
MD8P  (>0  !ZDP  ;94  &&7  !5F0  29L  #^< 0 YG0X -YT7 #:>(@ T
MGBP ,YXU #*>/@ QGD< ,)]0 "Z?6@ MGV0!*Y]Q 2F>?P(GGI ")IZA B2>
MM0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@  BY(
M '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  GJB(
M)JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JKL0 9
MJ\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>
M  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A
M !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0
M#;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>
MJP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%
M'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2
M  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M
M1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@
MT1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6
MX   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$
M "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0
M .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0
MZ>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.
M   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1
M  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(
M /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -
MWP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z
M#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y
M  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D
M_P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_
M +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H
M_P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A
M /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0
M^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P
M /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\
M9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X
M .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\
M_QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z
M &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .(
MOP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0
M /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8
MZ@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0
M!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@
M!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI
M -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@
MPA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_
M(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6
M:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6
M + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@
M[RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W
M(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,D
MZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0
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M!WP[_P9\._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20
MKT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%
M/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1
M_P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH
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M"&!._PA@3O\(XT<  ,U0  "^5P  LUL  *I=  "A70  F%H  (U3  "&4@P
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M'P!N7"L :UPV &A;/P%E6T<!8UM. F%:50-?6EP$75IC!5M::P99674(5UF
M"E59C M469H-4EFJ#E%9O Y06=@.4%GR#5%9_PM16?\*45G_"5%9_PA16?\(
MU%$  ,):  "T80  JF8  *!H  "7:0  C&<  'U@  !U7P, ;U\0 &M?' !H
M8"@ 9F S &-@/ %A8$0!7U], EQ?4P-;7UH$65]A!5=>:0957G,(4UY^"5%=
MB@M/79D,35VH#4Q>N@Y+7M0.2U[Q#$Q>_PM,7?\*3%W_"4Q=_PA,7?\(SU0
M +Y>  "Q90  IVH  )UM  "4;0  B6P  'AE  !O9   :60. &5D&0!B9"4
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M"3MPM0H[<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P
MG7D  ))[  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)
M>3< 2'E  $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5X
MLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X
M (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C(
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M 1R5^@$;E/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0
M89@  %6;  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;
MI#8 &J0_ !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B
M^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$
M $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L
M#;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %
MK_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M
M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK
M  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8
M +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   J
MN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+
M*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X
M  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@
M%<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P
MWB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E
M\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$
M  35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H
M .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP
M]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B
M    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6
M  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\
M_PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_
M '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\
MR0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9
M /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '(
M_P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T
M -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/
M$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V
M /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L
MYP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_
M#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T
M> #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9
M -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4
M_PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#>
M 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4
MZ ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,%
M /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7,
MR@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U
M"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46
M!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT
M +L/>P"Y#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/<
MI17_ *,5_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<
M&04 VQ , - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9
M=0"K&7P J1F$ *@:C "F&I0 I!J> *,;J "A&[0 GQS% )X<WP":'?,!F![_
M 9<>_P&6'_\!E1__ 94?_P&5'_\!_R8  /0G  #F+0  VB\  ,\M  #*)P
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M VTZ_P-M.O\#ZCD  -5"  #$2   N4L  *]+  "G20  GT0  )@^ 0"1/!
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M(@!V2"X <T@X '%(00!N2$D!;$A0 6I(5@%H2%T"9D=D F5'; -C1W8$84>
M!6!'C09>1YH'7$>I"%M(NPA:2-0(6DCQ!UI)_P9:2?\%6DC_!5I(_P1:2/\$
MVT0  ,9-  "X4P  K5<  *-9  ":6   D50  (9.  !]2P@ =TL2 '-,'P!P
M3"L ;4PU &M,/@!H3$8 9DQ- 61,4P%B3%H"84QB E],:@->3',$7$M^!5I+
MB@982Y@'5TRG"%9,N0E53-$)5$SO"%1-_P953/\&54S_!55,_P553/\%U4@
M ,)1  "U5P  JEL  *!<  "77   C5D  (%3  !W3P0 <4\0 &Y0' !J4"@
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M!T=9LPA&6<H(15GJ"$99_09&6/\&1EC_!4=8_P5'6/\%QU(  +A;  "K80
MH68  )AH  ".:0  @V<  ')@  !H7@  85T) %Q=$P!:71X 5UTI %9>,P!4
M7CL 4EY# %%>2@%/7E(!3EY9 DQ>80)*7FH#2%YU!$9>@@5$79 &0UZ@!T%>
ML0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@  GFH
M )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.9#@
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M RYQ^ ,N</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0
M<GT  &1\  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T
M>T0 ,WM, #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z
M]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0
M %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X
M*85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>
M@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,
M  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%
M !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\
M%(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%
MEP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>
M00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_
M  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H
M,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "
MJD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G
M_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL
M !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D
M +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P
MMO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X
M   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z
M  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T
MA9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #
MQP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=
M.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$
M &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP
M -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P
M\#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ
M  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8
M  #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD
M /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_
M !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\
M@P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J
M /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !,
M_P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_
M (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\
M\P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0
M /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\
M\P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#?
M /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\
M$@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"
M ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8
MR@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_
M !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -
M@ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^
M +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1
MZ  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_
M ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%
M_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2
M -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L
MKPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<
M#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+
M%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%]
M *$1A0"?$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\
MCA?_ (X7_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R
M%1X K18L *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;
M?P"2'(@ D!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_
M 8(@_P&"(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@
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MC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"W3L
M ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T/"L
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M!%!'L01/1\<$3D?G!$Y'^P1.1_\#3D?_ T]'_P-/1_\#S$8  +M.  "O5
MI%<  )I8  "15P  AE0  'M.  !P2@  :4@- &5(%@!B22$ 7TDK %U)- !;
M23P 64E# %=)2@!625( 54I9 51*80%22FH!44IU D]*@0-.2H\#3$N?!$M+
ML 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P  H5L
M )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!633H
M5$U! %-.2 !23D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/K@1%
M3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX  )5@
M  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C< 3U(_
M $Y21@!-4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1 5,$$
M/U3B!#]4^ - 4_\#0%/_ T!3_P- 4O\#P%   +)8  "F7@  G&(  ))E  "(
M90  ?6(  &Y<  !C60  658# %16#@!15A@ 3U8B $U7+ !,5S0 2E<\ $E8
M1 !(6$L 1UA3 $586P%$6&0!0EAN 4!8>P(_6(D"/5B9 SQ8J@,[6;\#.EG@
M SI8]P,Z6/\#.U?_ SM7_P,[5_\#O%0  *Y<  "C8P  F6<  )!I  "%:0
M>6<  &MB  !@8   55T  $Y;# !+6Q0 25P? $=<* !&73$ 15TY $-=00!"
M74@ 05Y0 $!>6  ^7F$!/%YL 3M>> (Y7H<"-UZ7 C9>J0,U7KT#-%_= S1>
M]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@  =FP
M &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \9$4
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M 2!Q_P$@<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@
M0WX  #A]   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >
M?U( '7]> !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[
M_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@
M #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP
M$HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .
MAO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2
M   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0
M  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\
MF((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9
MG@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D
M5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H
M (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@
M#*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3
MLEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5
M  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@
M  "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\
M ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !E
MHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'
M    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3
M  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K
M2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
MU@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N
M5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP
M "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E    Y@
M .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@
M_UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\
M'0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+
M /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\
M]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_
M "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H
MC #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_
M .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\
M_P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L
M (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -<
M_P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F
M /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (<
MV@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P##
M /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H
M+0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"'
M ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\
ML@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3
M #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0
MB "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_
M *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H
MOP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D
M (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)
M_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N
M *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8
ME@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'
M$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0
M,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+
M (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\
M[R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1
M&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>
MD0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@
M -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C(
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M 5PSL0%;-,8!6C3F 5DU^P%9-?\!633_ 5DT_P%9-/\!TC@  ,!   "S10
MJ$@  )Y(  "51@  BT   (([  !Y-00 <S,0 &\T&@!L-"4 :34O &<U-P!E
M-C\ 8S9& &(V30!@-E0 7S9; %TW8P!<-VL 6S=V 5DW@@%8.(\!5CB> 54X
MKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20  I$P
M )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>.CP
M73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]K ).
M/L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1
M  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY
M %4_1@!4/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"
M2$+> DA"]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+
M4P  @%   '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"
M0P!/0TL 3D-2 $U$6@!+1&, 2D1N 4E%>@%'18@!1D68 D5&J0)$1KT"0T;<
M D-&]0)#1O\"0T;_ 4-%_P%#1?\!P4<  +)/  "F5   G%<  ))8  "(6
M?E4  '%/  !F2@  7$8% %=&#P!41A@ 448B $]&*P!.1C, 3$<Z $M'00!*
M1TD 24A0 $A(6 !'2&$ 14EL $1)> %"288!04F6 4!*IP(_2KL"/DO8 CY*
M\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7   >UD
M &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%3$8
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M 2Y7_P$N5O\!LE<  *5?  ";90  D6D  (=J  !\:@  <6@  &-E  !88@
M35\  $-= @ \6PT .EP4 #A<'0 W7"8 -5TN #1=-@ S73X ,EU& #%>3@ P
M7E< +UYB "U>;@ L7WT *E^. "E?H  H7[,!)U_, "=?[0$G7O\!)UW_ 2A=
M_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0  26<
M #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H950
M)V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A
M8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN
M   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY;
M !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\
MI&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K
M=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X
M8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$
M )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@
M'((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )
M@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^
M  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X
M  ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4
M (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""
MB0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;
M   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN
M  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD
M:I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
MJ00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L
M=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP
M %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0
M +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P
MO8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J
M   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,
M  #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,
M -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   J
MM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4
M    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\
M  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P
M$<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
MYP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_
M@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T
M /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ),
M_^)]$$E#0U]04D]&24Q% ! 2_P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A
M /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T
M_P . /\ % #_ "$ _P N /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[
M 'L ^0"" /@ B #W (X ]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H
M[ #H /P YP#_ .4 _P#F /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P )
M /\ $ #_ !P _P I /\ -@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8
M[ !\ .H @@#H (@ YP". .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4
M /8 T0#_ -  _P#0 /\ SP#_ ,L _P#' /\ _P # /\   #_    _P $ /\
M#0#Z !8 ]@ C /, , #P #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V
M -@ ? #4 (( T@"( -  CP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\
MOP#^ +X _P"] /\ O #_ +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M
M !$ Z  < ., *0#? #4 VP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,,
M=0#! 'L OP"" +X B "\ )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X
M *P _P"K /\ K #_ *P _P"K /\ _P0  /\   #V    [@   .<   #?  P
MU@ 5 ,\ (@#* "X QP Z ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q
M '4 KP![ *T @@"K (H J0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T
M_P"< /\ G #_ )L _P"; /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0
M ,  &@"[ "< MP R +, /0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\
MH0!U )\ ? "= (0 FP"- )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ".
M /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0
M$@"N !X J@ J *8 -0"B #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O
M )$$=@"0!'\ C@6( (P%D@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\
M@ S_ ( ,_P" #/\ \14  . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B
M!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.
M<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_
M '03_P!T$_\ Z!X  -,F  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q
MD! ; (P1)P")$C( AA,[ (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W
M%70 =A9^ '06B@!R%Y8 <1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;
M_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6
M ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G
M:QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A
M(O\ URP  ,,T  "V.   JCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A
M'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U
M &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\
MSS(  +XY  "Q/0  IC\  )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K
M*", :2@L &8I-0!E*3P 8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL
M?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8
M +H]  "M0@  HD0  )A$  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\
M82XH %\N,0!=+CD 7"]  %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1
M,8@ 4#*7 $XRJ !-,[L 3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"
M  "I1@  GDD  )5)  "+1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E
M %@S+0!6,S4 53,\ %,T0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4
M2C>5 $@WI@!'.+@!1SC3 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F
M2@  G$T  ))-  "(2P  ?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W
M*@!0-S( 3S@Y $TX0 !,.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3
M $,\I %"/+8!03W0 4$]\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@
MF5   (]1  "%4   >TP  &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+
M.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y
MH@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0
M (U5  "#5   >%$  &Q+  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P
M1$ S $- .@!"04( 04%) $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X
M1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9
M  " 6   =E8  &A0  !=3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q
M #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$
M,DG) #%)ZP R2?X ,DC_ #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^
M70  <UH  &55  !;4@  4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*
M-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$['
M "Q.Z0 L3?T +4W_ "U,_P M3/\ L%   *18  "970  CV$  (9B  ![80
M<%\  &);  !86   3E4  $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R
M4#H ,5!" #!12@ N45, +5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93
MYP F4_P )U+_ "=1_P G4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64
M &!A  !57@  2EL  #]8   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8
M*E<^ "E71P H5U  )EA: "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?
M6/H (%C_ "!7_P A5_\ J%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH
M  !190  1F,  #M@   Q7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ
M "%>0P @7TP 'U]7 !Y?8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D
M&%[_ !E>_P 97?\ I&   )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,
M;   06L  #9I   M9P  (V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG
M/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_
M !%E_P 19?\ GV<  )9O  ",<P  @G8  'AX  !M>   8'<  %-V  !&=
M.W,  #%R   G<0  'G$  !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .
M<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN
M_P );O\ FV\  )%U  "'>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T
M "I\   A?   &'P  !%\!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T
M WQ(  %\50  ?&,  'QT  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P
M>/\ EG<  (Q\  "#@   >8,  &R$  !>A0  488  $6'   YAP  +8<  ".'
M   :AP  $H<   V( 0 &B0H  8D/  ")%   B!L  (@C  ")+   B38  (E"
M  "(3@  B%T  (AM  "(@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\
MD'X  (>#  !^AP  <8D  &.+  !6C0  28\  #R1   PD0  ))$  !J2   2
MDP  #90   :5    E@8  )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "6
M1@  EE4  )9E  "6>   E8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8
M (.*  !UC0  9Y   %F4  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP
M!*    "B    HP$  *,'  "C#   HQ   *05  "D'   I24  *8O  "F/
MIDL  *9;  "F;@  I80  *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1
M  !JE0  7)D  $Z=  !!H   ,Z(  ":C   ;I0  $:<   JI   !JP   *T
M  "O    L    +    "P!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\
M +=0  "W8@  MW@  +>0  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?
MG0  4*(  $*F   TJ0  )JL  !JM   0KP  ";(   "T    MP   +H   "\
M    O0   +X   "^    P (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#
M  #+50  S&H  ,R#  #,G   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@
M1*L  #:P   GL@  &K4  !"X   'NP   +X   #!    Q    ,@   #+
MRP   ,T   #.    T    -(   #5 P  V H  -L0  #>&   XB0  .,U  #D
M2   Y5P  .9S  #FC0  YJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4
M "BY   :O   #\    7$    QP   ,L   #/    U    -@   #<    W0
M -\   #A    XP   .4   #H    Z@   .T&  #Q#@  ]18  /@E  #Y.
M^4T  /IC  #[?   _)4  /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\
M%@#_ ", _P P /\ /0#_ $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P""
M /\ B0#_ (\ _P"5 /X FP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\
M\P#_ /( _P#L /\ X@#_ -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_
M !X _P K /\ . #_ $0 _P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8
M@P#T (D \@"/ /$ E@#O )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_
M .( _P#@ /\ U0#_ ,X _P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D
M_P E /T ,@#[ #X ]P!) /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D
M (, X@") .  D #> )< W "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L
M_P#* /\ R #_ ,( _P"^ /\ _P   /\   #_    _P   /L "P#V !, \0 @
M .T + #J #@ YP!# ., 30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P
MS "# ,H B0#( )$ Q@"9 ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W
M /\ M@#_ +0 _P"Q /\ _P   /\   #_    ]@   .X !0#G  \ X0 9 -L
M)0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\
M +@ @P"V (H LP"3 +$ G "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\
MI #_ *0 _P"D /\ _P   /P   #Q    Z    .    #4  L S  3 ,< 'P#"
M "H OP U +P /P"X $@ M0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *<
M? "E (0 HP", *$ E@"? *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_
M )4 _P"5 /\ _ $  / %  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ",
MKP N *L . "I $$ I@!* *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6
M 'T E "& )( D "0 )L C@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8
M_P"& /\ ] P  .00  #1$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F
M )X ,0": #H F !# )4 2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '<
MA@"  (0 BP"" )8 @ "C 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X
M!O\ ZA,  -8:  #&'0  NAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"
M*0"- S, BP0\ (@%1 "&!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\
M '@)A@!V"9( = J@ ',*KP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\
MX1P  ,LC  "\)@  L28  *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!
M#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0
M@@!K$(\ :1&= &@1K0!F$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0
M ,,J  "U+@  JB\  * M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R<
M<Q0P '$4. !O%3\ ;15& &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A
M&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ
M  "O-0  I#8  )LT  "2,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK
M &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X<
M5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K
M.@  H#P  )8[  "-.   @S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B
M+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3
M $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P
MG$$  ))   ")/@  ?SD  '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5
M*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<L
MH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44
M (]%  "%0P  >SX  '$Y  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\
M32TV $PM/ !*+4, 22U* $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@!
M,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)
M  "#2   >$0  &T^  !C.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R
M $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\
M.C?& #DWZ  Y-_P .C?_ #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  "
M3   =4@  &I#  !@/@  5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U
M-@ _-CT /C9% #TW30 \-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$
M #0[Y@ T._L -3O_ #4Z_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4
M<TT  &=(  !<1   4C\  $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z
M.CL .3M" #@[2@ W/%, -CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_
MY  O/_H ,#__ # ^_P P/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(
M &1,  !920  3T4  $5  P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@
M-#]  #- 2  R0%$ ,4%; #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J
M0_D *D/_ "M"_P K0O\ KDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2
M  !73@  34L  $-'   Z0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4]
M "U%1@ L14\ *T99 "I&9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/<
M)4?_ "5'_P F1_\ JD\  )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !5
M50  2U$  $!-   U2@< ,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+
M0P F2TP )4M6 "1,8@ C3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_
M !],_P @2_\ IU,  )Q:  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P
M1U@  #Q5   R4@( *E , "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @
M44D 'E)3 !U27P <4FT &E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1
M_P 94?\ HUD  )A@  "/90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\
M #A<   N6@  )5@( "!7#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4
M%EE0 !596P 466D $UIZ !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 1
M6/\ GU\  )5F  ",:P  @FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E
M   I8P  (&$! !A@"P 58!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+
M  YA6  -868 #&)V  MBB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\
MFV8  ))M  "(<0  ?G,  '5U  !J=   7',  $]R  !#<   .&\  "UN   D
M;   &VL  !-K!  .:@P #6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K
M4P $:V$  FMQ  !JA   :I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT
M (US  "$=P  >WH  '![  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@
M%78   ]V @ )=@H !'8/  !V%0  =AP  '8D  !U+   =38  '5!  !U3@
M=5P  '5L  !U?@  =),  '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ
M  " ?@  =H   &F!  !;@@  3H(  $&"   U@P  *8(  !^!   6@0  $((
M  J"   "@P<  ((-  ""$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4
M (%E  "!>   @8T  ("B  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![
MA   ;H8  &"(  !2B@  18L  #F,   LC   (8P  !>,   0C0  "8X   */
M    D ,  (\)  "/#@  CQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=
M  "/<   CX4  (Z<  ".LP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP
M9(T  %:0  !(DP  .Y4  "Z6   BE@  %Y<   ^8   (F0   )L   "=
MG0   )T#  "="0  G0T  )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@
M9@  GWL  )Z3  ">JP  G<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698
M $N9   ]G   ,)X  ".?   7H   #J(   >D    I@   *@   "J    J@
M *H   "K 0  JP<  *P,  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@
ML6\  +&(  "QH   L+H  *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C
M   QI@  (Z<  !>I   .JP  !:X   "P    L@   +4   "W    MP   +@
M  "Y    N@   +P#  "]"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(
M ,9Z  #&E   QJT  ,;(  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   D
MKP  %K$   VT   #MP   +H   "]    P    ,0   #&    Q@   ,@   #)
M    RP   ,P   #.    T 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K
M  #AA0  X9\  .&W  #ASP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0
M#;P   &_    PP   ,<   #*    SP   -,   #6    UP   -H   #<
MWP   .$   #C    Y@   .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X
M=   ^(\  /FF  #YN   ^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L
M /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H
M_0"0 /P EP#Z )X ^0"G /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F
M /\ W #_ -( _P#- /\ _P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\
M,P#_ #\ _P!* /X 5 #[ %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"*
M .T D0#L )D Z@"A .@ JP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\
MS #_ ,4 _P#! /\ _P   /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V
M #D \P!% .\ 3@#L %< Z0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L
MBP#8 )( U0"; -( I #/ *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_
M +@ _P"U /\ _P   /\   #_    _@   /< "0#Q !$ ZP < .< * #D #,
MX0 ^ -T 2 #8 %$ TP!8 -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #"
M (P P "4 +X G@"[ *@ N0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P
M_P"I /\ _P   /\   #Z    \0   .@  P#@  T V  6 -$ (@#- "T R@ W
M ,8 00#" $H OP!2 +T 60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4
MK0"- *L EP"I *$ IP"N *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"<
M /\ _P   /<   #K    X0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0
M.@"Q $, K@!+ *L 4@"I %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "&
M )H D "8 )L E@"G )0 M@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\
M^    .D"  #; P  S $  ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A
M #P G@!$ )P 2P": %( F !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L
MB@") )4 AP"A (4 KP"# ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H
M -P.  #*$   O@X  +4+  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4
MD  ^ (X 10", $L B@!1 (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![
M (\ >0"< '< J@!U +L = #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7
M  "_&0  LQD  *H5  "C$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W
M (  /@!^ $4 ?0!+ 'L 40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL
M; .8 &L#I@!I!+< : 7. &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V
M(P  JR,  *$@  "9&P  DA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(
M. !R"3\ < E% &\*3 !M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5
M & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P
MI"L  )HI  "2)   B1\  ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G
M$#D 91!  &001@!C$$T 81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83
MH@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(
M )4Q  ",+0  @R<  'HA  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30
M7!4[ %L60@!9%D@ 6!9/ %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,
M&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W
M  "'-   ?2\  '0I  !L(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW
M %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X
M1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#
M.@  >34  &\P  !F*@  7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB
M.@!)(D  2")' $<B3@!&(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?!
M #TGXP ]*/H /2C_ #TG_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P
M=CL  &PV  !B,   62H  %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#
M)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<L
MX  W+/@ -RS_ #<L_P X+/\ M3H  *=   "<1   D48  (=&  !]1   <T
M &@[  !?-@  53$  $PK!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD
M/"M! #LL2  Z+%$ .2U; #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q
M,?< ,C'_ #(P_P S,/\ L3X  *1$  "92   CTH  (5*  ![20  <$4  &5
M  !;.P  4C8  $@Q! !"+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^
M #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4
M+37_ "TT_P N-/\ KD$  *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !8
M0   3CP  $4W   ],PL .3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U
M1  O-4P +C96 "TV8@ L-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_
M "@X_P I./\ JT4  )]+  "43P  BU(  (%3  !W4@  ;$\  %])  !61@
M3$(  $(]   X. @ -#@/ #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J
M.DH *3M4 "@[7P G/&T )3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]
M_P C//\ J$D  )U/  "24P  B58  ']7  !U5@  :E,  %U/  !33   2D@
M $!$   V0 4 +ST- "T]$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@
M(T!2 ") 70 A06H ($%Z !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >
M0?\ I4T  )I3  "06   AEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*
M   S1P  *D,+ "9#$  E0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/
M !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\
MHE(  )=8  "-70  A&   'IA  !P8   95X  %E:  !/6   1%0  #E1   O
M3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,
M5P 43&4 $TUU !)-B  139P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<
M )1=  "+8@  @64  '=F  !M9@  8V0  %9A  !*7@  /UL  #58   K5@
M(E0! !I2"@ 64A  %5(6 !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .
M4V( #51R  Q4A  +5)@ "52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D
M  "(:   ?FL  '1L  !K;   7VH  %)G  !%9   .F(  #!@   F7@  '5T
M !5;!0 06@P #EH1  Y:&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX
M!%MM  -;@  !6Y0  %NH  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$
M;@  >W   ')R  !G<0  67   $QN  ! ;   -6L  "II   A9P  &&8  !%F
M 0 ,90H !V4/  1E%  #9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I
M  !D>P  9(\  &.D  !CNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0
M>'<  &UX  !@=P  4G8  $9U   Y=   +G0  "-R   :<0  $G$   UQ   &
M<0@  ' -  !P$@  <!<  &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O
M=0  ;HH  &V@  !MM@  ;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT
M &5^  !8?@  2WX  #Y^   R?@  )GT  !Q\   3?   #7P   9]    ?04
M 'P+  !\#P  ?!,  'P9  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P
M>H0  'J:  !YL0  >,X  '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%
M  !/A@  0H<  #6(   IAP  '8<  !2'   -B   !HD   "*    B@   (D&
M  ")#   B0\  (D3  ")&@  BB(  (HL  "*.   BD8  (E6  "):   B7P
M (B4  "'JP  AL8  (7J  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%
MCP  .)$  "N1   ?D@  %)(   V3   $E    )8   "7    F    )<   "7
M!0  EPL  )@.  "8$P  F1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+
M  "8HP  E[P  );B  "6]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0
M+)H  !^;   4G   #)X   .?    H0   *,   "E    I0   *4   "E
MI@(  *<(  "G#0  J!$  *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "J
MF@  JK,  *K0  "I[P  J?L =8\  &>4  !9F   2IP  #R?   MH@  (*,
M !.E   +IP   :D   "K    K@   +$   "R    L@   +,   "T    M0
M +8   "X!   N0L  +L0  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0
MP:8  ,#!  "_XP  OO, :I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP
M    LP   +4   "X    O    +\   #!    P0   ,,   #$    Q@   ,<
M  #)    RP   ,X(  #1#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D
M -RP  #<R0  W., 79\  $^E  ! J@  ,J\  "*R   4M0  "K@   "[
MOP   ,,   #&    RP   ,X   #1    T0   -0   #6    V0   -L   #>
M    X    .0   #G!@  ZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A
M  #TM@  ],< _P ) /\ !@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$
M_P!, /\ 50#_ %T _P!E /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W
M )D ]@"B /0 K #S +D \0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D
M_P#$ /\ _P ! /\   #_    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!&
M /H 4 #W %@ ] !? /( 9@#P &P [P!R .T > #L 'X Z@"% .D C #G ),
MY0"< ., I@#A +$ WP#! -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y
M /\ _P   /\   #_    _P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D
M2@#F %( XP!9 .  8 #> &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5
M ,P GP#) *H QP"X ,4 S0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\
M_P   /\   #_    ^0   /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/
M $P S !3 ,D 6@#' &  Q0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +<
MF "U *, LP"P +$ P@"N .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P
M /\   #U    ZP   .$   #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4
MN !- +8 5 "S %H L0!? +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C
M )P H "I )X N "< ,X F@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$
M  #E    V0   ,T   #$  8 O0 / +< & "S "( L  L *T -@"I #X IP!&
M *0 30"B %, H !9 )\ 7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4
MCP"B (T L "+ ,, B0#C (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1
M    Q0   +T   "V    K@ + *@ $@"D !P H  F )P +P": #< EP _ )4
M1@"2 $P D0!2 (\ 6 "- %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P";
M 'X J0!\ +L >@#5 '@ \@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0
MN P  *X(  "H    H@ % )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$
M $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '
MI !N +0 ; #* &L Z@!J /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14
M *02  "<#@  E@<  )  "0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $
M=0!& ', 3 !R %$ < !7 &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B
M *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<
M  "3%P  BQ$  (0,  !^! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)
M &<#1@!F TP 9 12 &,$60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T
M5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+
M(0  @QL  'L4  !T#@, ;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+
M0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _"
M $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0
M?20  '0>  !L%P  91$' %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2
M$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5
MWP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L
M &\F  !F(   7AD! %<4#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX
M2!9$ $<73 !%%U0 1!== $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP [
M'/8 /!S_ #P<_P \'/\ M3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM
M  !A)P  62$  %$;"0!,&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q!
M $ <2  ^'%  /1U9 #P>9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0
M-2+_ #4A_P V(?\ LC0  *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=
M+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA
M10 X(DT -R)7 #8C8@ T(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_
M # F_P P)O\ KS@  *(^  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P
M42X  $@H 0! ) P /2,1 #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R
M)DH ,2=4 # G7P O*&P +BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ
M_P K*O\ K#P  )]"  "41@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,
M $0N   \*0D -R@0 #4H%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@
M+"M2 "LL70 J+&H *"UY "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F
M+O\ J3\  )U%  "220  B$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T
M   X+P8 ,BT- # M$P N+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/
M "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\
MID,  )I)  "030  AD\  'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V
M-@( +C(, "LR$0 I,A< *#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U
M6  ?-F4 'C9U !PWAP ;-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<
M )A-  ".40  A%,  'M4  !Q4P  9E   %I,  !020  1T4  #U!   S/0
M*CD) "4W#@ C-Q0 (C@; "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9
M.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51
M  "+50  @E@  'E9  !N6   9%8  %A1  !.3P  14L  #I'   P0P  )T %
M " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&
M$D%P !%!@@ 009< #T&L  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")
M6@  @%T  '9>  !L70  8EL  %97  !,50  05$  #9.   L2P  (T@  !M%
M"0 71 \ %404 !1%&P 312( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M
M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8
M?6(  '-C  !J8@  8&$  %->  !'6@  /%<  #)5   H4@  'U   !=.!  1
M3 P #TP1  Y,%P .3!X #4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.
M>P "3H\  4ZD  !-N@  3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@
M '%I  !H:0  7&<  $]D  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D
M"54.  =5$P &51H !%4B  -5*@ "530  %4^  !52@  5E<  %9E  !5=P
M58L  %6@  !5M@  5-0  %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O
M  !C;@  5FP  $EJ   ]:   ,F8  "=E   =8P  %6(   YA   )8 @  V -
M  !?$0  7Q<  %\>  !?)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<
M %V<  !=L@  7,\  %SO  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !=
M=   3W,  $)R   V<   *V\  "!N   7;0  $&P   IL   ":P8  &L+  !J
M#P  :A0  &H:  !J(0  :2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8
M  !GK@  9LH  &7M  !E_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P
M2'H  #MZ   O>@  (WD  !EX   1=P  "G<   -W    =P(  '<(  !V#0
M=A   '85  !V&P  =B,  '8N  !U.@  =4<  '56  !U:   ='P  '22  !S
MJ@  <L0  ''I  !P^P  </\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,
M #*$   E@P  &H,  !&#   *@P   H,   "$    A0   (0#  "#"   @PT
M (,0  "#%0  A!P  (0F  "$,@  A#\  (-/  "#8   @G4  (*,  "!I
M@+T  '_C  !^^0  ?O\ @H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-
M   ;C0  $8X   J.    CP   )$   "2    D@   )(   "2 0  D@<  )(,
M  "2$   DQ4  ),=  "4*   E#8  )1%  "35P  DVL  )."  "2G   D;8
M )#8  "/\P  C_\ ?H<  '"*  !AC0  4Y   $63   WE0  *98  !R7   1
MF   "9D   ";    G    )X   "@    H    *    "@    H0   *$$  "B
M"0  HPX  *04  "E'0  IBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)
M  "CZP  HOH <XX  &21  !6E0  1YD  #F<   JG@  ':   !&A   (HP
M *4   "G    J0   *P   "N    K@   *X   "O    L    +$   "R
MLP8  +4-  "W$P  N1X  +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "Z
MW@  N?( 9Y4  %B9  !*G@  .Z(  "RF   =J   $:H   >L    KP   +$
M  "T    N    +L   "\    O    +X   "_    P    ,(   #$    Q@
M ,@#  #+"P  SQ(  -$@  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q
MU.( 6YT  $RB   ]IP  +ZP  !^O   1L0  ![4   "X    NP   +X   #"
M    QP   ,H   #,    S    ,X   #0    T@   -4   #8    VP   -\
M  #B    Y@L  .L3  #L)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4
M_P # /\  0#_  0 _P ) /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_
M %D _P!@ /T 9P#\ &T ^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /
MIP#N +, [ #$ .L X0#J /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P
M /\   #_    _P   /\ # #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %,
M\ !; .X 80#L &< Z@!M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #;
M *P V "[ -0 T0#3 /  T #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\
M  #_    _P   /T " #W !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5
M -D 6P#6 &$ TP!G -$ ; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4
MP "R +X Q0"\ .4 N@#[ +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^
M    ]0   .P  P#E  T WP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,(
M50#  %L O@!A +P 9@"Z &P N !R +8 > "U (  LP"( +$ D@"N )X K "J
M *D NP"H -4 I@#S *0 _P"C /\ H0#_ )L _P"8 /\ _P   /L   #P
MY0   -@   #.  D QP 1 ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L
M %0 J@!: *D 7P"G &4 I0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )<
ML@"6 ,< DP#H )( _@"1 /\ D #_ (T _P"+ /\ ^0   .L   #=    SP
M ,8   "\  0 M0 - +  %0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X
MF0!3 )< 60"6 %X E !D )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$
M +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^ /\ [    -H   #)    O@   +8
M  "N    IP ) *$ $ "< !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!-
M (< 4@"& %@ A != (( 9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0
M<P#, '$ [0!P /\ < #_ '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A
M    FP # )0 # "/ !, B@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D
M3 !W %( =@!7 '0 70!R &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90##
M &0 Y !C /H 8P#_ &( _P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P
MCP,  (D !P""  X ?@ 5 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J
M $P :0!2 &< 6 !F %\ 9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@
MW !8 /0 6 #_ %< _P!7 /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\
M 'X)  !W 0H <@ 0 &X %P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8
M70!, %P 4P!: %H 6 !B %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-
M!/  307_ $T%_P!-!?\ OQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42
M  !N#0( 9P8, &,#$0!? AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9'
M %$&3@!0!U4 3@=> $T(9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\
M0PW_ $,-_P!$#?\ N20  *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F
M%   7P\% %D+#0!5"A, 4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-
M20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_
M #L1_P \$?\ M"D  *8O  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0
M618  %$1" !,#Q  2A 6 $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^
M$DT /1)6 #P280 Z$VT .1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06
M_P T%O\ KRX  *(T  "7-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X
M $P8! !&% T 0A02 $ 4&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH
M-A=3 #477@ S&&H ,AEY # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N
M&_\ K#(  )\X  "4.P  BCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?
M  ! &@H /!D0 #H9%@ X&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0
M "X=6P M'6< +!YV "H>B  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\
MJ38  )T\  "2/P  AT$  'U   !T/@  :3H  %\U  !6,   32L  $0E   [
M( < -AX. #,>$P R'AD ,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA
M6  G(F4 )B)T "4CA0 C(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH
M )H_  "/0P  A44  'M$  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@,
M,2,, "XB$0 L(A8 *B(= "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B
M)F, (2=R !\G@P >*)< '2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#
M  "-1P  @TD  'I)  !P1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@)
M "@G#P G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V
M&RMO !HL@0 9+)4 %RVI !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+
M2P  @DT  'A-  !N3   9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L
M#0 A+!( ("P8 !\M'@ >+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M
M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P
M@%$  '92  !M4   8DX  %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <
M,A  &S(5 !DR&P 8,B( %S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V
M?0 /-I$ #C:F  TWO  --]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8
M '56  !J50  8%,  %5/  !,3   0DD  #A%   N00  )#T  !PZ"  6. X
M%3@2 !0X&  3.1\ $CDF !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *
M.XT "3RB  <\N  '/-4 "#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');
M  !H6@  7E@  %-5  !)4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0
M  X_%0 ./QP #4 C  Q *P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H
M 4&?  !!M   0=   4'N  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F
M8   75X  %%;  !%5P  .E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'
M$@ '1QD !D<@  5(*  #2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;
M  !(L0  1\P  $?M  !'^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@
M660  $Q@  ! 70  -5L  "I9   @5P  %U4  !!3   +4@< !5$-  %0$0
M4!8  % =  !0)0  4"X  % X  !00P  4%   %!>  !0;P  4(,  $^8  !/
MK@  3LD  $[K  !-^P  3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD
M $9G   Z9   +V,  "1A   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,
M %H9  !9(0  62D  %DS  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP
M5\4  %;I  !5^P  5?\ C&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N
M   S;0  *&L  !UJ   4:   #6<   =G    9@,  &8)  !E#0  91$  &05
M  !D'   9"0  &0N  !D.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$
M %_F  !?^@  7O\ AV\  ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K
M=@  ('0  !9S   .<P  !W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P
M%P  <!X  ' G  !P,P  ;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB
M  !J^   :?\ @W<  'Q[  !S?0  97X  %=_  !)?P  /'\  "^    B?P
M%WX   ]^   '?@   '\   !_    ?P   'X   !^!0  ?@H  'X-  !^$0
M?A<  'X@  !^*P  ?3D  'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X
M]0  =_\ @'\  '>"  !I@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD
M  >*    BP   (P   "-    C0   (P   ",    C ,  (P(  "-#0  C1$
M (T7  ".(@  CB\  (X_  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P
MB?\ >X4  &V(  !>B@  4(T  $*/   TD0  )I(  !F3   .E   !I4   "6
M    F    )H   ";    FP   )L   ";    FP   )P   "=!0  G0L  )X0
M  "?%P  H"0  * T  "@1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D
M<(P  &&/  !3D@  1)8  #:9   GFP  &9P   ^=   %GP   *$   "C
MI0   *@   "I    J0   *D   "J    JP   *P   "M    K@$  + )  "R
M#P  LQ@  +0G  "T.0  M4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),
M %67  !'FP  .)\  "FB   :I   #J8   2H    JP   *T   "P    M
M +8   "X    N    +D   "Z    O    +T   "_    P    ,,   #%!P
MR0\  ,H:  #++   S$   ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@
M   ZI0  +*D  !RK   /K@  !+$   "T    MP   +H   "^    PP   ,8
M  #(    R    ,H   #+    S0   ,\   #2    U0   -D   #=    X04
M .8/  #G'@  Z#(  .E(  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_
M    _P & /\ #0#_ !4 _P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H
M8@#X &@ ]@!N /4 = #T 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"]
M .4 V #D /, X@#_ .  _P#0 /\ Q #_ +P _P"V /\ _P   /\   #_
M_P   /\ "0#_ !$ _P < /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F
M &( Y !H ., ;@#A ', WP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P
MR0#) .D R #_ ,< _P#! /\ MP#_ *\ _P"K /\ _P   /\   #_    _P
M /@ !0#R  X [@ 7 .H (@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P
MS !B ,H 9P#( &T Q@!S ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T
M -T LP#W +$ _P"P /\ J #_ *( _P"> /\ _P   /\   #Y    [P   .8
M  #?  L U@ 2 -  ' #, "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!;
M +4 80"S &8 L0!L +  <@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L
MGP#N )T _P"< /\ F0#_ )0 _P"1 /\ _P   /8   #J    W0   ,\   #'
M  8 P  / +L %P"W "  LP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *(
M6@"@ %\ G@!E )T :P"; '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B
M (L ^@") /\ B0#_ (8 _P"# /\ ]    .0   #4    R    +\   "U  $
MK@ + *D $@"E !L H0 C )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P".
M %D C0!> (L 9 ") &L AP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D
M\0!X /\ =P#_ '< _P!U /\ Y0   -$   ##    N    *\   "H    H  &
M )H #@"5 !4 D0 > (X )@"+ "T B  U (8 / "$ $( @@!' (  30!_ %(
M?0!8 'L 7@!Y &4 > !M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I
M /T : #_ &@ _P!I /\ U0,  ,,'  "V"   JP8  *(   ";    E    (T
M"@"( !  @P 8 '\ ( !\ "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2
M &T 6 !K %\ :0!F &< < !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8
M7 #_ %L _P!; /\ R0T  +D0  "L$0  H1   )<-  "/"   B    (( !0![
M  T =P 2 ', &@!O "$ ;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &
M4@!? %D 70!A %L :@!9 '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_
M %  _P!0 /\ OQ0  + 8  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @
M:P . &< % !D !L 80 B %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3
M %0 4@!< %  90!. '  3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8
M_P!% /\ N!L  *H@  ">(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800*
M %T $ !9 !8 5@ = %0 (P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\
M1P%7 $8!80!$ FP 0P)Y $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \
M!_\ LB(  *4G  "9*0  CBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(
M# !/!1$ 3 47 $H&'@!(!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3
M #T)70 ["F@ .@IV #@+AP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\
MK2<  * L  "5+P  BR\  ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&
M# T 0PP2 $$,&  _#!\ /@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.
M6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP
M )TQ  "2-   AS4  'TT  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D
M.Q / #D0%  W$!L -A A #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L
M$F, *A-Q "D3@@ G%)4 )A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV
M  "/.0  A3H  'LY  !Q-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10-
M #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V
M)!AO ",8@  A&9, (!FG !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-
M/0  @SX  'D]  !O.P  93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8
M#P J&!0 *1@: "<8(  F&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL
M !T=?@ <'9$ &AZE !D>O  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00
M@4(  '="  !M0   8SP  %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E
M'1( (QT7 "$='0 A'20 (!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B
M>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8
M '5&  !L1   8D$  %<\  !-.   1#0  #PP   S*P  *B8# ",B"P @(1
M'B$5 !PB&P ;(B$ &B(H !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2
M)HT $2>B ! GN  .)]8 $"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*
M  !J20  8$8  %5!  !,/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2
M !@G&  6)Q\ %2@E !0H+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL
M#2R?  PLM0 ++,\ #"SO  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I
M3@  7DL  %-'  !*1   0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M
M%0 2+1P $2TC ! M*@ /+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<
M  8QL0 &,<L !C'K  <P_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@
M75   %),  !)2@  0$8  #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -
M,QD #3,@  PT*  +-#$ "C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   V
MKP  -L@  #;H   V^0 !-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4
M %%2  !'3P  /$P  #%(   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q<
M!CL>  4[)@ $.RX  CLX  $\0P  /$\  #Q>   \;@  /($  #R7   \K
M.\4  #OG   [^   ._\ D5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8
M  !"5   -U$  "U.   C2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;
M  !#(P  0RL  $,U  !#0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,
M $'F  !!^0  0?\ CE@  (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]
M6@  ,E@  "=5   >4P  %5$   Y/   )304  DT+  !,#@  3!,  $L8  !+
M'P  2R@  $LR  !+/0  2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD
M  !(^   1_\ BU\  (-D  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80
M+%\  "%=   86P  $%D   I8   #5P,  %<)  !6#0  51   %45  !4&P
M5",  %0M  !4.0  5$4  %13  !49   4W<  %.-  !2I   4;T  %#B  !0
M^   3_\ B&<  ']K  !W;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@
M !IF   19   "V,   1B    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX
M %XH  !>,P  7D   %Y/  !>7P  77(  %V(  !<H   6[D  %K?  !9]P
M6/\ A&X  'QR  !U=0  :W8  %UU  !/=   0G,  #5S   H<@  '7   !-O
M   ,;@  !&X   !N    ;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB
M  !J+0  :CH  &E)  !I6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\
M@'4  'IY  !P>P  8GL  %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $
M>@   'H   !Z    >@   'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X
M)0  >#(  '=!  !W4@  =V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT
M '6   !G@0  6((  $J#   \A   +H4  "&%   5A0  #84   .%    A@
M (<   "(    B    (<   "'    AP   (<$  "'"0  APX  (@3  "('
MB"D  (@X  "'2@  AUT  (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&
M  !<B   38H  #^,   QC@  (X\  !:/   -D    I$   "2    DP   )4
M  "6    E@   )8   "6    E@   )<   "7    EP<  )@-  "9$P  FA\
M )HM  ":/P  FE(  )IH  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0
MD   09,  #.6   DEP  %I@   V9   !FP   )T   "?    H0   *0   "E
M    I    *4   "E    I@   *<   "H    J0   *H$  "L#   KA,  *XA
M  "N,P  KD<  *Y=  "N=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F
M-9P  ":?   7H0  #:,   "E    IP   *H   "L    L    +(   "T
MLP   +0   "U    MP   +@   "Y    NP   +T   "_ 0  PPL  ,45  #%
M)0  QCD  ,=/  #':   QH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8
M !FH   -JP   *T   "Q    M    +<   "Z    OP   ,$   #$    PP
M ,4   #&    R    ,H   #-    SP   -(   #6    VP   . ,  #A&
MXRL  .1!  #E6@  YG0  .:1  #EK   Y<0 _P   /\   #_    _P ! /\
M"@#_ !( _P = /\ * #_ #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I
M /  ;P#O '0 [0![ .L @0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X
MV0#_ -D _P#* /\ O@#_ +4 _P"P /\ _P   /\   #_    _P   /\ !@#_
M  \ _  8 /@ (P#T "X \  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P
M: #9 &X U@!T -0 >P#1 (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[
M ,  _P"[ /\ L #_ *@ _P"D /\ _P   /\   #_    ^P   /,  0#M  P
MZ  3 ., '@#@ "@ V@ R -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#!
M &< OP!M +T = "[ 'L N0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H
M_P"I /\ H0#_ )L _P"7 /\ _P   /\   #T    Z0   .    #5  @ S@ 0
M ,D & #% "( P0 K +P -0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$
MJ@!F *D ;0"F '0 I !\ *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5
M /\ D@#_ (T _P"* /\ _    /    #C    U    ,@   "_  , N0 - +,
M$P"O !P K  E *D +@"E #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!?
M )8 9@"4 &P D@!U )  ?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\
M@0#_ 'X _P!\ /\ [0   -T   #,    P0   +@   "N    IP ) *( $ ">
M !< F@ ? )< )P"4 "\ D0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0
M7P"" &4 @ !M 'X =P!\ (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_
M '  _P!N /\ W0   ,D   "\    L0   *D   "A    F0 # ), # ". !(
MB@ 9 (< (0"$ "D @0 P '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R
M %\ <0!G &\ < !L 'L :@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$
M_P!A /\ S0$  +P%  "O!0  I0(  )P   "4    C0   (8 " "!  X ?  4
M '@ &P!U ", <@ I '  , !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D
M8P!@ &$ :0!? '0 70"! %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5
M /\ P0P  +(.  "F#P  FPX  )(+  ")!0  @@   'L  @!U  L <  0 &P
M%@!H !T 9@ C &, *@!A #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!;
M %0 9 !2 &X 40![ $\ B@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\
MN1(  *H6  ">%P  E!8  (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!=
M !@ 6@ > %@ ) !6 "H 5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D
M7P!' &D 1@!V $0 A0!# )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD
M *0>  "8'P  CA\  (0<  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !,
M4  9 $X 'P!, "4 2@ K $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^
M &4 / !R #H @0 Y ), . "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D
M  "4)@  B28  '\D  !U(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4
M $0 &@!" "  0  E #\ *P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$
M,P1N #$%?@ P!9  +P6C "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0
M+   ABT  'LK  !R)P  :"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&
M%0 Y!QL . <A #8()@ U""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML
M "D+?  H#(\ )@RB "4,MP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@
M@S(  'DQ  !O+@  92D  %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q
M#!8 +PP< "X-(@ M#2@ *PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/
M>P @$(X 'Q"B !T0MP <$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<
M '8V  !M,P  8R\  %DJ  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!(
M*! 8 "<0'@ E$"0 )! J ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :
M$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[
M  !K.   830  %<O  !.*P  128  #TA   T'   +1<% "83#  C$Q  (A,5
M " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D
M$QB> !(8LP 1&<X $1GO !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I
M/0  7SD  %4U  !,,   0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7
M%P 9&!X &1@D !@9+  7&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<
M  X=L0 -'<L #1WL  X=_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@
M7CX  %,Z  !*-@  03(  #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4
M'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HB
MK@ )(L< "2+G  HB^P +(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0
M %(_  !).P  0#@  #@T   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD
M$"(@  \B)P .(R\ #20Y  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #
M)L0 !";E  0F]P &)O\ E4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$
M  !'00  /SX  #<[   M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=
M  LH)0 **2T "2DW  <J0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$
M "OC   K]@  *O\ DD8  (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'
M1P  /D0  #-    I/   (#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O
M(P #+RL  C U   P/P  ,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A
M   P]0  +_\ D$L  (90  !]5   =58  &M6  !B50  6%,  $Y0  !%30
M.DD  "]%   E0@  '#X  !0[   ..04 "3<+  0V#P !-A,  #89   V(
M-BD  #8R   W/0  -TD  #=7   W9P  -WD  #>/   VI0  -KT  #;@   U
M]0  -?\ C5   (16  !\6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X
M "I+   @2   %T8  !!#   +000 !$ *   _#@  /A$  #X6   ^'0  /B8
M #XO   ^.@  /D8  #Y4   ^9   /G8  #V,   ]HP  /+L  #S>   []0
M._\ BE<  ()<  !Y7P  <&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52
M   ;4   $DT   Q+   &2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L
M  !&-P  1D,  $91  !&8   17,  $6)  !$H   1+@  $/<  !"]0  0O\
MB%T  ']B  !W90  ;F<  &=H  !;9@  3F,  $%A   T7@  *5P  !]:   5
M5P  #E8   =4    4P$  %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/
M,@  3S\  $]-  !.70  3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64
M 'QI  !T;   ;6X  &)M  !4:P  1VD  #IG   M90  (F0  !AB   08
M"5\   !>    7@   %T#  !<"   6PP  %H/  !:$P  61D  %DB  !9+0
M63H  %E(  !86   6&L  %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP
M  !S<P  :',  %IR  !,<0  /W   #)O   E;@  &FP  !%K   ):@   &H
M  !I    :0   &@   !G P  9@@  &8,  !F#P  910  &4<  !E)P  9#0
M &1#  !D4P  9&4  &-[  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N
M>0  7WD  %%Y  !#>0  -G@  "EX   <=P  $78   IU    =0   '4   !V
M    =0   '0   !T    <P(  ','  !S#   <A   '(5  !R(   <BP  '([
M  !Q3   <5\  '%T  !PC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@
M57\  $>    Y@0  *X(  !Z!   2@0  "H$   "!    @@   (,   "#
M@P   ((   ""    @@   ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""
M0P  @58  (%L  " A@  ?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<
M #R)   NB@  ((L  !.+   *BP   (P   "-    CP   )$   "2    D0
M )$   "1    D0   )$   "2    D@(  ),)  "4#P  E!D  )0G  "4.
ME$P  )-B  "3?   DY@  )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2
M   AE   %)4   J6    EP   )D   ";    G0   )\   "@    H    *
M  "@    H0   *(   "C    I    *4   "F!P  J!   *@<  "H+0  J4
M *E6  "I;P  J8L  *BH  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4
MG0  "I\   "A    HP   *8   "H    K    *X   "O    KP   +    "P
M    L@   +,   "T    M@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)
M  # 8@  P'X  ,";  # MP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP
M *H   "M    L    +,   "V    NP   +T   #     OP   ,$   #"
MQ    ,8   #(    R@   ,P   #/    TP   -H'  #;$P  W24  -X[  #?
M4P  X&X  -^,  #=J0  W<( _P   /\   #_    _P   /\ !P#_ !  _P 9
M /\ ) #_ "\ _  Z /D 0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\
MYP!U .8 ? #D (0 X@"- .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$
M /\ N #_ *\ _P"I /\ _P   /\   #_    _P   /\  @#[  T ]P 5 /,
M'P#O "D Z@ T .8 /0#B $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N
M ,P =0#* 'T R "% ,8 D #" )L P "I +X N@"[ -D N0#W +@ _P"T /\
MJ0#_ *( _P"= /\ _P   /\   #_    ]@   .X   #G  H X0 1 -P &@#7
M ", T  N ,L -P#' #\ Q !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8
M;@"T '4 L0!^ *\ B "M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_
M )4 _P"1 /\ _P   /P   #N    XP   -@   #-  4 Q@ . ,$ %0"] !X
MN0 G +4 , "R #@ KP!  *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"?
M &X G@!V )L @ "9 (P EP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8
M_P"# /\ ^    .D   #<    S    ,$   "X    L@ * *P $0"H !@ I0 A
M *( *0"> #( G  Y )D /P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &<
MBP!O (D > "& (0 A "1 (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U
M /\ Y@   -,   #&    NP   +$   "G    H0 % )L #0"7 !, DP ; )
M(P", "L B@ R (@ . "& #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H
M '< <0!U 'P <P") '  F !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\
MTP   ,,   "U    JP   *,   ";    D@   (P "@"' !  @P 6 '\ '0!]
M "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@
M:@!F '0 9 "! &$ D0!? *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0
M +8"  "I @  GP   )8   ".    AP   (  !0!Z  P =0 1 '$ & !N !X
M:P E &D *P!G #$ 9@ W &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8
M &X 5@![ %0 B@!2 )L 40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-
M  "@#0  E0P  (P(  "# @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ?
M %T )0!; "L 60 Q %@ -@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@
M2@!U $@ A !' )4 10"H $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9
M%0  CA,  (01  ![#0  <P@  &P   !E  , 7P + %L #P!7 !0 5  : %$
M'P!/ "4 3@ K $P , !+ #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O
M #X ?@ \ )  .P"C #H N  Y -D . #U #@ _P X /\ K!<  )\;  "3'0
MB1P  '\9  !U%0  ;!   &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!%
M "  1  F $( *P!! #$ /P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0
M>@ R (P ,0"> #  LP O ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0
M 'HA  !Q'0  9Q@  %\3  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L
M.@ A #D )@ W "P -@ R #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J
M (@ * "< "< L  F ,D )0#J "4!^P#_XGT024-#7U!23T9)3$4 $1(E ?\
MHB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,, @ ]
M!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01# "@$
M30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\ GR@
M ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X#@0
M,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *2@ ?
M"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T  ) Q
M  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P  +1 &
M "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7#E,
M%@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU  "$
M.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4! ",1
M!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$ $1)?
M ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""/
M>#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8 P 9
M% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<  P7
M;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0   =T$
M &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7&@@
M$A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<:0 %
M''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44  &Q%
M  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00 #QT+
M  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P  (7D
M "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*  !B
M20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*  DC
M#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<  ":,
M   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@3@
M5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K#@ !
M*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*   K
MH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P  5E$
M $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0  ,A
M #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   QG@
M,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<  $E3
M   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\  #D2
M   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG   -[,
M #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18   X
M50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0  !!
M%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$  #[0
M   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R6P
M)ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+$@
M2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-  !%
M\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@  'V
M !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$   5!0
M %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/[P
M3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD   YG
M   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!   & 7
M  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0  6?\
M>W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M<0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1  !M
M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX >7H
M '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]    ?0
M 'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\$@
M?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X   &6!
M  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@   (P
M  "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#   CA,
M (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(  !+
MBP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L   "<
M    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P  *(6
M  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _DP
M,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
MJ@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-  "Y
M&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG   (Z
M !.B   (I    *<   "J    K    *\   "R    MP   +D   "[    N@
M +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4#P
MU1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P   /\
M P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H YP!?
M .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+ .
MR0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P   #V
M  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9 ,L
M7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T L@#R
M +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@  8
MV0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0 6 "R
M %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F )L
M_P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $ OP +
M +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40"> %8
MG !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (< ]P"&
M /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP ' *4
M#@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %  B0!5
M (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S /\
M<P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0 "P"0
M !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !. '8
M5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L 8@#_
M &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!  T
M?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &< 3@!E
M %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_ %0
M_P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H ;P /
M &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7 $X
M5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $< _P!'
M /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P , %\
M$ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@ 20!0
M $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \ /\
MK!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4 #0!1
M !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+ #T
M4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\ IA8
M )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(  X
M1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #, 3P Q
M %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P  )4@
M  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L /  /
M #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H %4
M)@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F  "&
M*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  , #$
M$  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %( 'P!>
M !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$+0
M>2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%#0 F
M Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9< !8&
M:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0  =S(
M &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?"0T
M'0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +:0 .
M#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8  &PU
M  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H %0P.
M !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *$'D
M"!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ  !A
M.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +  X.
M#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8  Q.+
M  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@/0
M5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3#@ *
M$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)   8
MGP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@  5C\
M $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &&1$
M!!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <G0
M'+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540  $M
M  !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q   !\4
M   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP  (;(
M "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&  !"
M0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42   F
M&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K   "7,
M   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!20
M-40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M%@
M+1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+   J
M[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30  ,$D
M "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%   -!L
M #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q[@
M,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\  "!,
M   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@  #PA
M   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0  -_\
M@5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3   0
M40  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<  !%
M)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\ ?F$
M '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +60
M E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/(@
M3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD  '1L
M  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@   &(
M  !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'   6B@
M %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T  !I
M=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T   !M
M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$  &<O
M  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?>@
M4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M>@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F  !V
M-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@   18(
M #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")    B
M (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")+
MB#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H  "J,
M   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@   )<
M  "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0  G3,
M )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5   0
ME@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<   "G
M    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<  +0]
M  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@  ()T  !&?   %H0
M *,   "F    J0   *P   "O    LP   +4   "W    M@   +<   "X
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M______________________________________________\
M         0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R
M,S0V-S@Y.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK
M;&YO<'%S='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.D
MIJ>HJJNLK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>
MW^#BX^3FY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________
M____________________________  $" P0%!@<("0H+# T.#Q 1$A,4%187
M&!D:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$
M149'2$E*2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q
M<G-T=79W>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>
MGZ"AHJ.DI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+
MS,W.S]#1TM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X
M^?K[_/W^_VUF=#$      P$A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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M__________^6-        $^G______________________________9I'0
M"0P&"5*Q_____________________________\L[#A,U3%M-3%[#________
M_____________________ZE@-F"&G[:LJ;C9________________________
M_____^"7C;[E_______________________________________M^?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____Z]G*O,?__________________________________\^:@6U:1HCJ____
M____________________________Q'P^)A   %2P____________________
M___________@@SP      "Z'[?____________________________^L4Q
M     !=MUO____________________________N ,0        EAS/______
M_____________________]): @        !=S/______________________
M_____Z@U          !<T____________________________WT-
M  !4UO__________________________[GU%          !$U/__________
M_________________*ID+P(   0B-TE8SO__________________________
M_^FD:T$H/V-_E:>ZVO______________________________U;*LLLSD^O__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y;N7=V+(____________________
M_____________]N>9S8*  *,________________________________R'\_
M!0    !>S______________________________9@3D        \JO______
M______________________^>3          CD/______________________
M_____]QO&@         0??G__________________________Z](
M    ;^[__________________________X03            9.;_________
M________________[%$             5][_________________________
MN!4             2-;_________________________=!0
M.,_________________________YHEH3            (\7_____________
M____________WYM<+           #;K__________________________^^Q
M?54Y(A$' 0(1(K+______________________________]^_I9F8FJ"LO=K_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^.^G8!\^_________________________________*WA%<P#@ =K/______
M________________________THI,%0      <O/_____________________
M_______6?S8         2\G___________________________J1/@
M    +ZO__________________________\!:            &I7_________
M_________________XTD            "(3_________________________
MYUX              '?_________________________M"4
M &K_________________________?0               %OT____________
M___________]*P               $SK______________________^E
M             #SA______________________\P#                "W9
M_____________________YF*82<              "?7________________
M_______MOHE5)P           "7<__________________________[*G79=
M2CPR+2PP.4?>_______________________________]YMW6TM#3V>3_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________[]2[UO______________________
M___________GN(]J2R\5;_______________________________Y*%G- <
M    /,G____________________________6@CL         $I?_________
M_________________^V%,0           &__________________________
M_Z9"             %#A________________________[&D
M #?)________________________LR\              "*V____________
M____________>0               !"G_______________________R-
M              "9______________________^I                  ",
M______________________]&                  !_________________
M_____]\                   !T_____________________Y<
M          !J_____________________\X                   !C____
M__________________\I(@$               !A____________________
M__^YHX!7-Q<           !H___________________________ZTZZ4AGQU
M<7!R=X&4____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________]NZG8)I:=/_________
M_____________________\B393T9    '9[_________________________
M___;CDP3         &[__________________________]M\+
M $77_________________________XLJ             "*T____________
M____________PD0               .7________________________?0$
M              !________________________G-@                !J
M______________________^=                  !8________________
M______]&                  !'^/___________________^D
M           UZ?___________________Y8                    EV___
M_________________[P                    8SO__________________
M_^L                    /PO____________________\
M       *N?____________________\G                   *M?______
M______________]P                   -N?_____________________@
MG(QP54(S)AL4#PT.$AHFO_____________________________GDV-+.S,O,
MS];@_/______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O3O./________________________________2J85E2"P2
M 87____________________________QJW$\#P       $_@____________
M_____________]5_-0           !^R________________________XW4=
M              ")________________________D",               !G
M_______________________50P                !(]O______________
M______^*                   NW?____________________\X
M           7R/___________________[X                    $MO__
M_________________YP                     I?__________________
M_[H                     D____________________]P
M        @O____________________\                     =/______
M______________\3                    :/____________________]"
M                    8/____________________]Z
M    7?_____________________1                    8?__________
M____________)                   9O______________________R:R9
MB7UV<6QI9V9G:W!ZC/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^+%JI%Y87?_____________________________
MW:9W4"P,     #'$_________________________^"23A,           "/
M________________________TG =              !@________________
M_______N;P\                WXO____________________^6'
M           4P/____________________]                     H___
M_________________ZX                     B?__________________
M_YX                     <O___________________[P
M        7____________________]H                     3?______
M______________H                     ._____________________\.
M                    *OG___________________\S
M    &^G___________________]>                    #]O_________
M__________^/                    !M#____________________0
M                 ,K_____________________*P
M ,C_____________________@                    ,O_____________
M________]Q8!!04# 0       08-&,O_______________________SKX=C/
MS,W/T-+4U]SBZO______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________QVL;_
M______________________________'&HX1H33(8 !6K________________
M__________^Y?$88          !Q________________________UWPO
M           [X______________________?9 D                ,M?__
M__________________]T P                  C?__________________
M_\45                    :O___________________YD
M        2____________________[8                     ,/W_____
M_____________]<                     &>?___________________8
M                    !=/___________________\.
M     ,'___________________\O                     *__________
M__________]2                     )[___________________]Y
M                 ([___________________^E
M (#____________________8                     '3_____________
M________-@                   &W_____________________?
M             &G_____________________UPT                  &C_
M_____________________W                   &'_________________
M______]0/$9.5%E=861H;'!V?HG_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^_5NZ.+<UJ5___________________________XOXYD02$%      !2_/__
M____________________]YU6&              7P?__________________
M___E;!8                 C?____________________]C
M        7O___________________YT                     -?S_____
M_____________Z$                     $=G__________________\H
M                     +O__________________^X
M     *'___________________\,                     (K_________
M__________\M                     ';___________________]-
M                 &3___________________]O
M %+___________________^4                     $#_____________
M______^\                     ##____________________J#@
M             "+_____________________1                    !7_
M____________________@0                    OU________________
M____R L                   +L_____________________UX
M          #E_____________________\D<                  #:____
M__________________^= 0             '#A?%____________________
M____U;F\P<?.U=OAYNWT^_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________^-_/____________________
M_________^S&I8AM5#LA!P RWO_______________________]>262D
M        H/______________________B38                 9_______
M______________]F                    ,O;__________________Y4
M                     \C__________________Z<
M     *#__________________]<                      'S_________
M__________\                      %[___________________\E
M                 $/___________________](
M "S___________________]J                     !C_____________
M______^+                      7S__________________^O
M              #A___________________5                      #/
M____________________)                     "^________________
M____5                     "N____________________BP
M          "?____________________RPX                   "2____
M_________________U<                   "&____________________
M_ZH*                  !Y______________________]M
M      !F_______________________W50                !%________
M_________________VHC*S4_2E5@:G5^AY&<________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________HS[:=@VE.N?______
M___________________LLH-<.AT"        >_______________________
MQ6TI                0/____________________^#&P
M    !\O__________________Y(                      )C_________
M_________Z0                      &K__________________]T
M                 $'___________________\.
M !W___________________\Y                      #H____________
M______]@                      #.__________________^%
M              "W__________________^H                      "C
M___________________+                      "0________________
M___O%@                    !]____________________/@
M          !L____________________:0                    !:____
M________________F0                    !)____________________
MTA8                    Y_____________________U@
M       I_____________________Z(                    9________
M______________56                   $______________________^[
M+P                  ^/______________________JRD
M    S________________________\E'      <3("X^4FB$[?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________35R?____________________________K2L))W74(H
M#   2O_______________________\5]11<             $=C_________
M___________$4                    )___________________Z(,
M                 &C__________________Y0
M #;__________________]H                       ?L____________
M______\5                      #$__________________](
M              "B__________________]U                      "#
M__________________^=                      !I________________
M___#                      !2___________________G#P
M           ^____________________,P                     K____
M________________6                      8____________________
M@0                     %____________________K
M        ____________________WB(                     \O______
M_____________UP                     W____________________Y\
M                    S/___________________^A*
M    M_____________________^@%@                  G/__________
M____________>@(                 =________________________WH+
M               %3/________________________^B5VAT@(V<J[S0Y___
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________MX___________________________
MTJ-Z6#HI(QP6#@8  )______________________K%(.
M &G__________________^1#                     #3_____________
M_____WD                       #C_________________\T
M              "R__________________\3                      "%
M__________________]/                      !=________________
M__^#                       Z__________________^R
M           <___________________; P                     "____
M________________*@                      ^___________________
M3P                      Y___________________=
M        U/__________________FP                      P/______
M____________Q <                     K?__________________\#,
M                    FO___________________V<
M    AO___________________Z,                     <O__________
M_________^-$                    7/____________________^1!@
M                0?_____________________K7P
M'?______________________RDL                  /______________
M_________\M7   ,&"0Q/TY@=(NGQ___________________________U^?R
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Z]3-Q\*^NK>SL*VIJ*7____________________=?E,_,",9
M$0D"          #;_________________W8                       "G
M_________________[H                       !U________________
M__\'                      !&__________________].
M           :__________________^,                        _?__
M_______________!                        V__________________Q
M&0                      OO__________________1
M        I/__________________:P                      C?______
M____________D0                      >?__________________MP
M                    9O__________________WB$
M    4____________________TH                     /___________
M_________W<                     *____________________ZP*
M                %O___________________^=%
M /____________________^*                     /______________
M_______630                   /W_____________________IRX
M             -7______________________Y@J           &&"U%8.#_
M______________________^H8W2!CYRKN\WB^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___B,X!)0T-?4%)/1DE,10 2$O__________________________________
M____________________________Y\NWJ9V5CHF$@'QX='!L:&60________
M_________[QJ2"T9"@                 Q__________________\
M                   #__________________]"
M    W/________________^.                        LO__________
M_______.                        C?__________________*0
M                :___________________6@
M3O__________________A@                      -/______________
M____K@                      'O__________________U!<
M            "O__________________^CT                      /__
M_________________V4                      /__________________
M_XX                      /___________________[P9
M         .____________________%.                     -C_____
M______________^+                     +_____________________,
M0P                   *'_____________________D1D
M     'K_____________________\G0*                $5__________
M_____________^AT$Q\L.$538G*%F[32]?__________________________
MU^CT________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________[]_/Q[NSK
MZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/__________
M______]+)0L                     DO________________^(
M                9O_________________7
M/?__________________,P                      &/______________
M____;                        /__________________G0
M             /__________________R0P                      /;_
M________________\34                      -__________________
M_UL                      ,O__________________X(
M         +?__________________ZD&                     */_____
M_____________],O                     (W___________________]>
M                     '?___________________^3!P
M     %[____________________-0P                   $#_________
M____________AQ                   !S_____________________V%X
M                  #______________________[].       .'"P^4FJ&
MI<C________________________"?(R:I[;%UNC]____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________NX=?/R<.^NK:QK:FGIJ:G
MKO________________^^AFU;3$ W+R@B'!80"P0     %/______________
M___7!0                       /__________________-
M             /;_________________=@                       -+_
M________________L                        ++_________________
MX20                      );__________________U$
M         'S__________________WD                      &;_____
M_____________Z                       %'__________________\<C
M                     #S__________________^Y+
M     "?___________________]T                     !#_________
M__________^C%@                    #____________________83
M                  #_____________________B \
M  #_____________________RU,                   #_____________
M_________Z4X           )'31.:XS_______________________^9.4-1
M7VY]CJ"UR^7_____________________________Z_G_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Z\RYK*&9D8N&@7QX='!K:&9F:/'_
M________________844R(Q@.!@               )[_________________
M?@                       '7_________________PP
M         %+_________________^S<                      #+_____
M_____________VH                      !;__________________Y8
M                      #__________________[\;
M      #__________________^9"                      #_________
M__________]I                      #___________________^0 @
M                  #___________________^Y+
M  #T___________________H7                     #9____________
M________D1@                   "\____________________RE,
M              "=_____________________Y@N             ! I1F;$
M_____________________^Y_'0P:*#=&5VE^E:_,[O__________________
M_______GH*JYR-CI_/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________WU\.OFXM_;
MV-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_____
M____________TB41 P                    #__________________T(
M                      #__________________WT
M      #__________________[ +                      #V________
M_________]TY                      #<__________________]B
M                  #%__________________^)
M  "O__________________^O(@                    "9____________
M_______62                     ""____________________<@
M              !I____________________H2@                   !.
M____________________TUP                    S________________
M_____Y8N               5,E)W_____________________^!R$P   0\?
M+T)8<(NHR.S________________________*;VY^CIZPP]CO____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________G@TLC NK6PK*BEHI^=
MFYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4________
M_________Y(                       "M_________________\P>
M                  "+__________________M2
M  !M__________________^                       !1____________
M______^I&P                     Z___________________00@
M               C___________________U:                      ,
M____________________CQ0                     ________________
M____N#X                     ____________________Y6T#
M            _____________________Y\W               0+U!T____
M_________________]UR%      &%RI!6G64MMK_____________________
M__^\6$149'6&FJ_(X_______________________________TLWA\?______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T<G-U
M>'^0_________________^M/.C H(1L5$ L' @         C____________
M______]I                        __________________^;"@
M                ___________________(.0
M___________________P8P                      ________________
M____B@X                     ____________________L#0
M            ____________________U5L                     ____
M_________________X4:                   #[/__________________
M_[%)               8.5V!_____________________^5['@      #"$X
M4F^/L]G_______________________^[6"DY25IL@)>PS>W_____________
M________________LYZTQ=?K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________^N_GX=S9
MUM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=97F5Q
M__________________^_,1\6$ H%                ________________
M___M5@                      Z/__________________@@0
M            S/__________________JR\                     L___
M________________TE<                     F___________________
M]WP0                    A?___________________Z(W
M      4KE/___________________\MA @            PL4':>T?______
M______________6-,       #2,[5W:9ON7________________________#
M8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y_______
M______________________________W_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________W<[%O[RYMK2S
ML;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EFH?__
M________________IR8.!P(                 5O__________________
MSE                      .O__________________]'D+
M        (?___________________Y\R                    #O______
M_____________\18                "#%:A/___________________^E_
M'P          !B=+<9K"Z?____________________^G20     "%R]*:(JN
MU?S________________________3=1XF.$I>=8^KR^__________________
M____________KG*%F*S"V_;__________________________________]_O
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________[^RJJ:CH:"?GZ&C
MIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??______
M_____________YXN!@                   /___________________\-6
M                   50?___________________^=[&@             )
M-&"+M/____________________^?/P         $)4IQF<+K____________
M___________&9@\    3*D1B@Z?-]?_________________________KCC4K
M/E%H@9V\WO______________________________OG9_E*G!W/G_________
M_________________________]+8\_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?I*RV
MPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?__________
M__________^F00$           <V8X^ZX?_____________________&90H
M      0G3'.<Q.S________________________EB"\  !,J1&*"ILST____
M________________________JU V2F%[EK36^O______________________
M________TH=\F+'+Z?___________________________________]3.[?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________[>7C
MX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0[?__
M________________________G5-'24U15F!SBJ_6_/__________________
M________LE8 &C50;8NNTO?_____________________________S6\^7WN9
MM]?Y________________________________[I^#IL+A________________
M_____________________^/.Z___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________P
M
M
M        ____________________________________________________
M____________________________________________________________
M__________________________________________________________\
M  #_[@ .061O8F4 9(      _]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! @(" @(" @(" @(# P,# P,# P,#_\
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M(Y672)EUIY.*.1LE(U58Y'=BH8 ?$4^T1; ] .YERV2J>GG?;<[=&BM5KO\
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M>US7L:YJHDRCEBE3FBD9(GI8Y':>SHO!2Y)-"\1R
M
M
M
M
M
M
M          $+75U%;*.JN-RK*6WV^@IYJNNKZZHBI*.CI*>-TM15555.^."G
MIX(FJY[WN1K6HJJJ(<4\\%-#+4U,T5/3P1OFGGGD9%##%&U722RRR*UD<;&H
MJJY51$3M"JB(JJNB)Q55X(B)VJJ@PH=7'C#85@*W/"NF>@M^Y.5,9-25.XMT
M;4)@%DJ-%C<^QT;/J];F=5 [FY94?3VY'(U[)*N-7,.E>[?5_9;!]9LNVD%/
MDEU:CXI<BJDD^\%%)Q:JT,+5CFO$S%UT?K'3:Z*CI6JJ$GJKJQFK*=$D=YY%
MUY$_X*<%>OO>R#7(WCWBW5WURJHS3=O.+]G.03<[(:F\56M';*=ZM<M%8[13
M,@M%@MW,U'?5Z*""'FU=R\RJJXY\QS#*<ZNDEZRV^5]\N#^9K9*R7]"IF.5%
M6"BI(DCI*"GU37NX8XV:\=->)(Y99)G<\KW/=ZUX)ZD1.#4]@'8/H+ZT<GZ-
M=VH;O*^X7?:;+YZ*V[H8A3N21U3;XWO92Y198)'-B;DV-I4/DA3F8VKA=)3/
M<Q)&R15_L-O1<]F\M95O6HK,2N[X:;)[1&J.66G:Y4BN=$QRHQ+G;>\<YB:M
M25BNC<J<R.;$454ZEE1>*Q.T21J>CS.3^N;[X-TS$LLQO.\8L&9X?>*+(<6R
MBTT-]L%[MTBRT5SM5RIV55'5P.5&O1LL,B*K7-:]CM6N:CD5$S16F[6V^VR@
MO5GK(+A:[I205UOK:=W-#54E3&V6&:-51'(CV.3@J(YJ\%1%14*J:YKVM>U4
M<UR(K53L5%XHH*A)@?0(>KJZ2WTE57U]53T5#14\U765E7-'34E)24T;IJBJ
MJJB9S(:>GIX6*][WJC6-15541#BFFAIH9:BHEBIZ>GBDFGGFD9%###$Q7RRR
MRO5K(XHV-57.541$353\<YK&N>]S6L:U7.<Y4:UK6IJYSG+HB-1$XJ#"[U8^
M.KT<]/'WQQ[;>Y5/4KN)2++ VT[;5]+#@-%5Q2.C<V\[GU$-99I8%Y':.LU/
M>EYM$<C$7F3HAO+XAFQNV7UJV8M53;JY/"KXTH\5J(8\<@G8Y6JVNRV5D]"^
M/YJZ+0Q5ZZZ(J-1=4M?D6[.,V7GAH7NOE:W5.[H7M2C8Y%T_1:]R.B5/_L39
M?7H#6ZZF/&WZZNH9]PM5CSV#8+!ZM98X\9V7958[>9*57HL'WRW#J*BKSF2L
M;$G)*M#66VDGYG:TR(J-;BSW7Z_.H;<QU31V_(X]N,?F5[6VG TFME<Z'F18
M_K63RRS9"^=&)H]:>>EADU76)$T1+(7W=3+;RKXX:Q+/2.U1(+7S0RJW7ASU
MKE=5J_3@O(YC5_J08E;I=+G?+C77B]7&ON]WN=5-6W*Z72LJ+A<;A65#UDJ*
MNNKJN26IJZJ>1RN?)(YSW.75553IA5UE7<*JHKJ^JJ:VMJYGU%565<\M355,
M\KE?)-45$SGRS32.75SG*JJO:I;J2225[Y97OEDD<KWR2.<][W.75SGO<JN<
MY5[57B#FM=T?0/5KT66ED762)%3F8[31)H57@CTT3F3@DC4T714:YMQ]JMS[
MKMG?VUU/WE79:U8X;Y:4?HVKIFNX3TZ.5&1W"E1RK$]=$756.7E<ICS\1_P^
M-M/$)V+K-O\ )6T>/[FXJRY7O9G<SZOK789E<](C%H;C-##+5UN#Y,ZGA@O%
M"B.26..*HC:E52TTD<)64C*N)6+P>W58W_U+M.Q?/R.\Z%<1R1S,;)$Y'L>B
M.:Y$5-45-471R(Y-4\RHBF4"P7^U9/9Z"^V2KCK;;<8&ST\S%XHB\'PS,^E#
M4P/1621NT<QZ*U4U0\Y#?+9'<SIRW6S79;=_&:W$MP,#O-19[W:JR.1(IN14
MDH;O:*I\<<=UQZ^4+XZNWUL.L%91S1S1JK'HI1TL3X9'1R-5KVKHJ+[RHOG1
M4[%/LG!:<XP               "IL1S7,MO[[2Y1@66Y-A&2T.OU+(L1OUUQ
MN^T>KF/7ZK=K-5T5?3ZNC:OS)$XM3T$715]=;:AE7;JVKH*N/^QU-%434M0S
ML7YDT#XY&\4\RE9X#N/N'M3DU#FNUV>9GMMF5LU^]N6X#E%\P[)K?S/CD=]1
MOV.UUNNM)J^)KE[N5NJM1?,A]-<YBHYCG,<G8YJJU4]A4T4S*]-?CN]7.T#Z
M"R[N16+J*PZG5D<O[*6LQG<&"E:]%5E#G-CHGP5DG*YVLEUMMRG>O*G>M1"^
M6*]0V:658J>]-I\GH6Z(OUO2DN;6(O9'<*>-6O737C-%*Y?2AL/='7VH+KXZ
M?GVO'=_8,8ZNMO:1T<4W[-FQX9NQ2T39&JL5MW-QJVRTUPEY'/5TM\L]YJ9%
MY4[YC6Z$T@N]3%HDG+.W^N^:_3U/3XT4V-NE#Q6ND3JQEMV/6'-'[;;F5_<P
MQ[:[H?4\<O%PK951B4N+WE*J?&LLEFF1W<P4E6MP?&WG?2QIP3M#AV\.%YBZ
M*FIZ];7=9.5J6J[<E+/)(O#DI)^=U+6*JZZ-8_O%3BK$-O?H2\=7H!Z\)[1B
M6+[C2;-[S73ZO3P[-[VK;L0R&[7*96Q)181D25U5AF=SU%0CDIZ6@KUNTD3>
M\DH84X)/*:X4]2B(CN[>O_:Y-$5?^"OT7?"9)RZ1F0(X
M
M
M
M
M
M
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M ^1FMULT]=11=]&RH=3U#E@;4%/5PU*?H;M')VQNX/3VOSR>M#N@5R9(R)
M
M
M
M
M
M
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MS0]O#R]'EVG$YNG%.SX 4S5TW;P[/9]DE,T6A\ I>L@^EY?#Z"4S1]OK\O?
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MR6&:)[HY8W(YJJBHI-T77BG%%XHJ><BC[(\
M
M
M
M
M
M                                               &(KKB\0!V$27G
M9W8NXQS9E'WMNR_<&CDBGIL3D7O(JRQXV[1\51D\7T9ZM%6.W.U8SFJD<ZFZ
MF[U[]+975F(X/4-?>&\U/=K_ !.22.U.XMFHK<J(YLES;V/EUY:=?FMUEU6.
M55M?R<T,*_/['R)V,]+6^EWK\WL]@P)UD-36U%16UDU15UE9/-55=74ROJ*F
MJJ:A[I9ZBHGD=)+-/-*]7/>Y5<YRJJKJ=%9F2S/DFF<^665[I999'ODDEDD<
MKGR2/DU<][WKJJJNJJ215UXKQ5>*JOG!*IJ'37AK[7EQ4A'T_J\O@ )%547;
MP3V_;)?-3^KR\_F\P!3-92::\/>\_P!TE,\.FO#R\O< *2KJ;37AZ?C\O,2:
MHB[5T\OE^,X7)HOJ\P*1K8/I+IZ_+CYR2SQ]OE[/RGR"DJV'37X??0DU0SM\
MONKQ *(OMJI;I155OK8TEIJJ-T4C>',G8YKV+^=DB>B.:OF<B*4Y=K;372BJ
M:"LC22GJ8UCD;P14[%1[%X\LD;T1S5\SD12$KZ&GN5'44-6SO*>IC6.1OG3B
MBM>U?SLD;T1S5\SD13@JJ:*KIY::9O-',Q6N]*>='-7S.8Y$5%\RH=/;[8:F
MP72IMM2BN6%W-%*B:,J*=^JPS-T[.9O:FJ\KD5/,=4KW8ZBQ7*HMU2B*L2\T
M,VGS:BG?JL,S$771'M[4_.N14[4.MMXLM19KA/05"*Y8U1T4J)RLG@?JL4S=
M?,Y$T5-5Y7(J>8Z^WYU39+A/052_.9H^*314;/ _58IF>E'(FBIV-<BIVH2G
MNOZWW]/A4E:1^PGL)^82SNO5I[?R*4^Z\_U_M?<3AJ?O=_UJ>]\.NI^]WZ_>
M^Z?O<IZO=4X_OSQ^G[7#Y3\[K^M]_P"Z?BQZ^A?93\T=SZM?;7X]#D;>?Z[3
MV]/AU0^5C3T*GEZSY6+U(OL</D/E8O4OM<?E(J.\_P!=V>OR]X^59Z%]T^%B
M]E/?0XUB].FOK33[I,8;SV?/]_R3Y3C='ZO;0XUC]2+[RG&L7J5/?0G$%X[/
MG>7L%6VRM2JB2)R2+40LUE<JJ])&(K6MFYE57HY5<B/UU3FT5%^=RM[]=/6[
M"Y/;V89?ZESLAM%+K;:N=ZK)>+7 U&\KWO572W&WLT1^OSI8='\5;(XT:?'O
M\+./IUS:JZP]AL8DIMB]S+]R[JXS9Z9'6S:7<R^5;ECO%)2P-1UHP#<.NF7N
M6\JTELO3G4K'Q15MNI&5+0U\=4G)JB2(FNG]4B=JIZT\Y,SLX:UQ,0
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MK**KB@K*.IC?#-''(QS4G;'M>U',5'-7L5/+M*V(XNH?0
M
M
M
M
M
M                                                    !A\Z\^MJ
M>UNNNQVS-Z8VY.9/;MP\WM50[O;4JJ^&KQ+'ZR+1L=SY=6U]7$Y5IM5@8K9T
MD6+J3OGO-)3?6L*P^L1*A6OI[_>J61>>E7BR6U4$S=$;4JG">5JZQZ\C='\R
MME%=6Z:P0KQ[)'IYO2QJ^GTKY@85&6[A]%?<7U>R=-FTJ>CW?NZ$F!^/MVB:
M<OO+I[O _'4J>CL]'#W^(!+*B@X+PX>79V$)+3::\/+M]L IRLHN"\/B)9-!
MV\/8\O+0 I*NI.WAQ3U>_P"X2:H@TUX %&5]-V\/+3WO>)%41=O#R]!^.35-
M/<]D%$U\&G-P]/H\D)#41Z:Z>7O^6IP HVNB[?DU]STKJ2.H9V^C[GM^8 I"
MLC[>'EZ/E)+,WM^3VE +2Y[C27R@66G9K<:%'R4RM1.:>/MEI57SK(B<S/0]
M$[$52W6;8XV]T"RP,1;A1(^2F5$^=.S@LM,OIYT1%9Z'IIP15*3RZP)>J#O(
M6:U]&CI*?3@LS%T62F5?/SHFK?0Y/,BJ4!N'C#\@LSYZ%FMWMS7ST:-3YU5'
MIK-0JOG65J:Q^B1$3@CG'7/NNU-':HNBIIV*G:B\."H=?^Z5%5%1&JG!>'%%
M\Z*G L<L6BZ*B(J+HJ*G%-.WAIVH=/I+PK55JN5'-545J\%14X*BMX(U44=U
MZG>7M'[W?K][[H[I/5_Q4.'[\^;GX_\ 4CN_^%Y>T?BQZ^A?93\T_.Z_X/N?
M<.1MY_K]/;T^X?/=^A3Y6+U(OL</D/E8?5[B_*1<=Y_K_?T_,^ ^%C]2+[';
M\2GPL>GI3C[1\+%[/L*A,X;QV?..-8_1JB^A?+4XG1>K7V.TX71>KVT[/<)U
M3WCL^=Z//\OG/QBO@D;+&JL>Q55',56\%3E<U5:J*K7M545/.BJA$VVX5]EN
M-'=K74RT=PM]1'54E3$O+)#-$Y%:J:ZM<U>*.:Y%:YJJU45%5"A=R-ML*W<P
M/+]L=Q\<M^6X'GF/W/%\LQRY-D6CN]DN],^DK:61\$D-532K')S13PR1U%/*
MULL3V2,:]*BHKTZ-['LDY7-5%147L5/B73W"KX)FU$+)V-<UCU<W1SFN5KV:
M<S'.;HBN;JB]C55%1=$U0R=[9;@4.XF,T]X@1E/<8%;27JWM5=:*X,8BO5B.
M57+253?T2%RJOS%Y57F:Y$\T[Q+^@7-?#WZD;]M;=&W*\;8Y(ZLRG9'/:UL4
MB9=@4M6L<-'<:JD@IJ1,QQ*61M!>(&Q4Z]^UE5'"REJZ5S[KVNXQ7.E;/&J(
M]-&S1Z\6/T_^BY.*>HY2X9CS)B      ?;&ZKV>QZ_S#Z:W7V .W@A'Q1ZZ<
M/9]?W$.=$UX(<S6Z=O:OO'.B(B$TABUT\NW[GN'.UO8B>VOQD0QONK[Q^DYI
MX>SAY>CU$2QGF3L3M\O213&>;W5!/*:#LX?+Y<"*8WL7W$(MC.Q?-YD/IK=>
MWL3WRH*:G7@1C&>[YU]!&QQ_=7XD.8J*EI]=.!&QL[.'L)\9'1L]KXD!4M)3
M:\O#7T_'Z".CC]6OQK\B$?%'V>KWO9]:G,UO*GK\Y4]'2]G#S_ 1\;/N^M?0
MA,(H_+T>OV5/H[_=$G65G_2+F[:JA=6Y'M?D%5 W.MOWU*I3UD7S8OO_ (\D
MSOJ]LRJ@@3]#E^;'5QM2"?YO=R17&P;,[AA]=S1J^IM=0]J5]O5VC7IP3OZ;
MF7EBJHV]B\$>GS7<-%;ED\*[Q3MXO#6W:CN-KDNF<=/^97"DCW>V9EKU;1W.
MF3NZ=<QPQ*J1**P[B6>F:G<SIR07&%B4M6O)W,U-&4TKH%U[6N^DWS>RG]<;
M>.UVZ&#[RX/8=Q=N[[2Y#BN0TJ5%%6TZ\LT$K?FU5NN5*[]'M]UM\^L513RH
MV2*1JHJ=BKW!M=TH;S0P7&W3MJ*6H;S,>W@K53@^.1B_.CEC=P<U>**>E=T]
M]0FT?5-M%A^^.QV86_-MN\VM[:VU76B=W=31U,?Z'<;%?;=(J5=DR.R5:.IZ
MVBJ&LGIIV*UR=BK.F/:]J.:NJ+Y:+Z%0N 3 O2?0
M
M
M
M
M
M                                           !C(Z\>L!^VUOJMG=L
M;FU-P[S1JS*K[1O1TF$V:LA:K:.E>C',9DMXI955KD7O*&G7O41LDD+V=;M\
M=VEQVGEQ'&ZE$O\ 61<MTKH7:NLU',Q%2&)VBHVY5<3N"HO-#&O-P<YBI+:Z
MK[M.YB7]$<GSE3\XB^9/ZY4]Q 8,8+<KE5RHKG*JJKEU555>U55>.JKY_?.D
M\=,J\53S]J]NJZ^WJ29&>GCZ@3-EMX?1U]KTIZD<OOD6VD[%T7AZOS%/K1$[
M$0'S);M$7YOO:+JOM-4_'4FGL^M/ATXCE1?,@)/56_371-/:]W@04U-IKP]?
MI\E/AS/.GN?("E:ZBX+P\OC0D]1!V\/N_=.,%$W&DTUX>7N=I(:B'M33W0"A
M+C3(G-PX>UP]W4IZJB[>'YJ>H H2XP+Q737U\?DT*>JH^WV^/P^;S'$]-%U]
M(*&N$6BN[?/[)3]0SM\O+SGP"C*Z/3F]WV$\_;YR1U#>*]OW.P I*L9VIY)K
MP]Y"3S)\2_%H 6"SBPI15OWRIV\M-6O<LS6I\V&K7YSE\R(VH1>9/ZY'>HLE
MFEA2BK/OC3L1*:L>[OD:G"*KXJY>"<&U"?.3C]+F]1:?,+&E)5??&F9I35CU
M[YK6\(JI=7.71--&SHG,G]<CO4=+-_<0DQJZLRFW1*EGODSFUK6(JLHKRY'2
M/U1$1K(KBQ%D;Q7]$;)V(K4*#[OU^]]THCN_7[WW2C.Z7U_\53KI]^?-S\?^
MI'=^OWONGXL?L+[/DI^+'YE7W4^Z<C;S_7:>WI[?H/E8U]2^7K/E8O4B^QY(
M?*Q>I/:X*1D5Y[/G>_Y?(?"Q^I4]:>2H<:QZ>E/9\D.-8O93WT)K#>.SY_H\
M_E]PXUC7U+Y>LXG1^KVT.%T7J_XOR$\IKNO#Y_OG"L?HX>I?+4X'1^K7UIVG
M Z+V_6G:5'27?73YWO\ E^81%#/]5EY7<K8IE8V17*]&LT7YLWZ&CE58D<NJ
M<KM6JO#714N#M?GM9MWD]/=(UDFM-6K*.^4+7+I44#G\9F,3YKJNA55DB7M5
M=6:HU[C'=XF/0/AWB"]-&1[47)MKM&Y=@[_*]E,]K8'\^(Y[24RI#2UM531R
MUC<3RZG9][KO$UD[4IY&53(7U5)2JRO<<R=UMJXY5<KJ>31E3'K]*)5XO1-=
M.\8JZM]SSE1\/,K7)YG-<U[5];7-56N:OF5%5%,FE#6TERHZ6X4%1%545;3Q
M55)4PNYHIZ>=C9(I8W>=KV.14/,YSG",LVTS/*]N\\L-?B^;8/D-WQ3+,<NC
M&QW"R9#8:Z>VW:V5;8WR1+-1UM,]BN8Y\;].9KG-5%6_,4L<\4<T+VR12L;)
M&]JZM>QZ(YKD7T*B@BBE3D  /IK=5]7G^0_435= "-BC^3[B>LYT33@AR,;Y
MU]KY3F:W1/7YR9PQ:^7EKI[YSM;IZU4B&-\ZI[!]$Y@A[.!$,;YO/YU\O013
M&+[:^\">4\'9PT]K4BV,3VD]]2+8SW$[?6I^M35?A)]34Z<"+C9V>GS)Z"-C
M9V>GX$.?LX(5%2TW9P]XC8V>Y\*D;''V</83T^M05+24W9P\O+R\Y'1L^ZOQ
M(1\4?P^[Z_80Y6MTXKV_!]TJ>CI>SAYO+T$?&SL\M$^4F,4?EZ?7["'V531T
MOT>'H(^*/U:?$GRJ3"*/L\NSSKZD.1C?.OM?*5914G9JA,(H^SA]S[JDRBC[
M/+V_94Y#(-T.]7.3=*N=(E0M5>-J,KK*5F>8M&C99H^1O<0Y1CZ2/8RGO]KB
M=\YG,V*MIVK#)HY(98+CX-EE5BM=H[FFM56]B5]*G%6Z?-;4T^JHB5$:+Q37
M1[>"\>54S!^$;XI.?^&]O,B7!UQRGIKW(NEO@WGVZIT9455.D4:T=)N'A#9Y
M8HZ/-<=@D3O(N=E/=Z)BTLZM>VDJ:2+IWK$NJZ\KOI-^/V3:^QG);#F6/67*
M\7NE+>\=R&VTEWLMVHGJ^EK[?70MGIJB+F:R1G/&].9CVM>QVK7-:Y%1.UE-
M4P5E/#54LK)J>HC9+#*Q=6R1O1'-<FNBIJB]B\4\YZ4VWFX6%;LX+B6YFW&2
M6S,,#SNP6S*,2R>SRNFMUZL5XI8ZR@KJ=9&1S1=Y#(G/%*R.:&1'1R,8]KFI
M-$5%1%1=47BBD\.<K(_0
M
M
M
M
M
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M0.Y/FN7@JZI_6JOF]LV%2_AOGD8
M
M
M
M
M
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M(O:B)[9D!*X-@(^P
M
M
M
M
M
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MHZZG5ROIJR"6)WSF*AS%0',7,
M
M
M
M
M
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MJ!<NW6K5K?F+YM$T7C[/H*JI:/7153WCE!4C;3\WZ+>ST>@F:4?#Z*Z>PG
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M2.7F<U%_3(R5D;3X
M
M
M
M
M
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M015*1SQ<RNBF:YB\6J";'(5L
M
M
M
M
M
M            "39'?[9BF/7[*+U/]6L^-V:Z7^[5.B+]7MEGH9[C7SZ.<QJ]
MU2T[W<51.':0=QKZ:UV^NN=8_NZ.W4=37U4G#]#IJ2%]1._BJ)\V*-5[4/QS
MD8USG<$:U7*OJ1-5]Y :E.7YK==SMP<NW!O;GK<\PR.Z7Z=CGJ]M*ROJI):6
M@B<[BE-;J164\3>QL4343L,55TO%5DM^NU_K55:F[W"JKGHJJY(DGE<^*!BK
M_P!KIXN5C4\S6HGF*5<]997/=VO<KO8\Z)[")P!5]@A3YBZ>=/5Q[53VT)_;
MH_H^?RT^ ^P7PQZFU6-$3T=GM)[?F*_ML7T>">;S^CY3[9]+V/S/C!??':-%
MY.';I[_#7VD0N%;(.#>';ZE7W%[3E!?*QVQ'(SYO!-$[.*^OS_F%?V^EU1.'
ME[ZG(Q//[@*U=:52+56)IIZ./E[1/5HM&=B=GHXG("W]^H6L1Z:<%1>'K]CM
M*<N-.B([A[WR_(<3T\_I[?9!8S(H41'\/<33BNJ?"6_N;.#M.U-?8^X? +%9
M"S^R<./%4]7#WN*EOKFSZ6GI7X-4]\X7?27R\P+'W]/I^RON)Q*!N")H[R\W
MW3Y!9F^IQ>GF15^)/C*&KT^E[/Q+\IP+VK[*_""T5X[7>S\11E=\7Q'X"U]V
M_P"V>ROPE(U?8OL_&IQ/[?:^-06XN7Y[VRF*GS^W_P#5'P"AJ_L]M?A)!4=O
MM_\ 9 %(U7:[V?C0DLW;[:?  4]4^?R_J25O[?:^-3B?V^U\:@E4GY[V?C(0
M^ 2JMBYFM>B:JW@[TZ+V>XOPDMN,*/8V5$U5GS7?\%>*>X[X27U\/.ULB=K?
MFN];57AK["K[YB;\4S:-;EA>*;VVBD5U?AM7'BN62PLU<_&+W4.DLU;4O\T-
MHR%ZP-1.*NNG'@WA*',]'%/1Y=I(W,X>E/?)(^/U>TO9[1A.H;IQ3YW8FOMK
MQ(=S."^CT>@AGL]SS+Z"$>SU</?0K6VW+71.;WR%>SS>9>Q?1]TA'L]U/?(.
M1G;Z?A0KRV5_T?G^7ND(]ONI[Y!R-]Q?>4@9&?<^0N):Z[Z.B^CBJD(]OG\R
M]OLD%(WU=G!?6GI(&1GO^\I<BU5NO+\[7L[?B0@I&]OI3X"!D;YO1Q0@)&]O
MKX+[)<RTUGT>/H\_K]/R$'(WW%(&1O;Z^*>R2^1O;Z^"^R7-M-7]#CZ/+0NI
M@5R^N4[[;,[6HHD185=+J^6E551K4:^5SU^K+\WYJ(QK%:G!>*]X.EK.G7&V
M5^"5\J.J;,UUQLKGR:ODME1,OUVE:CEU5*&KE1[=-?F3:<$;QTMOM*W1/!A^
MXF"=;N$6Q\=IW4FI-L]YFP,3ZO2;@6"RI^P+*'_HLDG/E>&V>>W5"M9'!#)8
MH'*KIJQRKW5V/RI:ZVU&-U4B+-;D6KMZN=JY]'-)_=$"(O'2FJ'HY.U=)-."
M-+M4M/V</+W#N#&SLX</A4U:8V=GO?*7Z*EI*;LX<2.CC]OT_(A'Q1]GN_=7
MT(<S6Z<5[?@*GI*7LX>A/+R^4CXV?=]2>A"811]GE[:GT551TO9P)A%'Y>CU
M>RI,8H^SR]M3E8WSK[15=%2:Z<"811]GEIKYD]:DQBC[.'E\JGV5?14G8FGO
M$QBC]7EZ-29Q1^KR]&OPG*UNG%>WX"KZ&C3AP\OC)E%'ZOD_,0F<479Y>W\A
M]]O!"L:&C[/F^S]U29Q1]GE[?L^@FD,79Y>7K.=J:)Z_.5I0T?T4T7S>;X"9
MQ1^KR]&OPDVAB\O+WC[:W5?5Y_D*UM]%]'A[G;[:^R32&+LX>7I^0FL,79Y>
M7'W3F+C6*R/JG-5R+' WZ<B-^DO_ -;C5>"O7S_U*<5\R+.*:G5VBKP:GGT[
M?4GF5=>TJZQV.2X2HZ3GAI&\7R\JZRJBZ=S JIRND<J<7+\UB<5U71KN5K=.
M*]OP%U:*FC@C9%$Q&,:B(U$3WUUXJO:NOG)RQJ,:B(FGG]OU^LO);:6.".**
M&-L<<;>5C&IP:B+KY]555555RJJJJJJJJJJJ?94%.SL_-\O,<[$[5]I/C*QH
M8NSA]SU+Z@3ZF9V</>\NWXSG8G'7T%94$7T>'EZE] ,J/1SF:WK *_$JJ;GK
M</N"_56N<O.MEO#IJNF1.9RN?W%P94M73@QBQIPX:UYCE3WM(^G<NKJ=_P W
M_P"Q2ZN;[.CT=[":&Y;X"_4 [<'IFR?8^\U_?Y!L3E+ELT,TCEG=M[GTE=>[
M0C5FD=)4?>W*::[PNY/F4].^E9HW5NH[>E0F=0
M
M
M
M
M
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M^;7W9KY&)3K<*^&._P")R=V_YKJJ7*+#2T<3DTD:VL>B*J.<UPRM%=F[$
M
M
M
M
M
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MNE!*CDT1R24M4Q=?/J"-/HJ$
M
M
M
M
M
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M78<4J\#J62.5TE.S;^^W7#[9"Y>*<OWDLU*]B(JHD;VIP5%1!=PCSO>
M
M
M
M
M
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MIZT3VE\Q R)P7U+\>A 2^?\ X7RDNF\_K1/AT+IV=WT/<]SBGO$%)VN]CXB
ME3Z7LZ^[^:2Z7\][7Q%U+.OT/^I]\@I/-[9 2_GO:^(ETWQI\!=:SN^A[2^X
MNB^Z0#^SV_B4E\OY[VOB)=+Y_P#A?*76LR_1T\WPHNOQD#+PYO93WU127R_G
MO:^(ETG!43UK\1=BS+]'U?*BD%+Y_P#@_*2^7\][7O:*2V7LU_K5][\TNO9U
M^C[GQD$Y5:K7-545%U147145-%145.**BD#)JBJJ*J+P<BIP5%3LX^9=4);,
MFJ*B\45$147S\2[%F73E]Q%]Q=3)WMC>&99AN/7Q'QOGJJ&..M[I)$:RXTBN
MI:]G+*KI6HE5 Y4YE55:J*BJBHY<U.S65_LZVUQ')'R-EJZJU1TUS<BKK]]K
M8]]MN3WM<JO8LU72/D:BZKR/:NJHJ*OFJ>(MT]0],76SU#;06VCBH<9M.>56
M28134T,L=%2X-GU)29SB-MHWRHB5#+!8\AAMTCVJK?K%'(W@K51.\V+7);Q8
M;97*O-+)3-CJ%U__ $BG58)U7754YY(U<FOF5"\%%2=B<I=R*/LX>7J]:G3B
M&/LX>KR]:E2HB(FB%>62R5MQF;3T-)-53*J(K8F*[EUX(LCN#(V>M51/63:F
MII9G(R*-TCEX<K$55][@UJ>=>PG=#;ZBK=R4\+Y5YFM<J(C8V*[7E[R5ZMBC
M:O*NBN5$70Y&,5ZZ(B^T7PL&VDK6QS7F=(45K7?5*56NE37D=RRSJBQL5/G-
M5&<WF5'%5T=A?P?5/1G8O=QJCGZ\/I/^BFGJU*RHL?CC:U]7)WCU1KNXB56L
M;KW$G++*J(][M%DC>UB-T<B.:]R$8V!?SRZ)Z$[?8]"%UJ"V4-LB2&AIHX&<
M.96IK(]4T3621VLDCN'G52HH:>&G;RPQM8GG5.+E_P"$Y=7*5$QC(F)%$QD4
M2:*D<;>5NJ(C4<[SO?RHB*YRJY?.JG.UK6]B:>OS^Z31B:)ZU\D.8Y8TU77V
MD]E3Z(V-OO?"H)K SL_-]2>X"8PM[/<^-3F:FB)[I/:6/LX?#Y?F F\#>SU_
M'\:(<C$U=[''R]LJ6DC[/+3\Q03FG9V>_P"]YO<.8JJBB^C[FGQ?(">TS.S\
MSRUXD0G#@5?0Q=GM?F+ZP5!3,[/N^7I.=$T1$*TH(OH\/+U+[8*BI8^SRX_#
MV_"1#4T1$]WV2N+?#]'7U=O#WT[05)21]G#R]'I["(:FB(GEK^:5Y;8>S@ON
MII[X,CO2I7K/@%TM[G:OMV2U7(FOT:>LH+?,SAS*J*M0V5>Q$]O4K"R.UI7L
M_J)5T]AS&*GOHIML^!YE"W3I9S;%II$=/B.\5[6GC1VO=6F_XOBEPID5JRO5
MJONL5<O!K&*G9J[G4'9PG)F<
M
M
M
M
M
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MZ9))&HNO.QKM-&ZCN"3\V!P
M
M
M
M
M
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M1+HY5UXHK4]8.Z14!L>@
M
M
M
M
M
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MBIZF*#N:3\V.
M
M
M
M
M                                                           :
M2>ZEJ=B^\&ZF-OC^KOQ[<K.;&Z%&+$D+K3E%TH'1)&]>=B1K!IHO%--%,+&3
MTJVS+\IMSF\CK?DE\H58C5;R+2W.I@5J-7BWE[O31>*%)RIRRR-_J9'I[CE0
M'!;*C3EX^M/0OI]G@?M++V>7#R0XP7#MM9]'CQX>?TI\:E34DW9]P=G% 5Y;
MZ[@WCZ.'J^4J&FJ--./N^=/0ISHJ*@*NI;CHB<??U]'L>GS<2=0U/9QT7R[3
M]!-V7/A]/7U:^2D8E5P[??\ NH <<MSX?3U3U+K\&A\OJN';[_W= "05ERU1
M?G</+VN'N$NFJN"\=0"C+C<->;YWI\Y(ZFIUUX^VO:I\.=IP3VU\O."@;G7:
M\WSN''M^/V"FZNHUUXI[OEV'$"W=SK/I?.[==.*^7PE-5<VFJ:^7I +?7.H^
MEQ]/EP0IJJE[>/R?F'RY=$]G@"W]PG^DFOI^YVE.5,G;Q\O+X#A!0]?-Q=Q]
M/DJ$@J7]ON_)\0!1U;)V^7M?(22=W;Y=G9V>95 *9J7]OEY>8E,R^;VO<XK[
MX!(YW=OJU][@GNJ0$B_27T\$^#X#@5=55?6"7/7L3V_D(<_ <8 "KIQ7@B<5
M5?,%5$157@B<57U(%73BO!$XJJ^8A:^NH[70UESN-5!0V^W4E175];52L@IJ
M.CI(7U%555,TBMCA@IX(W/>YRHC6HJJ26HG[QRKV,3@U/.J)\:J4_55'>R*[
ML8G!J>=41>WVU74D-54=X]7(OS4X-7T-3XU4U;NK#>VIZB][+[F4#YTQ*U,;
MC."4<S%B6#&;9/.Z*MEAT:K*R^5L\U;*CM7Q]^V%7*V)FD"]_G]Q"7/?[OF3
MT$ND>GM>;UJ66MU J*B(WL]*$*]WNK[Q"2.\VOLJ04C^WC[*_$7!M=#IR_-T
M[.*?)Z"$>[S>9.WV2"D=[_!/8(&1_O\ O(7'M5%]'AZ.SXT(*1W;Z5^ @9'>
M]V>M2 E=[_!/8+EVFC^CP]'EZB#D=[B$%(ORJ0$KNWW$^,N;::3Z'#T>7YA!
M2+[JKJOE[) 2.]_BI+Y7=ON)\9=&T4OT>'H^+Y/N$%([M7VD^X0$CM?;7WD)
M=*[M]Q/8+I6>F^AJGH\O7V$%(OO=I 2.[?7P3R]9+Y7:^VOO(73L]/\ 1X>C
MY3NMX?%ODKNHFCJ6(]6VG#LHN,JL:BM;'(RBM*+(JKJUG>W1J(O]4J)YSM[T
M)6Z6OZ@K=51H]667%\FN,RM1%1L4M+#9T61?,SO[JQ-?ZI4,/7CAY;0X[X?^
M=6>KD8RHS[/-LL3M;7\W-+7464TN<R1Q<O#O$MF&5#N/#E:OGT+][<TR_?>-
MZ(OZ%2U#W>PYK8OAE0SOF;PTC2^8 !^M3540 $4Q..OH^,$7"WL3VO=XKI[
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M[F5TTF?U=8B\.;O8$@@TT7327CKYAVT)T9^0
M
M
M
M
M
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M1_*%WR_?7SO_ "BN/]N '^NL\6__ 'C76!_#CG'ZZC^4+OE^^OG?^45Q_MP
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M7U<W+W5LJ*S[T7B17KHB16>\LM]SET<J(O+$J(JHB]J:@9'R[(
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MM4_U>*2=SW,A[Z5SN5.&KE4 VO#NR
M
M
M
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M)L-;EU5E&95C4CY%<ETR"NH[7*]_!9G36&V4C^9431%1J:HU%476(T[]
M     \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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ML<B.:YKFJJ.:Y%U14X*AW-145$5%145-45.**B]BHOG10#Z/T
M    TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^U^\@'FB&(@
M ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M
M
M
M                                                          #"
M5XV.WZW':O9[="G@5TV&YQ=\1KI(F)S-MV<6AEQBFJ7IHY8*:X8;'&S5=&/J
ME1-%>NO2GK4L"U&+8?D\;%5]GO=7:)W-:FJ4][I&U#'2N3CW<=19FM;KP1TO
MK)/>(]8HI/ZAZM7V'IKQ]A6>^#7>HJKZ/'T&/B"9>&BDD8[S>X"JZ2KTTX_(
MJ$XAGTT74^P5)35O9HOL_=U)K%4>OY "<15^GG]OXU0C63]G'T>7I (I+EI^
M>^#XCE[]?ZK_ .D <,EPX+\Y?>3X#X=4>E?)?9U4 E517ZZ\>'H^+TD))4)Q
MX^7'W_+0 IZKKM=>.G;[?ODKFJ-=>/E\H!2M96=O'R\O<)1//V\?+Y3Y<[3V
M04C6U6NO'[OJU)+43:^7EVG""D:VI[>*^?7SDFGE]?L^7K^  I*LG[5U)-/)
MV^7L>CV0"F*J;77V_+VR53/UUX^G[J^V 4]42=OEZ?S262NX^_[7F"KHFH)/
M,_M]WXD(%[N"KZ>'E[1#KQX@ELSVL;J]S6M;\YSG+HB)Z55>"$,Y[6-5[W(U
MK4U<YRHB(GI55X(?+WLC:Y[W-8QJ:N<Y41J)Z55>"$ONUVM=AMM9>+W<:*TV
MJW0.J:ZXW&IBHZ*D@9IS2U%3.]D43$543553551.U2FZR[<^L5.JM9Q1TNBH
MYR>AO#5K5]/;[!3-?>>\1T-+S-8O!TJ_-<Y/0Q.UK5]/;[!3%?>TD1T-*JM8
MO!TJKRN<GH8G:UJ^GM]@Q/=276E=,M@N&#[/RUUFQV9):.ZYFJ/H[S>H%YHY
M:>QQKRU%FMD[>V=W)62M71$A3F1\F61%]*^S^:2)9-/0GL^2$B[WUM^'X%,<
M#+/_ %OO?"I\K)[">SY(<:R^M5]CR1%/A9?6J^\A,H+/_6>]Y:'$Z3UJOP'$
MZ3VOA.%TOK]I.TGM+:>SYOO?F^2G"Y_I7VD.!TGM>M>U2'?)^8G;[94]%:M-
M/F^]YON$.]_I]I"&?)P]">^OJ(5\GW$\R>R5C0VOL^;V:+V>;\PAGO\ =\R>
M@AGO^XGQD(^3MX^ROR%;T%L^:WYOH\Q#/?[J^\0DC^WCQ^!"#DD^XGQJ5U;;
M;]'YOH(1[^WT>=?20;W^XGOJ04C_ %^ROI7T(7#ME OS=6Z]GF(1[_/[B$%(
M_M]*]OJ0@9']OO\ J3T%QK70?1T3T<%^3S$*[F<J,:BN<Y41$:FJJKET1J(G
M%552#>Y571$U55T:B:JJJJ^9.W52 E>B:KKIP[55$T1.U57S%R+50_1T;Z.'
MG3V/;,V/1!TPR;9V=NZ6<4+XL\R6W]U9K55Q*R;$\>JVLE=WT,B(Z"_7AB-6
M='(DE- B0_-<^=JYBNC'INEV[M3=S,UH719OD-#W=FME7$K9\6L56UKWNGBD
M1'4]\N[-.]1422GI](EY7/F8:>GC)>(U2[_Y._IHV4R%*W9?!+PD^=Y/:*IK
M[9NAG-KF<V"EH*N!52Z8/AU2U5IY&O6EN5R_NIC98J:AJ'=CL-QS[V4Z5U7'
MRUD\:)'&Y-'4\+D1?G(OT9I$[?.U.':JH9"3OJ8'"N0 #Z8FKO8X^7M@ BHT
M[5]I 1L+>*>CXD[?5Q!,(F_$GRJ?;$U77T?"3JG9V?<\O2":0M[/+U(ARE14
ML?9P\O@!.(&=GM?(ASM31$*GHX^SM_,\_M><$\IV=GYOEYCE8G:OM%6T479^
M;[OJ!/J9G9P][R[?C.=B<=?05E00_1X>7J7VP5#2Q]GYGE]TB&)QU]'QE;6^
M'BGM>I?;\P*CI(^SAZ/+W/@(EB<54KNW0=G#T>;XT!4M)'V>7W>WB1#$[5]I
M/C*]ML*?-[/-YU!5%''V</+M]XB6)HFOI^ N%;(/H\/1IVK\.B JRWT[Y9(X
MHV*^21[8V,:FJN>]41K&^MSEX$6QJ\&HG%=/=4N78;=45M52T5)!)45=7/#3
M4U/$WFDJ*B>1L4,,;&ZN=))(]$1/.J@R>6*VML]EM%I9II;;;0T.J=CEI::.
M%S]41-5>YBJJ^=5U*MC;R1L8GYQC6_\ %1$-XG:S#(-N=L]O< IVQI%A6%8O
MBR+'HK9'V*RT5LEG5R(WO)*B6F=(]ZIJ]SE<O%5!-3[*]        !YP?VWG
M\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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M\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
M                                              =3>N?:Y^\'2=O;
MAM+!]8NK,.J<IL,3(UDJ);Y@]13YA;:.DT17-J+I-9/JB*G:E0J+\U5+4;XX
MN[+]J<ULT4?>526>6Z4#4;S2/KK))'=Z:&+1%5)*I]%W*>J147@JD+6Q][2S
M,3MY.9/98J/1$]:\N@-+FDJM-./W/5[9AFAF]?EY=I2(*EI:OL^=H36*;LX^
M7EYSE:[7@O;\()]!6=G'W_+0F$<_KT\O1VI[1]@FD==Z]?+M(ME0OI^3WOD
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MX:;=?@O=/U6: :09CK
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MV8 W/3("
M
M
M
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M:@ET]=V_.U\O>U^$AI)^WCKY>[[I\J]5]7EZ026HJ^W5R^_Z_,0$L_K\OC^
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M?*KHK<U8HUX+4O1.]=YOT)B\(TT\ZZN]2%O[GESY5=%;D6)BJJ+4R)^B._\
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M           'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L
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M']S+-OP[=^U^S &YZ9 0
M
M
M
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M\%[I^JS0#2#,=8
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M         :87VVC\07I1_*_I_P")C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M      >EW]B7_$%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
M
M
M
M
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MMOFD9I37#<"X,6*PTK=>7O?O'1.GN+U8[FAJ(Z7F3EE!W3)\;,H
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MGQ:!7N=DN-MGJZ>D@;Q;+>*!T3:^T(C53G>]KZ9KEY4F<NFH&!XZU
M        &TK]DMZ\JGI6\2FW=/>3WN2AVEZW+''M1<:2HG6.U46\F.MN-_V4
MOLD:R-5]PN-QFN6+TS6M>KYLE8KD1K.9G<WH?W+?A>[D6+5E0L=CW$IDLDK'
M.TACO]*DM5CU2J:\99972T;-$75U6FO!-4 ]6,S5@        &F%]MH_$%Z4
M?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0           >EW]B7_ !!>J[\K
M^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M
M
M
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MKUN=;3??.\W3OJY:>&E6?OKU<+C/'^@4[&\K'-9PUTU554#N>7
M
M                                                  *?DRS%8<HI
M,'FR;'XLUK['69/0XA)>;<S**W&K=74=LN&0TF/NJ4NU18Z&Y7"GIYJMD*T\
M4\\<;GHY[46%6NHFUK+<ZLI6W"6FDK(Z!:B)*V2DBDCAEJF4JO[]]-%-*UCG
MHWE:YR(JZJ@!4!%
M
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MX@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MHG];Z #8D.U0
M
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M.95XJB^8 ]:TSA
M
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MOJJEJ**JJ:*KB=!54D\U+4P/T1\-13R.BFB?HJIS1R,5%]: $G.
M   ]+/[$MFM7<.A+JTV\D[Q:/%.K./+Z5SDB6-)L[V?V^L]7%&Y$[_YJ;>QN
M5KEY$5^K417/5<NOAXW!\NVV<6I=>[HLW2O8JZ:<USL5K@>U%^EP^]2+IV<>
M':H!NBF0,
M
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MNM$R[4J5T:N7@ULM&Y[57S(H![D9L;
M
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MM.">VOEYR433=O'R\O=!#/?IZU7WCB)3--V\?+Y?@!P@EKWJ]=5[/,@ /@
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M3E+X@                \X/[;S^-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK-
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MM6FGJ^[=%003R1M[BF>O,J(W5--=5 ,57]+ \$K^<;N!_P"SOO?_ ,R"RO\
M+:Z>/\:[I_DKD7ZW #^E@>"5_.-W _\ 9WWO_P"9 _EM=/'^-=T_R5R+];@!
M_2P/!*_G&[@?^SOO?_S('\MKIX_QKNG^2N1?K< /Z6!X)7\XW<#_ -G?>_\
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M5CFOJ]S]PZI[6\C7U.:Y).YK=57E:Z6YN5&ZJJZ=FH!)?]83U]?SX>K_ /\
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M45U-<;374UQH:A$715@JZ.6:GE1%_J7* 5P3$
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M355*3J-W-UZQZ2U>YVX=5(UB,;)49IDD[T8BN<C$?+<G.1B.<JZ=FJJ 2?\
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MJ*US535%14X*BH <A^@
M   &$;Q:?"?L76?CE;O-LU;;?8^J7&K9!%&U):&U6K>6S6Z&.GI,7RBMK9Z.
M@H<FMU'&D=IN\\C6MC8VCJW?5NXEHN@?6=T:V[?>USYU@M+36_=ZU4D;&IST
M]'1YU04K&Q0VF[U$\D%-3W:E@:C:*MD<B(QJ03+W7=OI[5;C;>PY-3ONELC;
M%?Z>-."<K&72*-NC:>=SE:UM0QJ:12*O8G*[YNBL&$_:'[/WOW?I*>IWPW6P
M;:JDYVNJK'C%!<-Q,JA1BL6:BJ^>7%L<H*E_SF)+#75[(U^=R2?17I7M_P"%
MKN=>.XJ=Q<YQC"J5_*^2WV2GJLNO36IRJ^";]$LMGIY7IJU)(ZJJ:WMY7?17
M&]E.]UKQZOKK1!8+Q4W2VUDU%6T]R9]Y&P3T[W13,>RHCJ*]DL<C51624\:^
MG0&5W97P5^B/:A::OR;&,EWLO\"Q3)7[G7Z22S15+6Z2_5L2Q>'';#4T4BKP
MAN,=RY4_/*O$[R;=>'9TXX.L-5>;->-QKI$L<GUG,KH]UNCF:FC^YL5E9:;9
M-3/5?['6-K-/ZI5XEF[UO9FUUYXZ.>DL=.Y)&<ENIVNJ'1OX-[RKK%J962L3
ML?#W*Z\092,4P[$,#LM-C6#8KC>&8Y1:_4[!BECMF.V6DU:QB_5K5:*6CH8-
M61M3YD:<&HGF.ZMCQ^P8Q;H;/C5DM&/6BF_^U[58[;16FW0:HUJ]S0T$-/31
M:M:B?-:G!$+5UE=6W&H=57"LJJ^J>B(^IK*B:JJ'HU-&HZ:=[Y'(U.S5> *D
M)N0H/Q51$!\N<C4!#O?YU[?,GEY@2Z:;MX^7E[@(9[]/6J^\<3G:\$[/A)3/
M/IKQ\OD!#.=YD[?.OEYSX)1--V\00KG>9.SSKY>8$JFF[>/EY>Z"&>_W/A.-
MSM>">VI*9Y]->/E\H(5[_.OM(<9)YINWCY>7N AGO\Z]OF3R\P)5--V\00SW
MZ>M5]XXW.UX)[:DHGGUUX^7R@AG.\R=OG7R\YQDIFF[>/EY>Z"%<[S)V>=?+
MS E,TW;Q\OE^ $,]^OJ1/?.-SM>">VI*)Y^WCY>7N AGO\Z]GF3R\YQDIFF[
M>((9[_.OM("4SS]O'R^-5!#/?YU[?,GEYCX<[3@GMKY><E$TW;Q\O+W00SWZ
M>M5]XXB4S3=O'R^7X <():]ZO75>SS( #X        !-+-9KC?[C36JU4SZJ
MMJG\L<;>#6M3B^65Z_-B@B;Q>]=$:B'VQCI'(QB:N7RU7T(A7>VFVF:;O9I9
M-O\ ;^R5-_R>_P!2D%'1P)RQ01-^=57"X53M(:"UT$*+)45$BMCBC:JJO8BC
MO#@6"T&$6I*:+NZFZ5*-?=+BC-'3R)Q;!"KOGLHZ?71C>',NKE35=$GM/3M@
M9HG%Z_3=Z5]">AJ&U5TC=)^(=+. 1V6A2CO6?7R."ISO-6TRQS7:M;J^*UVU
M9D6HI<<M"O5E-$O*LKN:>1J22*UHKLB#MF                  #S@_MO/X
MT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6           >EW]B7_$%ZKO
MROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(                          !
MXW/VC2X45S\:[KZJ:"HCJH(]S,/M[Y(E56MK;3L_MS:KC3KJB?HE'<*.6)_H
M>Q3 ;U7RQS=0NYSXGH]J7B@B54[$D@L5IAE9[,<L;FKZT ,)IUY
M  /1U^Q"8B^BZ8>N7/%AF;'DF_.VF(LJ'5%.ZGE?A.WMPO,D,5*U?K4,T#<_
M:Z21Z=W*V1B,XQR:98?#KH5CP[<>Y<KN6KR6T4*.5S%:JV^URU"M1B?/:YJ7
M--57@J*FG8H!O!F1<       TPOMM'X@O2C^5_3_ ,3&Z)C^\0[]S+"?P[;^
MU^\@'FB&(@           ]+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S
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M99'JKY))'JJN<JJJJNJG6!SG.<KG*KG.57.<Y55SG*NJJJKQ554 XS\
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MV^H7'\PCB[RLQ&[3QI6N1C.:6HLU4B1PWJB9HJJL:-GC:FLD4:*U5 S>G8H
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MB*NNMO7?&9+N]N7>X7]Y35V;9&ZCDU1W/0P72IIJ%^K5<WYU'"Q>"JB>950
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MEIYN[O\ ?H.+7+>[A3O7N*2=O;1T[DBY7*V5\Z:*@&KX=.
M             #()X>_B?=8WAD;IP[F=+&Z%=8:"NKJ.HSS:?(I*^^;.;J4=
M&U\3+?N!@K+A0TMPFCI9I(J>Y4DM'>;>V5ZT=93JYRK=':W>+/=G[TV\87>9
M*:*22-]SLE6LM18;U'&BM2*Z6U)8V2N1CE:R9BQU$2.7NY&ZJ >I/X/'CQ=*
MOBTXA%C=DFAV9ZKL;LK;AN#TY93>*:HN%9!31M^^.7[27R1M&FXV"Q/XSNC@
M@NEI<J-KJ6*)]-4U69C8;J5PK?"@;24[FX_FU)3][=,3K9V.ED:Q/T6NL=2J
M1_?:VHOTE1K9H%X2,1JL>\#.:=CP                  "5WR^67&;+>,DR
M2\6O'L=QZUW"^7^_WRX4EILMCLMII)J^ZWB\76OFIZ&VVNVT-/)-45$TC(H8
MF.>]R-153AJ:FGHZ>>KJYX:6DI89:FJJJF5D%/34\#'2S3SS2N;'###&U7.<
MY4:UJ*JKH >=CXY/VJ_,=R[GF'2KX7N7W+"=K8&UN.;@=6MLBJ+5G6X4CTFI
M+G:MCI:ED5QP7#6L<K/V2=W!?:^1%?0+0P,945N*GJ-ZU:^[S5^%[-U\UNLS
M>\I+IG$+707*ZJO,R:#'%>C9;;;T1=/K>C:F1>,7=M1'R :.-75U5?55-=75
M-16UM;435=965<TE355=54R.FJ*FIJ)G/FGJ)YGJ][WJKG.555553',][Y7O
MEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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MQ]\RI1WAL+%?/78U-.]9*F)&-5\E*]5J:=J.7]$C:LJ@;$!VI
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M"[:<D-%?)%T;%(U&PU;EY=&3<J3 ;K)D*
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M  [A%>       &F%]MH_$%Z4?ROZ?^)C=$Q_>(=^YEA/X=M_:_>0#S1#$0
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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MVS<:D@7ZM,Q&TM#F%-3QZR55%$J]W3WN*-BOJ:5NC7HBRPHC$?'"!M8'=4
M             X:BHIZ.GGJZN>&EI:6&6HJ:FHE9!3T]/ QTLT\\TKFQPPPQ
MM5SG.5&M:BJJZ'R][8VN>]S6,8U7O>]4:UC6HJN<YRJB-:U$U55X(@!YAOVC
M[[0Q?NM?*LOZ(.CC+JBT='&)7AUHW*W%L%54TM?U/Y)9JABU$$=4UM/-!LG8
M;M J4-(U59D%1 VX3N?3_4XHL._5EU35.X=;7[=8%7/@P&AJ%@N]UI7O9+F-
M73O3G:CT1CFX]33M_0F)PJG-25VK>[:T#3_.B(
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MAZNJ,GQ^)8X6UTLCN,UVMKY&Q5*K\Z5CF2_.<LJM VR#NZ
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M,@IZ:G@8V*"""")K8H888FHUC&HC6M1$1- ?0.8
M   'G!_;>?QI^A_\G_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]
M+O[$O^(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
M        #S9_M?\ XJMLWTWBQ;PW-E<EI[KMSTZ9(N9]1%VM%5%/17[J CH*
M^T6?;_ZW2O>R>GV@L%UJVW*)'JS[_P!SEIIXF5-I:IB3Z[MZH<DOU%M+CU8V
M:TXI5_?#*IX'M='4Y0D4L%/:^=BJCFV*EG>DK==/K,SF.1'P( :3YCS
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MLJR6;NXF\]+8[-"]RT%AM*2.?#0TK51.\E77FGF<B/GDU<NC4:UH&/ M6
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M6+)$RKA;(^EJ.[<YK*NCE5T4S=5Y)6.:O% "^Q4@
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MU)1//KKQ\OE!#.=YD[?.OEYSC)3--V\?+R]T$*YWF3L\Z^7F!*9INWCY?+\
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MV(V7#[!3(U4H;/2I$^JE:WD^MW.NE=+<+O7O:FCZBJEFG?\ GGJ":'V5X
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MV[RFH6ZT..V;O.>&RV2&1[J:E;I\Q]5*KEEJ)$3]$F>JIHU&M:!C5+1@
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M>&I*[5$7GK^U4X- W>S(H
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MFFJ:F:6HJ*B62>>>>1\LT\TKUDEFFED5SY997N5SG.55<JZJ 2\X@
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M)69D<U9R,K,BO/=\E1?+Y)$QM76R:_.93,5O=T\6J]U UK55SN9S@,CY=D
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MD3ZB[8D^9WS:6_00+)<K8U[G<K(KK0P++&W@G?P*B:OFX@>CH980
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M)9ZC#J]NNG?-O\7<6R)%7@B_?^.C=Y]>73M75 /80,\(
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MV2/NU>Z16<ELI*5O(KW*[333554$:?15(
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M_;BYO=H'\%I:[*+U/1HBM8QR-HWUJTK.=(TYM&)S*FJZJ =+BWP
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M5SFW]VR._P!JAJ:FGC<KFT5SA5U+=[?JJN<OU"YP2Q(J\7(Q%\X!W'*^
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M;W7"SUS)*[&+^V+NH;Q;$>C')(Q%<V"Y4+W)'4PZKR.5KDUC?&YP&*<LH
M        5KMKGM]VKW&P#<_%IW4N3;<9MBN>XY4LD?"^GON'WV@R&T3MEC_1
M(G17"W1N1S>+535.),;1<ZFRW:V7BB<K*RTW&BN=(]%5JLJ:"IBJH'(Y.+5;
M+$BZIV 'O+X%F=DW'P;"]P\:G^M8YGF)XYF=@J=6K]8LF46>COEJGU8KFKWM
M#71NX*J<399MEPI[M;;?=:-W/27.AI+A2OX?/IZV".I@=PX?.BD10"K".
M
M                                                  /.#^V\_C3]
M#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
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MZ5$ZPV.^SMQ7(T5RI$EKO4T,,=7+IKHRUW)D%4Y417*R%S4^D >R09\@
M  #Q9?'1R2X95XP/B)7.Y.YJBEZH-Q<;C7O)I?\ P?AU='B%I;S5$DLB<MKL
M<*<J*C&:<K$:Q&M37TZD*N6MWWW5FF75[,RNM(G%SOT*@D2A@35RN7A#3MX=
MB=B:)H@!BA+)           'K0?9*]IK=MQX+>S&6T5/2P5F_&[6_N[-[= V
M5L]1<;7N3==DJ:HN'>1L:ZJ=8MG*)K%8KF+3-BXZZHF;[H?L<5IZ?<?KHVL;
M)DM\R>^5"M14<^6&[38ZQTNJ)J]::P1HFFJ<B- -E@[=
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MLK9E=W'+F5@:Y47EBD=2VN_T[5<O,C6RNHY6,;JFKY7:(NJJ!OTF38
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MQ
M                                                      'G!_;>
M?QI^A_\ )_W"_C%@,3?B)_X:;=?@O=/U6: :09CK
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MW+W-S/-9'O=!>;U4K:VOUUALE'RT%D@5%TT=%:J6%':(FK]5T34 Z&EM
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MM<UR(YKD5%34U['L=&YS'M<Q['*Q['HK7,<U51S7-5$5KFJFBHO%% .$^0
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MTT51TZ[:/B=SM;07N%5Y7-TEILIOM/,W1R-7YDT3DU[%TU35-% ,YYV/
M               /'Y^T_P!PHKGXZ/734T%1'501UG3M;WR1*JM;6VGI,V&M
M5QIUU1/T2CN%'+$_T/8I@AZQI8YNI#<A\3T>U),5B54[$D@P?&H96>S'+&YJ
M^M # :=90          #UT/LJ%FK+7X'_2I75*PK#D>5=1UYMZ1/<Y[:.#J,
MW1QYZ5#58U(YOK]AG5&HKD[M6KKJJHF<WHJIY(>G3"I'\O+5UN65$6BJJ]VW
M*[S2KSIHFCN]IG>GAH ;%!VK   +7[W;N8?L!LUNQOKN%6?>_!-FMM\VW1S&
MM16\]/C.!8W<LHO3X6N_LE1][[7(D;$U5\BHU$551"39%?:#&+!>\DNDG=6V
MP6FXWFODX:MH[922UE0K=>U_=0KHGG7@ >%MU!;VYKU*;Z[Q=0FX]7]=SS>S
M<S-=T<LF:^1].R^9QD-PR*NHZ%LBJL%KM\M>M/20MT9!311QL:UC6M36^RC(
MKAEV27[*;L_O+ED-XN-YKG(JJU*FXU4M5)''K]&&)TO*QJ:(UB(B(B( 6@)"
M         ;5?V0[HSI^HWQ-JC?K)[*VYX'T8[<W#<N.:IA946[_.]G#ZC!MJ
MJ*JAD:J)54E%/?[]12)HL-;8(GIQ1#NIT+8 S+-X'Y-64Z36S;^TRW='/:CX
MOO[<5?;K+&]JI]..-U34QK^=DI44 ]4TS2                       'C!
M^/#T?4/1!XJO5ILWCEKAM.WM[SIN\>UM%1QOBME%@.\U#3[A6ZPVADK6RI;<
M*NE[K+!'S<RZVI?G/^F[7]ZE<#CVZWJSBP4D+8+747+[_6:.-%2&.V9!&RZQ
M4T".^=W5OFJ9*9-=?[#VKVJ!B#+$@        &4CP5NK->BCQ0^CG?FMNC;3
MB%%NU:=OMRJJHJ6T]NAVQW=@J=L,YN-S25[*>:EQRQ97+=F-E5&LJ:"*1%:Y
MC7-O-T]YO_F\WDP+)9)D@H8[Y!:[N]SD;$VSWUK[-<I9N94:YE)35JSIKP1\
M35X*B* >U@;"0      !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@
M&D&8ZP            #T0?L<'A?T&-X#F/BB[L8XV3*L\FR7:/I<CNM)S+9L
M$M57]Z-U=T;1WR/C979;D=)/C-'4L2.IIZ.U72)%6GN"\V5+H(V<BI+97[RW
MNDUK;FZLL6&I,S7ZO;87]Q>KS!S(J))75<;J.-Z:/;'#,GT9>(&]N9)@
M            #QC_ !].E6CZ/?%KZR=K+%;6VS"<CW&;O5@$%/3MI;9%BN^5
MHM^Z*6JRP-1J16G$K_DU?8XFZ(C5MCFMU:B.7 !U-X5'@>^&?66FA2&W5=V3
M(;6UC49"VBR."*\]Q3M33E@H:FLEID3S=SPX<0##N6&           /7J^RT
MY7/E'@>]'L%4M1)58I<.H'%)*BH>Q_UB"AZC]V+A;$@1B(K*>BM%UIZ5J.X_
MH"KV*AG5Z,JYU;TZ8&U_.KZ*7**%7N5%YFQY9>Y8>73L9'!,QB:_U(!L'':,
M
M                                                     \X/[;S^
M-/T/_D_[A?QBP&)OQ$_\--NOP7NGZK- -(,QU@
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M/NIE5)U%X!%$G=TC[)O=2_LPR&&WT^B,I+;9=R:B^VRGA9I'%%0M:Q$8C43
M?U580W!-\\WH*>%(+=>JUF5VMK4T8M-D3/K]4V)NB(R&GNSZF%K4X-;&B)P
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M/K.)97=Z%8%75S**ZMI[W33HB)HD<U575+4XJO-$[S: &V =V@
M        #Q&?%QWKINHCQ.^N_=ZW5?U^R9-U0;MT.+U_UA*IM=AN(957X3AE
M:R5/F)'5XICE'(UC5<R)KD8USFM1RZ[F^60LRK>'<J^Q/[VFK,QOD=%+S\_>
M4%#6RV^WR(Y.&CZ*DC5$35&HNB*NFH!CM+5           'M1^!UM)4;)>$7
MX?."5<#J6MFZ:L#W KJ62-\4U)7[PP5&[U=2U$4DTSXZJFJ\Y?'*U5321KOF
ML^@W8.Z<[&_'=C-KK;(U62.Q&VW21BHK7,EOS77V1CVJYRH]C[DJ.]:=B=B
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M(UUN]@N]@J)&M7D1;!<(+A3)(Y/FI)(W(I.77151BZ:HW@!HWF.0
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M9L&*6>/N[9CUIH;11(J-1[X:&GC@2:7E1$=45"L621W:Y[E5>*@%Z"H
M            #S2_MLFUL5BZZ.E'>&"F[ANY/2W5815RL8UD59<MJ]T<MNDM
M3(Y&HZ6L;;-SZ2%[E55[F*)O!$XXBO$-LS:;<C";\UG*EVPQ]N>Y$1$DFLMY
MKIE>O#C(D-X8U5_J4:GF -+LQ^           'K ?9$JBHG\&K XIIYIHZ/?
MK?BGI(Y97R,I:=V2456Z"G8]RM@A=554LJM;HU9)'.TU<JKFTZ%WN=L%;4<Y
MSDCR;)6,15548U:N-ZM8BKHUJO>JZ)PU55\X!L\'<0
M
M                                   \X/[;S^-/T/\ Y/\ N%_&+ 8F
M_$3_ ,--NOP7NGZK- -(,QU@
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M<B(EXO\ =,@J6-7YW)C]!%04R/TX]U(_(GJB+P<Z/7M: ><D8H
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M:EM/8MQ:>GLW/*]&0P9)2RR28[,]SET_NIU1/1M1$U=+51JJHC5 /59,U
M              !C*\87KILWAV>'CU&=24]VAMV=4.&UV";)4KI8FU=WWPS^
MDJL?VYAH:>5K_KK;!=)W7NMB:G,EJM54_@C%5+/[\;D4^U6U>5Y:Z=L5RCM\
MEMQUFJ(^?(KHQ]+:6QM5%[SZM,Y:B1/_ *S ]?, >)\][I'.>]SGO>Y7O>]5
M<Y[G*JN<YRJJN<Y5U55XJIKT*JJJJJJJJNJJO%55>U57SJH!\GX
M=F^B[IMR+K"ZM.G3I?Q9E0EUWRW@P;;R6LIFH]]DL=]OM)#E.3RHNO\ <>*8
MPE9<JA41SD@I'JC7+HBUAM_B57GF<8IAM$CN^R._6VU.D8FJT]-4U,;:VL<G
M_P!;HJ/O)G=J\K%[0#W1<>Q^S8G8+'BV.6ZGM&/8U9[9C]AM-(CFTMKLUFHH
M+=:[=3-<Y[FT]%0TS(V(JJJ-:G$V0:6EIZ&EIJ*DB9!2T=/#2TT#-49#3T\;
M8H8F(JJJ,CC8B)ZD )P<X  !YSOVW7?U]ZZ@NB;I@HZQS8-NMH<_WROM'#(O
M<U%;N[F%-@V.NK6MD<Q:JU4FS5P6%%:U\<=P>NJME33%'XB63K491MYAT<GS
M;58KID=3&U>#I+[7LMM*LB:Z<\++!+R\$5$E7T@&C28XP          #VA?
M5VJ@V;\'/P\\1IX/J\=WZ=,7W5='R0LYI]]JVZ[WU,^D#G,7ZS4[AODU5>=W
M/J]$>KD38%Z9[*VP;";64+6\J3XI1WI4T:FKLEDGR)[M&JJ?/==57TKKQXZ@
M&7,OF                       :4WVV_$*6MZ*NCO/7TDCZ[&NJ.\XA3UR
M4D;XJ:ES?:?*KS64CZY8734\E;-M] ]L39&-F2G<YS7K$U68]?$0H62;>X%<
MU8JR4F95%"V3D16L9<;)6U$C%DY5<Q9'6MJHU%1'<JJJ+RIH!YL!B1
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MY45VGCYZ7"[#=LB7F:JQNK96PV.@C54X)*R6[NG9KYX-?, >KV9LP
M           #S^?MS-%1QUOAA7)E-"VOJZ7K-HJFL;&U*B>CM\O2K/0TTLNG
M,^&EFN=0Z-J\&NF>J?24Q@>(['&DFSLJ,:DKV;@1OD1$YG1Q.PIT;%7M5K'3
M.5$\RN7T@&@:8Q@          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_ (49
M)_WQ  ;/QW&
M
M    /.#^V\_C3]#_ .3_ +A?QBP&)OQ$_P##3;K\%[I^JS0#2#,=8
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M<4         TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
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M9"[1/T.OO%SMU-$_5>/&AIZENFG'F[>&B@>G89A@
M  #5?^V$[20[A>$-59TE+"^KV'ZDMFMQ6UJT_/4T]!D:9/L[5TT=2V2-]/2U
M=7N?2ND:[GBD?#'JSG;&]G2_KQL;;IL4^Y<C5DQK+;!=4DY=7LBJ_KEA>Q'H
MJ*UDC[PQ51=456IPU1%0#RIS"N           9"/"9W6?LEXG70)N6M4VBH;
M!U;;$TM_JG/IXTBQ+)=P[%BN9*DE744E)$YV*7NL:CI98XFJJ*]S6HJI=+9"
M]KCN\.V-WYTCBI<XQME4]5:G+0U=UIJ*OXO?&Q%6BJ).+G(U/.J( >W@;$P
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MGI:>)JTZJD<$$;6M3T( 5-_K]_&2_P!X3U ?IQ8_UA(S^4WOY^^EE']\4_\
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M?F(F3KPY[RO/NICTCUT5N*WFDC\R*U;W0W!_%VFKN:F3@GFXKV 'H!&3X
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M_P!\0 &S\=Q@
M
M    #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
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M[JWIS-75%9B=KB>JM^:E'!?JNH8U$=SISK71*NJ:+RIHO: ;ZIDP
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M')B.!K)QLE+4K)<;TUFG))D-PC2-)XN9.=M+$UM.Q53G[YS&R(!KA'4T
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M&-TLEQ;&5='5N6>%R8]9:5%C71(U3E1K6HC4UV]\[FZ\;S;IW!7*]LN?95#
MY>=%6EH[S64=)JCUYFK]5IV</-V:(G  QWEJP
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M:'H(MS:+8RHJD1$==\XO]>Y45RJO=45FM::\R:)HEN[&\//VJH!M;'=<
M               T _MSG_RN_P#IL_\ PCF,/Q'O_0U_ZP__ #& - ,QA@
M        'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O\ PHR3_OB  V?CN,
M
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MFZ^7LDBR/<3,+I32MY9*&6^U\5M>FB(NMLIIH+?JJ)Q7N]5\X!T/+:
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MK^*^=0"RQ3P
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MH5_<#M_X49)_WQ  ;/QW&
M
M              /.#^V\_C3]#_Y/^X7\8L!B;\1/_#3;K\%[I^JS0#2#,=8
M         !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M                   $#<[9;;W;;A9KS;Z&[V>[T-7;+M:;G24]?;;G;:^G
MDI*ZWW"AJXY:6MH:VEE?'+%(QT<D;E:Y%150XYH8:B&6GJ(HYX)XWPSP3,;+
M#-#*U6212QO1S)(Y&.5'-5%14710#R8/M)7@VTOA@]45NW+V0LM53]'74Q77
MN];844;*NKI]H,\H.YK<PV7K+E*LZNM-*RL;<L9DJ'MJ)[1)+2+]8EM=3538
M0>K;8-FSF917?':=[,"R^2HJ+-&B/>RQ7.+EDK\?DF<KM8&)(DM&KU1SH%5G
MSEA>]P&MH=20          #L3TD=2N>]'74WL9U1;8U#H<UV.W*QC<"U4RU$
M]+2WRELUPC=?<3NLM,^.=UAS+'Y*JTW&-KD66AK96:IS%5X-EUSP+,,;S*SO
M5MPQR[T=TA9S.8RI93RHM313*Q4<M-7TJO@E1%3FCD<GG /<=V/WAPGJ%V9V
MGWXVUN#KIM]O-MSAFZ&%5\C$BGJ,8SK'K?DME=5P(YZTM<R@N3&SPN7GAF:Y
MCM'-5#8TQR_6[*<?LF2VB59K7D%IM]YM\JIHY]'<J6*KI^=NJ\DB13(CF]K7
M:HO% "Z1.0    #3"^VT?B"]*/Y7]/\ Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M           #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
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MBH8ZIH9J>:6GJ(I()X)'PSP3,=%-#-$Y6212QO1KXY(WM5'-5$5%310"!.,
M                              [-](W1SU']=.]>-]/_ $O;7Y!NAN/D
M<C97TEJIUBLF+V-E1!3U^79SDE0D=FP[#[2^I8E3<:^:&!KY(XF*^>6*)]88
M-@66;D9#28QAMFJKS=JM4560-TIZ.G1S6R5URJW:4]!00*].>65S6HJHU-7.
M:B@>JCX(G@#[#^$UA<.X65S67>GK2R^RLILZWGGM<;K+M_25L,K;AM_L;2W&
MD9<\>QE8JA8+C=9>2ZY YBOF;2TJPVZFS3=.W3'C6R-O;=:UU/D.X-?3HRY9
M Z%%I[6R1KDEM>.,E8DU+1JUW++.[2:J5-7<C.6)@&P8=H@        #P)LL
MOO[*,IR7)?JOU']D607F^_4N_P#K/U/[[7&IK_JOUGN:?ZQ]7^L<G/W;.?37
ME371-9&NJ?KM;65G)W?UNJJ*GN^;G[OOY7R\G/RLY^7FTUT37T $@(4
M                                              V/?LH'^VUZ<?P
MZB/XCLX.V71+^,/BG_ZKRK]KMQ /6[,XP    !YP?VWG\:?H?_)_W"_C%@,3
M?B)_X:;=?@O=/U6: :09CK           /7Z^RX_["CH9_Z3/_OA]01G:Z-?
MQ;=N/_+#]OF4 &?X[/                   &@']N<_^5W_ --G_P"$<QA^
M(]_Z&O\ UA_^8P!H!F,,           ]7K[(;_L;<+_* WV_5RUF;+H5_<#M
M_P"%&2?]\0 &S\=Q@
M
M         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M         >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
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M$0           >EW]B7_ !!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("
M    >*CXW5OK;9XNWB+TU?3R4L\G5IO!<&1RHB.=17;**NZVZH315_0ZRWUD
M4K/2QZ&O=U$Q21;Z;K-D:K'+G%]E1%[5CFK'S1.]A\4B.3U* 8M2S
M    !Z>/V*:MHY/"_P"H2VLJ875])UZ[CUM31MD:M1!1W#IZZ8X*&IEBUYF0
MU4ULJ&QN7@YT+T3Z*F8CP]I(UV<RF)'M65FYEVD?&BIS-CEQ;#VQO5.U&O="
MY$7SJU?0 ;@YWP                       ,?GBS310>%AXE;YI8X6.Z!.
ML.%'RO;&U9:CIZW#@@B1SU1%DGGD:QC>USW(B:JJ%K][W-;LONZKE1J?YL<\
M;JJHB<SL6NK6IJOG<Y41/2J@'B%&NN             >[)T96>BQ[H^Z4;!;
M6R-M]CZ:]B[/0-FD665M%;-K\6HJ5LLJHBR2)! WF<O:O$V2MOX(Z7 \)IHM
M4BI\1QN"-'+S.[N&S44;-5\Z\K4X@'90JX       H/<[=';?97 LGW2W=SO
M$]L]N,+M<]ZRS.,XOUMQK%\?M=.B=Y672\W:HI:&EC5SD8Q'/YI)'-8Q'/<U
M%EEXO-IQZV5EYOMRH;/:;?"ZHKKC<:F*CHZ6%O;)-43N9&Q-5T35=5541-54
M T6/%(^V.T%KFR3:'PL\/I;W4,;<;14]6&[F-U+;5#*J.IXKOL_M%>XJ:HN#
MHM>^IKCEL$</.WDELDT:H]<;V\O7O%"ZKL6S% RH<B2P/S>^4C^Y:[BUL]AL
M50UCI=/I,EKFHW5-'4[DX@&A[O9O?NWU'[IYEO;OKN!DFZ.Z^X-T^_.89SEE
M<M?>[U7-IX**G[V1&QP4U'04%+%34M-!'%34E+#'##''%&QB8U<BR*^99>J_
M(LDNE7>;W=)N_K[C72=[45$B,;&WF71&LCBB8UC&-1K&,:C6HC41 "UA)0
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ML@_68 ?T)CK[_G7='_\ ?.]'^BT?ZO'<W_';!/\ C9!^LP _H3'7W_.NZ/\
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MFQBZ45MMUXIF4EH==?K;JBY4,M#&]4K+;3PK"QD[E7YZ+KIIKV &ZN9"0
M #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\ PTVZ_!>Z?JLT T@S'6
M >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<?^6'[?,H ,_QV>
M     - /[<Y_\KO_ *;/_P (YC#\1[_T-?\ K#_\Q@#0#,88          !Z
MO7V0W_8VX7^4!OM^KEK,V70K^X';_P *,D_[X@ -GX[C
M
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MMK-I]L*MC7-95;>854L:_3F:V?&[9*UKM%5.9$=QT734 [M%PP
M                                  #S@_MO/XT_0_\ D_[A?QBP&)OQ
M$_\ #3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=
M&OXMNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8
MP_$>_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O
M[@=O_"C)/^^( #9^.XP
M
M           !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M        #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                      /)L^UO6.AM/C/[KU](DB5&3[,;!7RZ*]S%:ZNI
M\"IL:C6%&QL<V/[VX]3HJ.5R\Z.7714:F$7KCIXX.H&]RLUYJS'\8J)M=-.\
M;;&4B<NB(J)W5*WMUX^X :S1U!           -C?[*)FE3BWC<=--C@69(MR
M,&ZB<+K$B9"YCJ:AV'S_ '$:E0Z14?'#];P*)46/5_>(U%^:KE3MAT3W!U'U
M$8C3-YM+M;<KM[^5&JBMCQJYW5.?7BC>>V)V<==/-J >N"9R     #3"^VT?
MB"]*/Y7]/_$QNB8_O$._<RPG\.V_M?O(!YHAB(           /2[^Q+_ (@O
M5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!     /*\^V,;6RX+XMMMS9M-R
M4F]72YM#G'UQC')%/<L=O6>;65E-)*K6L=64M#@%&Y[45RMAFB5?I(AA>Z];
M*ZV[XPW'DTCR'#;%<>\1%Y72TE1<K+(Q5TT61D=LC54\S7-](!JE'2@
M      WL/L/6Y4=NWC\0/9^2;67,=L]B=RJ2G=J[ECVURG<3%[A-#K,C8^=V
MZ]*V72-5?RQZN3D1'9)/#HNZ17_="PJ[C7V?&[NQJZKHEHK;K1RN;\[1NJWM
MB+PXZ)QX 'HD&50                       US?M6>Y,> ^"?U)69*KZG7
M;KYIL)MM;9&SN@FED=O+AN>W2E@Y7M67ZYCF!UL4K/G(ZG=)JFFJIU1ZUKNE
MKZ><MI^?NY;W<,9M$*H[E<JK?Z"YS,;HJ<W>4ELD1R>=JJ >1R8-0
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MA+6MGWQW6HU:K$?G.07%C51$Y8[Q7RW>)&HC(T2/NZY.5-.#=.*]J@8P2S@
M         ![6O@FY8[-/"-\.:\/J9*I:/I$V5Q-)9::*E<UN!8=;L%93)%"R
M-CHZ-F.)"R14YYF,21RN<Y7+L*=/%<MPV,VHG5ZO[O!<>H=58UBHELH(K:C-
M&HB*D:4G*B]KD35=54 RAEY
M        #S@_MO/XT_0_^3_N%_&+ 8F_$3_PTVZ_!>Z?JLT T@S'6
M    >OU]EQ_V%'0S_P!)G_WP^H(SM=&OXMNW'_EA^WS* #/\=G@
M         #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\ ,8 T S&&
M   >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #9^.XP
M
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M1R/2.+*K%?\ &WO<J(WF6E9?:9CE5>V:LL4;&^E[D0 ]9TS>@
M           &DM]MMWMCQ[I%Z.>GB"N[FMW4Z@\JW8JZ2&H='-4V?97;ZKQA
M8ZN*-Z++;WW7>RGE1LB*QT],QR?.B16X\?$0R)*7!<"Q5LG+)>LIK;W(QKM'
M/@QZUOH^5[475T2SY"QVB\%<Q%[4 /-P,2H          !G[^S#;*2;T^-+T
ME]_0NK;#M,_<K>O(GM9*Y*"/ ]MLG7%*YZQJU&-CW'NED9JY4;K(B+S*J-=V
M=Z.\>7(>H+!^:-9*:QK=\AJET<O=I;+36?4I%TTT1+M-3IQX<?/V 'K^F=L
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MJ8]4UCJ8*"FAA14[8ZJ1/. >BX96@
M           #R7/M9^T#ML/&?WDR=M)]3HM]]J-B]WZ"-E/%34TK:? Z/:"Y
M5=,V%K&R?7;]M+62SR*G/)5/E<Y5555<('6_8EL_4#?ZQ(^[CR6R8W?8D1K6
M,<C;9'8II&(U$1>\J;'(KE[5>KE4 UJCJ,           >O)]EHW+AW%\$OI
M1HUG;/=-M+MO?MI>E;P2*:T;VY[?K) K=/FNBP_);8B\5YE^=PUT3.GT97=M
MUZ>,)CYD=-:)\BM%1I^==!D5SJ:=NGI2@K(=?3V@&PH=I0
M                              #S@_MO/XT_0_\ D_[A?QBP&)OQ$_\
M#3;K\%[I^JS0#2#,=8          !Z_7V7'_ &%'0S_TF?\ WP^H(SM=&OXM
MNW'_ )8?M\R@ S_'9X                   T _MSG_ ,KO_IL__".8P_$>
M_P#0U_ZP_P#S& - ,QA@          'J]?9#?]C;A?Y0&^WZN6LS9="O[@=O
M_"C)/^^( #9^.XP
M
M       !YP?VWG\:?H?_ "?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
M    #TN_L2_X@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M                ..::*GBEGGEC@@@C?---,]L<4,4;5?)++(]6LCCC8U5<
MY51$1-5/QSFM:KG*C6M17.<Y41K6HFJJJKP1$0 \.SQ+NH^EZN_$!ZP^I"UU
M[KGC>Z_4%N3D&#UKT<CY=N*;(JNS;:L=SLB=S4^ VNVQKJUJZL[$[#7.W=RQ
MF=;H9YEL,BS4E[RB[U5ND775;2RJDI[0BZHBZMMD,2=B=@!T>+<@
M  &?;[,!C'[*/'&Z)(Y:6HJ*&QU&_63UTE._N_J?WBZ9=Y:NU54[NWZO^R'Z
MG&Y.//WB-[%54[.='-']=ZC=NT<Q[XZ9^35DBM73N_JV(7]\#W+_ %'UKNT7
MTZZ 'L!&=P     TPOMM'X@O2C^5_3_Q,;HF/[Q#OW,L)_#MO[7[R >:(8B
M          #TN_L2_P"(+U7?E?U'\3&UQEW\/']S+-OP[=^U^S &YZ9 0
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MRO35$7@;(5'5TUPI*6OHIF5%'6TT%725#->2>FJ8FS03,U1%Y)8GHY-41=%
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M,L%V?;6V2RR,>Z.>*Z7^>*TP55,]KF*E1;8JI]4WC_VCS]B@>+L:_(
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MJY%;&4:,C:JZ]W'48Z]RZ<$=+Q[0#=I,AP
M                  !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;=?@O=/U6
M: :09CK           /7Z^RX_P"PHZ&?^DS_ .^'U!&=KHU_%MVX_P#+#]OF
M4 &?X[/                   &@']N<_P#E=_\ 39_^$<QA^(]_Z&O_ %A_
M^8P!H!F,,           ]7K[(;_L;<+_ "@-]OU<M9FRZ%?W [?^%&2?]\0
M&S\=Q@
M                                                          #S
M@_MO/XT_0_\ D_[A?QBP&)OQ$_\ #3;K\%[I^JS0#2#,=8          !Z7?
MV)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
M        &OG]I4\1N@Z /#;W%LV,WV&@W]ZKJ&_]/^S5#3UOU:]VZWY%:'4N
MZ^Y%"R&6*O@AV_P:YO9!6P__ &G?KK:N9425#J[U<[L1;8;27:GHZEL63YM'
M58O8(VR<E1%%5P<E[NT:-5)&MM=MF5&R-^A4S0Z]H!Y"9@I
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M<T5*_'+W<K+4KIRMDDMU7+3=_'Q5%AJ&QH]BHJHYCD5%5% +'%.
M  'K??9;>N.#K"\*[;'"+]>)+ANKT@UB]..;0U=0^:NFQ3':2*X;-7QC99)9
MOO7-MK5TEHCD<[]$K+'5Z(C6HAG'Z,]QFYYLO9[=4U"RWK!)/V)W%LCU=*ZB
MI6)+8*E$<JN[EUH>R!%5>,E,_P! !L=';$                   H7=#<G#
MMF]M=P=W=Q+Q#CV ;783E.X>;7VH170V;$\,L==D60W.1K?G/;0VFW2R<J?.
M=RZ)Q4EMYN]!8+1=+[=9VTMLLUNK;K<:EW%M/0V^FDJZJ943BO=P1.73M70
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MEO-'4R1(J\7SQ0QIQ<@!Z=AF&
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M #/\=G@                  #0#^W.?_*[_ .FS_P#".8P_$>_]#7_K#_\
M,8 T S&&           >KU]D-_V-N%_E ;[?JY:S-ET*_N!V_P#"C)/^^( #
M9^.XP
M                                                         !YP
M?VWG\:?H?_)_W"_C%@,3?B)_X:;=?@O=/U6: :09CK           /2[^Q+_
M (@O5=^5_4?Q,;7&7?P\?W,LV_#MW[7[, ;GID!
M    .O?5-U3;%]%^Q>>=1W4=GEKV[VIV[M;KA>[W<'++5U]7*O=6K&\;M46M
M=D669%7*VEMUNI6OJ*NH>UK6Z:JE+9IFF-[?8W<\LRRYPVJR6J%9:BHE7626
M1?FP4E) W]$JZZKDT9%$Q%>]ZZ( >.KXOGB@;F^*[U@93U"9?3W#%]N+)3R8
M1L'M945C:B#;C:VWU]556ZGK6T\CZ"IS3)JFH?<;[61\W?5DJ0QO6DI:6./
MMOMO'>-[,[K<IKVRT=IIV+;L9LKI.=MILL4KWQ,DY56)]PK'O66ID37FD=RH
MO(QB(!BU+,@            'H=_8A^GJIMFU_7#U4W*WR)3YCG&VFPN'W&2-
M6-1-O[)=\^S^"G>YB++'52[B8]SJURM1]-IVHIE0\.S%GPV;<;-9HEY:^XVC
M&:"94T3_ ,%T\]SNC6*J?.1[KK2Z\=-6 &]Z9*     #3"^VT?B"]*/Y7]/_
M !,;HF/[Q#OW,L)_#MO[7[R >:(8B           #TN_L2_X@O5=^5_4?Q,;
M7&7?P\?W,LV_#MW[7[, ;GID!       /,3^V/\ 0X[9'KHV\ZR,4L_U;!.L
M'!V4&7U-+3Q-I*3?#9VAL^-7U]0E+&R*A_91MW5X_50]ZG>UM;27*9'/5LG)
MAYZ]]N5QW<BU9]10<EMSRW)%7/8UJ,9D=AC@I*E7<B(D?URU/I7MYOG22,E=
MJNBZ :>9T-           -@7[-]XGM%X:_B!6!VY60_>7IGZF*.V;-;Z5-94
MK!9<3GGN3JC;3=JXM56Q-CV\R>LDAK*B152EL%XNDC6OD1B':#I,WBCVCW0I
M5N]5]7Q#+XX;!DCY'JVGHG.FYK1?)4X-1+562*V1R_0I9YE1%70 ]?%CV2,;
M)&YKV/:U['L<CF/8Y$<US7-54<UR+JBIP5#.NBHJ(J*BHJ:HJ<45%[%1?.B@
M'T?H                !IJ?;!_$JH-BNE/&O#ZVYR"%N[?5:ZBR7=F"BEUK
M\3Z=L3O3*J*FJG,Y):&JW6SVSPT5.K7.2:U6>[0S,1D\2NZ"=>&[D6-X52;7
M6FJ;]_,U6.KO;8U_1*'%:*H1[6/5-%C?>KG V-NBKS003M<FCDU \S(Q!
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MBFBD:CXY8I&*YDD<C'(K7(JHJ+JAW_:YKFHYJHYKD1S7-5%:YJIJBHJ<%14
M.0_0                                      "C]P\#QC=/ ,XVQS>V
MQWG#-QL/R; \NM$VG=77&,OLM;C]_MLNK7)W==:KA+$[5%31W80%UMM'>K9<
M;/<8DJ+?=J"LMM= [LFHZZGDI:J)>WA)!*Y/; /#&ZP>F_*^C_JFZ@.E_-6U
M#LAV+W8S3;F>NJ(/JRWVW8]>JJEQ_*:>%%5&V_+<>2EN=*J<'4U7&[SFN%GF
M)5N"9GE&'7!'+58W>[A:72/;R?68J6H>REK&M_\ K5=2\DS/2QZ '7 I,
M      JC",URO;;-,0W%P2_7#%LXP'*+!FN&Y/:9?J]UQS*\6NU)?,=OULG5
MKDAN%HN]!#40OT7EDC1=",MUPK;1<*&ZVVIEHKC;*REN%OK('<L])6T4[*FE
MJ87<>66">-KFKYE0 ]KGPIO$"P;Q,>A_9GJDQ2IM=/E%]L<&,;T8?;IVO=M[
MO9C-)24FX6*34RS355);WW*1MQM"S\LU38KA15+FM[[1-A793="W;O;<X_F=
M$^%E94TS:/(*")R*MKR*C8R.Z43F<SGLB694E@YOG/II8WK]( R+EUP
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M;]7+69LNA7]P.W_A1DG_ 'Q  ;/QW&
M
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M[*PWVGB1\V&Y1:KK4/1G,]MLN,=38JEK=$5R-6MN-*]WF1L>J]G #ROS"^
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M
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M999Y9)YY))III'RS32O=)+++(Y7R222/57OD>]5555555750"#.,
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M6XS;<SQ?(,3N[.>VY%9Z^SUFB(KV0U]-)3K/%KIRU%.YZ21N145KVHJ*BIJ
M>'IU6=->Y71YU'[S],&[UM=;-P]D\^OF#7]$AFAI+HVVU'/9LGLZ5#6RS8[F
M%AGI;K;)E32HM];#*G!Z&NAFN(W? LLR##K[$L-UQVYU-MJOFN:R9(7:T]9!
MS:.=2U],YD\+OST4C5\X!U^*7
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M_84=#/\ TF?_ 'P^H(SM=&OXMNW'_EA^WS* #/\ '9X
M  T _MSG_P KO_IL_P#PCF,/Q'O_ $-?^L/_ ,Q@#0#,88          !ZO7
MV0W_ &-N%_E ;[?JY:S-ET*_N!V_\*,D_P"^( #9^.XP
M
M                                    !YP?VWG\:?H?_)_W"_C%@,3?
MB)_X:;=?@O=/U6: :09CK
M              /IC'2.:QC7/>]R,8QB*YSW.5$:UK415<YRKHB)Q53]1%54
M1$555=$1.*JJ]B(GG50#UNOLSWA3U'AP=#E+G6ZV-.L_51U7ML.Y6[5+<8'Q
M7G ,+IZ.IDVJVAJ8IFQR4%=CEGNU1<[Q Z*.HAOEWJ:29TK*&G<W.-TA[*OV
MFVY9<KW2+!FF;?5KO?&2M5*BV6]D;ULMB>CM%CDI()W33M5$<VIG>QVJ1LT
MV/#MB       :87VVC\07I1_*_I_XF-T3']XAW[F6$_AVW]K]Y /-$,1
M       !Z7?V)?\ $%ZKOROZC^)C:XR[^'C^YEFWX=N_:_9@#<],@(
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M"*-B+WM?8.9ROX<TE(YWSOT"-C@/-$,1
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MH_7L=5NCT5>ZD: >F(9>@        #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
MPTVZ_!>Z?JLT T@S'6           >OU]EQ_V%'0S_TF?_?#Z@C.UT:_BV[<
M?^6'[?,H ,_QV>                   - /[<Y_\KO_ *;/_P (YC#\1[_T
M-?\ K#_\Q@#0#,88          !ZO7V0W_8VX7^4!OM^KEK,V70K^X';_P *
M,D_[X@ -GX[C     &-CQ(_%AZ-/"QVVHLZZH,]J(<ER:GKY-M]FL(I:3(MW
MMS9[=R-J_P!B^,SU]LI*.ST4LC&5-WNE7;[13R/9$^I2>2**2TF[6]N ;+VB
M.Y9E<WMJZQDBVG'[<QE5?;PZ+1)/J=&Z6%D=/&Y41\\SXH&*J(K^96M4#3YR
M#[5'XN?6MEM\QKPP?#DIZK'*"H=12UM#MCN[U4;A6A*B*2.AN-]NV#IB&WN(
M]XV1*ET-=:ZN&%S6HZHDC:]9.A]5UH[Y[A5U31[.[4,?21N6-9([/?<TNL',
MU4CEJ9[=]0M5#JB\_+)"]K=$U>J:Z@0MR\:_[55TW0KGF^GAY5>4X!2TM'<;
MW+E71?NW#CEHM,M.VKGGN.3;3Y/9G8O5?5:A$<^Y3.92U#$9+#S-DB=\2]0O
M6GB3?OGDFUCZVUL9'+4K6[?WQM)! K$D<Z6LLE93K1OY'\5E<J,>FCFZHK5
MS ^&!]K"Z,>MG),:V9ZF,<DZ+]]\BJ*>TV"LRC)Z;)-@\XO<[HZ>DMUHW/FH
M;#5X1?+O/S.AH<AH:6A:YT=-#=:NJDCC???9SK;V_P!PZNDL&7TB[?Y+5.9!
M2R5E8RKQFXU#E1C(H+PZ.F?;JF=VJMCJHV1IP8V=[U1% VMCNN
M
M                             ><']MY_&GZ'_P G_<+^,6 Q-^(G_AIM
MU^"]T_59H!I!F.L
M        W&/LK_@EUO5ENY9O$+ZDL1D_DQ;%Y8VHV4QJ_P!"B6_?C>O&*[GC
MNZ4=4Q4NVV>T=WIFRUDJM^J7/(8HJ!'3QT5VIF=]NB_IXDS>^T^Z>6T*_L.Q
MNNYL>HZJ/]"R7(:.35)^[>GZ/9['.S61=.2:J1(M7)'.Q /3@,P0
M!IA?;:/Q!>E'\K^G_B8W1,?WB'?N983^';?VOWD \T0Q$           'I=_
M8E_Q!>J[\K^H_B8VN,N_AX_N99M^';OVOV8 W/3("           :2GVLCP7
M'[ZX#6^)GTUXDZIWCVGQV&DZHL2L5$LE=N5M%8*2."V;J4M+3:/J\NVEMT'<
MW1>[DEK<8:QZR,2SQQSX\.MSI]7)+9)N_B-"K[_9*5L>94--'K)=[%2L1L-Z
M8QG%]=8XF\LW!724:(NJ=PB. \W(Q+
M         &\)]EL\!BNWARO#/$PZP,+DI]G<,ND-_P"E7:[)J%\;MU<TM-1'
M-;-ZL@MM7$G/MOAUPB[RP0O1/OW=X&U:_P#@^DC;<LB_1GTT27ZMM^[V>6]6
MV&WS-JL*LU9&J+>KA ]'0Y#50O3C::"5NM*U?_MB=J/_ +$Q$E ]'0RP@
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MLE/2[BX]2,=71M5(X\DM<:1PI?Z.)=.2I9*Y&5L+=6LD<V1FC).2,#9@.W@
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M>][U5SGN<JJYSG*JJYSE7557BJDL555555555=55>*JJ]JJOG50#Y/P
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MY9'*KY9'.>Y5<Y54"[1/         #S@_MO/XT_0_P#D_P"X7\8L!B;\1/\
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M7WRRI?JIU!8[C;)\6DU5M5)>K)7.8E,B*Z58>9O!($50/09,HH
M
M                          !YP?VWG\:?H?\ R?\ <+^,6 Q-^(G_ (:;
M=?@O=/U6: :09CK
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M,1           !Z7?V)?\07JN_*_J/XF-KC+OX>/[F6;?AV[]K]F -STR @
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M!#2TE+#%34M+31,@IZ:G@8V*&""&)K8X888VHUK6HC6M1$1- ":',
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MZ)(]%>YK$CA:YRI'''&C6- L$4P
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M5YFQ2/1.2EN]+&Y$J*=='-=\YO-&YCW 8FRR(
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M_<+^,6 Q-^(G_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_I,_\
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MUXFPC(HT8SE5'UU!&Z65?S\E2Y55550#T-S*<
M
M              ><']MY_&GZ'_R?]POXQ8#$WXB?^&FW7X+W3]5F@&D&8ZP
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M553'@][Y7OEE>^221[GR2/<KWO>]5<][WN57.>YRZJJ\54 ASX
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M4.1P0M5M#4IJC6SHB4TZJG*K7JL30-?8ZN@
M     &=KP<_ 6ZIO%CS"ARNDI;ALOTC6.\+2YWU%Y%9Y9*2[OH*IL5TP_9^S
MU3Z3]G^:)R/BFEC>VTV=S56MJ&S+!25/9/83IGS/>ZOCK6,EQ_!J:?DN65U=
M.Y8YUB?RS4%A@>K/OI<$T5'.1>X@7^R.1W*QX'JR=$G0UTU>'KL+C/3KTN[?
M4.$8+86MJ[O<Y64M9FFX>4RT\-/<\\W)R>*DI*K+,RO#:=C9:F5K(J>GCBI:
M2*FHJ>GIHLUFW>W&([6XS1XIAMKCMUMID1\\RHR2X76M5K6S7*[5B,8^NKYT
M:FKU1&M:C6,:R-K6- [=%<@            'G!_;>?QI^A_\G_<+^,6 Q-^(
MG_AIMU^"]T_59H!I!F.L           ]?K[+C_L*.AG_ *3/_OA]01G:Z-?Q
M;=N/_+#]OF4 &?X[/                   &@']N<_^5W_TV?\ X1S&'XCW
M_H:_]8?_ )C &@&8PP          #U>OLAO^QMPO\H#?;]7+69LNA7]P.W_A
M1DG_ 'Q  ;/QW&   -#'[<+LY>J[!/#^Z@:&CF=CN+9=OILYE%>O>NIX+UGM
MFV]S; Z-NC>YAFJJ';?(WKJO-(V%-$T8IC1\1>P5$EMVORB.-RTM'79)8*R7
MBK&U%SI[7<;9'_4M<^.TU:^E4;Z@#=.Z4M_,8ZINF;8/J/PVNH[ACN]VT>!;
MET,M"]'14TN68W;[M<;3,SF<^EN%CN=1-155/)I+355/)%(C9&.1,@V$Y-1Y
MIA^,99021RTF16*V7>-8UU:QU=213RP.3559+33.=&]B_.8]JM7BB@'DT>#1
MT";&>)3XK63],'4169Y0[;W6U[_YE53[<7^W8UDR7?$*^6KM38KI=;#D=(RC
M=+4.[YBTRN>FFCFF$38+;'&]W-[*S#LJ?<H[1/#E%>]UIJHJ.L[^AE=) C9I
MJ:K8D:N<O,G)JOI0 [<?:1? LVI\*";IRW5Z7*O="^]/^[4>1[?9C4[F7VU9
M3=<5WBL3ILCLT"WRT8[B]-';\YPJ:H=14BTSY&28]6R+*J2-:VN>K3INLFR3
ML3O6&/O-3B]\2KM=>^[U,-;-17ZF5U73M^LP4E&Q(KE;W/6-G(JHM+(NO%$0
M#T O!!W0Z<]YO"\Z2MQ>F+;3 =G<$O>W-+191MIMW;*:UV?$MWL8GEQ3=R@K
M(F,9<J^Y3YU8ZRH2X7%7W"Z4DT%9,^3OVR.R?=.MYQ2_[-X/=<.M%LL-MJ+2
MR.LM%JA9#!0WVC<M%?(I$1$FEF=<J:1W>RZRS1N;(Y5YD50-3OQ@-T&]2OVK
M_P ,O9K;.#[_ %PZ6]S.B+'<UAHECJ5@O=CWSGZG=P:ML\#7?W/CFU>044E1
M&JN6GFHZA'*UW,UO23?>\_LNZVMH+!:&_69<,O&W=+<&QZ/Y:BGR-V871_,U
M%^9266JC5Z?G71NUTXH@'H0F4<
M
M   \X/[;S^-/T/\ Y/\ N%_&+ 8F_$3_ ,--NOP7NGZK- -(,QU@
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MU;+E5UIV,^IN>UK966&V=Y/3VB-VBIWG-+5*USFK-R+R@&?0[-@
M   'R][(V.DD<UC&-<][WN1K&,:BN<YSG*B-:U$U55X(A^*J(BJJHB(FJJO!
M$1.U57S(@!Y>_P!I9\?&^];6Y.5=$'2=F\U'T9[9WYUHW#R_&:Y[(NIW<'':
M]%JJQ]RIN[6NV9Q"\TO)9J6-[Z.]UM/]]Y'5$7WL2EPX]774U4[AW>MVZPBX
MNCP"T5*P76OHY51,PNE)+\^196:=Y8*"H9I3L15CJ)&]^JN;W/(!J(G18
M    R+>%]X:6^_BG=4>,].6RU/\ >:U,C9DF[NZ]RM\]=BNS^V]+51073++U
M%%-2K<[I4RRMI+1:HYHIKI<98XN\@@;455/=;9S:+)=Z,SH\3Q]OU>!$2KOM
M[FB=)16&TL>ULU=4(US.^F>Y49!"CFNFE<B:M:CGM ](R^_9-O!OR#9_"MLY
M=I-S+!E^(XO1X_6;ZXEN]EMJW1R^OB8Y]PRG)[?=)[]M767RZ7":2=W+C;*>
MG:YL$$<=-''"W+34]$6P=58;=:%L=XI:ZAHXZ63)*&^UT-YKY6HJRUE9%,ZI
MLLE1-*Y7<*1&LU1K41B(U ,._4!]B"QB=:JX]+'77?K4C7/2BQ#J VLM^0+,
MQS-8W56XVW5[QI*9T3VZ.1F+2I(C]45G)RR6%RCPZJ-W/+A>Y-3#HJ]W0919
M8JKF14X<]VM512<BM5..E$[77S:<0,.6\OV03QA=M)*E<"QSI\ZAZ=DG]RKM
M7O;;,<K*B!S9'QNEI]]+1L]34U0UK6MD8E1(QLCM&/D8BO+"7_H3WYM"O^]E
M)BV5,1?F?>7(H:21[5U5.9F206%C'HB(BIS*B*O!53B 8U-QO I\8/:R2>+)
MO#NZG+FZGU[Q=N< J=X8W<J4;E[B7:.HS>*JX5S-.Z<_56R(G&*7DM'=NFW?
MBS*Y*S:O,)E9V_>FV/OR+_8U^:ZQNN+7_P!D3Z.OG_J7: =3LDZ">N?#4J'9
M?T7]6.*)25S[95KDG3IO!8DI;E&^6.2WU"W3#J5(*Z-\#VNB=I(BL<BIP4HB
MKVSW'M_/]?V_S>B[N187_6\4OU-R3(KD6)_?4#.61%:OS5X\% *-_DG]4W\V
MK?\ _@;W%_YN$O\ V$YG_BCD_P"D%U_Y( /Y)_5-_-JW_P#X&]Q?^;@_83F?
M^*.3_I!=?^2 #^2?U3?S:M__ .!O<7_FX/V$YG_BCD_Z077_ )( /Y)_5-_-
MJW__ (&]Q?\ FX/V$YG_ (HY/^D%U_Y( /Y)_5-_-JW_ /X&]Q?^;@_83F?^
M*.3_ *077_D@ _DG]4W\VK?_ /@;W%_YN#]A.9_XHY/^D%U_Y( /Y)_5-_-J
MW_\ X&]Q?^;@_83F?^*.3_I!=?\ D@!QS=*G5#3Q2SS]-V_<$$$;YIIIMGMP
MXXH8HVJ^2661^.M9''&QJJYRJB(B:J?CL+S%K5<[$\F:UJ*YSG6&Z(UK4355
M55I=$1$ ++7:SW>PUTELOEJN5FN4+8WS6^[4-5;JZ)LT;98724E9%#/&V6)Z
M.:JM1'-5%3@4_/3STLBPU,$U/,U$5T4\;XI&HY$<U59(UKD1R+JG#B@!+3A
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M9EN^"9)(V'^Z4MK[A&ZWW-(?T:6SU]7$S1TB*6JWJVQH=WMN,APBJ?%3U5=
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M@FX=WP2NJXFMK9+K/8;I75V9I%(Q(V1OE:L%&G+W<D;Y7(WN^Z5P'HWF5\
M
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M<1Q_&V.9R2R6FUTE+55+45%UK*YD?UVM=P3YTLCW:(B:Z(@!V@*R
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M>U"PDT$U-+)3U$,M//$Y62PS1OBEB>WM9)'(C7L<GG1410"7G$
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M%             /;)\&C=.KWG\*7P^L_N-1)672KZ5-H,;O%=,L;I[A>]O\
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MN:O:A82:":FEDIZB&6GGB<K)89HWQ2Q/;VLDCD1KV.3SHJ(H!+SB
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M?K]MFEIII:;Z[E^07&EYI:2:HIW=]15<<B<KUT1VBZ+JB 9CB_8
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M!]5I?JOU'ZM3_4OJ_P!5^I]S']5^J]WW/U;ZOR]U]7[KYO)IR\O#30 G!S@
M
M
M
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MQU$\3^+)HK?5LN+X'IHNK)TI>14\Z.\P![9!L-
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M"Q6>WVB%6M^BU8[?3T[%:WS)IH@!>(GP
M
M
M
M
M
M        !(\GR"WXEC60Y5=ED2UXS8[MD%R6%84E2WV:@J+E6+$M3-34Z2)3
MTSN7O)(V:_2<U-52&K*J*AI*JMGU[FCIIZJ;EY>;NJ>)TLFG.YC->1B]JHGI
M5 #P3L\S.][C9SF>X62S_6LCSO+,BS._U.KE^L7O*+Q67NZSZO5SE[ZNKI'<
M55>)K/7.X5%VN5PNE6[GJ[E75=PJG\?G5%9/)43.XZK\Z215 *4($
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MZ^XP\%5=4[FJ;HOYY./G ,RY?X
M
M
M
M
M
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M7+Q55U7B 7^*G
M
M
M
M
M
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MA<U5T6-[NU$T4#V)#/.
M
M
M
M
M
M                                  >,S]H Z7*WI+\7+K.P-+?)18QG
MNZ%PW]P.7NTCHJS%-^&MW,6*U-YG.^]^.9+?[E94UTTEM;T35J(JX ^I[#9,
M'WSW MG=+'1W.\RY/;'::1R462HEXY8$U5>ZI*NJEI_^%"OF ,-I8,
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MYIE@R7<-*2Z/BFC:D]OQR!LRV*D5517QR5T50ZKD35.$T;7-1T:@&TT=S@
M
M
M
M
M
M
M            #2$^V8>'=<=T-D=HO$5VYQYUPR+I[;%M!OS+0QQ.KEV8R^_R
M5FW^4U3>[;//;<#W+O=312HQ[WL;E7?*Q(8)I(\=?7[M5+><=L6ZUII5EJ\6
M1+%DRQHBR?L?KJE9+76O3EYG0VR[U#XW:*JHE;S:<K7*@'G!&)L
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M8*A9F\JOYHDAN#^\;R(JZIJFB:@%=?RLNEC^<OT__P ,NW7_ #C)C^S?"_\
M&_%_T_M/_*P!_*RZ6/YR_3__  R[=?\ .,?LWPO_ !OQ?]/[3_RL M_DGB%=
M F&_7_V7]<71_BOWJ[O[Z?LDZE]E['][>^[KNOK_ -],UI?J?>]^SE[SEYN=
MNG:A+*O=+;*@[WZ]N-@E%W&G??6\OQ^F[GFY>7O>^N#.[UYDTUT[4 .K6?\
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M6M:C6HC6M1&M:U$1K6HFB(B)P1$0 Y#]
M
M
M
M
M
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M2O;VIR7*U=XG]SSO:B,;=+8LC8JEFC=7:2-1(Y&:@8C2Q@
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M'20-1."?.EJ*B33GJ*RJE59)I7ZOED<KG*JJH!?(J,
M
M
M
M
M
M
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MR)NLU+(Y7L5%5JR1\LC@,4Y90
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M/4SOU?++(KI99%5[W.<JJH%X"?
M
M
M
M
M
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M[!%3;#[<7RFG^N4U5@^VMQ6M=E-ZM<W*V.\9%)5(LD$=526^VSIPRC[*]%N
M;</I+[F#H<^RV%8YHG5M*C,:M-2QW>,?;K1+WBUM1"[1$GJU?Q:CV10N -J
M[H
M
M
M
M
M
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MWINZ2-_MW;;='<M+E6+;:9,[ 8^S1]PW%N%#0X):85U1$DJ[C"Q55$1=2O\
M%-JMR<Y=$F)8-D]]BF71E;16BL6V)ZY;K+'';8&KKVOE:@!L8])?V-/Q#=W9
MK3=^J7<O9WI(Q2I;%)<[-'<4WSW:HD=J]8(\:P6XT&VKW<J<KGKF"K&YR+W;
M]%0[7X/T";IWUT$^9W>PX/1/Y5FITE_9)?(T7BK4H[;+':%73@J_7^"KV* ;
M771#]EE\*KI FL^49EMQ>NKS<^VN@JOV5=2=5;\EPVEKV) Z7[S[-VBAM6V[
M[:L\"/ACO='?JN%7.1*IR*=U]NNC'97!'4];<+349U>85:_Z[EKXJN@9*G*K
MOJ]@@CAM*P\S=6I4QU+V_P!6H!L86FTVJPVRWV2QVRWV6S6FCI[=:K1::*FM
MULMEOI(FP4E#;Z"CCAI:*CI86(R.*-C6,:B(B(B':Z"""FABIZ:&*GIX(V10
MP01LBAABC:C61Q11HUD<;&IHB(B(B $P.4
M
M
M
M
M
M
M             L_OA_F"_8%<OY2?^9__ #7\/OO_ )\/V%_L"[.'WR_9[_\
M>]V?_720Y'^QC[V2_LN^\/WF_P"W_LC^]_WL_P#WOWS_ +E]T U9>L;^AS][
M=_\ /;_(,^^'>?W=_)/_ &<_7_KG,_7N_P"0_P#-^N=_KWWFY_[/YSICGO\
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M+>7E3ETY=$Y>73EY=.&FG#30 Y#]
M
J                                                     /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781237680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Oct. 20, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,476,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782057392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 7,642.3<span></span>
</td>
<td class="nump">$ 7,315.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprograms', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">406.5<span></span>
</td>
<td class="nump">317.6<span></span>
</td>
<td class="nump">1,144.2<span></span>
</td>
<td class="nump">996.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">48.8<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">180.4<span></span>
</td>
<td class="nump">265.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3,077.8<span></span>
</td>
<td class="nump">2,955.8<span></span>
</td>
<td class="nump">8,966.9<span></span>
</td>
<td class="nump">8,576.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales, excluding amortization of acquired intangible assets</a></td>
<td class="nump">370.0<span></span>
</td>
<td class="nump">416.9<span></span>
</td>
<td class="nump">1,120.8<span></span>
</td>
<td class="nump">1,100.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">446.4<span></span>
</td>
<td class="nump">529.0<span></span>
</td>
<td class="nump">1,666.0<span></span>
</td>
<td class="nump">1,439.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">433.8<span></span>
</td>
<td class="nump">462.7<span></span>
</td>
<td class="nump">1,363.1<span></span>
</td>
<td class="nump">1,452.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">108.9<span></span>
</td>
<td class="nump">99.7<span></span>
</td>
<td class="nump">674.9<span></span>
</td>
<td class="nump">281.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">82.5<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">61.2<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">1,424.3<span></span>
</td>
<td class="nump">1,530.5<span></span>
</td>
<td class="nump">5,088.5<span></span>
</td>
<td class="nump">4,312.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,653.5<span></span>
</td>
<td class="nump">1,425.3<span></span>
</td>
<td class="nump">3,878.4<span></span>
</td>
<td class="nump">4,264.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(43.6)<span></span>
</td>
<td class="num">(58.1)<span></span>
</td>
<td class="num">(149.4)<span></span>
</td>
<td class="num">(169.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,609.9<span></span>
</td>
<td class="nump">1,367.2<span></span>
</td>
<td class="nump">3,729.0<span></span>
</td>
<td class="nump">4,094.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">383.8<span></span>
</td>
<td class="nump">337.0<span></span>
</td>
<td class="nump">892.6<span></span>
</td>
<td class="nump">1,047.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,226.1<span></span>
</td>
<td class="nump">1,030.2<span></span>
</td>
<td class="nump">2,836.4<span></span>
</td>
<td class="nump">3,047.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 2,836.5<span></span>
</td>
<td class="nump">$ 3,053.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
<td class="nump">$ 13.32<span></span>
</td>
<td class="nump">$ 13.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="nump">$ 13.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">219.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">213.3<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66022249&amp;loc=d3e33749-111570<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782146656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 2,836.5<span></span>
</td>
<td class="nump">$ 3,053.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="num">(35.5)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">43.9<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
<td class="nump">146.7<span></span>
</td>
<td class="num">(62.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">9.4<span></span>
</td>
<td class="num">(18.1)<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(76.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">1,235.5<span></span>
</td>
<td class="nump">1,014.8<span></span>
</td>
<td class="nump">2,827.0<span></span>
</td>
<td class="nump">2,976.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 1,235.5<span></span>
</td>
<td class="nump">$ 1,012.2<span></span>
</td>
<td class="nump">$ 2,826.9<span></span>
</td>
<td class="nump">$ 2,971.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613674-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781908368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,548.1<span></span>
</td>
<td class="nump">$ 2,326.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,960.2<span></span>
</td>
<td class="nump">2,568.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,567.5<span></span>
</td>
<td class="nump">1,441.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">518.0<span></span>
</td>
<td class="nump">300.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,007.2<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">967.0<span></span>
</td>
<td class="nump">1,093.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,568.0<span></span>
</td>
<td class="nump">8,732.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">3,062.0<span></span>
</td>
<td class="nump">2,829.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">2,995.9<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,019.4<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,127.5<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,300.4<span></span>
</td>
<td class="nump">1,335.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,073.2<span></span>
</td>
<td class="nump">22,876.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable and other financing arrangements</a></td>
<td class="nump">573.2<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">121.3<span></span>
</td>
<td class="nump">231.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">298.7<span></span>
</td>
<td class="nump">279.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,455.2<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,448.4<span></span>
</td>
<td class="nump">3,419.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable and other financing arrangements</a></td>
<td class="nump">5,938.3<span></span>
</td>
<td class="nump">6,512.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">120.7<span></span>
</td>
<td class="nump">93.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">716.9<span></span>
</td>
<td class="nump">722.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,224.3<span></span>
</td>
<td class="nump">10,748.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">59.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(329.4)<span></span>
</td>
<td class="num">(319.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,107.7<span></span>
</td>
<td class="nump">15,071.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,611.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,860.5<span></span>
</td>
<td class="nump">12,140.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(11.6)<span></span>
</td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,848.9<span></span>
</td>
<td class="nump">12,128.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 23,073.2<span></span>
</td>
<td class="nump">$ 22,876.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6940098592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781561984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,836.4<span></span>
</td>
<td class="nump">$ 3,047.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and acquired in-process research and development</a></td>
<td class="nump">992.0<span></span>
</td>
<td class="nump">505.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">97.4<span></span>
</td>
<td class="nump">117.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(39.7)<span></span>
</td>
<td class="num">(56.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">126.9<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(225.8)<span></span>
</td>
<td class="num">(238.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(170.3)<span></span>
</td>
<td class="num">(155.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(504.5)<span></span>
</td>
<td class="num">(175.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">170.5<span></span>
</td>
<td class="num">(147.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(250.2)<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">3,032.7<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">4,472.6<span></span>
</td>
<td class="nump">5,185.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(4,093.9)<span></span>
</td>
<td class="num">(5,631.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="num">(120.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(636.8)<span></span>
</td>
<td class="num">(434.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(910.4)<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(12.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(2,193.6)<span></span>
</td>
<td class="num">(1,903.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(1,365.4)<span></span>
</td>
<td class="num">(348.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(10.7)<span></span>
</td>
<td class="num">(12.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ Inc.</a></td>
<td class="nump">302.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Repayments of Bank Debt</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">37.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(1,671.9)<span></span>
</td>
<td class="num">(326.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(832.8)<span></span>
</td>
<td class="nump">776.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">54.4<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,326.5<span></span>
</td>
<td class="nump">1,308.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 1,548.1<span></span>
</td>
<td class="nump">$ 2,084.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772464352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS and relapsing MS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. We intend to invest in the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the following new standards effective January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounting Standards Update (ASU) No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method. We have performed a review of the new standards as compared to our current accounting policies and our review of customer contracts and collaborative relationships remains in process. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues and revenues from anti-CD20 therapeutic programs. During the fourth quarter of 2017 we plan to finalize our assessments over the impact that these standards may have on our results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. The adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. The new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard will be effective for us on January 1, 2018. We expect to adopt this standard using the modified retrospective method applied through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. The new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard will be effective for us on January 1, 2020; however, early adoption is permitted. We intend to early adopt this standard as of October 31, 2017, during our annual review of goodwill. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for us on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will be effective for us on January 1, 2019; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6935721232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Acquisitions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May 15, 2017, we completed an asset purchase of the Phase 3 candidate, CIRARA (now known as BIIB093), from Remedy Pharmaceuticals Inc. (Remedy). The target indication for BIIB093 is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) recently granted BIIB093 Orphan Drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. Under the terms of the purchase agreement, we will have responsibility for the future development and commercialization of BIIB093 and have agreed to pay Remedy certain development and sales based milestone payments, which are substantially payable upon or after regulatory approval, as well as royalties on future commercial sales. Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. Upon closing of the transaction, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment, which was recorded as acquired in-process research and development in our condensed consolidated statements of income as BIIB093 has not yet reached technological feasibility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772453296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Hemophilia Spin Off</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company trading under the symbol "BIVV" on the Nasdaq Global Select Market. The spin-off was accomplished through the distribution of all the then outstanding shares of common stock of Bioverativ to Biogen shareholders, who received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution, Biogen and Bioverativ entered into a separation agreement and various other agreements (including a transition services agreement, a tax matters agreement, a manufacturing and supply agreement, an employee matters agreement, an intellectual property matters agreement and certain other commercial agreements). These agreements govern the separation and distribution and the relationship between the two companies going forward. They also provide for the performance of services by each company for the benefit of the other for a period of time. In addition, under the terms of the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The services under these agreements generally commenced on February 1, 2017 (the distribution date), and are expected to terminate within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the distribution date, with the exception of the manufacturing and supply agreement, which has an initial term of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with a five year extension at Bioverativ's sole discretion and a further five year extension with Bioverativ's and our consent. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to these services, which is reflected as a component of other revenues in our condensed consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as cost of sales in relation to these services during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the United States (U.S.), which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement. Under this arrangement, we distributed these products as an agent of Bioverativ and also provided related cash management services in connection with sales transactions, including the collection of receivables and the remittance of applicable discounts and allowances. Our consolidated financial position and results of operations did not reflect recognition of activity or balances related to these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items, primarily in selling, general and administrative expenses, in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these amounts were not significant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our condensed consolidated statements of income for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$217.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$604.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936316736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Reserves for discounts and allowances</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">422.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,681.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,123.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(320.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,547.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(431.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(519.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">102.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6625998432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">208.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">647.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. Balances transferred to Bioverativ related to work in process and finished goods inventory totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923633264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(532.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,675.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,002.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,067.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,934.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,295.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,276.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,019.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balances in the table above as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflect the elimination of certain amounts transferred to Bioverativ in connection with the completion of the spin-off of our hemophilia business. For additional information relating to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements. In-process research and development balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amortization of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$108.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$674.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$281.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. Amortization of acquired intangible assets for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$413.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of amortization and impairment charges related to our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property related to TECFIDERA, as further discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$322.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Corporation plc. The net book value of this asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,293.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The increase in acquired and in-licensed rights and patents during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$40.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payments due to Ionis Pharmaceuticals, Inc., which became payable upon the approval of SPINRAZA for the treatment of SMA in the E.U. and Japan, respectively, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Samsung Bioepis, which became payable upon the approval of IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. and net amounts related to our TECFIDERA license rights, as described below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to the agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we agreed to pay Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this agreement, representing the fair value of our license to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016. For additional information related to this agreement, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We paid the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in February 2017 and recognized an intangible asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The asset represented the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property related to TECFIDERA revenues for the period January 2017, the month in which we entered into this agreement, through December 2020, the last month before royalty payments could first commence pursuant to this agreement. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information related to these disputes, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As we prevailed in the U.S. proceeding in March 2017, we evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded an impairment charge to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute. We also continue to amortize the remaining net book value of the U.S. and rest of world intangible assets in our condensed consolidated statements of income utilizing an economic consumption model. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption of intangible assets. Our most significant intangible assets are related to our TECFIDERA, AVONEX and TYSABRI products. Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of TECFIDERA, AVONEX and TYSABRI. This analysis is also updated whenever we determine events or changes in circumstances would significantly affect the anticipated lifetime revenues of either product. Our most recent long range planning cycle was completed in the third quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">404.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">389.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">256.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">244.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">762.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,127.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of the hemophilia business as of the distribution date. For additional information relating to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in goodwill during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits) and payable to the former shareholders of Fumapharm AG or holders of their rights. Other includes changes in foreign currency exchange rates. For additional information related to future contingent payments to the former shareholders of Fumapharm AG or holders of their rights, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661633360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,250.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,238.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">628.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> material impairments of our assets measured and carried at fair value during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In addition, there were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or inputs utilized or transfers between fair value measurement levels during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair values of Level 2 instruments classified as cash equivalents and marketable debt securities were determined through third party pricing services. For a description of our validation procedures related to prices provided by third party pricing services, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,536.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,049.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,867.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,030.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,048.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,494.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. For additional information related to our debt instruments, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">492.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">515.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$280.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our contingent consideration obligations valued using Level 3 measurements were reflected as components of other long-term liabilities in our condensed consolidated balance sheets with the remaining balances reflected as a component of accrued expenses and other.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929147008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">871.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,042.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,043.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">954.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">957.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,960.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,961.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,792.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,795.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,362.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,472.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,185.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$84.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$99.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and investments in venture capital funds where the underlying investments are in equity securities of biotechnology companies.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6926834448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges, and, accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses for the effective portion of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. To the extent ineffective, hedge transaction gains and losses are reported in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,573.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,637.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The portion of the fair value of these foreign currency forward contracts that was included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We expect all contracts outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020 attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020 with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in our condensed consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$366.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$902.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recognized as a component of other income (expense), net for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, as compared to net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivatives</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivatives are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772439136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,580.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,439.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2016 we purchased land in Solothurn, Switzerland for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), where we are building a biologics manufacturing facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$968.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$481.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to the construction of this facility. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$235.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the construction of this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929147008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, increased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$720.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily driven by net income attributable to Biogen Inc. of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, partially offset by share repurchases totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as described below, and an adjustment to retained earnings of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$852.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the spin-off of our hemophilia business, as described in Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock. This authorization does not have an expiration date. All share repurchases under this authorization will be retired. Under this program, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased and retired </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$348.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> remains available to repurchase shares under this authorization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock, which was completed as of March 31, 2017. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we repurchased </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this program. We did not repurchase any shares of common stock under this program during the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Noncontrolling Interests</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772453296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(176.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(33.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(329.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(78.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(258.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6915239952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,053.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772556112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-based Payments</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We estimate the fair value of our obligations associated with our performance units and cash settled performance units at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, restricted stock units, cash settled performance units and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen&#8217;s and Bioverativ&#8217;s equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding unvested awards for employees transferring to Bioverativ were converted to unvested Bioverativ awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume weighted-average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">2017 Omnibus Equity Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan) for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, restricted stock units, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017 or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017 are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;1.5-to-1&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772473264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the same periods in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to a lower relative percentage of our earnings being recognized in the U.S., a high tax jurisdiction, along with a higher deduction for U.S. manufacturing activities. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we are earning a lower benefit from the orphan drug credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for fiscal 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772453296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(66.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(188.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(149.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(169.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets include prepaid taxes totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$714.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$817.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">611.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">241.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">157.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,455.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pricing of TYSABRI in Italy - AIFA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the first quarter of 2017, we reached an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods. As a result, in the first quarter of 2017 we recognized EUR</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in revenues for sales which were previously deferred. These amounts were previously accrued for and included in the table above in Other as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information regarding our agreement with AIFA relating to sales of TYSABRI in Italy, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our 2016 Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6935583552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2007 we entered into a collaboration agreement with Neurimmune SubOne AG (Neurimmune), a subsidiary of Neurimmune AG, for the development and commercialization of antibodies for the treatment of AD. Neurimmune conducts research to identify potential therapeutic antibodies and we are responsible for the development, manufacturing and commercialization of all products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and are required to fund </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the research and development costs incurred in support of the collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts incurred by Neurimmune for research and development expenses in support of the collaboration and reimbursed by us were immaterial for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with other variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total carrying value of our investments in biotechnology companies totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our investments in Neurimmune and other variable interest entities, please read Note 18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929460752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 1, 2017, we finalized an agreement with Bristol-Myers Squibb Company (BMS) to exclusively license BMS-986168 (now known as BIIB092), a Phase 2-ready experimental medicine with potential in AD and progressive supranuclear palsy (PSP), and made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to BMS. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. PSP is a rare condition that affects movement, speech, vision and cognitive function.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, we received worldwide rights to BIIB092 and are responsible for the full development and global commercialization of BIIB092 in AD and PSP. We may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former stockholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we triggered a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payable to the former stockholders of iPierian upon dosing of the first patient in the Phase 2 PSP study for BIIB092 and we may pay the former stockholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments, and potential royalties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment were recognized as research and development expense in our condensed consolidated statements of income for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie Inc. (AbbVie) aimed at advancing the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of relapsing forms of MS in the U.S. in May 2016 and in the E.U. in July 2016. Under the agreement, we and AbbVie conduct ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits are shared equally. Outside of the Collaboration Territory, we are solely responsible for development and commercialization of ZINBRYTA and will pay a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 the European Medicines Agency (EMA) announced that it had provisionally restricted the use of ZINBRYTA to adult patients with highly active relapsing disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) or with rapidly evolving severe relapsing MS who are unsuitable for treatment with other DMTs.&#160;These restrictions followed the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. The outcome of the EMA review process may affect the market for ZINBRYTA, which may result in the impairment of all or a portion of certain assets related to ZINBRYTA. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our condensed consolidated balance sheet includes ZINBRYTA related assets, primarily related to inventory, prepaid tax and intangible assets, totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$200 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Offsetting these amounts, we also have an unrecorded tax benefit related to certain ZINBRYTA assets totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognizes revenues on sales to third parties and we recognize our&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;share of the co-promotion profits or losses as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income. The collaboration began selling ZINBRYTA in the U.S. in the third quarter of&#160;2016. During the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenue of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of an overall net loss within the collaboration, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in each of the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognize revenues on sales to third parties in product revenues, net and record the related cost of revenues and sales and marketing expenses to their respective line items in our condensed consolidated statements of income as revenues are recognized and related costs are incurred. We also reimburse AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses in the E.U. and Canada, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. We began to recognize product revenues on sales of ZINBRYTA in the E.U. in the third quarter of 2016. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits in the E.U. and Canada, as compared to net income recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA (nusinersen)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis Pharmaceuticals, Inc. (Ionis) under which both companies develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of SMA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the agreement, during the third quarter of&#160;2016,&#160;we exercised our option to develop and commercialize SPINRAZA and paid Ionis a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;license fee in connection with the option exercise. This amount was recognized as research and development expense in our condensed consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA was approved for use in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively. These approvals triggered milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;during 2017, which were capitalized in intangible assets, net in our condensed consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$197.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$438.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA in the U.S. and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$73.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$82.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA outside of the U.S. Pursuant to our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in royalty cost of sales within our condensed consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung Biologics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar pharmaceuticals.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership interest was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflects the effect of additional equity financings in which we did not participate. We maintain an option to purchase additional stock in Samsung Bioepis that would allow us to increase our ownership percentage up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;The exercise of this option is within our control.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis one quarter in arrears when the results of the entity become available, which is reflected as equity in loss of investee, net of tax in our condensed consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our investment, we suspended recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenue on sales of BENEPALI and FLIXABI in the E.U. in the first and third quarters of 2016, respectively. We reflect revenues on sales of BENEPALI and FLIXABI to third parties in product revenues, net in our condensed consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our condensed consolidated statements of income to their respective line items when these costs are incurred. In August 2017 the European Commission granted a marketing authorization in the E.U. for IMRALDI, an adalimumab biosimilar referencing HUMIRA, triggering an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment due to Samsung Bioepis, which was capitalized in intangible assets, net in our condensed consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss in accordance with the cost sharing provision of the commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits, as compared to net expense recognized of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect sharing of the net collaboration profits in the prior year comparative periods.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. For the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$23.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in connection with these services as a component of other revenues from collaborative and other relationships in our condensed consolidated statements of income, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in the prior year comparative periods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these and our other significant collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781906064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 6, 2015, a qui tam action filed on behalf of the United States and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts, and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss is pending. The United States has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder on October 20, 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Abbreviated New Drug Application Litigation relating to TECFIDERA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June, July and September 2017 we filed patent infringement actions pursuant to the Hatch-Waxman Act against parties who filed Abbreviated New Drug Applications (ANDAs) for generic versions of TECFIDERA. We have sued the following parties in the United States District Court for the District of Delaware: Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Hetero USA, Inc., Impax Laboratories, Inc., Prinston Pharmaceuticals, Inc., Slayback Pharma LLC,&#160; Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd., Cipla Limited, Glenmark Pharmaceuticals Pvt. Ltd., Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Shipla Medicare Limited, Sun Pharma Global FZE, Torren Pharmaceuticals, Ltd., TWI Pharmaceuticals, Inc., Windlas Healthcare Pvt., Ltd., Accord Healthcare Inc., Par Pharmaceuticals, Sandoz Inc., Sawai (USA), Inc. and Zydus Pharmaceuticals (USA), Inc. We have also filed actions against Stason Pharmaceuticals, Inc. in the United States District Court for the Central District of California, Zydus Pharmaceuticals (USA), Inc. in the United States District Court for the District of New Jersey, Accord Healthcare Inc. in the Middle District of North Carolina, Par Pharmaceuticals in the Southern District of New York, Sandoz, Inc. in the District of Colorado and Mylan Pharmaceuticals in the United States District Court for the District of West Virginia. No trial has been scheduled in any of these matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the U.S. Patent and Trademark Office (USPTO) declared an interference between Forward Pharma&#8217;s pending U.S. Patent Application No. 11/576,871 and our U.S. Patent No. 8,399,514 (the '514 patent). The '514 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. In March 2017 the USPTO ruled against Forward Pharma. Forward Pharma has appealed to the U.S. Court of Appeals for the Federal Circuit and the appeal is pending. For additional information regarding this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the European Patent Office (EPO) issued a written decision confirming its earlier revocation of our European patent number 2 137 537 (the '537 patent), which we have appealed. The '537 patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The EPO has scheduled a hearing for January 2018 on Biogen&#8217;s and others&#8217; oppositions to Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. The settlement and license agreement that we entered with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the EPO and the Technical Board of Appeal and the Enlarged Board of Appeal, as applicable, to make a final determination. For additional information regarding this matter, please read Note 6, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangibles Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Patent Revocation Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss Pharma International AG filed actions in the District Court of The Hague (on January 11, 2016) and the German Patents Court (on March 3, 2016) to invalidate the Dutch and German counterparts of our European Patent Number 1 485 127 (&#8220;Administration of agents to treat inflammation&#8221;), which was issued in June 2011 and concerns administration of natalizumab (TYSABRI) to treat MS. The patent expires in February 2023. In July 2017 the District Court of The Hague ruled that the Dutch counterpart of the patent is invalid and we have appealed. A hearing has been scheduled in the German action for early 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On May&#160;28, 2010, Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer Inc. (Pfizer) (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. The court has consolidated the two lawsuits, and we refer to the two actions as the &#8220;Consolidated '755 Patent Actions.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono have all filed counterclaims in the Consolidated '755 Patent Actions seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees, and EMD Serono and Bayer have each filed a counterclaim seeking a declaratory judgment that the '755 Patent is unenforceable based on alleged inequitable conduct. Bayer has also amended its complaint to seek such a declaration. Trial has been set for the first quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that provide assistance to patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On July 1, 2016, we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On December 29, 2016, we received a civil investigative demand from the federal government for documents and information relating to our relationships with entities providing clinical education and reimbursement support services. We regard this matter as closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6926834448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and E2609 Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2014, we entered into a collaboration agreement (Eisai Collaboration Agreement) with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize two Eisai product candidates for the treatment of AD, BAN2401, a monoclonal antibody that targets amyloid-beta aggregates, and E2609, a BACE inhibitor.&#160;Under the Eisai Collaboration Agreement, Eisai had an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for AD (Aducanumab Option).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 23, 2017, Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement (Aducanumab Agreement) for the joint development and commercialization of aducanumab. Under the Aducanumab Agreement, the two companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The companies will continue to share equally in the potential profits (losses) in rest of world markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Agreement, we will continue to lead the ongoing Phase 3 development of aducanumab and will remain responsible for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of development costs for aducanumab incurred in support of the agreement until April 2018. Eisai will then reimburse us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of development expenses for the period April 2018 through December 2018, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> thereafter. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, both companies will continue to jointly develop BAN2401 and E2609; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai have also agreed to co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai will distribute AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets (excluding China).  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to our collaboration arrangement with Eisai, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our 2016 Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neurimmune</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On October 23, 2017, we amended the terms of our existing collaboration agreement with Neurimmune. Pursuant to the amended agreement, we agreed to make a one-time </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in royalty rates payable on potential commercial sales of aducanumab.&#160;Our royalty rates payable on potential commercial sales of aducanumab will now range from the high single digits to low-teens.&#160;This payment will be recognized in the fourth quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the amended agreement, we also have an option that will expire in April 2018 to further reduce our royalty rate payable on potential commercial sales of aducanumab by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in exchange for a one-time </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of the Aducanumab Agreement, Eisai may elect to share in the benefit and cost of the royalty reduction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For&#160;additional information relating to our collaboration agreement with Neurimmune, please read Note 17,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782178032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), SPINRAZA for the treatment of spinal muscular atrophy (SMA) and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, OCREVUS indicated for the treatment of primary progressive MS and relapsing MS, and other potential anti-CD20 therapies under a collaboration agreement with Genentech, Inc., a wholly-owned member of the Roche Group.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities, particularly within areas of our scientific, manufacturing and technical capabilities. We intend to invest in the future across our core growth areas of MS and neuroimmunology, Alzheimer's disease (AD) and dementia, Parkinson's disease and movement disorders, and neuromuscular diseases including SMA and amyotrophic lateral sclerosis (ALS). Further, we see opportunities to invest in emerging growth areas such as pain, ophthalmology, neuropsychiatry and acute neurology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar therapies that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics Co. Ltd. (Samsung Biologics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, and FLIXABI, an infliximab biosimilar referencing REMICADE, in the European Union (E.U.). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these unaudited condensed consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K). Our accounting policies are described in the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Notes to Consolidated Financial Statements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form&#160;10-K and updated, as necessary, in this Form&#160;10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three and nine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates under different assumptions or conditions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the following new standards effective January 1, 2017:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounting Standards Update (ASU) No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of these standards did not have a material impact on our financial position, results of operations or statement of cash flows; however, the adoption of ASU No. 2016-09 resulted in the reclassification of certain prior year amounts in our condensed consolidated statements of cash flows to conform to our current year presentation. Specifically, amounts previously disclosed in net cash flows used in financing activities related to our excess tax benefit from share-based compensation have been reclassified to net cash flows provided by operating activities and amounts related to cash paid when withholding shares for tax withholding purposes, previously disclosed in net cash flows provided by operating activities, have been reclassified to net cash flows used in financing activities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information related to these standards, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies: New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Form 10-K.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The FASB has subsequently issued amendments to ASU No. 2014-09 that have the same effective date and transition date of January 1, 2018. We expect to adopt these standards using the modified retrospective method. We have performed a review of the new standards as compared to our current accounting policies and our review of customer contracts and collaborative relationships remains in process. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have not identified any accounting changes that would materially impact the amount of reported revenues with respect to our product revenues and revenues from anti-CD20 therapeutic programs. During the fourth quarter of 2017 we plan to finalize our assessments over the impact that these standards may have on our results of operations, financial position and disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The new standard amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in a company's results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for us on January 1, 2018. Based on our current investment holdings, the adoption of this standard is not expected to have a material impact on our financial position or results of operations; however, it will result in the reclassification of certain investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on their balance sheet and disclose qualitative and quantitative information about their leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the impact that this standard may have on our results of operations, financial position and disclosures. The adoption of this standard is not expected to have a material impact on our net financial position, but may materially impact the reported amount of total assets and total liabilities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. The new standard will be effective for us on January 1, 2020. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2016 the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. The new standard clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and beneficial interests in securitization transactions. The new standard also clarifies that an entity should determine each separately identifiable source or use within the cash receipts and cash payments on the basis of the nature of the underlying cash flows. In situations in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use, the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for the item. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our statements of cash flows upon adoption.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory. The new standard eliminates the deferral of the tax effects of intra-entity transfers of an asset other than inventory. Under the new standard, entities should recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard will be effective for us on January 1, 2018. We expect to adopt this standard using the modified retrospective method applied through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The adoption of this standard is expected to have a material impact on our net financial position; however, the final effect of the adoption of this standard will depend on the nature and amount of future transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business. The new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. The new standard will be effective for us on January 1, 2018; however, we have adopted this standard as of January 1, 2017, with prospective application to any business development transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment. The new standard eliminates Step 2 from the goodwill impairment test. Under the amendments in ASU No. 2017-04, an entity should recognize an impairment charge for the amount by which the carrying amount of a reporting unit exceeds that reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. The new standard will be effective for us on January 1, 2020; however, early adoption is permitted. We intend to early adopt this standard as of October 31, 2017, during our annual review of goodwill. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. The new standard will require that an employer disaggregate the service cost component from the other components of net benefit cost. The new standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allow only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on the condensed consolidated statements of income. The new standard will be effective for us on January 1, 2018. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities. The new standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period for the premium to the earliest call date. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The new standard will be effective for us on January 1, 2018; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The new standard provides guidance to better align an entity&#8217;s risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The new standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. The new standard will be effective for us on January 1, 2019; however, early adoption is permitted. The adoption of this standard is not expected to have a material impact on our financial position or results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661629952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and liabilities charged against equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721665-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1474-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=SL51724579-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721675-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721663-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721659-107760<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721671-107760<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721677-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764214432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract', window );"><strong>Sales Discounts, Returns and Allowances, Goods [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of the changes in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">482.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">51.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">605.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">422.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,681.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,123.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(320.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,227.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,547.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/credits relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(70.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(431.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(17.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(519.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">102.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">516.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">45.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in condensed consolidated balance sheets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">197.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">166.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">664.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923633264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">208.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">647.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">698.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">170.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,007.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,001.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,031.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781692192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(532.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(523.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2,675.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">329.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,634.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">371.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">680.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">648.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks&#160;and&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">tradenames</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed&#160;rights&#160;</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and&#160;patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,002.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1,067.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,934.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,481.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(776.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,705.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8,295.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4,276.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,019.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,742.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,934.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,808.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon the above, the estimated future amortization of acquired intangible assets is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 (remaining three months)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">421.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">404.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">389.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">256.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">244.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,669.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">762.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">9.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,127.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929539904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,584.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,870.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">567.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,250.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,238.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">628.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">106.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted&#160;Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant&#160;Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,663.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,172.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">561.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,558.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,533.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">481.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Carrying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875% Senior Notes due March&#160;1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">561.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">553.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">558.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,536.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,486.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,521.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,485.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,049.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">994.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,026.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">993.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,867.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,735.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,796.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,734.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,030.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,721.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,874.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,721.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7,048.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6,494.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,808.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,499.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations that includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">492.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">515.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">506.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">30.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">61.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">522.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">521.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782871856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents on the accompanying condensed consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">126.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">42.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">871.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">741.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,266.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,184.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of September 30, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,042.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,043.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,541.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">916.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">954.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">957.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">566.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,408.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,409.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,255.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,258.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,156.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,016.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,019.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">557.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,960.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,961.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,568.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,569.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,792.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,795.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,552.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,559.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">269.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">276.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,022.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5,026.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,398.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,406.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">888.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,362.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,472.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,185.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6625998432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.02534113060429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,573.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">39.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss franc</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,637.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">871.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments on our condensed consolidated statements of income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months Ended September 30,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Effective Portion)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized into Net Income</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">(Ineffective Portion)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivatives, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of September 30, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">80.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">24.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivatives:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivatives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927063360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock', window );">Reconciliation of equity attributable to noncontrolling interests</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to NCI, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value of net assets and liabilities acquired and assigned to NCI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Translation adjustment and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">NCI, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917142672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">57.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(334.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(319.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(176.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(24.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">14.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">15.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(162.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">146.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(9.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(33.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(187.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(329.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, Net of Tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(78.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(17.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(62.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, as of September 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(258.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(300.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from Accumulated Other Comprehensive Income</font></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(18.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6940104912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,226.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,836.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,053.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">211.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">213.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">219.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782197872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">19.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">55.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">71.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(10.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(31.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">29.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">88.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">17.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">26.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">81.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">13.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">7.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">43.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">127.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(7.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">40.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624131200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">35.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">23.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783142944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Three Months <br clear="none"/>Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Nine Months <br clear="none"/>Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(61.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(66.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(188.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(4.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(15.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">6.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(43.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(58.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(149.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(169.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">As of <br clear="none"/>September 30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of <br clear="none"/>December 31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations and milestones</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">611.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">467.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">438.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">241.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">282.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">180.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">130.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">190.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">195.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">157.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">134.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued TECFIDERA litigation settlement and license charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">606.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">685.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,455.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,903.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917142672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939618896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 120.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782383440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hemophilia Spin Off (Details) - Bioverativ<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">144.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">116.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">314.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other, net</a></td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets transferred, net</a></td>
<td class="nump">1,008.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">87.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">67.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities transferred, net</a></td>
<td class="nump">$ 155.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2510-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782739152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin Off (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98.6<span></span>
</td>
<td class="nump">$ 180.4<span></span>
</td>
<td class="nump">$ 265.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416.9<span></span>
</td>
<td class="nump">1,120.8<span></span>
</td>
<td class="nump">1,100.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,622.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539.6<span></span>
</td>
<td class="nump">7,642.3<span></span>
</td>
<td class="nump">7,315.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217.0<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
<td class="nump">$ 604.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativTransactionServicesAgreement', window );">Term of Bioverativ transaction services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TermofBioverativManufacturingandSupplyAgreement', window );">Term of Bioverativ manufacturing and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativManufacturingandSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Manufacturing and Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativManufacturingandSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TermofBioverativTransactionServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of Bioverativ Transaction Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TermofBioverativTransactionServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782666960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,123.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(1,547.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(519.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2017</a></td>
<td class="nump">664.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">422.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(320.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(70.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2017</a></td>
<td class="nump">102.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">482.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">1,681.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="nump">11.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(1,227.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(431.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2017</a></td>
<td class="nump">516.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract', window );"><strong>Analysis of the amount of, and change in, reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of December 31, 2016</a></td>
<td class="nump">51.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(8.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/credits relating to sales in current year</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/credits relating to sales in prior years</a></td>
<td class="num">(17.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance as of September 30, 2017</a></td>
<td class="nump">$ 45.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of the amount of, and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ReserveForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769569728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 664.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">197.4<span></span>
</td>
<td class="nump">166.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract', window );"><strong>Summary of total product revenue reserves included in consolidated balance sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total reserves</a></td>
<td class="nump">$ 467.2<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769493376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 208.1<span></span>
</td>
<td class="nump">$ 170.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">647.6<span></span>
</td>
<td class="nump">698.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">175.5<span></span>
</td>
<td class="nump">170.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">1,031.2<span></span>
</td>
<td class="nump">1,039.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">1,007.2<span></span>
</td>
<td class="nump">1,001.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630535536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory Inventory (Details Textual) - Bioverativ<br> $ in Millions</strong></div></th>
<th class="th">
<div>Feb. 01, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">$ 116.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">84.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2473-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_WorkinprocessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=biib_FinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786252416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 108.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.7<span></span>
</td>
<td class="nump">$ 674.9<span></span>
</td>
<td class="nump">$ 281.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">8,295.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,295.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,276.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,276.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,934.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,019.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,019.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment made to Forward Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA intellectual property charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract', window );"><strong>Intangible Assets and Goodwill (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2017 (remaining three months)</a></td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2018</a></td>
<td class="nump">421.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">404.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">389.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">256.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">244.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">30.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">413.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(532.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(532.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(523.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,675.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,675.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,634.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">329.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">4,002.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,002.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,481.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,067.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,067.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(776.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,934.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,934.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,705.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="nump">40.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Samsung Biosimilar Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite until commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI product | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,293.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,293.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a,h)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779516464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 383.8<span></span>
</td>
<td class="nump">$ 337.0<span></span>
</td>
<td class="nump">892.6<span></span>
</td>
<td class="nump">$ 1,047.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">$ 4,127.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,127.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=SL51721533-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=65878427&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=SL51721673-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783974976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 5,022.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,184.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,558.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">522.1<span></span>
</td>
<td class="nump">$ 492.1<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">$ 521.6<span></span>
</td>
<td class="nump">$ 515.7<span></span>
</td>
<td class="nump">$ 506.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">628.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,584.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,870.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">567.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, Level 1 | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,184.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,039.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">6,238.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,533.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,584.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,663.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,870.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">567.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">522.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">522.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82895926&amp;loc=d3e24584-111560<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785433920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 6,494.7<span></span>
</td>
<td class="nump">$ 6,499.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">7,048.3<span></span>
</td>
<td class="nump">6,808.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">561.7<span></span>
</td>
<td class="nump">583.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">553.1<span></span>
</td>
<td class="nump">558.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,536.2<span></span>
</td>
<td class="nump">1,521.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,486.5<span></span>
</td>
<td class="nump">1,485.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,049.4<span></span>
</td>
<td class="nump">1,026.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">994.0<span></span>
</td>
<td class="nump">993.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,867.0<span></span>
</td>
<td class="nump">1,796.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">1,735.9<span></span>
</td>
<td class="nump">1,734.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">2,030.8<span></span>
</td>
<td class="nump">1,874.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,721.9<span></span>
</td>
<td class="nump">$ 1,721.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13476-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6940088224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">61.2<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">492.1<span></span>
</td>
<td class="nump">515.7<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="nump">506.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 522.1<span></span>
</td>
<td class="nump">$ 521.6<span></span>
</td>
<td class="nump">$ 522.1<span></span>
</td>
<td class="nump">$ 521.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781544480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques', window );">Changes in valuation techniques</a></td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 280.0<span></span>
</td>
<td class="nump">$ 246.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsChangesInValuationTechniques">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the changes in valuation technique(s) and related inputs used to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsChangesInValuationTechniques</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770329456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 1,184.3<span></span>
</td>
<td class="nump">$ 2,039.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">126.4<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">871.1<span></span>
</td>
<td class="nump">741.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 144.8<span></span>
</td>
<td class="nump">$ 1,266.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770020832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 5,022.2<span></span>
</td>
<td class="nump">$ 5,398.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">5,026.2<span></span>
</td>
<td class="nump">5,406.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,042.9<span></span>
</td>
<td class="nump">1,408.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,043.1<span></span>
</td>
<td class="nump">1,409.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,541.8<span></span>
</td>
<td class="nump">1,255.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,541.7<span></span>
</td>
<td class="nump">1,258.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">916.0<span></span>
</td>
<td class="nump">1,156.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">916.8<span></span>
</td>
<td class="nump">1,156.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">954.0<span></span>
</td>
<td class="nump">1,016.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">957.0<span></span>
</td>
<td class="nump">1,019.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">566.2<span></span>
</td>
<td class="nump">557.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">566.3<span></span>
</td>
<td class="nump">559.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 33.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781755264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">$ 1,960.2<span></span>
</td>
<td class="nump">$ 2,568.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">1,961.2<span></span>
</td>
<td class="nump">2,569.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">2,792.9<span></span>
</td>
<td class="nump">2,552.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">2,795.7<span></span>
</td>
<td class="nump">2,559.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">269.1<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">269.3<span></span>
</td>
<td class="nump">277.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">5,022.2<span></span>
</td>
<td class="nump">5,398.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 5,026.2<span></span>
</td>
<td class="nump">$ 5,406.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927541328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 888.1<span></span>
</td>
<td class="nump">$ 2,362.2<span></span>
</td>
<td class="nump">$ 4,472.6<span></span>
</td>
<td class="nump">$ 5,185.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (1.2)<span></span>
</td>
<td class="num">$ (1.1)<span></span>
</td>
<td class="num">$ (4.4)<span></span>
</td>
<td class="num">$ (2.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781705488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">17 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772536288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 84.9<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784322912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="nump">$ 113.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (49.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="num">$ (5.7)<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">366.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 902.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember', window );">Investments and other assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value, net</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">80.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of Derivatives designated as Hedging Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, net</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,637.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,637.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">(18.8)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in product revenue for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in earnings of Foreign currency forward contracts due to hedge ineffectiveness</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,573.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">39.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.900% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DerivativeInstrumentsTextualAbstract', window );"><strong>Derivative Instruments (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior Notes interest rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624177-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784393328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment Property, Plant and Equipment (Details)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>CHF (SFr)</div>
</th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,580.6<span></span>
</td>
<td class="nump">$ 1,439.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968.8<span></span>
</td>
<td class="nump">$ 481.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Contractual commitments for the construction of the facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland | Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Land purchase</a></td>
<td class="nump">SFr 64.4<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656442688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract', window );"><strong>Reconciliation of equity attributable to non-controlling interests</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, beginning of period</a></td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (11.5)<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to NCI, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Fair value of net assets and liabilities acquired and assigned to NCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Translation adjustment and other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">NCI, end of period</a></td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="num">$ (2.7)<span></span>
</td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="num">$ (2.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of equity attributable to non-controlling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReconciliationOfEquityAttributableToNonControllingInterestsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770468816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,365.4<span></span>
</td>
<td class="nump">$ 348.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Equity increase during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">2,836.5<span></span>
</td>
<td class="nump">3,053.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Adjustment to retained earnings reflecting spin-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember', window );">2016 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases under the 2015 Share Repurchase Program</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 348.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember', window );">2011 Share Repurchase Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramYearToDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770372784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (319.9)<span></span>
</td>
<td class="num">$ (224.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24.8)<span></span>
</td>
<td class="num">(78.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="num">$ (18.1)<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(76.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(329.4)<span></span>
</td>
<td class="num">(300.9)<span></span>
</td>
<td class="num">(329.4)<span></span>
</td>
<td class="num">(300.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176.5)<span></span>
</td>
<td class="num">(17.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(104.5)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(104.5)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">(33.2)<span></span>
</td>
<td class="num">(36.5)<span></span>
</td>
<td class="num">(33.2)<span></span>
</td>
<td class="num">(36.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated other comprehensive income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334.2)<span></span>
</td>
<td class="num">(195.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income loss before reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.7<span></span>
</td>
<td class="num">(62.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net current period other comprehensive income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.7<span></span>
</td>
<td class="num">(62.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, as of the end of the period</a></td>
<td class="num">$ (187.5)<span></span>
</td>
<td class="num">$ (258.4)<span></span>
</td>
<td class="num">$ (187.5)<span></span>
</td>
<td class="num">$ (258.4)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84158357&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939932560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">$ (43.6)<span></span>
</td>
<td class="num">$ (58.1)<span></span>
</td>
<td class="num">$ (149.4)<span></span>
</td>
<td class="num">$ (169.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">383.8<span></span>
</td>
<td class="nump">337.0<span></span>
</td>
<td class="nump">892.6<span></span>
</td>
<td class="nump">1,047.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="num">(2,622.5)<span></span>
</td>
<td class="num">(2,539.6)<span></span>
</td>
<td class="num">(7,642.3)<span></span>
</td>
<td class="num">(7,315.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">1,226.1<span></span>
</td>
<td class="nump">1,032.9<span></span>
</td>
<td class="nump">2,836.5<span></span>
</td>
<td class="nump">3,053.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(18.8)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(15.3)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Unrealized Investment Gain (Loss) | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="num">(18.8)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
<td class="num">(15.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769745808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc</a></td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 1,032.9<span></span>
</td>
<td class="nump">$ 2,836.5<span></span>
</td>
<td class="nump">$ 3,053.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">218.9<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">219.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
<td class="nump">213.3<span></span>
</td>
<td class="nump">219.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770862656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 43.1<span></span>
</td>
<td class="nump">$ 53.9<span></span>
</td>
<td class="nump">$ 127.6<span></span>
</td>
<td class="nump">$ 158.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">40.6<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">147.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(31.8)<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(19.5)<span></span>
</td>
<td class="num">(22.7)<span></span>
</td>
<td class="num">(55.7)<span></span>
</td>
<td class="num">(65.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(23.6)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
<td class="num">(71.9)<span></span>
</td>
<td class="num">(94.6)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (29.7)<span></span>
</td>
<td class="num">$ (36.1)<span></span>
</td>
<td class="num">$ (88.2)<span></span>
</td>
<td class="num">$ (105.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786964480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 43.1<span></span>
</td>
<td class="nump">$ 53.9<span></span>
</td>
<td class="nump">$ 127.6<span></span>
</td>
<td class="nump">$ 158.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(10.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">40.6<span></span>
</td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">147.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">92.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember', window );">2017 Omnibus Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock available for grant under the 2017 Omnibus Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770024720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
<td class="num">(11.40%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">23.80%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
<td class="nump">23.90%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934471472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income tax payment, including penalties and interest</a></td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770300832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations and milestones</a></td>
<td class="nump">$ 611.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">664.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">664.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">241.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses accrual</a></td>
<td class="nump">180.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">190.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Construction Payable</a></td>
<td class="nump">157.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued TECFIDERA litigation settlement and license charges</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">606.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">2,455.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,455.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,903.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">54.2<span></span>
</td>
<td class="nump">$ 43.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(61.8)<span></span>
</td>
<td class="num">(66.0)<span></span>
</td>
<td class="num">(188.8)<span></span>
</td>
<td class="num">(195.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on sales of investments, net</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="num">(4.9)<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(5.1)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(14.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(43.6)<span></span>
</td>
<td class="num">$ (58.1)<span></span>
</td>
<td class="num">(149.4)<span></span>
</td>
<td class="num">$ (169.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 467.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 467.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6938288832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 714.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 817.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,539.6<span></span>
</td>
<td class="nump">$ 7,642.3<span></span>
</td>
<td class="nump">$ 7,315.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductLiabilityContingencyLineItems', window );"><strong>Product Liability Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8364; 41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductLiabilityContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductLiabilityContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6781990336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 49.7<span></span>
</td>
<td class="nump">$ 47.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement', window );">Research and development cost in support of collaboration agreement</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development cost in support of the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostInSupportOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785494064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 446.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 529.0<span></span>
</td>
<td class="nump">$ 1,666.0<span></span>
</td>
<td class="nump">$ 1,439.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">ZINBRYTA related assets</a></td>
<td class="nump">23,073.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,073.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,876.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">180.4<span></span>
</td>
<td class="nump">265.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">82.5<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">2,622.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539.6<span></span>
</td>
<td class="nump">7,642.3<span></span>
</td>
<td class="nump">7,315.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">ZINBRYTA related assets</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecorded tax benefit</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payments</a></td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCostRoyaltyExpense', window );">Direct Operating Cost, Royalty Expense</a></td>
<td class="nump">34.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="nump">197.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals [Member] | SPINRAZA | Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase in acquired and in-licensed rights and patents</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Royalty payments per the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Ionis Pharmaceuticals [Member] | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Royalty payments per the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCostRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty expense incurred and are directly related to goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCostRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771684528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2012</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 82.5<span></span>
</td>
<td class="num">$ (0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
<td class="nump">$ 180.4<span></span>
</td>
<td class="nump">265.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Biosimilar Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum', window );">Percentage of stake in entity maximum</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share with Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">$ 80.5<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Revenue related to technical development and technology transfer services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity method investment ownership percentage maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771228592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Eisai (Details) - Subsequent Event - Eisai<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">E.U.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6917564224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Neurimmune (Details) - Subsequent Event - Neurimmune<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Neurimmune</a></td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest', window );">Additional potential payment to Neurimmune</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalPotentialPaymentstoNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Potential Payments to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalPotentialPaymentstoNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M7'_X781=,'9K_['Q65"V\.LNY!=02P,$%     @ DX182YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M3@M*KE)/4S7G0PL9%I)U8WL$4X\N_@)02P,$%     @ DX182T'&O%UE!0
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M:80"[831Q$);TOO#Z9R'^!CP3<#D-F<2*KD:\Q2,CTU)DR ()-0^,'#<;O
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M?(]G.XW99'C3SS^(+=^X_ U02P,$%     @ DX182[/;?-ZV 0  T@,  !D
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M_FS&,1L-A]WT@]C\C?-_4$L#!!0    ( ).$6$O231 ZM@$  - #   9
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MX.DZ?+NJ<!OAVS<*_Y-_MTJPBP2[#TM<BWFODBUZJL V<9H<*4VOXR0OO//
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MF XTWM3&*N[1M USG05>19"2+-UL;IGB0M,BB[ZS+3+3>RDTG"UQO5+<OIU
MFB&G"?UP/(FF]<'!BJSC#3R#_]Z=+5IL9JF$ NV$T<1"G=/[Y'C:A?@8\$/
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M/A'L_UOB6LSQKR1LT5,-KDG3Y$EI>Y,F>>&=!_:!IS?Y'3Y.^Q?A&FD\N=J
M+YOZ7UL; *5L[G"$6OQ@LZ&@#O%XCV<WCMEH!-M-/XC-W[CX!5!+ P04
M" "3A%A+DUWSO+(!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6QM4V&/FS ,_2M1?L %:'>W58!TO6G:I$VJ;MKM<PH&HDMBEH1R^_=+ F6L
MXPNQC=_SL^/D(YI7VP$X\J:DM@7MG.L/C-FJ \7M'?:@_9\&C>+.NZ9EMC?
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ML-F04/EPW./9CF,V&MYTTP]B\S?.WP%02P,$%     @ DX182XA"GE^U 0
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M-"X<;_W93&,V&0[[^0>QY1N7OP%02P,$%     @ DX182T8VC!:P 0  T@,
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M?-G4_\;: "AE=X,CU.$'6PP%38C'MWAVTYA-1K#]_(/8\HW+7U!+ P04
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MJ+])E90&;"K1C2VXL4_%8G"HC-O>VKV:!F8RC.SGMX L#U+^%U!+ P04
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MH3)NN[=[-0W,9!C9SV\!61ZD_"]02P,$%     @ DX182P^-RF;< 0   04
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M0=-/&;EXHAESG#!TA=DL".+8%PD:DSC2#^4T7KZ-.MR&\NU:?;^/$^RB!+M
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M[\WPDH? Z78<4C+]4^3_ %!+ P04    " "3A%A+Q?G[!<<!   W!   &0
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M'3LEW\NNF:AVTQ=B?4>*TU!D^F.EN_X+4$L#!!0    ( ).$6$L[U_'> @(
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M/*^RFGX8U,OYG*4/QQ_;[+%JOC;K7'2O)74_JOS0OW*U.K[W=?T_4$L#!!0
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M95'W?V?/;W53[H<H+95]]O/TN3OTGQ]#_,]A>  ?!O#S ":C \0P0% 'R&&
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MC ;0Y6[QMDH,XA+!]<PIGHB33!% A5T1Q[7,*;Z(^Z;'RTL,XA+!BL IQF@
M18G$(.X-!=8503%%PE<,L$  %5X@@55%3#!% JN*H)BB 11+;13B$@G<K%'<
MT "*$HE!7")8DP3%:PR@*)$8Q"6"E4T C[$4@1!8V<0$CR&P)@F*QQA T73$
M("X1K$8".0L9"(%U1$QP%A(K@*0X"^D[BW$ZHA"7"*Y]B1Q%P)1(7/MR@J.0
MN&HEQ5'(ZU4;A;A$ NT5Y"0"-QD2UYN<X"0DKC=)<1*2V&0!N%B71>+ZE11/
M(:_7;Q3B$L'U*REN0E+:+)+>9Y%8""3%4$A2JP6A@KT6A45%46R%\@V#YL)Z
MK0F ,TJ()-1LQ/*B)E@+A>5%4:R%HO5;$"S8;U%8JQ3%8:CK6A6%N$2P5BF*
MPU!^FP(F!L#"B0ETEI'1"*TU%CXUP6@H+%2*8C04L9F!<)%FAL*2I9#E"(7
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M'0RH#G*D&CO:A3OZ!0Q7-H8ZAGF>-,C<%,3H7/H@5)JY<@2K!(8Z!BM'=B^
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M<R]S:&5E=#4W+GAM;'V5VXZ;,!"&7P7Q )QM8$60&JJJE5HIVJK;:R=Q EK
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M<EX8DU1Y!IY*KU;%=!FT]")U-U5]/E64:2#9,%=+?RG9Y3]02P,$%     @
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M?.)RNQ)[JB>Z/G#2CX\5F%[,[1]02P,$%     @ DX182]8Z-R'7 0  ;@0
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MV+D:.W@,C.S#Y<33'Z+Z"U!+ P04    " "3A%A+2?<N V %  "\'@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R565UOHS@4_2LH[Q/P)U"ED9JD
M:%?:E:H9[>XS3=PF&@A9H,WLOU\^W!3LXX:\-($>7ZZ/.<?WQHMS4?ZL]DK5
MWJ\\.U;WLWU=G^Y\O]KN59Y6\^*DCLU_7HHR3^OFLGSUJU.ITETW*,]\&@32
MS]/#<;9<=/>>RN6B>*NSPU$]E5[UEN=I^=]*9<7Y?D9F'S>^'U[W=7O#7RY.
MZ:OZH>J_3D]E<^5?HNP.N3I6A^+HE>KE?O9 [A(IV@$=XN^#.E>#[UX[E>>B
M^-E>_+Z[GP5M1BI3V[H-D38?[VJMLJR-U.3QKPXZNSRS'3C\_A$]Z2;?3.8Y
MK=2ZR/XY[.K]_2R:>3OUDKYE]??B_)O2$Q(S3\_^#_6NL@;>9M(\8UMD5??7
MV[Y5=9'K*$TJ>?JK_SP<N\^SCO\Q# ^@>@"]#"#BRP%,#V"? _B7 [@>P*<^
M0>@!8NH3I!X@/P?(;CUZLCKV-VF=+A=E<?;*_@4ZI>U[2NYDL[[;]F:WG-W_
MF@6HFKOO2R[CA?_>!M*858^A PQE8\C&AI Q(K$1C(H+QF^2O&1*4:8K:F<Q
M?L0:(+B1Y]4@C]>#)#9$<CP3!CEGW7@VY#P,<  . _ N !\%,/A>]9BHPQS[
M%2'FJDW )#TF'&"^\7@>X70%3%> = W:5STF'CZ&S,T%%E8NP=Q<81OS3<Q#
M8Y%M$)%SB><DX9PDF!/# 4(8()S^$D0P0 0R,,E &&$L\->842(Q3"0& 1Q<
MD@";4#"=#.+P,3*!#@@*3:-"(,?[3J!5/1 *0L2.$-@CR TF0;!+$& 346!Z
M.[>$QZ0TE;<AM@T 6 )@<4#GQ)$WM@L"_")RA<#J)-)F+Z*.$%B?) 19F.:H
M04/VQ-"2Q@_".B9 @)$K!%8@B:=/EV()TN#Z=%<:-)PNF9N;RA10HD%B '),
MF6*]4Z#2R%5/8)52>@-K6*6436&-680$-FL30 D .;<MBDV!(E-PA<#ZI.(&
MWK ^*=@^H]#D35JSC8)!Y:&)NX(:IX.U3I'672&PBFET RE8Q11LI#8I,5"7
MZ=930(D&#27HV*(8M@R&+,,5 JN8D>FL,:QB!O9:BS4-&A)"N47;)%0"4-PE
M0N9H (!MQ([-G6$=,SZ]/F!8QPSMLV9]P.S"G$@6SF.3NVFX!."BD P*]''F
MV#X8L(_842$P+'EV0_W-L.09VK@M_B)+9=(LP3=70.-DL'DP8!ZQ0TD<ZYG?
M4(5SK&<.=N78W \U:-SK1::QKQ%,6)J%P<3<Z(8?$2QPO74<.PT'3A,[JA:.
MA<]O:?T=O3_8P&V*[:H^F N38!O4<&(1C$*9_30.Y>(&VQ$'=A0[1,"Q+W!0
M]COIQ;[ 02D02Y->N^RW.%D#4,.)-.FU4=*FUP8Q)[O8K#@PJ]CU_F.+X:#+
M<+$KL,4(4#)8[ J[@;!>R[4&#7^[,JQW ^(T"V Z@T:%8Y3CIQR!;4\@VW/]
M1(;-18!FQ$DN-A>!FA%S/Q)V"T%$R.R?T:;A$H#[8C\7V-,$\C1')2D<OS&"
MIL3)'W8/@9H2BS^[W6"Q*=C-)%2B40*^P^.,L5D)VZQ$X J!?4& OL7)&_8%
M@?H6BS?0D@#>IJ 287<NCHPEMB%IVY ('/6CQ)*7H'-Q\2:QY"7J7$S>-&AH
M3U9ULYD"2C0(.^8X7^PO$O@+<;&&A2YOZ%HD%KH$90(5)FL(9+YL5T!],O[@
M("U7Y6MW#%IYV^+M6+<3&=R]'+4^T/8@SKB_(G=K NYOR-UC?Y#Z&;X_U_TS
M+5\/Q\I[+NJZR+M#NI>BJ%63>U/,S;R]2G>7BTR]U.W7L/E>]N>I_45=G/19
ML7\YL%[^#U!+ P04    " "3A%A+^L2XXVH"  "L!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6R-5>V.FS 0?!7$ P VWQ%!NB17M5(KG:YJ^]LA
M3D 'F-I.N+Y];>-P!)Q3\B/89F9V=HV]64_H&RLQYM9[4[=L;9><=RO7946)
M&\0<TN%6O#D2VB NIO3DLHYB=%"DIG:AYT5N@ZK6SC.U]D+SC)QY7;7XA5KL
MW#2(_MO@FO1K&]C7A=?J5'*YX.99AT[X)^:_NA<J9NZH<J@:W+**M!;%Q[7]
M!%;/0!$4XG>%>S896S*5/2%O<O+ML+8]Z0C7N.!2 HG'!6]Q74LEX>.O%K7'
MF)(X'5_5OZCD13)[Q/"6U'^J R_7=F);!WQ$YYJ_DOXKU@F%MJ6S_XXON!9P
MZ43$*$C-U+]5G!DGC5815AKT/CRK5CU[K7^EF0E0$^!(@/ZG!%\3_ \"^)00
M:$+P*"'4A'!&<(?<53%WB*,\HZ2WZ/ ]=$A^=F 5BNTJY*+:'?5.U).)U4L>
M>C!S+U)(8S8#!DXPT!\AKI ?8T!3C U<\$//OXVQ-6&"6\QNB8%I?(MY-NF$
M9K.^L2"^$O!O!"*S0& 4")1 <",P<[D;,+'"M H#PL1SHEDR!EC@I\Z=XH=&
M.Z'!3F(6B(P"T>,%B8T"L<%!.BO(@$DGF:91XB2S>L2+>@0)<.YL;V(TDRS-
M &]F9L DDS#0OQ,D-09)#4& 60!XYF/I/5YU<.=D X.+Q='6Y]^?)!L%3N!-
M?F!V5#5GN@T17.R".[F!&DQ/JATPJR#GELL#.ED=6\X3E#?8;'T#5MOA9ON0
M&?K8#T1/5<NL/>'B?E2WV)$0CH5)SQ'??2E:YSBI\9'+82S&=.@?PX233O=&
M=VS0^7]02P,$%     @ DX182P15Y;)\ @  T@@  !D   !X;"]W;W)K<VAE
M971S+W-H965T-C,N>&ULC59=DYHP%/TK#.\E@""LH\PL2J>=:6><W6G['#$J
MLT!H$F7[[YL/9#%DQ1=)+N>>>TX2<UFVF+S1$T+,>J_*FJ[L$V/- @":GU %
MJ8,;5/,W!TPJR/B4' %M"()[F525P'?=.:A@4=O)4L:V)%GB,RN+&FV)1<]5
M!<F_%)6X7=F>?0V\%,<3$P&0+!MX1*^(_6JVA,] S[(O*E33 M<608>5_>PM
MLEC@)>!W@5HZ&%O"R0[C-S'YOE_9KA"$2I0SP0#YXX+6J"P%$9?QM^.T^Y(B
M<3B^LG^5WKF7':1HC<L_Q9Z=5G9L6WMT@.>2O>#V&^K\A+;5F?^!+JCD<*&$
MU\AQ2>6OE9\IPU7'PJ54\%T]BUH^6_4FNJ:9$_PNP>\3>.U[";,N8?:1$-Q-
M"+J$X-$*89<0:A6 \BX7<P,93)8$MQ91QZ&!XM1YBY!O5RZ"<G?D.[Z>E$<O
M2>C-EN BB#I,JC#^ .-KD,T8XO4(P 7T*GR3BM0?5[@ML#8@ DW#)$EVE^1&
MYLRX6#.9/[M9K$\( B-!( F"&X)06VV%B22FEI@OGN?,M?4PH%S'TU;$3*45
MS,8HW_ED]T*CJ]#@2M.;*DPX*.)JCA3B:2C6=R+-D0$TLIT90*$3FQW-C8[F
M!D>:E'0^Z6@2L9E$9/.1%]=Y,EN)C%8B@Y58LQ)-6HD,,O33-LF2W6>Y,1,;
MS<0&,T^:F?BA_X\!-3YM#U%E$U3*%AA<R!4B1]D=J97C<\W$E3*(]@WXV1<7
MNA9/O<7:,\0WO&&K_OI!K[K]3TB.14VM'6:\C<C+_H Q0UR[Z_#M.O$/C'Y2
MH@,3PXB/B6JS:L)PTWU!@/XS)OD/4$L#!!0    ( ).$6$NUF'*5]P(  ((+
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;)56VXZ;,!#]%<0' +:Y
M)4HB;6YJI59:M6K[S"9.@A9P"DZR_?O:QLN"/>QF7X)MSIPY,QXF,[NQ^KDY
M4<J=E[*HFKE[XOP\]?UF=Z)EUGCL3"OQYL#J,N-B6Q_]YES3;*^,RL+'01#[
M9997[F*FSA[KQ8Q=>)%7]+%VFDM99O6_)2W8;>XB]_7@1WX\<7G@+V;G[$A_
M4O[K_%B+G=^Q[/.25DW.*J>FA[G[@*9;E$@#A?B=TUO36SLRE"?&GN7FZW[N
M!E(1+>B.2XI,/*YT18M",@D=?S6IV_F4AOWU*_M6!2^"><H:NF+%GWS/3W,W
M=9T]/627@O]@MR]4!Q2YCH[^&[W20L"E$N%CQXI&_3J[2\-9J5F$E#)[:9]Y
MI9ZW]DTRT6:P =8&N#,0OM\S(-J O!F$[QJ$VB"\UT.D#:)[/<3:(#8,_#99
M*OOKC&>+6<UN3MT6T#F3=8JFL;C?G3Q4UZG>B0MHQ.EU$>%@YE\ED<8L6PSN
M83 90M8V!'4(7PCH5&!(Q1+;'H8.5@ B-#1\2++YF&1K0R(\$@H!$TH4 1D0
M8)@@! E"11 .",QTMYA$8:HVW22./".8C0TC8>I-8#41J"8"U)B);S&3GIL$
M!QZ!W<2@F]AR$R9&%<9VS!C''C(*!8 %!/>";C7'EF:<DMB+C S:,!)$Q(OA
MV!(PM@1(H>%GG5A^T@A[*>PF!=VD@)L1G1.08')_Y:( ;B8!H,&\1PU*!SD-
MC)ZS E"1A5K?Q;7YB&L8VDB?1$!HJ2D'V>7B):8:&X2\D1:#P';Y@/ =/4*#
MTL&78.<&?Z9'(+CG(0+H&:. NQX*/U%]<*M"0*\B1KQ;#8KZ'_Y8)<"M"MF]
M"J@$NW&@L8Z(X+:!H+YA77)B7]_@CZ#UY/?&@9+61S7,-<Z.72HND]X[[0;&
M!RS'">-\B:8K!)ROT733CH-O].UT^CVKCWG5.$^,BR%&C1H'QC@5Z@-/7,-)
M#,3=IJ '+I>)6-?M5-AN.#OKB=?OQN[%?U!+ P04    " "3A%A+4&@) 68$
M  ":%@  &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R5F%N/JS84A?\*
MXGT VURC)-),0M5*K30Z5=MG)G$N.H!38":G_[[F,AEL+Q+./$P"6=[>>\/Z
M,%Y>1?6]/G'>6#^*O*Q7]JEI+@O7K7<G7F2U(RZ\E+\<1%5DC3RLCFY]J7BV
M[P85N4L]+W2+[%S:ZV5W[K5:+\5[DY]+_EI9]7M19-5_+SP7UY5-[,\3W\['
M4].><-?+2W;D?_+FK\MK)8_<6Y3]N>!E?1:E5?'#RGXFBY2%[8!.\?>97^O1
M=ZLMY4V([^W!;_N5[;49\9SOFC9$)C\^^(;G>1M)YO'O$-2^S=D.''__C/Y+
M5[PLYBVK^4;D_YSWS6EEQ[:UYX?L/6^^B>NO?"@HL*VA^M_Y!\^EO,U$SK$3
M>=W]MW;O=2.*(8I,I<A^])_GLON\#O$_A^$!=!A ;P/DW/<&L&$ ^QK@WQW@
M#P/\N3,$PX! F\'M:^^:N<V:;+VLQ-6J^OOADK6W'5D$\G+MVI/=U>E^D_VL
MY=F/=<#(TOUH PV:EUY#1QK*5,G6E'P%<64"MRPHRN*%FC.H$VR PM=R>!@D
MO1M$29/!9K%N/%.:17$ 'P;PNP"^$D!O9:^).DW9:9X829Q$JZ67Q6,9G:HF
M@,D$(!F]I[TF46;QG5C+!:BBV)GH3 B3"4$R@99,:$Q# D=K7PI$(XV2200S
MB4 FH>:(R+A&B:.U;F-JGDCL:-[:1F;K$D<K/ 6B*'02;_0W8;<8EAB#$B.M
MQ-B<DU&S2B3S//UNW<Z+ECZ,IA27P.(24%R, Q /,]&;[W,R@54RP^F#2"F7
M>(:[D&RL4O.!@'TF=(;9!]%XHL"X%X&(3%F=8(P2-L/L@TB=A^C)F"+/F8 @
MP4@FB,FAGHQOS!,ZH9Z,*2(CD9H,1C)!3-:=20!N?4=_8 *5<6MM9X5*'X12
M"\-X)XCO$[8FF,LD^@E78NX1!#[#E2:$@L@TI:F2UIU*!Y.*(%09IDP )"3]
M#5]"W10Z*28?]68X<Q II9LW#5!-@IQBB%($4=V:%$$TI,:Z8- %:G\F\L$0
MI0BBNCNIR4<)=5^_7AND"PV#SHR6/HJFEH>Q3 &6?6\B!(8I]>=[E&($4H1
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MYW7[:VW/M>"%8I&N%.EK]\S*]GE1_&]FL %6!OAJ(->^94"4 7DW\&\:^,K
M_^@*5!E0;06WT]X&,TY%NEI4_&)573Z<TB;MT)S*[=HVD^WNM/_)>-9R]F5%
M?;QP7QHBA5EW&-S#8#*$Q"8$71&N=.#J!8:\6&-SA>$"&P#A:SY,DB0W209N
M$C!8I+4G@V 1F, '"?R6P.\1^$@+=@<)6TC90NY\X@1:.  4C1R-*P90R)\Y
M6N 2"!;T80-E%%1&#64DU*5UF%EO'1(1)]*D=2C:1Y%0$V8R13.L!RDQF9#G
MA["J %05&*JPML@Z,%RYPP'&#M5D03A*9KK3,8 + Q\[VHE+ D/<74@0A=6%
MH+K0S$8MT.O0\ 9A'.B)M@%@'L'.3--FPG!$ CU4B0DC'NV?@8&V"-06&=JH
M/Y+0,Y!@]O&SCCRXM'K3\568P7:CR#@3$(SJ*1&#9 8L 6'.F+:1:P,!\1U)
M/@36_'N$/Q%AN!XC,EU/%6:@UM,S<Z-0_>/DZ=$%B) 3ZL$%EQM)703?$LB\
M)LQBJD#]A3Q]JS<*=%,6Q*-74A"$1T3!%P0R;PCJC\4%KL8H^$3&P"4/ 37/
MB*Q9?SRCXGT$%(,@_:-D C14!1<[9%8[(&&BJ5S83$/B:4AR$S*4 Y=>-)N^
M=A5FLG ",*IO00R247T[$PCF.2,?%!B^%+!Y*5#C5E"@<) 2^@<%"-*5@2"]
M9H$@_;)T>QU%P:I#V][5UI:?2]&<R=[LM86\QTU'HLVOT7R#@/E8MIQ=@_A.
MW_6K/]+JD)6U]<2%[(/:;F7/N6#2=QD6VSK*%ODZR-E>-*^A?*^Z/K$;"'Y2
M/;![;<17_P%02P,$%     @ DX182R?0J7P& P  K@P  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C<N>&ULE5?1;ILP%/T5Q <$;# A41*IA$R;M$E5IVW/
M3N(DJ( 9.$GW][,-I6!N$OI2;'/N\3W'SNUE<>7E:W5B3%AO69I72_LD1#%W
MG&IW8AFM)KQ@N7QSX&5&A9R61Z<J2D;W.BA+'>RZ@9/1)+=7"[WV7*X6_"S2
M)&?/I56=LXR6_R*6\NO21O;[PDMR/ FUX*P6!3VRGTS\*IY+.7-:EGV2L;Q*
M>&Z5[+"TG]!\@T(5H!&_$W:M.F-+2=ER_JHFW_9+VU49L93MA**@\G%A:Y:F
MBDGF\;<AM=L]56!W_,[^18N78K:T8FN>_DGVXK2T0]O:LP,]I^*%7[^R1A"Q
MK4;]=W9AJ82K3.0>.YY6^J^U.U>"9PV+3"6C;_4SR?7S6K^9>DT8'("; -P&
MR+WO!7A-@/<1X-\-\)L ?^P.I D@Q@Y.K5V;&5-!5XN27ZVRO@\%5=<.S8D\
MKIU:U*>CWTD_*[EZ61$_7#@71=1@HAJ#.QCL]2'Q$():A",3:+/ 4!81'N[0
MWV -('PCAX<DF[LDO30]T"Q/QWL]LV8P@0\2^)K [Q(0UW"[QDPU)J^MQ#B8
M(,,0 .9Z>#(S3!G"<.@%$V(X,X1Y+O$F 2R.@.+(T)T;ER  XP/ '$-U5&-F
M73D(38R;L(90X<":&D5Z*.->;R#,C1.?@J*F0U,(A@E"D" $7#&RC,*!7G?@
M"80Q;D$,84Q'[N_5$S0#!<T 04:RT0P\9J,NK2'4S!0>0RAO(.L15T\8<N%:
MZ@+2R V*&^48C;\O"*RE3P@#601F2<? ,9HE9@PH;D#=GXA1T38/>/JBX,J+
M/$#4] 8%7'N1_PEKX0J'R!AK":#6_'<V!A2/ 6T>@/JRX,*+H,H;WJ" RQSZ
M1)U#<*%#4*4;F N5G\&]A4 #<T<P;1Z :EE.I]?*6'G4C6]E[?@Y%\J2SFK;
M7#]AU:L9ZQ&:KQ&P'JMF7/=V'_1U)_^#EL<DKZPM%[)#U'W<@7/!9.ZRNMO6
M27X\M).4'80:3N6XK#OH>B)XT7P=..TGRNH_4$L#!!0    ( ).$6$N>EQ<A
M20,  +\-   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;)5776^;,!3]
M*XCW L:8CRB)U$"F3=JDJM.V9YHX"2K@#)RD^_>S#:7$OK1I'@(VYQ[?<[ O
M]OS"FN?V0"FW7JJR;A?V@?/CS'7;S8%6>>NP(ZW%DQUKJIR+9K-WVV-#\ZT*
MJDK7][S0K?*BMI=SU??0+.?LQ,NBI@^-U9ZJ*F_^K6C)+@L;V:\=C\7^P&6'
MNYP?\SW]2?FOXT,C6N[ LBTJ6K<%JZV&[A;V/9JM42(#%.)W02_MZ-Z24IX8
M>Y:-;]N%[<F,:$DW7%+DXG*F*2U+R23R^-N3VL.8,G!\_\K^18D78I[REJ:L
M_%-L^6%AQ[:UI;O\5/)'=OE*>T'$MGKUW^F9E@(N,Q%C;%C9JG]K<VHYJWH6
MD4J5OW37HE;72_<D2OHP.,#O _PA0(S]7@#N _!;0/!N0- '!+>.0/H HHW@
M=MJ5F5G.\^6\81>KZ>;#,9?3#LV(>%T;V:G>CGHF_&Q%[WE)2#)WSY*HQZPZ
MC#_"^/@:DID0-"!<D<"0A0]EL?+-$:X'2 %$H.7P(<GZ79*K-#%H%E;Q>&Q6
MZ,$$ 4@0*(+@B@!I;G>82&%JA0FPHX%2$T2PH[VWS 0A/W)"S10 16)GPA<"
MRB* +,W[58=)1L/<^0[19 $@[&A,&0 R50$@Y#D1K"H$586 *FW>KT)CF,#3
M<TE-$!FGTJGJ0.3J97F:*),(!=&4J @4%0&BM(6TBD#OM-F50JA UYX!*(R<
M6!,&H(+Q[+@2%H/"8D,8]N'X!(Q/;E_;R(-+J0=X2_1:Z@&V)<9"@&"^;TP:
M"$:(#EM#L) X)!G_)K1.?#:0:3>>8 !+_CWR/V$X7(X1OL5P##B)C34*P<1$
MU6L/!(N0DWBC']+=!V*2X#;WX<\(,K\C.)Y@@"LV(I]P'RZ/"*J/AOMF6?-T
MYS^$9!]#ULBLC7?C.G.M"*Z-""J.X00%7(50_ E?X4*$DEM\38RO]IV?Z L_
MA6 XU'<3&02+8WWRKR$8\HBCUUEWM/FL:+-7)X'6VK!3S:4WH][AM''OR\VK
MUK]"LQ0!_9D\G:C-[AM]=[3YD3?[HFZM)\;%EEEM;'>,<2K2]QPQ?P[B-#4T
M2KKC\C82]TUWI.@:G!W[XY([G-F6_P%02P,$%     @ DX182\6,-R=V P
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M7XEXK]KFKOW@[-PUKG;?/:__ U!+ P04    " "3A%A+X3K7.M\"   F#
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M;8R9@MEX@$D?8++[S,!0B!H*$8$9,(0Q<V (868N,(0Q'C"$,3YN*$(-18@
MV.PQQH#-F& ,^*[2!W0RC(EP0U/4T!01 -L@QABPB@G&@%5,$68.5C'#F _.
MBAEJ:(8(@ \]QABPBLD#3(HQ<(40IK=U!X;FJ*$Y,@@\@C$&'!P)QL!# 6/
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M\=9[+\U-<5^12P!ES3YIZ$)#[V]G#?'\.0E=34(C8+M,4A;K@,TJ8!,!FT^
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M":-Q#U- 0!@!/\&?13I+>*(:L*YSP*L-SA=-'Y Z5;;)Z# M'WOY,;E$A(3
MQGC">H0#@/&%D[$.:O%:!IPDP"D2?64=_ZXKX-7 $0!9@.O(<+F#/[_ KI*$
MQL0OX)6&H<U@%7+SHG$_P"^\T.9?])3C]3I/)YMUC BVSJ)EML1CRS/"8,2^
M!)!I7>PW7V6XUVD&YX^DK<(4S5MP3DS@*I?X=5P W0!<7L)J"O_@<R8Z3^<;
MI+9?-\HO27K_ ,,<QE\ JX!]"D7>%'3U(F _T\T\1H2O(45[D'_@*2!C/<!S
M0!YV,X.=A-^-VCAHLZ3#]V(:O,1G5-G3IR4(A//TG["/>Z (!2-4 B@%5*%(
MIG"9URG )_X2IW."+UP@(L:[4&GGJ-.X>(CNYMEC])#,[I.=.+ES(+QK2/ F
M0)Z1XF63>7I/E&+7D"R=3;<1RH#%G&EF//MM4ZSK:"L3K*P1HG(#=\Y8]]HS
M<+;V_6]X\>O&WQ/W7\?S>#E-0'8"C:)X"9Z?)U,08;KU(HQ*TLPRJQ<2,0D)
M-Z$44F]@87@1RP^^C_//"</(XW25 T]1_4&V.TU@I(G@>&7%F^0ETM$ED/SE
MND:,E]L:;+6!;>Y\!L0Z((GK;3M:S6-1D! F)#(T,,624%+[U-LLFSW"Z=5M
MB.],07/Q'=FU_OK?])#G:3Q)YW0TU9.69U8H7K%HM<S60)=6\9:.U2_@+ET"
M2I*$F,,-OV?27%E0_+M_NQ$3FG_/-XF77OSLN\_-[+#"1K]J-^?)79*C\(A"
MB,[2@&CS;'E_"%1AL6LYO.X=#Z#JE)K#=T+BM/HPFB=^*%;Q-/GW/ZU0ILV_
M)'_Z2U01$H0"SI(ID4%FS0_9' 3.XCL1SJI(KULO6(M;Q2K(ONH<=3I=+R;4
M;0&97.U[G6'SB^,9D#C 0H#0*DYGAR0VK%* 6 VB;!8H3B2S6A:"-+PJ1J^!
MTQE!IW(V.<GG6UUYO"9YNOX(#5L)X/E__O=)KWO\8P-4/S1PD?HYZL>HH) 1
ML;^>N[2N8KQ2#PF0W'B.W.95]'V#*2H0I=[PA4(K0U:D3YB,FK%K3V1ZF0B)
MW.P-"$@O8JAG*EX5@?J$%&0**FL]?1T[^:= *0(X(&! "I1HZ<5[E"[@T_0E
MXY\G@/4 =1;. M6=E.JO4'[);',XB1&H>+L O+7JJ:.17OFK(6L/2&/)0&/V
M16R+UF'0F7AE%9!5(6)_[K$/HS#:9OVZ&L2+9VZL3LTS)P^']"6=P28FVUH$
M> HI6?]] FFN$!.2F;Q"!B!:ZR)>JUH"MV6QCVQWM0%,BHMGO''68/6 @V5Z
M#M?AS681KP#]%M'X+>,P4Y2=LZ]VB6FU5B$>5.P&3YB12N>D:FT=O)\Z(R-Z
M[#@CN[5UP)DJC\9;)C &@FE1;(C$HX4/7V+ULN%*!S+0;C0E]H6*$;[&ZM47
M.L$OM2K6=;+2U<%*7L?+S]%Y,GGJ%BATZR!5]VH+1!L$47* 1(C^8IO#GFK,
MQ=U=,B4NEOS.%SI"N[^[W-DSQFK4G=J@3]^G2Q0]Z$P?R+"39A7C\XX1$J1H
MN]Z]V2S@%F[QH9OT?IG> 1>'NR#4$Z>^ N98(TO^I>:1'0S<S%.8>6(_R*IA
MGOU7&+W>%""P <OZ""CV)4T>5>I*@5Y%]_-L M+&),V(5( 4O"&9A3 [7FX!
MXZ>$2'!ZL[28(IZ2U5EX'OV]B)>;NUAMJ\P1YRD_*=HGK@00?95D*Z .\"/^
M])BN'X#(P1%L"K@O&Y#HLGN:'<>@+V8)F[?1G(T+0*PLCJ*/FUP()2QMQ1X#
M9!]H?D^BVXNS-Y?G%]?C=C3^^>.'B[^UHZMW%V^O+\]_;4>WO]Z,7U]?MJ._
M7WYX??WK[9@F>S-^?_7K]9@N.,C$ZQ2764SG20YR&$@Z[V\.VM'-U>6'Z_'?
M^2E$'R0I:Y7="@ &+'VQ*=!&![HF2*BKAVW4NGD_/N!)/KT?P[+>-[P/$,T3
MI+O_ #E_561Y&L/<1]$O0$[G118]Q "#*5!GD,"CB1XK#GSGQ,8<#8@%0Q9D
ME!7>2(#[]>7MI[^-/]1/O,R6AS]EL_O/Z?*[(IIO%ZN';!&WX>+FV3*=RC?3
M+=H/YLGF<[)(XZAU]N[=@14.0'9D3M".WH[__NO/8SB.&1PFGE#MM#  +Q[E
M> :9G_OCV?7%SY]NGAICE:=T#\BL =! +'E_0\,B'5\5B&;O;]IFH2O09>&*
M$)*%%A+$T0U(P'!TL!WKM(AA<);1";!O 25!Z9@^M(E<P^C1(V@N\^UA]HBZ
MT2)93& 4H3'7V13^_S;/-BLZRV*S0D-!E $.S_+-O;M7V[(P&25WL&L4>N$D
M-O</--S4Z;9EN@$ @#&G?-/<H.U&6=49@^@'AU#VB8R6NEF*Z 6:PYJ/:KXE
M4*3(]>!.XE)P/P60'( J+*B.*B#(EDQ=XI63Z @HJ,0MF>F2,("<!W=[MX'W
M ?^G.?DF-HAH\/D^SQ[A(-S<<N9$,M+%8K-$2@);'\__^9"DBR0'Q!;J$;7&
MYP<"B@5A E '("4I:#Q+\QC)<@!!@@-\F>6HF;;]/.ZB*UD2^H.[A2O/JL-B
MFQ$9P*L#:(Q^.D-5QN]N#HY 4,L1 =O1(XI\20CT$"2PFOP>)P@ 4&SP<-%
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M;_N0\Y#"+V4IQ]T36,KE L,N$A>E<T'FXR3AS*7#U^0O%R^[600K4WKR@NV
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M$;5 M$@F:!9.9LDB/H 7@?VB9WI&MSPF\TZ>25P32Z^\'&Y/@&8;&O]0 XA
MN)BD,\W>0E$#PS_$0DU9\&\RR4TYQYH[8]-T!+?SYGQ\X).*[K&9$8RJT/B8
MK]#H>\[5>CSEH=**#(!P2Q3Y"L]X_QZ7+RJ!1T*4S\<4H4Q:3GGJ-S&PB%M
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M=-\,!\>@$1WL.7"PPN,.+ @&&?2[M+X6W']<<VO8/:4_2F"O(3V@"8$">4H
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M,;Q.JFXD0E7U] 6! ""USM-_<BR';S:)[TG3,"XL>V2,DF\XY+>L-E<MK]2
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M"]O0TW!'06$)P4'EEVUJ_;['_MJH7)3W1+G^S7LQ]"%4OM1@G^;V=8\^M;6
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M<'9Y\$W#!6' IDPT#%<>1:%!OHL2SX&$_GWP;%/<E>6-T.@B&V.5)9<2P'&
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MZ[JI2JF=5\+<XS@:G1P]_V67LAS#>3WK;<YQQE?'!?HS*:V>>.;9 U ICGU
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MUFZ6,=Q#+LZS?VM)+>#!CO6:UI(-D' =SK6QN>*F!A!*SZ_C9Y1@V.\$*HI
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MN-FT0<Q?S&9BE.&V&5KEV)<@ T _8)?3G",;J0EIH@W3,U]B31"[#+/'Q ?
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MD /3L\A]X]N1)H%HO[:G'7]M"[0+L;,60@1P\:"SB$)ZR-$Q\H!C+Q>2;D@
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M 0K'F-(H2%+'H5-TH^N#072_<+S/7,8+PGUWMZ* &]5=U+<P ILL)$\PEIF
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M0 )YJ&Z^]B[49C_,%UB)5^WF7S^@)?:_/6N.1FL0P^K]]3WPVC.X@[P7@D"
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MDQC)3B(_*)%V+R*6=X#NE,AU!_>Z072DL#-/;@OA&OVFY)YN_8D[[FT4HC
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M_$><D@Z^%@_B3[!01OMK.8:FHQ0#$FS7]+-I20DZWW8$AQ/CBP_-Q]SS;M4
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M^.R/W9FOE6R/=]?8_Z?(Y2]02P,$%     @ E(182U<'2!YV @  KRX  !H
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M+K!7@C9+^'HKT%OY>BO06_EZ*]!;^7HKT%OY>BO06_EZ*]!;^7H'H'?@ZQV
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M<U!+ 0(4 Q0    ( ).$6$MF\PM@@@   +$    0              "  >D
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ DX182[/+34#O    *P(
M !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ DX182YE<G",0!@  G"<  !,              ( !MP(  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " "3A%A+IX;8S58"  "O!P  &
M        @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ DX182T'&O%UE!0  _AH  !@              ( !A L  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ).$6$OA'XS)/@,  )\,   8
M              "  1\1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " "3A%A+\8);E),$  !N%@  &               @ &3%   >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ DX182R#3$=7' 0
M9P0  !@              ( !7!D  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( ).$6$NU!'Q7C00  $D5   8              "  5D;
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "3A%A+?>0*
M(+8!  #2 P  &               @ $<(   >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ DX182U[9=EVT 0  T@,  !@
M ( !""(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ).$
M6$M1B4U"M $  -(#   8              "  ?(C  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " "3A%A+L]M\WK8!  #2 P  &0
M        @ '<)0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( ).$6$O231 ZM@$  - #   9              "  <DG  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ DX182R5F6_RT 0  T@,
M !D              ( !MBD  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " "3A%A+X /].[0!  #2 P  &0              @ &A*P
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ).$6$LIMW=>
MM0$  -(#   9              "  8PM  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ DX182S06="&U 0  T@,  !D
M ( !>"\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "3
MA%A++]ZU&+4!  #2 P  &0              @ %D,0  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ).$6$O&&*.RM $  -(#   9
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M970R,2YX;6Q02P$"% ,4    " "3A%A+1C:,%K !  #2 P  &0
M    @ 'F/   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M ).$6$N$H\*QM $  -(#   9              "  <T^  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ DX182P8\UCFP 0  T@,  !D
M             ( !N$   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " "3A%A+P>#L_[0!  #2 P  &0              @ &?0@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ).$6$NY6$I M $
M -(#   9              "  8I$  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ DX182W.V-,SK 0  9@4  !D              ( !
M=48  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "3A%A+
M[DZ+P;@!  #2 P  &0              @ &72   >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( ).$6$LQTX$6Q $  #<$   9
M      "  89*  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ DX182V&J$C*W 0  T@,  !D              ( !@4P  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "3A%A+;K SGM0!  "<!
M&0              @ %O3@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( ).$6$M&'FN>U $  )P$   9              "  7I0  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ DX182P^-RF;<
M 0   04  !D              ( !A5(  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " "3A%A+,K@(,,T!  "<!   &0
M@ &85   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ).$
M6$L%--J:N0$  -(#   9              "  9Q6  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ DX182V5^^H?  0  -P0  !D
M         ( !C%@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " "3A%A+5R)EI[@!  #2 P  &0              @ &#6@  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ).$6$OQB ^,P@$  #<$
M   9              "  7)<  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ DX182XL1?9&S 0  T@,  !D              ( !:UX
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "3A%A+Y0!V
MGL<!   U!   &0              @ %58   >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( ).$6$O%^?L%QP$  #<$   9
M  "  5-B  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MDX182QO50)[& 0  %00  !D              ( !460  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " "3A%A+]C>:>T<"  !F!P  &0
M            @ %.9@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( ).$6$LHCGMP&P,  !,,   9              "  <QH  !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ DX182V9&8:=B P
M]0X  !D              ( !'FP  'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " "3A%A+.]?QW@("  #R!0  &0              @ &W
M;P  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ).$6$N&
MIS>@+ (  )4&   9              "  ?!Q  !X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ DX182]26MV3B 0  *04  !D
M     ( !4W0  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ).$6$N96O9/I (  %X)   9              "
M <6)  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ DX18
M2VQT6.F% @  L@D  !D              ( !H(P  'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " "3A%A+H_M+;58"   :"   &0
M        @ %<CP  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( ).$6$O!]&..B 0  +\8   9              "  >F1  !X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ DX182P '3/=? @  O@<
M !D              ( !J)8  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " "3A%A+ A+E6UT"   ]!P  &0              @ $^F0
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ).$6$O6.C<A
MUP$  &X$   9              "  =*;  !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ DX182VSUB#_" 0  +00  !D
M ( !X)T  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "3
MA%A+2?<N V %  "\'@  &0              @ '9GP  >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ).$6$OZQ+CC:@(  *P'   9
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M970V-BYX;6Q02P$"% ,4    " "3A%A+)]"I? 8#  "N#   &0
M    @ %1M@  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M ).$6$N>EQ<A20,  +\-   9              "  8ZY  !X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ DX182\6,-R=V P  20\  !D
M             ( !#KT  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " "3A%A+X3K7.M\"   F#   &0              @ &[P   >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ).$6$MX,Q' I@$
M )H#   9              "  ='#  !X;"]W;W)K<VAE971S+W-H965T-S$N
M>&UL4$L! A0#%     @ DX182S[&GT;T P  %1(  !D              ( !
MKL4  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " "3A%A+
M!F],TWH"  !6"   &0              @ '9R0  >&PO=V]R:W-H965T<R]S
M:&5E=#<S+GAM;%!+ 0(4 Q0    ( ).$6$M-;F2/] $  #,%   9
M      "  8K,  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%
M  @ DX182^Z&9,;2!   [!@  !D              ( !M<X  'AL+W=O<FMS
M:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " "3A%A+.Z<Q+=@"  "#"@
M&0              @ &^TP  >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+
M 0(4 Q0    ( ).$6$O4?1K-2 (  ,('   9              "  <W6  !X
M;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ DX182UA^7LCH
M 0  ! 4  !D              ( !3-D  'AL+W=O<FMS:&5E=',O<VAE970W
M."YX;6Q02P$"% ,4    " "3A%A+U5@ZO[*>   J@@( %
M@ %KVP  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "3A%A+RTNS
M\XL"  !C#P  #0              @ %/>@$ >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( )2$6$O2:E\E/04  )@R   /              "  05] 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "4A%A+5P=('G8"  "O+@  &@
M        @ %O@@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "4A%A+BP!PMAX"  "$+0  $P              @ $=A0$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     5P!7 -,7  !LAP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>309</ContextCount>
  <ElementCount>303</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>103</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Hemophilia Spin Off</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOff</Role>
      <ShortName>Hemophilia Spin Off</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Reserves for Discounts and Allowances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</Role>
      <ShortName>Reserves for Discounts and Allowances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Hemophilia Spin Off (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffTables</Role>
      <ShortName>Hemophilia Spin Off (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOff</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Reserves for Discounts and Allowances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</Role>
      <ShortName>Reserves for Discounts and Allowances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowances</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2323301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2324301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Hemophilia Spin Off (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffDetails</Role>
      <ShortName>Hemophilia Spin Off (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Hemophilia Spin Off (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffDetailsTextual</Role>
      <ShortName>Hemophilia Spin Off (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Reserves for Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails</Role>
      <ShortName>Reserves for Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ReservesForDiscountsAndAllowancesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Inventory Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryInventoryDetailsTextual</Role>
      <ShortName>Inventory Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2416404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2416405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2419401 - Disclosure - Property, Plant and Equipment Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentPropertyPlantAndEquipment</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2423402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2423403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2424402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2424403 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2429401 - Disclosure - Subsequent Events - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsEisaiDetails</Role>
      <ShortName>Subsequent Events - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Subsequent Events - Neurimmune (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsNeurimmuneDetails</Role>
      <ShortName>Subsequent Events - Neurimmune (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20170930.xml</File>
    <File>biib-20170930.xsd</File>
    <File>biib-20170930_cal.xml</File>
    <File>biib-20170930_def.xml</File>
    <File>biib-20170930_lab.xml</File>
    <File>biib-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0000875045-17-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-17-000029-xbrl.zip
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M7>:!S]$T[C<!W!C)0T)5^(K3%N8#0=5)OIZO!#=%I4=<5%IWX=I+''0>]O$
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MJHQC9!\V0BZV:Q+<&HJ.@$7&G!&C(O@]8;1W"-"5Q\_73#G9VZ+KH 56!0F
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MEC'^MY]BO;6/_UF@4G &!I0(H;E RJ3E>H85P2 &N<)/K'6-A6V-F,4'WYJ
MOC*2+!=G%-27)V)28;\6:(;U.B0Q2PXPG<*.(1LCU42ETX@H%1#CO+!>6YN=
MXA^2CD6;(@AW/#EMB)0LCH$Z/I8PS!P+W&07+5Y"Q\--J(>,W\U-MRPZYFLK
MC6U9EH%[R<F!L%R%H(QV0)YB%/"(,]@Z%[W1@N=J!#'C5!WWME:^-U;L[_S
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M5BVYN\7A#7.Y2XP9WU"07@#NC^F&.8V*NXBP#9K..OX#[N(7<[=_>3D"=8#
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M'6?UF)PA:6K64=3&#'N\XG71*M-]S=9-.6QUUP/@PDLOG2+:*,%IP.#*(TA
M1("!L,^W?'+IL[]_HR4N\BO2$"L -P@N J=&:.<8:+AV$5"&(=D!&M>95*ZP
MTFZWWTZ[L/!R[-(Y(^;/5M5YUO09C->G8CCL%IV+HKKL5]=W]_32C8;E765,
M.I0Q@!4XT0)@:0B&><<<=49F13 R"XU6HFH_? C7-]W^;5&,+W1<C*KV%7QX
M<I1+JZ(%5LAZ3:/D@#"- T<9L%5*>A-(?JJ>Q3DU8L*[5O5',1RSX#=8]=*,
M-R$>>6%X',]LBNG^C!0N2BH<%R(+CWF=:?]<7A?_2//Q4K?I856F*70K<T(#
M$!;21:44XE:GRVY*<86%<#Y=.,VD0&66MAZL>/CKNK8@"HP#EI;'5,] 0H+6
M$.?[:*R7$')EI<FX+O0_NZC\MM_.*Y<N6M5R?RN"%Q$1)Q!FW$JKA":$PW]D
M3'XU.[2FXJAX,+NST/TW+(,B$>)N^'\>O>:<2J4$"> JF30)#&<^DM3'2J[(
MFF$UNK]@[Z[2Y;Q5P@"49M!;,)7@&)4R0<3HE(G:.K80V-29%9^*\;"D7R#0
MK%K=\4W_Z[(WO@282O$>FG4LXTX4@1GA U&1DP@0GZ9;,!"^VX!L/H/Z:03@
M09CT^\X@%E'41B)"DA%N#=%44<=I!!>##-;Y=83#*LX21FR*L1CU%@NDL>2I
M^H>: & +MCP(2K#-!WBI@P+-)4Q8$V-YCD$-&(A H!"]$26Q84Y2B"TTM21K
MHGDO #4E_D4@"T' SP!/:0@ >616&V>]X*F050I+LT24)@<%6?-9L2G(4NF:
M)8L*A,#Q8*0%> %PTX$V$.5SO(UE5B)X* 9L#679: 5541,/< (B;BNT1Q"!
M82RL#CXOE$2\-KYAUS"+AZ!!'8R77(_[!*&83MM8D)0 OLB\A<@K:FK.FG5A
MEK0&!TZY9 %Q8Y!VW ;0(,-H"L_RNU#9\4^=&;(=L*6H,#K-*%6!<9I:$@#D
M2,TF"&,FA/Q6*3N<U,A=YK.T4*E?N$?.CV-W*R!J08QHYYWA>?71 3WM<CYL
MBK6(<Z Q*$2<.H]@8R,2BF"JB* @)7DSQL,!SN5,6!-K886I2[?YE+"<: @W
MP,EJHW@:Q1U$WF#K</AB.>TO@EJ.8.%4P#I:,)X1&VVYQ()AAJ0),^X*B9J*
MP:90*]V-8M2BD+H5ZQ"MTTKHE-21J9EE!K7R(\]#T;\UI 5D$ZR59PEM(F05
MUB )J8N6%1!\9=I =&UD8.?Y+$."%R 6@+K3X8<UJ3;," ^.0[N0!658U\92
M[ AH(66UIDQSIR07CF@B6*3$6PK 7.:#SX^%%=N!6#$:IAA26J26!\$9RPU!
M)#B<Q$9E00NA!X58N\MG>4!7"C E=AIQAL&<PC^$:>1MP,RC3''H03'6CO)9
MUA!LC% \]5%"'MR,28<%R.K4S$5GSD5F=4@U8L*:&,MX<"/8!H2IY-XZL!LF
M@*M-544HL#RC*0]W2K*<^!>!+*X]DP1+'U.U.8' 77"FO;6"6#ZC"8(Z8)9[
M(2LV!5D&3*$P @(M %DN]6\*P8('2>A"$9<E] Z8UY4[2F<AC&WJZ.M1(#RD
M\78B2&:L)I@3(S-3D+K_'Q$/7@*R/';140Q&@LN4U;(6W"@%&4'I@IC-(E%^
MP/*"S5BS=C8+@ /1F!EDY5T"G"&LP6CJ<>?(>AP:;L"*[8"LI#!(:.R##CPB
MIFE,9I11R:B#T#[SJGA?YF1V4> * T"4(S)0'[#UC)LHE: 1<V4AU+#PI[Q7
M%MV,I)GU>R\G;=&4")QZF"L! :6$7?)2FRB4]:E"P 3MLN@2S[@U=##:E@SZ
M\,:E%A4 =CF8+_#F5#% _TA($^'7S*\QNAG&V1%I"V>U"(%DZK#HC>).>!69
M,T G;)V.<49G!B(W"V5FTC;1K^'#Y9O>L-7[6G[I%G>SUM;6+H9-.DEB6EJ(
M0K162@<:"?AB!+@TS_'H/,&Q<$$O7/JB;0A2:*>QX4BQ5'*G('9B8"BD83*8
M?!N(PIGV[&SM2[0CA."9MB1Z&KD"Q2=8L2BL=H(;E9_F8Y3COAVO_0G#5?TT
M@>Y#=3__80+Y%^W+L@/^:EDI"P0W2BJN923<6, Q6!IOB/":I?N$^2C!O6[4
M0A,=I$=>RZ!2#\&@C'(Q8D:,D9%)G^5TA&1[W:C?M[I1%$%4RB45DEINHS5>
M,7"GQFL2J!+91C%,7[!3Z2]OKF]:936>SW<'_U;:(3$904:=*HX-5I8!Y*'6
MIN,;GYJE*2?4K'[!BU>0K?'9FI;6ZPM+F0B1()(&C7)M>%0">PYAC5(S$EU$
MR?S6^6QVS5C*HKI\AJR!\))1[C%G*H!I0=)H;9E*+?/ROFP4R3R+O\Y25A#&
M_WKSWG[\_;.9(8N3^^J"0"X 8" Z&HR5HQ919BU241F+\^,7A+(\V9R5;]0D
M#';1,4#5@:"0;I 8 [M,N-=82A5B9@D4<'(V*V<UW%J\KD5[3)R*-%TKMM%S
MJ;!!#H4@E0=- ."?WT#@]\*V^KH.,>[]8$.S61"IJQBVSFE.P(A83 0;-Y0E
M$&5F^TQR@S^/:?7@[,%F85-O!:7*8\<"I])9K"C#$NQ3Y):KS+M(3O.@H-Z\
M/=AT:VQ",D+,I:XQ$H/3"00+*YV'V(/SK+I\_RS=+?W&HA"I@UB3J]2D1 EK
MD'%:"LLCRU/JDO,Y5G![C-CRY/2#643 P)$"<&="*8YQ $#C&8J@SL@S-N.D
M-Z\@JS=G#V<1&9%*I!X#:61#<$HA&5/;F* XQ$=9 D@0FN>^Z\W;@UE$90%N
M,Q)UH)0+JK1$Q%*!,?5,.)_E#??/TMW2'[##J748TX!2+<.:D32R2H"%%);$
M+,4@[BO%-Y2M#Y=3@RL7SZV<,:L,/XV<G)<WW_/\S+E)6^T123=^->(:0SA"
MI',$*XR!JRQ+; *"45D)^OHLF^+XMU;933V18[_ZU.H6:5+MQ(#:NP@\910'
MP+-!N6;\*H/5*C+CD<$<,)CVS!(+Q@FB;$'RYNJ<(9$1N.8*MTO=PG I&D<0
MQ+G"8HZ\TH1YXHP/:38AGS%Z Q&1F=PM4O?TOC7#497*)PPW,@:.%=?<0GBJ
MO=16,HJR+ /L8PYXYJ[E!2N>9>G&\NZZK<&SY@[IS[;5_J/H/'WH?']Q=, I
M78 /3H!+CQ'@)E$>=L9R'Q'CA(B%J:GSV)J#(2_)TDQ0XHT$AQBQU]Y@(TGD
MB#&&36[D1%[D?1Y;=#  YZ-ST@A'+4.<*6\$M2FRP(@CB?,3Q./=FAWS,;C4
MOHPCI2UG(25_%54*BX"3R\C2+C44==>O;OIIR.NTISTA5^&QB,ZD9NW&@#VB
M%F1=0+A'A13(DVR3SG%S#N8L%(3BH$5I6I/BB%O#, &C!/]$(0+*[Q\+B#?/
M584.YB\8L@*"?3!SU*1YZ\:DZ_$<&$4DD_G8F6/>G-UR4EMM:42IA2KEV!L-
MZ!5"(T$P(A+G+3#K*.^_??I<C4F_-;W.+RFV[SWUBSL)EV&IPDY+\.&8I$ZX
MFOI 2;00S1)$4)WE?6^;<S"7 9N2ZOJBP")=1_<0"4KK45#@UK'4>1$ EGFG
MAG/9I8.Y#$VCB0XQR83G5!IP\.!"L.48XO.8=],XYLW9L3'B,K4E<=P% 3$T
MUP0<L>2*(A>CUGFUQM[E_5WK7_TJ7==(>5=PL_?SK8:W$YF[I^M=LQWR?87$
MTG-N@8!LYM+<9 AA-;7<IXM.8)YQD/EY&4,J*Q"M/2_>]WNKL<-%@X1!*I@T
M"88&A7 JT>0J8"41R[N5$)ZW*ZD/.YYT;5VYD"CB("3!!"A,E]PT. 1J$G\B
M<7F,A_%];Y+C8<3*0D&%<521(-)5%B69(2H5+='4R$B9O!,YAH76V%Z\ZU?#
MKZVO!3PT[A$\,P&T&F=0(%)$D:J*"&=<:7!$DBDM"*/,A"PSF<^_.S*VK"PS
M)% ?&7((J\"5CV!1J(=@3S* PC:_C,^YW&\B:U7>/#S__,5E-2XQ *9T-ETZ
MX JG_J(Z$J]%*C0T><YZ1F7:ULE?.&Q72^73%!R(#P%1@=$7/GHKA? 0H.17
M?#DB><7D+E9<OR3[P8)(9Q'RJ4"  S[!BNA4X^B1 ,&VEOBL2N#\MN9P(:3A
M%(5T'A4%H&N?/*.&"#(PAZV,F8N<-47Y/+;H8/$CP%=/0W2"N<B-AAV34C-
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MB?<C1LZEQU*#ZR9!3DWRM^)J9"*K#03#P_$PXOS:;[ZS0%, I-E:V6,/$I7
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M.N_JLOX63.TDZ:,IN=1@),NTSW\7OQ:(GJLRN0$[B^+CNT!S7Z':G!+FUO*
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M]L/H0GZE'M&;+Q-7UPPZ0W3Q90/,E?@GB0KJ_'D'%!LF#YTQ&]^=\S"D=G%
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M4$$,ZY2+&U.K&+%5U[-Q8P>677.W\4)L_&3N4OM#) +U;*D#AXI>LH:>*&3
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M6Y/%08GS%M@DXM"=TWO5)$Z\C+.D_ERM1SK[@IQ[*#55'PAR<Y@LYVJIIYC
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M!QAA":.;/PW$/U,Y$ &@%2&H,<7S62AZRW$?LJ?_N2@";R36+H0N@9Y"!(Y
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M-4">N.HU?VW"' H6B 5?<%% 9+-\ <F]6%TU557/_X@/O?$2&)6;O>]O?(S
MZH,I]14,Q^O/P^&I0T+ ^OPA2M$>RQI+M@3G95*.(HZKCU;R=3@<3G7N:$Z'
MJ0YO(&]_RUP686"QJ_D/[T7FBN"\ 9]P,4=0[>D#4!;4>A(Y SZ8^EY-]EG(
M1" 2J(09">8$F/>9RI_PS+Y[:41/@)$%7N4.Q2!G7="K:>  Y"?B%?CN./LT
M?_[\*7$"/TR+.@Y]88FC33"WU1>&LIX2 KT<D-8)NGB#.9#\#V .TCGOX-DZ
M=772QWGF*APH Z@2@BLMUD"<>N+"N-J9?X#?T @"33Q@GT"U,[6QBB\%C7]W
M^6Z4-03QPIQ ,=^',U_GFQ=QJ"W1HUF4Z38 =?+H/?C<CF.>Q+WON9WT(0P'
M3Y[O+T>G=H@ZV8IJVAU+;_7;JFYTC;;1DCIF2[&,5LM0V[W+B#K-Z0H0B(1%
M\UCX46 3I>,TDQ-G#.9W;G"!S@4<]")ADKDC)WK,#1EG7G&V(>R@.!V#A0#O
M&R"\HDL>/L4W!Z/*#C1>VK207M 4OR\^-$ X\)?!"J^9/5C$59D+EDU^S<_O
MI'?B>SQQW.GW_;GCR1LD(_@(<\H#V2(R,(GYS?3#BKTQ']1BXND\N=I8F]&\
M>^YJ-B9%_F%[A'QMG#Z?4^N-]Q_U]I,>_!MO-T]Y\+3N-'?B^1JO^WX')_)-
MWCJ=G3"+M;_,\A([B&JG0;7:I0O-ARN?Z$D]%X.^4;G\MYS9(O[VE+D3#Z$_
MR-YFEWP*BIBU0&8] YY\C0N[W,V9,(OJ[9R"=9#*+H/8)Z2<UB_$U6W X&$^
M!H6+.W)>9TH?C^E[<>*-,62U:Y2I%J/^Q1MR4@[%*P?U"+IA"RWKRH*=,$Z(
M!8D%CVFPS#<<3@J][87-$1(A$J$CLN(G3B!.'$AV!+'@!;,@V1$D0B1"5=D1
M5!-M4S)[<NU[;I8S-W'P*, ^Q=1K)M55'R 6SY/5:T7=NPQ]S2A7.SPLG#X;
MM_MR0!6)=2MH6F/Y+;4DP!M._)=!SZ/5C]+4"GJBU(8#J4;*I8,AX=VY5SBY
MTE6E65RI6RK(3-!'T$?0=PK0)TL%UG:J QL=TUXC;"J>/C6&H&)!Y\2QI7C?
MD%"#4(-0XP)0XTI7U.*LD'/SLHKUJPAL"&PN&FQDJ[A(S[E8**>P$UP%;W2S
M(EY\L".N5#R\6;VZY]/5!L>1>?U:4>=K2OO2QVH4>6&-(-6&)!795.+2XVNT
M*4!"N/_FGM(P6GK3K(P)S\7QI.T]DN1:2;*J6$V=E"D9KI5+VCD(5!D6*<D*
MR<K9R@H:CJI6G+"<FWU(&Q,D8F]51RVY*9$R6I[G*43CCP$UM\'U) I%NX]-
M78#>S$I'IV9ULG<;#/C0"[P$VQ@DGK_:H(6@G7SZLGUZPZ0$5 J0DP@>400S
M:IJ*K)3/AR2()(@DB*0+*697*TD[!X'*1$@S*:! DD*2LE522K#Z2%Y(7LY6
M7DBSG&BHN@KFN,<^L]A3.9Y+DQ/4-8T<!QLX8W[".=!'CIB?+N%.5Y-<7#1
M*T[?7'PP@.)Q)($4&"=!)$$\14$D54C1"XI>O"UZ0<$+$A02% J+D[R0O)!B
MH:AX!;QANW^D7L0'(DO;"V9-->:B)<8>US-,OA2_IS8@AY!0NY9-Z@)"48)J
MH@1:0Y(42J"C4!T)X1&KK<@-R6@UK<J8\%Q.TU*U%9+D6DFRTK!4K8*N*)>B
M3DG6+C \HC8T4Z:"LR0K)"O;ZZVT6D93+IJ%SL4^+-8B) &[0 %3&BU)+RY
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M(3I(4\YM;0*.I!*(XXCCZD(XXCCB..*X^A..]A$*R[DEOVN#WV7)!O7E(AU
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M),>4P$523%),4DP)7&00G[P(5AF2VOUT73WE]\HJ4 N_E?!TKK'0@!B0Y@C
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MDZ!U*1$L216XYZN#D$3!R)FPG#$T RZ8@H0]>YT>JBN5VDYY:&EDVV(4LI%
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MSY*Q5!PEC^(H1B^;\RW=XYY/>>W]E;Z]VJVGSE>E\[1)Z)7Q^/X1S@Y4XJ3
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M:N->-QX$J.]J'!KL$9MI"V:!%>'0HE5(,2^:C@ QZITBF,Y?!7"0(7RKWJ9
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M<L5X#KB5<VY^[\-+\,.5 TT)_0 ;%XU^QYE-PBY+7J+Z!J349%_GLECB4?[
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M&&^W;ZU;NX\O[M(K;^\7^OK]3L3F>#0[KS.S@VS)&A^W/B#T#M@[IC>Y3\*
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MLH_BD7WQIWR%P1\=.YR<#X?-0:O;Z@U,LP?]&W3?)MH(RN3RF13GR1]_?ZY
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M'K#K,W].NWN)PS@2%I^J.]6J433S=?R"S\"S!)9&2O[Z^?;CEXO_=S&/1(0
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M1#=G/ @=(=,36#$>:]:(7<(;,0I4APQM\)KL<Q3(B$-3X[74>=L;V%]_A&^
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MPB>4^:T')"/8W=9"O[M*IK?-XK4*LGC_U@!"#9712#JV _P!6HK:!3,O$(@
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M;U!)J4%,@4+9O-!2;%P2;3]7/* I9QSW#!L=ZN)0<X@G<D5O0%%9)/!O&!4
MJBHHE52?PHI :BTYAIS"^XP_*9#!.V3*Y,8X;\!<Y(F[H780A*?_Q-M_P"QE
M0#4>B'(L$@5(C5$S:ZS&V#1Z^6-S$7%OC_@:;V6#(XQCM32WJ+X(NNV!V>YN
M<MC^&3GLCD]97:< GSSV/Q%X_CV5-[X+I,?^A"Z'T&6N2[2-':R"!G^,!'#A
M.&&+WSP'\?XU7#C;,0JE_NH1;&L$V%%%U!2]P4W-KTUVY<@P<(!++H%)0N48
MX&_SK^$%O_[_[+UI<^)(UC;\>>979/AY.FY7!*8EL0GW$H'![O$=7>5JVS/S
M]O,MD1*C*2$Q6NQR__KW9*8$ H/-(D%*G(Z8*0-:3YYSG27/ IXPM<8Q5Y$2
M,=.GX6C,P9CGCLC; F!(VX#GE\P 0'@PCN_2[$BY$;,!DEQR ZJ%D;Y$WA[<
M4BAY_MC$I2]$F.(LX%*>:(&0L6]P3U@]5TZBB@(FYDVE&&+!;=TY?'#+!ZX
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M[KP@<EZ"!$@Q!O]+,&5:HNF/WBG1G"7P4\N*^>8UW' :<(4C4D!!]FR?R$/
M54SV)F,WJ1(0&Y;Q+$:?O0O[#L:,<#:3_@POHAITN<0SK2=EHQ%;7>HYW^Z:
M19;>%[*W#4\V:E22[6SRA;W,NR-\Y:YN#&:9T .B5<*K_/]MFIPTM>M^YZ9_
MW3):6LOH=7H-O=$WKMHWK5:[=75M'+3)R8<B8QQ(9&Z$^H6W$T$G^+=&/'C+
M;(..!>I+9TONZR3U?3<S_L@TM'@ .]H&=1DF^]?G-[V'JT^<G:2\A<GO8C^?
MGS#T[6P%-+7]:<3U:[+UPCL<B#8Y":,*"P)XN$[^Z;F"4?EE7YQ0-!"PXC!<
M)SV) DM+FT?"3I&-4.1KA;-'%P?S%^97>&51YMZB9<'[Y=)O:Y]%_<[*6NEX
MRNT0_LX?2E=^QL2A>.S?R7*^J5[@G#:G]IRXLSU284UV+M^E1Q)]8JZ;O/TO
M9]J9^!S":J2?DU=Y0Z#WA)RL(\ZJ+N\OCAV-I:K[L-/58ENMS0_>NM'\-CVW
MWC#3TMLO=(SC^%4(K\R"UNV-&W*]VVE_+PH<HXG=2@S]YU3L]9_W'O[Y2:93
M@9-UH8&?-8 +/0N'2EHS_V"VV-@[?_2G<$=3;WVZG!?O1^1K+#="^CPN?C>=
MI2X,V# BMUX8!=+;VICZ:]NAH5RB7%9)+A_^F9&\#M^BGC7Q(Q?DFN^#O)+/
M+!K[,BWD?WV^S_$O^#WF*2J)0#:,!@CD U@*KC-Z31-<'^&!$A,AV?M;O![/
M_IOA@FAS@N*)XHGBN4X\NS70>1.^$2\C?!>@2[F7N/!E(I$=W02)O)WPV%/B
MXX ,7H. ^J^,D0?>Y^#B2NQ\?DV:"LUE\8,4\DT$L7SVO.C,DO@J\WC#W)!/
MLZFW=8]J:YPC/Y@GVHK- !J.">_%'/Y$QOX+N'5!3=8691YJB2&22\_S[P)F
M):U7YT4.:41R&CAP3SXDE] )7^DPK2!8DQ&<Z9RX\'Q)]RJQKY_V7DQ:;XBK
M3^&I>&!)[GL_2!_7XD&GVNS.F5P:[MF*<#-_' _\T<R=XN3KA*Q\VV/>%R?=
MV4R>@7WGW<Y(1+^#7^PQOKLFPO"BI\>%W.6WLJ(B5E)LQL_))B^W]!2SJ@O>
M^FP6ILT\B4AJ2-XL\U3B$E.^Q2)V;WA<=RSKK>5#)75E\,#9GZ9Q +PC>GAM
M1J2/'J^V^9N^1^^#%98<+$KT7A'!;!&7<&!EZ]5#5Q)LWGKU4I@PV1\6 E]%
M/;=XRAIV9JU:T.MV5M34E%'2WL-5&F',Z*:F,%;N08?Q!H<"A=,VX,DV63\.
M(W_" _B)P=+6VK.TT3">\N@]+YSC#OTLYA\D%P00\X'K$TD%GR*0;)1-Z9SP
ME$X@#]PG>+U( JT6>8J!#8'[92)C-E277BE,TCKYM@/P;W*OO]CL[@++>?43
M=V]&_!6>?-XT@ROT9&=5@/_L#9-F4T(_R.AKP$8NX[2(1#8E>$EV8A?,0[GI
M,_#42TN:;\G><Y(W!MK@[9WE>XEE$?5R\3#D&2W92+!(79N9A$NK)N\O],4L
MAW4Q-ITTC9NY=G;2UVDQO&F*S67Y[/PV,O*];%/Q_9BDW;9O2YT4L"CP1>=?
MT2I7>(KSEAK %R*QG&^_<^4(ZY>$TA>CKE1FY8DZ^B439567[K00?G[)=/7$
M%HSD6UGCX;JR 8HC,HFR>_/ A#P%.-F:X[9(G?2$Z50HV,QZ ,WWE!NR75FG
M8'1/2T1$?C+'(;F"G&DS1+;&5/:<%7L@8K<NM9TY3TKK6=BY4D#$W@7/4Q#,
M($0NP8Q,1^A,T]OY03+C(?D@0(?WN+GH#PR-WR"@4Y$ GTF#&L2S:MP1SVD>
M+R5ABBR!*=_]CWQ9B,B!0/1ZYWUUP\0X?F9!=O<E%>$%5I\ ; IJ)8["2J>@
MMFI[A;]68O[QF$L%54JF:K7]GEH!EP?09;XSEXGL@C-\]RQVMLGY0SR,9)S8
M:%WH&OC!]QF%(?K @ 47!S/7*[/7-R_+G'^9YAPX*;PNJ T!I^&\<6\HX9IO
M7,^%8'$-%Y26: $XNY<S?Z7EB029DR2+,1E-<S(ANT1.J.UPGR&MF>4QL1%U
M M[IF<L&;ZPG*<!SL3,_)2DLB<1R/V#^TTP1RFXVJ7[ZGW U*Z^@U*R8@1?Z
MOB85?[-'3ZB5U+;+YH?\M9.WG,QBAAFRSO1@HE73EM!S@S/3UU#>C('JOWY+
M.'&!9%<UR1+]@(A<H-<3DKL6D4AY)W R+PH!:CF!K/"V_P/:)7G1#+'](=?B
MXD;30"KS7H8UYGD>LCHD7'=OT3Z:-V0229^S;*+LT\F @A.F3&4G+><3UYT[
M_VQ*D\0-_FAB>YLO><# _ FY]@/NY'D@:1*[R$2<4SL24Y+EV\TJ ;+<Q-=*
ME.]SH%X\;BX$<\/-XMDCL,9.^$W40::.&V_SRR])TYZZ_HMX[7 L5 V\$Y,_
MRQQ_W@,T$.\+7C>5TIYQ]E9,=;;Y'E*F-Z=@K\DP*467Y)7D67'M%5(@]MB'
M6:M*\'M(LF6TJ0UUE=8F9"V8.=^2)&80OHT4B82^V4T=*7C2'I.OFMLV?R9<
M!0LD7F\NB1\%I3(R6$'%EBG?_5"S&37R.P\LS#PBLVE\>L]-D7D<0&V>*<)$
M/"QU500SS%69.U=@:?8'3RD1DN?*>PK/@W?E'U(WD1_&HJS>8MPV@HM(TY?_
M\%_>1C+]8F$4Q="/H^1Z_/I" P:BQZM<Z7VDHCO/7I\-^TE$/-64BW985@[R
ML\+(VWCQ7@+' W&K@L?#.!)/O=IFGEG*<^-9 F]F]>47;M:(J9ZD+?8,6BME
M>F.]_=B7&H8/!LCN;+;!?ERR%Q>/A 5<><D57#[WA5C6( #GE[F"X4748LX&
MF55, 5.J&B=[FW_.;*7LS6KS//$TLKSRPISQ,AH%;I% PD*>V*)UMFAOI.-I
MY)6$4<!/6[8HDK@&/RKAUJQT#)EPKL5G.1)DILJ%F21)[DJ2IVBQH/KE$R9^
M9G* S?/AQ5.G"?EP:[!3_F*R7STO_G-FZ7A+]!%E-_+Q9T]N 8Z)#6[YZG3!
M=5WW/@FZ+E]_'Q@TM-P1: N57T%5W8N?P"C?!$):-=DC=(8&?/OD1FR?)*!A
M-+C3V7]C]/03&19GW/-@WC010O%-LA&[$CA<4-DC+LLK_$P1J%N]E;CL0[XU
MQ(1Y"UP^&RT3R*]@&>"DV G'XFM1O%O+]JF"<_]B@7\!4C<5AO4PRL+2/"GV
MS2_2R92GS5K'!Z+KZ@QSX/C,QH;CS6)M:2K)7$(6+I'28^@'@4C'K,UGAD5+
MH=;DE<.DR_Q(U+[,D\0S5GXMS6[/E((MD@*>-PX$6J5CP#XZ QRT*0\DL@O_
MA1>AN,Z(92Z3QB9KW.J( F<8RVWC6?V1N.RB<YQZN)*GY"9H$E60)!+>2^K+
M_)70DX=RDQ*65>$-7G8P9S^Y0)[4+:^IEY4ZR4FM=M9W3.*"PJL- 68LX1OS
M;A"<#1(/03!LD!6(9.LT6: $/Q? VN/#1&?K+>(%KD#F.?<+1Q&@+*:SC,"D
M+\6;^\UN)3%R+EQBK!2\M9PS)><A+.Z&R\=-"Q[2=Q>[L0LOG/AH4V ,<.\Y
MKRY)XXR8O#M;^L[)_NO<Z7>=;TQ&3X;2T.=U%3Z/4' \7*#PXG.FCKH#0+&O
M7YJSZEF;:5#I#/+;;"? #]5.6_2/X<;5(_T^-U [3:YK;ODFQ<6U%,K'9&-*
M)(Q(0T\62CUR-N89?A[OD[""!YCKB!Y[B8DJ QJP6FE,AWY/V"-,>KG 31,D
MF.^&B9*=Q(*2&D"(CS._[X<&:R()BPYM8EKRA^ X+K:U+&E_RU;);Q_FPV>1
MFWGBW6:G\(JEO0,W*S>_LC*RX=:7;(J8F0%)P>V=B!K@9W:1E#?)@*)0++8#
M1(O<9.LRF1_)RQQ%7=:\\F3(.R5Y(H::= $#-DWBJZFX?2SE^[JW2YE.LM5C
M6K,U^B"F)=9C$2P3G3!/QQ'!]5A\N:#GJH<D"YT_WT&2CMA#N4J-G/[<R)D'
MGK26-%^#3#+O &R)9 >%\\CL"N\:JPF(+)PX+R^432QXZA+?<P_!Q6-R9MC,
MFA#2F?1!?Y):54CR*.O 9B>E)?L+LYLDW57EI1<C9^+:?'\\XE$L$5CAP;34
M%<P$R^4W3P$?393>UTK"YN?<7A:S7;F;-^(=B64C0 Y'4;I7DHQ;6S"&$E#B
M)B=<.I[*H8[  C18<6 2X>6GK'G)7;$J(X.SGG^SNJ:LO$GP6*IBJDEK?IH!
M+III.,_!SWN=K[D--W+]J=S#F@OD:<MCDVOV>6O8BUE'V$R-<QJ.:FFK$NVY
M]P-K,SOO=A9;>E_)/T1L2HRYA_*47B 3G(+CHJS*SJ2/\$$RRV_RQC>8*W$N
MR//K6F/>"7AFE29X/7Q-3'3I%B3!ECF8TTS/BQA@161]LK2J<?&WA?;-<X%>
M4CIBXEAF<S-Y;&G \FMGMK/FSS&C% ]36?-<P3</L5^0)_.LLI'F3!V*40.\
M"[.(E_V;9;HS9XY<*<*IT=F8R; M\R!$8H,'#^!F,F'2-\5X4\YI= O3*]:C
M0^=-UO\]B](\@"N9Z#SW!D1EG$S[3]'A:R8=6W;,C,A78>W!"5_Y9BY\W_>3
M\7V+O\*WP9N[B8/7\76B9.>! EER(+0D?7KB[4:2_KYIUQL1A^5;R^!@>]$<
MC.9[SN('P1+<C$R3NZW53R$"%C.[ MB1QU&B6>(?YSZ0J>78[IJ'2;L8;_(L
M\]UKX:?,(W+"2.'1;+BW^_K>[59=53KZ -I"/<A@.)V*;."_Z-Q.7_6$:=!Z
MFJ[GPH4G/-ZY;L]_M@IBF#@/&200FP[[7G@#F3\7\=A:VK$AY$DXD?0=YTGI
M"6T2<WVCN@-YBF(!"\2NC;#+K,DPMTAJX9;-%]\+V"@&JG->ODE#E=+&Z8L&
MD?/TK8:N71C<W@$$FSCQA/3DWDV"9![Y&L-SB P)7O@K+BDJ?N>C;]?G:V7V
M@I)HL'2 A7RE%3.SZUOI]9>S0<;,%3M;E(N1>,BAL'P"4,8I *^[31*\$V>E
M46TQIH1C O=%9"N(8O?*IS[OBIGA\ UVS==LCY\.^V]DUF]?KO=@ =U$QRD1
M$DI\J&Q=WAM>F"FZF7Z3R1=)G#O=;TY:[X+!*#9F9BUO9+1NH40JW0B28WY3
M=3XWZ[E+)_+W)MF'S"3E 3UG+Y6;:_JN]8O@7LA&Z <,KAL;-FIXY(X>I_QR
M.6JF+(GS0'IR+U-RM@'#"P-)-J[CU)NSZH+_QQ,'>9MVFAF'FZG>FZ_YW'WC
MSS1.GFDQU3\-QF;D:^@G:9;P;/ 4\QY\DTSNR.R9^:5%.I5TXE??)34^ITL&
M/#\ZS:!<12+@=-&U4F+RB$=>DG/H(L'%,_-FI)G$A$5:<*)E;$IIR<+KA6EB
MWT):]?*#SO=I9^9H^J;S_>#9:XI'M(6M.4L873639B^%6'9(>=N%;-NF8MF&
M9%_Y\)0@>OW*IP'W/)LG1HO@W&"6Z;95,[+6S>"J/^@"G5NMZX[9;3<&5_IU
MT]1:+>U&-P_:C&RYEZ&1,V8:F4;7'5/OMM=W+A0TKA%!9=GK/*5S+NI#F;9K
M\U>=SEZ5I:\JS%".&($MD\% HO@8:4NTX NCFG!597Z_W.%B8B\<3G$2/[>W
MYA<N9=-W[\WG]A1:#?5_]5K+U.IM E=P5XU]R;6^E+]<T:_3;'3KC0.]3G6K
MY(I?JK1-<>;%DO[6!9?_)>5XH&YY0]N#V,'J]J=]@+.B<1QX-?+PXD1_L< 5
M1634$B4[U<+Y;-GDBM$5;5$U.8N=N++%-5E#(FZJ%<JI[6:]>1@<DX/U^*E6
M2,Y%IM=WT=$6[,QBX;IMU%L'>4=1H\] D[_(N-(P=F1N.25#!Q;XR;'"S#0L
MX6DD,E#I:N@*X[S("BC:WNBVS;I9%>.I:>H'$L=%+5R;[PPQFR3CN<#-EH,?
M9%^"IX"%"R6/R4;,_+C4VST)N9VQ=]KG(1;NR&3B1+,=J$,"N=%HU;7#R$&Z
M!?'^XF\9C=@FHI"-1-PSR;6_4<?C=55W7J83Y2/?>MDF$-'1.M>MZ[[>;E\;
MK1NS:5XUNWU=,[6^UNO==-NGV17]<<R6JA(F/%]R'@25PZ5XTKN8!KERPVN^
MT2,#E@G8B.F'LMA4EFAQXR 4;:I2,)(=LL/W^UYOT8-RU4(L]*74ED:?\<_9
MB\IY!XL>B);M9;E5-]$M6$BV!]4U>*<A#X<$%Z*OS#1DE^D?;SAF=;_1>0_+
M]D)SRQEI-^X7*I^IV?IAVXZE"^?K>YZ^[_FE/KW<3X\O7Y:7WZYS\-"/(G^R
MV/&7:ZPL;&8_R^,7O@H$W!J;=$/.8/GZAKMFOAIR?KF9[?F^U;.P$K.7Z)R]
M3\$$ZA/ZZ-/O1*0\D?^CB?]VHO!*T%]-0YZ2SH)BJ;@Z-G:3&)J/XX Q\AF.
M&<MH_# @%I_!]<N9YWOL[$=^\+48JSIS!PAX 5LLAF(LS#N#\4*VR[%C@PFR
MM97G>&.@\II>T\BL13+K%Y[W6!RO[H3!12Q*B3!Z]8*=WWJIOQQ^VD44&GN*
MPI!:WW@%CV=?)'L'MO@OI^5(;B^\DS?W5DRDYGLGU!JN6:^5(1U$]+T1?5\V
M/CUN7<N?;R/JR)]'YT^$6839"K#QZ7'K_C"[]:@CI2SA0O/M/@CF'Q,!U@+V
MYLRK%LT785?NU^5%X ^UVWN$+H">0@B.0%#3-.MZX415A@/?U5-KH@ZHU7/3
MZOECGBJ,M5/R0=Z4JR)F2>.EUF@;=2,WG%*%:Q".*@9'RBM -,&4,\&:M6;'
MJ.<6 U.?!Q'U*H9ZJC 6&F%%4JI5T\U6W40C; LXPDC::EZZ7\AC5=)D4YB$
MJEIE*D/8"III]4;A5*L*D*%==7CZ*(Q !S>=5(86<3T]OS Z8@9B!IHS:,YL
M23.CGEL"BA)<A-!4+6A2&('0G'FSXX;F#,9RMHSER$IDM'[0^CD"S<[U'/,#
M/B+;7#C+K?=6T'&;DAXTH="$0A-J'3'.<PP)50UX$&I4AQHTI4[7E&K6FVA*
MH2E5:7Q3F)70E'IC2N48VZX:\&P'-9D@UH^BW=K*X]]M.;A%Z\#%CH.+X]?O
MXNANE.DP+V92\5D] 1OS(7G/3([?WKH987/0-P>-1E=O&]W6S>"FVV]=7S6;
M-U>#QJ!U91B'G8K N>?=;H2\ ]XA6(1W(Y0M 1W>2UJTVILU#)S-YXIY#\Y@
MME3,EK6.V1D!\\EWLY5*AL;MWFHP0R$^6ML9O6Y"^07<5[S[8+=;-[66UC8-
MHPVO;+9R[$78R:47H='8KRN:89Q24S?%3B_WT^/+E^7EUR')[ IJ]&NH<!\M
MI/2VE)9V)'F8#0C^W9<FZ!94G[]D"SOYK29S+[$>[]]8C]DY4NGHV:SU*!=H
M!Q=FM3UTC%Z+Y6\04ZVNH;E5%RD7"4,V+W._46S/ANW9*A".5ZP]FV(,N98%
ML=&E@BR(2(I(6@$V/CUNW1]FCSB90YGV![OL)?TFID^=RX3O3WP<='9BU3-U
M7+&7PB>>\;:8:L%%J2DOPR=RNXV<L^]3YH7LJ(DFZO<;JD@666F[QZQ*,=/J
MW8/1=*M,CPIQ+>:?*9Q_5E8^.WAR6FEA+\-LIJ$;N7&;,IR#!=H5@R2TY-"2
MVZ'NLOBV$VC)(6RJ"YLEY3.TY+:K0=#RZ]%\4GBV<X&"RL.2JP]K^]'G&#R6
MY/E%]#L9,H^-G&BG".GLQ8R/=F3RW#C<8F\%^Z6B_UH!Q-I8SJH@3D4%@U!>
M4%Y0+Q4_/ 7E#.6LLGI)RZ]U6E7DI*1N:%+K;.Q25%YUEU1I6FV>!EALMNI'
M^*0T$9'A"F XY"OD*P0R9#A5:85 5BV35HU\=HN&8\+7D8R9_73<KN;EH^<]
M>V9>O!75,+JU-L'&S''H)K;C+*,,8XSLZ#&R\U9^0;*J"1N*%V[U'$H9MO)K
MJH_*$*45E>&.N9#8CQG3'3%"=DP>NYNR@$;PS"1)<D1W.Y=DDE;A]D55-LG5
MDT/E<.HD;0-TE-%15DR\3D^-X3!PE#-48_NHL=R&H)VV&D,7%UW<8W4[0_M@
MK7U0?!@=[8.3P:K3LP]R%""4$Y03U$>Y!8U0'Z&<G:(^PAH^=#S1\<Q'FK"5
M3+'JOHBVJ*CV3QZY3D_M8TL9E!=T1U$_H;Q52MZJ(%:HGRKIGJI3T(RTPLX,
MR'#JT@H[,R!?(9 I2D1D. 0R;#%SN!V%1S^B+@F8Y=(P=$9 ALCQO;!&/!81
M?\2W&JHCO4>7V/?5PL(DY<;T.[']F,^KW6>4,@[/RG,%<+I6$<U_]J;Z2<RK
MP6X)58/FDC+B@3&WRM JP;25XP";3:EY$I")(%E^D$3[%>W7 NS70V(NVJ]H
MOU81FDO*B&B_YFR_ZFB_JF"_9J+</T84B+;R^!5___QC'%X\43J]O%^* ]_%
MT=VH9UGQ)'9IQ&Q1^-SW)]. C9D7.L],9J0_\ML] G&N7-_Z]NO?__9S>L4'
M:\SLV&7B,D',[-\=.G1<)W)8N'@6D-[C]+UGHU_.;@:&IG?^:/SY.#@CC@U?
M4"NZ:-U<Z=W6]6 P,+56T]"Z5\U63S,-K=/I:=V6?O;KTGIE:?_H3%A(OK 7
M<N]/Z'K$SIP.*\4NDFT,W=!^6."U-C"6X ?' P4073:,'?8Y=F&(A)"S]FJ$
M>C;Q14DZD#!TPB@4D?LQ(R/?!1T%3WSY+A.]]\H;D&E!>6A+9.&?LQ?U_&!"
MW05*ZOR8V84%ZQ*+N6YRS"]GVIGX#()II9^W7^ 7QX[&E]UN'7A':YN&T8;W
M,UL_I.@ DN_2:<@NTS]^6I;V^2-F-Y%FB&&NW"#;?!M*/F"G\</'D+024>7Y
M^IZG[WM^J4\_[.UWVI9<U)!OU9E*VY9FOA#(+R<^O4@H&?JNG9@@MQZ!B[E\
MZW*G0J@/4S8^H/J14SHR2V !Z+*@V$58=.56+TE/*"%^SU7)J ]L&K')$%16
M0ZNM/8K; .@B'B%!Z? 8<WRFWH6-!\Q*N%A_EXLW'@2\G4H <BN%]\79O/TX
M"( 'R-0/N%_"UX2["_ 2_%MA]MJB[3#_;0C/)M-8A&D,-V5A!,MQU&E)2M39
MJ!2KWB,4K7)(9 7-VKJ.W9MSBV6B(B^X1DLM#,H7=4H.+N)Z+5/++_FJ*JB!
MAM.[(P\O B8"N"1@<.PS"\G(#XCMA!9HDDC:293'"JEGX<"&/)1^L]W!WF&H
M] OPWD^F2+O9,.L;>\ZHZ$Y;T5U/IJ[_RA@\VH3OB\E8 -=K2:<LU&HY:#6C
MJ=>[J-50JZ%6VQ6H#-/(3X2J(BFHU=;$O7DNPM!/(MLX4"\_3::;.&L -1EJ
MLCW 26]HJ,E0DVT8B/1?J<NS/H5/YCH6SQ_UGLB(H3[+19]U<]P50'V&^NP$
M]5FWA1MKJ,\V]<R\, IB2SAF<.HT\)\"%J(NRT.7M3KY!?Y1EZ$N.T%=UFC6
M-=1EJ,NVJ2A[O.[?W ZN[WN$%^C)'%H2LBARV83GV<X]-T:L,0V>T'7#KOZH
M]%#I'5^L9,)(JXD.'"J]+89X%Z*^#EDKJ)H<KBI_T-HY[K3M2MRJB#,JOL-)
M:A4$4HJ@V:KG5DG[$=6J(FG[*DZSJII3]@RG:]N0%,-HV% 0&PJJ :FK\F)K
MS58KQWJ/G>FN#!>C#:1NB2BV RRLP!3; 1JUKM;(L=[]0RA4A>\.9(ONVMMO
M\TY\:_OW?=0&\'<_W+ZIG][H]P=71KMKM*];7<,PM5:GV[DQ^S>-CJ;US>,T
M]<OPP4*3OUV&&>UD8V>[]Q'9$R^,)Q,:P'&A:.YGC:GW!'_#A>E\;6:= #.K
M X?PY2'G+BS0I^QL'S)\%8<"0\+;O<N-[Y'PO58])6\;"!1_<CSYD#2._/0+
M:2>(;Y+F;YJ67R]!0\NEF6##.*5^>HJ=7NZGQY?'E]_I= U[:&(/346H_CZE
MC]=5\)]>P. 9_@)S[3?J>"$YYZ8S"S\1WR,/S(H#89:3WC-U7&'8\'8M#]1E
M-;!4A/'VB(,9B]@R0B;.AXG[-!R3&UAB\@]F@Y>"?(M\JPS?CF)P,FWR$-$H
M%OU=O_IA%+#("62>XY7L&$*^NM1#SD7.585S'^$:H2O3<GOV?^(PXNQZU+:V
MR)7(E3P=8(= ]J%'L2NS4;!+//B*NKPU8XU0H; 6&H]OTV#\H*VMRTIQ5?M>
MEW9C< 5!S_5#U*N_18$*[V2OH')N$Q8/.>"D;$8# BH"ZO$!M=4Y )XJPX#'
M3"]#+$0L1"Q4&0O/&T:.]0YH7*)QB8!:)LY$0,T=4!O- XRS0$1%1$5$59$S
M$5%S1U2]>X!1"HBHA]N8TJI:\'OW44D!&;*1'S 2,,NE8>B,@%1B .L6_(WM
MH=8%]G!X*(;N#IG[@ *XO%79:1] !G=2U0JK#O1O4([5DF,-I1BE&*6XW%*L
M-]L'V-M!@QA%$$5PG2(U<NRSBIH4HU/[=2^?R!GV\^ 3L\DH\"?;M<4H!!BP
M%>RB[L9&L*C92Z7948"7C.^BFARB!*,$HP07+\%%#!M!049!1D%&049!1D%&
M0=Y^VF6]@1)\E*$-JP)E^D'$]QB!,M['QHJ#@+>XF<)1_K&B8B<FX&T<9HL:
M6"D-?&(">*ZWC1QU+&Y8H1RC'&,"%THQ2C%*,29PH4%<>A$\9$AJ\^HZ->7W
MO%O4=*<="(]UC;D&Q$YG_/=20\T'-HV2CIJ:Z*A9T+A<G&**4TS51?;"LGMV
M(3I".YJ&59J/BI"-D%U :%MK'G+8*H(V@C:"-H(V@O9^W?30T#X^XR-F(V:7
ME'41LP]O:)L=-+2/S_D(V@C:)65=!.W#&]I&M]Y4A^P(VIOO5OX8\<'7JXX_
M6!I&AH;P^NQB+$<?ZH;VPT_OC5Y<O&WF*@O(R!MRB*LX'H"^_)R]C><'$^HN
M<(K.CYE=6!"(6,QUDV-^.=/.Q&=@!BO]O()0C\Z$A>0+>R'W_H2^T3<3&CPY
MGGQ(&D=^^H7D7O'-BV-'8S@:")&P*:RZ2Z<ANTS_^&F9[>;/G=V'GN=H:"MS
M'S;?RI;/U#!^^%@X5@I]\DY[GK[O^:4^O=Q/CR^/+[_3Z=I!;[]3B=L1YA7O
M;)4<;'+Q^:U'X&(N[U2^4Z4;3HG>F-;_] (&S_ 7L\EOU/%"<OZ['X8L_$1\
MCSPP*P;+S0&KI/=,'5<8-B,_( _4937""Q?]$7FDW_,RY=''1R;.FXG[-!R3
M&UAB\@]F/[$0^1;Y5AF^'<7@9-KD(:)1+!)>O_IA%+#("=B$UX-?,8^-G(A\
M=>'*R+G(N8IP[B-<(W3%,!G2L_\3AQ%GUVWFRB!7(E?FSI5^1-T=8IJ[]N[=
ME9AE#2&OJM 8,"LIT-!%@49N>['%UG I2-C<]J&JO)LD P1:?GW.3VH/*-^M
M>M32B&"(8#M12M=RSS0]/LL<L]X>L0BQ"+%H-VNJT4%S"LTIA##5. LA;&,(
MT[NM_+IY(H8AAB&&(88=&,,,HUG7$,,*QS <VK>>B'<?-1XG0S;R Y:9ZF>)
M7<!MMOXV[O^V"UJJUJE-AGORB_9@0.=D+(G3DY-SO5/O'E4%J@[0:*FC?.VC
MAW)KMX]Z".6DLG)RWC:.'!)'/83R56'YZICY>42G+5\8S5A/Q-[$C[THS 0K
MF$U&@3\AU++B2>S2B!UKV%H!6;M*BKI65*,'S'5!E8EREI&SW (G*&<H9RAG
M:^3L"/.]4=Y0WE#>4-Y0WE#>RK1%<"IRAL/MU1]N7R'YS"W/M2KRAWH.Y61E
M*LEQLRE5AV;<PD/Y4L).1#V$<E)9.<%4$M1#"LI7$?&,4DU03_)0VH?;-L.2
MG)PB*#@-/9V&GELHH)CA,67FW<--A3D2)0^9FI"; ?3QK!=5> X=#76KL!'M
M$.T*=/@."'=H4R)((D@B2)8.)!OM TYM191$E$241)0L'4H:+?. <U(1)A$F
M$281)DL'DPVML.HGA,D=]W'6SXE>]??//\;AQ1.ET\L':\SLV&5WH]Z\1E>T
M)>MG,T9O1<(H'_/VR._S"%2Y<GWKVZ]__]O/;R_5IT'P"BOR+^K&+.QY]G48
M.1-^Y1OJ!/+;N]& #:-;+XR"6 PS6KPP+(O':7_/1K^<W0P,3>_\T?CS<7!&
M'!N^H%9TT6\V>KK9O1GTVYU6NW]E#IK=JT9O8-YT!AU3-\Y^75K+[+I\,/QY
M%2N\&7Z=Y</V='&,=8-SX2&8Y7',R BH2JAG$RLA/'D6-.:;6'X<$!LH39PY
MJ6OD!2X_)C1@Y'?VS-RY!C*(Z]"AXXHQE#5Q1!A/)C1P^+@_&I*1[X(:#"_?
MY='WJ+8!I1>TD[(#PN78VFZWKAFM1E/7&UI;:QK=_&:!Z^U<9H$W6S@4&5\>
M7[[2+W_$\6K*CKO.(:^KLV=>UY!:WYX"/_9LK@[\X/+_V.*_HA,N#S$4,'DA
MH]6AUE#^]F9$8&]U(DT' P&Y!0)RX]4*L.1[3+@\.7'C9*Z=H/4(8T)5@M[5
M"W%^ZQ&XF,L;6.]4=HC#63>F-?>T-_71E'A@$19 O9"_7D"AV9@'T\ 5"@X*
M#@H.:AL4&A0:U#:["PX6&JUIT^)'+"13^BJV)B*?W,039@,I2.^W8X+2VG!5
M6?=3%V-4.6<"?!3;JV(&P J"-G*<K:T\_QVSSBC78'+%[ ^$0H1"%: POVY^
MRO,?EEQ6"_$4QJY\T:HX6APN";-=U_,B!V(&8@9BQDE@1FX=&JN"&1B@6L<J
M9J?U WE@GN,'1(:K[)B1SS2PQG/HD9D4V]3?;]XQZTB94\=R'5IMO9Y;6M1:
MXE5%;C%4DL-6#8K@D@BV&OE9U2<O@BAI)]A^M64V\M-B*"DH*=65E):97TN6
MJD@*NF.KF<6H=S5MA3LV+ZS06]P5,[9Q\-$.7&,'ZK56HWV 3>VJ2"TZ8^B,
M%2"$33//IF6G+H0H:R=H9((F,W0T,U%64%8VD)6FV<(I2^B2;<8NC7K;6+5#
M]L8EV\:/0&MPK36H-;LY]F8\=6L073(4PJV%L-MMYI=!<O(BB))VDD:F9K1Q
MI#3*"LK*A[+2[>98658524%W;#6S@&72VFB';)M@&%J":]TQLYWCO/>3MP71
M'4,AW$$(.XU6CHW83UT(4=9.T,@$(>IB70S*"LK*1K+2:.8W;;,JLH(NV9H,
MU[JQ4=)BLQB73-'.W,>R%HV:UBAL,O@6Y*V*U*-+=PB7#H5XV>4S]*)F;Z$0
MHYE;H*Q60233X&>G6=0X96SIA+*&LI9U.?-,8#X56=O3)=4KZY,^^A%UB^&F
MO*;LJF!SJ=1:\B,B[]-[4N6632N(VJEI33/'%I,[D[8J.(E._.[&"D(C0J,Z
MT-BN-;O-'!MH(32BNZ8> BH,= >&MI(C6()9IF;F6-3T$<T0FA":$)H0FC:"
MIF:W>T!/LRK0E F\_1CQX4XKCU_Q]\\_QN'%$Z73RP=KS.S897>C=#Z8&+D5
M]CS[.HR<"8V8S<?MR6_O1@,VC&Z], KB"?.B\)'?]1%(=.7ZUK=?__ZWGU==
M.!S#Y?@_U_^-G6?JOCT3%L'CE+YGHU_.;@9\:/<?C3\?!V?$L>$+:D47C5:_
M=]6]:IBM?J?5O+[J=9K]=O-ZT&[T&XU.KWOVZ]+*95?AT9FPD'QA+^3>G]#U
MD)DY'7B878SE0#+=T'Y8D+0VB)7@#,<#!(XN&US.#A)2'#,R\EU ?W@4(A:=
MA/%D0@,X+B1^')"1XU'/<JA+:!BR*"0O3C0FL)(Q\*'#Q'AJEX4AB<;4(UUM
M#ODV?0W)*/ G\!,C-JP]/W8:!]:8AHPXGN7&-K/A#V+!:A+JV?(/-E]7XGOB
M;&I9_@3$BK,47UT@4\CXIH,G@N"<K\B0NO"D\ )C!L]Y^2[;O[<R&ZSF@I+1
MEE:/?\Y>U/.#"747%ESGQ\PN+.EN,==-COGE3#L3GP%)K/3S]GSXXMC1&/Z$
M=TI #,#)I=.07:9__+0,2/.'RL;>9Z!FKMQIV3QZ+Q^IT_CA8]1<"=')*^UY
M^K[GE_KTP]X>!]!79@#](0/*[R_!(2:(+L;I5B])3VB_=7;7/%>TH=76'L6-
M$W0>\T]#P%F^&R/+^VP\8%;"Q?J[7+QQ8X!CY9PK,WQN%TN][T\F+!!V^)1.
MV?L#RW&\I$(;73A>4F9#&>T#],!2A@,QAJQN#'DGS%.%L52?)%=:S!+7:^@Y
M=H90A644SM:L;++F';RYQY^6! S^#!G\.PM]TJ> ,1'QWL6SP5X2BY9%T\!N
M+F@['*&2H0KRE"&3:>A&;GQ4%7E!_;::93X#)5_)A ;?6$1&@)>HRG)0969'
MQRF.J,M0E^T.3)UFCK.(JR(IJ,56,\O#V ^BBX@%$V*S(5R664E:2R':##M"
M+(:$FSEV9,)^$*@-#R:I51!(*8(UH]T^7%.6JLC:OOK4K*I"Q1KUTNU/8R%F
MID65;C:Q1AUM$E5VJK':Z2#4*RF"B>OQWIC=_*;R8+73;M5.'Q<EK2EG\B=3
MYH4T<GRO[X?1C1\\C&G KFC([*_TE>\2]P+@BR>Y8=QSX5KBZ+O1_,#EJX17
MKU]=ZFU=%64:?;/7-'M]LVFTNH-.K]\QS4;':)B#7J/5, Y:%24Z.2VSD(IE
M4B%?AXLAE15)\Y4@[#O_F_'**=]R1)&2J)YBU!KSE%M>7[7VY&G@/P5T@H5,
M:2%3MULWM9;6-@VC#>]GMO(K:]+;N=0U-5NG5-JCV.GE?GI\^;*\_$X5;>CH
MS!^WHW;P]7AU.&#[B6+GQW' &/D,QXS#M14WUQZOG5ZH,4.O')GUX,SZ!0S$
M GD5ZX>Q?KB4I9:;U ]C[2_6_AX9QK<IW$46K Q8;EZ;='S&120M+QLCDF(^
MYC95!;*>((SX=D7L.5L5R.4NU$ILSZN4*G(ZF2!YSDA2@8LPR4/=) _,X=B
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M%>#LGL6[-I3JJ3_3X!O[H+^$:L]\_CM[9B[1MU$,"%H(6GGSX0/<WAD!B8#
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MYK5@52^:54QJ-JF+Q9I6K&D],HQO4Y"*+%@9L*Q:AP%$4C79&)$4<RJWFAK
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M,HP##&.HBOBBT9'#E@V*X*((ZK6VB98_"B$*X1&%T-!0#:($H@0>40)KNM%
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MW9\IB%XX56R4N:-"GMQ[U$NIZE/J4XW%[W3Y>/OHE\02Z#FC@R$E.[FIILT
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MCB?.HF9#O$_=UW\'WD'G>+]S4+)\>M]I[^-^M]6FZK:+_</6":S<]QW0;U0
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M*0 +!* VSO"=P2\67DD<P"MST2X3.KT&[GOR>&R;PV@J8J8XXB'DRC$(JDB
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M;,L#3F>VJJV8+,]F<*X?:5U44)+]Z_P'EH*[TX3R-*&D(A1R%ZL_E5NA/!\
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MO,O)><.I.";!AD&MH#4T'3PM9H9\^)6',NAP[\3[N_@4I&K'2\.VW8N#LW4
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MM*W!!O(&6K_H=-;RL.1@0JS#FKX?-=Z8'#=GCJOQ[Y/QX(;*#Z$C*8YMK_R
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M4CK$)-5(ZP"+NH$I!SO/V.B]2EZ=NP/DF.FY[_3H"4HIJMXD)?DE[IKCV\5
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M>!P2#,>2G+& @"G#LA*KB>0J!DY5#U7]M"ZKH7DR$("G<,+?VJQ;0_8PG?S
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MW@8U4-;I,7?B1^+L&6E"SL/G?"YNYM,NLJ,=+IU1BJLR_HP>\_,8LUC=4GT
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MY)VEB&C"D5/6<6-($.$11![UF:@-L]X/H'*Z_*:KFFL0;M[[6E_P##<W//,
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M>D6-(28 ;(I:AB0Q"KYG:N'+EE2:1 GN$UY>QLP[(Y(.#_<Y4;5]+@ZVA3=
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M^%9O!+/['5B$?O23SVXR="MU1J!U*]4!XO6:DO]P\!G^XR__'U!+ P04
M" "4A%A+)FP-1\IB   ]O@0 %0   &)I:6(M,C Q-S Y,S!?9&5F+GAM;.Q]
M6W?;2)+F^_Z*VMKGZLK[9<[T[LEKM<]QV5[;U3,[+S@T!4N<I@@W+RZK?_U&
M4B)U,4F ()"$5+73ZY)E9"+SBP^9$9&1$?_^?[Y=3W_X6LX7DVKVUQ_Q7]"/
M/Y2S<74QF5W^]<??/OQD/KA7KW[\/__[?_S[__SII_^T[U__X*OQZKJ<+7]P
M\W*T+"]^^'VRO/KA/R[*Q3]^^#ROKG_XCVK^C\G7T4\_W3;Z8?W#=#+[Q[^E
M/SZ-%N4/WQ:3?UN,K\KKT>MJ/%JNWWVU7'[YMY]__OWWW__R[=-\^I=J?ODS
M08C^O&VU]XGTMY\VC_V4?O43)C]1_)=OBXL??X 9SA;K=S=XR>;Q]*\7RVV#
MAP_SGV__<?OH=UW_3M?/8JWUS^M_W3ZZF.QZ$#K%/__GKZ\_K"'Y:3);+$>S
M<?GC__X?/_QPB]R\FI;OR\\_I/_^]O[5HTX^3:K+<C:Y*,=_&5?7/Z='?C9C
M$-)JFN3S=GE5SEUU_65>7I6SQ>1K^0H$?%V^KA:+AH_!\->CN)J7G__ZXZ?)
MY!. C"72%"6(_U<_;UO>?"G_^N-B<OUE"F+Y>2A@^'(YFDPS8_+DI<.&!I\%
M&SQP<#Z./DW+S+1Y_,X.@?GG:K*8I'6[P82^?[:7@=S1X&/Y;;D:38\9UNZ6
MG0W25=/IZ%,UAWWN:VEFMP)[7T[7^][B:O*E%L/F/60<]%%/W*-\^EQ/?/&@
M( K PN7-K^7RJKIX-?M:+I9)M<J)5;,1= C:[ )6J?("?EA4T\E%6L+L:)KT
MG0]79;E<_#8;K2XF\-OZV1_=U3FF\6XT!T"ORN5D7+\LG=IOOQ/\L(0_U_1X
M^]F-%E=Q6OU^HKR:=9EQ6M]OI!U.L$'G^:;:]>SZGI OYV!6+M?0+9;SM1%:
MNT0>;-3OT!HNXDW:]CO09III@Z;=#?/.QP [5I@M87]Z-?M<S:_7NU;M.!NT
M[6R@832?36:7BW?E_,,5+,AU@]OW?&\#:DC"FF:]#:\9]0ZWZFYP:U6H=C"/
MGNKXY4W%M>OA?H;2T)XZU*;C@37DS(YG.QM('$WF?Q]-5^6OY6BQFI>-MJ*#
MC?H=6D-:-6F;9:"U'J1&C;,,E9PR5))UJ T_Y2.ZZ'?8S3[T!DV[&^9D!I;8
M9#0]0@,]U*;7@37]Z.N;YAAF_2??H&V.@=9_\ W:YA@H/6&@-.= FZY+C7OH
M==#UPVC%D".Z[75Z#1?=VI:=#?)OY77UY6HRG8P^?)G,WG[^7#>VO0WZ&U+#
MI;:N7>\#;/BE-6S>WW";D;"F66?#NW5L?1Q]JQ_2CD?[&$9#ONUOT>.@&G*L
MMF$?0VS&J[T-.AS2<C2[G$#?9K$HEPLSN_BEJBY^GTP;X%;;-,<P&S.P:0\9
M!UVK:A[118YA-V5MPPXZ'/)7V/>K>:W+[+L'NQ]"8S[N?K[[ 3U]4^-EL5G[
M[@?<E&4['^]T.'='T*]F?Q_-)^DU0.UR#K]>^_,GS0;9N).\0S^"I\?VU=E$
M7D/OEXW.6KY_LK-!W(4UW1\U;DV.[9GC[?SKQGAT1_FGT) 4;?O+/Z'&#S9=
M%OM_<WZ0FBVX+;OK;#KOYM67<KZ\>3<=W9ZI_G,U^9+>NO<?ZF;4OL<S3JKA
M)WIRQYU-\7VY*.>PB<1J[B>+<;6:K55",YU6OZ=HHMJI-.X@WY ;"N'8?K)/
MH-8 .;JC?%-HMFH=V4UGPU^'!]C1(H7'W30ZGMG?HL=!-21R;</^AUA+U?J6
M/0ZR&1GKVG4WP-6G1?G/%;PA?&W$O3W/]S:@,%F,)DW)UZ!M;P-]4Z[FD^OK
MU:QI %/C#CH<\O7U:'[S]O.'R>5L\GDR3AO[>+W436:7[T!=&S<P58_K)?/@
MFSW56$*]O7*0L'3+@';OW O,:#[>8'/WXT-XMK<=)[/ESQ>3ZY_OGOEY]-0_
MO><^Y>:*9+J+R=>S'#5P3[<<%/R<(JJKV4\7Y>?1:KIL.<2]_?0XX.IZ-)F=
M/MY'W70^W'7O/UV7UY_*>=NQ[NJCZX%>07_S\>I3^=,6FI;#/=#3WD$#:2:S
M]86RU_#7NZ?3N,YT6?=VH.6W93F[2-'X QSJSF5\.^(TWLV(I]5XER374OP\
M6GQ:BW*U^.ER-/KR<UI>?RZGR\7F-^L%]R>$[ZZ$_Z^[7Q<-APD@E:^6Y?5V
MH-/1IW+ZUQ]A4$7;K@IDJ"78$F>BX$H22XECC"CX'^6"F<>@3-,U^6I^)\5^
M4=GZE=9:\H$Y/WZP$,HSQ%"4WB(>#36(>Q\BTAI[$W"C&=TST\S'/U3SBW+^
MUQ^WEL3=AW[4/I52$N025=4A/C 5^,5Z7?JW\;0"X^6O/R[GJ_+^E]5L"=]*
MF*Y? 4M2>7GK*\M)D=LHZX1@-4MJM_DV.?25'&Q76&-$D#PX'SA7\#]CN.,&
M1X>95MYF)-"!#>![0K65\SZZ= #.FCT9B/!DJ/Z1(K*# #N?+SQ1B@BG.<,4
M)JFT@YE:Y0E61G.*"NV],CQ$I:GA-,(_:<*12# S@RC-R(R]6N(!7IPFT.H,
M$#XO_B!"!$S($LLE%PAIA@/&5AL,OXF(GX<>C^9R7G8<!U NX3_8B-^4R]]F
M\W(TG?RK?' -_1<8?-J+?WUD-QQ6OQIU57CDD34$!V8EQU(;*WA4S%#*H_,L
MY*3,+MOH>[Z<*-DJ*V#GH=!FR!' \^5B<CE;*WGS_[N"R7V^F<PN-U?,_U9>
M7);'TJI=]X6WQMH0")$,<?B +;484R81H]Y+'%M3C3Q'JF4!\0ST\TE"Y84M
M9_##,AWS+LS%?Z]NOZ5CB-:@H\)RHZ5@P06'N9%,&T>1T%89!AL^:T\I^NPH
MU3U<9R#/QSD,^S8I2SO2'.B@L( K+-4$8\QXX$A9QP3GGCCKD->L-5G8LR-+
M=S"=@22'G!6PL+[]_''T[70/U::GPD@:,494&L]XM,$(28A!D7K*&/)9E>IF
MM,GFV.D7RES4.C1T6WZNYN7[<CP=+1;KXZ9UPJ@&-#NAUP*@L2QB[K5V7+I@
M@@V,(T*5E,([.3Q-*1OE\L&:BWY/QYL4P@9PNM4\Y;UZ5\XGU44#/G;YF@*^
M5XT$D=@XP[5%QL#.0U%4E 3E;/LUL3>]*QM!SXCS$!;,$U?&[<PU8Y)BCX(Q
MA(,F8DP@1GG)#<:>Q@$J:X-8 EOB=\^<?_]YQ\GH8$],G\3693PR??J9WZO1
M;U<@@B;3:'":VN%;"E#>G:6P^1EL*5(^:FNII8S3@!%_C@>M.#)/@J>$QFB=
MEQ)+OIT1V$-#.6@]BQ0/G\$>!]T?\ P6+%X6I#,66>HD5]J;+4#2A/8J>-XS
MV,9R/NH,]CAPGM<9FF)8!BLH?%;:>.P04ML/C$>EBIU!<<_CJ+6QW!H=IK5#
MZF6QX1F>J.8EP=F]A=E/5*FQ#J-T)N.%\HX&B\T&$>H(&IZ_\$3)GGJB>AQ@
M?YZHWA\&2D81=TXH,.^(L-3;R#;("1O\\/R$?5(M"XCG\@HVM11JE-Y3NBV<
M1]8Q215UU#--9)1X^Z&"/IF1;N?0B3-B-W26U6I3IW5<4!4,=MA)[3P%G)@2
M88-6M%P/6PG/0Y2.V'D2XG_R]#!J@S0/7B(]GQ<M:[7#TSHNF,0!5"@F8Y0T
M$NE4W.YP2I(!ABSDHD='K&R%<RY6OJEF*<?**%V(O1UN^/8E5:PY0+B];0K$
M&&C(T3LI+14!(4FW'[SU[!EPZ1SN]J[PS,69;:K/NV'>A1$>8,R>%@416F'D
M0L36,!^HT6P[/R,=R6@D/".^=(-F+K9\&$W+Q?OR:SE;E2FW9CIV/G32LN/Q
M0A!FE#$J.L)@K>8&F[A=LI$98 C)$'C2 939HD0VZ]\=I0^Y);Y[M@B&$&2"
MM"H*1IGA0;HM\05J[]KJ+?YC"/0X%<=L*DJY_/ZB_BZUY.%S!:8X2*H-]=P3
MXA@U9,MSQ5![_Q-_R9PX!<-G%Q>T*Z%5YZD?]A5R[O%%AW)U9HQZLJL%\#%)
M8SNTUPW"F XU*[A/<6H*::P\1T9JS[DVTA--@P&NGS$N:7Q57JRFY=O/.R:P
ML#</_E8;N71D5X73R%!":#3><J>5LHYR;@G\$)63@XEMZD:T3[6<?M$:=#C3
MCAG7G.GL:0&V@XLZ""J\9%QZ9JG!,:'CD6 DYK3<CSNNZ4WZ51_ Y=*9=HTV
M_3@OZ]W<M6T+HST.F@D;.6-. H2!BQ@"5=YS8N,S33UQLH@;4*97(%\&NY#'
M.%@7O2"8\V2-8(LM8QZKR$&/'>0Y27[N' =3/36^3[*8?@-6R75Y<?/N:C2_
M'HW+U1*,D^G>(XF:%C!F(;SPP6M (VBGC?%(,ZDD,IJ$ ?J'.Y1#U0=&N3[Y
M;1+@ZF[Z&V#*Q2_SPW9Y7=-"<6,0;+V.(0HS1M;*Z'BP3$4'OVE_,3\G*TY7
M9#O&*8,Y[JHIR+N:KPO<F]FML?V^O+TKOKB:?.G7YJU__5%/W%O.9S.9'X]W
M/A_-+F]+\\+8WU2S\9Y_7M_0'XW74VAB8G?YFH(GS81+@0Q&R!M8M1RG%MEH
MA);.-8IZ[MLD[V#"S8WVKEY6&-A7/(O$,5A G* VI(/J-;)2*9<S8.2@67\>
M.NUU YP)_T$["MZG6=:%>VZ>*7#T:9-Q*%IKC:$.&[>9N =3>?C.@/P<>!HL
MTA+,;-%(:7SUH47W3Q4P6X*M4=$$[V(D43"YG4>T?.!AEL?+8Y=$3\+B^<IV
MD"9W7I&>1Y2_ J37J^M:83YZKI!@=W@3N#*,<<)\P ;=S45A1]WP#*I6DJBZ
MPR";/$??FLGSX7,%YHA(V'A@+E)Y@X5%&T04PJ&](MA?F%07\CP!@USRC G3
M\C5H$1=/2PG;FU]'_UW-73K3K]&\CNBE"%$XC&(,Q.CH)8J&;W%0VK?/P=KW
MO9KAZ&;]P3T VMV/_\VHP9V&(WLJ+&*8<$V%Y\(;PJ.48;NLPN^'K07V(OGF
M[.H0T3^9-DB=]#D2K*.#HE>SUY-QBB.\>#=:IN7\\"G1GL>+( 2+SGA-84DW
M'K9V+S:C#9*U#PGO37?M31Y5YW#E6C4^PMO>?GZP>=<H0#N?+Y2-1.J N5(<
M1Z6L"78S-VMD>S?4\5'?SU75Z0+8;$D4OL-GM!N2^GP)Q_54>*:%@=4X>EB3
M:?3&I'N*MWAHZ\2PE9H39?PT34(6[/[DU"#5EV%3J2-%Q<XGBV4U_?6FG"\^
M_',U^?3IL*:R[_F"8&<=04YCC+DG6&.ZW7NI&:*JTIM$JN[Q:J^(IKRXHUF-
M^OGPH<)(%BAS45K,/+9.N1BW\R1R@/<0LTCR%)!:B\]\^O3WR?[CB^^>*1!F
MSFE0HSW1.$AI(M6;<449VGN[^\LOG4-X)V#4_M.K9I/%XZBV.C-P;XN"1>$1
M03XJ++!41!FS72ZP$.UO</67U3G+1]D58ME"!^?5Q6J\?#O_4,Z_@A%;8PON
M>CREO^;>:D$U(HXH3)'8GN:DP[^,7'BNIF 'N&9F3(+F;K"+6O?BWC:%5K#@
M(<8QEL8KC)"]5U\Q=F38UMUI8MO-@<Y >IF$&*1I-A >=*0H_->K-_;]__MH
M#BL'CY\JI+)4:H<-%HX9:B756\<IQ3%K JUF"D$'.%==X=%:5A_>O7KSWOQ7
MC:P>/U48;HA%(2@C$2B=P6"^"<G1(;*<Z1_/(ZN3\,B6FV63[/*7LKJ<C[Y<
M)6VR:2K\IVT*JZFPW 3NM8R"((W]_1P5:G\-^?B4"\]52>L*W&P$NHUA?CC:
MVHUY;YL"6X\-YS80'S3C%#FM-G.,8"$-6U/K0'9/V= Q4B^3%8-4UX9$AE-(
ML"C'?[FLOOX\KE:SY?SFE@-W?WDJ_KM?%[]]V"'G^W\LJ,2!II1"W$MB(NBN
MBFX1 )5V>'I<!]A7)\*0Z]N]GZ.?+);SR:=5 CE6\W)RN=^G?D3K@C*%'"*1
M*L*"@O_GZ2;N10OK!J@:=B?^_G#*=KF@7)3PKBO0B'SYM9Q67];%0VY3B(5O
MX^GJ8C*[O+O!>O%J!FHU:-(+5RT.9?T[H5>00> (1:F<1TQ283ACV^_(V:QE
M5YKQ:1 7YO)!WOXHZ.)B+9/1]-?)M%PLJUEY=TEZ[\'0WA8%,JD,-N*P[#+0
MP 7FJ7+('4Z*M+=.>EMVSDJ3;N%L38$'U&S.@H.-"JH#4]XPX^RZJJ8/:G/J
M DNX;U\MM+?SPO,3H4M$L\7^K$,P#X7TK!\H."&.(AQB1,9)@$>3S=FH)L&V
M3S_1VSGC(/:/5NCEDGVJ)#6N+F>IEM3'T;>[#,F'R+"G18&$L8)@*;"Q6FIL
MD=AJZ42S]JM%;WE$!\&.;N!L'^.U3A>RN!K-R^KSN/H"(%5I9O!#&D8UGU:+
MW5F&CVE>:&8D4S+"TJ>M55@9N9U-BLMN30[Q(LG1([:Y%I9U!IF'B;4/9S/?
M]7AA(\=,(\XU-0CP,\C:K?8<;/MRL?)%LJ9#+%NO)X_2!-TR-=$TL1B,I'W+
MR.%6!8]4>/C_,EBO,//,&[(9NV.^O>&J7B0/NH>T-1WN[N+$<E=&H"=/P$)F
MG3*12\<]1>FH7OKMF"QN;WCJEROFUO -X%YD"IJMX+?C>3E:E+Z\_>^!3>+H
MO@KM)!8\.$*UYM)JI\EVU0.UZH1\'>A%<BH7TMD.V#JHJ2)#=/!E(>\-QS@2
M2?W&AV>,5B=PZ&7[33L L_6^ R0=)Q?,9?GV\_OJ9C1=3LJ%2=Q]M"_NVY0:
M-B^(X=IAJ@U!WCGIM$5X.YO@3PB0>\&^TG[ S;6B^ G8Z\MM29CDY;^=Q$U]
M/;C:MH5)L6E*,^P(S#5PP<S&EC,:NQ-.?%^FS[4O9._9=,:<L/5/W!;^_K5<
M7E4/*L&?/3OK?9S8G@&^;I![M7DGA4#440-ZAZ/*165H1#Q(RK@E&'X:1&;5
M/9-HGBWU4 >  $KIW#3U 4L6+6"P10!HG_-H]V &U#Z$NC>_:8>(C8:<L[1N
MQM__MBQ3FHVZ^-43NBVLXAX)@4F,C"-KJ##A7GHH9VV"EB&NW;#G2')VB&DN
MA6C?D&L#&0\W+*+$@1 -G[Z7!H/5$/T68HQ,&'B,:Q9!5QD0?>D\&F94[#.D
M3T>F^X?1]6(UN[23:C&YGDQ'<W,Y+]>[:LV]FIIV!;=@5D01HB/$* /X,+H9
MO\!T@#55NA)(U1],YUL=TI#?_CXKY\D2NO<I'+50[.FCL $;E5P/QD0;B'%6
M;[\@2[+6"6P:>=N_8MT7?*U7BL8#NDN0NV_E.+:? B%GC!>($<R5=S8(BS;S
MX\&V+Z/<7V!V?_3( 6''%%DDI]!X65Z\6Y^+?D@A%L>18U</A80%V'LNJ'-:
M2&*E9V0S)X-(>^==;[Z[\]"B _"&%9^ C8W!8<NCX '&&AG9DMD&/<"RZGT+
MOE/ GE/($I*2:^T"888QQ**EV&VUI\#;ARSU%@6907/H *DL#OG9Q3IQ+/RP
MJ*:3BU06W8ZFH]FX_'!5ELO%;[/1ZF*R3'79=GK6NZK6UG@<[V#EG &XZ^1&
M^0>UO;NY>/O9C197<5K]?DZ0'HWG^U+V QE9SL'X<C[YNCX_>C5;+.>K]1#R
MO_'<!U+W@UK$T63^]]%T5;YN< 9UL%UAHF=>"V<H8]SP&(6,3#M.(O;6QT;W
M(7H*NMH,=O%@!@^7D-=I,"!=>W/_ /!U.1^-ERFWJ;WY6WEQ"5NU+Q>3R]GZ
MV;JCJOY>6B"#HQ+,&,NPD]H[+L4=TF ^V/8W83L^WNJ(+T^#L88"[*!/P7SY
M:7F_Y-2<;7W_<!$U!R5$QL!MD @S2RRY@X):C =;RV\(['@:C7$JNMF">1X-
MM-%IP[XFA2.@ B.O-)86--IUD8KM#)5FPSZO.D5D!Z5_,D(OD0N#/',: @6Z
M.D,"K;2:OZF6Y>+C[]6["D!Y ]OPG1O2K\J/O\-_;V[_K#E6.KZK(C@2F6-<
M(N:LDQ9YRS:S5,X/L*S@Z0*KLF*6:U%PJSE8V..;&G7BX6,%I<PI(0VB3$KL
MO=9LH^919W#.M"W/79$X =>6V9ON7GB7ONGN;]_E;[K[?6&FT[LA3@XD6CWT
M>,&#)MP@890A B&NO.>;62$\]&K![014]8;+2Y'Z(!6$\PG[#$(.O[T_)%3X
MYX(A2Y!B& 5,,6A&A)%P-VIE'!]00$DWX#^5Y/$89)'<+_;=(<G!/Q>"$6*%
MY$@YKB3#L#6ANU%K+GS[4YK.#_#[D=SQ&&21G#/^D.3@GXOU*A.DIAXSRB.U
M\G[4F)U0X;GS,_9^)'<\!GDD][=X4')_BP6W3(1 O.8:DVBBUG)C2VHK;<[*
M%.>1W-$8Y#)R;@^DMD=4&S6_QN8YT*HPW#FE@L6"&VRDXAQOY^DH:[\S]ER0
M<H F4'<PGYE.M=ZT@^T*XJUSU" G F-6.8'I!C\MK?##MI,ZD6(S9IR$U\OF
MR""MJN%1XSR46,<'U>9-?O!4H;B K9='V(UI5,X91?EV'I@.L,Q)1W+9E6BA
M%2;9(NLV%[/O;F/7BGEW@P)F0KT7$GN)K4 ^I-+=&\U7H/81MKT%7O<C\4[@
MR1I6^:::59M!WV+2F H-FA<V>H&]2W&)&G/J"<.;8PH-VG;[1!R]A5[W1(SN
MP<IW_KHC<.P7 .-UM5AL]>J'Z0]J8SS:=%@0H8*.F'%* J*P9E*EMGMN,.U]
M0SU74!R@[9)% KGXN6.TM>KJWC8%T21Z2HA%2AL-WSE16Q^.MA8-VYSI6[!5
MOS"^3,H,TKIY-DSI*/(DA<%_3F'P\]N;#H>#2W8_72CC,78T6"T"$<''X.)6
MCXL&YY1T,VVF ]RKKG$Y789;+:J\U9]J2G37M2MX"*#7:<8,9@H19878');I
MZ%Q[N?9FOO0EUVX0.J=J^GZR^$<+!733K" <<:$H\<@Z6.28$6)KJ'O#VR?(
MZ;D&Y#-1,UOBG)]1#Z%I$'"ZOUE!@M:1&*:Y"<)[AJ+=6O^6ZX%[R+L1XEYF
M=(;72V;(L]$@STN,\Q#BKN9=^#:^2CDT-^.N]9\=;%<0(I@W$7;Q*(2*V"B]
M4:F,,\WNL.4.5>Y"=$^O6'4(4KXSM&4Y+Q?+]Z-E^>'WT9=:)NQN4#!0UZ@D
MBD:/B \V..0VLR/RA"JCO6FEO5"@$W1RR7Z7PE6CC>YK4B!%#;$.!Q*"H,(R
MHC9KJ $UO'VRH^-K\SQW3;0CC,_)HEH-8W^C(@8486Y*:RP$Y991L5TG#3(#
M=VJ>+KP&;#@)J9?*BT'JG4.BPQD/;F\#()>WM3^:'=;N:%($9(WC3#&CJ9(Z
M1!(V[B(3I!/#TS.[$->NT]G3T<DJ_P>)@)I)_[L&A<8FIG1!$2$M-8\:]M3-
M[##1 U0P^Y+]J=CDDKP9C^>K\N+U9/1I,IVD^ARULM_7I+#.2V5 4Y:,8(>U
MTF@[0Z?D $,S>I!^1^CD#MFY#5Y?'L.#NJ9%]-H0$20UDG'D$#%DN]99@=K?
MC>\M65Y?JT%W*&4^T'Y@+]48G;L;I+C62!"UWG/':!#:F,TQC^-&MS<YCR_L
M^=Q-SDX0/A]_FL9#?->DL)9CQ64Z+.024TMLV*CA3L+DAVULGBJV6A:<A-)+
MY,,@C<RAT.!<9URWXRPOS.)NZ/=G/+6:1H/6A73.6:<51@(S)[$3:#MOX\P
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M [?I<Y6PGE-*'%?IHN5PEI[L=.D,M5S<@#UVOCX+&TU!A;^N9K>8F"58U9]
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M@X8]$78]B:V11IUP1[,WX[XWEO2$62?,@ ?+]>" RC#.7?3=_%DU)\GQO18
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MM2KH2$PJ+8C2L4S[6(N.716#Y.5WV7>&*+-!.TSZAZPV?UV. 10N4(0<V'3
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M)B$&:2X,A <=[?OF[V_?A/\\O-D_?*:PU%MC*/.,!BDP5DK9[;B(\</3]#O
MN.H&C=92^O#NU9OWYK_,83D]?JI =%WL$W'IF8M<(HFWFB.-)]1F[4WG[EA2
M)^%Q2NSO8G(]F8[F-3KT=P\6P06D>$1!28,5*(0A;%<1!IK_\+3GCB5V*B3M
MP[#*\><)0#6JB<!Z_%@AM>%<1YO*1L(BX#42F_!C%=P)X32]93WL6&"G 9)+
M:WD/VGN=%;-]I@!+&U@6O0L**V+ VKN_)(FM:E_9YOA\<D,S7=J"E%70M<ZJ
M!T\5U)OH@B8T&H()LP[YC4-7"18''JW40AZ[)'H2%L]7MH,T+_**]#RB_!4@
MO5Y=UPKST7.%)(I+01TL4#JI LK)+1X>[*[A61ZM)%%UAT$V>8Z^-9/GP^<*
M 5,0+GI& C')"8KB)I)-(7M"K8[>[)-.Y'D"!ODB[!XK#6_*9?AV=[%ODP7%
M?%HLYZ/QH6R]QW13!(L]=RI$&4#WE$:!E;8]$3.GU*P_P\G!ZY,S;O2(72X6
MF>MJOIS\:WWS\^WGIQ,ZP)O##0NKB.,V(H#6(RMM9&IKJ%B)!IEQK ]A5CVB
M=OY0E=\6Y>?5]/7D\Z$\/DV:%XA13"*SDEKON#1<F,U*K<TI7I4>(S,S\*4'
M[$XX?3X8BGJ0"\=U4!!)(Q,TI>'##O3H*/'&0Z$];-S#\['URH9>T3O_*K+X
M95XM6H;GKIL6 3E DD?JL<5"6^00V<R8P&^'Y^([\^K1"K>!7%+Z#J>#VNUQ
M7158D,B9B$1;0R3!RF]O[NB@1/LT6SW6.<G I)YQ/)?-M/X*CN-3DPX 9FZ0
M4\8[H;TFF&&WB3_27)]@)_58[20+BWI ;P#[EQF/5]>KZ6A97CQ4\-OM:'LZ
M*X3W0CH1C $+P6,BO;1;+<^Q]B<>\EESJG<D!\"OP_66#C<L(J?,>6:)9!$A
M)BQ2]]8!"NW7(O52>7,\:D/R^9WHZRNH##XP[QU)%8>-L<QM=4)E3^"+?M9\
MZ0&[7*QY#9*X'-U6!EXN;Y/TPH*X@C]_'X%L+CY6ZQJ&[T;SY<T!^AS53^&8
MXCX2IB21"EDI&-YB0;$<8&13K[[B/L$[)Y'"MR\I9OY(VMRU*CABECL27 R.
M&0%+K=ZZ*BS&[96:<UQ%Z(<D[: :@-;RKIQ/*OCM>%Z.%J4O;__;3I'9W5>A
M9 P!&<!8*RQ!H7/;S)(Z*MM^C>G-[],K??H&\)Y4/1:NJ"OI\"0A1<::#IN!
MO&Y0P.&[9PN#+<.ICI0DE&LJM"+6@Q+"1$AU.AMQM9]YW<>D;4;=O#3#HQ8%
MP2XZI$!5]J!D!6VI#UQ+[R-FR)F<Y\,'ZS"<()V]11=.06+T9X6%@V9+EC37
MW'$? (* E..@;ZE4+LC"<DN55BIK"O"6(:4M*7B><@K'P9WM=O5@,M(++&C
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ML/"6!L.E!<-'"!6$3H[^Z"-!$GZ*YDJ3;+I)[(C8AX%JZLP0E&CL'1(A2IX
MI HS@IS0/ BNW20398:0^WE =&^YE'[U<;F:_[[;I#,LGDZT.-UR]-280@G8
M< GRE@G"-:4*#%&?JN/@;Q?L!"M_N@)?#0-)-I?ZWV?KVQ9-[_]P7<&=<1;9
MH)WQ7')CI!+,ZL"(-$ZJ[N+-=@+J%+;V2S =.4Z]7J<V.WLSV#Z^,8WW$WN9
MW>JV]3XPQ.,*YJP1W"%. P9@HTB;YF'SM,Z0*]4S.M*G75AZ4HC_('M[Z+T(
MUB(<--&,@QVL0G0D.AF#0U9<$.,94G6:,)7/P[.S!O:7V?IOY?;7;77SM]\
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M/N_GAKR:H(.@!SFU2BLZ#YGK"D[@I%D%;!!8-C$09[D.M::%1-;3MD94 _K
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MC=%?(D5@]L=>&YPPK2S4U!F-G+!&R6[=PBI%?90(1'UR;A'8@(D4@3AN>HI
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M-6WA^E4SL+^[:7[RM7D9C4D'L$6&<B8<15PR2KIXY3+NH?DD (:%W,G9,#X
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M$9D<,PVIS&;=T^V&K"R^)*;-N[WO0R]N%P:KI2UOR@#ENGZSMURLFI,YS^$
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MN<OI0^@?S8Z_GH5^<%5^^%26:[6X[@[&S.YV^QPK76]Z?*Y6L[N?EM7#Y[8
M;KZXK7^GV6A\**_?;9^Y;V;UW'"+G;'6.\><TR#8LMWMHXC&7P&5'3+Q DL-
M L.&T-"GM98^D.\<YT!0F_N2\0YPT2 N?I[=EP/N&#^_@_MNYWYWOHT;D1+<
MFO'&J=Q$']U?GI2GI[& ,352GKT6:SKPHD:Z*!QU7+;+.LISZBQ!7EA"@>78
M0=,IFU8TZEF=5 P2L3!'X@0JRZBT6%$* 4*6,R@$=KG?9GU6M)*6C;,YH=_P
M,@7^1Q@OSK+4G,C=D2$@MS>FH>G9K:Q.V\<C5F/TO/K2M/2EG<- ZA70 #(C
M,,.< 6^VY314@U[W63__R83[,%(PBSE&5!HFZV?7=$A*+3$A$<V]#K/#$[&V
M$$]/CP68K,S$:=<.2LK*2SP[$<LN65E*6W.)8:O?PLM3(P^MNB23,8$EEW3L
MU1C=(;$>^NWV#BD&I'3 J/JLH*4R]&_,VDY-+"!1M^D]\_$DR#ET "JI#>5
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MY"<M=9FE059LUZS^W($[\?SF*%$]9&48P=/2FH&V'!"@,1B*3D8<!#0$$:0
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M!G?1 "]JY,7?-MC'U=HT[XRBM]D=,[;F_K_<O5MW&SF6)?Q7XNVK6LM9@VL
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MDP"3:"5+J@'%%GJDKFP6.;L!H[1$45L9.0 :/Y85\*$ $H02@+AU&CG-G-5
ME?DO='3S<3<0!Q;JNHC? G<>YNZR.+V,\U:>G8(,C)[;*+BD ^>AX)>EX.DV
MP>7]$90%^'6Q_D>U;1^E^MMJN>VO_ %BH=#6(4$AI$(I8D$O*PXA&O;BW;D6
MRE*6QBDK2^YUBY:<,\&AGR(A(-3%52P=],)=AZM[X:YX:)!%K%F'TA:PXI^
MKS@QW1'5(BI:2$-6^4,9BUC?3\#<L)7]\ZYVNLY7V*+^95-/+>='$C.#A?Q8
M"^ITW21"7#\O[ZM_JS;;ZN8W_]_U\GJ[>^/TN%T'+=302<,DD, 10<!^FX%J
M[2*D-J@]2227' NCO)6L>9Y)&4Z<P[14%D.477@;E+_\:&$6ZSW.@4*<AN(
M69Z<VSB1;N 5';[B '"L:*=A-T+")V=YF*"W;)_MPF,%/H2(4W*?E,09B']:
M>^I<W2UB8M"+S;=/U79[UQX%NJW7]XO5[@11WRI"2%DJL30 (8B< WR_\6%9
MQ-V\@+88%,3Z]81RNJ0*8S_MT;)$C%()&(/9+W9[A,6F@UA\/V#LKC+%S 8I
M> V8"R:F-&XF>(7-(=- "EHC)H&)Z1TV!8RF.6P>>)V+4[- 0A9G, >DM*;.
MT]<B3V6=:,T!RKF6R&FB*=$<B+(_2NYD2:)J7)]J0W I?-1&I+& 0D;\4L>O
M<]HL$K-8Y"Z(>00K)MX?S5Q8*GP*TN(4_9BO3\/4)=$)KF %2D7F/#++HZUX
M>K@K"2MAA=;Z0^I-5/O1=[!OBTUU=&3!*%A"[(PV$!--N+1Z/V\W+Z=&9!]>
M:TI XBCRH0$UAAJ@N+7,FI*4$  C<=03$8,2#_LK*-TZ[?L.8O$][LS7:$H#
M(LPIN8S<6MO?XVE)[+$-/OTUFLV8\F\3LCJP)-R9+CHVI?"*]:?BR%2DS2"(
M3&9*G:%313Z/DN3RT;M]%2+%N9.^QUC#>*F),*+$W3#C #,:=:PL-38$.62(
M0!^#(TH)4= RBJ%DQAA!<>Z#:>EO+KX;6GYN<J^'A<QS=GC<[';*M8^*S7WY
M^:@+[#;ON],F;Q[_6F/8!>O1)7;,F4#_4EU@'@N$BUG_])6=BWHAV0'&4T=C
MWC\T,^J'VV[1)!^VW^IU@_T* 5FB4A!@--4*^EG6@5['C"[CW@I-CDYHZ@!!
M3G+**2-: E(ZC:#E4D*5_5K<+F705@2[O_>BU,66BQ^+Y5US^;CP:]'BJS=O
M6SRL_$ IMM^J8MS=F MZ.FS&FK>3)Y^S.JN:+K+K+ ?#9G9J,M8O8XY,9NL#
M\YBT+FA_[&')S)X(RJ1]>KB_7ZQ_[AI[AM;^WGQ9R<VFOEXV!8W^?;G]9I:W
MM]7:H_VX;MZUO=_(+YOM>G&]O<("0BR M K2$G+!B8-['3/,1N3=T@)S"BOE
ME &(0RH<D\9 6 )&+&6<V_S'@W;F-&+4E;+L%.OZ6-FJSJ9BL3>J^)>WJKCI
MS6KJ7;9V162B)G9P0!9POIZ-G*&2NK3X>V]23)YQ8N]&9"7GZ^5A.<RGWOYE
ME+?'9CV3LGLJ1WH9%\X@HWHAP^N+#Y_(*[S=DKNZ.8OQRG**(!.$(8DD$8)2
MO5_<4$U06% 0V2BUDANA95D2197$@C*G!$&\-,0W''649MB$_XI(1-X#3D1U
MV#KR AS'3;U[@">SUH5]A>8\5XJ#B#NS>DO,_#R69*F->GH[.0=G:37P?;7]
M</MY\?N5DA)IX4K)A(-*^WB+'+8FN $YM'#?N'-0"B9+@QBD1$F.N("8$4]"
M:0T0$RR"OFSK[>(NA_:%4YQ2 [-PFTL+WQ0>;A/ >L!SU,6>S-'Z&.V5/Y).
MQALW2"\'<CCM3K]>?%]Z/6G^5MXW#[U?E<AIZAAV6@,IB15<Z7[T PO0U:KZ
MVMC^>>J-_^=0+0)6*0T,%8A"PV6I66FA+*5SDIBP<SFBDXQG5D6<^-[C.KVP
M;4N:7V)3?X"#I]S<S^34D4?8TASH>%,<=XW.O#_B/O\S'V7?[Q_>*^8Q#UV<
MA2S[_V.]$K:=<FY*?;NZOGNXJ6[>KEI <G6S^X?-%49828!="?PJG7%J#>:]
MJCEK7/"]N*$ M+,2*4:,88PZ'SLSS0%5C@,I/+#<CPR]EBTIECOH_HNB74/L
MGEAI'M'<_4S4KD@N/X7L?\S 10/VX@MU<F%1]*C]%[O3@!YX_Z^S\$O,SL4,
M_#-PC^*U;:CC4?1\_(S>E!A&W,GMA\Q^F,-&0VX3ZPG[==P"L#_D\%OUO5YO
MFQ-;GZJO;0FI*PP$441H6I; KSQ].Y12Q0U"!"C(0<RYMS/-(+^2)8HYQS2C
M2'LC&2@)=98J01W*?3_\<#IIO<=6;';@XM9:8[@,6RY-1&/<M'1@\ "K^/0:
M@UF6*J?Y.;/:2$#J/!8,*0RIDW>XB+#][<H/X&JS?;OZ]/!EL[Q9+M8_KR M
MC=)E":$?0A)2;0'OAXZC-*:$T8N?KP"U&FGMS5$4(Z$01- @;Y?30.BHLY6#
MTO$]JB8:V.QQ%7^ZJS:;8OMML2J^+G]4JZ8.P.ZUNS]'A'+#. V(G[.3&:="
M>Q9]['L E)VHB( V.V'#HM67N]_8(/0E8T]%F*.(F4'X. Y_G:J+#'VTLJE2
MX0/-YH_F+/Z/Q5VC[]W388I:@K6FP&(.D..&&-DNZ""UT#$U[!'*<RU28CE!
M):1"8XJ$%8P 71I-I/2ADXC:P1OYJ&1;A:59F;5?'"$=^SKD*,;#(L7IR8[,
M923A.?,SC&>H.W?T/RGU\P@M$]MT\MG#=(R%ZN#;55-JKYDV]Y7U2TY*"C2'
M"#F@2E028OLAR/U?Q(C>"Q]O%#%8*P10<^Y/.V%*C@$R3(L2"I2[V/P!T?#W
M,(:0%J9;F?F*C2FCJ,JB1L\).2,](]B;A\Z,,:!.UI/&*(A>;*NOS46A-@KO
MJWQ9BKC!TC&)I;+0+ROVD[H ,JKN5D!S0E IE&;&6T=Q\S"(5)Q1@9!1DL+<
M=T*?#IO'& <^<)&"Y2$2E)W@H9*TN=#;$Z_3$RQ0H[B=HV"-,^BL@"7@*E30
M='U_7ZVOEXN[CXOOU;IOBR$G@2&06TTA$](AVH\NI4H5=V;VY39*J[@HC</$
M0@HMD "8TEIC2D6E05%E\ ;EX@ZPBN\-KCB-&DA<F"SE9RQ.B8ZH:@%=J&S@
MB[2<4:!Q-,Y#=$;:4*?L6''2\EO55QV37]=5]U;-KD$H+1= ^U4$AIA;J*W:
M#Q,+05!-ZI!F+"HI\>M( 1VU3 G.)"04$&Y-*;+7>_K@96FU_/IM6ZRK'\VO
M-]N.?2&VQ1YLG.Z,835,?"8B-$Z!#J"* ZH+R=!I@LYH40)6YR%(*0RID_>X
M.&GZM5Y5/[OG6]S#ZF;_AI"PA!L%B&22885$Z75PGX^E)D:63C2A$"N)M,!I
MBBE0/EB RD&'&7-&.9-;DEI4Q7WWC-!M@RM.?882%Z8\$W 6ISH=7;M7EUI(
M%Y*<EYDY(S<CJ9R'U(PUHD[:O>(DQE1?MI^JZX?U<KL\5!;71FC*"1%..(F%
M\\.D'R?,6A&WKGJQ"281(F6I_&H#4^P_$S&)F2V5]/^!=HI;V/5Z^XO7IOOB
MQ@,L-GN$<5(SC, PH<G.7)S,-'"* YX+:<Q+I)Q1F%$<SD-?QIE0)^Q3D4F;
M%W?.WNVK+39;94XPP@6Q?FD'?*BTVY\I,62$Q<0QK[6%' 58E) X)RF!2#!O
M+BZ9T909SEGF@.;,?O*[H<5Q1],;F.29D-G(=,\X4O/D?LZS=2X+E(CG>6A6
M,FN>9H:2LA2C9$?-R:U>K-<_EZNO_[:X>Z@.5;(@8%QC*GVHQI@RAA#:CS@
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M7J?H1V/#JO?UMFI*X-2WMY_7B]5FT;XJ<F6 ]:U(KB&&DAL/1/4W#AVCD1<
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MB"NE(KA41$6]FYANOGE3-!"+OW<@D\P5,02/$?Q,W"91[5!:)U3O UW1$CR
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M1."=C.J ]<XE.(Y3[([<YIFF'<87Y;@'&K/ 2<9SQ,KF$GP/6]*$=.JQ"YE
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M=&";3%P'MSC"^V:_++Q46!#+[!DUS.:D>0AF/O/JB3I['MEMUV57A#'H%U@
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M]VJUJ1[_=O-#ZPYQL[W>/GC0?,AO;S__[7_+]^WAKN5-M?^--\6_OBVOO_7
MHW'KQ6IQLQA[0RVP-[PP#V;I3#.XH9;<I#KCX(N+M#\T37UJ.N8.Q_MJ>X4$
M)!R5@D@"J.4$6(7[IHC!D1?4!C61?8YL4<5%V\.X"HNXLY,4-[FU<(H=E#>%
M!S-MT/T2'6<"[U'LS2/X'F="G; W#5NJ7Q$HN?#R5&),#%/$<'S(! A-8S8'
M@C\T<];_<_,K_10>N=T:3DS<FCPI)\-"WLLLP ,6WL'<S&/,Q\,^L=".M#MT
M;.O:1\]-I:\NN#VZC@U*;C#ABF-M&"!:N7TL0H'F<0'"X&:R!PD-LJZTW0Y:
M9'YN.(%AFC )<W$:T4)J.>M!72QS=XJ=,T(RFM!Y",MX,^K$'2U>>#[<_K6N
M;S:?ZKN;*\61=$HB:'5SP:(Y ('Z5C0#-EYO8CY]&IEID@M-Q/;&BTU3_:K-
M,MS7Z^WR/_=5V1;7_WQ8KMLC"%O_ <OFE.EBLZEBSP%'\QLN1[F(C5>AAK 6
M2]& F5YZCIAX17&&<#8?H1F$_@5]&<Y"^%IE4_F?_=;4 SKD[G::9OM1)W>#
M[.WJX[J^KC:;!MP5=M(B:J&!H 0<2&$([1%A*ESL#F0^)!-L+W3@GR9!8]='
M&9T1NJ2:AQ=B5V%']!_A[@.NXD][Z(4\3!C%#GW1P/_SU$NXP42?7?7E=]\\
M9'822Y^M+:=B-_C]RV[OY:_5JEHO[CPN>7._7"V;2+0Y);^#=H6%=99HHQPC
M2)?$KW_WF\T$EB!.J1,UFEV4=SC?%%\[I*TZ+!YAC7Q[,A';85)\ 9KC5'?/
M[U^/^'T,LA?@B=]^#&+NC(PFIGX>BIG:J*=O,.;@;%P8NU?@*TN,@8X[I!$S
M3)>E9?M6N3!E3%65L6U%)>@'%*P_Q#?-EG@;WZPSAJ<1)(\)0?/PFRC,/(22
M<P@B]U1%!XKQ),]#VI)9$Q3P#64IZ!"?KN_\U_6Z37!U!UGNZLVF.?#2',9W
M4EN!B,.4*L2U %2!O7Q2"$.$+$4[F47L$;K=>9[B3W=M/=@=Q(@#9&,Y/:];
M4],9F_:;$Y,1)_ F9'38P;LQS(8=.SM/P:G39HF(F\$ALU26U.F[55QXZA;+
M];\M[AZJ7ZO%YJ$K2O#OR^VWOZWJ+YMJ_:,I1?!V]?UAN_FM:HA9WBU;?+\U
M-6G6NTI:FW?+Q1?_+]N??UTL5TV=V+>K[DV0MZN^0-&5D<2Y4F(L*5 :8EUR
MV^-7MH17J^KK8EO=A(6Z\\$=-)Q%-YR/30P>S7]JP/VY:/I"<S#UUEM>_&A,
M+QJS]]9WY0A7S2W7YKOV6.I-U?6F:6._R7QS)HJ<7_^81SPZ0U[JN8_LZ 7_
M=OUPO7UHL&@OWE^KS15&G#(%!=,(E0(+3:G;A^-(R\A5?GP#F:/B1YB*ZPY4
M]!I^ &_!"_>\E$6OUH_8TJ^PE6M]_HR1\XORX03.0_G&F?!\^3V6CZ'G^JXT
M;"J5<H:-1"7BH*1F?WRP>9@BYNQN](=/<H;W^NE)OG$'^5YG+$Q%LI(5NW9^
M>G#OLJ?U(D[I!;,V#]D8#O^54WF1/ 3?$?K>QORKK\>/RPCL)*&L>4J&&HV!
MLOM !TL3I1A#/C^S:.SJ5[2W#.OONR5/I&8,HBU,-G(S%J<<>S2/W[*:^,;0
M<TK.*,@8 N<A(J,L>'I=:#0;P2]4U:OZ<6/]5BF"1!#+(0(88P(HXX;L;S
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M6");GM:C3<A0<,+C<5.FOE\L5U<&<8Y*+2B!?CG#N-"^Y=U $A2#&%5ZN06
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M6WZS26"OJV_5:K/\41VN];SSZOUV6]UOKIKCP99J5#I-E: 6 $!WXU=1H]A
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M0DLD$1IZRQ7>7[8UL531;%G>Q@_)I_A/\4AH#28>4P\Q11 JX0Q66K P@9:
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M6 _*^33$=UB3GK_+.SQ?K=?KO\Q7I9ZOXZ; ?7P1:]N8IA :0+G7@@$M-6!
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M<1.? HS?"6KC]C.&%FGGI7TY\++.J$[,&T@B\!!(JF)G3!&MF?Y4XE47#+%
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M?-!N/I="SZDY7A:*)S#ORV-7E;MS]HA#?\R7CS?QY>55B(LAY?SX^/!P]_T
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M/:.Z.3TT#<G-:F$U7G_/>=)A%?Y^= +6/ :I66YFPF,+#*1<0B>5UL)#T:@
MISK7;M1I0 I;C[TQ@D!(=7Q74@1TWB!+M&,,Y3_7$($5Y;>'<KG>;817=0IV
MM45X?.D[YY&'K@[+<=)A!%^-<,"A=NR1&6^*G2&33:M/4C_848:>GIV&_H]K
M<J^#"X/PG6LQY,] ]Q;0$<29<!92$+ 90XC%P@7MV4_5(<^UY'D&$<,^!%,#
M';*2.B6U1-(C S!DR!D(,\>([8S\KEK>O@V_?3]*0.CCGSQ+*?E=,\[*RI.
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M.$G:D/UQ-C6S&%L%/+12."0P=5(T9?8T#\UVV))]H17I0HKEG>$::"JD%@)
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ME5UWKP=E,=NN]:6WJI.VJ%M3.@VQZ6/ JUO2B5RT%9L_%LMJ51_MV1[7F5%
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MUU@J-[MB3M5ZW>JQ.NV8@81!HY16FG !J&YP  IDVL;(\.UGSU4#Y'U5IKN
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M+^CO[]T_N1\:A^/G<EG>+-H>\AV0WG:IT;C,IF5 #;:]ZKTTVQQ7Y%ZEZXS
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MJ#^K9?507\N-!?Z.UKYFB"J&$:0J/HA+%$5,DJ910U72?;N>367>EJK1=5#
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M.E /I;55?#E]1J'1%H6D%ALN' D2K\5N+*B8]';6VMWG \4HQ8;IT HEC"F
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M)(]$RRMLB9QNDM^FA]=XO3CS#J)\+MRDXLX7U?4HE7?^//BV*)JS#4@;>@3
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M.,05>.:<95XK*E.@A8\2G%MO)"!15<SB%Y,/V!D5UXG@IX:=QE0]GDM@+U=
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M*YLNI2*5'F:^F/86&&[L$[1"T%BN%'*"":>Q=GBY1L-MD]"<^O&#&4-S>@7
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MDCP^:*U1\[6M3T1S!W,7=0,!E*(,"BVHIX QY])C*GYV1<VS(V\/Y'?(N#Y
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MP:2<+$NIWO\R*$?IFO?AGC4IAVXP'L5FV^15MCD$JXCW3&&L*- &8L.$6_)
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MBHH?)P@:*(4$JQ4:P<_L@K@#Y+1$V=Q!!P\1I--],+2K:_!6*L0<QXH3"@Q
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MGM)2))UDBL;3GT.MN!*-'C#W,&R@,X1U1.]64!4;%O/)Q6T0Y[D.^LM?J_H
MVW_4$,FK(2; 2!]WE.8"206Q4,Y@:Z*V>5ZQ]MUAK7/2MP$[7\W&\TG^9S'>
M,L7T+[5!M_>80:>2DH 2:N,F@PS$'::PEE91A2"G3<I&[1T\<,*0ZYKPK0 N
M32O-,<GB%]/SU7A?J-4?+6@MJ7<X"G;.J,5(N;BU;*0M5<28>OF.VXH@.&60
M=4;RX_@7WM9XS+:A1X!1*2"$&">QI8)PR:&PJ8"RXU#R>E[9T[GOZLX9=2A%
M<R'FJ?6[WPW6CIY!(B6 CEO12D,A5-IQZIRGF#% HW ^;Z_$ 7Q_66"J5?H>
M T\UP1,<1@Y1K3R*M@CR4,2#VWD@ 7<:")#U*<*I(V5/8A[G8%K!N?;!M.H1
M1((]PI1I9VA*PZ\1)EIJC#Q  C:)9>ME8H"VP=(.77MP"_YB1B=^"^XXH! K
M#XE@4=M(E'?2>^6L15#@6J=E-ZO]='%37,Z&Q?NK9=C.O';OI$P,G>C[)W_;
M$,2SZ^:\I2\$ZP%$1@L=57)*F)(:,(^TE59Z"M297:"V Z>7!0F/PHKL>1&Z
M2T%,B?9.*LZLH%Z:^">NA5?&1_DJ<9.ZSCV$8':T')* >"^.9$=B9PF(L1-&
M8:\L4(PZ):4!\2C70F *F#BW:))6D7!  N+]J'U,E+6=@%@ZR)EW*;F\H9)C
MX9B)YXX#VCJ+P/EF=6D##8<D(-Z/X+DC]'>+_#I>R0-&"T@RJE*55B?3]I8R
M6D;2&XM3;C+NFOB;>NBQ//;1VSV'OI^W)0I#X2P40$)#A0!"(6(,PU!QYXS+
MFL/]KAB7U>6GZ6 \[12_G>*GA><F^_'DF ?ZO\KIS:NTD)/G>2$_OD@JMECE
MA]GXXF8PV9I"IJM/!B$YP(9YKFFD,)92$![%T)RI-IYLY^;US8GXGC#M1+?%
M+U&'>UM-)F]&%\/997'Y9N0&XU%LEG&?;)Y#RKYJC7*&<R2I9$(;CJQ#P HH
M%=5-KF;K>\#EP\89%=>#:7'YN7-]YX1W3VNL/-'M]*F83H</MDR^_?/DHX$P
M"XP@RK&HTPJ$HCF&#$3<&$.8,TUR2=</^WN^8?[:*VVS[?LQ%YRPEFDA 061
M-<@*QK@0U'B,##*B2:G.O4,*'\P%-SH?0'?/D1[<G7XNODUG@^'S>9WX#6K*
M[H,=@@("3H4"2AH(&8.:$DPC(_ZZ0=WM#:+<8PF1Y]P92C&0$;Q6(0R-9 Z0
M)B=EGR\-&L&IHQO4_5AQ*F^<"1(,6F4$=I9JA;4"W)+TW_0$A9S9K51V+.Q^
M%[T? T[Q770DC-0I)[Z$G"*M-*02:BT0,P9#WB1 K(<0:\+BNN^B]Z/HN3V"
M!=@(35,P'(CK!DY#1K2WECCAO3^W H'-0=#F$]C]:'^J3V"!L29:)HHRS"AQ
M4$F%&" &6T0I>UFO_=1O+CM#6$?T/J\GL$)Q 8 "UB2GBO!2>PDD\L!K)6RC
ML*!3>F[=&&N=D_Y\GL J#&S*GV&]%501)1ED&E/"O6-0-BIN>DJOKIM"KFO"
MG_836*@$M)8*%G4$JK%*05=,0JB%5!CA)I=BI_3.NC'(.B/Y]Q.(1B2E%#%(
MC1+4*Z>,L=PHI+1G!HF&V;;/TU/1/9USX6^><OS-[=V@'*>]:6X&X^OM-9K6
M=@A."<PY(1@83I5(3S<< X(IJ F7],S2NW7*_W55 IH2_*@AW''*D3"3-Z/T
M+P^[K[BX&95_S/8.Y=HZ5B#$4XN=IXX2*H56$CH.*?%<*.5YD^<L/;1,<X*P
M:UX<QW/[9A2Y5$RF'P?3XM,T!3HLE(C!=?VWOML&"4X#+0E2AGE,L9 ""P0Q
MXU0F]=8T>2O>0_LU)R([8T*/(S/>5:.+>7F$;;?.C<9-U209Y!Q+[.,AXH30
M&@%G,,"19,:>77VRG)#-R9EC1FW,=>O)\_F<>+2&9 (*RJ000*4S3"O&"?-*
M0>>U\K7>/'0=K7%0&:$YKU)\C8[3^[U6S$8+WPD"8. %DEY#2#VE@G@IL4(D
MJK0,-<HSU^]G>(W M3%V(S]+<IV2CVLT@_'X/LY]OLZT1#>9EK?IJ%^M?O+^
MZKE:< B\6_A.D%'KM=I:$X^$>%1$]0-0:@%$_W][;];=1JZLB;[?/].8 L-+
MKX6QNGJY;%_;^_0]]P6+):5DGDTQ?4BJ=FG_^@8H49)ED4SF@$S1WH,MT0DP
M$?$A$!&(@0NNM2Q:CNP,X%V>)<7MY0;[]8<8Y>]#E)N@?(BOBYQQKI$P6">]
M2/D@>:)UL($A03 173*C)EGB:!"P3X SI53&I/JFEYTMGNW5T73%9]VKL_C(
MHB79 3FP?]<6O8'FV'R2F&Q08XU2GC$&.C@M';;8>"V<R<'7X^F1=K;^FO^?
M7_VOV2(O)BWDC]GJG]4F ^UI,4T$38O9HI(J7_E)HZP&ZJ3&R<0)Q!DA/2:F
M:#1O"3DR!&SJTFP846@\) ?\-+)#>8XI,]0%AY(T9TH1 DEU26HZ"NFTF8(-
MFL&6UO "<\WS 0Z,C]GIP;+;1>4VBLHKP7*T@&5:<Z14T=(MP_M2AP#& 06[
M+[*74IR?R/,E?>^1R/X?'X[.,$>M(8@P#\(&Y;BDB#AAD_!3Y,Q:W?7,Z;IG
M\HX#&IL,R.MZ-?_WEH%'RTL='QR5 JV,%2ZM%:@6DFLC!:3MZ(P&W,7LGR"H
MNK#](()ZH&TI1-GZYJ9:9<7DX^Q;M3H*HE>?C]P;J;@+E'F<>P)HA!SW/F=I
M@G;DC#7?[NQ^J?'V0.!2X/E4?7NH5**O5]7]W<E1!.T?%+$G'%B2X H'\,(H
M*31F@)CTCBO:Y>YN@N$/ X*H-QJ70M(?];*ZNS?KPNWR\CB*7A\0#1&<:8^"
M!0K(!(VP"3A0(8(SH=/M[P3#%09$4"_T+1D4\V16',7.:X]'H0EAG)O<UA2H
M]XH(387G1J<_L.\2Z#+)N($!L=,#?8NI/Z]:$^\:1"H?&1E) $23TLA"T, P
M42(MGG+A+"2"RBX7Q!,\RX:US_JE=4EL/?=;;KZ[!6S@6FLV090H0"!*!Z0"
M<*HT\6 4%5@I9'S9QM0E)%=O:'@%9;V3>QI@:PVRZ /+S?R$0#PO&\MT'+B
M M;"),.X2_&CR8*K3Q"<A+$3J3W^U<6+E+8SOKN@#I3AB#&@)L>#YQ@CRT6N
MQ,F(IXU\]T/?7>B_$D^V[<OJU>?9=Y=CC>\OCLP1K7+*<2VELA8<\9I0'[0'
MR32BJ%.RU:0]A/T!9.\=1K^D+V:YS_ZK7F43XB& Z34:';[<:#A#Y#;1DU&9
M%LQ!!ZT3R;VSW"*&$'=G=GTV "Y>FOB#T'U"N#M:TZCQ')$(*BEG&C0.8)C.
M_?XTR,!5$,CQ,\L.[!T9IR.O%=U;I]3;>O6M7LTVU?>N"WN?N7 X@;[)V)A[
MVS(#% 4$@ -3'&&N*2-(V.!)T98#)=3H 3A<#TOSOK'SOEYV@<_+X1&)($!;
M@K''0 (W@B6*)<-6I9U&1-%V*^>+H(YD;PVBW^I$TV56-$^4/D<'1N<\"=H@
M;D.R*9E57@#&)!/,8BN[Y!1/,KIY8.#T3?!>(=-4Z#09&TVR7 1BVB'DP EN
MF,=>$(J]P0Z%+JZ?2=Z(C "<CC1OC9T_ZM7F>G9=I25^V'RM5MNL*S.[^&=U
M>:+\.7VFF$CE!"4\8$J3NBB-DDK@)&<=]NDMNY1$.[ETT!G@:G .#(NRIB*K
MU631"HFQ\)8RB<!9HIP'"T'FJO$,?)=X /X+:X,PH90#X25=CH8-O#X@(LB6
M!4J2VQ(P*MG!)-BTI00H*8GJ C'Q<T&L5T*7S^_=[Z=[UR">X*1YDHY)2%#$
M>N(X<"&-L9P2;W/>BT2\RQDZZ>B"H7RA0U*_6"6TO6_>X"KL^.#HL'".*N>T
M5  H4=-SZ3TETA+$Q=G%&0R$B9?5T?HF_/AP:P6S:&7N^T&-M)#L90N9@$(9
MJJ2QB:9=_!23A%>?C&^,J1.I/#Z6],7%[<WM(I=*^&U5K]?_6*ZJV6+^[_1K
M4C%,=56OJB^SO]M)MF9SQ]QV4R 9@C0:F&82J)9!"H88%CIT2;6:X&$["BZ'
M8<64X9L[5 X%W^_FC@J[9'H%"LG<!X*QELD4TT;R=#@IQ,N4MRC8CG%B .["
MC D ^":9_'D9MEZWU!^?SQ")AV T9A0#!6ZT8C9;<;G$1S(249G>H#M96F]F
MBS.$8@>"CQ]2^"*,Z8Q#"C5%1&K+.),4"QLTI8%J0A(. A=CED/8CZV\IC]F
MFS[LRM>GBMI;)I4WB'F#F9&!>+>C"DH4.C<S8 C -!85O?!@_$/J^V7D=LCS
MY8=E]9_5;/58EJH'C+X^<<3 G,?48X43J420R<1ZI!;!1>,2QS5<N\*I)6Y[
MX<ND4=Q="VLZ>=1:<2^D0Y))!KD?N'L4,CEEZ]SBC*:-YBZ\F1JB]=6F6J5U
M??FZJF^OO^;.-GF)ZSY%]-'OB%XDO=<ZCHF7C ;!/=8[&EIJNI0XF60XU.3P
MW3>+W@K,^Y;AC;XG,DX"20HC3GIC;FA!.'VDI2*TB^]RDD%<;P;N7=C4.B+G
MI)=N)*#[F#9B["5.2W=6603<,3 /YQI'V3ER;A%A@X-T!*X4QN0Q:=K7U#%(
M(B@8#@A9%WC.S\4[*@#0+E&PDXP@FS(VNW!F?#6AW;6X I'V'0J02^@:<"I'
MLCRL4GK413:>'%XVIL.\V/%](L7'PM7W>2O?[8QMC?43T'9LJIBI*IRP0F ;
M)-)IKSWN-(XZ1='*7Q@<B@_CW^70G^8N1]B03J$@P>2.6F!4H%@HH8)61!C4
MJ-K3,)3XN*HOJNIR'1+.,\BVY=.W$+X[%-AV@"PM9XQ:2.PDLR:D,SM1RG@F
MF>/@07&F>)<*:Q/,H1X"//48C!A?<=H&5'QZ%@_43I7Z<9IH";>*2&QHH@1&
M2DO#K#,,@@G2NZ*171.[;&P+R@'I/S$DYL">EEK]*_-$:Z3@(JAM>@.21B,M
MA-.2Y3*M034*!WA+85K3P6(K!HRO7>6.)[>SQ4^C8R6&,Q"2:AHP&(0EQ8P9
MK2C75CC<2%@W]DE5J]EU]72:OM9Q9K_7J<'@&+2Q1!N:M'<)6NO<JA HT5B1
M@#WKLMTG&34P!*/K@:D^XAX_ON\G$2BG%XMM(NCSCT[:] <FB#0@;+'0U(<
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M?0";5 ''C'>.T9 V#NG4V7J"?LC!,/6RT6Q9MHPE91[N_7]"8<,9LU3BI(*
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MXIH18JW*U;XH=/%V_931J]W.[QY85!A\V7!X>-GCM:OWCHG>$E!8$D:P!4G
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M<2RE-(_O1<IV""C&["[\J?NA9&L.?_[X^_M/^O_7AWG\_5,1T6")8PB$8S:
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M_C+!O#\2CPVF+^DMCE<I.#HX<H(#9>!SE!3@;9\>JI1QP+%3DG=1-R8(K'X
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M8(0/:K?F0$*71-0I9D(/AK"^*=TZ/N6[Z)CJOA_7>I;7_52R\V5XR:$Q,=$
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M%$*$)S/&2P7$L6 %MU;OUD>".;/KK(X\;ACK<QI-WV:L#T*Y;)(C2DC' 6%
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M.3,P+GAS9%!+ 0(4 Q0    ( )2$6$M\]]YG/",  #.( 0 5
M  "  78: @!B:6EB+3(P,3<P.3,P7V-A;"YX;6Q02P$"% ,4    " "4A%A+
M)FP-1\IB   ]O@0 %0              @ 'E/0( 8FEI8BTR,#$W,#DS,%]D
M968N>&UL4$L! A0#%     @ E(182R]).RK+$ $ D7D, !4
M ( !XJ " &)I:6(M,C Q-S Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( )2$6$L7
MTD#ROI<  $]X!P 5              "  >"Q P!B:6EB+3(P,3<P.3,P7W!R
;92YX;6Q02P4&      8 !@"* 0  T4D$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
